"Rank","NCT Number","Title","Status","Study Results","Gender","Phases","Enrollment","Funded Bys","Study Type","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","URL"
1,"NCT01916239","Pomegranate Extract Supplementation in Colorectal Cancer Patients","Completed","No Results Available","All","Phase 1|Phase 2","60","Other","Interventional","June 2012","February 2015","April 2015","August 5, 2013","null","April 14, 2015","Hospital General Universitario Reina Sofía, Murcia, Spain","https://ClinicalTrials.gov/show/NCT01916239"
2,"NCT01126112","Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer","Completed","No Results Available","All","Phase 2","33","Other|Industry","Interventional","May 2010","July 2014","July 2014","May 19, 2010","null","March 24, 2015","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01126112"
3,"NCT01431196","Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer","Completed","No Results Available","All","Phase 2","29","Other|NIH","Interventional","February 2011","June 2012","December 2013","September 9, 2011","null","May 19, 2016","Clínica Universidad de Navarra, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT01431196"
4,"NCT01413295","Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","All","Phase 2","52","Other","Interventional","August 2011","September 2014","September 2014","August 10, 2011","null","November 4, 2014","Hospital Clínic Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01413295"
5,"NCT02067481","Effect of a Diet and Physical Activity Intervention in Breast Cancer Survivors","Completed","No Results Available","Female","Phase 2","42","Other","Interventional","March 2013","July 2013","July 2013","February 20, 2014","null","February 20, 2014","Instituto Catalá de Oncología, Barcelona, L´Hospitalet de Llobregat, Spain","https://ClinicalTrials.gov/show/NCT02067481"
6,"NCT02622880","Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients","Completed","No Results Available","All","Phase 4","68","Other|Industry","Interventional","February 2013","December 2013","June 2014","December 7, 2015","null","December 7, 2015","Hospital Universitairo La Paz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02622880"
7,"NCT00958386","Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)","Completed","No Results Available","All","Phase 2","61","Other|Industry","Interventional","August 2009","July 2014","July 2014","August 13, 2009","null","March 24, 2015","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00958386"
8,"NCT01043484","Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer","Completed","No Results Available","All","Phase 2","90","Other|Industry","Interventional","December 2009","January 2013","August 2016","January 6, 2010","null","October 19, 2016","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01043484"
9,"NCT00885885","Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases","Completed","No Results Available","All","Phase 2","80","Other|Industry","Interventional","May 2009","March 2015","March 2015","April 22, 2009","null","August 1, 2017","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00885885"
10,"NCT01161316","Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours","Completed","No Results Available","All","Phase 2","194","Other","Interventional","August 2010","June 2015","June 2015","July 13, 2010","null","July 27, 2015","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01161316"
11,"NCT01303029","Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer","Completed","No Results Available","All","Phase 2","120","Other|Industry","Interventional","February 2011","June 2015","June 2015","February 24, 2011","null","August 1, 2017","Spanish Cooperative Group for Digestive Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01303029"
12,"NCT00875771","Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients","Completed","No Results Available","All","Phase 2","80","Other|Industry","Interventional","April 2009","May 2012","May 2012","April 3, 2009","null","August 1, 2017","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00875771"
13,"NCT01071655","Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer","Completed","No Results Available","All","Phase 2","195","Other|Industry","Interventional","February 2010","November 2013","November 2013","February 19, 2010","null","March 24, 2015","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01071655"
14,"NCT01115751","A Study in Patients With Advanced or Metastatic Cancer","Completed","No Results Available","All","Phase 1","80","Industry","Interventional","March 2010","July 2012","July 2012","May 4, 2010","null","July 31, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain","https://ClinicalTrials.gov/show/NCT01115751"
15,"NCT01875380","Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer","Completed","No Results Available","All","Phase 2","46","Other|Industry","Interventional","June 2013","April 2016","April 2016","June 11, 2013","null","August 1, 2017","Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain","https://ClinicalTrials.gov/show/NCT01875380"
16,"NCT01583777","Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer","Completed","No Results Available","All","Phase 1","6","Industry","Interventional","September 2013","April 2015","April 2015","April 24, 2012","null","July 22, 2016","Hospital Universitario Madrid Sanchinarro, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01583777"
17,"NCT01704703","Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques","Completed","No Results Available","All","Phase 2","72","Other","Interventional","October 2012","July 2016","July 2016","October 11, 2012","null","August 1, 2017","Spanish Cooperative Group for Digestive Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01704703"
18,"NCT00969410","A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases","Completed","No Results Available","All","Phase 1","19","Industry","Interventional","August 2009","March 2011","March 2011","September 1, 2009","null","April 12, 2012","Investigational Site 1, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00969410"
19,"NCT02406794","Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors","Completed","No Results Available","All","Phase 1|Phase 2","156","Other","Interventional","May 2016","September 2016","March 2017","April 2, 2015","null","March 31, 2017","Regional University Hospital Virgen de la Victoria, Malaga, Spain","https://ClinicalTrials.gov/show/NCT02406794"
20,"NCT02928432","SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone","Completed","No Results Available","Male","Phase 2","26","Other","Interventional","June 2013","September 2016","January 2017","October 10, 2016","null","January 27, 2017","Spanish National Cancer Research Centre (CNIO), Madrid, Spain","https://ClinicalTrials.gov/show/NCT02928432"
21,"NCT01557101","Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population","Completed","No Results Available","All","Phase 4","200","Other","Interventional","April 2012","April 2013","June 2013","March 19, 2012","null","January 9, 2014","Digestive Service, Huc, La Laguna, S/c de Tenerife, Spain|Hospital Universitario de Canarias, La Laguna, S/c de Tenerife, Spain","https://ClinicalTrials.gov/show/NCT01557101"
22,"NCT01567488","Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET","Completed","No Results Available","All","Phase 2","43","Other","Interventional","June 8, 2011","September 1, 2014","June 7, 2017","March 30, 2012","null","January 3, 2018","Instituto Catalán de Oncologia, Hospitalet de Llobregat, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01567488"
23,"NCT01484080","Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates","Completed","No Results Available","Female","Phase 1|Phase 2","140","Other","Interventional","October 2011","November 2013","April 2014","December 2, 2011","null","April 16, 2015","Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|MD Anderson Cancer Centre Madrid, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01484080"
24,"NCT02201823","Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients","Completed","No Results Available","All","Phase 1","27","Industry|Other","Interventional","February 2014","March 2015","April 2015","July 28, 2014","null","July 2, 2015","Hospital Clínic, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02201823"
25,"NCT01734564","Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors","Completed","No Results Available","All","Phase 2","15","Other","Interventional","November 2012","December 2016","December 2016","November 27, 2012","null","April 11, 2017","Clinica Universidad de Navarra, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT01734564"
26,"NCT01108484","Program of Exercise, Diet and Control of Psychological Stress in Cancer Survivors","Completed","No Results Available","All","Phase 3","120","Other","Interventional","March 2010","July 2015","August 2015","April 22, 2010","null","May 17, 2016","GIAFYS headquarters, Miranda de Ebro, Burgos, Spain|GIAFYS, Miranda de Ebro, Burgos, Spain","https://ClinicalTrials.gov/show/NCT01108484"
27,"NCT01380249","PDM08 Clinical Trial in Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","22","Other","Interventional","June 2011","June 2012","January 2013","June 27, 2011","null","January 7, 2013","Hospital Universitario La Paz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01380249"
28,"NCT02316327","Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab","Completed","No Results Available","All","Phase 4","19","Other","Interventional","July 2013","September 2016","October 2016","December 12, 2014","null","October 5, 2016","Hospital Clinic, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02316327"
29,"NCT00555672","Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer","Completed","Has Results","All","Phase 1","34","Industry","Interventional","August 2008","December 2009","August 2010","November 9, 2007","January 5, 2011","December 19, 2011","Pfizer Investigational Site, L'hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00555672"
30,"NCT02210364","Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).","Completed","No Results Available","All","Phase 1","81","Industry","Interventional","April 2013","October 2016","October 2016","August 6, 2014","null","December 14, 2016","Brussels, Belgium|Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02210364"
31,"NCT01090960","A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors","Completed","No Results Available","All","Phase 1","52","Industry","Interventional","March 2010","February 2015","February 2015","March 23, 2010","null","July 4, 2016","Barcelona, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01090960"
32,"NCT01314105","BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer","Completed","Has Results","Female","Phase 1","19","Industry","Interventional","March 2011","July 2013","April 2016","March 14, 2011","November 20, 2014","February 1, 2018","1199.119.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1199.119.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1199.119.34003 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat, Spain","https://ClinicalTrials.gov/show/NCT01314105"
33,"NCT01844661","Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.","Completed","No Results Available","All","Phase 1|Phase 2","20","Other","Interventional","January 2013","December 2014","January 2016","May 1, 2013","null","February 19, 2016","Hospital Universitario Niño Jesús, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01844661"
34,"NCT00884845","Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors","Completed","No Results Available","All","Phase 1","35","Industry","Interventional","January 2009","June 2011","June 2011","April 21, 2009","null","March 26, 2014","Montefiore Medical Center, New York, New York, United States|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Intituto Universitario Dexeus, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00884845"
35,"NCT01799694","Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO)","Completed","No Results Available","Male","Phase 2","10","Other","Interventional","July 2011","February 2013","February 2013","February 27, 2013","null","March 8, 2013","Hospital Universitario La Paz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01799694"
36,"NCT00877474","Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","30","Industry","Interventional","March 2009","June 2011","June 2011","April 7, 2009","null","November 4, 2015","Cancer Research Center. University of Chicago Hospitals., Chicago,, Illinois, United States|Vall d'Hebron University Hospital., Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00877474"
37,"NCT02020577","Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours","Completed","Has Results","All","Phase 1","58","Industry","Interventional","December 2013","January 2015","April 2016","December 25, 2013","February 12, 2016","June 22, 2017","1200.122.33001 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1200.122.34001 Boehringer Ingelheim Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02020577"
38,"NCT01495247","Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer","Completed","No Results Available","Female","Phase 1|Phase 2","18","Industry","Interventional","January 2012","May 2014","May 2014","December 19, 2011","null","July 23, 2014","Novartis Investigative Site, Dijon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT01495247"
39,"NCT00733616","Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status","Completed","No Results Available","All","Phase 2","44","Other|Industry","Interventional","November 2008","May 2012","May 2012","August 13, 2008","null","February 20, 2013","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00733616"
40,"NCT01471847","A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab","Completed","No Results Available","Female","Phase 1","5","Industry","Interventional","February 2012","June 2012","June 2012","November 16, 2011","null","March 1, 2018","Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01471847"
41,"NCT01970553","Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors","Completed","No Results Available","All","Phase 1","47","Industry","Interventional","May 2011","October 2013","October 2013","October 28, 2013","null","April 1, 2015","Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario Virgen del Rocio, Seville, Spain|University College of London Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01970553"
42,"NCT00879905","A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","64","Industry","Interventional","May 2009","July 2012","July 2012","April 13, 2009","null","October 19, 2012","Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toulouse Cedex 3, France|Novartis Investigative Site, Barcelona, Cataluña, Spain","https://ClinicalTrials.gov/show/NCT00879905"
43,"NCT02053220","Mechanism of Action Trial of ColoAd1","Completed","No Results Available","All","Phase 1","17","Industry","Interventional","June 2013","April 2015","April 2016","February 3, 2014","null","September 9, 2016","Hospital Universitario Madrid Sanchinarro CIOCC, Madrid, Spain|Hospital Universitario Virgen del Rocío, Seville, Spain","https://ClinicalTrials.gov/show/NCT02053220"
44,"NCT01148758","A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer","Completed","No Results Available","All","Phase 1","7","Industry","Interventional","May 2010","September 2010","September 2010","June 22, 2010","null","November 2, 2016","Leuven, Belgium|Barcelona, Spain|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01148758"
45,"NCT02045589","A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer","Completed","No Results Available","All","Phase 1","8","Industry","Interventional","January 2014","October 2016","September 2018","January 27, 2014","null","October 1, 2018","Institut Català d'Oncologia, L'Hospitalet De Llobregat, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02045589"
46,"NCT01046240","Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy","Completed","No Results Available","All","Phase 1|Phase 2","29","Other","Interventional","October 2009","November 2010","November 2010","January 11, 2010","null","January 27, 2015","Clinica Universidad de Navarra, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT01046240"
47,"NCT00773526","A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.","Completed","No Results Available","All","Phase 1","52","Industry","Interventional","November 2008","September 2011","September 2011","October 16, 2008","null","November 2, 2016","Villejuif, France|Barcelona, Spain|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT00773526"
48,"NCT01548170","To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib","Completed","No Results Available","Male","Phase 1","12","Other","Interventional","April 2011","July 2011","July 2011","March 8, 2012","null","March 8, 2012","Hospital Universitario Ramón y Cajal, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01548170"
49,"NCT01831089","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","69","Industry","Interventional","September 2013","July 2016","July 2016","April 15, 2013","null","July 27, 2016","New York, New York, United States|Madrid, Spain|Bellinzona, Switzerland","https://ClinicalTrials.gov/show/NCT01831089"
50,"NCT01703910","Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","Completed","No Results Available","All","Phase 2","29","Other|Industry","Interventional","November 2012","November 2012","December 2014","October 11, 2012","null","October 9, 2015","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01703910"
51,"NCT01513174","Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone","Completed","No Results Available","All","Phase 1|Phase 2","186","Other","Interventional","August 2011","July 2016","July 2016","January 20, 2012","null","April 26, 2017","H. Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO Hospitalet, Hospitalet, Barcelona, Spain|H. Gen. Universitario de Alicante, Alicante, Spain|H. Vall d'Hebrón, Barcelona, Spain|H. Teresa Herrera, La Coruña, Spain","https://ClinicalTrials.gov/show/NCT01513174"
52,"NCT01792310","A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours","Completed","No Results Available","All","Phase 1|Phase 2","54","Industry|Other","Interventional","May 2013","September 2016","September 2016","February 15, 2013","null","December 6, 2016","Vall D'Hebron Institute of Oncology, Barcelona, Spain|Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre, Bilbao, Spain|Onkologikoa, San Sebastián, Spain|Sir Bobby Robson Cancer Trials Research Centre, The Northern Centre for Cancer Care, Freeman Hospital, Newcastle, Newcastle upon Tyne, United Kingdom|The Royal Marsden Hospital Drug Development Unit, Sutton, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT01792310"
53,"NCT01956734","Virus DNX2401 and Temozolomide in Recurrent Glioblastoma","Completed","No Results Available","All","Phase 1","31","Other|Industry","Interventional","September 2013","December 2015","March 2017","October 8, 2013","null","October 24, 2017","Clinica Universidad de Navarra, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT01956734"
54,"NCT02561832","A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer","Completed","No Results Available","All","Phase 1","20","Industry","Interventional","November 2015","February 2017","February 2017","September 28, 2015","null","February 15, 2017","Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT02561832"
55,"NCT01156870","First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor","Completed","No Results Available","All","Phase 1","114","Industry","Interventional","September 8, 2010","April 7, 2017","April 7, 2017","July 5, 2010","null","May 10, 2017","Investigational Site Number 840002, Cincinnati, Ohio, United States|Investigational Site Number 840001, San Antonio, Texas, United States|Investigational Site Number 250001, Toulouse Cedex, France|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724001, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01156870"
56,"NCT02082665","Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam","Completed","No Results Available","All","Phase 1","6","Industry","Interventional","February 19, 2015","July 1, 2016","August 1, 2016","March 10, 2014","null","July 24, 2017","GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02082665"
57,"NCT01283945","Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors","Completed","No Results Available","All","Phase 1|Phase 2","134","Industry","Interventional","July 2010","September 2016","May 4, 2017","January 26, 2011","null","April 12, 2018","Institute Gustave Roussy, Villejuif, Paris, France|Hopital Louis Pradel, Lyon, France|European Institute of Oncology, Milano, Italy|Vall d' Hebron University Hospital, Barcellona, Spain","https://ClinicalTrials.gov/show/NCT01283945"
58,"NCT00849329","A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer","Completed","No Results Available","All","Phase 1","12","Industry","Interventional","March 10, 2009","November 24, 2009","November 24, 2009","February 23, 2009","null","November 14, 2017","GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Songpa-gu, Seoul, Korea, Republic of|GSK Investigational Site, Hospitalet de Llobregat (Barcelona), Spain","https://ClinicalTrials.gov/show/NCT00849329"
59,"NCT00721266","A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.","Completed","No Results Available","All","Phase 1","102","Industry","Interventional","June 2008","June 2011","June 2011","July 24, 2008","null","November 2, 2016","Toulouse, France|Villejuif, France|Barcelona, Spain|Sevilla, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT00721266"
60,"NCT02382263","Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer","Completed","No Results Available","All","Phase 1|Phase 2","224","Other","Interventional","April 2013","April 2016","April 2016","March 6, 2015","null","July 6, 2016","Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, A Cosuña, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Complexo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Complejo Hospitalario Regional Virgen de Las Nieves, Granada, Spain|Complejo Hospitalario Gregorio Marañón, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT02382263"
61,"NCT02028442","Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients","Completed","No Results Available","All","Phase 1|Phase 2","61","Industry","Interventional","September 20, 2012","April 29, 2016","April 29, 2016","January 7, 2014","null","March 22, 2018","GZA ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerp, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|Ghent University Hospital, Ghent, Belgium|Institut Catala d Oncologica, Barcelona, Spain|START - Hospital Universitario Madrid Sanchinarrio, Madrid, Spain|Hospital Universitario Virgen del Rocio (HUVR), Seville, Spain","https://ClinicalTrials.gov/show/NCT02028442"
62,"NCT01332604","GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","41","Industry","Interventional","July 2011","June 2015","June 2015","April 11, 2011","null","November 2, 2016","Los Angeles, California, United States|Aurora, Colorado, United States|Rochester, Minnesota, United States|Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01332604"
63,"NCT01126749","Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer","Completed","No Results Available","All","Phase 1|Phase 2","92","Industry","Interventional","April 2010","May 9, 2015","July 20, 2016","May 20, 2010","null","August 28, 2017","Birmingham, Alabama, United States|Tucson, Arizona, United States|Fort Myers, Florida, United States|Saint Petersburg, Florida, United States|Ann Arbor, Michigan, United States|Las Vegas, Nevada, United States|East Orange, New Jersey, United States|Rochester, New York, United States|Chattanooga, Tennessee, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Webster, Texas, United States|Huntington, Virginia, United States|Northfork, West Virginia, United States|Aachen NW, Germany|Berlin, Germany|Essen, NW, Germany|Goch, NW, Germany|Hamburg, HH, Germany|Tuebingen, BW, Germany|Wiesbaden, HE, Germany|Maastricht, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Barcelona, Spain|Barcelona, Spain|Elche- Alicante, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Sabadell, Spain|Dnipropetrovsk, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Leicester, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01126749"
64,"NCT01207323","A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors","Completed","No Results Available","All","Phase 1","66","Industry","Interventional","November 9, 2010","December 3, 2013","April 23, 2018","September 22, 2010","null","May 1, 2018","Uni of Colorado Cancer Center; Anschutz Cancer Pavilion, Aurora, Colorado, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01207323"
65,"NCT01082068","Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer","Completed","No Results Available","Female","Phase 1|Phase 2","72","Industry","Interventional","June 2010","April 2013","April 2013","March 8, 2010","null","June 3, 2016","Investigational Site Number 1537, Los Angeles, California, United States|Investigational Site Number 1601, Denver, Colorado, United States|Investigational Site Number 1238, Fort Meyers, Florida, United States|Investigational Site Number 1441, Chicago, Illinois, United States|Investigational Site Number 1138, Boston, Massachusetts, United States|Investigational Site Number 1331, Ann Arbor, Michigan, United States|Investigational Site Number 1330, Detroit, Michigan, United States|Investigational Site Number 5201, Columbia, Missouri, United States|Investigational Site Number 1252, Durham, North Carolina, United States|Investigational Site Number 1214, Nashville, Tennessee, United States|Investigational Site Number 5246, El Paso, Texas, United States|Investigational Site Number 3321, Nantes Saint Herblain, France|Investigational Site Number 3324, Paris Cedex 05, France|Investigational Site Number 3415, Barcelona, Spain|Investigational Site Number 3419, Barcelona, Spain|Investigational Site Number 3413, Madrid, Spain|Investigational Site Number 3420, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01082068"
66,"NCT02200081","Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC","Completed","No Results Available","All","Phase 2","103","Industry","Interventional","March 2014","November 2016","October 5, 2017","July 25, 2014","null","November 15, 2018","Medizinische Universitaet Innsbruck, Innsbruck, Austria|Universitair Ziekenhuis Gent, Gent, Belgium|Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden Württemberg, Germany|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02200081"
67,"NCT02051751","A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer","Completed","No Results Available","All","Phase 1","19","Industry","Interventional","March 5, 2014","August 19, 2016","August 19, 2016","January 31, 2014","null","April 7, 2017","Highlands Oncology Group, Fayetteville, Arkansas, United States|Horizon Oncology Center BioAdvance, Lafayette, Indiana, United States|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT02051751"
68,"NCT01572727","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation","Completed","Has Results","Female","Phase 2|Phase 3","416","Industry","Interventional","August 2012","June 2015","June 2015","April 6, 2012","January 27, 2017","March 9, 2017","Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States|Arizona Oncology Associates Dept of Oncology, Phoenix, Arizona, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|California Cancer Care Marian Speciality, Greenbrae, California, United States|Rocky Mountain Cancer Centers RMCC Hale Pkwy, Greenwood Village, Colorado, United States|H. Lee Moffitt Cancer Center & Research Institute SC, Tampa, Florida, United States|Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2), Atlanta, Georgia, United States|Northwest Georgia Oncology Center NW Georgia Onc, Marietta, Georgia, United States|University of Kansas Cancer Center Univ Kansas 2, Kansas City, Kansas, United States|Norton Healthcare, Inc., Louisville, Kentucky, United States|Washington University School of Medicine Regulatory, St. Louis, Missouri, United States|University of Nebraska Medical Center Unv Nebraska Med Ctr (2), Omaha, Nebraska, United States|University of New Mexico Cancer Research Center Dept of Univ New Mexico, Albuquerque, New Mexico, United States|New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Troy, New York, United States|Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-1, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center OUHSC 2, Oklahoma City, Oklahoma, United States|Northwest Cancer Specialists Vancouver Loc, Portland, Oregon, United States|Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas, United States|University of Texas Southwestern Medical Center Harry Hines, Dallas, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio, San Antonio, Texas, United States|Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA, Reston, Virginia, United States|Novartis Investigative Site, Sydney, New South Wales, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Liège, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Sint-Niklaas, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Le Mans Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Fulda, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Sapporo, Hokkaido, Japan|Novartis Investigative Site, Isehara-city, Kanagawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, St.- Petersburg, Russia, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Laguna, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan|Novartis Investigative Site, New Taipei City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Maidstone, Kent, United Kingdom|Novartis Investigative Site, Glasgow - Scotland, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01572727"
69,"NCT00706030","Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer","Completed","Has Results","All","Phase 1|Phase 2","92","Industry","Interventional","April 29, 2008","October 2009","June 7, 2018","June 27, 2008","May 8, 2018","August 9, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albert Einstein Cancer Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Hematology Oncology Associates of Rockland, Nyack, New York, United States|Carolinas Hematology-Oncology Associates, Charlotte, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|AZ Klina Brasschaat, Brasschaat, Belgium|Institut Jules Bordet, Brussels, Belgium|St.-Augustinus Hospital Oncology Department, Wilrijk, Belgium|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, Beijing, China|Tianjin Cancer Hospital, TianJin, Tianjin, China|Centre Paul Papin, Angers, France|Institut Paoli Calmette, Marseille, France|Institut Curie, Département d'Oncologie Médicale, Paris, France|Institut Claudius Regaud, Toulouse, France|Queen Mary Hospital, Hong Kong, Hong Kong|UNIMED Medical Institute, Hong Kong, Hong Kong|Martini Ziekenhuis / Afdeling Interne Geneeskunde, Groningen, Netherlands|Centrum Onkologii Ziemii Lubelskiej, Oddział Chemioterapii, Lublin, Poland|Wojskowy Instytut Medyczny, Klinika Onkologii, Warszawa, Poland|Centro Oncologico de Galicia, A Coruña, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Arnau de Vilanova, Servicio de Oncologia Medica, Lleida, Spain|Hospital 12 de Octubre, Servicio de Oncologia Medica, Madrid, Spain|Onkologiska Kliniken Universitetssjukhuset i Lund, Lund, Sweden|National Taiwan University Hospital, Taipei, Taiwan|Broomfield Hospital, Chelmsford, Essex, United Kingdom|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Christie NHS Foundation Trust, Manchester, Lancashire, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00706030"
70,"NCT01562275","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors","Completed","Has Results","All","Phase 1","67","Industry","Interventional","April 2012","January 2015","January 2015","March 23, 2012","March 28, 2016","March 28, 2016","Boston, Massachusetts, United States|Detroit, Michigan, United States|Nashville, Tennessee, United States|Barcelona, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01562275"
71,"NCT01117428","Sym004 in Patients With Advanced Solid Tumors","Completed","Has Results","All","Phase 1|Phase 2","111","Industry","Interventional","March 2010","February 2015","May 2015","May 5, 2010","July 12, 2017","October 15, 2018","South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States|UZ Brussel, Medische Oncologie, Brussel, Belgium|UZ Gasthuisberg, Digestive Oncology Unit, Brussel, Belgium|UZ Antwerp, Oncologie, Edegem, Belgium|Medical Oncology Department, Vall d´Hebron University Hospital, Barcelona, Spain|Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01117428"
72,"NCT01338753","Study to Evaluate Markers of Response in Locally Advanced Breast Cancer","Completed","No Results Available","Female","Phase 2","74","Other|Industry","Interventional","October 2009","October 2010","May 2011","April 19, 2011","null","September 10, 2013","Hospital Obispo Polanco, Teruel, Aragón, Spain|Hospital Miguel Servet, Zaragoza, Aragón, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital de Donosti, San Sebastián, Guipúzcoa, Spain|Onkologikoa, San Sebastián, Guipúzcoa, Spain|Hospital de San Millan, Logroño, La Rioja, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital de Tudela, Tudela, Navarra, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital General Yagüe, Burgos, Spain","https://ClinicalTrials.gov/show/NCT01338753"
73,"NCT01373164","A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer","Completed","Has Results","All","Phase 1|Phase 2","170","Industry","Interventional","June 2011","November 2015","December 2016","June 14, 2011","May 16, 2018","May 16, 2018","Florida Hospital Tampa HPG and Foregut Surgery, Tampa, Florida, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussel, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clermont-Ferrand, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montbéliard, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Friedrichshafen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mönchengladbach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reutlingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo De Alarcon, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01373164"
74,"NCT00741260","Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer","Completed","Has Results","All","Phase 1|Phase 2","105","Industry","Interventional","December 9, 2008","November 2010","June 2018","August 26, 2008","November 9, 2017","September 5, 2018","USA Mitchell Cancer Institute, Mobile, Alabama, United States|Pacific Shores Medical Group, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|The Care Group, LLC. dba Horizon Oncology Center, Lafayette, Indiana, United States|Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States|Arena Oncology Associates, PC, Lake Success, New York, United States|Dayton Clinical Oncology Program, Dayton, Ohio, United States|Berks Hematology Oncology, West Reading, Pennsylvania, United States|HOPE Oncology, Richardson, Texas, United States|Cancer Therapy and Research Center at The UT Health Science Center Institute for Drug Development, San Antonio, Texas, United States|Mater Private Centre for HOCA, South Brisbane, Queensland, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Associacao Hospital de Caridade Ijui, Ijui, RS - Brazil, Brazil|Associacao Hospitalar Moinhos de Vento Instituto de Edicacao e Pesquisa, Porto Alegre, RS, Brazil|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, Beijing, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, China|University Hospital Center Zagreb Department of Oncology, Zagreb, Croatia|UNIMED Medical Institute, Comprehensive Centre for Breast Diseases, Hong Kong, Hong Kong|Orszagos Onkologiai Intezet ""B"" Belgyogyaszati osztaly, Budapest, Hungary|Josa Andras Oktatokorhaz / Onkoradiologiai Osztaly, Nyiregyhaza, Hungary|Yonsei University Health System-Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Department of Hematology/Oncology, Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center Department of Medicine Division of Oncology, Seoul, Korea, Republic of|Republican Clinical Oncology Dispensary, Kazan, Russian Federation|GUZ Perm Regional Oncology Dispensary, Perm, Russian Federation|Leningrad Regional Oncology Dispensary, Saint Petersburg, Russian Federation|GUZ City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|Saint-Petersburg State Medical University n.a. acad. I.P. Pavlov, Laboratory of Thoracic Oncology of Pulmonology Research Institute, Saint Petersburg, Russian Federation|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00741260"
75,"NCT01901146","Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer","Completed","No Results Available","Female","Phase 3","827","Industry","Interventional","April 29, 2013","May 5, 2016","January 27, 2017","July 17, 2013","null","April 10, 2017","Research Site, Brest, Belarus|Research Site, Grodno, Belarus|Research Site, Minsk, Belarus|Research Site, Minsk, Belarus|Research Site, Salvador, Bahia, Brazil|Research Site, Ijuí, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Jaú, Sao Paulo, Brazil|Research Site, Santo André, Sao Paulo, Brazil|Research Site, São Paulo, Sao Paulo, Brazil|Research Site, Sofia, Sofiya, Bulgaria|Research Site, Veliko Tarnovo, Veliko Turnovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Moncton, New Brunswick, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Santiago, Chile|Research Site, Fürstenwalde, Brandenburg, Germany|Research Site, Frankfurt am Main, Hessen, Germany|Research Site, Frankfurt, Hessen, Germany|Research Site, Bonn, Nordrhein-westfalen, Germany|Research Site, Bottrop, Nordrhein-westfalen, Germany|Research Site, Berlin, Germany|Research Site, Athens, Attica, Greece|Research Site, Athens, Attica, Greece|Research Site, Heraklion, Crete, Greece|Research Site, Thessaloniki, Nea Efkarpia, Greece|Research Site, Debrecen, Hajdu-bihar, Hungary|Research Site, Szolnok, Jasz-nagykun-szolnok, Hungary|Research Site, Nyíregyháza, Szabolcs-szatmar-bereg, Hungary|Research Site, Szekszárd, Tolna, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, San Fermo della Battaglia, Como, Italy|Research Site, Bari, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, Piacenza, Italy|Research Site, Varese, Italy|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, San Luis Potosí, San Luis Potosi, Mexico|Research Site, Queretaro, Mexico|Research Site, Toluca, Estado de Mexico, Mexico|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Warszawa, Lubelskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Rybnik, Slaskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Cluj-Napoca, Cluj, Romania|Research Site, Ploiesti, Prahova, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Brasov, Romania|Research Site, Cluj, Romania|Research Site, Obninsk, Kaluzhskaya, Russian Federation|Research Site, Saransk, Mordovia, Russian Federation|Research Site, Moscow Region, Moscow, Russian Federation|Research Site, Arkhangelsk, Primorskiy, Russian Federation|Research Site, Saint Petersburg, St. Petersburg, Russian Federation|Research Site, Yaroslavl, Yaroslavlr, Russian Federation|Research Site, Chelaybinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Sabadell, Barcelona, Spain|Research Site, A Coruña, La Coruna, Spain|Research Site, Lérida, Lleida, Spain|Research Site, Alcorcón, Madrid, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Kyiv, Kiev, Ukraine|Research Site, Uzhgorod, Transcarpathia, Ukraine|Research Site, Lutsk, Volyn, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Nottingham, England, United Kingdom|Research Site, Peterborough, England, United Kingdom","https://ClinicalTrials.gov/show/NCT01901146"
76,"NCT02081495","A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer","Completed","No Results Available","All","Phase 1","35","Industry","Interventional","August 2014","November 2015","November 2015","March 7, 2014","null","November 11, 2016","Los Angeles, California, United States|Brussel, Belgium|Wilrijk, Belgium|Edmonton, Alberta, Canada|Barcelona, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT02081495"
77,"NCT01008475","EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer","Completed","Has Results","All","Phase 1|Phase 2","232","Industry","Interventional","October 2009","April 2015","April 2015","November 5, 2009","March 30, 2016","March 30, 2016","Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Sofia, Bulgaria|Research Site, Strovolos, Nicosia, Cyprus|Research Site, Brno, Czech Republic|Research Site, Horovice, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research site, Hannover, Germany|Research Site, Heilbronn, Germany|Research Site, Landshut, Germany|Research Site, Leipzig, Germany|Research Site, Munich, Germany|Research Site, Recklinghausen, Germany|Research Site, Ulm, Germany|Research Site, Thessaloniki, Cyprus, Greece|Research Site, Mournies Chania, Greece|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szolnok, Hungary|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Ramat Gan, Israel|Research Site, Rechovot, Israel|Research Site, Tel-Aviv, Israel|Research Site, Elblag, Poland|Research Site, Gdańsk, Poland|Research Site, Gliwice, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research, Arkhangelsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Barcelona, Spain|Research Site, Elche, Spain|Research Site, Madrid, Spain|Research Site, Mallorca, Spain|Research Site, Santander, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Terrassa, Spain|Research Site, Valencia, Spain|Research Site, Aberdeen, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01008475"
78,"NCT01298193","Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients","Completed","No Results Available","Female","Phase 4","212","Other|Industry","Interventional","May 2011","March 2013","April 2014","February 17, 2011","null","May 19, 2015","Badalona, Barcelona, Spain|Alcalá de Henares, Madrid, Spain|Alcorcón, Madrid, Spain|A Coruña, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Jaén, Spain|Lleida, Spain|Lugo, Spain|Madrid, Spain|Valencia, Spain|Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01298193"
79,"NCT01204710","A Study of Olaratumab (IMC-3G3) in Prostate Cancer","Completed","Has Results","Male","Phase 2","123","Industry","Interventional","October 2010","September 2012","October 2013","September 17, 2010","November 2, 2018","November 2, 2018","ImClone Investigational Site, Charleroi, Belgium|ImClone Investigational Site, Edegem, Belgium|ImClone Investigational Site, Liège, Belgium|ImClone Investigational Site, Olomouc, Czechia|ImClone Investigational Site, Prague, Czechia|ImClone Investigational Site, Praha 5, Czechia|ImClone Investigational Site, Aachen, Germany|ImClone Investigational Site, Augsburg, Germany|ImClone Investigational Site, Bonn, Germany|ImClone Investigational Site, Dresden, Germany|ImClone Investigational Site, Essen, Germany|ImClone Investigational Site, Frankfurt, Germany|ImClone Investigational Site, Freiburg, Germany|ImClone Investigational Site, Mainz, Germany|ImClone Investigational Site, Mannheim, Germany|ImClone Investigational Site, Münster, Germany|ImClone Investigational Site, Rostock, Germany|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Debrecen, Hungary|ImClone Investigational Site, Kecskemét, Hungary|ImClone Investigational Site, Miskolc, Hungary|ImClone Investigational Site, Nyíregyháza, Hungary|ImClone Investigational Site, Pécs, Hungary|ImClone Investigational Site, Szeged, Hungary|ImClone Investigational Site, Meldola, Italy|ImClone Investigational Site, Milano, Italy|ImClone Investigational Site, Roma, Italy|ImClone Investigational Site, Rozzano, Italy|ImClone Investigational Site, Trento, Italy|ImClone Investigational Site, Kraków, Poland|ImClone Investigational Site, Lublin, Poland|ImClone Investigational Site, Poznań, Poland|ImClone Investigational Site, Warszawa, Poland|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Palma de Mallorca, Spain|ImClone Investigational Site, Pamplona - Navarra, Spain|ImClone Investigational Site, Sabadell - Barcelona, Spain|ImClone Investigational Site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01204710"
80,"NCT01234337","Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer","Completed","Has Results","All","Phase 3","537","Industry","Interventional","February 21, 2011","May 12, 2014","October 20, 2017","November 4, 2010","September 3, 2015","November 6, 2018","Greenbrae, California, United States|Sylmar, California, United States|West Palm Beach, Florida, United States|Joliet, Illinois, United States|Evansville, Indiana, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Jackson, Mississippi, United States|Springfield, Missouri, United States|Albuquerque, New Mexico, United States|Lake Success, New York, United States|Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|Bristol, Tennessee, United States|Memphis, Tennessee, United States|El Paso, Texas, United States|Burlington, Vermont, United States|Madison, Wisconsin, United States|Mar del Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Garran, Australian Capital Territory, Australia|Liverpool, New South Wales, Australia|Waratah, New South Wales, Australia|Adelaide, South Australia, Australia|Bendigo, Victoria, Australia|Frankston, Victoria, Australia|Perth, Western Australia, Australia|Linz, Oberösterreich, Austria|Wien, Austria|Liege, Liège, Belgium|Brugge, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Hasselt, Belgium|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Shenyang, Liaoning, China|Beijing, China|Beijing, China|Nanning, China|Shanghai, China|Tianjin, China|Xi'an, China|Ceske Budejovice, Czechia|Nova Ves Pod Plesi, Czechia|Nymburk, Czechia|Olomouc, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 5, Czechia|Praha 5, Czechia|Clermont Ferrand Cedex 1, France|Lille, France|Nantes, France|Saint Cloud, France|Toulouse, France|Erlangen, Bayern, Germany|Frankfurt, Hessen, Germany|Offenbach, Hessen, Germany|Köln, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Stendal, Sachsen-Anhalt, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Athens, Greece|Heraklion, Greece|Ioannina, Greece|Larissa, Greece|Patras, Greece|Budapest, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Szentes, Hungary|Szolnok, Hungary|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Bologna, Emilia-Romagna, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Ravenna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Monza-Brianza, Lombardia, Italy|Ancona, Marche, Italy|Palermo, Sicilia, Italy|Pisa, Toscana, Italy|Nagoya, Aichi, Japan|Matsuyama, Ehime, Japan|Suita, Osaka, Japan|Hidaka, Saitama, Japan|Kita-Adachigun, Saitama, Japan|Bunkyo, Tokyo, Japan|Koto-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Kagoshima, Japan|Osaka, Japan|Gdansk, Poland|Gdynia, Poland|Poznan, Poland|San Juan, Puerto Rico|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Santiago de Compostela, A Coruña, Spain|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|Castellón de la Plana, Castellón, Spain|Palma de Mallorca, Illes Baleares, Spain|Reus, Tarragona, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Lleida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Palma de Mallorca, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Stockholm, Sweden|Stockholm, Sweden|Truro, Cornwall, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Northwood, United Kingdom","https://ClinicalTrials.gov/show/NCT01234337"
81,"NCT01712217","A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib","Completed","No Results Available","All","Phase 1|Phase 2","220","Industry","Interventional","October 2012","December 2016","May 16, 2017","October 23, 2012","null","January 19, 2018","Mayo Clinic-Scottsdale, Scottsdale, Arizona, United States|University of California, San Diego Medical Center, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Sharp Clinical Oncology Research-Sharp Memorial Hospital, San Diego, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale University School of Medicine-Yale Cancer Center, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Northwestern University The Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Indiana University Melvin and and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic-Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center Eppley Cancer Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Oncology Hematology in Cincinnati, Cincinnati, Ohio, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|The Pennsylvania State University-Penn State, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|The West Clinic, Germantown, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin-Carbone Cancer Center, Madison, Wisconsin, United States|Atlantic Clinical Cancer Research Unit, Halifax, Nova Scotia, Canada|McGill University Health Center, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie De Quebec, Sainte-Foy, Quebec, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Cancer Care Manitoba, Winnipeg, Canada|Centre Hospitalier Regional Universitaire Besancon, Besancon Cedex, France|CHU de Caen-Hopital Cote de Nacre, Caen, France|Hopital Saint Antoine, Creteil Cedex, France|Centre Hospitalier de Grenoble, Grenoble, France|CHRU de Lille, Lille cedex, France|Institut Paoli-Calmettes, Marseille, France|Hopital Tenon, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Benite Cedex, France|CHU Toulouse-Hopital Larrey, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun Jeonnam, Korea, Republic of|National Cancer Center, Korea, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitari Quiron Dexeus Barcelona, Barcelona, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain","https://ClinicalTrials.gov/show/NCT01712217"
82,"NCT01503983","Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive","Completed","No Results Available","All","Phase 2","45","Other","Interventional","August 2011","December 2013","May 2015","January 4, 2012","null","August 27, 2015","Hospital Lucus Augusti de Lugo, Lugo, A Coruña, Spain|Hospital Provincial de Pontevedra, Pontevedra, Vigo, Spain|Hospital Juan Canalejo, A Coruña, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Arnau de Vilanova de LLeida, Lleida, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital de Orense, Orense, Spain|Hospital Universitario Cnetral de Asturias, Oviedo, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Xeral Cies, Vigo, Spain|Hospital de POVISA, Vigo, Spain","https://ClinicalTrials.gov/show/NCT01503983"
83,"NCT01763710","Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer","Completed","No Results Available","Female","Phase 2","60","Other","Interventional","December 2012","December 2015","December 2015","January 9, 2013","null","March 29, 2016","Hospital Universitario Del Sureste, Arganda del Rey, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Infanta Cristina, Parla, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01763710"
84,"NCT01669239","Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer","Completed","No Results Available","Female","Phase 2","83","Other","Interventional","June 2013","January 2016","January 2016","August 20, 2012","null","November 6, 2017","Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Spain|Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain|MD Anderson Cancer Center Madrid, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Sant Joan de Reus, Reus, Spain|Hospital Sagrado Corazón USP, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Macarena, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Hospital Universitario Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01669239"
85,"NCT01139775","A Study in Non Small Cell Lung Cancer","Completed","Has Results","All","Phase 1|Phase 2","76","Industry","Interventional","February 2011","May 2013","August 2014","June 9, 2010","May 18, 2018","May 18, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Baden-Wurttemberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munster, Nordhein-Westfalen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coswig, Sachsen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lübeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rheine, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Asturias, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mataro, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo de Alarcon, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01139775"
86,"NCT00909987","Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum","Completed","No Results Available","All","Phase 2","46","Other","Interventional","March 2009","January 2013","June 2013","May 29, 2009","null","October 11, 2013","Hospital General Universitario de Elche, Elche, Alicante, Spain|Complejo Sanitario Parc Taulí, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Arnau de Vilanova, Lérida, Spain|Hospital La Paz, Madrid, Spain|Hospital de Navarra, Pamplona, Spain|Hospital La Fe, Valencia, Spain|Instituto Valenciano de Oncología (IVO), Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00909987"
87,"NCT00721409","Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer","Completed","Has Results","Female","Phase 2","177","Industry","Interventional","September 15, 2008","November 29, 2013","December 20, 2017","July 24, 2008","March 19, 2015","August 8, 2018","Central Hematology Oncology Medical group Inc., Alhambra, California, United States|UCLA Hematology/Oncology - Alhambra, Alhambra, California, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|UCLA West Medical Pharmacy (Drug Management Only), Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Drug Management Only: UCLA West Medical Pharmacy, Los Angeles, California, United States|Drug Management Only, Los Angeles, California, United States|Regulatory Managment, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|TORI -US Central Administration (Regulatory Management), Los Angeles, California, United States|TORI -US Central Administration, Los Angeles, California, United States|TORI Central Administration (Regulatory Management), Los Angeles, California, United States|TORI Central Administration (Regulatory Managment Only), Los Angeles, California, United States|TRIO-US Central Administration, Los Angeles, California, United States|UCLA Hematology/Oncology, Los Angeles, California, United States|UCLA, Hematology/Oncology, Los Angeles, California, United States|Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, United States|Central Hematology Oncology Medical Group, Inc, Pasadena, California, United States|Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Santa Monica-UCLA Medical Center and Orthopaedic Hospital, Santa Monica, California, United States|UCLA Hematology Oncology-Santa Monica, Santa Monica, California, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Duluth, Georgia, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Lawrenceville, Georgia, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Snellville, Georgia, United States|Illinois Cancer Specialists, Chicago, Illinois, United States|Resurrection Medical Group, Chicago, Illinois, United States|North Shore Oncology-Hematology Associates, Crystal Lake, Illinois, United States|North Shore Hematology Oncology, Highland Park, Illinois, United States|North Shore Oncology-Hematology Associates, Libertyville, Illinois, United States|North Shore Hematology Oncology, Skokie, Illinois, United States|Regulatory Office: Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Fort Worth, Texas, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, United States|Virginia Cancer Specialists, PC, Woodbridge, Virginia, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|CSSS Champlain-Charles-Le Moyne Local HS-0054, Greenfield Park, Quebec, Canada|Centre Paul Papin, CRLCC, ANGERS Cedex 9, France|CHD Vendee, La Roche Sur Yon, France|Gemeinschaftspraxis, Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany|Gemeinschaftspraxis Haematologie-Onkologie, Dresden, Germany|Martin-Luther-Universitaet Halle-Wittenberg, Halle/Saale, Germany|Universitaetsklinik und Poliklinik fuer Gynaekologie, Martin-Luther-Universitaet Halle-Wittenberg, Halle/Saale, Germany|Nationales Centrum fuer Tumorerkrankungen, Heidelberg, Germany|Frauenaerzte Pruener Gang Abts & Partner, Kiel, Germany|Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Universitaetsklinik Mainz, Mainz, Germany|Onkolog. Gemeinschaftspraxis, Muenchen, Germany|Frauenklinik vom Roten Kreuz, Muenchen, Germany|Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen, Muenchen, Germany|Mutterhaus der Borromaeerinnen, Innere Medizin I, Trier, Germany|Szent Margit Korhaz, Onkologia, Budapest, Hungary|Orszagos Onkologiai Intezet, Kemoterapia B, Budapest, Hungary|Fovarosi Onkormanyzat Uzsoki Utcai Korhaz, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Onkoradiologia, Gyor, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz és Egyetemi Oktato Korhaz, Onkologia, Miskolc, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es, Nyiregyhaza, Hungary|Markusovszky Egyetemi Oktatokorhaz, Onkoradiologiai Osztaly, Szombathely, Hungary|Bon Secours Hospital, Cork, Ireland|St. James's Hospital, Dublin 8, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|Divisione Oncologia Medica Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, Meldola, FC, Italy|M.O. di Oncologia - Azienda USL di Rimini - Ospedale ""Cervesi"", Cattolica, Italy|Ospedale Civile di Faenza Centro Oncologico, Faenza, RA, Italy|Unita' Operativa di Oncologia, Ospedale Civile di Lugo, Lugo, RA, Italy|Ospedale Civile di Ravenna, Ravenna, Italy|Azienda Unita Sanitaria Locale di Rimini, U.O. di Oncologia ed Oncoematologia Ospedale degli Infermi, Rimini, Italy|Ospedale Villa San Pietro, Roma, Italy|National Cancer Center, Center for Breast Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Federal State Budgetary Scientific Institution, Moscow, Russian Federation|Pyatigorsk Oncology Center, Pyatigorsk, Russian Federation|State Budgetary Healthcare Institution ""Samara Regional Clinical Oncology Dispensary"", Samara, Russian Federation|Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic, Ufa, Russian Federation|Department of Oncotherapy, National Hospital, Bloemfontein, South Africa|Eastleigh Breast Care Centre, Pretoria, South Africa|Ico-Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital General Universitario Vall D'Hebron, Barcelona, Spain|Centro Oncologico de Galicia, La Coruña, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Department of Oncology and Medical Radiology, SI ""DMA of MOH, Ukraine, ""MI ""Dnipropetrovsk City, Dnipropetrovsk, Ukraine|Municipal Treatment-and-Prophylactic Institution 'Donetsk City Oncological Dispensary' Radiology dep, Donetsk, Ukraine|Municipal clinical treatment-and-propyilactic institution ""Donetsk regional oncology center',, Donetsk, Ukraine|Kyiv City Clinical Oncologic Center, Kyiv, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Centre, Lviv, Ukraine","https://ClinicalTrials.gov/show/NCT00721409"
88,"NCT01607957","Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies","Completed","No Results Available","All","Phase 3","800","Industry","Interventional","June 17, 2012","January 24, 2014","May 23, 2016","May 30, 2012","null","October 6, 2017","Arizona Center for Cancer Care, Glendale, Arizona, United States|California Cancer Associates for Research and Excellence, Fresno, California, United States|Ronald H. Yanagihara, MD, Gilroy, California, United States|LAC and USC Medical Center, Los Angeles, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|San Jose Medical Group, San Jose, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Illinois Cancer Care, P.C., Peoria, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Ochsner Clinic Fndtn, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Gabrail Cancer Center, Canton, Ohio, United States|Hickman Cancer Center at Flower Hospital, Sylvania, Ohio, United States|Hematology/Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Royal North Shore Hospital, Sydney, New South Wales, Australia|The Queen Elisabeth Hospital, Woodville South, South Australia, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Studley Rd, Heidelberg VIC, Melbourne, Australia|Sir Charles Gairdner Hospital, Perth, Australia|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Universitaet Wien, Wien, Austria|Universitaetsklinik fur Innere Medizin, Wien, Austria|Wilhelminenspital Wien, Wien, Austria|Cliniques Universitaires UCL St. Luc, Brussels, Belgium|Erasme University Hospital-ULB-Brussels, Brussels, Belgium|Grand Hospital de Charleroi, Charleroi, Belgium|Antwerp University Hospital, Edegem, Belgium|University Hospital Gent, Edegem, Belgium|University Hospital Gent, Gent, Belgium|Leuven University Hospital - Campus Gasthuiseberg, Leuven, Belgium|University Hospital Gasthuisberg, Leuven, Belgium|Klinika onkologie a radioteraie, Facultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Institute of Oncology and Rehabilitation Ples, Nova Ves pod Plesi, Czechia|CHU de Becançon, Besancon, France|University Hospital of Bordeaux, Bordeaux, France|Centre Oscar Lambret, Lille, France|CRLC Val d'Aurelle, Montpellier, France|Hopital Saint Antoine, Paris cedex 12, France|Centre Eugene Marquis, Rennes cedex, France|Onkologische Schwerpunktpraxis Kurfuerstendamm, Berlin, Germany|Praxiskooperation Bonn-Euskirchen-Rheinbach, Bonn, Germany|Universitatsklinikum Carl Gustav Carus - Dresden, Dresden, Germany|Medizinische Klinik am Krankenhaus Nordwest GmbH, Frankfurt, Germany|Uniklinik der Martin-Luther-Universitaet Halle-Wittenberg, Halle (Saale), Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Uniklinik Koeln, Koeln, Germany|Johannes Gutenberg Universität Mainz, Mainz, Germany|Interdisziplinaeres Tumorzentrum Mannheim, Mannheim, Germany|Staedtisches Klinikum Muenchen / Klinikum Neuperlach, Muenchen, Germany|Klinikum der Universität München - Großhadern, München, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Bon Secours Hospital, Cork, Ireland|Adelaide and Meath Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Fondazione Poliambulanza, Brescia, Lombardy, Italy|Universita Delgi Studi de Genova (UNIGE)- Azienda Ospedaliera. Universitaria ""San Martino"" (Ospedale San Martino), Genova, Italy|Fondazione IRCCS Instituto Nazionale dei Tumori Milano, Milano, Italy|A.O. Ospedale Niguarda Ca' Granda, Milan, Italy|A.O. R.N. ""A.Cardarelli"", Naples, Italy|Seconda Universita degli Studi de Napoli, Napoli, Italy|AOU San Luidi di Orbassano, Orbassano, Italy|Azienda Ospedaliero, Pisa, Italy|Arcispidale S Maria Nuova, Reggio Emilia, Italy|Ospedale di Rimini, Rimini, Italy|Ospedale di Sondrio, Sondrio, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|KKR Sapporo Medical Center TONAN-Hospital, Sapporo, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Diaz - Universidad Autonoma de Madrid, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Universitario Morales Messeguer, Murcia, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Karolinska University Hospital, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|St James' Institute of Oncology, Leeds, United Kingdom|University College London Hospitals Foundation NHS Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT01607957"
89,"NCT02650193","A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.","Completed","Has Results","Female","Phase 2","25","Industry","Interventional","December 2015","October 2017","October 2017","January 8, 2016","October 23, 2018","October 23, 2018","CRU Hungary Kft.,CRU Early Phase Unit, Miskolci Semmelweis Kórház és Egyetemi Oktató Kórház, Miskolc, BAZ Megye, Hungary|Debreceni Egyetem Klinikai Központ, ÁOK, Onkológiai Klinika, Debrecen, Hajdú-bihar Megye, Hungary|Országos Onkológiai Intézet, Budapest, Hungary|Hospital Universitario Arnau de Vilanova, Lleida, Cataluna, Spain|Hospital Universitario de Fuenlabrada, Servicio de oncologia, Fuenlanbrada, Madrid, Spain|START Madrid - CIOCC, Unidad de fases 1 planta 3, Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Arnau de Vilanova. planta 6, unidad de Oncología, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02650193"
90,"NCT01020448","Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","Completed","Has Results","Male","Phase 3","339","Industry","Interventional","November 2009","November 2011","June 2013","November 25, 2009","July 15, 2015","August 24, 2015","Hôpital Erasme, Brussels, Belgium|UZ Brussels, Brussels, Belgium|UCL Saint-Luc, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven, Leuven, Belgium|CHU de Liège, Liège, Belgium|Fredericia Sygehus, Fredericia, Denmark|Frederiksbergs Hospital, Frederiksberg, Denmark|Herlev University Hospital, Herlev, Denmark|Odense Universitets hospital, Odense, Denmark|Clinique Rhône Durance, Avignon, France|Hôpital Pellegrin, Bordeaux, France|CHU Henri Mondor, Créteil, France|CHU Michalon, Grenoble, France|Chru Lille, Lille, France|Hôpital Nord, Marseille, France|Clinique Beau Soleil, Montpellier, France|Private practice, Nancy, France|CHU Nantes, Nantes, France|CHU Pasteur, Nice, France|Hôpital Val de Grâce, Paris, France|Institut Mutualiste Monsouris, Paris, France|Hôpital Henry Gabrielle, Saint Genis Laval, France|Hôpital Foch, Suresnes, France|CHU Toulouse, Toulouse, France|IRCCS Fondazione S. Raffaele del Monte Tabor, Milano, Italy|AOU San Luigi Gonzaga, Torino, Italy|P.Stradins Clinical University Hospital, Riga, Latvia|Center of Oncology, Riga, Latvia|Medical University Clinics, Kaunas, Lithuania|University Hospital, Klaipeda, Lithuania|University Oncological Institute, Vilnius, Lithuania|Ziekenhuis Amstelland, Amstelveen, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Diaconessenhuis, Leiden, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Medical Center, Arad, Romania|Oncology Institute, Bucharest, Romania|Sc E-Uro Srl, Cluj Napoca, Romania|Oncomed, Timisoara, Romania|Hospital Valle Hebrón, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Juan Canalejo, Coruña, Spain|Hospital General Universitario, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Infanta Sofía, Madrid, Spain|Instituto de Oncología, Valencia, Spain|Bristol Royal Infirmary, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|University Hospital Wales, Cardiff, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Derby City Hosptial, Derby, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Falkirk & District Royal Infirmary, Falkirk, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Lister Hospital, Stevenage, United Kingdom","https://ClinicalTrials.gov/show/NCT01020448"
91,"NCT01450319","Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype","Completed","Has Results","All","Phase 2","73","Industry","Interventional","December 2011","December 2014","December 2014","October 12, 2011","June 15, 2016","November 28, 2016","Research Site, A Coruña, Spain|Research Site, Asturias, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Navarra, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01450319"
92,"NCT01518283","Study of Weekly Cabazitaxel for Advanced Prostate Cancer","Completed","No Results Available","Male","Phase 2","74","Other","Interventional","May 2012","June 2016","July 2016","January 25, 2012","null","July 2, 2017","Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain|Institut Català D'Oncologia L'Hospitalet (Ico), L'Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sant Joan de Déu, Manresa, Barcelona, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario de Ourense, Ourense, Spain|Hospital Virgen Del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01518283"
93,"NCT02365805","Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer","Completed","No Results Available","Female","Phase 2","30","Other","Interventional","April 2014","October 10, 2016","October 10, 2016","February 19, 2015","null","March 13, 2017","Hospital Universitario Puerta del Mar, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario Juan Ramón Jimenez, Huelva, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario Virgen Macarena, Seville, Spain|Hospital Universitario Virgen del Rocío, Seville, Spain|Hospital Universitario Nuestra Señora de Valme, Seville, Spain","https://ClinicalTrials.gov/show/NCT02365805"
94,"NCT00900627","Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)","Completed","Has Results","All","Phase 1|Phase 2","330","Industry","Interventional","June 2009","April 2012","February 2015","May 13, 2009","September 29, 2014","January 20, 2016","Research Site, Brussels (Jette), Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Brno, Czech Republic|Research Site, Jicin, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 4 - Krc, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, Villejuif Cedex, France|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Györ, Hungary|Research Site, Szeged, Hungary|Research Site, Lido di Camaiore, Italy|Research Site, Modena, Italy|Research Site, Treviglio, Italy|Research Site, Ciudad de Panama, Panama|Research Site, Lima, Peru|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Uppsala, Sweden|Research Site, Chur, Switzerland|Research Site, Glasgow, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT00900627"
95,"NCT00610714","AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer","Completed","Has Results","Female","Phase 2","211","Industry","Interventional","April 2008","August 2009","January 2012","February 8, 2008","September 20, 2011","December 18, 2012","Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Alborg, Denmark|Research Site, Herning, Denmark|Research Site, Naestved, Denmark|Research Site, Paris, Cedex 04, France|Research Site, Avignon, France|Research Site, Bordeaux Cedex, France|Research Site, Caen Cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Montpellier Cedex 5, France|Research Site, Nantes, France|Research Site, Pierre Benite Cedex, France|Research Site, Reims Cedex, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Amsterdam, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Lima, Peru|Research Site, Coimbra, Portugal|Research Site, Funchal, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Baia Mare, Maramures, Romania|Research Site, Alba Iulia, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Cordoba, Andalucia, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Hospitalet Dellobregat(barcelo, Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Coventry, United Kingdom","https://ClinicalTrials.gov/show/NCT00610714"
96,"NCT00642018","A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer","Completed","No Results Available","Male","Phase 2","150","Industry","Interventional","March 2008","August 2011","April 2012","March 24, 2008","null","June 1, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heilbronn, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen-Planegg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kielce, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olsztyn, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Benidorm, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elda, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain","https://ClinicalTrials.gov/show/NCT00642018"
97,"NCT01899053","Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies","Completed","No Results Available","All","Phase 1","101","Industry","Interventional","July 2, 2013","March 24, 2017","April 30, 2018","July 15, 2013","null","August 27, 2018","Boston, Massachusetts, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States|Barcelona, Spain|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01899053"
98,"NCT01617668","A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer","Completed","Has Results","Female","Phase 2","209","Industry","Interventional","August 2012","September 2014","September 2014","June 12, 2012","August 31, 2016","October 17, 2016","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Cedars Sinai Medical Center SC, Los Angeles, California, United States|University of California at Los Angeles UCLA SC, Los Angeles, California, United States|Stanford University Medical Center Stanford, Stanford, California, United States|Yale University School of Medicine Yale Univ, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC, Tampa, Florida, United States|Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center Dept Onc, NY, New York, United States|Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State, Columbus, Ohio, United States|Vanderbilt University Medical Center Vanderbilt - Thompson Ln, Nashville, Tennessee, United States|Baylor College of Medicine Dept of Oncology, Houston, Texas, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 2, Madison, Wisconsin, United States|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Itajai, SC, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Düsseldorf, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Brighton, East Sussex, United Kingdom|Novartis Investigative Site, Kingston Upon Thames, Surrey, United Kingdom|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01617668"
99,"NCT01103323","Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","Completed","Has Results","All","Phase 3","760","Industry","Interventional","April 2010","July 2011","January 2014","April 14, 2010","November 19, 2012","June 24, 2015","Beverly Hills, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Mission Hills, California, United States|Orange, California, United States|Redlands, California, United States|Santa Maria, California, United States|Aventura, Florida, United States|Jacksonville, Florida, United States|Peoria, Illinois, United States|Cedar Rapids, Iowa, United States|New Orleans, Louisiana, United States|Ann Arbor, Michigan, United States|Rochester, Minnesota, United States|St. Cloud, Minnesota, United States|Jefferson City, Missouri, United States|Neptune, New Jersey, United States|New York, New York, United States|Fargo, North Dakota, United States|Toledo, Ohio, United States|Scranton, Pennsylvania, United States|Charleston, South Carolina, United States|Sumter, South Carolina, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Green Bay, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Capital Federal-Buenos Aires, Argentina|Concord, New South Wales, Australia|St Leonards, New South Wales, Australia|Woolloogabba, Queensland, Australia|Woodville South, South Australia, Australia|Footscray, Victoria, Australia|Parkville, Victoria, Australia|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Roeselare, Belgium|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Belo Horizonte, Minas Gerais, Brazil|Ijuí, Rio Grande do Sul, Brazil|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Qingdao, Shandong, China|Beijing, China|Beijing, China|Changchun, China|Chongqing, China|Chongqing, China|Fuzhou, China|Fuzhou, China|Ha'erbin, China|Hanghzou, China|Shanghai, China|Shanghai, China|Tianjin, China|Brno, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Praha, Czech Republic|Avignon, France|Le Mans Cedex 2, France|Lille Cedex, France|Lille Cedex, France|Marseille, France|Montpellier, France|Paris, France|Reims, France|Rennes, France|Strasbourg Cedex, France|Freiburg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Hannover, Niedersachsen, Germany|Oldenburg, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Porta Westfalica, Nordrhein-Westfalen, Germany|Trier, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Debrecen, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Petach Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zrifin, Israel|Brescia, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Sapporo, Hokkaido, Japan|Osakasayama, Osaka, Japan|Takatsuki, Osaka, Japan|Hidaka, Saitama, Japan|Kita-Adachigun, Saitama, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Utsunomiya, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Kochi, Japan|Kumamoto, Japan|Osaka, Japan|Amsterdam, Netherlands|Hoofddorp, Netherlands|Leeuwarden, Netherlands|Leiden, Netherlands|Aveiro, Portugal|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Hospitalet de Llobregat, Barcelona, Spain|Sabadell, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Chur, Graubünden, Switzerland|Genève, Switzerland|Ankara, Turkey|Instanbul, Turkey|Istanbul, Turkey|Izmir, Turkey","https://ClinicalTrials.gov/show/NCT01103323"
100,"NCT02278133","Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations","Completed","No Results Available","All","Phase 1|Phase 2","20","Industry","Interventional","December 2014","May 31, 2016","June 23, 2017","October 29, 2014","null","October 9, 2017","Memorial Sloan-Kettering Cancer Center (MSKCC) MSKCC (3), New York, New York, United States|Medical University of South Carolina Oncology Dept, Charleston, South Carolina, United States|University of Texas/MD Anderson Cancer Center Onc. Dept,, Houston, Texas, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc, Madison, Wisconsin, United States|Array BioPharma Investigative Site, Parkville, Victoria, Australia|Array BioPharma Investigative Site, Leuven, Belgium|Array BioPharma Investigative Site, Edmonton, Alberta, Canada|Array BioPharma Investigative Site, Vancouver, British Columbia, Canada|Array BioPharma Investigative Site, Toronto, Ontario, Canada|Array BioPharma Investigative Site, Bordeaux, France|Array BioPharma Investigative Site, Marseille, France|Array BioPharma Investigative Site, Tel-Aviv, Israel|Array BioPharma Investigative Site, Milano, MI, Italy|Array BioPharma Investigative Site, Amsterdam, Netherlands|Array BioPharma Investigative Site, Singapore, Singapore|Array BioPharma Investigative Site, Barcelona, Catalunya, Spain|Array BioPharma Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Array BioPharma Investigative Site, Madrid, Spain|Array BioPharma Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02278133"
101,"NCT01973660","PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer","Completed","No Results Available","Female","Phase 2","151","Other|Industry","Interventional","October 2013","June 2016","December 2017","October 31, 2013","null","September 19, 2018","Hospital de Torrevieja, Torrevieja, Alicante, Spain|Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Consorcio Hospitalario Provincial de Castellón, Castelló de la Plana, Castellón, Spain|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain|Hospital Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Luis Alcanyís de Xàtiva, Xàtiva, Valencia, Spain|Hospital Universitario Infanta Cristina, Badajoz, Spain|Vall d'Hebron University Hospital, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Instituto Dexeus, Barcelona, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Arnau de Vilanova de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01973660"
102,"NCT00910091","The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer","Completed","Has Results","Female","Phase 2","73","Industry","Interventional","August 2009","January 2012","July 2013","May 29, 2009","September 30, 2015","September 30, 2015","Onze-Lieve-Vrouwzickenhuis-Campus Aalst, Aalst, Belgium|Centre Jules Bordet, Bruxelles, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|Sint Augustinus, Wilrijk, Belgium|Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Gynekologicko-porodnicka klinika, Praha, Czech Republic|Krajska zdravotni s.r.o. - Masarykova nemocnice Usti nad Labem, Usti nad Labem, Czech Republic|Hôpital Jean Minjoz, Besançon, France|Institut Bergonié, BORDEAUX cedex, France|Centre François Baclesse, CAEN cedex 05, France|Centre Oscar Lambret, LILLE cedex, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, MARSEILLE cedex 9, France|Institut Curie, Paris, France|CHU Poitiers, POITIERS cedex, France|Institut Jean Godinot, REIMS cedex, France|CHU Reims, Reims, France|Centre Eugène Marquis, Rennes, France|Centre Henri Becquerel, ROUEN cedex 1, France|Centre René Gauducheau, SAINT-HERBLAIN cedex, France|Institut Gustave Roussy, Villejuif, France|BAZ Megyei Kórház és Egyetemi Oktató Kórház, Sugártherápiás és Onkológiai Intézet, Miskolc, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Orvos-és Gyógyszerésztudományi Centrum, Szeged, Hungary|Daugavpils Regional Hospital, Daugavpils, Latvia|Piejuras Hospital, Oncologic Clinic, Liepaja, Latvia|Riga Eastern CUH - Latvian Oncology Centre, Department No 9, Riga, Latvia|Kauno universiteto medicinos kliniku onkologijos ligonine, Kaunas, Lithuania|Vilniaus universiteto Onkologijos institutas, Vilnius, Lithuania|Institutul Oncologic, Chisinau, Moldova, Republic of|Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland|Uniwersytet Medyczny, Poznan, Poland|Oddział Ginekologii Onkologicznej Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Centrum Onkologii Instytut Marii Sklodowskiej Curie, Warszawa, Poland|Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Russian Federation|Medical Radiology Research Center of RAMS, Obninsk, Russian Federation|GUZ ""Orenburg Regional Clinical Oncology Dispensary"", Orenburg, Russian Federation|Perm Regional Oncology Dispensary, Perm, Russian Federation|GUZ of Stavropol Territorial Clinical Oncological Dispensary, Pyatigorsk Branch, Pyatigorsk, Russian Federation|FGU ""Research Institute of Oncology named after N.N.Petrov"", Saint Petersburg, Russian Federation|Saint-Petersburg GUZ City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|OOO ""Sibmedcenter"", Tomsk, Russian Federation|H. Universitario Vall d´Hebron, Barcelona, Spain|H. Universitario 12 de Octubre, Madrid, Spain|H. Universitario Central de Asturias, Oviedo, Asturias, Spain|H. Clinico Universitario San Carlos, San Carlos - Madrid, Spain|Oblasnyi onkologichnyi klinichnyi dyspanser, misto Uzhgorod. Uzhgorods'kyi natsionalnyi universytet, Chernivtsi, Ukraine|DU ""Instytut medychnoi radiologii im. S.P. Grygorieva AMN Ukrainy"", Kharkiv, Ukraine|DU ""Natsionalnyi instytut raku"", m. Kyiv, Kyiv, Ukraine|Lvivskyi derzhavnyi onkologichnyi regionalnyi likuvalno-diagnostychnyi tsentr, Lviv, Ukraine|Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, United Kingdom|St James's University Hospital, Leeds, United Kingdom|University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom|University of Liverpool Clatterbridge Centre for Oncology, Liverpool, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00910091"
103,"NCT01111825","Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer","Completed","Has Results","All","Phase 1|Phase 2","99","Industry","Interventional","April 2010","July 2016","July 2016","April 28, 2010","November 7, 2017","September 26, 2018","Western Regional Medical Center, Inc., Goodyear, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States|Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States|Roskilde Hospital, Roskilde, Denmark|Institut Gustave Roussy, Villejuif, France|UNIMED Medical Institute, Wan Chai, Hong Kong|Hospital Universitario Sant Joan de Reus, Tarragona, Reus, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Edinburgh Cancer Center, Western General Hospital, Edinburgh, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01111825"
104,"NCT00846027","A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer","Completed","Has Results","Female","Phase 2","90","Industry","Interventional","January 2009","December 2011","January 2013","February 18, 2009","June 26, 2014","July 23, 2014","Elda, Alicante, Spain|Manresa, Barcelona, Spain|Cádiz, Cadiz, Spain|Las Palmas de Gran Canaria, Las Palmas, Spain|Alcorcon, Madrid, Spain|Marbella, Malaga, Spain|Vigo, Pontevedra, Spain|Sagunto, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Burgos, Spain|Cordoba, Spain|Granada, Spain|Granada, Spain|Huelva, Spain|Jaen, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Murcia, Spain|Sevilla, Spain|Sevilla, Spain|Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00846027"
105,"NCT01276379","Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab","Completed","No Results Available","All","Phase 2","221","Other","Interventional","January 2011","March 15, 2017","December 21, 2017","January 13, 2011","null","May 10, 2018","Hospital Provincial de Castellón, Castelló de la Plana, Castellón, Spain|Hospital Son Espases, Palma, Malllorca, Spain|Hospital Son Llàtzer, Palma, Mallorca, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital Infanta Cristina de Badajoz, Badajoz, Spain|Hospital de Barbastro, Barbastro, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital General Yagüe, Burgos, Spain|Hospital Sant Jaume de Calella, Calella, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital General Universitario de Elche, Elche, Spain|Hospital de Jaén, Jaén, Spain|Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Fundación Jimenez Díaz, Madrid, Spain|Hospital de Móstoles, Madrid, Spain|Hospital Universitario la Paz, Madrid, Spain|Hospital de Mataró, Mataró, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital de Navarra, Pamplona, Spain|Hospital de Sagunto, Sagunto, Spain|Mutua de Terrassa, Terrassa, Spain|Hospital Virgen de la Salud, Toledo, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01276379"
106,"NCT01188187","Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer","Completed","No Results Available","Male","Phase 3","1022","Industry","Interventional","November 2010","February 2014","June 2014","August 25, 2010","null","October 14, 2016","Teva Investigational Site 100, Birmingham, Alabama, United States|Teva Investigational Site 086, Los Angeles, California, United States|Teva Investigational Site 263, Los Angeles, California, United States|Teva Investigational Site 093, Marina del Rey, California, United States|Teva Investigational Site 097, San Diego, California, United States|Teva Investigational Site 090, Fort Collins, Colorado, United States|Teva Investigational Site 106, Fort Myers, Florida, United States|Teva Investigational Site 094, Port St. Lucie, Florida, United States|Teva Investigational Site 096, Atlanta, Georgia, United States|Teva Investigational Site 103, Baton Rough, Louisiana, United States|Teva Investigational Site 098, Ann Arbor, Michigan, United States|Teva Investigational Site 112, Detroit, Michigan, United States|Teva Investigational Site 032, Rochester, Minnesota, United States|Teva Investigational Site 204, Las Vegas, Nevada, United States|Teva Investigational Site 107, Cincinnati, Ohio, United States|Teva Investigational Site 266, Greensboro, South Carolina, United States|Teva Investigational Site 102, Myrtle Beach, South Carolina, United States|Teva Investigational Site 084, Memphis, Tennessee, United States|Teva Investigational Site 101, Nashville, Tennessee, United States|Teva Investigational Site 116, San Antonio, Texas, United States|Teva Investigational Site 059, Tyler, Texas, United States|Teva Investigational Site 063, Tyler, Texas, United States|Teva Investigational Site 047, Newport, Virginia, United States|Teva Investigational Site 104, Norfolk, Virginia, United States|Teva Investigational Site 029, Seattle, Washington, United States|Teva Investigational Site 862, Bonheiden, Belgium|Teva Investigational Site 860, Brussels, Belgium|Teva Investigational Site 864, Edegem, Belgium|Teva Investigational Site 863, Gent, Belgium|Teva Investigational Site 002, Calgary, Alberta, Canada|Teva Investigational Site 023, Edmonton, Alberta, Canada|Teva Investigational Site 118, Abbotsford, British Columbia, Canada|Teva Investigational Site 007, Surrey, British Columbia, Canada|Teva Investigational Site 001, Vancouver, British Columbia, Canada|Teva Investigational Site 085, Victoria, British Columbia, Canada|Teva Investigational Site 024, Winnipeg, Manitoba, Canada|Teva Investigational Site 028, Halifax, Nova Scotia, Canada|Teva Investigational Site 025, Hamilton, Ontario, Canada|Teva Investigational Site 108, Kingston, Ontario, Canada|Teva Investigational Site 091, Oshawa, Ontario, Canada|Teva Investigational Site 003, Ottawa, Ontario, Canada|Teva Investigational Site 004, Toronto, Ontario, Canada|Teva Investigational Site 087, Toronto, Ontario, Canada|Teva Investigational Site 026, Montreal, Quebec, Canada|Teva Investigational Site 027, Montreal, Quebec, Canada|Teva Investigational Site 551, Angers Cedex 9, France|Teva Investigational Site 552, Avignon, France|Teva Investigational Site 553, Grenoble, France|Teva Investigational Site 555, La Roche-sur-Yon Cedex, France|Teva Investigational Site 557, Marseille, France|Teva Investigational Site 558, Nice Cedex 2, France|Teva Investigational Site 560, Paris Cedex 05, France|Teva Investigational Site 559, Paris Cedex 15, France|Teva Investigational Site 561, Saint Herblain Cedex, France|Teva Investigational Site 566, Saint-Brieuc Cedex, France|Teva Investigational Site 562, Saint-Priest-en-Jarez Cedex, France|Teva Investigational Site 563, Toulouse, France|Teva Investigational Site 564, Vandoeuvre-les-Nancy Cedex, France|Teva Investigational Site 550, Villejuif, France|Teva Investigational Site 607, Aachen, Germany|Teva Investigational Site 609, Berlin, Germany|Teva Investigational Site 613, Berlin, Germany|Teva Investigational Site 604, Darmstadt, Germany|Teva Investigational Site 612, Dresden, Germany|Teva Investigational Site 618, Greifswald, Germany|Teva Investigational Site 600, Hannover, Germany|Teva Investigational Site 606, Heidelberg, Germany|Teva Investigational Site 615, Heinsberg, Germany|Teva Investigational Site 611, Homburg/Saar, Germany|Teva Investigational Site 617, Kempen, Germany|Teva Investigational Site 608, Marburg, Germany|Teva Investigational Site 616, Meiningen, Germany|Teva Investigational Site 614, Muenchen, Germany|Teva Investigational Site 601, Muenster, Germany|Teva Investigational Site 602, Nuertingen, Germany|Teva Investigational Site 603, Stuttgart, Germany|Teva Investigational Site 610, Tuebingen, Germany|Teva Investigational Site 605, Wuppertal, Germany|Teva Investigational Site 691, Budapest, Hungary|Teva Investigational Site 694, Budapest, Hungary|Teva Investigational Site 692, Debrecen, Hungary|Teva Investigational Site 697, Debrecen, Hungary|Teva Investigational Site 696, Gyor, Hungary|Teva Investigational Site 698, Miskolc, Hungary|Teva Investigational Site 699, Nyiregyhaza, Hungary|Teva Investigational Site 693, Szeged, Hungary|Teva Investigational Site 695, Veszprem, Hungary|Teva Investigational Site 506, Jerusalem, IL, Israel|Teva Investigational Site 507, Haifa, Israel|Teva Investigational Site 505, Petach Tikva, Israel|Teva Investigational Site 502, Ramat Gan, Israel|Teva Investigational Site 503, Tel Aviv, Israel|Teva Investigational Site 501, Zrifin, Israel|Teva Investigational Site 753, Arezzo, Italy|Teva Investigational Site 758, Catanzaro, Italy|Teva Investigational Site 760, Cesena (FC), Italy|Teva Investigational Site 752, Genova, Italy|Teva Investigational Site 755, Lugo (Ravenna), Italy|Teva Investigational Site 759, Meldola (FC), Italy|Teva Investigational Site 763, Milano, Italy|Teva Investigational Site 754, Napoli, Italy|Teva Investigational Site 756, Napoli, Italy|Teva Investigational Site 761, Rimini, Italy|Teva Investigational Site 750, Roma, Italy|Teva Investigational Site 762, Roma, Italy|Teva Investigational Site 764, Rozzano (MI), Italy|Teva Investigational Site 765, Verona, Italy|Teva Investigational Site 404, Cheongju,Chungbuk, Korea, Republic of|Teva Investigational Site 401, Goyang-si Gyeonggi-do, Korea, Republic of|Teva Investigational Site 400, Seoul, Korea, Republic of|Teva Investigational Site 402, Seoul, Korea, Republic of|Teva Investigational Site 403, Seoul, Korea, Republic of|Teva Investigational Site 406, Seoul, Korea, Republic of|Teva Investigational Site 405, Yangsan-si, Korea, Republic of|Teva Investigational Site 851, Amsterdam, Netherlands|Teva Investigational Site 852, Rotterdam, Netherlands|Teva Investigational Site 853, Sittard-Geleen, Netherlands|Teva Investigational Site 803, Barcelona, Spain|Teva Investigational Site 808, Barcelona, Spain|Teva Investigational Site 809, Barcelona, Spain|Teva Investigational Site 816, Dos Hermanas, Spain|Teva Investigational Site 814, El Palmar, Spain|Teva Investigational Site 807, Guadalajara, Spain|Teva Investigational Site 800, Madrid, Spain|Teva Investigational Site 801, Madrid, Spain|Teva Investigational Site 806, Madrid, Spain|Teva Investigational Site 813, Madrid, Spain|Teva Investigational Site 815, Manresa, Spain|Teva Investigational Site 810, Murcia, Spain|Teva Investigational Site 811, Palma de Mallorca, Spain|Teva Investigational Site 805, Pamplona, Spain|Teva Investigational Site 804, Sabadell - Barcelona, Spain|Teva Investigational Site 802, Valencia, Spain|Teva Investigational Site 704, Brighton, United Kingdom|Teva Investigational Site 701, Cambridge, United Kingdom|Teva Investigational Site 709, Coventry, United Kingdom|Teva Investigational Site 705, Guildford, Surrey, United Kingdom|Teva Investigational Site 703, Manchester, United Kingdom|Teva Investigational Site 700, Surrey, United Kingdom|Teva Investigational Site 710, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01188187"
107,"NCT00952497","A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer","Completed","No Results Available","All","Phase 2","48","Industry","Interventional","June 2009","October 2011","January 2012","August 6, 2009","null","February 8, 2012","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Central Georgia Cancer Care, P.C., Macon, Georgia, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Hospital Vall d' Hebron, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain","https://ClinicalTrials.gov/show/NCT00952497"
108,"NCT01629615","A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer","Completed","No Results Available","All","Phase 2","50","Other|Industry","Interventional","June 2012","October 2015","October 2015","June 27, 2012","null","April 19, 2018","Dana-Farber at Faulkner Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Hospital Universitario Vall d´Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01629615"
109,"NCT00934856","A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer","Completed","Has Results","All","Phase 1|Phase 2","98","Industry","Interventional","July 2009","October 2013","October 2013","July 8, 2009","April 6, 2017","April 6, 2017","Charlotte, North Carolina, United States|Houston, Texas, United States|Dijon, France|Saint Herblain, France|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Dundee, United Kingdom","https://ClinicalTrials.gov/show/NCT00934856"
110,"NCT00851084","Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer","Completed","Has Results","All","Phase 2","268","Industry","Interventional","February 2009","April 2011","January 2012","February 25, 2009","June 25, 2013","June 7, 2016","Sanofi-Aventis Investigational Site Number 036004, Douglas, Australia|Sanofi-Aventis Investigational Site Number 036001, Hunter Region Mail Centre, Australia|Sanofi-Aventis Investigational Site Number 036003, Hunter Region Mail Centre, Australia|Sanofi-Aventis Investigational Site Number 276003, Berlin, Germany|Sanofi-Aventis Investigational Site Number 276007, Dresden, Germany|Sanofi-Aventis Investigational Site Number 276001, Hannover, Germany|Sanofi-Aventis Investigational Site Number 276006, Homberg, Germany|Sanofi-Aventis Investigational Site Number 276004, Mannheim, Germany|Sanofi-Aventis Investigational Site Number 276002, Münster, Germany|Sanofi-Aventis Investigational Site Number 276005, Recklinghausen, Germany|Sanofi-Aventis Investigational Site Number 380005, Bari, Italy|Sanofi-Aventis Investigational Site Number 380001, Firenze, Italy|Sanofi-Aventis Investigational Site Number 380002, Milano, Italy|Sanofi-Aventis Investigational Site Number 380003, Taormina, Italy|Sanofi-Aventis Investigational Site Number 380004, Torino, Italy|Sanofi-Aventis Investigational Site Number 410003, Busan, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410004, Cheongju, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410005, Daegu, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410002, Daejeon, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410007, Goyang-Si, Gyeonggi-Do, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410006, Seoul, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410001, Seoul, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410008, Ulsan, Korea, Republic of|Sanofi-Aventis Investigational Site Number 643002, Pyatigorsk, Russian Federation|Sanofi-Aventis Investigational Site Number 643005, Saint-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643001, Sochi, Russian Federation|Sanofi-Aventis Investigational Site Number 724005, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724004, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724001, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724002, Sabadell, Spain|Sanofi-Aventis Investigational Site Number 724007, Santiago De Compostela, Spain|Sanofi-Aventis Investigational Site Number 724003, Valencia, Spain|Sanofi-Aventis Investigational Site Number 826004, Leeds, United Kingdom|Sanofi-Aventis Investigational Site Number 826001, Leicester, United Kingdom|Sanofi-Aventis Investigational Site Number 826002, Manchester, United Kingdom|Sanofi-Aventis Investigational Site Number 826003, Slough, United Kingdom|Sanofi-Aventis Investigational Site Number 826005, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00851084"
111,"NCT01669252","Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer","Completed","No Results Available","All","Phase 2","163","Other|Industry","Interventional","August 2012","June 2015","June 2015","August 20, 2012","null","November 6, 2017","Institut Gustave Roussy, Villejuif, France|Klinikum des Landkreises Deggendorf Frauenklinik Mammazentrum, Deggendorf, Germany|Brustzentrum im Krankenhaus Köln-Holweide Priv. Doz., Köln, Germany|Brustzentrum der Universität München, Munic, Germany|Klinikum Südstadt Rostock, Universitätsfrauenklinik und Poliklinik, Rostock, Germany|Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE, Coimbra, Portugal|Hospital da Luz, Lisboa, Portugal|Instituto Portugues de Oncologia de Porto Francisco Gentil, EPE, Porto, Portugal|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Spain|Complejo Hospitalario de Castellón, Castelló de la Plana, Spain|Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Marina Salud de Denia, Denia, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitari Sant Joan de Reus, Reus, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital de Torrevieja, Torrevieja, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Hospital Universitario Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01669252"
112,"NCT00988208","Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer","Completed","Has Results","Male","Phase 3","1059","Industry","Interventional","November 11, 2009","January 13, 2012","November 28, 2016","October 2, 2009","September 5, 2013","April 4, 2018","Hematology Oncology Associates, Phoenix, Arizona, United States|Northern AZ Hematology and Oncology Assoc, Sedona, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|City of Hope Cancer Center, Duarte, California, United States|Southwest Cancer Center - Escondido, Escondido, California, United States|Scripps Cancer Center - Clinical Research, La Jolla, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|The Angeles Clinc and Research Institute, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|Prostate Oncology Specialists, Marina Del Rey, California, United States|Stanford University Medical Center, Stanford, California, United States|Rocky Mountain Cancer Centers-Colorado Springs Circle, Colorado Springs, Colorado, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Melbourne Internal Medicine Associates, Melbourne, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Cancer Institute - New Hope, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, P.A.- West Gore Street, Orlando, Florida, United States|South Florida Oncology - Hematology, Tamarac, Florida, United States|Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, United States|Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States|Lutheran General Hospital, Park Ridge, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Hematology and Oncology Specialist, LLC, Metairie, Louisiana, United States|Maryland Oncology Hematology PA, Columbia, Maryland, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Summit Medical Group Overlook Oncology Center, Berkeley Heights, New Jersey, United States|Hematology-Oncology Associates of NNJ, P, Morristown, New Jersey, United States|Hematology Oncology Associates of South Jersey, Mount Holly, New Jersey, United States|New York Oncology Hematology P.C., Albany, New York, United States|Columbia Univ Medical Center, New York, New York, United States|Weill Cornell Medical College Dr. Feldman's Office, New York, New York, United States|New Bern Cancer Care, New Bern, North Carolina, United States|Cancer Centers of North Carolina, Raleigh, North Carolina, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Northwest Cancer Specialists-Tualatin, Tualatin, Oregon, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Cancer Center of the Carolinas, Greer, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Sarah Cannon Research Institute UK, Nashville, Tennessee, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology, PA, Austin, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A.-Fort Worth, Fort Worth, Texas, United States|Longview Cancer Center, Longview, Texas, United States|Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A. - Paris, Paris, Texas, United States|Southlake Oncology, Southlake, Texas, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, United States|Texas Oncology Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology-Texoma Cancer Center, Wichita Falls, Texas, United States|Veterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, United States|Cancer Outreach Associates, Abingdon, Virginia, United States|Fairfax Northern Virginia Hematology Oncology, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|VA Puget Sound HCS Seattle Division, Seattle, Washington, United States|Evergreen Hematology and Oncology, Spokane, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|Chris O'Brien Lifehouse, Camperdown, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Port Macquarie Base Hospital, Port Macquarie, Australia|Redcliffe Hospital, Redcliffe, Australia|Royal North Shore Hospital, St Leonards, Australia|Newcastle Calvary Mater Hospital, Waratah, Australia|Westmead Hospital, Westmead, Australia|Border Medical Oncology, Wodonga, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medical University of Graz, Graz, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Krankenhaus der Barmherzigen Brueder, Vienna, Austria|Medizinische Universitat Wien, Vienna, Austria|ZNA Middelheim, Antwerpen, Belgium|Hopital Erasme, Brussels, Belgium|Edith Cavell Clinic, Bruxelles, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|The Health Institute for Men CMX Research Inc, Toronto, Ontario, Canada|Les Urologues Specialises, Montreal, Quebec, Canada|Krajska zdravotni, a.s. Nemocnice Chomutov, o.z., Chomutov, Czechia|Fakultni nemocnice Motol, Prague 5, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad La, Usti Nad Labem, Czechia|Arhus Universitets hospital, Aarhus C, Denmark|Herlev Hospital, Herlev, Denmark|Rigshospitalet University Hospital, Kobenhavn, Denmark|Odense Universitetshospital, Odense C, Denmark|CRLCC Paul Papin, Angers 49, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Centre Georges Francois Leclerc, Dijon Cedex, France|Clinique Victor Hugo, Le Mans, France|Centre Oscar Lambret, Lille 59, France|Centre Leon Berard, Lyon, France|Clinique de Valdegour, Nimes, France|CHU de Poitiers, Poitiers Cedex, France|Centre Eugene Marquis, Rennes Cedex, France|CRLCC Centre Rene Gauducheau, Saint Herblain 44, France|Institut de Cancerologie de la Loire, Saint Priest En Jaroz, France|Hopital Civil de Strasbourg, Strasbourg, France|CHRU Hopital Bretonneau, Tours Cedex, France|Institut Gustave Roussy, Villejuif, France|Vivantes Klinikum am Urban, Berlin, Germany|Medizinisches Zentrum Bonn-Friedensplatz, Bonn, Germany|Diakonissenkrankenhaus Dessau gGmbH, Dessau-Rosslau, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Krankenhaus Nordwest, Frankfurt a.M., Germany|Onkologische Praxis Freiburg, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany|IORC- Innovation Onkologie Research and Consulting GmbH, Hamburg, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany|Vituro GmbH & Co KG, Leipzig, Germany|TU München - Klinikum rechts der Isar, München, Germany|Universitaetsklinikum Muenster, Münster, Germany|University-Hospital Tübingen, Tuebingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Alexandra General Hospital of Athens, Athens, Greece|Agioi Anargyroi Hospital, Athens, Greece|University Hospital of Larissa, Larissa, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|Fovarosi Onkirmanyzat Peterfy S.Utcai Korhaz-Rend.Int es Baleseti Kozp., Budapest, Hungary|Fovarosi Onkormanyzat Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Pecsi Tudomanyegytem Altalanos Orvostudomanyi Kar, Pecs, Hungary|The Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Ordine Mauriziano, Candiolo, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy|Ospedale Vito Fazzi, Lecce, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy|Ospedale di Mirano, Mirano (VE), Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Ospedale degli Infermi di Rimini, Rimini, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Miserico, Udine, Italy|Hospital Angeles Lindavista, D.f, Df, Mexico|Consultorio de Especialidad en Urologia Privado, Durango, DGO, Mexico|Hospital Fatima, Sinaloa, SIN, Mexico|Consultorio Privado- Dr Jose Arturo Rodriguez Rivera, Zapopan, JAL, Mexico|VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arhem, Netherlands|Amphia Ziekenhuis Molengracht, Breda, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Gemini Ziekenhuis, Den Helder, Netherlands|Albert Schweitzer Ziekenhuis Amstelwijck, Dordrecht, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Twee Steden Ziekenhuis Tilburg, Tilburg, Netherlands|VieCuri Medisch Centrum Venlo, Venlo, Netherlands|Isala Klinieken, Zwolle, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Regionalny Osrodek Onkologiczny WSS im. M. Kopernika, Lodz, Poland|ZOZ MSWiA z Warminsko- Mazurskim Centrum Onkologii, Olsztyn, Poland|NZOZ Olsztynski Osr. Onkologiczny Kopernik Sp.z o.o, Olsztyn, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, Poland|Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland|4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw, Poland|Moscow Oncology Clinical Dispensary 1, Moscow, Russian Federation|Medical Radiology Research Centre RAMS, Obninsk, Russian Federation|State Institution of Heath Omsk Regional Oncology Dispensary, Omsk, Russian Federation|Russian Scientific Center for Radiology and Surgical Technol, St. Petersburg, Pesochny Vlg Saint Petersburg, Russian Federation|NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, Russian Federation|Oncology Dispensary 2 of Krasnodar Region, Sochi, Russian Federation|Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Groote Schuur Hospital, Cape Town, W Cape, South Africa|The Oncology Centre Durban, Durban, KZ-Natal, South Africa|Westridge Medical Centre, Durban, KZ-Natal, South Africa|Netcare Oncology and Interventional Centre, Goodwood, W Cape, South Africa|Dr. H. Malan, Polokwane, South Africa|Pretoria Urology Hospital, Pretoria, South Africa|Hospital del Mar, Barcelona, Spain|Hospital Durán i Reynals - Instituto Catalàn de Oncologìa ICO, Hospitalet de Llobregat, Barcelona, Spain|Hospital Arnau de Vilanova, Lérida, Spain|Hospital 12 de Octobre, Madrid, Spain|HCU Virgen de la Victoria, Malaga, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Mutua de Terrassa, Terrassa (Barcelona), Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Lanssjukhuset Ryhov, Jönköping, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|Centrallasarettet Vasteras, Västerås, Sweden|Clatterbridge Centre for Oncology NHS Trust, Bebington, Wirral, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|St George's Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie NHS Trust Hospital, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Northern Lincolnshire and Goole Hospitals NHS Foundation Trust, Scunthorpe, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT00988208"
113,"NCT01936363","Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer","Completed","Has Results","Female","Phase 2","65","Industry","Interventional","September 30, 2013","May 31, 2015","November 30, 2017","September 6, 2013","April 7, 2017","February 20, 2018","Research site, Augusta, Georgia, United States|Research site, Chicago, Illinois, United States|Research site, Indianapolis, Indiana, United States|Research site, Silver Spring, Maryland, United States|Research site, Boston, Massachusetts, United States|Research site, Boston, Massachusetts, United States|Research site, Ann Arbor, Michigan, United States|Research site, Detroit, Michigan, United States|Research site, Kansas City, Missouri, United States|Research site, Saint Louis, Missouri, United States|Research site, Kalispell, Montana, United States|Research site, New York, New York, United States|Research site, Cincinnati, Ohio, United States|Research site, Columbus, Ohio, United States|Research site, Middletown, Ohio, United States|Research site, Nashville, Tennessee, United States|Research site, Houston, Texas, United States|Research site, Northmead, New South Wales, Australia|Research site, Greenslopes, Queensland, Australia|Research site, Subiaco, Western Australia, Australia|Research site, Kortrijk, Belgium|Research site, Leuven, Belgium|Research site, Hamilton, Ontario, Canada|Research site, Toronto, Ontario, Canada|Research site, Montreal, Quebec, Canada|Research site, Montreal, Quebec, Canada|Research site, Quebec, Canada|Research site, Bordeaux Cedex, Gironde, France|Research site, Chorzow, Poland|Research site, Palma Mallorca, Baleares, Spain|Research site, Madrid, Spain|Research site, Madrid, Spain|Research site, Sevilla, Spain|Research site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01936363"
114,"NCT00678392","Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer","Completed","Has Results","All","Phase 3","723","Industry","Interventional","September 2008","August 2010","February 2016","May 15, 2008","March 27, 2012","March 24, 2017","East Valley Hematology and Oncology Medical Group, Burbank, California, United States|Maurice Berkowtiz, MD, Burbank, California, United States|Agajanian Institute of Oncology and Hematology, Downey, California, United States|Los Angeles Hematology/Oncology Medical Group, Glendale, California, United States|Ronald Regan UCLA Medical Center, Loa Angeles, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Drug Shipment: USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|LAC-USC Medical Center, Los Angeles, California, United States|USC Norris Cancer Hospital and Clinics, Los Angeles, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Metropolitan Hematology/Oncology Medical Group, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Agajanian Institute of Oncology and Hematology, Montebello, California, United States|Brian LeBerthon, MD, A Medical Corporation, West Covina, California, United States|Agajanian Institute of Oncology and Hematology, Whittier, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Denver: Division of Medical Oncology, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|Georgetown University Hospital, Lombardi Cancer Center, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Georgetwon University Medical Center (Drug Shipment Address), Washington, District of Columbia, United States|Florida Cancer Specialists, Bonita Springs, Florida, United States|Florida Cancer Specialists, Bradenton, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|University of Miami Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|Florida Cancer Specialists, Englewood, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States|Orlando Regional Medical Center, Orlando, Florida, United States|Florida Cancer Specialists, Port Charlotte, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Peachtree Hematology-Oncology Consultants, P.C., Atlanta, Georgia, United States|Chattanooga Oncology and Hematology Associates, PC, Ringgold, Georgia, United States|Mountain States Tumor Institute, Boise, Idaho, United States|Mountain States Tumor Institute, Fruitland, Idaho, United States|Mountain States Tumor Institute, Meridian, Idaho, United States|Mountain States Tumor Institute, Nampa, Idaho, United States|Mountain States Tumor Institute, Twin Falls, Idaho, United States|Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Cental Indiana Cancer Centers, Carmel, Indiana, United States|Central Indiana Cancer Centers, Fishers, Indiana, United States|Cental Indiana Cancer Centers, Greenfield, Indiana, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|St. John's Mercy Medical Center, St. Louis, Missouri, United States|St. John's Mercy, David C. Pratt Cancer Center, St. Louis, Missouri, United States|St. John's Mercy Medical Center, Washington, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Cancer Center at Hackensack University Medical Center - The Hillcrest Building, Hackensack, New Jersey, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Department of Medicine MSG @ SUNY HSC @ Syrcacuse, Inc., Oneida, New York, United States|Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc., Oswego, New York, United States|Suny Upstate Medical University, Syracuse, New York, United States|Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc, Syracuse, New York, United States|Raleigh Hematology Oncology Associates, DBA, Cary, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Investigational Chemotherapy Services, Durham, North Carolina, United States|Albermarie Hospitals, Elizabeth City, North Carolina, United States|Virginia Oncology Associates, Elizabeth City, North Carolina, United States|Raleigh Hematology Oncology Associates, P.C., Raleigh, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States|Ohio State University, Columbus, Ohio, United States|James Care in Kenny, Columbus, Ohio, United States|Monarch, Mayfield Heights, Ohio, United States|Lake University - Ireland Cancer Center (LUICC), Mentor, Ohio, United States|UHHS - Chagrin Highlands, Orange Village, Ohio, United States|UHHS - Westlake, Westlake, Ohio, United States|Oncology Associates of Oregon, P.C., Eugene, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Cancer Centers of the Carolinas, Easley, South Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Hematology and Oncology Associates of SC, LLC - Eastside Medical Center, Greenville, South Carolina, United States|Cancer Centers of the Carolinas, Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas, Spartanburg, South Carolina, United States|Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States|Chattanooga Oncology Hematology Associates P.C., Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Vanderbilt-Ingram Cancer Center-Cool Springs, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Chattanooga Oncology & Hematology Associates, Hixson, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology - Central Midtown, Austin, Texas, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncolgoy - Austin North, Austin, Texas, United States|Texas Oncology - Austin Northwest, Austin, Texas, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology - Cedar Park, Cedar Park, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Investigation Products Center (IPC), Fort Worth, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|Research Fulfillment Center (Drug Shipment only), Fort Worth, Texas, United States|US Oncology Research & Clinical Pharmacy (drug shipment only), Fort Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Fort Worth, Texas, United States|Genitourinary Cancer Center, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology - Seton Williamson, Round Rock, Texas, United States|Texas Oncology - Round Rock, Round Rock, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology - Clear Lake, Webster, Texas, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Virginia Cancer Specialists, PC, Woodbridge, Virginia, United States|Virginia Mason Medical Center, Section of Hematology/Oncology, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|The Canberra Hospital, Medical Oncology, Garran, Australian Capital Territory, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Ballarat Oncology & Haematology Services, Ballarat, Victoria, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Heidelberg Repatriation Hospital, Austin Health, Heidelberg West, Victoria, Australia|Austin Hospital, Austin Health, Heidelberg, Victoria, Australia|Med. Abt. KH Barmherzige Brueder Wien, Krankenhaus der Barmherzigen Brueder Wien, Wien, Austria|Universitaets-Klinik fuer Innere Medizin I, Wien, Austria|Clinica Oncologistas Associados, Rio de Janeiro, RJ, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita, Porto Alegre, RS, Brazil|Fundacao Pio XII Hospital de Cancer de Barretos, Barretos, SP, Brazil|Fundacao Antonio Prudente, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|RSM Durham Regional Cancer Centre Lakeridge Health Oshawa, Oshawa, Ontario, Canada|The Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|Beijing Cancer Hospital, Beijing, China|Sun Yet-Sen University Cancer Center, Guangzhou, China|Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China|Tianjin Oncology Hospital,biology treatment department, Tianjin, China|Centre Leon Berard, Lyon, Cedex 08, France|Hopital Saint-André, Bordeaux Cedex, France|Hôpital Henri Mondor, CRETEIL Cedex, France|Institut Paoli-Calmettes, Marseille Cedex 09, France|Hopital Europeen Georges Pompidou, Paris Cedex 15, France|Centre Eugene Marquis, Rennes, France|Centre Rene Gauducheau - Service Oncologie Medicale, St Herblain Cedex, France|CHRU de Tours - Hopital Bretonneau, Tours Cedex 1, France|Centre Alexis Vautrin, Vandoeuvre les Nancy, France|Institut Gustave Roussy / Service d'Immunotherapie, Villejuif Cedex, France|RWTH Aachen, Urologische Klinik, Aachen, Germany|Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany|Innere Klinik und Poliklinik fuer Tumorforschung, Universitaetsklinikum Essen, Essen, Germany|Klinikum Region Hannover Krankenhaus Siloah, Hannover, Germany|Klinikum der Johannes-Gutenberg-Universitaet, III. Medizinische Klinik und Poliklinik, Mainz, Germany|Ludwig-Maximilians-Universitaet Muenchen, Klinikum Grosshadern Urologische Klinik und Poliklinik, Muenchen, Germany|Klinikum Oldenburg gGmbH, Klinik fuer Innere Medizin II Onkologie / Haematologie, Oldenburg, Germany|Alexandra University Hospital / Oncology Dept., Athens, Attiki, Greece|""Theagenio""Cancer Hospital / 3rd. Dept. of Clinical Oncology, Thessaloniki, Macedonia, Greece|Fortis Memorial Research Institute, Gurgaon, Haryana, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Dept. of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India|Christian Medical College & Hospital, Ludhiana, Punjab, India|Bhagwan Mahaveer Cancer Hospital and Research Center, Jaipur, Rajasthan, India|Oncology Department, Dublin 24, Ireland|UOC Oncologia Medica, Ospedale San Donato, Arezzo, Italy|Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano (PN), Italy|Dipartimento dei laboratori diagnositici e per le terapie cellulari, Aviano (PN), Italy|Azienda Ospedaliera Spedali Civili di Brescia, Unita' Operativa Oncologia Medica, Brescia, Italy|Struttura Complessa di Oncologia, Cremona, Italy|UOC Oncologia Medica B, IRCCS AO Universitaria San Martino, Genova, Italy|Fondazione IRCCS, Istituto Nazionale dei Tumori, SC Oncologia Medica 2, Milano, Italy|Divisione di Oncologia, AORN Antonio Cardarelli, Napoli, Italy|Istituto per lo Studio e la Cura dei Tumori Fondazione Pascale, Napoli, Italy|Unita' Operativa Oncologia Medica 2, Regione del Veneto, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Struttura Complessa di Oncologia Medica A, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Oncologia Medica, Padiglione Flajani, I piano, Roma, Italy|UO di Oncologia ed Ematologia, Istituto Clinico Humanitas, Rozzano (MI), Italy|Sapporo Medical University School of Medicine, Sapporo-shi, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|University of Tsukuba, Graduate School of Comprehensive Human Sciences, Department of Urology, Tsukuba, Ibaraki, Japan|Kinki University Hospital, Osakasayama, Osaka, Japan|Hamamatsu University School of Medicine, Hamamatsu-City, Shizuoka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|Tokyo Women's Medical University Medical Center East, Department of Urology, Arakawa-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi, Japan|Akita University Hospital, Akita, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu University Hospital, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto, Japan|Tokushima University, Tokushima, Japan|Yamagata University Hospital, Yamagata, Japan|National Cancer Center, Urologic Oncology Clinic, Center for Specific Organs Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Dong-A University Medical Center, Department of Medicine, Division of Hemato-Oncology, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Catholic University of Korea, Seoul St. Mary's Hospital, Department of Oncology, Seoul, Korea, Republic of|Centrum Medyczne HCP, Poznan, Wielkopolska, Poland|Wielkopolskie Centrum Onkologii im.Marii Sklodowskiej-Curie, Poznan, Wielkopolska, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Klinika Onkologii, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznan, Poland|Pracownia Tomografii Komputerowej, Poznan, Poland|Klinika Onkologii, Wojskowy Instytut Medyczny, Warszawa, Poland|Klinika Urologii i Onkologii Urologicznej, Wroclaw, Poland|Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia, Obninsk, Kaluga Region, Russian Federation|Cancer Research Center named after N.N. Blokhin, Biotherapy Department, Moscow, Russian Federation|Cancer Research Center named after N.N.Blokhin, Chemotherapy Department, Moscow, Russian Federation|Russian Research Center of Roentgenology and Radiology, Moscow, Russian Federation|The Main Clinical Hospital of the Ministry of Internal Affairs of Russian Federation, Moscow, Russian Federation|Moscow Research Institute of Oncology P.A. Herzen, Moscow, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|National Cancer Centre Singapore, Singapore, Singapore|Onkologicky Ustav sv. Alzbety, Bratislava, Slovakia|Narodny Onkologicky ustav, Bratislava, Slovakia|Nemocnica s poliklinikou Zilina, Zilina, Slovakia|Institut Catala D'Oncologia L'Hospitalet, L'hospitalet de Llobregat, Barcelona, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Vall D¿Hebron, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario Virgen de La Victoria, Malaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Universitetssjukhuset, Onkologiska kliniken, Linkoping, Sweden|Norrlands Universitetssjukhus, Onkologkliniken, Umea, Sweden|Onkologkliniken, Vaxjo, Sweden|Chang Gung Medical Foundation-Kaohsiung Branch, Kaohsiung Hsien, Taiwan|Taichung Veterans General Hospital, Department of Surgery, Taichung, Taiwan|Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|Royal Marsden Hospital, London, England, United Kingdom|Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Bebington, Wirral, United Kingdom|University of Birmingham, CRUK Institute for Cancer Studies, Birmingham, United Kingdom|Royal Bournemouth & Poole Hospitals, Bournemouth, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrooke`s Hospital, Cambridge, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Department of Medical Oncology, St. Bartholomew's Hospital, London, United Kingdom|University Department of Medical Oncology/Oxford Cancer Centre, Oxford, United Kingdom|Royal Marsden Hospital NHS Foundation Trust, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT00678392"
115,"NCT00974311","Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy","Completed","Has Results","Male","Phase 3","1199","Industry","Interventional","September 30, 2009","September 15, 2011","November 2, 2017","September 10, 2009","October 30, 2012","October 5, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Premiere Oncology of Arizona, Scottsdale, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Tower Cancer Research Foundation, Tower Hematology Oncology Medical Group, Beverly Hills, California, United States|USC Westside Prostate Cancer Center, Beverly Hills, California, United States|City of Hope, Duarte, California, United States|Cancer Center Oncology Medical Group, La Mesa, California, United States|LAC & USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|c/o Prostate Oncology Specialist, Inc., Marina Del Rey, California, United States|North County Oncology Medical Clinic, Inc,, Oceanside, California, United States|Medical Oncology Associates - SD, San Diego, California, United States|Sharp Memorial Hospital Investigational Pharmacy, San Diego, California, United States|Sharp Rees-Stealy, San Diego, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|City of Hope Medical Group, South Pasadena, California, United States|Stanford Hospital and Clinics Research Pharmacy, Stanford, California, United States|Stanford University Medical Center, Stanford, California, United States|Research Pharmacist, Aurora, Colorado, United States|University of Colorado Denver, Anschutz Cancer Pavilion, Aurora, Colorado, United States|C/O: Thomas Ferencz R.Ph., BCOP, New Haven, Connecticut, United States|Yale University School of Med, New Haven, Connecticut, United States|George Washington University-Medical Faculty Associates, Washington, District of Columbia, United States|Palm Beach Cancer Institute, Atlantis, Florida, United States|Palm Beach Cancer Institute, Palm Beach Gardens, Florida, United States|Palm Beach Cancer Institute, Wellington, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Peachtree Hematology-Oncology Consultants, P.C., Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital (MGH), Boston, Massachusetts, United States|Brigham & Women's Hospital (BWH), Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Institute, an affiliate of the UC San Diego Health System, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New Mexico Oncology Hematology Consultants, Ltd., Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Pharmaceutical Research Services, Durham, North Carolina, United States|Portland VA Medical Center, Portland, Oregon, United States|UPMC Cancer Centers, McKeesport, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Grand Strand Urology, Myrtle Beach, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Parkland Health and Hospital System, Dallas, Texas, United States|Texas Oncology, Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Virginia Cancer Institute, Mechanicsville, Virginia, United States|Virginia Cancer Institute, Midlothian, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Virginia Oncology Associates, Williamsburg, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Instituto Medico de Asistencia e Investigaciones S.A (IMAI Research), Buenos Aires, AR, Argentina|Instituto Oulton, Cordoba, Provincia DE Cordoba, Argentina|Clinica Universitaria Privada Reina Fabiola, Cordoba, Provincia DE Cordoba, Argentina|Policlinico Neuquen, Neuquen, Provincia DE Neuquen, Argentina|Policlinico Modelo de Cipolletti, Cipolletti, Provincia DE RIO Negro, Argentina|Instituto de Investigaciones Clinicas Cipolletti, Cipolletti, Provincia DE RIO Negro, Argentina|Sanatorio Mapaci, Rosario, Provincia DE Santa FE, Argentina|Instituto de Oncologia y Especialidades Medicas, Rosario, Provincia DE Santa FE, Argentina|Hospital Italiano Garibaldi, Rosario, Provincia DE Santa FE, Argentina|Centro de Diagnostico Dr. Enrique Rossi, Ciudad Autonoma de Buenos Aires, Argentina|Centro de Diagnostico Dr. Enrique Rossi, Ciudad Autonoma de Buenos Aires, Argentina|North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia|Sydney Cancer Centre, Concord, New South Wales, Australia|Mid North Coast Diagnostic Imaging, Port Macquarie, New South Wales, Australia|Port Macquarie Base Hospital Pharmacy, Port Macquarie, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Department of Medical Oncology, Randwick, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|PRP Diagnostic Imaging, Wentworthville, New South Wales, Australia|Sydney West Cancer Trials Centre, Department of Medical Oncology, Westmead, New South Wales, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Heart Care Partners, Auchenflower, Queensland, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Southern X-Ray Chermside, Chermside, Queensland, Australia|Cancer Care Services, Herston, Queensland, Australia|Icon Cancer Foundation, Milton, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Mater Private Cardiology, South Brisbane, Queensland, Australia|Queensland X-Ray, South Brisbane, Queensland, Australia|XRadiology, Toowong, Queensland, Australia|Department of Medical Oncology, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Peninsula Oncology Centre, Frankston, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Department of Medical Oncology, Nedlands, Western Australia, Australia|60 Eleanor St, Footscray, Australia|Western Hospital, Footscray, Australia|The Royal Melbourne Hospital, Victoria, Australia|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|ISOTOPIX Ambulatorium fuer, Vienna, Austria|Medical University of Vienna, Vienna, Austria|Cliniques Universitaires Saint- Luc, Brussels, Belgium|AZ Sint- Lucas, Ghent, Belgium|VZW Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge - Campus Kennedylaan, Kortrijk, Belgium|AZ Groeninge - Campus Sint Maarten, Kortrijk, Belgium|University Hospital Gasthuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Tom Baker Cancer Centre - Holy Cross Site, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Centre for the Southern Interior, Kelowna, British Columbia, Canada|B.C. Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Urology Specialists., Montreal, Quebec, Canada|Imagerie medicale de la Capitale, Quebec, Canada|CHU de Quebec, Quebec, Canada|Centre de rechereche clinique et evaluative en oncologie, Quebec, Canada|Hospital San Jose, Santiago, Chile|Instituto Nacional del Cancer, Santiago, Chile|Centro Investigacion Clinica del Sur, Temuco, Chile|Instituto Oncologico, Vina del Mar, Chile|Centre Paul Papin, Angers Cedex 9, France|Institut Bergonie, Bordeaux cedex, France|Centre Regional Francois Baclesse de lutte contre le cancer, Caen Cedex, France|Centre hospitalier de Cannes, Cannes Cedex, France|CHU Henri Mondor, Creteil, France|Centre Hospitalier Intercommunal Frejus-Saint Raphael, Frejus Cedex, France|Centre hospitalier departemental Vendee, LA Roche sur Yon, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Centre Leon Berard, Lyon Cedex 08, France|Groupement Hospitalier Edouard Herriot - Pavillon V, Lyon Cedex 3, France|Institut Paoli Calmettes, Marseille, France|Institut Curie, Paris, France|Hopital Europeen Georges Pompidou, Paris, France|Centre Hospitalier Lyon sud, Pierre Benite, France|CHU La Miletrie, Poitiers Cedex, France|Institut Jean Godinot, Reims Cedex, France|Centre Hospitalier, Saint Etienne Cedex 2, France|Institut de Cancerologie de la Loire, Saint Priest en Jarez, France|Centre d'Investigation Clinique, (CIE3), Saint-Etienne CEDEX 2, France|Centre Rene Gauducheau, SAINT-HERBLAIN Cedex, France|Hopital Foch, Suresnes Cedex, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Charite - Universitaetsmedizin Berlin-Campus Benjamin Franklin, Berlin, Germany|Gemeinschaftspraxis Fuer Nuklearmedizin, Berlin, Germany|Radiologische Gemeinschaftspraxis, Berlin, Germany|FacharztzentrumInnere Medizin, Berlin, Germany|Praxis Dr. Wolfgang Hoelzer, Berlin, Germany|Staedtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Technical University Dresden, Dresden, Germany|Martini-Klinik am UKE GmbH, Hamburg, Germany|Roentgenpraxis, Hamburg, Germany|Urologische Gemeinschaftspraxis Poppenbuettel, Hamburg, Germany|Medizinische Hochschule Hannover - Klinik fuer Urologie und Urologische Onkologie, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Universitaetsklinikum Mannheim, Mannheim, Germany|Universitaetsklinikum Muenster, Klinik fuer Klinische Radiologie, Muenster, Germany|Universitaetsklinikum Muenster, Klinik und Poliklinik fuer Nuklearmedizin, Muenster, Germany|Universitaetsklinikum Muenster, Klinik und Poliklinik fuer Urologie, Muenster, Germany|Abt.f.Diagnostische u. Interventionelle Radiologie, Tuebingen, Germany|Klinik fuer Urologie, Tuebingen, Germany|Nuklearmedizin, Tuebingen, Germany|Azienda Ospedaliero-Universitaria di Modena Policlinico, Via Del Pozzo 71, Modena, Italy|Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, TO, Italy|Azienda Ospedaliera ""Istituti Ospitalieri"" di Cremona, Cremona, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|VU Medisch Centrum, Amsterdam, Netherlands|UMC St. Radboud, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Regionalny Szpital Specjalistyczny im. Dr. Wladyslawa Bieganskiego, Grudziadz, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Regionalny Osrodek Onkologiczny, Lodz, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland|Wojewodzki szpital specjalistyczny im. Janusza Korczaka, Slupsk, Poland|Hopelands Cancer Centre, Durban, South Africa|GVI Oncology, Port Elizabeth, South Africa|Sandton Oncology Centre, Sandton, South Africa|Hospital Universitario Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Radiodiagnostic Cetir Clinica Pilar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Bishops Wood Hospital, Northwood, Middlesex, United Kingdom|Mount Vernon Hospital, Northwood, Middlesex, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Cancer Centre, Birmingham, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|University College Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom|Churchill Hospital, Oxford, United Kingdom|The Manor Hospital Oxford, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT00974311"
116,"NCT01262014","Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer","Completed","No Results Available","Female","Phase 2","28","Other","Interventional","December 2010","February 2014","December 2015","December 17, 2010","null","August 11, 2016","H. Alcorcón, Alcorcón, Spain|H. de la Santa Creu i Sant Pau, Barcelona, Spain|H Vall d'Hebron, Barcelona, Spain|H. Clínic Barcelona, Barcelona, Spain|H Reina Sofía Cordoba, Cordoba, Spain|Intitut Català d' Oncolgia L' Hospitalet, Hospitalet de LLobregat, Spain|HGU Gregorio Marañón, Madrid, Spain|Centro Oncológico MD Anderson Spain, Madrid, Spain|H Ramón y Cajal de Madrid, Madrid, Spain|H Madrid. Centro Integral Oncológico Clara Campal, Madrid, Spain|H de Sant Joan de Deu, Manresa, Spain|H Morales Meseguer, Murcia, Spain|H Son Dureta, Palma de Mallorca, Spain|H Son Llatzer, Palma de Mallorca, Spain|H. Parc Taulí, Sabadell, Spain|H Marqués de Valdecilla, Santander, Spain|H La Fe de Valencia, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|H General de Valencia, Valencia, Spain|H Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01262014"
117,"NCT00849667","Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse","Completed","No Results Available","Female","Phase 3","1100","Industry","Interventional","April 2009","December 2012","April 2013","February 24, 2009","null","July 20, 2015","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Oncology Specialties, PC, Huntsville, Alabama, United States|Arizona Hematology & Oncology Associates, Phoenix, Arizona, United States|St. Joseph's Hospital, Barrow Neurology Clinics, Phoenix, Arizona, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Providence St. Joseph Medical Center, Burbank, California, United States|California Cancer Care, Inc., Greenbrae, California, United States|University of California San Diego, La Jolla, California, United States|University of California Los Angeles Medical Center, Los Angeles, California, United States|Gynecologic Oncology Associates, Newport Beach, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Catholic Health Initiatives, Colorado Springs, Colorado, United States|Denver Health and Hospital Authority, Denver, Colorado, United States|Hematology Oncology P.C., Stamford, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|University Cancer Institute, Boynton Beach, Florida, United States|Gainsville Hematology Oncology Associates, Gainesville, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Jupiter Medical center Physician's Group, Jupiter, Florida, United States|Hematology/Oncology Associates, Lake Worth, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Florida Hospital, Orlando, Florida, United States|Sarasota Memorial Healthcare System, Sarasota, Florida, United States|Gulfcoast Oncology, St. Petersburg, Florida, United States|Oncology-Hematology Associates of W. Broward P.A., Tamarac, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Medical College of Georgia, Augusta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kaiser Permanente - Moanalua Medical Center, Honolulu, Hawaii, United States|Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, United States|Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|St. Francis Hospital & Health Centers, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|Central Baptist Hospital, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Norton Healthcare, Louisville, Kentucky, United States|Hematology & Oncology Specialists, Metairie, Louisiana, United States|John Hopkins University, Balitmore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Frederick Memorial Hospital, Frederick, Maryland, United States|Barbara Ann Kamanos Cancer Center, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Park Nicollet Institute, St. Louis Park, Minnesota, United States|Saint Francis Memorial Health Center, Grand Island, Nebraska, United States|Good Samaritan Hospital Cancer Center, Kearney, Nebraska, United States|The Center for Cancer and Hematologic Disease, Camden, New Jersey, United States|Hematology-Oncolgy Associates of NNJ-PA, Denville, New Jersey, United States|John Theurer Cancer Center at Hackensack University MC, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Cooper Cancer Institute, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Arena Oncology Associates, Lake Success, New York, United States|Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Piedmont Hematology & Oncology, Winston-Salem, North Carolina, United States|Catholic Health Initiatives, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Providence Oncology & Hematology Care, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Willamette Valley Cancer Center, Springfield, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|St. Luke's Hospital, Bethlehem, Pennsylvania, United States|Oncology Hematology Associates, DuBois, Pennsylvania, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Chattanooga's Program in Women's Oncology, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA, Austin, Texas, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology, PA, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|International Beneficence Clinical Research, L.L.C., Harlingen, Texas, United States|University of Texas Health Science Center at Houston Medical School, Houston, Texas, United States|South Texas Oncology and Hematology, PA, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|US Oncology Research, Wichita Falls, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Northern Virginia Pelvic Surgery Associates, Annandale, Virginia, United States|Peninsula Cancer Institute - Riverside Gynecology Oncology, Newport News, Virginia, United States|Harrison Bremerton Hematology and Oncology, Bremerton, Washington, United States|Providence Everett Medical Center, Everett, Washington, United States|Cancer Care Northwest-South, Spokane, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Aurora Health Care, West Allis, Wisconsin, United States|Hospital Zonal Especializado en Oncología de Lanús, Buenos Aires, Argentina|Consultorios Medicos Privados SA, Buenos Aries, Argentina|Fundación Sanatorio Güemes, Caba, Argentina|Clinica Universitaria Reina Fabiola, Códoba, Argentina|Instituto Medico Platense, La Plata, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Hospital Bocalandro, Loma Hermosa, Argentina|Centro Oncologico Integral, Mar Del Plata, Argentina|CER Instituto Medico, Quilmes, Argentina|Centro Médico San Roque, San Miguel de Tucuman, Argentina|Centro Medico de Alta Complejidad Cemac, San Salvador de Jujuy, Argentina|ISIS Centro Especializado de LUCE SA, Santa Fe, Argentina|Tweed Hospital, Tweed Heads, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|North Adelaide Oncology Clinical Trials, North Adelaide, South Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Landeskrankenhaus Villach, Villach, Austria|Kaiser-Franz-Josef Spital, Wien, Austria|Krankenhaus Wien-Hietzing, Wien, Austria|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge - Campus Maria's Voorzienigheid, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHU de Liège, Liège, Belgium|Sint-Augustinuskliniek, Wilrijk, Belgium|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Brazil|Instituto de Pesquisas Clínicas para Estudos Multicêntricos, Caxias do Sul, Brazil|Santa Casa da Misericórdia de Curitiba, Curitiba, Brazil|Instituto do Câncer do Ceará - ICC, Fortaleza, Brazil|Hosp. Araujo Jorge, Goiania, Brazil|Associação Hospital de Caridade Ijuí, Ijuí, Brazil|Clinica de Neoplasias Litoral, Itajai, Brazil|Hospital Amaral Carvalho, Jaú, Brazil|Liga Norte-Riograndense Contra o Câncer, Natal, Brazil|Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Clínica de Oncologia de Porto Alegre S/S Ltda, Porto Alegre, Brazil|Instituto Ribeirãopretano de Combate ao Câncer, Ribeirão Preto, Brazil|INCA - Instituto Nacional do Câncer, Rio de Janeiro - RJ, Brazil|Clínica Oncologistas Associados, Rio de Janeiro, Brazil|Hospital Santa Izabel - Santa Casa de Misericordia da Bahia, Salvador, Brazil|Clínica AMO - Assistência Multidiciplinar em Oncologia, Salvador, Brazil|Centro de Estudos de Oncologia da FMABC, Santo André, Brazil|Saúde ABC Serviços Médicos Hospitalares Ltda, Santo André, Brazil|Instituto do Câncer Arnaldo Vieira de Carvalho, São Paulo, Brazil|Certo Oncologia, São Paulo, Brazil|Hospital Premier, São Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cancer Center For The Southern Interior, Kelowna, British Columbia, Canada|British Columbia Cancer Agency, Surrey, British Columbia, Canada|BCCA, Vancouver, British Columbia, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Instituto de Terapias Oncologicas, Santiago, Chile|Instituto Clínico Oncológico del Sur, Temuco, Chile|Instituto Oncologico Ltda., Viña del Mar, Chile|Centre Régional de lutte contre le cancer Paul Papin, Angers Cedex 9, France|Centre Hospitalier Louis Pasteur, Le Coudray, France|Institut Paoli Calmettes, Marseille, France|Hôpital Saint Louis, Paris Cedex 10, France|Institut Jean Godinot - Centre de lutte contre le cancer, Reims, France|Helios Klinikum Berlin-Buch, Berlin-Buch, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Marien-Hospital Akademisches Lehrkrankenhaus, Düsseldorf, Germany|Frauenarztpraxis Dr. med. Gröll de Rivera, Ebersberg, Germany|Universitätsklinikum Essen, Essen, Germany|Krankenhaus Nordwest, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Kath. Marienkrankenhaus gGmbH, Hamburg, Germany|Universität Heidelberg, Heidelberg, Germany|St. Vincentius Kliniken Karlsruhe, Karlsruhe, Germany|Universitätsklinik Magdeburg, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Klinikum der Universität München - Innenstadt, München, Germany|Rotkreuzklinikum München, München, Germany|Klinikum Südstadt Rostock, Rostock, Germany|Klinikum Traunstein, Traunstein, Germany|University General Hospital of Heraklion, Heraklion, Crete, Greece|Alexandra Hospital, Athens, Greece|General Oncology Hospital Kifissias ""Oi Agioi Anargyroi"", Athens, Greece|University General Hospital of Patras, Patras, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Queen Mary Hospital, Pokfulam, Islands, Hong Kong|Tuen Mun Hospital, Tuen Mun, Hong Kong|Semmelweis Egyetem, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Petz Aladár Megyei Oktató Kórház, Gyor, Hungary|Bács-Kiskun Megyei Önkormányzat Kórháza, Kecskemét, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc, Hungary|Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelöintézet, Szolnok, Hungary|Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet, Veszprém, Hungary|Apollo Hospitals International Limited, Gandhinagar, Gujarat, India|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, Madhya Pradesh, India|Jehangir, Clinical Development Centre, Pune, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Dr. Kamakshi Memorial Hospital, Chennai, Tamil Nadu, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India|M.S Ramaiah Medical College and Teaching Hospital Ethical Review Board, Bangalore, India|Amrita Institute of Medical Sciences and Research Centre, Cochin, India|MNJ Institute of Oncology and Regional Cancer Centre, Hyderabaad, India|SK Soni Hospital, Jaipur, India|Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, India|Lakeshore Hospital, Kochi, India|Tata Memorial Hospital, Mumbai, India|Shatabdi Superspeciality Hospital, Nashik, India|Curie Manavata Cancer Centre, Nasik, India|All India Institute of Medical Sciences, New Delhi, India|Regional Cancer Centre, Trivandrum, India|Rambam Medical Center, Haifa, Israel|Linn Medical Center, Clalit Health Services, Haifa, Israel|Wolfson Centre, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|The Chaim Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Assaf Harofe Medical Center, Zerifin, Israel|Centro di Riferimento Oncologico, Aviano, Pordenone, Italy|Azienda Ospedaliera Santi Antonio, Biagio e Cesare Arrigo, Alessandria, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy|Centro di Ricerca e Formazione ad Alta Tecnologia nelle Scienze Biomediche, Campobasso, Italy|Azienda Ospedaliera Cannizzaro, Catania, Italy|Humanitas Centro Catanese di Oncologia, Catania, Italy|Azienda Ospedaliera Sant'Anna, Como, Italy|Ospedale di Faenza, Faenza, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Presidio Ospedaliero Vito Fazzi, Lecce, Italy|Ospedale Mater Salutis ULSS 21 della regione Veneto, Legnago, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST, Meldola, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Istituto Nazionale dei Tumori, Milano, Italy|Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy|Istituto Nazionale per lo studio e la cura dei tumori ""Fondazione Giovanni Pascale"", Napoli, Italy|Ospedale Sacro Cuore Don Calabria, Negrar, Italy|Istituto Oncologico Veneto, Padova, Italy|Ospedale Santa Maria della Misericordia di Perugia, Perugia, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Azienda Policlinico Umberto I, Roma, Italy|Policlinico Universitario ""A. Gemelli"", Roma, Italy|Azienda Ospedaliero-Universitaria di Udine, Udine, Italy|Akashi, Japan|Amagasaki, Japan|Chiba, Japan|Fukuoka, Japan|Hidaka, Japan|Hiroshima, Japan|Kagoshima, Japan|Kashiwa, Japan|Kawasaki, Japan|Koto-Ku, Japan|Kumamoto, Japan|Kure, Japan|Kurume, Japan|Matsuyama, Japan|Minato-Ku, Japan|Morioka, Japan|Nagoya, Japan|Nakano-Ku, Japan|Niigata, Japan|Okayama, Japan|Osakasayama, Japan|Osaka, Japan|Sapporo, Japan|Sendai, Japan|Shinjuku-Ku, Japan|Sunto-Gun, Japan|Tsukuba, Japan|Tsu, Japan|Yamagata, Japan|Yonago, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, In Cheon, Korea, Republic of|Cheil General Hospital & Women's Healthcare Center, Seoul, Korea, Republic of|Seoul national univercity hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Union Medica Quirurgica de Colima, Colima, Mexico|Triva Investigaciones Medicas Sociedad Anónima de Capital Variable, Morelia, Mexico|Hospital Regional de Veracruz, Veracruz, Mexico|VU Medisch Centrum, Amsterdam, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Orbis Medisch Centrum, Sittard-Geleen, Netherlands|Perpetual Succour Hospital, Cebu City, Cebu, Philippines|Cebu Gynecologic Cancer Care Clinic, Cebu, Philippines|Manila Doctors Hospital, Manila, Philippines|San Juan de Dios Hospital, Pasay City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|National Kidney and Transplant Institute, Quezon City, Philippines|Bialostockie Centrum Onkologii, Bialystok, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie oddzial w Gliwicach, Gliwice, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland|Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Olsztynski Osrodek Onkologiczny ""Kopernik"" Sp. z o.o., Olsztyn, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Pozna, Poznan, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3, Rybnik, Poland|Samodzielny Publiczny Szpital Kliniczny nr 2 PAM w Szczecinie, Szczecin, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Português de Oncologia Francisco Gentil, Centro Regional de Oncologia de Coimbra, EPE, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil (IPOLFG, EPE), Lisboa, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil (IPOPFG, EPE), Porto, Portugal|Hospital de São João, Porto, Portugal|Kursk Regional Oncology Centre, Kursk, Russian Federation|Russian Oncology Research Center named after N.N. Blokhin, Moscow, Russian Federation|Russian Oncology Research Center, Moscow, Russian Federation|Moscow Research Oncology Institute n.a. P.A.Gertsen, Moscow, Russian Federation|Medical Radiology Research Center of RAMS, Obninsk, Russian Federation|Ryazan Regional Clinical Oncology Dispensary, Ryazan, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Republican Clinical Oncology Center of Bashkortostan Republic Ministry of Healthcare, Ufa, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|Hospital Universitario Reina Sofia, Córdoba, Andalucía, Spain|Hospital Virgen del Rocio, Sevilla, Andalucía, Spain|Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Universitario Vall D'Hebron, Barcelona, Cataluna, Spain|Hospital Clinic i Provincial, Barcelona, Cataluña, Spain|Hospital de Mataró, Mataró, Cataluña, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Cataluña, Spain|Hospital Mutua de Terrassa, Terrassa, Cataluña, Spain|Hospital General Universitario de Elche, Elche, Comunidad Valenciana, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Comunidad Valenciana, Spain|Fundacion Hospital Alcorcon, Alcorcón, Madrid, Communidad de, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Communidad de, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Communidad de, Spain|Hospital 12 de Octubre, Madrid, Madrid, Communidad de, Spain|Hospital Clinico San Carlos, Madrid, Spain|Universität Zürich, Zürich, Switzerland|National Cheng Kung University Hosptial, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan|Municipal Institution of Cherkasy Regional Counsil ""Cherkasy Regional Oncology Dispensary"", Cherkasy, Ukraine|Chernivtsi Regional Clinical Oncology Dispansery, Chernivtsi, Ukraine|Kiev City Oncology Hospital, Kyiv, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Belfast City Hospital, Belfast, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Poole Hospital NHS Trust, Poole, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Clatterbridge Centre For Oncology, Wirral, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00849667"
118,"NCT01816594","NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer","Completed","No Results Available","Female","Phase 2","50","Industry|Other","Interventional","September 2013","February 2015","February 2015","March 22, 2013","null","September 23, 2015","Novartis Investigative Site, Concord NSW, New South Wales, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Düsseldorf, Nordrhein Westfalen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Gera, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Reus, Tarragona, Spain","https://ClinicalTrials.gov/show/NCT01816594"
119,"NCT01618370","Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases","Completed","No Results Available","Male","Phase 3","705","Industry","Interventional","July 22, 2012","August 13, 2014","February 28, 2016","June 13, 2012","null","March 31, 2017","Brugge, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Ottignies, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czech Republic|Ostrava, Czech Republic|Plzen - Bory, Czech Republic|Praha 4, Czech Republic|Praha 5, Czech Republic|Herlev, Denmark|København, Denmark|Odense, Denmark|Helsinki, Finland|HUS, Finland|Kuopio, Finland|Seinäjoki, Finland|Tampere, Finland|Angers Cedex 01, France|Avignon, France|Caen Cedex 5, France|Clermont Ferrand Cedex 1, France|Grenoble, France|La Roche Sur Yon Cedex, France|Lille Cedex, France|Lille, France|Montpellier Cedex, France|Montpellier, France|Paris Cedex 15, France|Paris, France|Paris, France|Poitiers Cedex, France|Saint Herblain, France|Suresnes, France|TOULOUSE cedex, France|Vandoeuvre les Nancy, France|Villejuif Cedex, France|Freiburg im Breisgrau, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Braunschweig, Niedersachsen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Recklinghausen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bremen, Germany|Hamburg, Germany|Magdeburg, Germany|Cork, Ireland|Dublin 6, Ireland|Galway, Ireland|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Zerifin, Israel|Napoli, Campania, Italy|Forlì, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Pordenone, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Brindisi, Puglia, Italy|Foggia, Puglia, Italy|Cagliari, Sardegna, Italy|Messina, Sicilia, Italy|Arezzo, Toscana, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Trento, Trentino-Alto Adige, Italy|Padova, Veneto, Italy|Treviso, Veneto, Italy|Verona, Veneto, Italy|Mexico, D.F., Distrito Federal, Mexico|México, Distrito Federal, Mexico|Alkmaar, Netherlands|Amsterdam, Netherlands|Leiden, Netherlands|Nijmegen, Netherlands|Zwolle, Netherlands|Bergen, Norway|Bodø, Norway|Lørenskog, Norway|Oslo, Norway|Oslo, Norway|Ålesund, Norway|Bialystok, Poland|Warszawa, Poland|Moscow, Russian Federation|Obninsk, Russian Federation|Santiago de Compostela, A Coruña, Spain|Córdoba, Andalucía, Spain|Hospitalet de Llobregat, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Santa Cruz de Tenerife, Canarias, Spain|Palma de Mallorca, Illes Baleares, Spain|Las Palmas de Gran Canaria, Las Palmas, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|León, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Málaga, Spain|Oviedo, Spain|Pamplona, Spain|Salamanca, Spain|Santander, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Eskilstuna, Sweden|Kalmar, Sweden|Karlstad, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umeå, Sweden|Uppsala, Sweden|Örebro, Sweden|Aarau, Aargau, Switzerland|Basel, Basel-Stadt, Switzerland|Chur, Graubünden, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bellinzona, Ticino, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Zürich, Switzerland|Cambridge, Cambridgeshire, United Kingdom|Romford, Essex, United Kingdom|Leicester, Leicestershire, United Kingdom|Edinburgh, Lothian, United Kingdom|Bebington, Merseyside, United Kingdom|Northwood, Middlesex, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Guildford, Surrey, United Kingdom|Sutton, Surrey, United Kingdom|Coventry, Warwickshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Aberdeen, United Kingdom|Belfast, United Kingdom|Bristol, United Kingdom|Cardiff, United Kingdom|Derby, United Kingdom|Glasgow, United Kingdom|Hull, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Plymouth, United Kingdom|Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01618370"
120,"NCT00915018","Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer","Completed","Has Results","Female","Phase 2","479","Industry","Interventional","August 21, 2009","August 2013","June 28, 2018","June 5, 2009","November 6, 2017","August 22, 2018","Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|North Broward Medical Center Cancer Center, Deerfield Beach, Florida, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Mid Florida Cancer Centers, Orange City, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|Phoebe Cancer Center, Albany, Georgia, United States|Dublin Hematology and Oncology Care, Dublin, Georgia, United States|Clintell, Skokie, Illinois, United States|Presence Hematology and Oncology, Skokie, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|CHRISTUS St. Frances Cabrini Hospital, Alexandria, Louisiana, United States|Hematology Oncology Services, Metairie, Louisiana, United States|Park Nicollet Institute, Saint Louis Park, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States|St. John's Medical Research Institute, Springfield, Missouri, United States|The Valley Hospital, Luckow Pavilion Office of Oncology Clinical Trials, Paramus, New Jersey, United States|Gaston Hematology and Oncology Associates, Gastonia, North Carolina, United States|Summa Health System Hospitals, Akron, Ohio, United States|Warren Cancer Research Foundation, Tulsa, Oklahoma, United States|Samaritan Hematology and Oncology Consultants, Corvallis, Oregon, United States|Pawtucket Memorial Hospital, Pawtucket, Rhode Island, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Santee Hematology Oncology, Sumter, South Carolina, United States|Tenessee Cancer Specialists, Knoxville, Tennessee, United States|Family Cancer Care, Memphis, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|El Paso Cancer Treatment Center, El Paso, Texas, United States|Texas Oncology-Allison Cancer Center, Midland, Texas, United States|Southlake Oncology, Southlake, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Charleston Area Medical Center, Health, Education, and Research Institute, Charleston, West Virginia, United States|The Queen Elizabeth Hospital, North Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Affinity Research Limited, Nassau, CB, Bahamas|N.N. Aleksandrov National Cancer Center of Belarus, Lesnoy, Minsk Region, Belarus|Institution Gomel Regional Clinical Oncology Dispensary, Gomel, Belarus|Institution of Healthcare Grodno Regional Clinical Hospital, Grodno, Belarus|Healthcare Institution Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Institut Jules Bordet, Brussels, Belgium|District Dispensary for Oncology Diseases Internal Unit- Plovdiv EOOD, Plovdiv, Bulgaria|District Dispensary for Oncology Diseases Internal Unit- Sofia EOOD, Sofia, Bulgaria|Specialised Hospital of ActiveTreatment in Oncology, Clinic of Chemotherapy, Sofia, Bulgaria|Hopital Charles, LeMoyne Le Centre Intégré de Cancérologie de la Montérégie, Greenfield Park, Quebec, Canada|Centre Hospitalier Régional de Trois-Rivières, Trois-Rivieres, Quebec, Canada|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, China|The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Cancer Hospital, Tian Jin, China|Clinical Hospital Osijek, Department of Radiotherapy and Oncology, Osijek, Croatia|University Hospital For Tumors, Zagreb, Croatia|Rigshospitalet, Copenhagen, Onkologisk Klinik, Copenhagen, Denmark|Hôpital Henri-Mondor, Creteil, France|Centre Leon Berard Departement de Cancerologie Medicale, Lyon, France|Centre Val d'Aurelle, Montpellier, France|Hopital Hotel Dieu, Service d'Oncologie Medicale, Bat B2, 5ieme, Paris, France|Hopital La Pitie-Salpetriere, Paris, France|Groupe Hospitalier Paris Saint Joseph, Oncologie medicale, Paris, France|Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, Perigueux, France|Clinique Armoricaine de Radiologie, St. Brieuc, France|Centre de Radiothérapie, Clinique Sainte Anne, Service d'Oncologie Libérale, Strasbourg, France|CHU Strasbourg Departement Oncologie & Hematologie Hopital Civil, Strasbourg, France|CHU Bretonneau, Centre Henry Kaplan, Tours, France|Sozialstiftung Bamberg Klinik fuer Haematologie und internistische Onkologie, Bamberg, Germany|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UNIMED Medical Institute, Comprehensive Centre for Breast Diseases, Wanchai, Hong Kong|Semmelweis Egyetem Radiologiai és Onkoterapias Klinika, Budapest, Hungary|Fovarosi Onkormanyzat Szent Imre Korhaz Klinikai Onkologiai Profil, Budapest, Hungary|Orszagos Onkologiai Intezet ""B"" Belgyogyaszati osztaly, Budapest, Hungary|Kaposi Mor Oktato Korhoz Onkologiai Centrum, Kaposvar, Hungary|Bacs-Kiskun Megyei Onkormanyzat Korhaza Onkoradiologiai Kozpont, Kecskemet, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc, Hungary|Szegedi Tudomanyegyetem Onkoterapias Klinika, Szeged, Hungary|Institute Rotary Cancer Hospital, AIIMS, New Delhi, Delhi, India|Jawaharlal Nehru Cancer Hospital, Bhopal, Madhya Pradesh, India|Tata Memorial Centre, Mumbai, Maharashtra, India|Central India Cancer Research Institute, Nagpur, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashilk, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Searoc Cancer Center, Jaipur, Rajasthan, India|Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India|B P Poddar and Medical Research Ltd., Kolkata, West Bengal, India|Kaplan Medical Center, Rehovot, Israel|Sourasky Medical Center, Tel Aviv, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Policlinico di Modena Oncologia ed Ematologia, Modena, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Policlinico Universitario Campus Bio-Medico, Roma, Italy|Ospedale San Pietro Fatebenefratelli, Roma, Italy|Ospedale San Giovanni Battista-Molinette, Torino, Italy|Hyogo Cancer Center, Hyogo, Akashi-shi, Japan|National Hospital Organization Beppu Medical Center, Oita, Beppu-shi, Japan|Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Bunkyo-ku, Japan|Chiba Cancer Center, Chiba, Chiba-shi, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka-shi, Japan|National Hospital Organization Mito Medical Center, Ibaraki, Higashiibaraki-gun, Japan|Hiroshima University Hospital, Hiroshima, Hiroshima-shi, Japan|Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, Kagoshima-city, Japan|National Cancer Center Hospital East, Chiba, Kashiwa-shi, Japan|Saitama Cancer Center, Saitama, Kitaadachi-gun, Japan|Kumamoto Municipal Hospital, Kumamoto, Kumamoto-city, Japan|Kurume Daiichi Social Insurance Hospital, Fukuoka, Kurume-Shi, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, Matsuyama-city, Japan|Iwate Medical University Hospital, Iwate, Morioka-shi, Japan|Aichi Cancer Center, Aichi, Nagoya-shi, Japan|National Hospital Organization Nagoya Medical Center, Aichi, Nagoya, Japan|Niigata Cancer Center Hospital, Niigata, Niigata-shi, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka-shi, Japan|National Hospital Organization Osaka National Hospital, Osaka, Osaka-shi, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Sapporo-shi, Japan|Tohoku University Hospital, Miyagi, Sendai-city, Japan|Tenri Hospital, Nara, Tenri-shi, Japan|Kanagawa Cancer Center, Kanagawa, Yokohama-City, Japan|Hiroshima City Hospital, Hiroshima, Japan|National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Shinko Hospital, Hyogo, Japan|Kumamoto University Hospital, Kumamoto, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Jichi Medical University Hospital, Tochigi, Japan|Toranomon Hospital, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Tokyo, Japan|National Cancer Center, Center for Breast Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Korea, Republic of|Yonsei University Health System Severance Hospital, Seoul, Seoul/Korea, Korea, Republic of|Piejuras Hospital, Liepajas Oncological Clinic, Liepaja, Latvia|Pauls Stradiņš Clinical University Hospital, Riga, Latvia|Riga Eastern University Hospital, Riga, Latvia|Hospital of Lithuanian University of Health sciences, Kaunas, Lithuania|Nacionalinis Vezio Institutas, Vilniaus Universiteto Onkologijos Institutas, Vilnius, Lithuania|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Sir Anthony Oncology Center, Floriana, Malta|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Wojewodzki Oddzial, Jelenia Gora, Dolnoslaskie, Poland|Magodent, Warszawa, Mazowieckie, Poland|Opolskie Centrum Onkologii, Opole, Opolskie, Poland|Zakład Opieki Zdrowotnej MSW z Warmińsko, Mazurskim Centrum Onkologii, Olsztyn, Warminsko-Mazurskie, Poland|Białostockie Centrum Onkologii, Bialystok, Poland|Hospital da Luz Servico de Oncologia Medica, Lisboa, Portugal|Institutul Oncologic Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Cluj, Romania|SC Oncolab S.R.L., Craiova, Dolj, Romania|Spitalul Universitar de Urgenta Bucuresti, Bucuresti, Romania|Institute of Oncology and Radiology of Serbia, Belgrade, Serbia|Clinical centre Nis Clinic of Oncology, Nis, Serbia|National University Hospital, National Cancer Institute, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|GVI Oncology, Port Elizabeth, Eastern Cape, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|University of Witwatersrand Oncology, Donald Gordon Medical Centre, Johannesburg, Gauteng, South Africa|Sandton Oncology Centre, Johannesburg, Gauteng, South Africa|Eastleigh Breast Care Centre, Pretoria, Gauteng, South Africa|Westridge Medical Centre, Durban, KwaZulu Natal, South Africa|GVI Oncology, Kraaifontein, Western Cape, South Africa|Hospital Universitari Arnau de Vilanova, Lleida, Cataluna, Spain|Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Galicia, Spain|Hospital Son Llàtzer, Palma, Illes Balears, Spain|Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain|Hospital Puerta De Hierro, Majadahonda, Madrid, Spain|Hospital Universitario Infanta Cristina, Parla, Madrid, Spain|Hospital Madrid Norte Sanchinarro Centro Integral Oncológico Clara Campal Ensayos Clínicos, Sanchinarro, Madrid, Spain|Hospital Costa del Sol, Marbella, Malaga, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Centro Oncologico MD Anderson, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Tumor Center Hirslanden Medical Center, Aarau, Switzerland|Spital STS AG Onkologiezentrum Thun - Berner Oberland, Thun, Switzerland|Kantonsspital Winterthur Medizinische Onkologie, Winterthur, Switzerland|Chang Gung Medical Foundation, Linkou Branch, Taoyuan, Taiwan|Ege Universitesi Tip Fakultesi Tulay Aktas Onkoloji Hastanesi, Bornova, Izmir, Turkey|Komunalnyy Zaklad Cherkasskyy Oblasnyy Onkologichnyy Dyspanser, Cherkassy, Ukraine|Chernivtsi Regional Oncology Centre Outpatient Department Bukovynian State Medical University Department of Oncology and Radiology, Chernivtsi, Ukraine|City Multifield Clinical Hospital, Dnipropetrovsk, Ukraine|Donetsk Regional Antitumor Center Department of Pretumor Diseases and Tumor Treatment, Donetsk, Ukraine|S.P. Grigoreva Institute of Medical Radiology Department of Chemotherapy, Kharkiv, Ukraine|National Institute of Cancer Department of Conseravtive Methods of Treatment, Kyiv, Ukraine|Volyn Regional Oncological Center, Lutsk, Ukraine|State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Mariupil Oncological Center, Mariupil, Ukraine|Sumy Regional Clinical Oncology Centre, Sumy, Ukraine|Guy's and St Thomas NHS Foundation Trust Management Offices 4th Floor Bermondsey Wing Guy's Hospital, London, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00915018"
121,"NCT01007942","Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer","Completed","Has Results","Female","Phase 3","569","Industry","Interventional","October 2009","June 2015","June 2015","November 4, 2009","April 5, 2017","April 5, 2017","University of Arizona / Cancer Center AZ Onc Assoc, Tucson, Arizona, United States|University of Arizona / Cancer Center Deptof Uof A/Arizona Cancer(3), Tucson, Arizona, United States|University of California San Diego - Moores Cancer Center La Jolla - UCSD Moores Cancer, La Jolla, California, United States|Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States|Georgetown University/Lombardi Cancer Center Dept.of Lombardi CancerCtr (3), Washington, District of Columbia, United States|Comprehensive Cancer Center - Boca Raton Deerfield Beach, Boca Raton, Florida, United States|Comprehensive Cancer Center - Boca Raton Dept.of BocaRatonCompCanCtr, Boca Raton, Florida, United States|Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States|Memorial Hospital Memorial Cancer Institute, Hollywood, Florida, United States|MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2), Orlando, Florida, United States|Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2), Atlanta, Georgia, United States|North Shore University Health System NSU, Evanston, Illinois, United States|Kansas City Cancer Center KCCC- South (2), Overland Park, Kansas, United States|Maryland Oncology Hematology, Owning Mills, Maryland, United States|Park Nicollet Institute Dept. of Park Nicollet, St. Louis Park, Minnesota, United States|St. Louis University Cancer Center SLU Cancer Center, St. Louis, Missouri, United States|University of Nebraska Medical Center Unv Nebraska Med Ctr (2), Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Las Vegas, Nevada, United States|Nevada Cancer Institute Dept. of Nevada Cancer (3), Las Vegas, Nevada, United States|Overlook Hospital - Carol G Simon Cancer Center Carol G Simon, Summit, New Jersey, United States|Clinical Research Alliance Dept.ofArenaOncologyAssoc(2), Lake Success, New York, United States|Duke University Medical Center Dept. of DUMC (2), Durham, North Carolina, United States|Northwest Cancer Specialists Tutlatin, Portland, Oregon, United States|University of Pittsburgh Cancer Institute DeptofMageeWomen'sHospital(2), Pittsburgh, Pennsylvania, United States|The Jones Clinic Dept .of The Jones Clinic (3), Germantown, Tennessee, United States|Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(6), Nashville, Tennessee, United States|Texas Cancer Center ( Medical City Dallas Hospital) Dept. of Texas Cancer Ctr. (2), Dallas, Texas, United States|Texas Oncology Presbyterian Hospital (2), Dallas, Texas, United States|Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States|Texas Oncology Texas Oncology - Sammons, Dallas, Texas, United States|Texas Oncology Midtown, Dallas, Texas, United States|University of Texas Southwestern Medical Center University of TX SW Med Ctr(2), Dallas, Texas, United States|University of Texas/MD Anderson Cancer Center SC-5, Houston, Texas, United States|Baylor College of Medicine Baylor, Houston, Texas, United States|Longview Cancer Center Longview Cancer Center (2), Longview, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States|Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler, Texas, United States|Utah Cancer Specialists Utah Cancer (2), Salt Lake City, Utah, United States|Virginia Cancer Specialists Fairfax No.VA (2), Fairfax, Virginia, United States|Virginia Oncology Associates Dept. of VOA (2), Norfolk, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute, Seattle, Washington, United States|Green Bay Oncology Green Bay Oncology, Green Bay, Wisconsin, United States|Novartis Investigative Site, C A B A, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Posadas, Misiones, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Southport, Queensland, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, East Bentleigh, Victoria, Australia|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Liège, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Sint-Niklaas, Belgium|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Novy Jicin, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Prague 5, Czech Republic|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Besançon cedex, France|Novartis Investigative Site, Hyères, France|Novartis Investigative Site, La Chaussée St Victor, France|Novartis Investigative Site, La Roche sur Yon Cedex, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Saint-Brieuc Cédex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Gerlingen, Germany|Novartis Investigative Site, Halle/Saale, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Recklinghausen, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Patra - RIO, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Sondrio, SO, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Maebashi-city, Gunma, Japan|Novartis Investigative Site, Sapporo, Hokkaido, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Ciudad De Mexico, Distrito Federal, Mexico|Novartis Investigative Site, León, Guanajuato, Mexico|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Jaen, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, La Laguna, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Fatih / Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Surrey, England, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT01007942"
122,"NCT00767520","Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer","Completed","Has Results","All","Phase 2","155","Industry","Interventional","February 2009","March 2011","December 2012","October 7, 2008","June 11, 2012","February 28, 2013","Compassionate Cancer Care Medical Group, Inc, Fountain Valley, California, United States|Compassionate Cancer Care Medical Group Inc, Riverside, California, United States|Pennsylvania Oncology/Hematology Associates, Philadelphia, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Prague 5, Czech Republic|Local Institution, Lille, France|Local Institution, Paris Cedex 13, France|Local Institution, Saint-Cloud Cedex, France|Local Institution, Dublin, Ireland|Local Institution, Gdansk, Poland|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Opole, Poland|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Torrevieja, Spain|Local Institution, Vasteras, Sweden|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Coventry, Warwickshire, United Kingdom","https://ClinicalTrials.gov/show/NCT00767520"
123,"NCT02301988","A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer","Completed","Has Results","Female","Phase 2","151","Industry|Other","Interventional","February 17, 2015","August 2, 2017","August 2, 2017","November 26, 2014","September 20, 2018","October 17, 2018","Arizona Oncology Associates, PC-CASA, Tucson, Arizona, United States|Sansum Medical Clinic, Inc., Santa Barbara, California, United States|Rocky Mountain Cancer Center - Lakewood (West), Lakewood, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mass General/North Shore Cancer, Danvers, Massachusetts, United States|Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Northwest Cancer Specialists - Portland (NE Hoyt St), Portland, Oregon, United States|Roper Bon Secours St. Francis Cancer Center, Charleston, South Carolina, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Texas Oncology-Tyler, Irving, Texas, United States|South Texas Cancer Center - McAllen, McAllen, Texas, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Son Llatzer; Servicio de Oncologia, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitari de Lleida Arnau de Vilanova, Lleida, Lerida, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón (Madrid), Madrid, Spain|Hospital Rey Juan Carlos; Pharmacy, Mostoles, Madrid, Spain|Hospital Regional Universitario Carlos Haya; hospital Materno Infantil, servicio de Farmacia, Málaga, Malaga, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain|Hospital Universitari Sant Joan de Reus; Servicio de Oncologia, Reus, Tarragona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia, Girona, Spain|Centro Oncologico MD Anderson International Espana, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Universitario de Fuenlabrada; Servicio de Oncologia, Madrid, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario; Oncologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02301988"
124,"NCT02273973","A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)","Completed","Has Results","Female","Phase 2","334","Industry|Other","Interventional","November 12, 2014","March 13, 2017","March 13, 2017","October 24, 2014","May 21, 2018","May 21, 2018","Breastlink Med Group Inc, Santa Ana, California, United States|MGH Cancer Center, Boston, Massachusetts, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|MSKCC @ Commack, Commack, New York, United States|MSKCC @ West Harrison, Harrison, New York, United States|Memorial Sloan-Kettering Cancer Center; Hematology/Oncology, New York, New York, United States|MSKC @ Rockville, Rockville Centre, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, Australia|Victorian Breast and Oncology Care, East Melbourne, Victoria, Australia|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie, Graz, Austria|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern ; Abt. f. Allgemein- und Viszeralchirurgie, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Brustzentrum - Ordination Dr. Wette, St. Veit/Glan, Austria|Klinikum Kreuzschwestern Wels; Iii. Interne Abt., Wels, Austria|Medizinische Universität Wien; Univ.Klinik für Chirurgie - Abt. für Allgemeinchirurgie, Wien, Austria|Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie, Wien, Austria|Krankenhaus Der Stadt Wien-Hietzing; Abt. Für Gynäkologie U. Geburtshilfe, Wien, Austria|Institut Jules Bordet, Brussels, Belgium|CHU Brugmann (Victor Horta), Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Instituto Brasileiro De Controle Do Câncer - IBCC; Laboratório De Patologia, São Paulo, SP, Brazil|Hospital Clinico Vina del Mar, Viña del Mar, Chile|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|MULTISCAN, s.r.o., Radiologicke centrum Pardubice, Pardubice, Czechia|Oblastni nemocnice Pribram, Pribram, Czechia|Hospital Oncologia; Oncology, Salvador, El Salvador|Centre Jean Perrin; Division De Recherche Clinique, Clermont Ferrand, France|Centre Jean Bernard, Le Mans, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis; Service Onco Thoracique, Paris, France|Centre Rene Huguenin; ONCOLOGIE GENETIQUE, Saint Cloud, France|CHI de Toulon - Hôpital Sainte Musse, Toulon, France|Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, Germany|Studienzentrum Berlin City, Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Evangelische Kliniken Gelsenkirchen GmbH; Brustzentrum, Gelsenkirchen, Germany|Universitätsklinikum Hamburg-Eppendorf (UKE); Klinik und Poliklinik für Gynäkologie, Hamburg, Germany|Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe, Hannover, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany|Rotkreuzklinikum München; Frauenklinik, Muenchen, Germany|Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe, Münster, Germany|Universitätsklinikum Ulm Am Michelsberg; Frauenklinik, Ulm, Germany|Marien-Hospital Witten; Frauenklinik Brustzentrum, Witten, Germany|Grupo Angeles, Guatemala City, Guatemala|Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, Guatemala|Szent Margit Hospital; Dept. of Oncology, Budapest, Hungary|Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary|Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont, Kecskemet, Hungary|B-A-Z County Hospital, Miskolc, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Ospedale degli Infermi, Rimini, Emilia-Romagna, Italy|Uni Degli Studi Di Genova ; Clinica Di Medicina Interna Ad Indirizzo Oncologico, Genova, Liguria, Italy|ASST DI CREMONA; Dip. Medicina - S.C. Oncologia, Cremona, Lombardia, Italy|Ospedale Per Acuti Mater Salutis Di Legnago, Legnago, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, Italy|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, Korea, Republic of|Centro Estatal de Cancerología, Chihuahua, Mexico|Instituto Nacional De Cancerologia; Oncology; Tumores Mamarios, Distrito Federal, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Centro Oncologico America, Panama, Panama|Hospital Nacional Cayetano Heredia; Hematology - Oncology, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Peru|Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdańsk, Poland|Wojewódzki Szpital Specjalistyczny im. M. Kopernika; Oddział Chemioterapii, Lodz, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Wielkopolskie Centrum Onkologii; im. Marii Skłodowskiej-Curie, Poznan, Poland|Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon, Warszawa, Poland|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Instituto Universitario Dexeus; Servicio de Oncología, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia, Girona, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Universitario de Fuenlabrada; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario; Oncologia, Valencia, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Fundación IVO, Valencia, Spain|Kantonsspital Baden; Frauenklinik, Baden, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|Fondazione Oncologia Lago Maggiore, Locarno, Switzerland|Royal Bournemouth General Hospital; Oncology, Bournemouth, United Kingdom|Frimley Park Hospital; Breast Resaerch Team, Camberley, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Christie Hospital, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02273973"
125,"NCT01022346","A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection","Completed","No Results Available","Female","Phase 2","206","Industry","Interventional","August 2009","September 2013","September 2013","December 1, 2009","null","August 15, 2016","Mobile, Alabama, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Colton, California, United States|Los Angeles, California, United States|Colorado Springs, Colorado, United States|Stamford, Connecticut, United States|Washington, District of Columbia, United States|Lake Worth, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Sarasota, Florida, United States|South Miami, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Marrero, Louisiana, United States|Framingham, Massachusetts, United States|Kansas City, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Lawrenceville, New Jersey, United States|Brightwaters, New York, United States|Bronx, New York, United States|New Bern, North Carolina, United States|Winston-salem, North Carolina, United States|Englewood, Ohio, United States|Gallipolis, Ohio, United States|Oklahoma City, Oklahoma, United States|West Reading, Pennsylvania, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Sandy, Utah, United States|Norfolk, Virginia, United States|Antwerpen, Belgium|Brussel, Belgium|Bruxelles, Belgium|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|Tienen, Belgium|Hus, Finland|Kuopio, Finland|Oulu, Finland|Tampere, Finland|Bordeaux, France|Dijon, France|Nantes, France|Paris, France|Reims, France|Strasbourg, France|San Juan, Puerto Rico|San Juan, Puerto Rico|Bilbao, Vizcaya, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01022346"
126,"NCT01310894","Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.","Completed","No Results Available","Male","Phase 3","413","Other","Interventional","February 2011","June 2015","August 2015","March 9, 2011","null","October 17, 2018","Dept. of Urology-University Hospitals Leuven, Leuven, Belgium|Department of Urology-Tampere University Hospital-, Tampere, Finland|Service d'Urologie - Centre Hospitalier Universitaire d'Angers, Angers, France|CHRU Hopital Jean Minjoz, Besançon, France|Site Médipole, Cabestany, France|Polyclinique Sévigné, Cesson Sévigné, France|Clinique d'Urologie et de Transplantation Rénale CHU Grenoble, Grenoble, France|Hôpital Claude Huriez, Lille, France|Hôpital La Conception, Marseille, France|Clinique Ambroise Paré, Neuilly sur Seine, France|Institut Mutualiste Montsouris (IMM), Paris Cedex 14, France|Hôpital Cochin, Paris Cedex 14, France|Hôpital Tenon, Paris, France|Institut Mutualiste Montsouris (IMM), Paris, France|Centre Hospitalier Universitaire Lyon Sud, Pierre-Bénite, France|Polyclinique les Bleuets, Reims, France|CHU Pontchaillou, Rennes, France|Clinique Urologique Nantes, Saint Herblain, France|Hôpital Foch, Suresnes, France|Centre Hospitalier Universitaire de Rangueil, Toulouse, France|Marien Krankenahaus GmbH, Bergisch Gladbach, Germany|ATURO-Gemeinschaftspraxis für Urologie und Andrologie, Berlin-Wilmersdorf, Germany|Klinikum Braunschweig, Braunschweig, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität, Dresden, Germany|Urologische Gemeinschaftspraxis, Emmendingen, Germany|Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center, Hamburg, Germany|Vinzenz Krankenhaus - Department of Urology, Hannover, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|University Hospital Schleswig-Holstein, Kiel, Germany|Ludwig-Maximilians-Universität München, Munich, Germany|Urologie 24, Nuremberg, Germany|Unità Operativa Urologia Lucca - c/o Azienda USL 2 - Ospedale Campo di Marte, Lucca, Italy|Unità di Chirurgia Urologica Mininvasiva, Roma, Italy|Unità Operativa Urologica di Savona, Ospedale San Paolo di Savona, Savona, Italy|Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia, Torino, Italy|Netherlands Cancer Institute, Amsterdam, Netherlands|Polikliniek Urologie-Catharina Ziekenhuis, Eindhoven, Netherlands|Hospital Universitari de Bellbitge-Servico de Urologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de A Coruña, A Coruña, Spain|Fundacio Puigvert-Department of Urology, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Department of Urology-Hospital Clinic, University of Barcelona, Barcelona, Spain|Hospital 12 de Octubre - Departmento de Urologia, Madrid, Spain|Complejo Hospitalario Regional Virgen Del Rocio-Department Urology, Sevilla, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Dept of Urology-University Hospital-, Malmö, Sweden|Anna-Seiler-Haus Inselspital, Bern, Switzerland|Kings College Hospital (KCH), London, United Kingdom|University College of London Hospital, London, United Kingdom|Oxford John Radcliffe Hospital Trust, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01310894"
127,"NCT00777101","Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer","Completed","Has Results","Female","Phase 2","233","Industry","Interventional","February 4, 2009","March 2011","June 3, 2018","October 22, 2008","November 9, 2017","August 9, 2018","Arizona Oncology Associates HOPE, Tucson, Arizona, United States|Southwest Cancer Care, Murrieta, California, United States|UC Irvine Medical Center, Orange, California, United States|Aptium Oncology/Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States|Redwood Regional Medical Group, Inc., Santa Rosa, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Hematology Oncology Associates, P.C., Stamford, Connecticut, United States|Palm Beach Institute of Hematology & Oncology, Boynton Beach, Florida, United States|Robert R. Carroll, MD, PA, Gainesville, Florida, United States|University of Florida, Jacksonville, Florida, United States|Hematology Oncology Associates, Loxahatchee Groves, Florida, United States|Mercy Research Institute, Miami, Florida, United States|Cancer Centers of Florida, Orlando, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Cancer Care Specialists Of Central Illinois, Decatur, Illinois, United States|Oncology Specialists, SC, Park Ridge, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Central Indiana Cancer Centers, Fishers, Indiana, United States|Hematology Oncology of Indiana, Indianapolis, Indiana, United States|Floyd Memorial Cancer Center of Indiana, New Albany, Indiana, United States|Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States|Owsley Brown Frazier Cancer Center (OBFCC), Louisville, Kentucky, United States|Purchase Cancer Group, Paducah, Kentucky, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Arena Oncology Associates, PC, Lake Success, New York, United States|Weill Cornell Medical College New York-Presbyterian Hospital Weill, Cornell Breast Center, New York, New York, United States|New York Oncology Hematolgy, PC, Troy, New York, United States|Oncology Partners Network, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cancer Care Center, Cleveland, Ohio, United States|University of Oklahoma Health Sciences Center Dept. of Hematology Oncology, Oklahoma City, Oklahoma, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Lancaster Cancer Center, Lancaster, Pennsylvania, United States|Allegheny General Hospital Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Center for Biomedical Research, Knoxville, Tennessee, United States|Thompson Cancer Survival Center Thompson Oncology Group, Knoxville, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Texas Oncology, P.A., Austin, Texas, United States|El Paso Cancer Treatment Center - West, El Paso, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|HOPE Oncology, Richardson, Texas, United States|Cancer Care Network of South Texas-HOAST, San Antonio, Texas, United States|East Texas Medical Center Cancer Institute, Tyler Hematology Oncology, Tyler, Texas, United States|Mater Private Centre for HOCA, South Brisbane, Queensland, Australia|Medical Oncology Royal Adelaide Hospital, Adelaide, South Australia, Australia|Western Hospital, Footscray, Victoria, Australia|Mount Hospital, West Perth, Australia|AKH Wien Universitaetsklinik fuer Innere Medizin I Klinische Abteilung für Onkologie, Wien, Austria|Institut Jules Bordet Unite du Chimiotherapie, Brussels, Belgium|District Dispensary for Oncology Diseases Internal Unit- Sofia EOOD, Dept. of Chemotherapy, Sofia, Bulgaria|UMHAT Tzaritza Yoanna, Sofia, Bulgaria|Interdistrict Dispensary for Oncology Diseases -Internal Unit- Department Oncotherapy and Palliative Care, Varna, Bulgaria|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Centre Hospitalier Affilie Universitaire de Quebec Hopital du St-Sacrement, Quebec, Canada|General Hospital Varazdin, Varazdin, Croatia|University Hospital Center Zagreb, Zagreb, Croatia|University Hospital Sestre Milosrdnice, Zagreb, Croatia|Fakultni nemocnice Olomouc Klinika onkologie, Olomouc, Czechia|Centre Oscar Lambret Departement de senologie, Lille, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU de Poitiers Service d'oncologie medicale, Poitiers, France|Institut Gustave ROUSSY Service de Pathologie mammaire, Villejuif, France|Universitaetsklinikum Hamburg-Eppendorf Klinik und Poliklinik fuer Gynaekologie, Hamburg, Germany|Nationales Centrum fuer Tumorerkrankungen Sektion Gynaekologische Onkologie, Heidelberg, Germany|Theagenio Anticancer Hospital of Thessaloniki, Thessaloníki, Greece|Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UNIMED Medical Institute, Comprehensive Centre for Breast Diseases, Hong Kong, Hong Kong|Fovarosi Onkormanyzat Szent Janos Korhaza es Eszak-budai Egyesitett Korhazai, Onkologia, Budapest, Hungary|Orszagos Onkologiai Intezet ""B"" Belgyogyaszati osztaly, Budapest, Hungary|Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont, Kecskemet, Hungary|Josa Andras Oktatokorhaz / Onkoradiologiai Osztaly, Nyiregyhaza, Hungary|Szegedi Tudomanyegyetem Onkoterapias Klinika, Szeged, Hungary|Hospital of County Veszprem, Veszprem, Hungary|Ospedale Misericordia e Dolce c/o UO Oncologia Medica, Prato, Italy|Istituto Regina Elena, Struttura Complessa Oncologia Medica A, Roma, Italy|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|National Cancer Center Hospital, Tsukiji, Tokyo, Japan|Aichi Cancer Center, Aichi, Japan|Chiba Cancer Center, Chiba, Japan|National Cancer Center Hospital East, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Hiroshima City Hospital, Hiroshima, Japan|Hyogo Cancer Center, Hyogo, Japan|Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Municipal Hospital, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Jichi Medical University Hospital, Tochigi, Japan|St. Luke's International Hospital, Tokyo, Japan|The Cancer Institute Hospital of Japanese Foundation for Cancer Research Department of Medical Oncology, Tokyo, Japan|Tokyo Metropolitan Cancer&Infectious disease Ctr Komagome Hp, Tokyo, Japan|King Hussein Cancer Centre, Amman, Jordan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Yonsei University Health System - Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Oca Hospital / Monterrey International Research Center, Monterrey, Nuevo Leon, Mexico|Bialostockie Centrum Onkologii im. M. Sklodowskiej-Curie w Bialymstoku Specjalistyczny Szpital Onkologiczn, Bialystok, Poland|Uniwersyteckie Centrum Kliniczne w Gdansku Klinika Onkologii i Radioterapii, Gdansk, Poland|Szpital Uniwersytecki w Krakowie Oddzial KIiniczny Kliniki Onkologii, Krakow, Poland|Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli, Lublin, Poland|Metropolitan Oncology Center, San Juan, Puerto Rico|Institutul Oncologic ""Prof. Dr. Alex. Trestioreanu"", Bucuresti, Romania|Spitalul Universitar de Urgenta, Bucuresti, Romania|Centrul de Oncologie Medicala, Iasi, Romania|Spitalul Clinic Judetean, Sibiu, Romania|Scientific Research Institute of Oncology N.N. Petrov, Pesochny, Saint Petersburg, Russian Federation|Russian Oncology Research Centre of RAMS, Moscow, Russian Federation|GUZ Perm Regional Oncology Dispensary, Perm, Russian Federation|Ryazan State Medical University I.P.Pavlov of Federal Agency in Healthcare and Social Development, Ryazan, Russian Federation|SIH Leningrad Regional Oncology Dispensary, Saint Petersburg, Russian Federation|GUZ City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|St. Petersburg State Medical University I.P.Pavlov of Roszdrav, Saint Petersburg, Russian Federation|SIH Oncology Dispensary # 2 Of Department of Public Health, Sochi, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Bashkortostan Republic, Ufa, Russian Federation|Institute of Oncology and Radiology of Serbia, Belgrade, Serbia|Klinicko Bolnicki Centar (KBC) Bezanijska Kosa (Medical Centre ''Bezanijska Kosa'' (MCBK)), Belgrade, Serbia|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Institute for Oncology Department for Medical Oncology, Ljubljana, Slovenia|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Eastleigh Breast Care Centre, Lynnwood, Gauteng, South Africa|Hopelands Oncology Centre, Durban, KwaZulu Natal, South Africa|GVI Oncology Trial Unit Room 110 Panorama Medical Centre, Kraaifontein, Western Cape Province, South Africa|Hospital Central de Asturias Servicio de Oncologia, Planta Baja Oeste, Edificio Principal, Oviedo, Asturias, Spain|Hospital Germans Trias i Pujol Servicio de Oncologia, Badalona, Barcelona, Spain|Corporacio Sanitaria Parc Tauli Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Mutua de Terrassa Servicio de Oncologia, Terrassa, Barcelona, Spain|Complejo Hospitalario U. de A Coruña Hospital Teresa Herrera Servicio de Oncologia, A Coruña, Spain|Hospital General Universitario de Alicante Servicio de Oncologia, Alicante, Spain|Hospital San Pedro de Alcantara Servicio de Oncologia, Caceres, Spain|Hospital Provincial (Reina Sofia) Servicio de Oncologia, Cordoba, Spain|Hospital Universitario Dr. Josep Trueta Servicio de Oncologia, Gerona, Spain|Centro Hospitalario de Jaen Servicio de Oncologia, Jaen, Spain|Hospital Gregorio Marañon Servicio de Oncologia, Madrid, Spain|Centro Oncologico M.D. Anderson Internacional, Madrid, Spain|Instituto Valenciano de Oncologia Servicio de Oncologia, Valencia, Spain|Hospital Clinico Universitario de Valencia Servicio de Hematologia y Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet Servicio de Oncologia, Zaragoza, Spain|University of Lausanne Hospitals CHUV, Lausanne, Switzerland|Kantonsspital Winterthur Medizinische Onkologie, Winterthur, Switzerland|Abteilung fuer Onkologie Departement für Innere, Zuerich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Division of Medical Oncology, Department of Medicine, Bangkok-noi, Bangkok, Thailand|Broomfield Hospital, Chelmsford, Essex, United Kingdom|Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, United Kingdom|The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00777101"
128,"NCT01934790","Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases","Completed","Has Results","Male","Phase 1|Phase 2","45","Industry","Interventional","December 22, 2013","June 4, 2015","April 12, 2017","September 4, 2013","September 29, 2016","March 26, 2018","New Orleans, Louisiana, United States|Omaha, Nebraska, United States|Syracuse, New York, United States|Kuopio, Finland|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Forlì-Cesena, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Bergen, Norway|Lørenskog, Norway|Córdoba, Andalucía, Spain|Barcelona, Spain|Málaga, Spain|Umeå, Sweden","https://ClinicalTrials.gov/show/NCT01934790"
129,"NCT00625664","Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer","Completed","No Results Available","All","Phase 3","337","Industry","Interventional","February 2008","February 2011","February 2011","February 28, 2008","null","May 5, 2016","Sanofi-Aventis Investigational Site Number 840068, Anchorage, Alaska, United States|Sanofi-Aventis Investigational Site Number 840035, Berkeley, California, United States|Sanofi-Aventis Investigational Site Number 840012, Burbank, California, United States|Sanofi-Aventis Investigational Site Number 840029, La Jolla, California, United States|Sanofi-Aventis Investigational Site Number 840046, Los Angeles, California, United States|Sanofi-Aventis Investigational Site Number 840003, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840005, San Bernardino, California, United States|Sanofi-Aventis Investigational Site Number 840033, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840031, Denver, Colorado, United States|Sanofi-Aventis Investigational Site Number 840032, Stamford, Connecticut, United States|Sanofi-Aventis Investigational Site Number 840034, Washington, District of Columbia, United States|Sanofi-Aventis Investigational Site Number 840021, Washington, District of Columbia, United States|Sanofi-Aventis Investigational Site Number 840001, Boca Raton, Florida, United States|Sanofi-Aventis Investigational Site Number 840048, Boynton Beach, Florida, United States|Sanofi-Aventis Investigational Site Number 840049, Jacksonville, Florida, United States|Sanofi-Aventis Investigational Site Number 840061, Lakeland, Florida, United States|Sanofi-Aventis Investigational Site Number 840060, Athens, Georgia, United States|Sanofi-Aventis Investigational Site Number 840030, Boise, Idaho, United States|Sanofi-Aventis Investigational Site Number 840024, Maywood, Illinois, United States|Sanofi-Aventis Investigational Site Number 840062, Peoria, Illinois, United States|Sanofi-Aventis Investigational Site Number 840039, Goshen, Indiana, United States|Sanofi-Aventis Investigational Site Number 840054, Kansas City, Kansas, United States|Sanofi-Aventis Investigational Site Number 840057, Paducah, Kentucky, United States|Sanofi-Aventis Investigational Site Number 840004, Metarie, Louisiana, United States|Sanofi-Aventis Investigational Site Number 840045, Baltimore, Maryland, United States|Sanofi-Aventis Investigational Site Number 840006, Detroit, Michigan, United States|Sanofi-Aventis Investigational Site Number 840026, Lansing, Michigan, United States|Sanofi-Aventis Investigational Site Number 840047, St. Joseph, Michigan, United States|Sanofi-Aventis Investigational Site Number 840009, Hackensack, New Jersey, United States|Sanofi-Aventis Investigational Site Number 840044, Lake Success, New York, United States|Sanofi-Aventis Investigational Site Number 840013, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840050, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840056, Rochester, New York, United States|Sanofi-Aventis Investigational Site Number 840015, Syracuse, New York, United States|Sanofi-Aventis Investigational Site Number 840041, Chapel Hill, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840007, Charlotte, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840019, Sylvania, Ohio, United States|Sanofi-Aventis Investigational Site Number 840020, Bethlehem, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840065, Dunmore, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840058, Woonsocket, Rhode Island, United States|Sanofi-Aventis Investigational Site Number 840052, Charleston, South Carolina, United States|Sanofi-Aventis Investigational Site Number 840002, Knoxville, Tennessee, United States|Sanofi-Aventis Investigational Site Number 840008, Houston, Texas, United States|Sanofi-Aventis Investigational Site Number 840018, Houston, Texas, United States|Sanofi-Aventis Investigational Site Number 840017, Lubbock, Texas, United States|Sanofi-Aventis Investigational Site Number 840016, San Antonio, Texas, United States|Sanofi-Aventis Investigational Site Number 840064, Temple, Texas, United States|Sanofi-Aventis Investigational Site Number 840010, Woodlands, Texas, United States|Sanofi-Aventis Investigational Site Number 840036, Seattle, Washington, United States|Sanofi-Aventis Investigational Site Number 840011, Madison, Wisconsin, United States|Sanofi-Aventis Investigational Site Number 840025, Marshfield, Wisconsin, United States|Sanofi-Aventis Investigational Site Number 840038, Milwaukee, Wisconsin, United States|Sanofi-Aventis Investigational Site Number 032002, Buenos Aires, Argentina|Sanofi-Aventis Investigational Site Number 032003, Ciudad De Buenos Aires, Argentina|Sanofi-Aventis Investigational Site Number 032004, Mendoza, Argentina|Sanofi-Aventis Investigational Site Number 032005, Rosario, Argentina|Sanofi-Aventis Investigational Site Number 032001, Santa Fe, Argentina|Sanofi-Aventis Investigational Site Number 036002, Adelaide, Australia|Sanofi-Aventis Investigational Site Number 036003, Bedford Park, Australia|Sanofi-Aventis Investigational Site Number 036004, St Leonards, Australia|Sanofi-Aventis Investigational Site Number 056005, Aalst, Belgium|Sanofi-Aventis Investigational Site Number 056001, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056002, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056004, Ottignies, Belgium|Sanofi-Aventis Investigational Site Number 056003, Wilrijk, Belgium|Sanofi-Aventis Investigational Site Number 056006, Yvoir, Belgium|Sanofi-Aventis Investigational Site Number 076006, Barretos, Brazil|Sanofi-Aventis Investigational Site Number 076004, Florianopolis, Brazil|Sanofi-Aventis Investigational Site Number 076001, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076003, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076002, Rio De Janeiro, Brazil|Sanofi-Aventis Investigational Site Number 076007, Sao Paulo, Brazil|Sanofi-Aventis Investigational Site Number 076005, Sao Paulo, Brazil|Sanofi-Aventis Investigational Site Number 124007, Edmonton, Canada|Sanofi-Aventis Investigational Site Number 124001, London, Canada|Sanofi-Aventis Investigational Site Number 124006, Montreal, Canada|Sanofi-Aventis Investigational Site Number 124003, Quebec, Canada|Sanofi-Aventis Investigational Site Number 124002, Weston, Canada|Sanofi-Aventis Investigational Site Number 152001, Santiago, Chile|Sanofi-Aventis Investigational Site Number 250006, Avignon, France|Sanofi-Aventis Investigational Site Number 250003, Bordeaux Cedex, France|Sanofi-Aventis Investigational Site Number 250005, Hyeres, France|Sanofi-Aventis Investigational Site Number 250011, Le Mans, France|Sanofi-Aventis Investigational Site Number 250004, Lyon, France|Sanofi-Aventis Investigational Site Number 250012, Perpignan, France|Sanofi-Aventis Investigational Site Number 250007, Poitiers Cedex, France|Sanofi-Aventis Investigational Site Number 250008, Saint Herblain, France|Sanofi-Aventis Investigational Site Number 250009, Strasbourg, France|Sanofi-Aventis Investigational Site Number 250001, Suresnes, France|Sanofi-Aventis Investigational Site Number 356003, Bangalore, India|Sanofi-Aventis Investigational Site Number 356007, Kolkata, India|Sanofi-Aventis Investigational Site Number 356004, New Delhi, India|Sanofi-Aventis Investigational Site Number 356001, New Delhi, India|Sanofi-Aventis Investigational Site Number 356002, Vellore, India|Sanofi-Aventis Investigational Site Number 356005, Vishakhapatnam, India|Sanofi-Aventis Investigational Site Number 376005, Haifa, Israel|Sanofi-Aventis Investigational Site Number 376004, Kfar Saba, Israel|Sanofi-Aventis Investigational Site Number 376003, Petah-Tikva, Israel|Sanofi-Aventis Investigational Site Number 376002, Tel Aviv, Israel|Sanofi-Aventis Investigational Site Number 376007, Tel Hashomer, Israel|Sanofi-Aventis Investigational Site Number 376001, Tzrifin, Israel|Sanofi-Aventis Investigational Site Number 380004, Bari, Italy|Sanofi-Aventis Investigational Site Number 380003, Lecce, Italy|Sanofi-Aventis Investigational Site Number 380005, Meldola, Italy|Sanofi-Aventis Investigational Site Number 380006, Pavia, Italy|Sanofi-Aventis Investigational Site Number 380002, Perugia, Italy|Sanofi-Aventis Investigational Site Number 380001, Roma, Italy|Sanofi-Aventis Investigational Site Number 380008, Viterbo, Italy|Sanofi-Aventis Investigational Site Number 484003, Aguascalientes, Mexico|Sanofi-Aventis Investigational Site Number 484007, Chihuahua, Mexico|Sanofi-Aventis Investigational Site Number 484005, Chihuahua, Mexico|Sanofi-Aventis Investigational Site Number 484004, Monterrey, Mexico|Sanofi-Aventis Investigational Site Number 528005, Amsterdam, Netherlands|Sanofi-Aventis Investigational Site Number 528002, Arnhem, Netherlands|Sanofi-Aventis Investigational Site Number 528006, Hoofddorp, Netherlands|Sanofi-Aventis Investigational Site Number 528003, Maastricht, Netherlands|Sanofi-Aventis Investigational Site Number 528004, Nijmegen, Netherlands|Sanofi-Aventis Investigational Site Number 528001, Sittard-Geleen, Netherlands|Sanofi-Aventis Investigational Site Number 528007, Zwolle, Netherlands|Sanofi-Aventis Investigational Site Number 616002, Poznan, Poland|Sanofi-Aventis Investigational Site Number 616004, Rybnik, Poland|Sanofi-Aventis Investigational Site Number 616001, Warszawa, Poland|Sanofi-Aventis Investigational Site Number 616005, Wroclaw, Poland|Sanofi-Aventis Investigational Site Number 643009, Chelyabinsk, Russian Federation|Sanofi-Aventis Investigational Site Number 643010, Kursk, Russian Federation|Sanofi-Aventis Investigational Site Number 643006, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643008, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643004, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643005, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643001, Obninsk, Russian Federation|Sanofi-Aventis Investigational Site Number 643003, Saint-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643007, Saint-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643002, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643011, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 710008, Bloemfontein, South Africa|Sanofi-Aventis Investigational Site Number 710003, Cape Town, South Africa|Sanofi-Aventis Investigational Site Number 710001, Cape Town, South Africa|Sanofi-Aventis Investigational Site Number 710007, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710009, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710006, Port Elizabeth, South Africa|Sanofi-Aventis Investigational Site Number 710005, Pretoria, South Africa|Sanofi-Aventis Investigational Site Number 724006, Badalona, Spain|Sanofi-Aventis Investigational Site Number 724001, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724004, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724008, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724003, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724010, Oviedo, Spain|Sanofi-Aventis Investigational Site Number 724013, Palma De Mallorca, Spain|Sanofi-Aventis Investigational Site Number 724007, Palma De Mallorca, Spain|Sanofi-Aventis Investigational Site Number 724009, Pamplona, Spain|Sanofi-Aventis Investigational Site Number 724011, Santiago De Compostela, Spain|Sanofi-Aventis Investigational Site Number 724012, Zaragoza, Spain|Sanofi-Aventis Investigational Site Number 752001, Umeå, Sweden|Sanofi-Aventis Investigational Site Number 752002, Uppsala, Sweden|Sanofi-Aventis Investigational Site Number 792002, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792003, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792004, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792006, Istanbul, Turkey|Sanofi-Aventis Investigational Site Number 792001, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT00625664"
130,"NCT01008150","Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer","Completed","No Results Available","Female","Phase 2","141","Other|Industry","Interventional","October 2010","September 2015","November 25, 2016","November 5, 2009","null","August 1, 2018","Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente-San Diego, San Diego, California, United States|CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Edward Cancer Center, Naperville, Illinois, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, United States|Yorkville Family Practice, Yorkville, Illinois, United States|St. Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|University of Missouri-Ellis Fischel, Columbia, Missouri, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University Hospital and Medical Center - SUNY Stony Brook, Stony Brook, New York, United States|CCOP Carolinas HealthCare System, Charlotte, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University/University Hospitals of Cleveland, Cleveland, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Kettering, Ohio, United States|Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|NSABP Foundation, Inc., Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|York Hospital, York, Pennsylvania, United States|Roper Hosp & Med Asso (Care Alliance Health), Charleston, South Carolina, United States|Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|West Virginia University Hospitals Inc., Morgantown, West Virginia, United States|University of Montreal Hospital Group, Montreal, Quebec, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Azienda Ospedaliera Fatebenefratelli Milano, Milano, Italy|MBCCOP - San Juan, San Juan, Puerto Rico|Galicia Hospital Universitario A Coruña, A Coruna, Galicia, Spain|Madrid Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Cataluna Hospital del Mar, Barcelona, Spain|Cataluna Hospital Quiron de Barcelona, Barcelona, Spain|Extremadura Hospital San Pedro Alcantara, Caceres, Spain|Cataluna Hospital Amau de Vilanova de Lleida, Lleida, Spain|Valencia Institut Valencia de Oncologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01008150"
131,"NCT00863655","Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","Completed","Has Results","Female","Phase 3","724","Industry","Interventional","June 3, 2009","December 4, 2014","December 4, 2014","March 18, 2009","August 31, 2012","May 2, 2017","Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Highlands Oncology Group DeptofHighlandsOncologyGrp(2), Fayetteville, Arkansas, United States|Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C, Anaheim, California, United States|Comprehensive Blood and Cancer Center Dept. of CBCC (3), Bakersfield, California, United States|Cancer Care Associates Dept.ofCancerCareAssoc. (2), Fresno, California, United States|Grass Valley Hematology Oncology Medical Group Dept. of Grass Valley Hem/Onc, Grass Valley, California, United States|Scripps Clinic SC, La Jolla, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, United States|Sharp Memorial Hospital SharpClinicalOncologyResearch, San Diego, California, United States|University of California San Francisco UCSF Medical Center, San Francisco, California, United States|Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ, Santa Monica, California, United States|St Joseph Heritage Healthcare Dept. of RRMG (4), Santa Rosa, California, United States|Comprehensive Cancer Center - Boca Raton Deerfield Beach, Boca Raton, Florida, United States|Florida Cancer Research Institute, Davie, Florida, United States|Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States|Memorial Hospital Memorial Cancer Institute, Hollywood, Florida, United States|MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2), Orlando, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Florida Medical Clinic PA Dept.ofFloridaMedicalClinic, Zephyrhills, Florida, United States|Georgia Cancer Specialists. Drug Ship, Decatur, Georgia, United States|Rush University Medical Center Study Coordinator, Chicago, Illinois, United States|Oncology Specialists, SC Dept.of Oncology Specialists, Park Ridge, Illinois, United States|Hematology Oncology of Indiana, Indianapolis, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Cancer Center of Kansas Dept.ofCancerCtr.ofKansas, Wichita, Kansas, United States|University of Louisville / James Graham Brown Cancer Center SC, Louisville, Kentucky, United States|Hematology Oncology Clinic Hematology Oncology Clinic (2), Baton Rouge, Louisiana, United States|Crescent City Research Consortium, LLC Dept of Hem&Onc Specialist - 2, Metairie, Louisiana, United States|Anne Arundel Health System Research Institute Wayson Pavilion, Annapolis, Maryland, United States|Mercy Medical Center Medical Oncology & Hematology, Baltimore, Maryland, United States|Weinberg Cancer Institute at Franklin Square Hospital, Baltimore, Maryland, United States|Maryland Hematology/Oncology Associates, P.A., Baltimore, Maryland, United States|Frederick Memorial Hospital Dept. of FMH-IRB, Frederick, Maryland, United States|Holy Cross Hospital Holy Cross, Silver Spring, Maryland, United States|Lahey Clinic Dept of Lahey Clinic (2), Burlington, Massachusetts, United States|Fairview Southdale Medical Oncology Clinic, Edina, Minnesota, United States|St. Louis Cancer & Breast Institute Dept.ofSt.LouisCancer&Breast, St. Louis, Missouri, United States|Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, United States|Regional Cancer Care Associates Dept. of the CCHD, Cherry Hill, New Jersey, United States|Trinitas Comprehensive Cancer Center Dept. of Trinitas, Elizabeth, New Jersey, United States|University of New Mexico Cancer Research Center Dept of UNM Cancer & Research, Albuquerque, New Mexico, United States|Clinical Research Alliance Dept.ofArenaOncologyAssoc(2), Lake Success, New York, United States|ProHealth Care, Lake Success, New York, United States|Beth Israel Medical Center Dept.ofBeth Israel Med. Ctr(2), New York, New York, United States|Weill Cornell Medical College Weill Cornell Med. Ctr., New York, New York, United States|Hematology Oncology Association of Rockland, Nyack, New York, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Cancer Centers of Southwest Oklahoma Cancer Research Dept.of Southwest Oklahoma, Lawton, Oklahoma, United States|Cancer Care Associates SC, Tulsa, Oklahoma, United States|Penn State University / Milton S. Hershey Medical Center Division of Oncology (2), Hershey, Pennsylvania, United States|Medical University of South Carolina -Hollings Cancer Center Dept. MUSC/HollingsCancerCtr, Charleston, South Carolina, United States|Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(5), Nashville, Tennessee, United States|University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr., Dallas, Texas, United States|The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2), Fort Worth, Texas, United States|University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(2), Houston, Texas, United States|Hope Oncology HOPE Richardson, Richardson, Texas, United States|Northern Utah Cancer Associates SC, Ogden, Utah, United States|Central Utah Clinic CRAD001Y2301, Provo, Utah, United States|Utah Cancer Specialists Dept.of Utah Cancer Spec. (2), Salt Lake City, Utah, United States|University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(2), Salt Lake City, Utah, United States|Medical Oncology & Hematology Associates of Northern VA Med. Onc&Hem Assoc. of No.VA, Reston, Virginia, United States|University of Wisconsin Hospital & Clinics UW ComprehensiveCancerCtr(2), Madison, Wisconsin, United States|Novartis Investigative Site, Nambour, Queensland, Australia|Novartis Investigative Site, Redcliffe, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Subiaco, Western Australia, Australia|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Sint-Niklaas, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Uberlândia, MG, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, St. Catharines, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Weston, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Olomouc, CZE, Czech Republic|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Praha, Czech Republic|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Menoufiya, Egypt|Novartis Investigative Site, La Roche sur Yon Cedex, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Saint-Nazaire, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Trier, Germany|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Antella - Bagno a Ripoli, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Saronno, Va, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Kitakyushu, Fukuoka, Japan|Novartis Investigative Site, Maebashi-city, Gunma, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Isehara-city, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Hidaka, Saitama, Japan|Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Kagoshima, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Christchurch, New Zealand|Novartis Investigative Site, Lørenskog, Norway|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Lleida, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Terrassa, Catalunya, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Broomfield, Chelmsford, United Kingdom|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00863655"
132,"NCT01492101","The BEACON Study (Breast Cancer Outcomes With NKTR-102)","Completed","No Results Available","Female","Phase 3","852","Industry","Interventional","December 2011","April 2016","June 2016","December 14, 2011","null","August 4, 2016","Arizona Oncology Associates, PC - NAHOA, Flagstaff, Arizona, United States|Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, Burbank, California, United States|University of Southern California, Los Angeles, California, United States|PMK Medical Group, Inc., DBA Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Wilshire Oncology Medical Group, Inc., Pasadena, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente, Vallejo, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Medstar, Washington DC, District of Columbia, United States|Pre clinical Science Bldg LR3, Washington, District of Columbia, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States|Northeast Georgia Cancer Care, Athens, Georgia, United States|Peachtree Hematology Oncology Consultants, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Summit Cancer Care, P.C., Savannah, Georgia, United States|The University of Chicago Medicine, Chicago, Illinois, United States|Oncology Specialists, Niles, Illinois, United States|Illinois Cancer Care, P.C., Peoria, Illinois, United States|IU Health Simon Cancer Center, Indianapolis, Indiana, United States|Hall-Perrine Cancer Center, 3rd Floor, Cedar Rapids, Iowa, United States|Kansas City Cancer Center, Overland Park, Kansas, United States|Louisville Oncology Clinical Research Program, Louisville, Kentucky, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center, St. Cloud, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Washington University in St. Louis, St. Louis, Missouri, United States|Missouri Baptist Medical Center, St. Louis, Missouri, United States|Frontier Cancer Center and Blood Institute, Billings, Montana, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hematology-Oncology Associates of Northern NJ, PA, Morristown, New Jersey, United States|The cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Cooper University Hospital, Voorhees, New Jersey, United States|UNM Cancer Center, Albuquerque, New Mexico, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Monte fiore, Bronx, New York, United States|Sciode Medical Associates, PLLC, d.b.a. Eastchester Center for Cancer Care, Bronx, New York, United States|Beth Israel Medical Center, New York City, New York, United States|Cornell University, New York City, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Hematology Oncology Associates, Charlotte, North Carolina, United States|DUMC, Duke South, Durham, North Carolina, United States|Sanford Research/USD, Fargo, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Comprehensive Breast Cancer, Columbus, Ohio, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Medical Oncology Associates of Wyoming Valley, PC, Kingston, Pennsylvania, United States|Cancer Centers of the Carolinas, Easley, South Carolina, United States|Sanford Research/USD, Sioux Falls, South Dakota, United States|The West Clinic, Memphis, Tennessee, United States|Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology-Abilene, Abilene, Texas, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States|Texas Oncology-Bedford, Bedford, Texas, United States|Texas Oncology-Medical City Dallas, Dallas, Texas, United States|Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|Texas Oncology-Fort Worth, Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Texas Oncology-Lewisville, Lewisville, Texas, United States|Texas Oncology-Mesquite, Mesquite, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A. - Plano, Plano, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Oncology - Sherman, Sherman, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Cancer TEAM Bellin Health, Green Bay, Wisconsin, United States|Institut Jules Bordet, Bruxelles, Belgium|GHdC - Site Notre Dame, Charleroi, Belgium|Universtair Ziekenhuis Antwerpen, Edegem, Belgium|UZ Gent Medische Oncologie, Gent, Belgium|UZ Leuven, Campus Gasthuisberg, trialbureau Algemene Medische Oncologie, Leuven, Belgium|Centre Hospitalier Universitaire de Liège- Site du Sart Tilman, Liège, Belgium|Centre Hospitalier Universitaire Ambroise Paré, Mons,, Belgium|GZA Ziekenhuizen, Campus St Augustinus, CLINICAL TRIALS ONCOLOGY, Wilrijk, Belgium|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Odette Cancer Centre OCC Clinical Research, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM-Hopital Notre-Dame, Montreal, Quebec, Canada|MUHC- Montreal General Hospital, Montreal, Quebec, Canada|Hôpital Charles-LeMoyne - CICM, Québec, Canada|Institut Bergonie Service Oncologie Médicale, Bordeaux, France|Centre Oscar Lambret, Cedex, France|Sorecoh, Le Mans, France|Institut Paoli Calmettes, Service Pharmacie, Marseille, France|Centra Regional de Lutte contre le Cancer, Montpellier, France|Institut Curie, UGEC, Paris, France|Hopital Tenon Service oncologie médicale, Paris, France|Centre Régional de Lutte Contre le Cancer Nantes Atlantique René Gauducheau, Saint Herblain, France|Institut de Cancérologie Gustave Roussy, Villejuif, France|Klinikum St. Marien Amberg, Amberg, Germany|Onkoplus, Berlin, Germany|Oncoresearch, Dortmund, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Wilhelm-Anton-Hospital gGmbH, Goch, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Universitaetsklinikum Ulm, Frauenklinik, Ulm, Germany|Istituto tumori Giovanni Paolo II-ospedale oncologico, Oncologia Medica e Sperimentale, Bari, Italy|Via Olgettina, Milano, Italy|Azienda Ospedaliero Universitaria Pisana, U.O. Oncologia Medica, Pisa, Italy|Oncologia Ospedale Infermi- Viale, Rimini, Italy|Istituto Nazionale tumori Regina Elena IRCCS, Roma, Italy|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of|Asan Medical Center, Songpagu, Soeul, Korea, Republic of|Hematology-oncology Department, Ajou University Hospital, Yeongtong-gu, Suwon, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Hematology-oncology Department, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Seoul National University Hospital,, Soeul, Korea, Republic of|VUmc, Amsterdam, Netherlands|MUMC, Maastricht, Netherlands|Tweesteden Ziekenhuis, Tilburg, Netherlands|Leningrad Regional Oncology Dispensary, Leningrad, Russian Federation|State Institution ""Russian Oncology Research Centre named after N.N. Blokhin RAMS"", Moscow, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov, Saint Petersburg, Russian Federation|Non-state Health Institution ""Dorozhnaya Clinical Hospital of OAO ""Russian Railways"", St. Petersburg, Russian Federation|St. Petersburg State Budget Healthcare Institution ""City Clinical Oncology Dispensary"", St. Petersburg, Russian Federation|Hospital Vall d'Hebron, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|MD Anderson Cancer Center Arturo, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Sant Joan de Reus, Tarragona, Spain|Clinical Trials Unit, Velindre Cancer Centre, Cardiff, United Kingdom|Beaston Oncology Center, Glasgow, United Kingdom|St James University Hospital, Leed, United Kingdom|NCRN, London, United Kingdom|The Christie Hospitals NHS Foundation Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Cancer Clinical Trials Centre, Weston Park Hospital, South Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT01492101"
133,"NCT01633060","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi","Completed","No Results Available","Female","Phase 3","432","Industry","Interventional","October 3, 2012","May 23, 2016","September 21, 2017","July 4, 2012","null","September 7, 2018","University of South Alabama / Mitchell Cancer Institute Univ South AL, Mobile, Alabama, United States|Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Compassionate Cancer Care Medical Group CCCMG, Fountain Valley, California, United States|Los Angeles Hematology/Oncology Medical Group Onc Dept., Los Angeles, California, United States|Cedars Sinai Medical Center SC-5, Los Angeles, California, United States|University of California at Los Angeles UCLA SC, Los Angeles, California, United States|Pacific Cancer Care, Monterey, California, United States|Rocky Mountain Cancer Centers SC, Denver, Colorado, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Emory University School of Medicine/Winship Cancer Institute Emory, Atlanta, Georgia, United States|Moanalua Medical Center. Attn: Oncology Dept, Honolulu, Hawaii, United States|Edward Hospital Edward Hospital, Naperville, Illinois, United States|Crescent City Research Consortium, LLC SC, Metairie, Louisiana, United States|Lsu Health Sciences Center/ Lsu School of Medicine Lsu, New Orleans, Louisiana, United States|John Ochsner Heart & Vascular Institute Clinical Trials Ochsner 2, New Orleans, Louisiana, United States|LSU Health Sciences Center Feist-Weiller Cancer Center, New Orleans, Louisiana, United States|University of Maryland Medical Center Univ Maryland, Baltimore, Maryland, United States|Mercy Medical Research Institute SC, Manchester, Missouri, United States|Morristown Memorial Hospital Morristown Mem, Morristown, New Jersey, United States|CINJ at Cooper University Hospital Dept of Onc, Voorhees, New Jersey, United States|Montefiore Medical Center Montefiore, Bronx, New York, United States|Clinical Research Alliance BKM120F2303, Lake Success, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|Northwest Cancer Specialists Compass Oncology -BKM, Portland, Oregon, United States|Oregon Health & Science University SC-5, Portland, Oregon, United States|University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|The West Clinic Dept. of the West Clinic, Memphis, Tennessee, United States|Texas Oncology PA Dallas Presbyterian Hospital SC, Dallas, Texas, United States|Texas Oncology Texas Oncology - Sammons, Dallas, Texas, United States|Texas Oncology SC-Austin, Dallas, Texas, United States|Texas Oncology Texas Oncology - Fort Worth (3, Dallas, Texas, United States|University of Texas Southwestern Medical Center UT Southwestern 2, Dallas, Texas, United States|Texas Tech University Health Science Center Dept of Texas Tech, El Paso, Texas, United States|The Methodist Hospital Cancer Center, Houston, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel De Tucuman, Tucuman, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Vratsa, Bulgaria|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Limoges cedex, Haute Vienne, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Reims Cedex, Marne, France|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint-Brieuc Cédex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Fulda, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Leer, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Mühlhausen, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Soest, Germany|Novartis Investigative Site, Tuebingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Marousi, Athens, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Patra - RIO, GR, Greece|Novartis Investigative Site, Thesaloniki, Thessaloniki, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, L'Aquila, AQ, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Monserrato, CA, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Sora, FR, Italy|Novartis Investigative Site, Lecco, LC, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pordenone, PN, Italy|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Salerno, SA, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Ivrea, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Mirano, VE, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Frattamaggiore, Italy|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Jaen, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Kalmar, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Blackburn, Lancashire, United Kingdom|Novartis Investigative Site, Ipswich, Suffolk, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT01633060"
134,"NCT02061085","Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment","Completed","No Results Available","All","Phase 2","53","Other","Interventional","July 2013","December 2015","December 2015","February 12, 2014","null","March 22, 2016","Zaragoza, Aragón, Spain|Oviedo, Asturias, Spain|Salamanca, Castilla y León, Spain|Barcelona, Cataluña, Spain|Badajoz, Extremadura, Spain|La Coruña, Galicia, Spain|Palma de Mallorca, Illes Balears, Spain|Gran Canaria, Islas Canarias, Spain|Pamplona, Navarra, Spain|Madrid, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT02061085"
135,"NCT02131064","A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","Completed","Has Results","All","Phase 3","444","Industry","Interventional","June 30, 2014","December 31, 2015","May 29, 2018","May 6, 2014","June 8, 2017","October 18, 2018","St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States|Cancer Care Assoc Med Group, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Md Anderson Cancer Center Orlando, Orlando, Florida, United States|New England Cancer Specialists, Scarborough, Maine, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|ProHEALTH Care Associates LLP, Lake Success, New York, United States|Hope A Women's Cancer Center, Asheville, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Roper Bon Secours St. Francis Cancer Center, Charleston, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Clinique Saint-Joseph, Liège, Belgium|Clinique Ste-Elisabeth, Pharmacie, Namur, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael'S Hospital, Toronto, Ontario, Canada|Chum Hospital Notre Dame, Montreal, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY, Quebec, Canada|Ico - Paul Papin, Angers, France|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Hopital Morvan, Brest, France|CHD Les Oudairies, La Roche Sur Yon, France|Centre Oscar Lambret, Lille, France|Institut Paoli Calmettes, Marseille, France|Centre Catherine De Sienne, Nantes, France|Centre Rene Gauducheau, Saint Herblain, France|Nouvel Hopital Civil - CHU Strasbourg, Strasbourg, France|Klinikum Sindelfingen-Böblingen; Frauenklinik, Böblingen, Germany|Luisenkrankenhaus GmbH, Brustzentrum, Düsseldorf, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Universitätsklinikum Mainz, Mainz, Germany|Interdisziplinäres Onkologisches Zentrum, München, Germany|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Regional Oncology Hospital Of Kursk; Chemotherapy, Kislino, Kursk Region, Russian Federation|S.I. Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|State Inst. Of Healthcare Orenburg Regional Clinical Oncology Dis, Orenburg, Russian Federation|Railway Clinical Hospital on Saratov - 2 Station Oao ""Rzhd"", Saratov, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia, San Sebastian, Guipuzcoa, Spain|Hospital Universitari de Lleida Arnau de Vilanova, Lleida, Lerida, Spain|Hospital Nuestra Señora de Sonsoles; servicio de Oncologia, Avila, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Fundacio Santa Creu I Sant Pau, Barcelona, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung, Taiwan|National Taiwan Uni Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Cherkassy Regional Oncological Hospital, Cherkassy, Ukraine|State Medical Academy; Oncology, Dnipropetrovsk, Ukraine|Karkiv Regional Oncology Center, Kharkiv, Ukraine|Lvov State Regional Center, Lvov, Ukraine","https://ClinicalTrials.gov/show/NCT02131064"
136,"NCT00887198","Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","Completed","Has Results","Male","Phase 3","1088","Industry","Interventional","April 28, 2009","March 31, 2014","May 25, 2017","April 23, 2009","April 9, 2015","June 25, 2018","Birmingham, Alabama, United States|Tucson, Arizona, United States|Bellflower, California, United States|Los Angeles, California, United States|Marina Del Rey, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Stanford, California, United States|Aurora, Colorado, United States|New Haven, Connecticut, United States|Boca Raton, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Kansas City, Kansas, United States|Metairie, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Dearborn, Michigan, United States|Saint Louis Park, Minnesota, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|East Syracuse, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Columbia, South Carolina, United States|Myrtle Beach, South Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Adelaide, Australia|Camperdown, Australia|Footscray, Australia|Frankston, Australia|Garran, Australia|Geelong, Australia|Heidelberg, Australia|Herston, Australia|Hornsby, Australia|Kogarah, Australia|Kurralta Park, Australia|Lismore, Australia|Liverpool, Australia|Malvern, Australia|Parkville, Australia|Perth, Australia|South Brisbane, Australia|Southport, Australia|Subiaco, Australia|Aalst, Belgium|Antwerpen, Belgium|Gent, Belgium|Hasselt, Belgium|Leuven Belgie, Belgium|Roeselare, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|London, Canada|Quebec, Canada|Caen, France|Clichy, France|Dijon Cedex, France|La Roche Sur Yon, France|Lyon Cedex 03, France|Lyon, France|Montpellier, France|Paris Cedex 15, France|Tours, Cedex 9, France|Villejuif, France|Aachen, Germany|Berlin, Germany|Braunschweig, Germany|Dresden, Germany|Düsseldorf, Germany|Hamburg, Germany|Hannover, Germany|Homburg, Germany|Kempen, Germany|Leipzig, Germany|Muenchen, Germany|Münster, Germany|Wuppertal, Germany|Athens, Greece|Larisa, Greece|Amsterdam, Netherlands|Heerlen, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Barcelona, Spain|Coruña, Spain|Madrid, Spain|Oviedo, Spain|Santander N/A, Spain|Santiago De Compostela, Spain|Göteborg, Sweden|Malmö N/A, Sweden|Stockholm, Sweden|Uppsala, Sweden|Växjö, Sweden|Birmingham, United Kingdom|Cambridge, United Kingdom|Glasgow, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Oxford, United Kingdom|Sutton, United Kingdom|Whitchurch, United Kingdom|Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT00887198"
137,"NCT01082549","Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)","Completed","No Results Available","All","Phase 3","780","Industry","Interventional","March 2010","April 2013","April 2013","March 8, 2010","null","March 17, 2016","Investigational Site Number 840306, Birmingham, Alabama, United States|Investigational Site Number 840207, Huntsville, Alabama, United States|Investigational Site Number 840351, Muscle Shoals, Alabama, United States|Investigational Site Number 840338, Anaheim, California, United States|Investigational Site Number 840353, Burbank, California, United States|Investigational Site Number 840341, Concord, California, United States|Investigational Site Number 840317, Duarte, California, United States|Investigational Site Number 840339, La Verne, California, United States|Investigational Site Number 840309, Loma Linda, California, United States|Investigational Site Number 840307, Los Angeles, California, United States|Investigational Site Number 840327, Maywood, California, United States|Investigational Site Number 840303, San Diego, California, United States|Investigational Site Number 840321, Santa Rosa, California, United States|Investigational Site Number 840326, Stockton, California, United States|Investigational Site Number 840310, Vallejo, California, United States|Investigational Site Number 840336, Denver, Colorado, United States|Investigational Site Number 840346, Norwich, Connecticut, United States|Investigational Site Number 840315, Newark, Delaware, United States|Investigational Site Number 840216, Ft. Lauderdale, Florida, United States|Investigational Site Number 840215, Jacksonville, Florida, United States|Investigational Site Number 840217, Lakeland, Florida, United States|Investigational Site Number 840205, Orlando, Florida, United States|Investigational Site Number 840104, Sarasota, Florida, United States|Investigational Site Number 840343, Athens, Georgia, United States|Investigational Site Number 840213, Augusta, Georgia, United States|Investigational Site Number 840347, Augusta, Georgia, United States|Investigational Site Number 840201, Gainesville, Georgia, United States|Investigational Site Number 840301, Lawrenceville, Georgia, United States|Investigational Site Number 840305, Marietta, Georgia, United States|Investigational Site Number 840314, Tucker, Georgia, United States|Investigational Site Number 840313, Chicago, Illinois, United States|Investigational Site Number 840218, Evansville, Indiana, United States|Investigational Site Number 840319, Indianapolis, Indiana, United States|Investigational Site Number 840329, South Bend, Indiana, United States|Investigational Site Number 840316, Wichita, Kansas, United States|Investigational Site Number 840320, Louisville, Kentucky, United States|Investigational Site Number 840308, Scarborough, Maine, United States|Investigational Site Number 840202, Bethesda, Maryland, United States|Investigational Site Number 840345, Salisbury, Maryland, United States|Investigational Site Number 840337, Royal Oak, Michigan, United States|Investigational Site Number 840328, St. Louis Park, Minnesota, United States|Investigational Site Number 840210, Bridgeton, Missouri, United States|Investigational Site Number 840212, Omaha, Nebraska, United States|Investigational Site Number 840318, Las Vegas, Nevada, United States|Investigational Site Number 840204, Morristown, New Jersey, United States|Investigational Site Number 840350, Chapel Hill, North Carolina, United States|Investigational Site Number 840330, Durham, North Carolina, United States|Investigational Site Number 840105, Cincinnati, Ohio, United States|Investigational Site Number 840302, Cleveland, Ohio, United States|Investigational Site Number 840348, Cleveland, Ohio, United States|Investigational Site Number 840335, Columbus, Ohio, United States|Investigational Site Number 840311, Bend, Oregon, United States|Investigational Site Number 840211, West Reading, Pennsylvania, United States|Investigational Site Number 840352, Charleston, South Carolina, United States|Investigational Site Number 840106, Columbia, South Carolina, United States|Investigational Site Number 840220, Spartanburg, South Carolina, United States|Investigational Site Number 840103, Chattanooga, Tennessee, United States|Investigational Site Number 840208, Chattanooga, Tennessee, United States|Investigational Site Number 840203, Collierville, Tennessee, United States|Investigational Site Number 840101, Nashville, Tennessee, United States|Investigational Site Number 840323, Fort Worth, Texas, United States|Investigational Site Number 840219, Newport News, Virginia, United States|Investigational Site Number 840102, Richmond, Virginia, United States|Investigational Site Number 840312, Seattle, Washington, United States|Investigational Site Number 840344, Tacoma, Washington, United States|Investigational Site Number 840322, Morgantown, West Virginia, United States|Investigational Site Number 840331, Wauwatosa, Wisconsin, United States|Investigational Site Number 056004, Brugge, Belgium|Investigational Site Number 056003, Brussel, Belgium|Investigational Site Number 056001, Liège, Belgium|Investigational Site Number 124003, Edmonton, Canada|Investigational Site Number 124006, Greenfield Park, Canada|Investigational Site Number 124005, London, Canada|Investigational Site Number 124007, Oshawa, Canada|Investigational Site Number 124004, Quebec, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250007, Brest, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250009, Limoges Cedex, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250004, Paris Cedex 13, France|Investigational Site Number 250010, Pierre Benite Cedex, France|Investigational Site Number 250008, Poitiers, France|Investigational Site Number 250001, Saint-Herblain Cedex, France|Investigational Site Number 250006, Strasbourg, France|Investigational Site Number 250005, Tours Cedex 1, France|Investigational Site Number 276002, Amberg, Germany|Investigational Site Number 276004, Berlin, Germany|Investigational Site Number 276007, Frankfurt Am Main, Germany|Investigational Site Number 276008, Großhansdorf, Germany|Investigational Site Number 276010, Halle/Saale, Germany|Investigational Site Number 276012, Heidelberg, Germany|Investigational Site Number 276009, Immenhausen, Germany|Investigational Site Number 276001, Löwenstein, Germany|Investigational Site Number 276006, München, Germany|Investigational Site Number 276003, Oldenburg, Germany|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348001, Mátraháza, Hungary|Investigational Site Number 348004, Nyíregyháza, Hungary|Investigational Site Number 376002, Kfar Saba, Israel|Investigational Site Number 376005, Petah-Tikva, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 376001, Tzrifin, Israel|Investigational Site Number 380006, Genova, Italy|Investigational Site Number 380001, Novara, Italy|Investigational Site Number 380008, Orbassano, Italy|Investigational Site Number 380002, Perugia, Italy|Investigational Site Number 380003, Roma, Italy|Investigational Site Number 380007, Roma, Italy|Investigational Site Number 442001, Luxembourg, Luxembourg|Investigational Site Number 528005, Breda, Netherlands|Investigational Site Number 528004, Eindhoven, Netherlands|Investigational Site Number 528001, Groningen, Netherlands|Investigational Site Number 528006, Maastricht, Netherlands|Investigational Site Number 528003, Zwolle, Netherlands|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616007, Lubin, Poland|Investigational Site Number 616004, Olsztyn, Poland|Investigational Site Number 616008, Torun, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616005, Wroclaw, Poland|Investigational Site Number 642002, Alba Iulia, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Cluj Napoca, Romania|Investigational Site Number 642004, Craiova, Romania|Investigational Site Number 642005, Hunedoara, Romania|Investigational Site Number 724009, Badalona, Spain|Investigational Site Number 724003, Barcelona, Spain|Investigational Site Number 724004, La Coruña, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724006, Madrid, Spain|Investigational Site Number 724002, Málaga, Spain|Investigational Site Number 724001, Palma De Mallorca, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724010, Valencia, Spain|Investigational Site Number 724007, Zaragoza, Spain|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826005, Leeds, United Kingdom|Investigational Site Number 826001, Manchester, United Kingdom|Investigational Site Number 826006, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01082549"
138,"NCT01288339","Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer","Completed","No Results Available","All","Phase 2","78","Other|Industry","Interventional","November 8, 2010","February 13, 2015","February 13, 2015","February 2, 2011","null","May 16, 2018","Hospital General Universitario de Elche, Elche, Alicante, Spain|Hosptial General de l'Hospitalet de Barcelona, Hospitalet de Llobregat, Barcelona, Spain|Corporació Sanitaria Parc Taulí de Barcelona, Sabadell, Barcelona, Spain|Hospital de l'Esperit Sant, Santa Coloma De Gramenet, Barcelona, Spain|Consorcio Hospitalario Provincial de Castellon, Castellón De La Plana, Castellon, Spain|Hospital Son Espases de Mallorca, Palma De Mallorca, Illes Balears, Spain|Hosptial Son Llatzer de Mallorca, Palma De Mallorca, Illes Balears, Spain|Hosptial de Logroño, Logroño, La Rioja, Spain|Hospital Universitario La Paz de Madrid, Madrid, Madrdi, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Xeral Cies de Vigo, Vigo, Pontevedra, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau de Barcelona, Barcelona, Spain|Complejo Asitencia de Burgos. Hospital General Yague, Burgos, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Institut Català d'Oncologia (ICO) de Girona, Girona, Spain|Centro Oncológico de Galícia, La Coruña, Spain|Hosptial Dr. Negrin de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain|Hospital Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Infanta Sofía de Madrid, Madrid, Spain|Hospital Universitario Puerta de Hierro de Madrid, Madrid, Spain|Hospital de Fuenlabrada de Madrid, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Hosptial de Sant Pau i Santa Tecla de Tarragona, Tarragona, Spain|Hospital La Fe de Valencia, Valencia, Spain|Instituto Valenciano de Oncología de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Dr. Peset de Valencia, Valencia, Spain|Hospital Miguel Servet de Zaragoza, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01288339"
139,"NCT01095003","Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer","Completed","No Results Available","Female","Phase 3","770","Industry","Interventional","May 2009","December 2011","October 2015","March 29, 2010","null","November 2, 2015","Buenos Aires, Argentina|Quilmes, Argentina|Rosario, Argentina|San Martin, Argentina|Tucuman, Argentina|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Vitebsk, Belarus|Bruxelles, Belgium|Liège, Belgium|Curitiba, Brazil|Porto Alegre, Brazil|Santo Andre, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brno, Czech Republic|Jihlava, Czech Republic|Tallinn, Estonia|Angers, France|Caen, France|Dijon, France|Le Mans, France|Lorient, France|Lyon, France|Montpellier, France|Nantes, France|Saint-Brieuc, France|Saint-Cloud, France|Saint-Herblain, France|Tours, France|Villejuif, France|Budapest, Hungary|Szekesfehervar, Hungary|Szolnosk, Hungary|Aurangabad, India|Bangalore, India|Bhopal, India|Calicut, India|Jaipur, India|Kolkatta, India|Mumbai, India|Patna, India|Pune, India|Trivandrum, India|Avellino, Italy|Cagliari, Italy|Cremona, Italy|Fabriano, Italy|Milano, Italy|Monza, Italy|Padova, Italy|Pisa, Italy|Rozzano, Italy|Verona, Italy|Chihuahua, Mexico|Leon, Mexico|Mexico City, Mexico|Saltillo, Mexico|Bialystok, Poland|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Lubin, Poland|Warsawa, Poland|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Moscow, Russian Federation|Ryazan, Russian Federation|Saratov, Russian Federation|St-Petersburg, Russian Federation|Stavropol, Russian Federation|Tambov, Russian Federation|Ufa, Russian Federation|Vladimir, Russian Federation|Volgograd, Russian Federation|Nis, Serbia|Sremska Kamenica, Serbia|Durban, South Africa|Kimberley, South Africa|Pretoria, South Africa|Sandton, South Africa|Barcelona, Spain|Lleida, Spain|Llobregat, Spain|Madrid, Spain|Oviedo, Spain|Valencia, Spain|Genolier, Switzerland|Lausanne, Switzerland|Winterthur, Switzerland|Taipei, Taiwan|Taoyuan, Taiwan|Cherkasy, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Khmelnitskyy, Ukraine|Kyiv, Ukraine|Simferopol, Ukraine|Belfast, United Kingdom|Chelmsford, United Kingdom|Keighley, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Peterborough, United Kingdom|Portsmouth, United Kingdom|Sheffield, United Kingdom|Southend-of-Sea, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01095003"
140,"NCT01740336","A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer","Completed","No Results Available","Female","Phase 2","183","Industry","Interventional","February 6, 2013","October 20, 2015","December 10, 2015","December 4, 2012","null","April 24, 2017","Arizona Oncology Associates, PC - NAHOA, Sedona, Arizona, United States|Pacific Cancer Medical Center, Anaheim, California, United States|California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States|Kaiser Permanente - Hayward, Hayward, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Bay Area Cancer Research Group, LLC, Pleasant Hill, California, United States|Kaiser Permanente Medical Center - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|Kaiser Permanente - San Francisco (2238 Geary), San Francisco, California, United States|University of California at San Francisco, San Francisco, California, United States|Kaiser Permanente - San Jose, San Jose, California, United States|Kaiser Permanente - Santa Clara, Santa Clara, California, United States|Kaiser Permanente - South San Francisco, South San Francisco, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, United States|Helen & Harry Gray Cancer Center-Hartford Hospital-CCD PRIME; Research, Hartford, Connecticut, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Cancer Specialists of North Florida, Orange Park, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Cotton-O'Neil Clinical Research Center, Hematology and Oncology; Cotton O'Neil Cancer Center, Topeka, Kansas, United States|Hematology Oncology Clinic, Baton Rouge, Louisiana, United States|Metairie Oncologist, LLC, Metairie, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr, Brookline, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Billings Clinic Cancer Center-CCD PRIME, Billings, Missouri, United States|Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States|ProHEALTH Care Associates LLP, Lake Success, New York, United States|Summa Health System, Akron, Ohio, United States|Aultman Hospital; Aultman Hospital Cancer Center, Canton, Ohio, United States|TriHealth Oncology Institute, Cincinnati, Ohio, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Hematology and Oncology Associates of Sc, Greenville, South Carolina, United States|Shivers Cancer Center at University Medical Center Brackenridge, Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology, P.A. - El Paso; West, El Paso, Texas, United States|Texas Oncology - Memorial City, Houston, Texas, United States|Texas Oncology, P.A. ;Sherman Cancer Center, Sherman, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Shenandoah Oncology Associates, Winchester, Virginia, United States|Puget Sound Cancer Centers, Edmonds, Washington, United States|Swedish Health Services, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Port Macquarie Base Hospital;North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|Sydney Haematology & Oncology Clinic, Wahroonga, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Border Medical Oncology, Wodonga, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Adult Hospital, Mackay, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Bendigo Hospital; Oncology, Bendigo, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Grou, Frankston, Victoria, Australia|Royal Perth Hospital; Medical Oncology, Perth, Western Australia, Australia|Lkh-Univ. Klinikum Graz, Graz, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Klinikum Wels-Grieskirchen, Wels, Austria|Krankenhaus Hietzing m.Neurolog. Zentrum Rosenhuegel, Wien, Austria|Institut Jules Bordet, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU Ambroise Paré, Mons, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|Fakultni nemocnice Brno, Brno, Czechia|Masarykuv onkologicky ustav, Brno, Czechia|Krajska nemocnice Liberec a.s., Liberec, Czechia|Multiscan s.r.o., Pardubice, Czechia|Nemocnice Na Bulovce, Prague, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Thomayerova nemocnice, Praha 4 - Krc, Czechia|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Institut Catala d´Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Hospital General Univ. Gregorio Maranon, Madrid, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain|Royal Sussex County Hospital, Brighton, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Barts Hospital, London, United Kingdom|The Christie, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, United Kingdom|Royal Stoke University Hospital, Stoke on Trent, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01740336"
141,"NCT01565083","A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer","Completed","Has Results","All","Phase 2","213","Industry","Interventional","April 2012","October 2015","October 2015","March 28, 2012","November 22, 2016","November 22, 2016","Tucson, Arizona, United States|Stanford, California, United States|Denver, Colorado, United States|Hollywood, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Marietta, Georgia, United States|Boston, Massachusetts, United States|Morristown, New Jersey, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Houston, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Fredericksburg, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Rio de Janeiro, RJ, Brazil|Barretos, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Herlev, Denmark|Herning, Denmark|København Ø, Denmark|Odense, Denmark|Avignon, France|Bobigny, France|Caen, France|La Tronche, France|Mont-de-marsan, France|Paris, France|Paris, France|Perigueux, France|Pierre Benite, France|Plerin, France|Rouen, France|Strasbourg, France|Tours, France|Villejuif, France|Dortmund, Germany|Dresden, Germany|Frankfurt am Main, Germany|Freiburg, Germany|Georgsmarienhütte, Germany|Goslar, Germany|Gütersloh, Germany|Hamburg, Germany|Heidelberg, Germany|Kaiserslautern, Germany|Kassel, Germany|Köln, Germany|Lebach, Germany|Leer, Germany|Moers, Germany|München, Germany|München, Germany|Neumarkt, Germany|Ravensburg, Germany|Wuerselen, Germany|Bologna, Emilia-Romagna, Italy|Aviano, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Cremona, Lombardia, Italy|Monza, Lombardia, Italy|Lido Di Camaiore, Toscana, Italy|Pisa, Toscana, Italy|Terni, Umbria, Italy|Negrar, Veneto, Italy|Oviedo, Asturias, Spain|Terrassa, Barcelona, Spain|Santander, Cantabria, Spain|Barbastro, Huesca, Spain|Palma de Mallorca, Islas Baleares, Spain|La Laguna, Tenerife, Spain|Badajoz, Spain|Madrid, Spain|Malaga, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01565083"
142,"NCT02053636","A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer","Completed","No Results Available","Female","Phase 2","76","Industry|Other","Interventional","December 2013","March 2017","April 4, 2017","February 4, 2014","null","April 26, 2018","Peter MacCallum Cancer Centre, East Melbourne, Australia|Westmead Hospital, Westmead, Australia|Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires St. Luc Oncology - Breast Clinic, Bruxelles, Belgium|Grand Hôpital de Charleroi Oncologie-Hématologie, Charleroi, Belgium|UZ Leuven Campus Gasthuisberg Dept. of General Medical, Leuven, Belgium|Clinique Sainte-Elisabeth Médecine Interne - Oncologie, Namur, Belgium|McGill University Department of Oncologie - Clinical Reserach Program, Montreal, Canada|Princess Margaret Cancer Centre, Toronto, Canada|University Health Network - Princess Margaret Hospital, Toronto, Canada|Institut Claudius Regaud Dpt d'Oncologie Médicale, Toulouse, France|Institut Gustave Roussy, Villejuif Cedex, France|Institut Gustave Roussy Dépt d'oncologie - Cancer du sein, Villejuif, France|Kliniken Essen-Mitte Klinik für Senologie - Brustzentrum, Essen, Germany|KLINIKUM OFFENBACH Klinik für Gynäkologie und Geburtshilfe, Offenbach, Germany|Klinikum Offenbach, Offenbach, Germany|Orszagos Onkologiai Intezet Kemoterapia B es Klin.Farm.Oszt., Budapest, Hungary|Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet, Debrecen, Hungary|Istituto Europeo di Oncologia Divisione Sviluppo Nuovi Farmaci per Terapie Innovative, Milano, Italy|Istituto Europeo di Oncologia, Milan, Italy|H. Valle de Hebrón Servicio de Oncología, Barcelona, Spain|Hospital Universitario Val d'Hebròn, Madrid, Spain|MD Anderson Cancer Center Unidad de Investigación Clínica, Madrid, Spain|H. Ramón y Cajal Servicio de Oncología Médica, Madrid, Spain|H. Clínico de Valencia Servicio de Hematología y oncología Médica, Valencia, Spain|Western General Hospital Edinburgh Cancer Centre, Edinburgh, United Kingdom|Royal Marsden Hospital, London, United Kingdom|The Royal Marsden NHS Trust Dpt of Medicine-Oncology, London, United Kingdom|Nottingham University Hospitals NHS Trust Department of Clinical Oncology, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT02053636"
143,"NCT01401166","Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","Completed","Has Results","Female","Phase 2","488","Industry","Interventional","October 2011","May 2013","December 2015","July 25, 2011","June 8, 2015","March 6, 2017","Barrie, Ontario, Canada|Brampton, Ontario, Canada|Kitchener, Ontario, Canada|Sault Ste Marie, Ontario, Canada|Toronto, Ontario, Canada|Saskatoon, Saskatchewan, Canada|Herning, Denmark|Odense, Denmark|Vejle, Denmark|Besancon, France|Bobigny, France|Bordeaux, France|Caen, France|La Tronche, France|LeMans, France|Lyon, France|Paris, France|Rennes, France|St Cloud, France|Strasbourg, France|Berlin, Germany|Deggendorf, Germany|Essen, Germany|Fuerstenwalde, Germany|Hamburg, Germany|Hannover, Germany|Magedburg, Germany|Mainz, Germany|Meiningen, Germany|Recklinghausen, Germany|Ulm, Germany|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Antella (FI), Toscana, Italy|Terni, Umbria, Italy|Gdansk, Poland|Warszawa, Poland|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Orenburg, Russian Federation|Saint-Petersburg, Russian Federation|St Petersburg, Russian Federation|Oviedo, Asturias, Spain|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Cordoba, Spain|Guadalajara, Spain|Huesca, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Sevilla, Spain|Sevilla, Spain|Zamora, Spain|Eskilstuna, Sweden|Gävle, Sweden|Jonkoping, Sweden|Sundsvall, Sweden|Baden, Switzerland|Zürich, Switzerland|Adana, Turkey|Ankara, Turkey|Bornova, ?ZM?R, Turkey|Gaziantep, Turkey|Brighton, United Kingdom|Cardiff, United Kingdom|Chelmsford, United Kingdom|Maidstone, United Kingdom|Nottingham, United Kingdom|Peterborough, United Kingdom|Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01401166"
144,"NCT02083653","Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer","Completed","No Results Available","All","Phase 2","254","Industry","Interventional","March 12, 2014","October 24, 2016","April 26, 2017","March 11, 2014","null","November 8, 2017","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Florida Cancer Specialists-Broadway, Fort Myers, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Texas Oncology, P.A., Tyler, Texas, United States|SMZ Süd - Kaiser Franz Josef Spital Wien, Wien, Austria|ULB Hôpital Erasme, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHU Ambroise Paré, Mons, Belgium|Clinique et Maternité Sainte-Elisabeth, Namur, Belgium|CHU Mont-Godinne, Yvoir, Belgium|ICO - Site Paul Papin, Angers Cedex 9, France|Institut Sainte Catherine, Avignon, France|Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux Cedex, France|Centre Georges François Leclerc, Dijon Cedex, France|Centre Léon Bérard, Lyon, France|CRLCC Eugene Marquis, Rennes Cedex, France|ICO - Site René Gauducheau, Saint Herblain, France|CHU de Toulouse - Hôpital Rangueil, Toulouse Cedex 9, France|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Germany|Uzsoki Utcai Korhaz, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Jasz-Nagykun-Szolnok Megyei Korhaz-Rendelointezet, Szolnok, Hungary|Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Presidio Ospedaliero SS. Trinità Sora, Sora, Italy|Azienda Ospedaliera S. Maria Di Terni, Terni, Italy|SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie, Olsztyn, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Torun, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|BHI of Omsk region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|St. Petersburg SHI ""City Clinical Oncology Dispensary"", St. Petersburg, Russian Federation|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02083653"
145,"NCT01419197","A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","Completed","Has Results","All","Phase 3","602","Industry","Interventional","September 2011","February 2013","August 2015","August 18, 2011","May 5, 2014","October 12, 2016","Tucson, Arizona, United States|Hot Springs, Arkansas, United States|Hayward, California, United States|Highland, California, United States|Oakland, California, United States|Roseville, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|San Jose, California, United States|Santa Clara, California, United States|South San Francisco, California, United States|Stockton, California, United States|Vallejo, California, United States|Walnut Creek, California, United States|West Hollywood, California, United States|Denver, Colorado, United States|Trumbull, Connecticut, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Coral Springs, Florida, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Plantation, Florida, United States|Marietta, Georgia, United States|Post Falls, Idaho, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Maywood, Illinois, United States|Fort Wayne, Indiana, United States|Sioux City, Iowa, United States|Wichita, Kansas, United States|Scarborough, Maine, United States|Bethesda, Maryland, United States|Columbia, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Lake Success, New York, United States|Charlotte, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Kogarah, New South Wales, Australia|South Brisbane, Queensland, Australia|Frankston, Victoria, Australia|Perth, Western Australia, Australia|Leuven, Belgium|Wilrijk, Belgium|Salvador, BA, Brazil|Goiania, GO, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Itajai, SC, Brazil|Sao Paulo, SP, Brazil|Moncton, New Brunswick, Canada|Toronto, Ontario, Canada|Regina, Saskatchewan, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Brno, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Angers, France|Bordeaux, France|Caen, France|Lyon, France|Montpellier cedex 5, France|Nantes, France|Nice, France|Nimes, France|Paris, France|Reims CEDEX, France|Rouen, France|St-Priest-En-Jarez, France|Strasbourg, France|Toulouse, France|Toulouse, France|Tours, France|Villejuif, France|Bielefeld, Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Kiel, Germany|Mainz, Germany|München, Germany|Ravensburg, Germany|Recklinghausen, Germany|Stuttgart, Germany|Trier, Germany|Troisdorf, Germany|Budapest, Hungary|Budapest, Hungary|Gyula, Hungary|Kecskemet, Hungary|Miskolc, Hungary|Szeged, Hungary|Szolnok, Hungary|Bangalore, India|Chennai, India|Kolkata, India|New Delhi, India|Pune, India|Pune, India|Beer Sheva, Israel|Hafia, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat-Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Potenza, Basilicata, Italy|Napoli, Campania, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Biella, Piemonte, Italy|Cona (Ferrara), Veneto, Italy|Kyunggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Oslo, Norway|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Moscow, Russian Federation|Samara, Russian Federation|Stavropol, Russian Federation|Kosice, Slovakia|Poprad, Slovakia|La Coruna, La Coruña, Spain|Bilbao, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Sevilla, Spain|Valencia, Spain|Umea, Sweden|Uppsala, Sweden|Örebro, Sweden|Bern, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Brighton, United Kingdom|Guildford, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Nottingham, United Kingdom|Sheffield, United Kingdom|Stoke-on-Trent, United Kingdom|Westcliffe-on-sea, United Kingdom|Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01419197"
146,"NCT00866697","Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Completed","Has Results","Female","Phase 3","940","Industry","Interventional","May 26, 2009","July 8, 2012","August 24, 2017","March 20, 2009","December 19, 2013","November 21, 2018","Novartis Investigative Site, Hayward, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Jose, California, United States|Novartis Investigative Site, Santa Clara, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Annandale, Virginia, United States|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Melbourne, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Klagenfurt Am Woerthersee, Austria|Novartis Investigative Site, Korneuburg, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Libramont, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Oostende, Belgium|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Koebenhavn Oe, Denmark|Novartis Investigative Site, ANGERS Cedex 2, France|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Bourg en Bresse Cedex, France|Novartis Investigative Site, Brest Cedex, France|Novartis Investigative Site, Caen Cedex 05, France|Novartis Investigative Site, Clermont-Ferrand cedex, France|Novartis Investigative Site, Colmar Cedex, France|Novartis Investigative Site, Grenoble Cedex 09, France|Novartis Investigative Site, Grenoble Cedex, France|Novartis Investigative Site, La Roche sur Yon Cedex 9, France|Novartis Investigative Site, Le Chesnay Cedex, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Lorient cedex, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Metz Cedex 03, France|Novartis Investigative Site, Mont de Marsan, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Nantes Cedex 2, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Orleans, France|Novartis Investigative Site, Paris cedex 05, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Paris Cedex 20, France|Novartis Investigative Site, Paris Cedex 4, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Perigueux Cedex, France|Novartis Investigative Site, Perin Sur Mer, France|Novartis Investigative Site, Pierre-Benite Cedex, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Saint-Herblain, France|Novartis Investigative Site, Saint-Priest en Jarez, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Suresnes, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy, France|Novartis Investigative Site, Esslingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mutlangen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Reutlingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Schwaebisch Hall, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ulm, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Bayreuth, Bayern, Germany|Novartis Investigative Site, Coburg, Bayern, Germany|Novartis Investigative Site, Deggendorf, Bayern, Germany|Novartis Investigative Site, Ebersberg, Bayern, Germany|Novartis Investigative Site, Eggenfelden, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Schweinfurt, Bayern, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Limburg, Hessen, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Offenbach, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Greifswald, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Braunschweig, Niedersachsen, Germany|Novartis Investigative Site, Georgsmarienhuette, Niedersachsen, Germany|Novartis Investigative Site, Gifhorn, Niedersachsen, Germany|Novartis Investigative Site, Goettingen, Niedersachsen, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Lueneburg, Niedersachsen, Germany|Novartis Investigative Site, Salzgitter, Niedersachsen, Germany|Novartis Investigative Site, Wolfsburg, Niedersachsen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Detmold, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Neuss, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Viersen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Quedlinburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Salzwedel, Sachsen-Anhalt, Germany|Novartis Investigative Site, Chemnitz, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Leipzg, Sachsen, Germany|Novartis Investigative Site, Radebeul, Sachsen, Germany|Novartis Investigative Site, Zwickau, Sachsen, Germany|Novartis Investigative Site, Gera, Thueringen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Waterford, Ireland|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Avellino, Campania, Italy|Novartis Investigative Site, Napoli, Campania, Italy|Novartis Investigative Site, Bologna, Emilia-Romagna, Italy|Novartis Investigative Site, Carpi (MO), Emilia-Romagna, Italy|Novartis Investigative Site, Faenza (RA), Emilia-Romagna, Italy|Novartis Investigative Site, Reggio Emilia, Emilia-Romagna, Italy|Novartis Investigative Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Como, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Campobasso, Molise, Italy|Novartis Investigative Site, Torino, Piemonte, Italy|Novartis Investigative Site, Torino, Piemonte, Italy|Novartis Investigative Site, Bari, Puglia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Perugia, Umbria, Italy|Novartis Investigative Site, Vicenza, Veneto, Italy|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Hiroshima, Japan|Novartis Investigative Site, Hiroshima, Japan|Novartis Investigative Site, Hokkaido, Japan|Novartis Investigative Site, Iwate, Japan|Novartis Investigative Site, Kagoshima, Japan|Novartis Investigative Site, Miyagi, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tottori, Japan|Novartis Investigative Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Kangnam-Ku ,Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Tromso, Norway|Novartis Investigative Site, Alcorcon (Madrid), Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Cartagena (Murcia), Spain|Novartis Investigative Site, Elche, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Sabadell (Barcelona), Spain|Novartis Investigative Site, San Sebastian, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Terrassa, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00866697"
147,"NCT01250379","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)","Completed","Has Results","Female","Phase 3","494","Industry","Interventional","February 2011","December 2013","March 2015","November 30, 2010","June 30, 2015","February 11, 2016","Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|San Miguel de Tucuman, Argentina|Feldkirch, Austria|Graz, Austria|Innsbruck, Austria|Krems, Austria|Salzburg, Austria|Steyr, Austria|Villach, Austria|Wien, Austria|Goiania, GO, Brazil|Porto Alegre, RS, Brazil|Itajai, SC, Brazil|Split, Croatia|Amiens, France|Angers, France|Besancon, France|Bordeaux, France|Boulogne Sur Mer, France|Brest, France|Caen, France|Clermont Ferrand, France|Dijon, France|Grenoble, France|Limoges, France|Marseille, France|Montpellier, France|Nancy, France|Nantes, France|Paris, France|Pierre Benite, France|Reims CEDEX, France|Rouen, France|Saint Gregoire, France|Saint Jean, France|St Cloud, France|St Priest En Jarez, France|St Quentin, France|Strasbourg, France|Toulouse, France|Amberg, Germany|Aschaffenburg, Germany|Berlin, Germany|Berlin, Germany|Bielefeld, Germany|Chemnitz, Germany|Dresden, Germany|Düsseldorf, Germany|Essen, Germany|Essen, Germany|Freiburg, Germany|Göttingen, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Heidelberg, Germany|Karlsruhe, Germany|Koeln, Germany|Mannheim, Germany|Muenster, Germany|München, Germany|Naunhof, Germany|Neuss, Germany|Nordhausen, Germany|Osnabrueck, Germany|Ravensburg, Germany|Stade, Germany|Stralsund, Germany|Wiesbaden, Germany|Athens, Greece|Ioannina, Greece|Patras, Greece|Thessaloniki, Greece|Budapest, Hungary|Budapest, Hungary|Szeged, Hungary|Beer Sheva, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Cosenza, Calabria, Italy|Benevento, Campania, Italy|Napoli, Campania, Italy|Reggio Emilia, Emilia-Romagna, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Monza, Lombardia, Italy|Macerata, Marche, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Catania, Sicilia, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Pontedera, Toscana, Italy|Verona, Veneto, Italy|Bardejov, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Nove Zamky, Slovakia|Presov, Slovakia|Santander, Cantabria, Spain|San Sebastian, Guipuzcoa, Spain|Palma De Mallorca, Islas Baleares, Spain|La Laguna, Tenerife, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Castellon, Spain|Cordoba, Spain|Leon, Spain|Lerida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Sevilla, Spain|Valencia, Spain|Zaragoza, Spain|Aarau, Switzerland|Chur, Switzerland|Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT01250379"
148,"NCT01125566","LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment","Completed","Has Results","Female","Phase 3","508","Industry","Interventional","June 22, 2010","June 8, 2013","June 7, 2018","May 18, 2010","August 21, 2014","July 31, 2018","Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Robert A. Moss MD, FACP, Inc, Fountain Valley, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|University of California, Los Angeles, California, United States|Cancer Care Associates Medical Group, Inc, Redondo Beach, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|North Shore Cancer Research Associates, Skokie, Illinois, United States|Cedar Valley Cancer Center, Waterloo, Iowa, United States|Pro Health Care Associated, Lake Success, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Utah Cancer Specialists Cancer Center, Salt Lake City, Utah, United States|Instituto Medico de Asistencia e Investigaciones S. A., Buenos Aires, Argentina|Hospital Britanico, Capital Federal, Argentina|Sanatorio de la Provodencia, Ciudad Autonoma de Bs As, Argentina|Sanatorio Parque, Rosario, Argentina|Port Macquarie Base Hospital (PMBH), Port Macquarie, New South Wales, Australia|St. Vincents Hospital (MEL), Fitzroy, Victoria, Australia|Peninsula Oncology Centre, Frankston, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Mount Medical Centre, Perth, Western Australia, Australia|Order Hospital Elisabethinen Linz, Linz, Austria|Kaiser Franz Josef Spital Vienna, Wien, Austria|Grodno Regional Clinical Hospital, Grodno, Belarus|N. N. Alexandrov National Cancer Center of Belarus, Minsk Region, Belarus|Public Health Inst. Minsk City Clinical Oncology Dispensary, Minsk, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Brussels - HOSP Jules Bordet, Bruxelles, Belgium|Edegem - UNIV UZ Antwerpen, Edegem, Belgium|Liège - HOSP St-Joseph, Liège, Belgium|Centro de Pesquisas Clínicas em Oncología, Cachoeiro de Itapemirim, Brazil|Hospital Santa Cruz, Curitiba, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, Brazil|Associação Hospitalar Moinhos de Vento, Porto Alegre, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Centro de Novos Tratamentos CliniOnco, Porto Alegre, Brazil|Instituto Nacional do Câncer - INCA, Rio de Janeiro, Brazil|Faculdade de Medicina do ABC, Santo André, Brazil|Centro de Referência da Saude da Mulher-Hosp Perola Byington, Sao Paulo, Brazil|BC Cancer Agency - Vancouver, Vancouver, British Columbia, Canada|Hopital Notre-Dame du CHUM, Montreal, Migration Data, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hop. Du St. Sacrement, Quebec, Canada|Instituto Clínico Oncológico del Sur - ICOS, Temuco, Chile|Cancer Hospital of Chinese Academy of Medical Science, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|307 Hospital of PLA, Beijing, China|Chinese PLA General Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|West China Hospital, Chengdu, China|Fujian Provincial Tumor Hospital, Fuzhou, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|NanFang Hosptial, Guangzhou, China|The Third Affiliated Hospital of Harbin Medical University, Haerbin, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Qilu Hospital, Shangdong University, Jinan, China|the 81th Hospital of PLA, Nanjing, China|Shanghai Ruijin Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Wuhan Union Hospital, Wuhan, China|Hospital Ceske Budejovice, Ceske Budejovice, Czechia|University Hospital Olomouc, Olomouc, Czechia|General Faculty Hospital, Prague, Prague 2, Czechia|MEDICON a.s., Praha 4, Praha 4, Czechia|El Manial Specialized Hospital, Cairo, Egypt|Oncology Centre- Mansoura University, Mansoura, Egypt|HOP Amiens Sud, Onco, Amiens, Amiens Cedex 1, France|CTR P Papin, Onco, Angers, Angers Cedex 9, France|HOP Jean Minjoz, Besançon Cedex, France|CLI Bordeaux Nord Aquitaine, Bordeaux, France|CTR J Perrin, Onco, Clermont-Ferrand, Clermont-Ferrand Cedex, France|CTR Jean Bernard, Onco, Le Mans, Le Mans, France|CTR Catherine de Sienne, Nantes, France|HOP Saint-Louis, Paris, France|INS Jean Godinot, Onco, Reims, Reims, France|CTR Eugène Marquis, Rennes Cedex, France|CTR René Huguenin, St Cloud, France|CTR Paul Strauss, Strasbourg Cedex, France|Universitätsklinikum Aachen, AöR, Aachen, Germany|Medizinisches Zentrum Bonn, Bonn, Germany|OnkoDok GbR, Bottrop, Germany|DONAUISAR Klinikum Deggendorf-Dingolfing-Landau gKU, Deggendorf, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Kliniken Essen - Mitte gGmbH, Essen, Germany|Gynäk.-onkol. Gem.praxis, Dr. Uleer, Hildesheim, Hildesheim, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|St. Elisabeth-Krankenhaus, Köln, Germany|Universitätsklinikum Magdeburg AöR, Magdeburg, Germany|Klinikum der Universität München - Campus Innenstadt, München, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Onkologische Praxis Oldenburg, Oldenburg, Germany|Universitätsfrauenklinik am Klinikum Südstadt, Rostock, Germany|Facharzt für Innere Medizin, Wuppertal, Germany|Gujarat Cancer and Research Institute, Ahmedabad, India|Sujan Surgical Cancer Hospital, Amravati, India|KIDWAI memoraial Institute of oncology, Bangalore, India|Sri Venkateshwara Hospital, Bengaluru, India|Dr. Rai Memorial Cancer Centre, Chennai, India|Bibi General Hospital and Cancer Centre, Hyderabad, India|Orchid Nursing Home, Kolkata, India|Natinal Cancer Institute, Maharagama, India|Shatabdi Superspeciality Hospital, Maharashtra, India|Central India Cancer Research Institute, Nagpur, India|Curie Manavata Cancer centre, Nashik, India|Jehangir Hospital Oncology Department, Pune, India|K.E.M Hospital, Pune, India|King George Hospital, Visakhapatnam, India|Beaumont Hospital, Dubliin 9, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|Mater Misericordiae University Hospital, Dublin 7, Ireland|St James's Hospital, Dublin 8, Ireland|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem 91031, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|The Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Israel|Sourasky Medical Center, Tel-Aviv, Israel|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Ferrara, Italy|Istituto Europeo di Oncologia, Milan, Italy|P.O. Monserrato, Monserrato (CA), Italy|Tokai University Hospital, Kanagawa, Isehara-shi, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, Japan|National Cancer Center, Goyang, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|P. Stradins Clinical Univ. Hospital, Oncology Clinic, Riga, Latvia|Riga East Univ. Hospital, Oncology Centre, Riga, Latvia|Hammoud Hospital University Medical Centre, Lebanon, Lebanon|Hospital of Lithuanian Univ.of HealthSciences Kauno Klinikos, Kaunas, Lithuania|National Cancer Institute, Vilnius, Vilnius, Lithuania|Hospital de Jesus, Colonia Centro, Mexico|Albert SchweitzerZiekenhuis, Dordrecht, Netherlands|Máxima Medisch Centrum, locatie Eindhoven, Eindhoven, Netherlands|Zuyderland Medisch Centrum, Geleen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Medisch Ethische Commissie Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Isala Zwolle, Zwolle, Netherlands|Hospital Nacional Adolfo Guevara Velasco, Cusco, Peru|Clinica San Judas Tadeo, Lima, Peru|Instituto Oncologico Miraflores S.A., Miraflores, Peru|Clinica Peruano Americana de Trujillo, Trujillo, Peru|Bialystock's Oncology Center, Bialystok, Poland|Wojewodzki Specialist Hospital No. 4, Bytom, Bytom, Poland|University Clinical Center, Gdansk, Gdansk, Poland|Provincial Specialist M. Kopernik Hospital, Lodz, Poland|Ziemia Lubelska Oncological Center, Lublin, Lublin, Poland|Oncology Centre of Olsztyn ""KOPERNIK"" Sp. z.o.o., Olsztyn, Poland|Wielkopolskie Oncology Centre n.a. Maria Sklodowska-Courie, Poznan, Poland|Military Medical Institute, Warsaw, Poland|Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, Portugal|CHUC, EPE - CHC-Maternidade Bissaya Barreto, Coimbra, Portugal|IPO Lisboa Francisco Gentil, EPE, Lisboa, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|St.Auton.Heal.Inst.""Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"", Kazan, Russian Federation|N.A. Semashko Central Clinical Hospital, Moscow, Moscow, Russian Federation|GUZ ""Regional Clinical Oncology Dispensary"", Ryazan, Russian Federation|Regional Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Johns Hopkins Singapore International Medical Center, Singapore, Singapore|St. Jacobs Hosp.Outpat.Pneumology&Phthisiology Dept,Bardejov, Bardejov, Slovakia|National Institute of Oncology, Bratislava, Bratislava, Slovakia|POKO Policlinic Dept. of Clinical Oncology, Poprad, Slovakia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Wits Donald Gordon Clinical Trial Site, Johannesburg, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|GVI oncology Medi Clinic, Kraaifontein, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Wilgers oncology, Pretoria, South Africa|Rondebosch Oncology Centre, Rondebosch, Cape Town, South Africa|Hospital del Mar, Barcelona, Spain|Hospital Universitari Dexeus, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Complejo Hospitalario Universitario Insular - Materno Infantil, Las Palmas de Gran Canaria, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Chang-Hua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan County, Taiwan|Hacettepe Universitesi Tip Fakultesi, Ic Hastaliklari ABD, Ankara, Turkey|Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali, Izmir, Turkey|Ninewells Hospital & Medical School, Dundee, United Kingdom|Guy's Hospital, London, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom|Queen Elizabeth Hospital, Woolwich, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01125566"
149,"NCT01186991","Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer","Completed","No Results Available","Female","Phase 2","185","Industry","Interventional","March 2011","March 2016","March 2016","August 23, 2010","null","January 20, 2017","Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States|St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States|Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States|Univ of California Los Angeles, Los Angeles, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|Sharp Healthcare; Oncology Research Program, San Diego, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States|Suburban Hematology Oncology, Lawrenceville, Georgia, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute.., Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|North Shore Hem Onc Associates, East Setauket, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|South Carolina Onc. Associate, Columbia, South Carolina, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|The Sarah Cannon Research Inst, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Institut Jules Bordet, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|AZ Sint Lucas (Sint Lucas), Gent, Belgium|CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|CHU Sart-Tilman, Liège, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|Institut Bergonie; Oncologie, Bordeaux, France|Centre Francois Baclesse; Gastro-Enterologie, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Centre Leon Berard, Lyon, France|Institut régional du Cancer Montpellier, Montpellier, France|Institut Curie; Oncologie Medicale, Paris, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Centre Rene Huguenin; CONSULT SPECIALISEES, St Cloud, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Praxis Dr. med. Klausmann; SHOD, Aschaffenburg, Germany|Klinik Johann Wolfgang von Goethe Uni, Frankfurt am Main, Germany|Klinikum rechts der Isar der TU München; Frauenklinik, Muenchen, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, Germany|Hospital Universitario Puerta del Mar; Servicio de Oncologia, Cádiz, Cadiz, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Instituto Catalán de Oncología; Servicio de Farmacia, Barcelona, Spain|Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia, La Coruña, Spain|Brighton and Sussex Univ Hosp, Brighton, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Mount Vernon Hospital; Centre For Cancer Treatment, Northwood, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, United Kingdom|The Clatterbridge Cancer Ctr For Oncolgy, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01186991"
150,"NCT01026142","A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)","Completed","Has Results","Female","Phase 3","452","Industry","Interventional","January 26, 2010","May 29, 2015","August 7, 2017","December 4, 2009","October 13, 2016","August 14, 2018","Fundación Investigar, Buenos Aires, Argentina|Hospital Britanico; Oncologia, Buenos Aires, Argentina|Instituto FIDES, La Plata, Argentina|Instituto de Investigaciones Clínicas Quilmes, Quilmes, Argentina|Instituto de Oncología de Rosario, Rosario, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|A.Ö. Landesschwerpunktkrankenhaus Krems; Abtl. F. Innere Med., Krems, Austria|Landeskrankenhaus Rankweil; Interne E, Rankweil, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Imeldaziekenhuis, Bonheiden, Belgium|AZ KLINA, Brasschaat, Belgium|UZ Brussel, Brussel, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|CHU Sart-Tilman, Liège, Belgium|Clinique Saint-Joseph, Liège, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|AZ Nikolaas (Lodewijk), Sint-Niklaas, Belgium|Oncologia Sul Capixaba Servicos Medicos - Oncosul, Cachoeiro Do Itapemirim, ES, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Centro Oncológico de Mogi das Cruzes, São Paulo- SP, SP, Brazil|Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Uni Hospital For Tumours; Dept of Medical Oncology, Zagreb, Croatia|Masarykuv onkologicky ustav; Oncology II, Brno, Czechia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Lekarske Fakulty Univerzity Karlovy Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie, Praha, Czechia|North Estonia Medical Centre Foundation; Oncology Centre, Tallinn, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, Estonia|C.H. Du Pays D'aix En Provence Service du Dr Blanc, Aix En Provence, France|Centre Oncologie Du Pays Basque, Bayonne, France|Centre Hospitalier Fleyriat; Oncologie/Hematologie, Bourg En Bresse, France|CHU Henri Mondor; Service d'Oncologie Medicale, Creteil, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Centre Leon Berard; Oncologie Genetique, Lyon, France|Centre Antoine Lacassagne; Hopital De Jour A2, Nice, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Antoine; Sce Oncologie, Paris, France|Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, France|Centre Henri Becquerel; Oncologie Medicale, Rouen, France|Centre Rene Huguenin; CONSULT SPECIALISEES, St Cloud, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Clinique Pasteur; Oncologie Medicale, Toulouse, France|CAMPUS CHARITÉ MITTE; Tagesklinik für Onkologie u.Hämatologie, Berlin, Germany|Klinikum Bremen-Mitte gGmbH; Frauenklinik, Bremen, Germany|Klinikum Sindelfinden Boblingen, Böblingen, Germany|Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie, Darmstadt, Germany|Klinikum Dortmund gGmbH Klinikzentrum Mitte, Dortmund, Germany|Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Essen, Germany|Klinikum Frankfurt Höchst GmbH; Klinik für Gynäkologie und Geburtshilfe, Frankfurt, Germany|Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH, Fulda, Germany|Universitätsklinikum Hamburg-Eppendorf; Zentrum für operative Medizin Klinik für Gynäkologie, Hamburg, Germany|HOPA MVZ GmbH, Hamburg, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, Germany|Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie, Hannover, Germany|ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik, Karlsruhe, Germany|Systemedic Frauenarzte Pruener Gang, Kiel, Germany|Institut für Versorgungsforschung in der Onkologie GbR Koblenz, Koblenz, Germany|St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Koeln, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany|St. Vincenz-Elisabeth-Hospital; Katholisches Klinikum Mainz, Mainz, Germany|Klinikum rechts der Isar der TU München; Frauenklinik & Poliklinik, München, Germany|Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe, Münster, Germany|St. Josefs Klinik; Medizinische Klinik, Offenburg, Germany|Praxis für Onkologie und Hämatologie, Recklinghausen, Germany|Johanniter Klinik, Stendal, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, Germany|GRN Klinik Weinheim, Weinheim, Germany|Queen Mary Hospital; Surgery, Hong Kong, Hong Kong|Queen Elizabeth Hospital; Clinical Oncology, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Oncology, Hong Kong, Hong Kong|Ogyi, Orszagos Gyogyszereszeti Intezet, Budapest, Hungary|Semmelweis Egyetem Onkologiai Központ, Budapest, Hungary|Fövárosi Önkormányzat Bajcsy-Zsilinszky Kórház; Onkológiai Osztály, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest, Hungary|Municipal Hospital of Uzsoki Utca; Centre of Oncoradiology, Budapest, Hungary|Hospital of Aladar Petz; Dept of Oncoradiology, Gyor, Hungary|Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek, Gyula, Hungary|Kaposi Mor County Hospital; Dept. of Oncology, Kaposvar, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Josa Andras Korhaz; Dept of Oncoradiology, Nyíregyháza, Hungary|Pécsi Tudományegyetem Áok; Onkoterapias Intezet, Pecs, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Fejér Megyei Szent György Kórház; Onkológiai Osztály, Szekesfehervar, Hungary|Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály, Szolnok, Hungary|Istituto Tumori Fondazione Pascale; Endocrinologia Oncologica, Napoli, Campania, Italy|Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli, Bologna, Emilia-Romagna, Italy|Ospedale Cervesi di Cattolica ; Unità Operativa di Oncologia ed Oncoematologia, Cattalica, Emilia-Romagna, Italy|AUSL Cesena; Servizio di Oncologia, Cesena, Emilia-Romagna, Italy|Ausl Ravenna-Osp.Infermi; Day Hospital Oncologia Medica, Faenza, Emilia-Romagna, Italy|Ospedale Umberto I ASL di Ravenna Presidio Ospedaliero di Lugo, Lugo, Emilia-Romagna, Italy|Azienda USL di Ravenna; Unità Operativa di Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia, Rimini, Emilia-Romagna, Italy|Istituto Regina Elena; Oncologia Medica A, Roma, Lazio, Italy|Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST DI CREMONA; Dipartimento Aziendale Oncologico, Cremona, Lombardia, Italy|Ospedale Mater Salutis; Dept of Oncology, Legnago, Lombardia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|IRCCS Fondazione Maugeri; Oncologia Medica II, Pavia, Lombardia, Italy|ASST LARIANA; Oncologia, S. Fermo Della Battaglia (CO), Lombardia, Italy|A.O. Città della Salute e della Scienza - Presidio Molinette; divisione oncologia medica, Torino, Piemonte, Italy|Ospedale Civile; Oncologia Medica, Sassari, Sardegna, Italy|ARNAS-Ospedale Civico Maurizio Ascoli; Unità Operativa di Oncologia Medica, Palermo, Sicilia, Italy|Azienda ospedaliero-universitaria careggi, Sezione di radioterapia del dipartimento di fisiopatolo, Firenze, Toscana, Italy|A.O. Universitaria Pisana; Oncologia, Pisa, Toscana, Italy|Severance Hospital, Seoul, Korea, Republic of|Seoul National University Hosp; Dept Internal Med Hem Onc, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Korea University Guro Hospital; Oncology, Seoul, Korea, Republic of|Oaxaca Site Management Organization, Oaxaca, Mexico|Centro Oncológico Estatal; ISSSEMYM Oncología, Toluca, Mexico|Vu Medisch Centrum; Afdeling Maag-, Darm- En Leverziekte, Amsterdam, Netherlands|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, Peru|Hospital Nacional Edgardo Rebagliati Martins, Jesus Maria, Peru|Clinica Anglo Americana - Centro de Investigacion Oncologia CAA, Lima, Peru|Unidad de Investigacion Oncologia Clinica - Piura; Unidad de Oncología Clínica, Piura, Peru|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Wojewodzki Szpital Zespolony; Oddzial Chemioterapii, Elblag, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, Poland|Wojewodzki Sziptal Specjalistyczny Im. Janusza Korczaka; Oddzial Onkologiczny, Oddzial Chemioterapii, Slupsk, Poland|Spitalul Clinic Sf. Maria; Departmental De Oncologie, Bucharest, Romania|Institute Of Oncology Bucharest; Medical Oncology, Bucharest, Romania|Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department, Bucuresti, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Cluj Clinical County Hospital; Oncology Dept, Cluj-Napoca, Romania|Medisprof SRL, Cluj-Napoca, Romania|Municipal Clinical Hospital Filantropia; Oncology, Craiova, Romania|Euroclinic Center of Oncology SRL, Iasi, Romania|Regional Oncology Hospital of Krasnodar; Oncology, Krasnodar, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Semashko Central Clinical Hospital; Dept of Chemotherapy, Moscow, Russian Federation|GUZ Perm Region Oncology Dispensary, Perm, Russian Federation|S.-Peterburg Pavlov State Medical University ; Haematology, St Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Hospital Clinica Benidorm, Benidorm, Alicante, Spain|Complejo Hospitalario Torrecardenas; Servicio de Oncologia, Almería, Almeria, Spain|Consorci Hospitalari de Terrassa, Terrassa, Barcelona, Spain|Fundacion Hospital de Alcorcon; Servicio de Oncologia, Alcorcon, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Sagunto; Servicio de Oncologia, Sagunto, Valencia, Spain|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Clinic i Provincial; Servicio de Farmacia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Provincial de Castellón, Castellon, Spain|Hospital Juan Ramon Jimenez;Servicio de Oncologia, Huelva, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ruber Internacional;Servicio de Oncologia, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Hospital La Paz, Madrid, Spain|Complejo Hospitalario de Pontevedra; Servicio de Oncologia, Pontevedra, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Univ. Nuestra Señora de Valme;, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Phramongkutklao Hospital;Dept Surgery/Surgical Oncology Unit, Bangkok, Thailand|Ramathibodi Hospital; Department of Surgery/Breast and Endocrine Unit, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Srinagarind Hospital; Department of Surgery, Khon Kaen, Thailand|Songklanagarind Hospital; Department of Surgery, Songkla, Thailand|Royal Bournemouth General Hospital; Oncology, Bournemouth, United Kingdom|Velindre Cancer Centre; Oncology Dept, Cardiff, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|University Hospital of North Durham; Oncology, Durham, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Peterborough City Hospital, Edith Cavell Campus; Oncology Department, Peterborough, United Kingdom|Great Western Hospital; Clinical Oncology, Swindon, United Kingdom|Royal Cornwall Hospital; Dept of Clinical Oncology, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01026142"
151,"NCT01204125","Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","Completed","No Results Available","Female","Phase 2","141","Industry|Other","Interventional","September 2010","October 2012","February 2017","September 17, 2010","null","March 22, 2017","Investigational Site Number 250001, Besancon Cedex, France|Investigational Site Number 250004, Bordeaux, France|Investigational Site Number 250006, Bron Cedex, France|Investigational Site Number 250003, Paris Cedex 10, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 250005, Villejuif, France|Investigational Site Number 276003, Erlangen, Germany|Investigational Site Number 276004, Hamburg, Germany|Investigational Site Number 276002, Köln, Germany|Investigational Site Number 276001, Mönchengladbach, Germany|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724009, Cáceres, Spain|Investigational Site Number 724013, Córdoba, Spain|Investigational Site Number 724006, Islas Baleares, Spain|Investigational Site Number 724012, Jaén, Spain|Investigational Site Number 724002, Lérida, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724016, Madrid, Spain|Investigational Site Number 724007, Reus, Spain|Investigational Site Number 724018, Santiago De Compostela, Spain|Investigational Site Number 724017, Sevilla, Spain|Investigational Site Number 724010, Sevilla, Spain|Investigational Site Number 724003, Torrevieja, Spain|Investigational Site Number 724011, Valencia, Spain|Investigational Site Number 724015, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01204125"
152,"NCT01918254","A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein","Completed","No Results Available","All","Phase 1","66","Industry","Interventional","August 6, 2013","October 7, 2016","October 7, 2016","August 7, 2013","null","September 12, 2017","Rigshospitalet, Onkologisk Klinik, København Ø, Denmark|Centre Francois Baclesse; Comite Sein, Caen, France|Institut régional du Cancer Montpellier, Montpellier, France|Institut Curie; Oncologie Medicale, Paris, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|University of Hannover; Medical School, Hannover, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01918254"
153,"NCT00811135","A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer","Completed","Has Results","All","Phase 2","88","Industry","Interventional","December 2008","December 2015","December 2015","December 18, 2008","December 8, 2015","September 29, 2016","Herlev, Denmark|Vejle, Denmark|Aix En Provence, France|Beziers, France|Creteil, France|Dechy, France|Lormont, France|Marseille, France|Narbonne, France|Paris, France|Paris, France|Paris, France|Paris, France|Rodez, France|Saint Jean, France|Saint Quentin, France|Toulouse, France|Moscow, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Bratislava, Slovakia|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Pontevedra, Spain|Salamanca, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Eskilstuna, Sweden|Sundsvall, Sweden|Uppsala, Sweden|Vaxjo, Sweden","https://ClinicalTrials.gov/show/NCT00811135"
154,"NCT00929240","A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer","Completed","Has Results","Female","Phase 3","287","Industry","Interventional","July 2009","June 2014","June 2014","June 26, 2009","March 3, 2015","March 3, 2015","Fortaleza, CE, Brazil|Belo Horizonte, MG, Brazil|Rio de Janeiro, RJ, Brazil|Ijui, RS, Brazil|Porto Alegre, RS, Brazil|Jau, SP, Brazil|Santo Andre, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Beijing, China|Beijing, China|Beijing, China|Hangzhou, China|Hangzhou, China|Shanghai, China|Alexandria, Egypt|Cairo, Egypt|Amiens, France|Angers, France|Besancon, France|Bobigny, France|Dijon, France|Hyeres, France|Le Coudray, France|Lille, France|Paris, France|Paris, France|Perigueux, France|Rodez, France|St Priest En Jarez, France|Strasbourg, France|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Bangalore, India|Hyderabad, India|Mumbai, India|Mumbai, India|New Delhi, India|New Delhi, India|Napoli, Campania, Italy|Trieste, Friuli-Venezia Giulia, Italy|Genova, Liguria, Italy|Saronno, Lombardia, Italy|Brindisi, Puglia, Italy|Antella (FI), Toscana, Italy|Bydgoszcz, Poland|Wroclaw, Poland|Dammam, Saudi Arabia|Jeddah, Saudi Arabia|Jeddah, Saudi Arabia|Alcoy, Alicante, Spain|Sabadell, Barcelona, Barcelona, Spain|Alcazar de S. Juan, Ciudad Real, Spain|Barakaldo, Vizcaya, Spain|Jaen, Spain|Malaga, Spain|Toledo, Spain|Valencia, Spain|Ankara, Turkey|Ankara, Turkey|Antalya, Turkey|Istanbul, Turkey|Sıhhiye, ANKARA, Turkey","https://ClinicalTrials.gov/show/NCT00929240"
155,"NCT01120184","A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)","Completed","Has Results","All","Phase 3","1095","Industry","Interventional","July 31, 2010","September 30, 2014","September 16, 2016","May 10, 2010","February 23, 2017","November 7, 2017","Arizona Oncology, Tucson, Arizona, United States|Uni of Arkansas For Medical Sciences; Arkansas Cancer Research Center, Little Rock, Arkansas, United States|Little Rock Hematology Oncology Associates, PA, Little Rock, Arkansas, United States|Scripps Cancer Center, La Jolla, California, United States|University of California; Moores Cancer Center, La Jolla, California, United States|Clnc L Trials & Rsch Assoc-Inc, Montebello, California, United States|Global Oncology, Inc., Monterey Park, California, United States|Southern California Kaiser Permanente, San Diego, California, United States|Sharp Healthcare; Oncology Research Program, San Diego, California, United States|Breastlink Medical Group Inc, Santa Ana, California, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States|Uni of Colorado Cancer Center; Anschutz Cancer Pavilion, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Christiana Care Health Srvcs, Newark, Delaware, United States|Washington Cancer Institute; Washington Hospital Center, Washington, District of Columbia, United States|Innovative Medical Research of South Florida, Aventura, Florida, United States|Northwest Oncology/ Hematology Assoc., Coral Springs, Florida, United States|Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Hematology Oncology Associates, Loxahatchee, Florida, United States|Uni of Miami School of Medicine; Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Northeast Georgia Medical Center; Oncology Research Dept-5C, Gainesville, Georgia, United States|Cancer Research Center of Hawaii; Clinical Sciences, Honolulu, Hawaii, United States|Mountain States Tumor Inst., Boise, Idaho, United States|Uni of Chicago, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Med Center, Maywood, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Siouxland Hematology/Oncology, Sioux City, Iowa, United States|James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, United States|New England Cancer Specialists, Scarborough, Maine, United States|York Hospital, York, Maine, United States|Anne Arundel Health System Research Instit-Annapolis Oncology Ctr, Annapolis, Maryland, United States|Mercy Medical Center; Medical Oncology & Hematology, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Spectrum Health Grand Rapids, Grand Rapids, Michigan, United States|St. Mary's Duluth Clinic Heath System, Duluth, Minnesota, United States|University of Minnesota., Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States|Columbia Comprehensive Cancer Center Clinic, Jefferson City, Missouri, United States|St. John'S Mercy Medical Center; David C. Pratt Cancer Center, Saint Louis, Missouri, United States|Mercy Clinic Cancer & Hematology, Springfield, Missouri, United States|Nebraska Methodist Hospital; Cancer Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Med Center, Lebanon, New Hampshire, United States|Hackensack Uni Medical Center; Northern Nj Cancer Center, Hackensack, New Jersey, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Presbyterian Medical Group, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Queens Medical Associates, Fresh Meadows, New York, United States|Queens Hospital Center, Jamaica, New York, United States|Arena Oncology Associates, Lake Success, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Weill Medical College of Cornell Uni, New York, New York, United States|Carolinas Hem-Oncology Assoc, Charlotte, North Carolina, United States|Carolina Oncology Specialists, PA - Hickory, Hickory, North Carolina, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Oncology Hematology Care - SCRI, Cincinnati, Ohio, United States|Providence Portland Medical Ctr, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Pharma Resource, East Providence, Rhode Island, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|Medical University of SC (MUSC), Charleston, South Carolina, United States|South Carolina Oncology Associates - SCRI, Columbia, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|West Clinic, Germantown, Tennessee, United States|Uni of Tennessee Cancer Inst., Memphis, Tennessee, United States|Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The Don & Sybil Harrington Cancer Center; Department of Clinical Research, Amarillo, Texas, United States|Uni of Texas Southwestern Medical Center, Dallas, Texas, United States|Uni of Texas - Md Anderson Cancer Center; Dept of Breast Medical Oncology, Houston, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|University of Washington, Seattle, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Fundación Investigar, Buenos Aires, Argentina|CER Instituto Médico Oncología, Florencio Varela, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Argentina|Mater Misericordiae Hospital; Chemotherapy Cottage, Sydney, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Wesley Medical Centre; Clinic For Haematology and Oncology, Auchenflower, Queensland, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, Australia|Peter Maccallum Cancer Institute; Medical Oncology, Melbourne, Victoria, Australia|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Oncology Consultants Limited, Nassau, Bahamas|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Instituto Nacional do Cancer - INCA, Rio de Janeiro, RJ, Brazil|Liga Norte Riograndense Contra O Câncer, Natal, RN, Brazil|Clinica de Oncologia de Porto Alegre - CliniOnco, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Cross Cancer Institute; Clinical Trials, Edmonton, Alberta, Canada|North York General Hospital, Toronto, Ontario, Canada|Cuse - Centre Universitaire De Sante; Site Fleurimont, Sherbrooke, Quebec, Canada|CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY, Quebec, Canada|Clinica del Country, Bogota, Colombia|Instituto Colombiano Para El Avance De La Medicina: Icamedic, Bucaramanga, Colombia|Centro Medico Imbanaco, Cali, Colombia|Instituto Cancerologico de Nariño, Pasto, Colombia|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie, Praha, Czechia|Nordsjællands Hospital, Hillerød, Onkologisk Afdeling, Hillerod, Denmark|Vejle Sygehus Onkologisk Afd, Vejle, Denmark|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, France|Centre Oscar Lambret; Senologie, Lille, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Institut régional du Cancer Montpellier, Montpellier, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis; Service Onco Thoracique, Paris, France|HOPITAL TENON; Cancerologie Medicale, Paris, France|Chu La Miletrie; Radiotherapie, Poitiers, France|Centre Rene Huguenin; ONCOLOGIE GENETIQUE, Saint Cloud, France|Institut de Cancerologie de La Loire; Radiotherapie, St Priest En Jarez, France|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie, Halle, Germany|Facharztzentrum Eppendorf, Studien GbR, Hamburg, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Magdeburg; Frauenheilkunde & Geburtshilfe, Magdeburg, Germany|Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz, Germany|Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Frauenheilkunde und Geburtshilfe, Minden, Germany|Rotkreuzklinikum München; Frauenklinik, Muenchen, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University Hospital of Larissa; Oncology, Larissa, Greece|Grupo Angeles, Guatemala City, Guatemala|Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, Guatemala|Szent Margit Hospital; Dept. of Oncology, Budapest, Hungary|Semmelweis Egyetem Onkologiai Központ, Budapest, Hungary|Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest, Hungary|Pécsi Tudományegyetem Áok; Onkoterapias Intezet, Pecs, Hungary|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Ematologia, Modena, Emilia-Romagna, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy|Ospedale Degli Infermi; Divisione Di Oncologia, Rimini, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia, Udine, Friuli-Venezia Giulia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Fondazione Salvatore Maugeri, Pavia, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano, Lombardia, Italy|Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, Italy|Ospedale Papardo- Piemonte;Oncologia Medica, Messina, Sicilia, Italy|Ospedale Misericordia E Dolce; Oncologia Medica, Prato, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|A.O.U.I. VERONA-OSPEDALE BORGO TRENTO; ONCOLODIA MEDICA-d.O., Verona, Veneto, Italy|Mikawa Breast Cancer Clinic; Breast Surgery, Aichi, Japan|Aichi Cancer Center Hospital, Breast Oncology, Aichi, Japan|Natl Hosp Org Shikoku; Cancer Ctr, Surgery, Ehime, Japan|Kitakyushu Municipal Medical Center; Surgery, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center;Breast Oncology, Fukuoka, Japan|Gifu University Hospital; Second Department of Surgery, Gifu, Japan|Gunma University Hospital; Department of Breast and Endocrine Surgery, Gunma, Japan|Hiroshima University Hospital; Breast Surgery, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center; Breast Surgery, Hokkaido, Japan|Hyogo College Of Medicine; Breast And Endocrine Surgery, Hyogo, Japan|Hyogo Cancer Center; Breast Surgery, Hyogo, Japan|Kanazawa University Hospital; Breast Oncology, Ishikawa, Japan|Iwate Med Univ School of Med; Surgery, Iwate, Japan|Sagara Hospital; Breast Surgery, Kagoshima, Japan|St. Marianna University School of Medicine Hospital, Breast and Endocrine Surgery, Kanagawa, Japan|Tokai University Hospital, Breast and Endocrine Surgery, Kanagawa, Japan|Kumamoto University Hospital; Breast and Endocrine Surgery, Kumamoto, Japan|Kumamoto City Hospital, Breast and Endocrine Surgery, Kumamoto, Japan|Kyoto University Hospital; Breast Surgery, Kyoto, Japan|Tohoku University Hospital; Breast And Endocrine Surgery, Miyagi, Japan|Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, Japan|Okayama University Hospital; Breast, Thyroid Surgery, Okayama, Japan|Kawasaki Medical School Hospital; Breast and Thyroid Surgery, Okayama, Japan|National Hospital Organization Osaka National Hospital; Breast Surgery, Osaka, Japan|Osaka University Hospital; Breast and Endocrine Surgery, Osaka, Japan|Saitama Medical University International Medical Center; Medical Oncology, Saitama, Japan|Saitama Cancer Center, Breast Oncology, Saitama, Japan|Shizuoka Cancer Center; Female Internal Medicine, Shizuoka, Japan|Shizuoka General Hospital; Breast Surgery, Shizuoka, Japan|Jichi Medical University; Breast Oncology, Tochigi, Japan|National Cancer Center Hospital; Breast and Medical Oncology, Tokyo, Japan|Toranomon Hospital; Breast and Endocrine Surgery, Tokyo, Japan|The Cancer Inst. Hosp. of JFCR; Breast Oncology Center, Tokyo, Japan|Showa University Hospital; Breast Surgery, Tokyo, Japan|Tokyo Medical Uni. Hospital; Breast Oncology, Tokyo, Japan|Kyorin University Hospital; Breast Surgery, Tokyo, Japan|Seoul National University Bundang Hospital; Hematology Medical Oncology, Gyeonggi-do, Korea, Republic of|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Korea University Guro Hospital; Oncology, Seoul, Korea, Republic of|Private Health Organization Acibadem Sistina Hospital, Skopje, Macedonia, The Former Yugoslav Republic of|Beacon International Specialist Centre, Petaling Jaya, Selangor, Selangor, Malaysia|Pantai Hospital Kuala Lumpur; Dept of Oncology & Radiotherapy, Kuala Lumpur, Malaysia|Sunway Medical Centre, Selangor, Malaysia|Centro de Investigacion; Clinica Del Pacifico, Acapulco, Mexico|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Núcleo de Especialidades Oncológicas, Guadalajara, Mexico|Centro Universitario Contra El Cancer, Monterrey, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Hospital Privado San Jose; Oncologia, Obregon, Mexico|Centro Oncológico Estatal; ISSSEMYM Oncología, Toluca, Mexico|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Waikato Hospital; Regional Cancer Center, Hamilton, New Zealand|Centro Hemato Oncologico Paitilla, Panama City, Panama|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, Peru|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Unidad de Investigacion Oncologia Clinica - Piura; Unidad de Oncología Clínica, Piura, Peru|Cebu Cancer Institute; Perpetual Succour Hospital, Cebu, Philippines|Cardinal Santos Medical Center, San Juan, Philippines|Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii, Bydgoszcz, Poland|Medical University of Gdansk, Gdansk, Poland|Centrum Onkologii, Instytut, Klinika Chemioterapii; Oddzial Chemoterapii, Krakow, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, Poland|Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon, Warszawa, Poland|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Coltea Hospital; Oncology, Bucharest, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Cluj Clinical County Hospital; Oncology Dept, Cluj-Napoca, Romania|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary, Pyatigorsk, Russian Federation|Ryazan State Medical University Named after I.P.Pavlov, Ryazan, Russian Federation|SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Tula Regional Oncology Dispensary, Tula, Russian Federation|GUZ Vladimir Regional Clinical Oncological Dispensary, Vladimir, Russian Federation|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Uni Hospital Linkoeping; Dept. of Oncology, Linköping, Sweden|Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling, Malmö, Sweden|Kantonsspital Baden; Medizinische Klinik, Onkologie, Baden, Switzerland|Universitaetsspital Basel; Onkologie, Basel, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|Changhua Christian Hospital; Hematology-Oncology, Changhua, Taiwan|Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Tri-Service General Hospital; Hematology and Oncology, Taipei, Taiwan|National Cancer Inst., Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Hospital; Internal Medicine, Chiang Mai, Thailand|Prince of Songkla Uni ; Unit of Medical Oncology, Songkhla, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, Turkey|Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey|Ege Uni Medical Faculty Hospital; Oncology Dept, Izmir, Turkey|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit, Glasgow, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|Royal Free Hospital; Dept of Oncology, London, United Kingdom|Guys Hospital; Management Offices, London, United Kingdom|Royal Marsden Hospital; Dept of Med-Onc, London, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, United Kingdom|Peterborough City Hospital; Oncology Ward, Peterborough, United Kingdom|Queen Alexandra Hospital, Portsmouth, Portsmouth, United Kingdom|Weston Park Hospital; Cancer Clinical Trials Centre, Sheffield, United Kingdom|Southampton General Hospital; Somers Cancer Research Building, Southampton, United Kingdom|Uni Hospital of North Staffordshire; Staffordshire Oncology Centre, Stoke-on-Trent, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|Royal Cornwall Hospital; Dept of Clinical Oncology, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01120184"
156,"NCT00829166","A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","Completed","Has Results","All","Phase 3","991","Industry","Interventional","February 2009","July 2012","September 2015","January 26, 2009","April 23, 2013","October 31, 2016","Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Anaheim, California, United States|Bakersfield, California, United States|Baldwin Park, California, United States|Bellflower, California, United States|Duarte, California, United States|Fontana, California, United States|Hayward, California, United States|Irvine, California, United States|La Jolla, California, United States|La Mesa, California, United States|Loma Linda, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Montebello, California, United States|Newport Beach, California, United States|Oakland, California, United States|Panorama City, California, United States|Riverside, California, United States|Roseville, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|San Jose, California, United States|Santa Clara, California, United States|Santa Maria, California, United States|Santa Monica, California, United States|South San Francisco, California, United States|Thousand Oaks, California, United States|Vallejo, California, United States|Walnut Creek, California, United States|Woodland Hills, California, United States|Fort Collins, Colorado, United States|Norwalk, Connecticut, United States|Norwich, Connecticut, United States|Stamford, Connecticut, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Fernandina Beach, Florida, United States|Fort Myers, Florida, United States|Ft. Lauderdale, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Lakeland, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orange Park, Florida, United States|Pembroke Pines, Florida, United States|Athens, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Carrolton, Georgia, United States|Cartersville, Georgia, United States|Decatur, Georgia, United States|Douglasville, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Nampa, Idaho, United States|Post Falls, Idaho, United States|Twin Falls, Idaho, United States|Chicago, Illinois, United States|Decatur, Illinois, United States|Effingham, Illinois, United States|Joliet, Illinois, United States|Morris, Illinois, United States|Peoria, Illinois, United States|Skokie, Illinois, United States|Zion, Illinois, United States|Bettendorf, Iowa, United States|Wichita, Kansas, United States|Paducah, Kentucky, United States|Covington, Louisiana, United States|Lafayette, Louisiana, United States|Marrero, Louisiana, United States|Metairie, Louisiana, United States|New Orleans, Louisiana, United States|Kittery, Maine, United States|Wells, Maine, United States|York, Maine, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Peabody, Massachusetts, United States|Brownstown, Michigan, United States|Dearborn, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Saint Joseph, Michigan, United States|West Bloomfield, Michigan, United States|Edina, Minnesota, United States|Maplewood, Minnesota, United States|Minneapolis, Minnesota, United States|Saint Louis Park, Minnesota, United States|Saint Paul, Minnesota, United States|St. Louis Park, Minnesota, United States|Joplin, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Saint Peters, Missouri, United States|St. Louis, Missouri, United States|St. Peters, Missouri, United States|Missoula, Montana, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Cherry Hill, New Jersey, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Parsippany, New Jersey, United States|Voorhees, New Jersey, United States|Santa Fe, New Mexico, United States|Brockport, New York, United States|Canandaigua, New York, United States|Fresh Meadows, New York, United States|Geneva, New York, United States|Greece, New York, United States|Lake Success, New York, United States|Mount Kisco, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Kinston, North Carolina, United States|Washington, North Carolina, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Middletown, Ohio, United States|Newark, Ohio, United States|Sandusky, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|East Providence, Rhode Island, United States|Columbia, South Carolina, United States|North Charleston, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Bryan, Texas, United States|Cypress, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Shenandoah, Texas, United States|Temple, Texas, United States|Fairfax, Virginia, United States|Gig Harbor, Washington, United States|Lakewood, Washington, United States|Puyallup, Washington, United States|Tacoma, Washington, United States|Milwaukee, Wisconsin, United States|Wausau, Wisconsin, United States|Banja Luka, Bosnia and Herzegovina|Sarajewo, Bosnia and Herzegovina|Belo Horizonte, Brazil|Curitiba, Brazil|Goiania, Brazil|Itajai, Brazil|JAU, Brazil|Joao Pessoa, Brazil|Porto Alegre - Rs, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Santo Andre, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|Ottawa, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Bogota, Colombia|Bogota, Colombia|Monteria, Colombia|Herlev, Denmark|København, Denmark|Odense, Denmark|Helsinki, Finland|Tampere, Finland|Turku, Finland|Avignon, France|Bordeaux, France|Brest, France|Caen, France|Dijon, France|La Roche Sur Yon, France|Montpellier, France|Paris, France|Saint Brieuc, France|Saint Herblain, France|Vandoeuvre-les-nancy, France|Aschaffenburg, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bonn, Germany|Dortmund, Germany|Freiburg, Germany|Fuerstenwalde, Germany|Hamburg, Germany|Karlsruhe, Germany|Kiel, Germany|Offenbach, Germany|Stralsund, Germany|Hong Kong, Hong Kong|Bangalore, India|Gurgaon, India|Kolkata, India|New Delhi, India|Pune, India|Aviano, Italy|Bologna, Italy|Candiolo, Italy|Genova, Italy|Meldola, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Negrar, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Rozzano, Italy|Sassari, Italy|Terni, Italy|Kyunggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Acapulco, Mexico|Oaxaca, Mexico|Toluca, Mexico|Newtown, New Zealand|Palmerston North, New Zealand|Diliman, Quezon City, Philippines|Quezon City, Luzon, Philippines|Bialystok, Poland|Gdansk, Poland|Krakow, Poland|Lublin, Poland|Opole, Poland|Poznan, Poland|Warszawa, Poland|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Kemerovo, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Ljubljana, Slovenia|Barcelona, Spain|Córdoba, Spain|Lerida, Spain|Madrid, Spain|Madrid, Spain|Santander, Spain|Sevilla, Spain|Valencia, Spain|Zaragoza, Spain|Eskilstuna, Sweden|Gaelve, Sweden|Goteborg, Sweden|Luzern, Switzerland|St. Gallen, Switzerland|Kaohsung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bournemouth, United Kingdom|Cardiff, United Kingdom|Denbigh, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|New Castle Upon Tyne, United Kingdom|Northwood, United Kingdom|Poole, United Kingdom|Preston, United Kingdom|Romford, United Kingdom|Sutton, United Kingdom|Weston Super Mare, United Kingdom","https://ClinicalTrials.gov/show/NCT00829166"
157,"NCT01478594","A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy","Completed","Has Results","All","Phase 2","265","Industry","Interventional","December 2011","September 2013","January 2015","November 23, 2011","April 3, 2015","July 8, 2015","Banner MD Anderson Cancer Research Center, Gilbert, Arizona, United States|Genesis Cancer Center, Hot Springs, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|University of California San Diego-Morris Cancer Center, La Jolla, California, United States|UC Irvine Medical Center, Division of Hematology/Oncology, Orange, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|University of Florida, Davis Cancer Center (VA), Gainesville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Queen's Medical Center, Honolulu, Hawaii, United States|University of Hawaii, Honolulu, Hawaii, United States|Kaiser Foundation Hospitals, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Illinios Cancer Care, Peoria, Illinois, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Associates of Oncology Hematology, P.C., Rockville, Maryland, United States|University of Michigan Health, Ann Arbor, Michigan, United States|NYU Cancer Institute, New York, New York, United States|Alamance Regional Medical Center, Burlington, North Carolina, United States|Tri Country Hematology / Oncology, Canton, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Oncology Hematology of Lehigh Valley, Bethlehem, Pennsylvania, United States|Northern Utah Associates, Ogden, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|St George Hospital, Kogarah, New South Wales, Australia|Tweed Hospital, Tweed Heads, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Medizinische Universitat Graz, Graz, Austria|Salzburger Landesklinken, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Ziekenhuisnetwerk Antwerpen - AZ Middelheim, Antwerpen, Belgium|Imelda VZW, Bonheiden, Belgium|AZ Sint-Lucas Brugge, Brugge, Belgium|AZ Groeninge - Campus Sint-Niklaas, Kortrijk, Belgium|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|QEII Health Science Centre, Halifax, Nova Scotia, Canada|Hopital De La Cite-De-La-Sante, Laval, Quebec, Canada|Hopital Saint-Luc - Pavillon Principal, Montreal, Quebec, Canada|Chuq Centre Hospitalier Universitaire De Quebec, Quebec, Canada|Masarykuv onkologicky ustav, Brno, Czech Republic|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic|Tampereen yliopistollinen sairaala, Tampere, Finland|Turun yliopistollinen keskussairaala, Turku, Finland|Orszagos Onkologiai Intezet, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Gyula, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Szekesfehervar, Hungary|Azienda Ospedaliero- Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Fondazione del Piemonte per I'Oncologia IRCC, Candiolo, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino - Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Amphia Ziekenhuis, Breda, Netherlands|Hospital Universitario Miguel Servet, Zaragoza, Aragon, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Cataluna, Spain|Hospital Mutua de Terrassa, Terrassa, Cataluna, Spain|Centro Oncologico de Galicia, Galicia, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Addenbrooke's Hospital, Cambridge, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Center, Glasgow, United Kingdom|University College Hospital, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|Christie Hospital, Manchester, United Kingdom|Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, United Kingdom","https://ClinicalTrials.gov/show/NCT01478594"
158,"NCT01196052","A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer","Completed","Has Results","All","Phase 2","153","Industry","Interventional","October 2010","June 2013","June 2013","September 8, 2010","June 26, 2014","October 6, 2014","Fort Myers, Florida, United States|Lafayette, Indiana, United States|Scarborough, Maine, United States|Kensignton, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Springfield, Missouri, United States|Omaha, Nebraska, United States|Lake Success, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Sioux Falls, South Dakota, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States|Tacoma, Washington, United States|Bruxelles, Belgium|Wilrijk, Belgium|Besancon, France|Montpellier, France|Saint Herblain, France|Bielefeld, Germany|Frankfurt am Main, Germany|Hamburg, Germany|Köln, Germany|Mönchengladbach, Germany|Rostock, Germany|Bologna, Emilia-Romagna, Italy|Lecco, Lombardia, Italy|Milano, Lombardia, Italy|Candiolo, Piemonte, Italy|San Giovanni Rotondo, Puglia, Italy|Perugia, Umbria, Italy|Vicenza, Veneto, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Tula, Russian Federation|Barcelona, Spain|Jaen, Spain|Lerida, Spain|Madrid, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01196052"
159,"NCT00958971","Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer","Completed","No Results Available","Female","Phase 2","165","Industry","Interventional","July 2009","March 2011","March 2011","August 14, 2009","null","February 12, 2013","Comprehensive Blood and Cancer Center Dept CBCC (3), Bakersfield, California, United States|Tower Cancer Research, Beverly Hills, California, United States|UCLA/ University of California Los Angeles Div. of Hematology/Oncology, Los Angeles, California, United States|Cancer Care Associates Medical Group Dept. of CCA, Redondo Beach, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Florida Cancer Specialists Dept.of FloridaCancerSpec. (2), Fort Myers, Florida, United States|Kansas City Cancer Center KCCC (3), Overland Park, Kansas, United States|Associates in Oncology/Hematology, P.C., Rockville, Maryland, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|UNC/ Lineberger Comprehensive Cancer Center Dept. of Linberger Cancer Ctr, Chapel Hill, North Carolina, United States|Northwest Cancer Specialists Northwest Office (2), Portland, Oregon, United States|Texas Oncology, P.A. Dept. of Texas Oncology, Bedford, Texas, United States|Texas Oncology, P.A. Austin, Dallas, Texas, United States|Texas Oncology, P.A. Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology, P.A. Texas Oncology - Sammons, Dallas, Texas, United States|Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler, Texas, United States|Fairfax Northern Virginia Hematology Oncology Fairfax NVH, Fairfax, Virginia, United States|Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care, Roanoke, Virginia, United States|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Toulouse Cedex 3, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Cuneo, CN, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Negrar, Italy|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Lleida, Cataluña, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00958971"
160,"NCT01322490","A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer","Completed","No Results Available","Male","Phase 3","1298","Industry","Interventional","November 28, 2011","September 25, 2017","December 15, 2017","March 24, 2011","null","January 9, 2018","Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States|Scottsdale Healthcare, Scottsdale, Arizona, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States|Desert Hematology-Oncology, Rancho Mirage, California, United States|San Bernardino Urological Associates, San Bernardino, California, United States|San Diego Clinical Trials, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|VA San Diego Healthcare System, San Diego, California, United States|Stanford Advanced Medical Center, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|The Urology Center of Colorado, Denver, Colorado, United States|Washington Cancer Institute, Washington, District of Columbia, United States|South Florida Medical Research, Aventura, Florida, United States|Manatee Medical Research Institute, LLC, Bradenton, Florida, United States|Florida Urology Physicians, Fort Myers, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Pinellas Urology, Inc., Saint Petersburg, Florida, United States|James A Haley Veteran Affairs Medical Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|North Idaho Urology, Coeur d'Alene, Idaho, United States|Jesse Brown VA, Chicago, Illinois, United States|First Urology PSC, Jeffersonville, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|The Iowa Clinic, PC Iowa Urology, West Des Moines, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Ochsner Cancer Institute, New Orleans, Louisiana, United States|Maryland Prostate Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Walter Reed Army Medical Center, Bethesda, Maryland, United States|National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States|Myron Murdock M.D. LLC, Greenbelt, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|VA Sierra Nevada HealthCare System, Reno, Nevada, United States|Delaware Valley Urology LLC - Westhampton, Mount Laurel, New Jersey, United States|The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Brooklyn Urology Research Group, Brooklyn, New York, United States|University Urology Associates, New York, New York, United States|Hudson Valley Urology, P.C., Poughkeepsie, New York, United States|Presbyterian Hospital Center for Cancer Research, Charlotte, North Carolina, United States|Northeast Urology Research, Concord, North Carolina, United States|Regional Cancer Care PA, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina, United States|St. Alexius Medical Center, Bismarck, North Dakota, United States|Gabrail Cancer Center, Canton, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Columbus Urology Research, Columbus, Ohio, United States|Willamette Valley Cancer Center, Springfield, Oregon, United States|Urologic Consultants of Southeaster PA LLP, Bala-Cynwyd, Pennsylvania, United States|Urological Associates Of Lancaster, Lancaster, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Ralph H Johnson VAMC, Charleston, South Carolina, United States|WJB Dorn VA Medical Center, Columbia, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|University of TN Medical Center, Knoxville, Tennessee, United States|The West Clinic, P.C., Memphis, Tennessee, United States|James H. Quillen Veterans Affairs Medical Center, Mountain Home, Tennessee, United States|Urology Associates, PC, Nashville, Tennessee, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|Central Texas Veterans Health Care System, Temple, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Salt Lake Research, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States|White River Junction Veterans Affairs Medical Center, White River Junction, Vermont, United States|Virginia Oncology Associates PC, Norfolk, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|The Schiffler Cancer Center, Wheeling, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Sydney Haematology and Oncology Clinic, St Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Monash Medical Centre - Moorabbin Campus, Bentleigh East, Australia|Barwon Health, Geelong, Australia|St John of God Hospital, Subiaco, Australia|Border Medical Oncology, Wodonga, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Ziekenhuisnetwerk Antwerpen - AZ Middelheim, Antwerp, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|AZ Maria Middelares, Gent, Belgium|UZ Leuven, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium|Southern Interior Medical Research Inc., Kelowna, British Columbia, Canada|Capital District Health Authority, Halifax, Nova Scotia, Canada|Brantford Urology Research, Brantford, Ontario, Canada|Cambridge Memorial Hospital, Cambridge, Ontario, Canada|St. Josephs Healthcare Hamilton Research Ethics Board, Hamilton, Ontario, Canada|Queen's University at Kingston, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|The Female/Male Health Centres, Oakville, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec Hotel Dieu, Quebec, Canada|Aalborg Sygehus, Aalborg, Denmark|Rigshospitalet, Copenhagen, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Herlev Hospital, Herlev, Denmark|Holstebro Sygehus, Holstebro, Denmark|Storstrømmens Sygehus Næstved, Næstved, Denmark|Skejby Sygehus, Århus N, Denmark|East Tallinn Central Hospital, Tallinn, Estonia|North Estonia Medical Centre Foundation, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Centre Paul Papin, Angers, France|Centre Hospitalier Départemental La Roche sur Yon, Luçon, Montaigu - Les Oudaries, La Roche Sur Yon, France|Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes, Lyon, France|Centre d'Oncologie de Gentilly, Nancy, France|HIA du Val de Grâce, Paris, France|Institut Curie, Paris, France|Fondation Hôpital Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Jean Godinot - Centre de lutte contre le cancer, Reims, France|Clinique Armoricaine de Radiologie, Saint Brieuc, France|Hôpital Bretonneau, Tours, France|Centre Alexis Vautrin - Centre Régional de lutte contre le cancer de Lorraine, Vandoeuvre les Nancy, France|Stadtisches Klinikum Muchen GmbH, Munich, Bavaria, Germany|Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum der Johann-Wolfgang-Goethe-Universität Frankfurt am Main, Frankfurt, Germany|Chirurgische Universitätsklinik Freiburg, Freiburg, Germany|Martini-Klinik am UKE GmbH, Hamburg, Germany|Klinikum der Friedrich-Schiller-Universität Jena, Jena, Germany|Universitätsmedizin der JGU Mainz, Mainz, Germany|Klinikum der Philipps-Universität Marburg, Marburg, Germany|Studienpraxis Urologie, Reutlingen, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Universitätsklinikum Ulm, Ulm, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Landspitali University Hospital, Reykjavik, Iceland|Soroka University Medical Center, Beer Sheva, Israel|Bnei Zion Medical Center, Haifa, Israel|Rambam Medical Center, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|The Chaim Sheba Medical Center, Ramat-Gan, Israel|Assaf Harofe Medical Center, Tzrifin, Israel|NKI-AVL, Amsterdam, Netherlands|VUMC, Amsterdam, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Radboudumc, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|AMEDS CENTRUM Sp. z o.o., Grodzisk Mazowiecki, Poland|Urologica Praktyka Lekarska Adam Marcheluk, Siedlce, Poland|Szpital sw Elzbiety - Mokotowskie Centrum Medyczne Sp. z o. o., Warsaw, Poland|Miedzyleski Szpital Specjalistyczny w Warszawie, Warsaw, Poland|Klinika Urologii i Onkologii Urologicznej, Uniwersytecki Szpital Kliniczny we Wrocławiu, Wroclaw, Poland|Ponce School of Medicine, Ponce, Puerto Rico|Alliance for Research and Knowledge, San Juan, Puerto Rico|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|Moscow Research Oncology Institute n.a. P.A.Gertsen, Moscow, Russian Federation|Clinical Oncology Dispensary, Omsk, Russian Federation|Orel Oncology Center, Orel, Russian Federation|Orenburg Regional Clinical Oncology Center, Orenburg, Russian Federation|St. Petersburg Medical Academy of Postgraduate Education, St. Petersburg, Russian Federation|St. Petersburg State Medical University n.a. I.P. Pavlov, St. Petersburg, Russian Federation|City Hospital #15, St. Petersburg, Russian Federation|""Orkli"" LLC, St. Petersburg, Russian Federation|""Clinic Andros"" LLC, St.Petersburg, Russian Federation|Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Regional Clinical Oncology Center, Vladimir, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain|Hospital 12 de Octubre, Madrid, Madrid, Communidad De, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital Nuestra Señora de Sonsoles, Avila, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall D´Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital General Universitario de Elche, Elche, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|MD Anderson International Espana, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Universitario Fundación Alcorcón, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Althaia: Xarxa Assistencial de Manresa, Manresa, Spain|Hospital General Carlos Haya, Málaga, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Fundación Hospital Manacor, Palma de Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Mutua de Terrassa, Terrassa, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Bristol Haematology & Oncology Centre, Bristol, UK, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|University of Surrey, Guildford, United Kingdom|Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, United Kingdom|St Bartholomews Hospital, London, United Kingdom|The Royal Marsden, London, United Kingdom|St Mary's Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, United Kingdom|University of Southampton, Southampton, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01322490"
161,"NCT01453257","Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","Completed","No Results Available","All","Phase 2","72","Other","Interventional","October 2009","October 2011","October 2011","October 17, 2011","null","October 19, 2011","Centro Integral Oncológico Clara campal, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01453257"
162,"NCT00950300","A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","Completed","Has Results","Female","Phase 3","596","Industry","Interventional","October 16, 2009","July 12, 2011","January 24, 2017","July 31, 2009","January 23, 2017","January 23, 2018","Centro Medico San Roque; Oncology Dept, Tucuman, Argentina|Caipo; Oncology, Tucuman, Argentina|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Hospital das Clinicas - UFPR; Quimioterapia, Curitiba, PR, Brazil|Liga Norte Riograndense Contra O Câncer, Natal, RN, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Instituto de Oncologia de Sorocaba - CEPOS, Sorocaba, SP, Brazil|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY, Quebec, Canada|Hospital Universitario San Ignacio, Bogota, Colombia|Grupo Salud Coop, Bogota, Colombia|Oncólogos de Occidente, Pereira, Colombia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Krajska Nemocnice Pardubice Neurologicka Klinika, Pardubice, Czechia|Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni, Praha, Czechia|Lekarske Fakulty Univerzity Karlovy Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie, Praha, Czechia|North Estonia Medical Centre Foundation; Oncology Centre, Tallinn, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, Estonia|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Institut Daniel Hollard; Chimiotherapie Ambulatoire, Grenoble, France|Hopital Albert Michallon; Oncologie, La Tronche, France|Centre Jean Bernard, Le Mans, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Institut Jean Godinot; Hopital De Jour, Reims, France|Centre Rene Huguenin; Medecine B, St Cloud, France|CAMPUS CHARITÉ MITTE; Tagesklinik für Onkologie u.Hämatologie, Berlin, Germany|Praxis Dr. Schoenegg, Berlin, Germany|Johanniter GmbH; Johanniter-Krankenhaus; Internistische Onkologie, Bonn, Germany|St. Johannes Hospital, Dortmund, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, Germany|Sankt Elisabeth Krankenhaus; Gynaekology, Leipzig, Germany|Klinik Lippe Lemgo; Frauenklinik, Lemgo, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, Germany|Klinik Obergöltzsch; Abt. Gynäkologie, Rodewisch, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, Germany|Centro Oncologico S.A., Guatemala, Guatemala|Queen Mary Hospital; Surgery, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Központ, Budapest, Hungary|Hospital of Aladar Petz; Dept of Oncoradiology, Gyor, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel|Rabin Medical Center; Oncology Dept, Petach Tikva, Israel|Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica, Napoli, Campania, Italy|ASST DI CREMONA; Dip. Medicina - S.C. Oncologia, Cremona, Lombardia, Italy|Fondazione Salvatore Maugeri; Servizio Di Prevenzione Oncologica, Pavia, Lombardia, Italy|Fondazione Salvatore Maugeri, Pavia, Lombardia, Italy|Gachon Medical School Gil Medical Center; Medical Oncology, Incheon, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, Korea, Republic of|Korea University Anam Hospital; Oncology Haemotology, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Hospital Privado San Jose; Oncologia, Obregon, Mexico|Centro Oncológico Estatal; ISSSEMYM Oncología, Toluca, Mexico|Centro Oncologico America, Panama, Panama|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, Peru|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Unidad de Investigacion Oncologia Clinica - Piura; Unidad de Oncología Clínica, Piura, Peru|Clinica Ricardo Palma, San Isidro, Peru|Wojewodzki Szpital Zespolony; Oddział Onkologii, Elblag, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, Poland|Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o., Olsztyn, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, Poland|FSBI""National Medical Research Center of Oncology named after N.N.Petrov"" MHRF, St Petersburg, Leningrad, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary, Pyatigorsk, Russian Federation|SBI for HPE ""Ryazan State Medical University n.a. I.P. Pavlov"" of MoH of RF, Ryazan, Russian Federation|SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|Saratov Regional Clinical Hospital & Pathology Centre, Saratov, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Tula Regional Oncology Dispensary, Tula, Russian Federation|GUZ Vladimir Regional Clinical Oncological Dispensary, Vladimir, Russian Federation|Vychodoslovensky onkologicky ustav, Kosice, Slovakia|Nzz - Oncology Outpatient Clinic, Poprad, Slovakia|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Cancercare, Cape Town, South Africa|Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Pretoria-East Hospital; 1 Sanwood Park, Pretoria, South Africa|Rondebosch Oncology Centre, Rondebosch, South Africa|Sandton Oncology Centre, Sandton, South Africa|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitari Sant Joan de Reus; Servicio de Oncologia, Reus, Tarragona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Skånes University Hospital, Skånes Department of Onclology, Lund, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Changhua Christian Hospital; Dept of Surgery, Changhua, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Chang Gung Medical Foundation-Taipei, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|National Cancer Inst., Bangkok, Thailand|Phramongkutklao Hospital;Dept Surgery/Surgical Oncology Unit, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla Uni ; Unit of Medical Oncology, Songkhla, Thailand|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Istanbul Uni of Medicine Faculty; Oncology Dept, Istanbul, Turkey|Dokuz Eylul Uni Medical Faculty; Oncology Dept, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, Ankara, Turkey","https://ClinicalTrials.gov/show/NCT00950300"
163,"NCT02116582","A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer","Completed","Has Results","Male","Phase 4","215","Industry","Interventional","May 23, 2014","May 8, 2016","September 29, 2017","April 17, 2014","June 8, 2017","November 15, 2018","Site BE32001, Brussels, Flemish Brabant, Belgium|Site BE32004, Gent, Belgium|Site BE32007, Hasselt, Belgium|Site BE32003, Kortrijk, Belgium|Site BE32002, Liege, Belgium|Site FR33015, Angers cedex 02, France|Site FR33009, Caen Cedex 05, France|Site FR33010, Creteil cedex, France|Site FR33014, Le Mans, France|Site FR33013, Lyon Cedex 3, France|Site FR33003, Marseille CEDEX 9, France|Site FR33008, Nantes Saint Herblain Cedex, France|Site FR33002, Nimes, France|Site FR33001, Paris cedex 15, France|Site FR33011, Paris, France|Site FR33007, Rennes, France|Site FR33005, Suresnes, France|Site FR33012, Villejiuf, France|Site DE49005, Nuertingen, Baden-Wuerttemberg, Germany|Site DE49015, Bergisch Gladbach, Northwest, Germany|Site DE49017, Duisburg, NRW, Germany|Site DE49014, Berlin, Germany|Site DE49003, Berlin, Germany|Site DE49009, Bonn, Germany|Site DE49010, Dresden, Germany|Site DE49016, Duesseldorf, Germany|Site DE49004, Goettingen, Germany|Site DE49001, Hamburg, Germany|Site DE49008, Hamburg, Germany|Site DE49007, Hannover, Germany|Site DE49002, Heidelberg, Germany|Site DE49012, Munster, Germany|Site DE49006, Tubingen, Germany|Site ES34004, Santiago de Compostela, A Coruna, Spain|Site ES34009, Badalona, Spain|Site ES34011, Barcelona, Spain|Site ES34006, Barcelona, Spain|Site ES34008, Barcelona, Spain|Site ES34001, Madrid, Spain|Site ES34003, Madrid, Spain|Site ES34002, Madrid, Spain|Site ES34010, Madrid, Spain|Site GB44001, Sutton, Surrey, United Kingdom|Site GB44004, Birmingham, United Kingdom|Site GB44009, Brighton, United Kingdom|Site GB44002, Glasgow, United Kingdom|Site GB44007, London, United Kingdom|Site GB44003, Northwood, Middlesex, United Kingdom|Site GB44010, Plymouth, United Kingdom|Site GB44006, Withington, United Kingdom","https://ClinicalTrials.gov/show/NCT02116582"
164,"NCT01360840","EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer","Completed","Has Results","Male","Phase 2","180","Industry","Interventional","April 2011","April 2013","July 2014","May 26, 2011","December 14, 2015","December 14, 2015","Research Site, Pleasant Hill, California, United States|Research Site, Chicago, Illinois, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Roanoke, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Bendigo, Australia|Research Site, Coffs Harbour, Australia|Research Site, Darlinghurst, Australia|Research Site, Frankston, Australia|Research Site, Gosford, Australia|Research Site, Kurralta Park, Australia|Research Site, Northmead, Australia|Research Site, Port Macquarie, Australia|Research Site, Randwick, Australia|Research Site, Turnhout, Australia|ZNA Middelheim Oncologie, Antwerp, Belgium|Brandord Urology Research, Brantford, Ontario, Canada|Exdeo Clinical Research Inc., Abbotsford, Canada|Can-Med Clinical Research Inc., Province of British Columbia, Canada|Sunnybrook Health Sciences Centre, Toronto, Canada|Research Site, Victoria, Canada|Research Site, Windsor, Canada|Research Site, Angers, France|Center Alexis Vaurrin, Bourgogne, France|Research Site, Caen Cedex 05, France|Hôpitaux Civils de Colmar-CH Louis Pasteur, Colmar, France|Research Site, Paris, France|Research Site, Reims, France|Institute Gustave Roussy, Villejuif, France|Research Site, Aachen, Germany|Universitätsmedizin Charité, Campus Benjamin Franklin, Urologische Klinik and Poliklinik, Berlin, Germany|Research Site, Darmstadt, Germany|Universitätsklinikum Carl Gustav Carus an der Techischen Universität Dresden, Klinik und Poliklinik für Urologie, Dresden, Germany|Research Site, Esslingen, Germany|Research Site, Freiburg, Germany|Research Site, Hannover, Germany|Research Site, Nürtingen, Germany|Studienpraxis Urologie, Reutlingen, Germany|Universitätsklinikum Tübinger, Klinik und Poliklinik für Urologie, Tübingen, Germany|Research Site, Blaricum, Netherlands|Research Site, Groningen, Netherlands|Research Site, Haarlem, Netherlands|Research Site, Gdańsk, Poland|Research Site, Lublin, Poland|Research Site, Łódź, Poland|Altay Regional Oncology Dispensary, Barnaul, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|State Institution of Healthcare Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Budzhet Clinical Oncology Center, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Krasnoyarsk State Medical University Oncology and Radiotherapy Territorial Dispensary, Krasnoyarsk, Russian Federation|Research Site, Omsk, Russian Federation|City Hospital # 2, Petersburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Presov, Slovakia|Research Site, Gauteng, South Africa|Research Site, Kwa-Zulu Natal, South Africa|Research Site, Pretoria Gauteng, South Africa|Research Site, Western Cape, South Africa|Research Site, Barcelone, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Sabadell, Barcelone, Spain","https://ClinicalTrials.gov/show/NCT01360840"
165,"NCT01234311","A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer","Completed","No Results Available","Male","Phase 3","1245","Industry","Interventional","March 2011","February 2015","August 2015","November 4, 2010","null","October 21, 2015","Tucson, Arizona, United States|Oxnard, California, United States|Santa Monica, California, United States|Santa Rosa, California, United States|Wellington, Florida, United States|Atlanta, Georgia, United States|Meridian, Idaho, United States|Melrose Park, Illinois, United States|Park Ridge, Illinois, United States|Jeffersonville, Indiana, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Jefferson City, Missouri, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Lawrenceville, New Jersey, United States|Buffalo, New York, United States|Poughkeepsie, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Springfield, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Salt Lake, Utah, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Salem, Virginia, United States|Burien, Washington, United States|Ciudad Autonoma de Buenos Aires, Argentina|Santa Rosa, Argentina|Venado Tuerto, Argentina|Camperdown, New South Wales, Australia|Coffs Harbour, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Tweed Heads, New South Wales, Australia|Richmond, Victoria, Australia|Subiaco, Western Australia, Australia|Bruxelles, Belgium|Gent, Belgium|Kortrijk, Belgium|Liege, Belgium|Botucatu, Sao Paulo, Brazil|Cachoeiro de Itapemirim - ES, Brazil|Curitiba, Parana, Brazil|Florianopolis, Brazil|Juiz de Fora, Minas Gerais, Brazil|Mogi das Cruzes, Sao Paulo, Brazil|Natal, Rio Grande do Norte, Brazil|Passo Fundo, Brazil|Porto Alegre, RS, Brazil|Rio de Janeiro, Brazil|Salvador/BA, Brazil|Sao Paulo, Brazil|Volta Redonda - RJ, Brazil|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Kelowna, British Columbia, Canada|Victoria, British Columbia, Canada|Brantford, Ontario, Canada|North York, Ontario, Canada|Oakville, Ontario, Canada|Santiago, Chile|Temuco, Chile|Vina del Mar, Chile|Beijing, China|Chengdu, China|Shanghai, China|Shantou, China|Wuhan, China|Bogota, Colombia|Cali, Colombia|Novy Jicin, Czech Republic|Olomouc, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Usti nad Labem, Czech Republic|Tartu, Estonia|Angers, France|Cannes, France|Marseille, France|Montpellier, France|Paris, France|Pierre Benite, France|Rennes, France|Suresnes, France|Dresden, Germany|Hamburg, Germany|Koln, Germany|Mannheim, Germany|Marburg, Germany|Munchen, Germany|Munster, Germany|Nurtingen, Germany|Tubingen, Germany|Weiden, Germany|Athens, Greece|Patras, Greece|Thessaloniki, Greece|Pune, India|Beer-Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat-Gan, Israel|Tel-Aviv, Israel|Zerifin, Israel|Cremona, Italy|Lecco, Italy|Meldola, Italy|Milano, Italy|Padova, Italy|Ravenna, Italy|Roma, Italy|Torino, Italy|Gwangju, Korea, Republic of|Seoul, Korea, Republic of|Liepaja, Latvia|Riga, Latvia|Beirut, Lebanon|Bsalim, Lebanon|Kaunas, Lithuania|Vilnius, Lithuania|Chihuahua, Chih., Mexico|Culiacan, Sinaloa, Mexico|Leon, GTO, Mexico|Puebla, Mexico|Zapopan, Jalisco, Mexico|Amsterdam, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Nijmegen, Netherlands|Tilburg, Netherlands|Christchurch, New Zealand|Nelson, New Zealand|Palmerston North, New Zealand|Tauranga, New Zealand|Panama, Panama|Arequipa, Peru|Bialystok, Poland|Lodz, Poland|Myslowice, Poland|Poznan, Poland|Warszawa, Poland|Wroclaw, Poland|Baia Mare, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Craiova, Romania|Ploiesti, Romania|Suceava, Romania|Timisoara, Romania|Ekaterinburg, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|St. Petersburg, Russian Federation|Vladimir, Russian Federation|Bratislava, Slovakia|Trencin, Slovakia|Sevilla, Andalucia, Spain|Zaragoza, Aragon, Spain|Oviedo, Asturias, Spain|Santander, Cantabria, Spain|Sabadell, Cataluna, Spain|Alcorcon, Madrid, Communidad de, Spain|Pamplona, Navarra, Spain|Barcelona, Spain|San Sebastian de los Reyes, Spain|Valencia, Spain|Göteborg, Sweden|Karlstad, Sweden|Stockholm, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Istanbul, Turkey|Chernivtsi, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine|Birmingham, United Kingdom|Chichester, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Northwood, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom|Scunthorpe, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01234311"
166,"NCT01494506","Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer","Completed","Has Results","All","Phase 3","417","Industry","Interventional","November 2011","February 2014","October 2015","December 19, 2011","February 12, 2016","June 17, 2016","Gilbert, Arizona, United States|Glendale, Arizona, United States|Scottsdale, Arizona, United States|Burbank, California, United States|Duarte, California, United States|Fresno, California, United States|LaVerne, California, United States|San Luis Obispo, California, United States|Boyton Beach, Florida, United States|Atlanta, Georgia, United States|Kansas City, Missouri, United States|St Louis, Missouri, United States|Henderson, Nevada, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|Columbus, Ohio, United States|Norman, Oklahoma, United States|Greenville, South Carolina, United States|Bedford, Texas, United States|Dallas, Texas, United States|Tyler, Texas, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Buenos Aires, Argentina|Rosario, Argentina|Santa Fe, Argentina|Westmead, New South Wales, Australia|Kurralta Park, South Australia, Australia|Boxhill, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Belo Horizonte, Brazil|Ijui, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Sao Paulo, Brazil|Montreal, Quebec, Canada|Horovice, Czech Republic|Olomouc, Czech Republic|Prague, Czech Republic|Pribram, Czech Republic|Bordeaux, France|Lille, France|Marseille, France|Berlin, Germany|Jens, Germany|Munich, Germany|Ulm, Germany|Budapest, Hungary|Pecs, Hungary|Szeged, Hungary|Szolnok, Hungary|Szombathely, Hungary|Castellana Grotte, Italy|Genova, Italy|Legnano, Italy|Naples, Italy|Roma, Italy|Hwasun-gun, Korea, Republic of|Seoul, Korea, Republic of|Port Elizabeth, South Africa|Pretoria, South Africa|Western Cape, South Africa|Alicante, Spain|Barcelona, Spain|Madrid, Spain|Santander, Spain|Valencia, Spain|Chiayi, Taiwan|Kaohsiung, Taiwan|Taiching, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01494506"
167,"NCT01239732","A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer","Completed","Has Results","Female","Phase 3","1021","Industry","Interventional","December 2010","March 2015","March 2015","November 11, 2010","June 10, 2016","June 10, 2016","Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Rosario, Argentina|Tucuman, Argentina|Graz, Austria|Graz, Austria|Innsbruck, Austria|Ried-innkreis, Austria|Salzburg, Austria|Steyr, Austria|Villach, Austria|Wien, Austria|Wien, Austria|Salvador, BA, Brazil|Fortaleza, CE, Brazil|Goiania, GO, Brazil|Curitiba, PR, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Piracicaba, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Calgary, Alberta, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Aalborg, Denmark|Roskilde, Denmark|Vejle, Denmark|Cairo, Egypt|Tanta, Egypt|Tallinn, Estonia|Tallinn, Estonia|Tartu, Estonia|Amiens, France|Bordeaux, France|Brest, France|Caen, France|Clermont Ferrand, France|Grenoble, France|Lille, France|Lyon, France|Marseille, France|Mougins, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Reims CEDEX, France|Strasbourg, France|Toulouse, France|Villejuif, France|Athens, Greece|Athens, Greece|Athens, Greece|Heraklion, Crete, Greece|Larissa, Greece|Patras, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szeged, Hungary|Bangalore, India|Bangalore, India|Hyderabad, India|Jaipur, India|Kochi, India|New Delhi, India|Pune, India|Dublin, Ireland|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Meldola, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Saronno, Lombardia, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Palermo, Sicilia, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Perugia, Umbria, Italy|Terni, Umbria, Italy|Shuwaikh, Kuwait|Daugavpils, Latvia|Riga, Latvia|Riga, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Bitola, Macedonia, The Former Yugoslav Republic of|Skopje, Macedonia, The Former Yugoslav Republic of|Distrito Federal, Mexico|Oaxaca, Mexico|Toluca, Mexico|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Blaricum, Netherlands|Breda, Netherlands|Capelle a/d IJssel, Netherlands|Den Haag, Netherlands|Den Haag, Netherlands|Deventer, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Leidschendam, Netherlands|Rotterdam, Netherlands|Sittard-Geleen, Netherlands|Utrecht, Netherlands|Bydgoszcz, Poland|Warszawa, Poland|Porto, Portugal|Bucuresti, Romania|Cluj Napoca, Romania|Iasi, Romania|Barnaul, Russian Federation|Moscow, Russian Federation|Obninsk, Kaluzhskaya Region, Russian Federation|Saint-Petersburg, Russian Federation|Stavropol, Russian Federation|UFA, Russian Federation|Dammam, Saudi Arabia|Belgrade, Serbia|Nis, Serbia|Bratislava, Slovakia|Kosice, Slovakia|Ljubljana, Slovenia|Maribor, Slovenia|Durban, South Africa|Johannesburg, South Africa|Sandton, South Africa|Elda, Alicante, Spain|Oviedo, Asturias, Spain|Llerena (Badajoz), Badajoz, Spain|Manresa, Barcelona, Spain|Cádiz, Cadiz, Spain|Jerez de La Frontera, Cadiz, Spain|San Sebastian de Los Reyes, Guipuzcoa, Spain|San Sebastian, Guipuzcoa, Spain|Palma De Mallorca, Islas Baleares, Spain|Palma de Mallorca, Islas Baleares, Spain|Santiago de Compostela, La Coruña, Spain|Las Palmas de Gran Canaria, Las Palmas, Spain|Leganes, Madrid, Spain|Reus, Tarragona, Spain|La Laguna, Tenerife, Spain|Santa Cruz de Tenerife, Tenerife, Spain|San Juan, Valencia, Spain|Barakaldo, Vizcaya, Spain|Bilbao, Vizcaya, Spain|Albacete, Spain|Alicante, Spain|Badajoz, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Burgos, Spain|Caceres, Spain|Castellon, Spain|Ciudad Real, Spain|Cordoba, Spain|Girona, Spain|Granada, Spain|Guadalajara, Spain|Jaen, Spain|La Coruña, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Malaga, Spain|Navarra, Spain|Salamanca, Spain|Segovia, Spain|Sevilla, Spain|Sevilla, Spain|Toledo, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valladolid, Spain|Zaragoza, Spain|Eskilstuna, Sweden|Falun, Sweden|Karlstad, Sweden|Umeå, Sweden|Uppsala, Sweden|Örebro, Sweden|Aarau, Switzerland|Baden, Switzerland|Bellinzona, Switzerland|Bern, Switzerland|Genève 14, Switzerland|Zürich, Switzerland|Taipei City, Taiwan|Taipei City, Taiwan|Taoyuan Hsien, Taiwan|Ankara, Turkey|Ankara, Turkey|Diyarbakir, Turkey|Istanbul, Turkey|Montevideo, Uruguay","https://ClinicalTrials.gov/show/NCT01239732"
168,"NCT02149108","Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)","Completed","Has Results","All","Phase 3","768","Industry","Interventional","September 25, 2014","May 13, 2016","August 25, 2016","May 29, 2014","July 21, 2017","July 21, 2017","1199.52.0108 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|1199.52.0105 Boehringer Ingelheim Investigational Site, New Haven, Connecticut, United States|1199.52.0101 Boehringer Ingelheim Investigational Site, Plainville, Connecticut, United States|1199.52.0121 Boehringer Ingelheim Investigational Site, Arlington Heights, Illinois, United States|1199.52.0123 Boehringer Ingelheim Investigational Site, Sioux City, Iowa, United States|1199.52.0104 Boehringer Ingelheim Investigational Site, Topeka, Kansas, United States|1199.52.0114 Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|1199.52.0113 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|1199.52.0125 Boehringer Ingelheim Investigational Site, Omaha, Nebraska, United States|1199.52.0119 Boehringer Ingelheim Investigational Site, Johnson City, New York, United States|1199.52.0115 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States|1199.52.0106 Boehringer Ingelheim Investigational Site, Sylvania, Ohio, United States|1199.52.0102 Boehringer Ingelheim Investigational Site, Nashville, Tennessee, United States|1199.52.0120 Boehringer Ingelheim Investigational Site, Fort Worth, Texas, United States|1199.52.5404 Boehringer Ingelheim Investigational Site, Cdad. de Córdoba, Argentina|1199.52.5405 Boehringer Ingelheim Investigational Site, Cdad. de Córdoba, Argentina|1199.52.5401 Boehringer Ingelheim Investigational Site, Ciudad Autónoma de Bs As, Argentina|1199.52.5403 Boehringer Ingelheim Investigational Site, Ciudad Autónoma de Bs As, Argentina|1199.52.5406 Boehringer Ingelheim Investigational Site, Ciudad Autónoma de Bs As, Argentina|1199.52.6102 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia|1199.52.6103 Boehringer Ingelheim Investigational Site, St Leonards, New South Wales, Australia|1199.52.6101 Boehringer Ingelheim Investigational Site, Wollongong, New South Wales, Australia|1199.52.6104 Boehringer Ingelheim Investigational Site, Heidelberg, Victoria, Australia|1199.52.6105 Boehringer Ingelheim Investigational Site, Nedlands, Western Australia, Australia|1199.52.6106 Boehringer Ingelheim Investigational Site, Perth, Western Australia, Australia|1199.52.4302 Boehringer Ingelheim Investigational Site, Linz, Austria|1199.52.4303 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.52.4304 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.52.3208 Boehringer Ingelheim Investigational Site, Aalst, Belgium|1199.52.3205 Boehringer Ingelheim Investigational Site, Bonheiden, Belgium|1199.52.3202 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1199.52.3207 Boehringer Ingelheim Investigational Site, Charleroi, Belgium|1199.52.3204 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1199.52.3203 Boehringer Ingelheim Investigational Site, Haine-Saint-Paul, Belgium|1199.52.3201 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1199.52.3206 Boehringer Ingelheim Investigational Site, Liège, Belgium|1199.52.3521 Boehringer Ingelheim Investigational Site, Luxembourg, Belgium|1199.52.1003 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1199.52.1004 Boehringer Ingelheim Investigational Site, Edmonton, Ontario, Canada|1199.52.1001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1199.52.1002 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1199.52.4202 Boehringer Ingelheim Investigational Site, Brno, Czechia|1199.52.4204 Boehringer Ingelheim Investigational Site, Hradec Kralove, Czechia|1199.52.4201 Boehringer Ingelheim Investigational Site, Prague, Czechia|1199.52.4502 Boehringer Ingelheim Investigational Site, Herning, Denmark|1199.52.4501 Boehringer Ingelheim Investigational Site, København Ø, Denmark|1199.52.4503 Boehringer Ingelheim Investigational Site, Næstved, Denmark|1199.52.4504 Boehringer Ingelheim Investigational Site, Odense C, Denmark|1199.52.3304 Boehringer Ingelheim Investigational Site, Lille cedex, France|1199.52.3307 Boehringer Ingelheim Investigational Site, Lyon cedex 8, France|1199.52.3305 Boehringer Ingelheim Investigational Site, Paris cedex 15, France|1199.52.3301 Boehringer Ingelheim Investigational Site, Reims Cedex, France|1199.52.4906 Boehringer Ingelheim Investigational Site, Dresden, Germany|1199.52.4905 Boehringer Ingelheim Investigational Site, Essen, Germany|1199.52.4904 Boehringer Ingelheim Investigational Site, Freiburg, Germany|1199.52.4903 Boehringer Ingelheim Investigational Site, Mannheim, Germany|1199.52.4901 Boehringer Ingelheim Investigational Site, Ulm, Germany|1199.52.8501 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.8502 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.8503 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.8504 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.9706 Boehringer Ingelheim Investigational Site, Beer Sheva, Israel|1199.52.9704 Boehringer Ingelheim Investigational Site, Petach Tikva, Israel|1199.52.9703 Boehringer Ingelheim Investigational Site, Tel Aviv, Israel|1199.52.3901 Boehringer Ingelheim Investigational Site, Genova, Italy|1199.52.3906 Boehringer Ingelheim Investigational Site, Milano, Italy|1199.52.3907 Boehringer Ingelheim Investigational Site, Napoli, Italy|1199.52.3905 Boehringer Ingelheim Investigational Site, Padova, Italy|1199.52.3903 Boehringer Ingelheim Investigational Site, Pisa, Italy|1199.52.3904 Boehringer Ingelheim Investigational Site, San Giovanni Rotondo (FG), Italy|1199.52.8102 Boehringer Ingelheim Investigational Site, Aichi, Nagoya, Japan|1199.52.8105 Boehringer Ingelheim Investigational Site, Chiba, Chiba, Japan|1199.52.8101 Boehringer Ingelheim Investigational Site, Chiba, Kashiwa, Japan|1199.52.8107 Boehringer Ingelheim Investigational Site, Ehime, Matsuyama, Japan|1199.52.8106 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan|1199.52.8108 Boehringer Ingelheim Investigational Site, Hokkaido, Sapporo, Japan|1199.52.8115 Boehringer Ingelheim Investigational Site, Hyogo, Amagasaki, Japan|1199.52.8112 Boehringer Ingelheim Investigational Site, Hyogo, Kobe, Japan|1199.52.8114 Boehringer Ingelheim Investigational Site, Ibaraki, Tsukuba, Japan|1199.52.8110 Boehringer Ingelheim Investigational Site, Oita, Yufu, Japan|1199.52.8116 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1199.52.8103 Boehringer Ingelheim Investigational Site, Osaka, Suita, Japan|1199.52.8109 Boehringer Ingelheim Investigational Site, Saitama, Kitaadachi-gun, Japan|1199.52.8104 Boehringer Ingelheim Investigational Site, Shizuoka, Sunto-gun, Japan|1199.52.8113 Boehringer Ingelheim Investigational Site, Tokyo , Shinagawa-ku, Japan|1199.52.8111 Boehringer Ingelheim Investigational Site, Tokyo, Koto-ku, Japan|1199.52.8202 Boehringer Ingelheim Investigational Site, Goyang, Korea, Republic of|1199.52.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.52.8203 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.52.8204 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.52.5201 Boehringer Ingelheim Investigational Site, Mexico, Mexico|1199.52.3101 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands|1199.52.3103 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands|1199.52.3102 Boehringer Ingelheim Investigational Site, Utrecht, Netherlands|1199.52.4801 Boehringer Ingelheim Investigational Site, Jelenia Gora, Poland|1199.52.4803 Boehringer Ingelheim Investigational Site, Poznan, Poland|1199.52.4804 Boehringer Ingelheim Investigational Site, Wroclaw, Poland|1199.52.3504 Boehringer Ingelheim Investigational Site, Almada, Portugal|1199.52.3502 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|1199.52.3505 Boehringer Ingelheim Investigational Site, Loures, Portugal|1199.52.3501 Boehringer Ingelheim Investigational Site, Porto, Portugal|1199.52.3506 Boehringer Ingelheim Investigational Site, Porto, Portugal|1199.52.0701 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1199.52.0703 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1199.52.0702 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1199.52.0707 Boehringer Ingelheim Investigational Site, Tyumen, Russian Federation|1199.52.3401 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1199.52.3402 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat, Spain|1199.52.3406 Boehringer Ingelheim Investigational Site, La Coruña, Spain|1199.52.3403 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.52.3404 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.52.3405 Boehringer Ingelheim Investigational Site, Santander, Spain|1199.52.3407 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1199.52.4601 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1199.52.4602 Boehringer Ingelheim Investigational Site, Uppsala, Sweden|1199.52.8805 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|1199.52.8801 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1199.52.8803 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1199.52.8802 Boehringer Ingelheim Investigational Site, Taoyuan County, Taiwan|1199.52.9005 Boehringer Ingelheim Investigational Site, Adana, Turkey|1199.52.9001 Boehringer Ingelheim Investigational Site, Ankara, Turkey|1199.52.9003 Boehringer Ingelheim Investigational Site, Antalya, Turkey|1199.52.9004 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|1199.52.9002 Boehringer Ingelheim Investigational Site, Izmir, Turkey|1199.52.4401 Boehringer Ingelheim Investigational Site, Aberdeen, United Kingdom|1199.52.4403 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|1199.52.4402 Boehringer Ingelheim Investigational Site, Middlesex, United Kingdom|1199.52.4405 Boehringer Ingelheim Investigational Site, Nottingham, United Kingdom|1199.52.4404 Boehringer Ingelheim Investigational Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT02149108"
169,"NCT00967018","A Long Term Safety Study of Degarelix in Patients With Prostate Cancer","Completed","Has Results","Male","Phase 3","77","Industry","Interventional","August 2009","November 2011","December 2011","August 27, 2009","December 24, 2012","January 3, 2013","Institut Jules Bordet, Bruxelles, Belgium|St. Elisabethziekenhuis, Turnhout, Belgium|Hopital Jean Minjoz, Besancon, France|Institut Bergonié, Bordeaux Cedex, France|Centre Francois Baclesse, Caen, France|CHU Henri Mondor, Creteil, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital de la Timone, Marseille, Cedex, France|CRLC Val d' Aurelle - Oncology Radiotherapy, Montpellier, France|Hôpital Saint Louis - Radiotherapy Departement, Paris, France|Hôpital Tenon, Paris, France|Clinique Francheville, Perigueux, France|CHU La Milétrie - Oncology Radiotherapy, Poitiers, France|Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France|Institut de Cancérologie de la Loire, Saint Priest en Jarez, France|Clinique Saint Brieuc, St Brieuc Cedex, France|Centre Paul Strauss, Strassbourg, France|Centre de radiologie Saint Louis, Toulon, France|Clinique du Parc, Toulouse, France|IGR, Villejuif, France|Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy|Policlinico S.Orsola Malpighi - Universita' degli Studi di Bologna, Bologna, Italy|Clinica Urologica 1 Universita Firenze, Firenze, Italy|Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy|Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milano, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone dell'Universita' degli Studi di Palermo, Palermo, Italy|Clinica Urologica - Azienda Ospedaliera di Perugia, Perugia, Italy|Azienda Ospedaliera S. Andrea - Universita' la Sapienza di Roma, Roma, Italy|S.C. Di Urologia - IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Azienda Ospedaliero Universitaria S. Giovanni Battista - Molinette, Torino, Italy|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Universidade Coimbra, Coimbra, Portugal|Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisboa, Portugal|Hospital S.João, Porto, Portugal|Hospital Universitario Principe de Asturias, Alcalá de Henares-Madrid, Spain|Fundacion Hospital Alcorcón, Alcorcon, Spain|Fundación Puigvert, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Clinico Universitario S. Carlos, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Manacor, Manacor, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Santiago de Compostela, Santiago de Compostela, Spain|Hospital Virgen Macarena, Sevilla, Spain|Fundación IVO, Valencia, Spain|Hospital Xeral de Vigo, Vigo, Spain|Investigational site, Göteborg, Sweden|SU/Sahlgrenska, Göteborg, Sweden|Helsingborgs Lasarett, Helsingborg, Sweden|Universitetssjukhuset MAS, Malmö, Sweden|Södertälje Sjukhus, Södertälje, Sweden|Uppsala/Akademiska sjukhuset, Uppsala, Sweden|Ankara University Faculty of Medicine - Sıhhıye, Ankara, Turkey|Cerrahpasa Faculty of Medicine - Kocamustafapasa, Istanbul, Turkey|Istanbul University Faculty of Medicine - ÇAPA, Istanbul, Turkey|Marmara University Faculty of Medicine - Altunizade, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT00967018"
170,"NCT01437566","Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy","Completed","No Results Available","Female","Phase 2","318","Industry","Interventional","October 2011","April 2016","April 2016","September 21, 2011","null","November 2, 2016","Birmingham, Alabama, United States|Hayward, California, United States|Oakland, California, United States|Roseville, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Jose, California, United States|Santa Clara, California, United States|South San Francisco, California, United States|Vallejo, California, United States|Walnut Creek, California, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Saint Petersburg, Florida, United States|Marietta, Georgia, United States|Joliet, Illinois, United States|Peoria, Illinois, United States|Wichita, Kansas, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Basking Ridge, New Jersey, United States|Hackensack, New Jersey, United States|Commack, New York, United States|New York, New York, United States|Rockville Centre, New York, United States|Sleepy Hollow, New York, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Tyler, Texas, United States|Richmond, Virginia, United States|Buenos Aires, Argentina|Santa Fe, Argentina|Kogarah, New South Wales, Australia|Wahroonga, New South Wales, Australia|South Brisbane, Queensland, Australia|Bedford Park, South Australia, Australia|Woodville, South Australia, Australia|Frankston, Victoria, Australia|Parkville, Victoria, Australia|Bruxelles, Belgium|Bruxelles, Belgium|Edegem, Belgium|Leuven, Belgium|Liège, Belgium|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Santiago, Chile|Temuco, Chile|Valparaiso, Chile|Vina del Mar, Chile|Brno, Czech Republic|Olomouc, Czech Republic|Praha 2, Czech Republic|Herlev, Denmark|København Ø, Denmark|Odense, Denmark|Roskilde, Denmark|Vejle, Denmark|Århus, Denmark|Paris, France|Berlin, Germany|Düsseldorf, Germany|Freiburg, Germany|Freiburg, Germany|Hamburg, Germany|Muenchen, Germany|Muenchen, Germany|München, Germany|Trier, Germany|Hong Kong, Hong Kong|Pokfulam, Hong Kong|Beer Sheva, Israel|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel-Hashomer, Israel|Zerifin, Israel|Napoli, Campania, Italy|Meldola, Emilia-Romagna, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Pisa, Toscana, Italy|Prato, Toscana, Italy|Terni, Umbria, Italy|Seoul, Korea, Republic of|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Penang, Malaysia|Penang, Malaysia|Tanjung Bungah, Malaysia|León, Mexico|Christchurch, New Zealand|Hamilton, New Zealand|Wellington, New Zealand|Lima, Peru|Lima, Peru|Lima, Peru|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Voronezh, Russian Federation|Singapore, Singapore|Barcelona, Spain|Lerida, Spain|Valencia, Spain|Zaragoza, Spain|Patumwan, Thailand|Songkhla, Thailand|Brighton, United Kingdom|Cardiff, United Kingdom|London, United Kingdom|London, United Kingdom|Stoke on Trent, United Kingdom","https://ClinicalTrials.gov/show/NCT01437566"
171,"NCT02141295","A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer","Completed","No Results Available","All","Phase 2","200","Industry","Interventional","June 30, 2014","July 29, 2016","February 1, 2017","May 19, 2014","null","April 5, 2018","Alabama Oncology, Birmingham, Alabama, United States|Arizona Clinical Research Ctr, Tucson, Arizona, United States|California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States|Fresno cCare, Fresno, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|David Geffen School Medicine, Los Angeles, California, United States|Va Greater Los Angeles Healthcare System, Sepulveda, California, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Research Inst., Nashville, Tennessee, United States|Ctr for Cancer and Blood Disorders, Fort Worth, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Monash Medical Centre-Moorabbin Campus, Clayton, Victoria, Australia|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Universitätsklinikum Innsbruck; Abteilung für Hämatologie und Onkologie, Innsbruck, Austria|Salzburger Landeskliniken LKH, Salzburg, Austria|Oö. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, Austria|Imeldaziekenhuis, Bonheiden, Belgium|UZ Antwerpen, Edegem, Belgium|Centre Paul Papin, Angers, France|Institut De Cancerologie De L'Ouest; Medical Oncology, Saint Herblain, France|Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica, Napoli, Campania, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|HM Sanchinarro - CIOCC; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Aberdeen Royal Infirmary; Medical Oncology Dept, Aberdeen, United Kingdom|Princess Alexandra Hospital, Harlow, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|Queen's Hospital; Oncology, Romford, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT02141295"
172,"NCT01767155","Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer","Completed","Has Results","Female","Phase 3","511","Industry","Interventional","April 2013","January 30, 2017","January 30, 2017","January 14, 2013","July 31, 2018","July 31, 2018","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|USC Norris Hospital and LAC+USC Medical Center, Los Angeles, California, United States|University of California, Irvine - Medical Center, Orange, California, United States|University of Colorado, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Women's Cancer Center, Covington, Louisiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medecine, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Institute, New York, New York, United States|Hope Women's Cancer Centers / Mission Hospital, Inc., Asheville, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Peggy and Charles Oklahoma Cancer Center, Oklahoma City, Oklahoma, United States|Hollings Cancer Center, MUSC, Charleston, South Carolina, United States|Sanford Research/USD, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Hospitals, Falls Church, Virginia, United States|Henrico Doctor's Hospital, Richmond, Virginia, United States|Froedtert & The Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|Alexandrov National Cancer centre of Belarus, Minsk, Belarus|Minsk City Clinical Oncologic Dispensary, Minsk, Belarus|Mogilev Regional Clinical Oncologic Dispensary, Mogilev, Belarus|Vitebsk Regional Clinical Oncologic Dispensary, Vitebsk, Belarus|Institut Jules Bordet, Brussels, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|Hospital Centre Liege University_CHU Sart Tilman, Liege, Belgium|CHWAPI, Tournai, Belgium|Clinical Center Banja Luka, Oncology Clinic, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Oncology clinic, Mostar, Bosnia and Herzegovina|Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina|Specialized Hospital for Active Treatment in Obstetrics and Gynecology, Pleven, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Hopital Notre Dame - CHUM, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Hotel Dieu de Quebec- CHUQ, Quebec, Canada|Masarykův onkologický ústav, Brno, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|Všeobecná fakultní nemocnice v Praze, Praha, Czechia|Copenhagen University Hospital ""Rigshospitalet"", Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Kuopio University Hospital, Kuopio, Finland|Tampere University Hospital, Tampere, Finland|Turku University Central Hospital, Turku, Finland|Klinikum Frankfurt Höchst, Frankfurt, Germany|Georg-August-Universität Göttingen, Universitäts-Frauenklinik, Abteilung für Gynäkologie und Geburtshilfe, Göttingen, Germany|Universitätsklinik und Poliklinik für Gynäkologie Martin Luther Universität Halle-Wittenberg, Halle, Germany|Universitätsklinikum Köln, Köln, Germany|University Clinic Münster, Münster, Germany|Klinik für Frauenheilkunde und Geburtshilfe der Universität Regensburg am Caritas-Krankenhaus St. Josef, Regensburg, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|St James's Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Waterford Regional Hospital, Waterford, Ireland|Barzilai Medical Center, Ashkelon, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Hospital, Jerusalem, Israel|Davidoff Center, Rabin Medical Center, Petah-Tikva, Israel|Oncology Institute Kaplan, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel Hashomer, Israel|Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|Istituto Nazionale Tumori IRCCS, Napoli, Italy|Istituto Oncologico Veneto, IRCCS, Padova, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy|Policlinico A. Gemelli, Rome, Italy|Academic Medical Center, Amsterdam, Netherlands|Maastricht University Medical Center (UMC), Maastricht, Netherlands|Haukeland University Hospital, Bergen, Norway|The Norwegian Radium Hospital, Oslo, Norway|Helse Stavanger HF, Stavanger Universitetssjukhus, Stavanger, Norway|Bialostockie Centrum Onkologii, Bialystok, Poland|I Klinika Ginekologii Onkologicznej i Ginekologii, Lublin, Poland|Wojewodzki Szpital Specjalistyczny, Olsztyn, Poland|NZOZ Magodent, Szpital Onkologiczny, Warszawa, Poland|Centrum Terapii Współczesnej ul., Łódź, Poland|Oncolab, Craiova, Dolj County, Romania|Spitalul Clinic Judetean Mures, Targu Mures, Mures County, Romania|Oncology Institute ""Prof. Dr. I. Chiricuta"", Cluj Npaoca, Romania|Centru de Oncologie Sf. Nectarie, Craiova, Romania|Spitalul Clinic Judetean de Urgenta ""Sf. Ioan cel Nou"", Suceava, Romania|Oncomed, Timisoara, Romania|GAUZ ""Republican Clinical Oncology Center"", Kazan, Republic Of Tatarstan, Russian Federation|FGBU ""RONC n.a. N.N. Blokhin"", Moscow, Russian Federation|Nizhny Novgorod Regional Oncology Dispensary, Nizhny Novgorod, Russian Federation|Pyatigorsk Regional Oncology Dispensary, Pyatigorsk, Russian Federation|FGBU ""NIIO n.a. N.N. Petrov"", Saint-Petersburg, Russian Federation|Budget Institution of Health / Leningrad Regional Oncological Dispensary, St. Petersburg, Russian Federation|Saint-Petersburg State Budgetary Institution Healthcare ""City Clinical Oncology Center"", St. Petersburg, Russian Federation|Republican Clinical Oncology Dispensary, Ufa, Russian Federation|Volgograd Regional Oncology Dispensary #3, Volzhskiy, Russian Federation|Hospital Vall d´Hebron, Barcelona, Spain|MD Anderson cáncer center, Madrid, Spain|Ramon Y Cajal Hospital, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Zina Memorial Cancer Hospital (LISSOD), Plyuty, Kiev Region, Ukraine|Municipal institution ""Dnipropetrovsk City Multidisciplinary Clinical Hospital No. 4"", Dnepropetrovsk, Ukraine|CCMP I Donetsk Regional Anticancer Center, Donetsk, Ukraine|Public health enterprise ""Kharkov regional Clinical Oncological Center"", Kharkov, Ukraine|Kiev City Clinical Oncology Center, Kiev, Ukraine|Zakarpatskyi Regional Clinical Oncology Dispensary, Uzhgorod, Ukraine|Vinnitsa Regional Clinical Oncology Dispensary, Vinnitsa, Ukraine|The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Imperial college Healthcare NHS Trust, London, United Kingdom|Nottingham City Hospital NHS Trust, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT01767155"
173,"NCT00937560","A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer","Completed","Has Results","Female","Phase 2","190","Industry","Interventional","June 25, 2009","July 31, 2012","July 1, 2013","July 13, 2009","February 24, 2015","November 6, 2017","Hospital Amaral Carvalho, Jau, SP, Brazil|Hospital das Clinicas - FMUSP, Oncologia, Sao Paulo, SP, Brazil|Centre Hospitalier Henri Duffaut; Hematologie, Avignon, France|Clinique Tivoli; Sce Radiotherapie, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie, Bordeaux, France|Ch De Brive La Gaillarde; Radiotherapie Oncologie, Brive La Gaillarde, France|Hopital Antoine Beclere; Service de Medecine Interne, Clamart, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Chi Alpes Du Sud Site De Gap; Med Interne Et Polyvalente, GAP, France|Institut Daniel Hollard, Grenoble, France|Hôpital Saint Joseph; Oncologie Medicale, Marseille, France|CHRA;Hematologie, Metz Tessy, France|Centre Antoine Lacassagne; Hopital De Jour A2, Nice, France|GH Paris Saint Joseph; Hopital De Jour Oncologie, Paris, France|HOPITAL TENON; Cancerologie Medicale, Paris, France|Hopital De La Miletrie; Hematologie Et Oncologie Medicale, Poitiers, France|Institut de Cancerologie de La Loire; Radiotherapie, St Priest En Jarez, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre Les Nancy, France|IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica B, Napoli, Campania, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica, Roma, Lazio, Italy|Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica, Campobasso, Molise, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Academisch Medisch Centrum; Inwendige Geneeskunde, Amsterdam, Netherlands|Medisch Spectrum Twente Enschede; Internal Medicine, Enschede, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|Mc Haaglanden, Locatie Antoniushove; Interne Geneeskunde, Leidschendam, Netherlands|Sint Elizabeth Ziekenhuis; Inwendige Geneeskunde, Tilburg, Netherlands|Isala Klinieken, Locatie Sophia; Inwendige Geneeskunde, Zwolle, Netherlands|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway|St. Olavs Hospital; Kvinneklinikken, Trondheim, Norway|Regional Clinical Oncology Dispensary, Krasnodar, Russian Federation|Oncology Hospital; Chemotherapy Dept., Moscow, Russian Federation|Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Medical Radiological Scientific Center; Department of Radiotherapy of Gynaecological Disease, Obninsk, Kaluzhskaya Region, Russian Federation|St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Sahlgrenska Universitetssjukhuset; Onkology, Gothenburg, Sweden|Uni Hospital Linkoeping; Dept. of Oncology, Linköping, Sweden|Norrlands Uni Hospital; Onkologi Avd., Umea, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Örebro University Hospital; Department of Gynecologic Oncology, Örebro, Sweden|Royal Marsden Hospital; Dept of Med-Onc, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00937560"
174,"NCT01308580","Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer","Completed","Has Results","Male","Phase 3","1200","Industry","Interventional","April 2011","August 2015","August 2015","March 4, 2011","October 11, 2016","April 17, 2017","Investigational Site Number 840002, Muscle Shoals, Alabama, United States|Investigational Site Number 840004, Hot Springs, Arkansas, United States|Investigational Site Number 840008, Anaheim, California, United States|Investigational Site Number 840010, La Jolla, California, United States|Investigational Site Number 840001, San Bernardino, California, United States|Investigational Site Number 840021, Stamford, Connecticut, United States|Investigational Site Number 840023, Jacksonville, Florida, United States|Investigational Site Number 840013, Lakeland, Florida, United States|Investigational Site Number 840003, Port St. Lucie, Florida, United States|Investigational Site Number 840007, New Orleans, Louisiana, United States|Investigational Site Number 840014, Baltimore, Maryland, United States|Investigational Site Number 840005, Rockville, Maryland, United States|Investigational Site Number 840017, St Louis Park, Minnesota, United States|Investigational Site Number 840011, Jackson, Mississippi, United States|Investigational Site Number 840016, Lincoln, Nebraska, United States|Investigational Site Number 840015, East Orange, New Jersey, United States|Investigational Site Number 840024, Raleigh, North Carolina, United States|Investigational Site Number 840020, Akron, Ohio, United States|Investigational Site Number 840006, Pawtucket, Rhode Island, United States|Investigational Site Number 840025, Chattanooga, Tennessee, United States|Investigational Site Number 840012, Corpus Christi, Texas, United States|Investigational Site Number 032002, Buenos Aires, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032003, Salta, Argentina|Investigational Site Number 032004, Santa Fe, Argentina|Investigational Site Number 036014, Adelaide, Australia|Investigational Site Number 036013, Bankstown, Australia|Investigational Site Number 036010, Box Hill, Australia|Investigational Site Number 036012, Camperdown, Australia|Investigational Site Number 036008, Coffs Harbour, Australia|Investigational Site Number 036001, Concord, Australia|Investigational Site Number 036015, Elizabeth Vale, Australia|Investigational Site Number 036009, Fitzroy, Australia|Investigational Site Number 036007, Garran, Australia|Investigational Site Number 036005, Heidelberg West, Australia|Investigational Site Number 036002, Malvern, Australia|Investigational Site Number 036006, South Brisbane, Australia|Investigational Site Number 036016, Subiaco, Australia|Investigational Site Number 036003, Wahroonga, Australia|Investigational Site Number 036004, Wodonga, Australia|Investigational Site Number 056007, Antwerpen, Belgium|Investigational Site Number 056008, Brussel, Belgium|Investigational Site Number 056001, Bruxelles, Belgium|Investigational Site Number 056002, Bruxelles, Belgium|Investigational Site Number 056009, Charleroi, Belgium|Investigational Site Number 056003, Gent, Belgium|Investigational Site Number 056012, Godinne, Belgium|Investigational Site Number 056016, Haine-Saint-Paul, Belgium|Investigational Site Number 056005, Hasselt, Belgium|Investigational Site Number 056010, Libramont, Belgium|Investigational Site Number 056013, Liège, Belgium|Investigational Site Number 056011, Ottignies, Belgium|Investigational Site Number 056004, Roeselare, Belgium|Investigational Site Number 056006, Turnhout, Belgium|Investigational Site Number 076016, Fortaleza, Brazil|Investigational Site Number 076012, Ijui, Brazil|Investigational Site Number 076015, Mogi Das Cruzes, Brazil|Investigational Site Number 076014, Porto Alegre, Brazil|Investigational Site Number 076010, Rio De Janeiro, Brazil|Investigational Site Number 076007, Salvador, Brazil|Investigational Site Number 076003, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076009, Sao Paulo, Brazil|Investigational Site Number 076001, Sao Paulo, Brazil|Investigational Site Number 076013, Sao Paulo, Brazil|Investigational Site Number 076008, Sao Paulo, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 124002, Greenfield Park, Canada|Investigational Site Number 124001, Oshawa, Canada|Investigational Site Number 124003, Ottawa, Canada|Investigational Site Number 124005, Owen Sound, Canada|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152001, Viña Del Mar, Chile|Investigational Site Number 250005, Avignon Cedex 9, France|Investigational Site Number 250008, Hyeres, France|Investigational Site Number 250001, La Roche Sur Yon, France|Investigational Site Number 250002, Nantes Cedex 2, France|Investigational Site Number 250004, Nimes, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250009, Reims Cedex, France|Investigational Site Number 250007, Reims, France|Investigational Site Number 250006, Saint Brieuc Cedex, France|Investigational Site Number 250011, Toulouse Cedex 03, France|Investigational Site Number 250003, Toulouse Cedex 09, France|Investigational Site Number 276003, Aachen, Germany|Investigational Site Number 276007, Dresden, Germany|Investigational Site Number 276004, Düsseldorf, Germany|Investigational Site Number 276001, Erlangen, Germany|Investigational Site Number 276011, Hamburg, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276010, Homburg, Germany|Investigational Site Number 276006, München, Germany|Investigational Site Number 276012, Nürtingen, Germany|Investigational Site Number 276008, Tübingen, Germany|Investigational Site Number 276002, Wuppertal, Germany|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348006, Miskolc, Hungary|Investigational Site Number 348003, Pécs, Hungary|Investigational Site Number 410003, Seongnam, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 528005, Arnhem, Netherlands|Investigational Site Number 528003, Blaricum, Netherlands|Investigational Site Number 528004, Hoofddorp, Netherlands|Investigational Site Number 528002, Nijmegen, Netherlands|Investigational Site Number 528001, Zwolle, Netherlands|Investigational Site Number 604003, Arequipa, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604002, Lima, Peru|Investigational Site Number 604004, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 616006, Lubin, Poland|Investigational Site Number 616002, Olsztyn, Poland|Investigational Site Number 616001, Rybnik, Poland|Investigational Site Number 616005, Siedlce, Poland|Investigational Site Number 616004, Torun, Poland|Investigational Site Number 642005, Alba Iulia, Romania|Investigational Site Number 642006, Baia Mare, Romania|Investigational Site Number 642009, Bucuresti, Romania|Investigational Site Number 642008, Bucuresti, Romania|Investigational Site Number 642001, Cluj Napoca, Romania|Investigational Site Number 642003, Cluj Napoca, Romania|Investigational Site Number 642004, Cluj Napoca, Romania|Investigational Site Number 642002, Cluj Napoca, Romania|Investigational Site Number 642012, Focsani, Romania|Investigational Site Number 642007, Hunedoara, Romania|Investigational Site Number 642013, Onesti, Romania|Investigational Site Number 643009, Ekaterinburg, Russian Federation|Investigational Site Number 643007, Moscow, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643006, Moscow, Russian Federation|Investigational Site Number 643008, Obninsk, Russian Federation|Investigational Site Number 643001, St.Petersburg, Russian Federation|Investigational Site Number 643010, St.Petersburg, Russian Federation|Investigational Site Number 643003, Tula, Russian Federation|Investigational Site Number 710003, Cape Town, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710005, Johannesburg, South Africa|Investigational Site Number 710004, Johannesburg, South Africa|Investigational Site Number 710001, Pretoria, South Africa|Investigational Site Number 724003, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724006, Málaga, Spain|Investigational Site Number 724005, Palma De Mallorca, Spain|Investigational Site Number 724004, Sabadell, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 158002, Taiching, Taiwan|Investigational Site Number 158003, Tainan, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 788004, Sfax, Tunisia|Investigational Site Number 788003, Sousse, Tunisia|Investigational Site Number 788002, Tunis, Tunisia|Investigational Site Number 792003, Antalya, Turkey|Investigational Site Number 792001, Bornova, Turkey|Investigational Site Number 792002, Istanbul, Turkey|Investigational Site Number 826002, Birmingham, United Kingdom|Investigational Site Number 826004, Colchester, United Kingdom|Investigational Site Number 826005, Glasgow, United Kingdom|Investigational Site Number 826006, Guildford, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826003, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826001, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01308580"
175,"NCT01308567","Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer","Completed","Has Results","Male","Phase 3","1170","Industry","Interventional","May 5, 2011","September 2015","May 2018","March 4, 2011","March 3, 2017","October 23, 2018","Investigational Site Number 840004, Muscle Shoals, Alabama, United States|Investigational Site Number 840009, Anaheim, California, United States|Investigational Site Number 840014, Bakersfield, California, United States|Investigational Site Number 840030, Sacramento, California, United States|Investigational Site Number 840003, San Bernardino, California, United States|Investigational Site Number 840012, San Francisco, California, United States|Investigational Site Number 840019, Denver, Colorado, United States|Investigational Site Number 840013, Boca Raton, Florida, United States|Investigational Site Number 840035, Jacksonville, Florida, United States|Investigational Site Number 840001, Port Saint Lucie, Florida, United States|Investigational Site Number 840015, Decatur, Illinois, United States|Investigational Site Number 840018, Wichita, Kansas, United States|Investigational Site Number 840010, Paducah, Kentucky, United States|Investigational Site Number 840008, New Orleans, Louisiana, United States|Investigational Site Number 840006, Rockville, Maryland, United States|Investigational Site Number 840238, Boston, Massachusetts, United States|Investigational Site Number 840138, Boston, Massachusetts, United States|Investigational Site Number 840038, Brookline, Massachusetts, United States|Investigational Site Number 840005, Detroit, Michigan, United States|Investigational Site Number 840021, Saint Louis Park, Minnesota, United States|Investigational Site Number 840016, Kansas City, Missouri, United States|Investigational Site Number 840020, Lincoln, Nebraska, United States|Investigational Site Number 840017, East Orange, New Jersey, United States|Investigational Site Number 840033, Albuquerque, New Mexico, United States|Investigational Site Number 840036, Raleigh, North Carolina, United States|Investigational Site Number 840011, Washington, North Carolina, United States|Investigational Site Number 840026, Akron, Ohio, United States|Investigational Site Number 840023, Cleveland, Ohio, United States|Investigational Site Number 840032, Dunmore, Pennsylvania, United States|Investigational Site Number 840007, Pawtucket, Rhode Island, United States|Investigational Site Number 840037, Myrtle Beach, South Carolina, United States|Investigational Site Number 840028, Chattanooga, Tennessee, United States|Investigational Site Number 036016, Bankstown, Australia|Investigational Site Number 036008, Camperdown, Australia|Investigational Site Number 036015, Coffs Harbour, Australia|Investigational Site Number 036001, Concord, Australia|Investigational Site Number 036017, Fitzroy, Australia|Investigational Site Number 036003, Herston, Australia|Investigational Site Number 036010, Hornsby, Australia|Investigational Site Number 036012, Kurralta Park, Australia|Investigational Site Number 036002, Parkville, Australia|Investigational Site Number 036009, South Brisbane, Australia|Investigational Site Number 036011, Subiaco, Australia|Investigational Site Number 036013, Wodonga, Australia|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112004, Vitebsk, Belarus|Investigational Site Number 076006, Passo Fundo, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076002, Porto Alegre, Brazil|Investigational Site Number 076004, Rio De Janeiro, Brazil|Investigational Site Number 076009, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076005, Sao Paulo, Brazil|Investigational Site Number 076003, Uberlandia, Brazil|Investigational Site Number 124002, London, Canada|Investigational Site Number 124007, Mississauga, Canada|Investigational Site Number 124005, Moncton, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124004, Quebec, Canada|Investigational Site Number 124006, Toronto, Canada|Investigational Site Number 156005, Beijing, China|Investigational Site Number 156002, Shanghai, China|Investigational Site Number 156003, Shanghai, China|Investigational Site Number 156004, Shanghai, China|Investigational Site Number 203002, Brno, Czechia|Investigational Site Number 203003, Novy Jicin, Czechia|Investigational Site Number 203001, Olomouc, Czechia|Investigational Site Number 203004, Praha 2, Czechia|Investigational Site Number 208002, Herlev, Denmark|Investigational Site Number 208001, København Ø, Denmark|Investigational Site Number 208003, Odense C, Denmark|Investigational Site Number 208004, Ålborg, Denmark|Investigational Site Number 246002, Helsinki, Finland|Investigational Site Number 246001, Kuopio, Finland|Investigational Site Number 246003, Turku, Finland|Investigational Site Number 250010, Besancon Cedex, France|Investigational Site Number 250002, Bordeaux Cedex, France|Investigational Site Number 250006, Caen Cedex 05, France|Investigational Site Number 250005, Lyon, France|Investigational Site Number 250003, Paris Cedex 05, France|Investigational Site Number 250004, Paris Cedex 10, France|Investigational Site Number 250001, Paris Cedex 15, France|Investigational Site Number 250007, Poitiers Cedex, France|Investigational Site Number 250008, Suresnes, France|Investigational Site Number 250009, Villejuif, France|Investigational Site Number 276003, Aachen, Germany|Investigational Site Number 276005, Berlin, Germany|Investigational Site Number 276001, Düsseldorf, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276002, Homburg, Germany|Investigational Site Number 276006, München, Germany|Investigational Site Number 376004, Kfar Saba, Israel|Investigational Site Number 376003, Petah-Tikva, Israel|Investigational Site Number 376002, Tel Aviv, Israel|Investigational Site Number 380001, Arezzo, Italy|Investigational Site Number 380004, Bari, Italy|Investigational Site Number 380003, Orbassano, Italy|Investigational Site Number 380005, Roma, Italy|Investigational Site Number 380002, Trento, Italy|Investigational Site Number 392001, Bunkyo-Ku, Japan|Investigational Site Number 392003, Chiba-Shi, Japan|Investigational Site Number 392006, Kashiwa-Shi, Japan|Investigational Site Number 392005, Koto-Ku, Japan|Investigational Site Number 392002, Osaka Sayama-Shi, Japan|Investigational Site Number 392004, Osaka-Shi, Japan|Investigational Site Number 484007, Acapulco, Mexico|Investigational Site Number 484008, Aguascalientes, Mexico|Investigational Site Number 484003, D.f., Mexico|Investigational Site Number 484004, Guadalajara, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484005, Queretaro, Mexico|Investigational Site Number 484002, San Luis Potosi, Mexico|Investigational Site Number 484006, Zapopan, Mexico|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604002, Lima, Peru|Investigational Site Number 616002, Bydgoszcz, Poland|Investigational Site Number 616001, Gdansk, Poland|Investigational Site Number 616003, Koscierzyna, Poland|Investigational Site Number 616005, Lodz, Poland|Investigational Site Number 616004, Poznan, Poland|Investigational Site Number 620003, Coimbra, Portugal|Investigational Site Number 620005, Lisboa, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620001, Porto, Portugal|Investigational Site Number 620002, Porto, Portugal|Investigational Site Number 642004, Baia Mare, Romania|Investigational Site Number 642008, Bucharest, Romania|Investigational Site Number 642005, Bucuresti, Romania|Investigational Site Number 642002, Cluj Napoca, Romania|Investigational Site Number 642003, Cluj Napoca, Romania|Investigational Site Number 642007, Hunedoara, Romania|Investigational Site Number 643004, Ekaterinburg, Russian Federation|Investigational Site Number 643008, Moscow, Russian Federation|Investigational Site Number 643003, Omsk, Russian Federation|Investigational Site Number 643002, Pyatigorsk, Russian Federation|Investigational Site Number 643007, Ryazan, Russian Federation|Investigational Site Number 643005, St-Petersburg, Russian Federation|Investigational Site Number 643001, Tomsk, Russian Federation|Investigational Site Number 643006, Yaroslavl, Russian Federation|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724007, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724003, Hospitalet De Llobregat, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724006, Santiago De Compostela, Spain|Investigational Site Number 752003, Malmö, Sweden|Investigational Site Number 752002, Stockholm, Sweden|Investigational Site Number 752001, Uppsala, Sweden|Investigational Site Number 158004, Kaohsiung, Taiwan|Investigational Site Number 158002, Taichung, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158003, Tao-Yuan, Taiwan|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792001, Istanbul, Turkey|Investigational Site Number 804009, Cherkasy, Ukraine|Investigational Site Number 804004, Dnipropetrovsk, Ukraine|Investigational Site Number 804010, Donetsk, Ukraine|Investigational Site Number 804006, Ivano-Frankivsk, Ukraine|Investigational Site Number 804003, Kharkov, Ukraine|Investigational Site Number 804002, Kyiv, Ukraine|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804007, Lutsk, Ukraine|Investigational Site Number 804005, Uzhgorod, Ukraine|Investigational Site Number 804008, Zaporizhzhya, Ukraine","https://ClinicalTrials.gov/show/NCT01308567"
176,"NCT01193244","Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer","Completed","Has Results","Male","Phase 3","1560","Industry","Interventional","October 1, 2010","January 1, 2014","April 7, 2016","September 1, 2010","May 17, 2017","May 17, 2017","Anchorage, Alaska, United States|Tucson, Arizona, United States|Duarte, California, United States|Highland, California, United States|Orange, California, United States|Sacramento, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Port St Lucie, Florida, United States|Jeffersonville, Indiana, United States|Kansas City, Kansas, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|Duluth, Minnesota, United States|Corinth, Mississippi, United States|Columbia, Missouri, United States|Jefferson City, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|East Syracuse, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Kettering, Ohio, United States|Tualatin, Oregon, United States|Hershey, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Piitsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Amarillo, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Denton, Texas, United States|Tyler, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Garran, Australia|Hobart, Australia|Kurralta Park, Australia|Nedlands, Australia|Perth, Australia|Redcliffe, Australia|Wodonga, Australia|Graz, Austria|Linz, Austria|Wien, Austria|Minsk, Belarus|Edegem, Belgium|Hasselt, Belgium|Kortrijk, Belgium|Leuven, Belgium|Namur, Belgium|Bairro Nazare - Salvador, Brazil|Barretos/sp, Brazil|Belo Horizonte, Brazil|Campinas, Brazil|Caxias Do Sul, Brazil|Curitiba, Brazil|Fortaleza/ce, Brazil|Ijui, Brazil|Joinville, Brazil|Lajeado - Rs, Brazil|Piracicaba - Sp, Brazil|Porto Alegre- Rs, Brazil|Porto Alegre/rs, Brazil|Ribeirao Preto - Sp, Brazil|Rio de Janeiro Rj, Brazil|Rio de Janeiro, Brazil|Santo Andre, Brazil|Sao Jose Do Rio Preto, Brazil|Sao Jose Dos Campos, Brazil|Sao Paulo, Brazil|Sorocaba - Sp, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Kelowna, British Columbia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Owen Sound, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Pointe Claire, Quebec, Canada|Quebec City, Quebec, Canada|Sherbrooke, Quebec, Canada|Las Condes, Chile|Santiago, Chile|Temuco, Chile|Valparaiso, Chile|Cali, Colombia|Hradec Kralove, Czech Republic|Praha 4, Czech Republic|Praha 5, Czech Republic|Joensuu, Finland|Oulu, Finland|Seinajoki, Finland|Tampere, Finland|Angers, France|Bordeaux, France|Caen, France|Creteil, France|La Roche Sur Yon, France|Lyon, France|Marseille, France|Nancy, France|Nantes, France|Paris Cedex 13, France|Paris Cedex 14, France|Paris, France|Poitiers, France|Saint-etienne, France|Villejuif, France|Braunschweig, Germany|Dresden, Germany|Hamburg, Germany|Hannover, Germany|Kassel, Germany|Kempen, Germany|Nurtingen, Germany|Tubingen, Germany|Wuppertal, Germany|Athens, Greece|Heraklion Crete, Greece|Larissa, Greece|Patras, Greece|Thessaloniki, Greece|Kowloon, Hong Kong|Shatin, Hong Kong|Dublin, Ireland|Galway, Ireland|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat-gan, Israel|Tel Aviv, Israel|Zerifin, Israel|Aviano, Italy|Novara, Italy|Roma, Italy|Torino, Italy|Chiba-city, Japan|Chiba, Japan|Fukuoka, Japan|Hamamatsu City, Japan|Hokkaido, Japan|Kanazawa, Japan|Kita-gun, Japan|Maebashi-city, Japan|Mito-city, Japan|Osaka-city, Japan|Osaka, Japan|Sakura City, Japan|Sayama, Japan|Sendai City, Japan|Shimizucho Sunto-gun, Japan|Suntou-gun, Japan|Tokyo, Japan|Yamagata City, Japan|Yokohama City, Japan|Yufu-city, Japan|Riga, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Durango Durango, Mexico|Mexico City Distrito Federal, Mexico|Zapopan Jalisco, Mexico|Amsterdam, Netherlands|Arnhem, Netherlands|Breda, Netherlands|Eindhoven, Netherlands|Heerlen, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Dunedin, New Zealand|Takapuna, New Zealand|Tauranga, New Zealand|Lima, Peru|Bielsko-biala, Poland|Wroclaw, Poland|Liepaja, Portugal|Lisboa, Portugal|Porto, Portugal|San Juan, Puerto Rico|Bucharest, Romania|Cluj-napoca, Romania|Moscow, Russian Federation|St Petersburg, Russian Federation|Singapore, Singapore|Nitra, Slovakia|Presov, Slovakia|Trencin, Slovakia|Zilina, Slovakia|Cape Town, South Africa|Durban, South Africa|George, South Africa|Port Elizabeth, South Africa|Barcelona, Spain|La Coruna, Spain|Madrid, Spain|Majadahonda, Spain|Pamplona, Spain|Sevilla, Spain|Valencia, Spain|Goteborg, Sweden|Stockholm, Sweden|Uppsala, Sweden|Aarau, Switzerland|Lausanne, Switzerland|Winterthur, Switzerland|Zurich, Switzerland|Taichung, Taiwan|Taipei, Taiwan|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kyiv, Ukraine|Zaporizhzhya, Ukraine|Aberdeen, United Kingdom|Belfast, United Kingdom|Bristol, United Kingdom|Cottingham, United Kingdom|Coventry, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Northwood, United Kingdom|Preston, United Kingdom|Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01193244"
177,"NCT00861614","Study of Immunotherapy to Treat Advanced Prostate Cancer","Completed","Has Results","Male","Phase 3","988","Industry","Interventional","May 2009","November 2012","August 2015","March 13, 2009","March 16, 2016","September 30, 2016","Southern Cancer Center, Mobile, Alabama, United States|Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States|Marsha G. Fink, Md, Inc., Fountain Valley, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States|Comprehensive Cancer Center, Palm Springs, California, United States|Va San Diego Healthcare System, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Suburban Hematology-Oncology Associates, Pc, Lawrenceville, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Cancer Care Specialists Of Central Illinois, Decatur, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Mid-Illinois Hematology & Oncology Associates, Ltd, Normal, Illinois, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Siouxland Hematology-Oncology Assoc., Llp, Sioux City, Iowa, United States|Hutchinson Clinic, Pa, Hutchinson, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States|Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|St Johns Medical Research Institute, Inc., Springfield, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Of Cincinnati, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|St. Luke'S Hospital & Health Network Laboratory, Bethlehem, Pennsylvania, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Associates In Hematology & Oncology, P.C., Upland, Pennsylvania, United States|Musc Hollings Cancer Center, Charleston, South Carolina, United States|Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Box Hill, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Curitiba, Sao Paulo, Brazil|Local Institution, Divinopolis, Sao Paulo, Brazil|Local Institution, Mogi Das Cruzes, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Temuco, Araucania, Chile|Local Institution, Santiago - Independencia, Metropolitana, Chile|Local Institution, Santiago De Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Brno, Czech Republic|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Aalborg, Denmark|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Kobenhavn O, Denmark|Local Institution, Odense C, Denmark|Local Institution, Besancon Cedex, France|Local Institution, Bordeaux, France|Local Institution, Clermont-ferrand, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pointe A Pitre, France|Local Institution, Villejuif Cedex, France|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Eschweiler, Germany|Local Institution, Mannheim, Germany|Local Institution, Wuppertal, Germany|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Gyula, Hungary|Local Institution, Kaposvar, Hungary|Local Institution, Kecskemet, Hungary|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Beer Jacob, Israel|Local Institution, Beer-sheva, Israel|Local Institution, Haifa, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Rimini, Italy|Local Institution, Siena, Italy|Local Institution, Sondrio, Italy|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Acapulco, Guerrero, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Puebla, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Mb Amsterdam, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Olsztyn, Poland|Ponce School Of Medicine, Ponce, Puerto Rico|Local Institution, Bucharest, Romania|Local Institution, Romania, Romania|Local Institution, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Obninsk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Benidorm-alicante, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, Cardiff, Glamorgan, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Scunthorpe, Lincolnshire, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom","https://ClinicalTrials.gov/show/NCT00861614"
178,"NCT01662869","A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer","Completed","No Results Available","All","Phase 3","564","Industry","Interventional","November 2012","December 2015","December 2015","August 10, 2012","null","November 2, 2016","Los Angeles, California, United States|Denver, Colorado, United States|Fort Myers, Florida, United States|St Petersburg, Florida, United States|Chicago, Illinois, United States|Albany, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Providence, Rhode Island, United States|Providence, Rhode Island, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Tyler, Texas, United States|Vancouver, Washington, United States|Port Macquarie, New South Wales, Australia|Sydney, New South Wales, Australia|Herston, Queensland, Australia|Box Hill, Victoria, Australia|East Bentleigh, Victoria, Australia|Nedlands, Western Australia, Australia|Brugge, Belgium|Leuven, Belgium|Sint-Niklaas, Belgium|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czech Republic|Olomouc, Czech Republic|Angers, France|Avignon, France|Besancon, France|Brest, France|Clichy, France|Marseille, France|Paris, France|Paris, France|Paris, France|St Herblain, France|Toulouse, France|Bochum, Germany|Essen, Germany|Hamburg, Germany|Leipzig, Germany|Ludwigsburg, Germany|Mannheim, Germany|Marburg, Germany|München, Germany|Guatemala, Guatemala|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Jerusalem, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Catanzaro, Calabria, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Firenze, Toscana, Italy|Prato, Toscana, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Kuala Lumpur, Malaysia|Sabah, Malaysia|Aguascalientes, Mexico|Monterrey, Mexico|Oaxaca, Mexico|Panama, Panama|Bydgoszcz, Poland|Gdansk, Poland|Krakow, Poland|Lublin, Poland|Rybnik, Poland|Warszawa, Poland|Ivanovo, Russian Federation|Omsk, Russian Federation|Ryazan, Russian Federation|Samara, Russian Federation|Tula, Russian Federation|Singapore, Singapore|Elche, Alicante, Spain|Santander, Cantabria, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Luzern, Switzerland|Zürich, Switzerland|Changhua, Taiwan|Kaohisung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Chiang Rai, Thailand|Hat Yai, Thailand|Lopburi, Thailand|Antalya, Turkey|Edirne, Turkey|Erzurum, Turkey|Malatya, Turkey|Samsun, Turkey|Sıhhiye, ANKARA, Turkey|Bristol, United Kingdom|Cardiff, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Southampton, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01662869"
179,"NCT01684878","Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)","Completed","Has Results","Female","Phase 3","208","Industry","Interventional","October 22, 2012","January 30, 2015","April 28, 2016","September 13, 2012","November 23, 2016","May 23, 2017","Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie, Wien, Austria|UZ Leuven Gasthuisberg, Leuven, Belgium|Herlev Hospital; Onkologisk afdeling, Herlev, Denmark|Rigshospitalet, Onkologisk Klinik, København Ø, Denmark|Institut Bergonie; Oncologie, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|CRLCC Val dAurelle Paul Lam, Montpellier cedex 5, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|Ch Lyon Sud; Chir Onc Gyne Sct Jules Courmont, Pierre Benite, France|Clinique Armoricaine Radiologie; Hopital de Jour, Plerin, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre Les Nancy, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Universitätsklinikum ""Carl Gustav Carus""; Frauenheilkunde und Geburtshilfe, Dresden, Germany|Evangelischen Krankenhauses Düsseldorf; Frauenklinik, Düsseldorf, Germany|Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Essen, Germany|Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Germany|Universitätsklinikum Freiburg; Frauenklinik, Freiburg, Germany|Universitätsklinikum Greifswald; Klinik für Frauenheilkunde und Brustzentrum, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf (UKE); Klinik und Poliklinik für Gynäkologie, Hamburg, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|UNI-Klinikum Campus Kiel Klinik f.Gynäkologie u.Geburtshilfe, Kiel, Germany|St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Koeln, Germany|Klinikum Konstanz, Frauenklinik, Konstanz, Germany|Klinikum rechts der Isar der TU München; Frauenklinik & Poliklinik, München, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, Germany|Hämatologisch/Onkologische Praxis Dr. Herbrick - Zipp/Prof. Dr. Decker, Studienzentrum, Ravensburg, Germany|Universitätsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, Germany|Universitätsklinikum Ulm Am Michelsberg; Frauenklinik, Ulm, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Klinik für Gynäkologie und gynäkologische Onkologie, Wiesbaden, Germany|Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica, Napoli, Campania, Italy|Istituto Regina Elena; Oncologia Medica A, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; S.C. Oncologia Medica, Genova, Liguria, Italy|A.O.Spedali Civili; Ostetricia e Ginecologia, Brescia, Lombardia, Italy|Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|A.O.U Pisana; Dipartimento di Ginecologia Oncologica, Pisa, Toscana, Italy|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, Netherlands|UMC St Radboud, Nijmegen, Netherlands|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Son Llatzer; Servicio de Oncologia, Palma de Mallorca, Islas Baleares, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Cordoba, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia, Girona, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Universitetssjukhuset; Onkologkliniken, Linkoeping, Sweden|Skånes University Hospital, Skånes Department of Onclology, Lund, Sweden","https://ClinicalTrials.gov/show/NCT01684878"
180,"NCT01121406","BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer","Completed","Has Results","Female","Phase 2","110","Industry","Interventional","April 2010","June 2014","June 2014","May 12, 2010","August 13, 2015","August 13, 2015","1230.18.32003 Boehringer Ingelheim Investigational Site, Brussel, Belgium|1230.18.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1230.18.32002 Boehringer Ingelheim Investigational Site, Gent, Belgium|1230.18.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1230.18.3321A Boehringer Ingelheim Investigational Site, Angers Cedex 9, France|1230.18.3307A Boehringer Ingelheim Investigational Site, Bordeaux cedex, France|1230.18.3301A Boehringer Ingelheim Investigational Site, Caen, France|1230.18.3322A Boehringer Ingelheim Investigational Site, Lille Cedex, France|1230.18.3313A Boehringer Ingelheim Investigational Site, Lyon, France|1230.18.3312A Boehringer Ingelheim Investigational Site, Nantes cedex 02, France|1230.18.3308A Boehringer Ingelheim Investigational Site, Nice cedex, France|1230.18.3314A Boehringer Ingelheim Investigational Site, Paris Cedex 20, France|1230.18.3302A Boehringer Ingelheim Investigational Site, Paris, France|1230.18.3309A Boehringer Ingelheim Investigational Site, Pierre-Bénite cedex, France|1230.18.3305A Boehringer Ingelheim Investigational Site, Reims cedex, France|1230.18.3320A Boehringer Ingelheim Investigational Site, Saint-Brieuc cedex, France|1230.18.3311A Boehringer Ingelheim Investigational Site, Strasbourg, France|1230.18.3310A Boehringer Ingelheim Investigational Site, Toulouse Cedex 9, France|1230.18.3315A Boehringer Ingelheim Investigational Site, Vandoeuvre les Nancy cedex, France|1230.18.42101 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1230.18.42103 Boehringer Ingelheim Investigational Site, Poprad, Slovakia|1230.18.34006 Boehringer Ingelheim Investigational Site, Badalona, Spain|1230.18.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1230.18.34005 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1230.18.34007 Boehringer Ingelheim Investigational Site, Girona, Spain|1230.18.34004 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat, Spain|1230.18.34002 Boehringer Ingelheim Investigational Site, Madrid, Spain|1230.18.34003 Boehringer Ingelheim Investigational Site, Madrid, Spain|1230.18.46005 Boehringer Ingelheim Investigational Site, Linköping, Sweden|1230.18.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1230.18.46003 Boehringer Ingelheim Investigational Site, Uppsala, Sweden","https://ClinicalTrials.gov/show/NCT01121406"
181,"NCT01151046","Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer","Completed","Has Results","Female","Phase 2","118","Industry","Interventional","June 2010","June 2014","September 2014","June 25, 2010","May 12, 2016","May 12, 2016","Achieve Clinical Research, Birmingham, Alabama, United States|Achieve Clinical Research, Birmingham, Alabama, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Wilshire Oncology Medical Group, Inc., Corona, California, United States|Southwest Cancer Center, Escondido, California, United States|Hematology Oncology Associates, INC., Oakland, California, United States|San Jose Medical Center, San Jose, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Pasco-Pinellas Oncology, New Port Richey, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Tennessee Cancer Specialists Oncology Clinical Trials Center for Biomedical Research, Knoxville, Tennessee, United States|Tennessee Cancer Specialists, Oncology Clincial Trials Center for Biomedical Research, Knoxville, Tennessee, United States|Hopital Maissoneuve-Rosemont, Montreal, Quebec, Canada|McGill University Jewish General Hospital, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Canada|CHA St. Sacrement, Quebec, Canada|Onkogologisches zentrum Munich, Munich, Germany|Brustzentrum HS Kliniken Wiesbaden, Wiesbaden, Germany|Medico-Diagnostically Center of International Institution of biological systems n.a.S.M., Berezina, Russian Federation|Railway Clinical Hospital, St. Petersburg, Russian Federation|Leningrad Regional Oncology Center, St. Petersburg, Russian Federation|City Clinical Oncology Center, St. Petersburg, Russian Federation|Vall d'Hebrón University Hospital, Barcelona, Spain|Hospital Clinic (Barcelona), Barcelona, Spain|Hospital Parc Tauli - Barcelona, Barcelona, Spain|Servicio de Oncología Médica / Hospital Universitario Gregorio Marañón, Madrid, Spain|Puerta de Hierro, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01151046"
182,"NCT01303172","A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer","Completed","No Results Available","All","Phase 2","110","Industry","Interventional","June 2011","February 2015","January 2016","February 24, 2011","null","December 2, 2016","Cyprus Oncology Centre, Nicosia, Strovolos, Cyprus|Adelaide, Meath & National Childrens Hospital,, Dublin, Ireland|St Vicents University Hospital, Dublin, Ireland|A.O. Santa Croce e Carle, Struttura Complessa di Oncologia Medica, Confreria, Cuneo, Italy|Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy|Azienda Ospedaliera San Gerardo Struttura Complessa Oncologia Medica, Monza, Italy|AOU Maggiore della Carità, Novara, Italy|Medical Oncology Department, Central University Hospital of Asturias, Asturias, Oviedo, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Gregorio Marañon, Madrid, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Department of Medical Oncology, Hospital Universitari La Fe,, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain|Airedale General Hospital, Skipton, West Yorkshire, United Kingdom|Royal Blackburn Hospital, Blackburn, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Ninewells Hospital,, Dundee, United Kingdom|Mount Vernon Cancer Centre, London, United Kingdom|The London Clinic Cancer Centre, London, United Kingdom|Peterbrough City Hospital, Haematology/Oncology Dept,, Peterborough, United Kingdom","https://ClinicalTrials.gov/show/NCT01303172"
183,"NCT00801242","Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer","Completed","Has Results","Male","Phase 3","220","Industry","Interventional","December 2008","June 2012","July 2013","December 3, 2008","September 3, 2014","September 3, 2014","Hospital St Jan Brugge, Brugge, Belgium|Erasme Hospital, University Clinics of Brussels, Brussels, Belgium|University Hospîtal St-Luc, Brussels, Belgium|University Hospitals Leuven, Leuven, Belgium|CHU Hôpital Sud, AMIENS cedex 1, France|Hôpital Pellegrin, BORDEAUX cedex, France|Centre Hospitalier René Dubos, CERGY PONTOISE cedex, France|Hôpital Gabriel Montpied, CLERMONT-FERRAND cedex 1, France|Hôpital Henri Mondor, Creteil, France|Hôpital Claude Huriez, LILLE cedex, France|Hôpital de la Conception, MARSEILLE cedex 05, France|Clinique Beausoleil, Montpellier, France|CHU Hôtel-Dieu, NANTES cedex 1, France|Hôpital Pasteur, NICE cedex 1, France|Hôpital Cochin, PARIS cedex 14, France|Hôpital Tenon, PARIS cedex 20, France|Hôpital Saint Louis, Paris, France|CHU Pitié Salpétrière, Paris, France|CHU Bichat, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU Le Milétrie, Poitiers, France|Hôpital Pontchaillou, RENNES cedex, France|Hôpitaux Universitaires de Strasbourg, STRASBOURG cedex, France|Hôpital de Rangueil, TOULOUSE cedex 9, France|Gemeinschaftspraxis Dres. Böhle, Rohde, Bad Schwartau, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Gemeinschaftspraxis - Tagesklinik Dres. Rulf, Langhorst, Erkrath, Germany|Urologische Gemeinschaftspraxis, Kempen, Germany|Gemeinschaftspraxis Dres. Rudolph, Wörner, Kirchheim, Germany|Facharzt für Urologie, Rosenheim, Germany|Eberhard-Kars-Universität Tübingen, Tübingen, Germany|Facharzt für Urologie, Wertingen, Germany|Praxisgemeinschaft f. Onkologie & Urologie, Wilhelmshaven, Germany|Praxis für Urologie, Zwickau, Germany|Azienda Ospedaliera S. Giuseppe Moscati, Avellino, Italy|Università degli Studi di Firenze, Bagno a Ripoli (FI), Italy|Azienda Policlinico Universitario G. Martino, Messina, Italy|Ospedale S. Raffaele, Milano, Italy|Università degli Studi di Padova, Padova, Italy|Policlinico Univ. Agostino Gemelli, Roma, Italy|Twenteborg Ziekenhuis, Almelo, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Atrium MC Kerkrade, Kerkrade, Netherlands|Maatschap Urologie-Diaconessenhuis Leiden, Leiden, Netherlands|UMC St.Radboud, Nijmegen, Netherlands|Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain|Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Virgen de las Nieves, Granada, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Spain|Instituto Valenciano de Oncologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00801242"
184,"NCT00976989","A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","Completed","Has Results","Female","Phase 2","225","Industry","Interventional","November 2009","June 2011","January 2016","September 15, 2009","June 20, 2016","February 6, 2017","Nassau, Bahamas|Banja Luka, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Porto Alegre, RS, Brazil|Sao Paulo, SP, Brazil|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Pula, Croatia|Heidelberg, Germany|Kiel, Germany|Regensburg, Germany|Trier, Germany|Troisdorf, Germany|Ulm, Germany|Heraklion, Greece|Thessaloniki, Greece|Roma, Lazio, Italy|Monza, Lombardia, Italy|S. Fermo della Battaglia (CO), Lombardia, Italy|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Mexico City, Mexico|Xalapa, Mexico|Auckland, New Zealand|Aveiro, Portugal|Lisboa, Portugal|Bucharest, Romania|Cluj Napoca, Romania|Iasi, Romania|Belgrade, Serbia|Belgrade, Serbia|Durban, South Africa|Durban, South Africa|Pretoria, South Africa|San Sebastian, Guipuzcoa, Spain|Barcelona, Spain|Cordoba, Spain|Madrid, Spain|Eskilstuna, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umea, Sweden|Baden, Switzerland|Zürich, Switzerland|Zürich, Switzerland|Taichung, Taiwan|Taipei, Taiwan|Bournemouth, United Kingdom|Derby, United Kingdom|Guildford, United Kingdom|Newcastle Upon Tyne, United Kingdom|Southampton, United Kingdom|Truro, United Kingdom|Westcliffe-on-sea, United Kingdom","https://ClinicalTrials.gov/show/NCT00976989"
185,"NCT01015118","LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer","Completed","Has Results","Female","Phase 3","1366","Industry","Interventional","November 17, 2009","April 1, 2013","September 15, 2016","November 18, 2009","January 15, 2015","December 7, 2017","1199.15.10113 Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States|1199.15.10030 Boehringer Ingelheim Investigational Site, Long Beach, California, United States|1199.15.10001 Boehringer Ingelheim Investigational Site, Santa Rosa, California, United States|1199.15.10005 Boehringer Ingelheim Investigational Site, Englewood, Colorado, United States|1199.15.10028 Boehringer Ingelheim Investigational Site, New Haven, Connecticut, United States|1199.15.10014 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States|1199.15.10010 Boehringer Ingelheim Investigational Site, Augusta, Georgia, United States|1199.15.10004 Boehringer Ingelheim Investigational Site, Savannah, Georgia, United States|1199.15.10011 Boehringer Ingelheim Investigational Site, Louisville, Kentucky, United States|1199.15.10003 Boehringer Ingelheim Investigational Site, Marrero, Louisiana, United States|1199.15.10017 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|1199.15.10103 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States|1199.15.10002 Boehringer Ingelheim Investigational Site, New York, New York, United States|1199.15.10012 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina, United States|1199.15.10020 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|1199.15.10019 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota, United States|1199.15.10024 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States|1199.15.10025 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States|1199.15.10029 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States|1199.15.10021 Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|1199.15.10013 Boehringer Ingelheim Investigational Site, Abington, Pennsylvania, United States|1199.15.10016 Boehringer Ingelheim Investigational Site, Allentown, Pennsylvania, United States|1199.15.10008 Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States|1199.15.10102 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States|1199.15.10006 Boehringer Ingelheim Investigational Site, Chattanooga, Tennessee, United States|1199.15.10104 Boehringer Ingelheim Investigational Site, Austin, Texas, United States|1199.15.10100 Boehringer Ingelheim Investigational Site, Bedford, Texas, United States|1199.15.10107 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1199.15.10108 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1199.15.10110 Boehringer Ingelheim Investigational Site, Fort Worth, Texas, United States|1199.15.10007 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1199.15.10105 Boehringer Ingelheim Investigational Site, Spokane, Washington, United States|1199.15.10112 Boehringer Ingelheim Investigational Site, Vancouver, Washington, United States|1199.15.61006 Boehringer Ingelheim Investigational Site, Camperdown, New South Wales, Australia|1199.15.61001 Boehringer Ingelheim Investigational Site, Waratah, New South Wales, Australia|1199.15.61004 Boehringer Ingelheim Investigational Site, Herston, Queensland, Australia|1199.15.61003 Boehringer Ingelheim Investigational Site, Southe Brisbane, Queensland, Australia|1199.15.61005 Boehringer Ingelheim Investigational Site, North Terrace, South Australia, Australia|1199.15.61007 Boehringer Ingelheim Investigational Site, Parkville, Victoria, Australia|1199.15.61002 Boehringer Ingelheim Investigational Site, Nedlands, Western Australia, Australia|1199.15.43003 Boehringer Ingelheim Investigational Site, Graz, Austria|1199.15.43001 Boehringer Ingelheim Investigational Site, Innsbruck, Austria|1199.15.43011 Boehringer Ingelheim Investigational Site, Krems, Austria|1199.15.43007 Boehringer Ingelheim Investigational Site, Kufstein, Austria|1199.15.43005 Boehringer Ingelheim Investigational Site, Linz, Austria|1199.15.43010 Boehringer Ingelheim Investigational Site, Salzburg, Austria|1199.15.43013 Boehringer Ingelheim Investigational Site, Wels, Austria|1199.15.43002 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.15.43012 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.15.32010 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1199.15.32012 Boehringer Ingelheim Investigational Site, Hasselt, Belgium|1199.15.32003 Boehringer Ingelheim Investigational Site, La Louvière, Belgium|1199.15.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1199.15.32007 Boehringer Ingelheim Investigational Site, Liège, Belgium|1199.15.32008 Boehringer Ingelheim Investigational Site, Sint-Niklaas, Belgium|1199.15.11005 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1199.15.11004 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1199.15.11008 Boehringer Ingelheim Investigational Site, London, Ontario, Canada|1199.15.11009 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1199.15.11003 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1199.15.11006 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1199.15.11001 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada|1199.15.42002 Boehringer Ingelheim Investigational Site, Brno, Czechia|1199.15.42003 Boehringer Ingelheim Investigational Site, Olomouc, Czechia|1199.15.42001 Boehringer Ingelheim Investigational Site, Prague, Czechia|1199.15.45004 Boehringer Ingelheim Investigational Site, Aalborg, Denmark|1199.15.45002 Boehringer Ingelheim Investigational Site, Herlev, Denmark|1199.15.45005 Boehringer Ingelheim Investigational Site, Herning, Denmark|1199.15.45001 Boehringer Ingelheim Investigational Site, Købenahvn Ø, Denmark|1199.15.45003 Boehringer Ingelheim Investigational Site, Odense C, Denmark|1199.15.35801 Boehringer Ingelheim Investigational Site, Helsinki, Finland|1199.15.35804 Boehringer Ingelheim Investigational Site, Jyväskylä, Finland|1199.15.35805 Boehringer Ingelheim Investigational Site, Kuopio, Finland|1199.15.35803 Boehringer Ingelheim Investigational Site, Oulu, Finland|1199.15.35802 Boehringer Ingelheim Investigational Site, Tampere, Finland|1199.15.33047 Boehringer Ingelheim Investigational Site, Aix-en-Provence, France|1199.15.33035 Boehringer Ingelheim Investigational Site, Avignon cedex 02, France|1199.15.33055 Boehringer Ingelheim Investigational Site, Besançon, France|1199.15.33003 Boehringer Ingelheim Investigational Site, Bordeaux cedex, France|1199.15.33004 Boehringer Ingelheim Investigational Site, Bordeaux, France|1199.15.33006 Boehringer Ingelheim Investigational Site, Caen cedex 5, France|1199.15.33025 Boehringer Ingelheim Investigational Site, Clermont-Ferrand cedex, France|1199.15.33048 Boehringer Ingelheim Investigational Site, Dechy, France|1199.15.33042 Boehringer Ingelheim Investigational Site, Fréjus, France|1199.15.33037 Boehringer Ingelheim Investigational Site, La Roche-Sur-Yon cedex 09, France|1199.15.33008 Boehringer Ingelheim Investigational Site, Le Mans, France|1199.15.33009 Boehringer Ingelheim Investigational Site, Lille cedex, France|1199.15.33020 Boehringer Ingelheim Investigational Site, Lyon, France|1199.15.33011 Boehringer Ingelheim Investigational Site, Marseille cedex 09, France|1199.15.33021 Boehringer Ingelheim Investigational Site, Monaco Cedex, France|1199.15.33012 Boehringer Ingelheim Investigational Site, Mont-de-Marsan cedex, France|1199.15.33052 Boehringer Ingelheim Investigational Site, Montpellier cedex 5, France|1199.15.33053 Boehringer Ingelheim Investigational Site, Mougins, France|1199.15.33038 Boehringer Ingelheim Investigational Site, Nancy, France|1199.15.33013 Boehringer Ingelheim Investigational Site, Nantes cedex 02, France|1199.15.33015 Boehringer Ingelheim Investigational Site, Orléans cedex 02, France|1199.15.33027 Boehringer Ingelheim Investigational Site, Paris cedex 20, France|1199.15.33001 Boehringer Ingelheim Investigational Site, Paris, France|1199.15.33051 Boehringer Ingelheim Investigational Site, PERIGUEUX Cedex, France|1199.15.33030 Boehringer Ingelheim Investigational Site, Plerin SUR MER, France|1199.15.33045 Boehringer Ingelheim Investigational Site, Saint Cloud, France|1199.15.33033 Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France|1199.15.33018 Boehringer Ingelheim Investigational Site, Strasbourg cedex, France|1199.15.33039 Boehringer Ingelheim Investigational Site, Thonon-Les-Bains, France|1199.15.33031 Boehringer Ingelheim Investigational Site, Vandoeuvre les Nancy cedex, France|1199.15.33050 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1199.15.49040 Boehringer Ingelheim Investigational Site, Aachen, Germany|1199.15.49070 Boehringer Ingelheim Investigational Site, Aalen, Germany|1199.15.49086 Boehringer Ingelheim Investigational Site, Aschaffenburg, Germany|1199.15.49002 Boehringer Ingelheim Investigational Site, Berlin, Germany|1199.15.49039 Boehringer Ingelheim Investigational Site, Berlin, Germany|1199.15.49041 Boehringer Ingelheim Investigational Site, Berlin, Germany|1199.15.49004 Boehringer Ingelheim Investigational Site, Bonn, Germany|1199.15.49042 Boehringer Ingelheim Investigational Site, Bonn, Germany|1199.15.49071 Boehringer Ingelheim Investigational Site, Bottrop, Germany|1199.15.49081 Boehringer Ingelheim Investigational Site, Böblingen, Germany|1199.15.49043 Boehringer Ingelheim Investigational Site, Chemnitz, Germany|1199.15.49005 Boehringer Ingelheim Investigational Site, Dessau, Germany|1199.15.49006 Boehringer Ingelheim Investigational Site, Detmold, Germany|1199.15.49007 Boehringer Ingelheim Investigational Site, Dresden, Germany|1199.15.49067 Boehringer Ingelheim Investigational Site, Dresden, Germany|1199.15.49008 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany|1199.15.49009 Boehringer Ingelheim Investigational Site, Ebersberg, Germany|1199.15.49010 Boehringer Ingelheim Investigational Site, Essen, Germany|1199.15.49066 Boehringer Ingelheim Investigational Site, Essen, Germany|1199.15.49089 Boehringer Ingelheim Investigational Site, Essen, Germany|1199.15.49045 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|1199.15.49011 Boehringer Ingelheim Investigational Site, Freiburg, Germany|1199.15.49068 Boehringer Ingelheim Investigational Site, Freiburg, Germany|1199.15.49083 Boehringer Ingelheim Investigational Site, Freudenstadt, Germany|1199.15.49046 Boehringer Ingelheim Investigational Site, Fulda, Germany|1199.15.49012 Boehringer Ingelheim Investigational Site, Fürstenfeldbruck, Germany|1199.15.49064 Boehringer Ingelheim Investigational Site, Greifswald, Germany|1199.15.49076 Boehringer Ingelheim Investigational Site, Gütersloh, Germany|1199.15.49014 Boehringer Ingelheim Investigational Site, Halle/S., Germany|1199.15.49015 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1199.15.49084 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1199.15.49073 Boehringer Ingelheim Investigational Site, Hanau, Germany|1199.15.49095 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|1199.15.49080 Boehringer Ingelheim Investigational Site, Henstedt-Ulzburg, Germany|1199.15.49047 Boehringer Ingelheim Investigational Site, Hildesheim, Germany|1199.15.49016 Boehringer Ingelheim Investigational Site, Karlsruhe, Germany|1199.15.49017 Boehringer Ingelheim Investigational Site, Kiel, Germany|1199.15.49062 Boehringer Ingelheim Investigational Site, Krefeld, Germany|1199.15.49018 Boehringer Ingelheim Investigational Site, Landshut, Germany|1199.15.49087 Boehringer Ingelheim Investigational Site, Ludwigsburg, Germany|1199.15.49019 Boehringer Ingelheim Investigational Site, Lübeck, Germany|1199.15.49020 Boehringer Ingelheim Investigational Site, Magdeburg, Germany|1199.15.49021 Boehringer Ingelheim Investigational Site, Mainz, Germany|1199.15.49022 Boehringer Ingelheim Investigational Site, Mainz, Germany|1199.15.49023 Boehringer Ingelheim Investigational Site, Mannheim, Germany|1199.15.49024 Boehringer Ingelheim Investigational Site, Marburg, Germany|1199.15.49025 Boehringer Ingelheim Investigational Site, München, Germany|1199.15.49026 Boehringer Ingelheim Investigational Site, München, Germany|1199.15.49027 Boehringer Ingelheim Investigational Site, München, Germany|1199.15.49048 Boehringer Ingelheim Investigational Site, München, Germany|1199.15.49065 Boehringer Ingelheim Investigational Site, Neumarkt i.d.Opf., Germany|1199.15.49029 Boehringer Ingelheim Investigational Site, Offenbach, Germany|1199.15.49082 Boehringer Ingelheim Investigational Site, Paderborn, Germany|1199.15.49030 Boehringer Ingelheim Investigational Site, Radebeul, Germany|1199.15.49061 Boehringer Ingelheim Investigational Site, Ravensburg, Germany|1199.15.49050 Boehringer Ingelheim Investigational Site, Regensburg, Germany|1199.15.49051 Boehringer Ingelheim Investigational Site, Rosenheim, Germany|1199.15.49052 Boehringer Ingelheim Investigational Site, Rostock, Germany|1199.15.49054 Boehringer Ingelheim Investigational Site, Saalfeld, Germany|1199.15.49031 Boehringer Ingelheim Investigational Site, Salzgitter, Germany|1199.15.49055 Boehringer Ingelheim Investigational Site, Solingen, Germany|1199.15.49092 Boehringer Ingelheim Investigational Site, Stadthagen, Germany|1199.15.49063 Boehringer Ingelheim Investigational Site, Stendal, Germany|1199.15.49093 Boehringer Ingelheim Investigational Site, Stralsund, Germany|1199.15.49033 Boehringer Ingelheim Investigational Site, Stuttgart, Germany|1199.15.49056 Boehringer Ingelheim Investigational Site, Stuttgart, Germany|1199.15.49090 Boehringer Ingelheim Investigational Site, Stuttgart, Germany|1199.15.49079 Boehringer Ingelheim Investigational Site, Suhl, Germany|1199.15.49034 Boehringer Ingelheim Investigational Site, Traunstein, Germany|1199.15.49057 Boehringer Ingelheim Investigational Site, Trier, Germany|1199.15.49035 Boehringer Ingelheim Investigational Site, Tübingen, Germany|1199.15.49058 Boehringer Ingelheim Investigational Site, Ulm, Germany|1199.15.49085 Boehringer Ingelheim Investigational Site, Viersen, Germany|1199.15.49001 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany|1199.15.49036 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany|1199.15.49059 Boehringer Ingelheim Investigational Site, Witten, Germany|1199.15.49037 Boehringer Ingelheim Investigational Site, Wolfsburg, Germany|1199.15.49060 Boehringer Ingelheim Investigational Site, Worms, Germany|1199.15.30001 Boehringer Ingelheim Investigational Site, Athens, Greece|1199.15.30003 Boehringer Ingelheim Investigational Site, Heraklio, Greece|1199.15.30002 Boehringer Ingelheim Investigational Site, Nea Kifisia, Greece|1199.15.30005 Boehringer Ingelheim Investigational Site, Patras, Greece|1199.15.30004 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|1199.15.39027 Boehringer Ingelheim Investigational Site, Asti, Italy|1199.15.39002 Boehringer Ingelheim Investigational Site, Avellino, Italy|1199.15.39003 Boehringer Ingelheim Investigational Site, Aviano (pn), Italy|1199.15.39004 Boehringer Ingelheim Investigational Site, Bari, Italy|1199.15.39005 Boehringer Ingelheim Investigational Site, Benevento, Italy|1199.15.39029 Boehringer Ingelheim Investigational Site, Brescia, Italy|1199.15.39040 Boehringer Ingelheim Investigational Site, Catania, Italy|1199.15.39007 Boehringer Ingelheim Investigational Site, Catanzaro, Italy|1199.15.39008 Boehringer Ingelheim Investigational Site, Faenza (RA), Italy|1199.15.39039 Boehringer Ingelheim Investigational Site, Ferrara, Italy|1199.15.39017 Boehringer Ingelheim Investigational Site, Genova, Italy|1199.15.39037 Boehringer Ingelheim Investigational Site, Lecce, Italy|1199.15.39009 Boehringer Ingelheim Investigational Site, Mantova, Italy|1199.15.39033 Boehringer Ingelheim Investigational Site, Meldola (fc), Italy|1199.15.39021 Boehringer Ingelheim Investigational Site, Milano, Italy|1199.15.39028 Boehringer Ingelheim Investigational Site, Milano, Italy|1199.15.39036 Boehringer Ingelheim Investigational Site, Milano, Italy|1199.15.39010 Boehringer Ingelheim Investigational Site, Modena, Italy|1199.15.39026 Boehringer Ingelheim Investigational Site, Monza, Italy|1199.15.39001 Boehringer Ingelheim Investigational Site, Napoli, Italy|1199.15.39022 Boehringer Ingelheim Investigational Site, Padova, Italy|1199.15.39011 Boehringer Ingelheim Investigational Site, Palermo, Italy|1199.15.39031 Boehringer Ingelheim Investigational Site, Palermo, Italy|1199.15.39023 Boehringer Ingelheim Investigational Site, Pisa, Italy|1199.15.39012 Boehringer Ingelheim Investigational Site, Pordenone, Italy|1199.15.39024 Boehringer Ingelheim Investigational Site, Reggio Emilia, Italy|1199.15.39013 Boehringer Ingelheim Investigational Site, Roma, Italy|1199.15.39014 Boehringer Ingelheim Investigational Site, Roma, Italy|1199.15.39034 Boehringer Ingelheim Investigational Site, Rozzano (MI), Italy|1199.15.39030 Boehringer Ingelheim Investigational Site, San Fermo Della Battaglia, Italy|1199.15.39018 Boehringer Ingelheim Investigational Site, Sondrio, Italy|1199.15.39006 Boehringer Ingelheim Investigational Site, Tappino (CB), Italy|1199.15.39019 Boehringer Ingelheim Investigational Site, Torino, Italy|1199.15.39020 Boehringer Ingelheim Investigational Site, Torino, Italy|1199.15.39032 Boehringer Ingelheim Investigational Site, Varese, Italy|1199.15.31009 Boehringer Ingelheim Investigational Site, 's-HERTOGENBOSCH, Netherlands|1199.15.31005 Boehringer Ingelheim Investigational Site, Amersfoort, Netherlands|1199.15.31004 Boehringer Ingelheim Investigational Site, Niewegein, Netherlands|1199.15.31003 Boehringer Ingelheim Investigational Site, Nijmegen, Netherlands|1199.15.31006 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|1199.15.31002 Boehringer Ingelheim Investigational Site, Utrecht, Netherlands|1199.15.47003 Boehringer Ingelheim Investigational Site, Bergen, Norway|1199.15.47001 Boehringer Ingelheim Investigational Site, Oslo, Norway|1199.15.47002 Boehringer Ingelheim Investigational Site, Stavanger, Norway|1199.15.47004 Boehringer Ingelheim Investigational Site, Trondheim, Norway|1199.15.48003 Boehringer Ingelheim Investigational Site, Gdansk, Poland|1199.15.48006 Boehringer Ingelheim Investigational Site, Lublin, Poland|1199.15.48001 Boehringer Ingelheim Investigational Site, Warszawa, Poland|1199.15.35102 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|1199.15.35104 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|1199.15.35101 Instituto Portugues de Oncologia Lisboa Francisco Gentil, Lisboa, Portugal|1199.15.35106 Boehringer Ingelheim Investigational Site, Lisboa, Portugal|1199.15.35108 Boehringer Ingelheim Investigational Site, Lisboa, Portugal|1199.15.35105 Boehringer Ingelheim Investigational Site, Porto, Portugal|1199.15.35109 Boehringer Ingelheim Investigational Site, Vila Real, Portugal|1199.15.70006 Boehringer Ingelheim Investigational Site, Barnaul, Russian Federation|1199.15.70005 Boehringer Ingelheim Investigational Site, Ekaterinburg, Russian Federation|1199.15.70007 Boehringer Ingelheim Investigational Site, Kazan, Russian Federation|1199.15.70001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1199.15.70002 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1199.15.42101 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1199.15.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1199.15.42106 Boehringer Ingelheim Investigational Site, Kosice, Slovakia|1199.15.42103 Boehringer Ingelheim Investigational Site, Nitra, Slovakia|1199.15.42104 Boehringer Ingelheim Investigational Site, Poprad, Slovakia|1199.15.42102 Boehringer Ingelheim Investigational Site, Zilina, Slovakia|1199.15.34001 Boehringer Ingelheim Investigational Site, Badalona, Spain|1199.15.34003 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1199.15.34006 Boehringer Ingelheim Investigational Site, Girona, Spain|1199.15.34004 Boehringer Ingelheim Investigational Site, Lleida, Spain|1199.15.34002 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.15.34010 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.15.34005 Boehringer Ingelheim Investigational Site, Palma de Mallorca, Spain|1199.15.34009 Boehringer Ingelheim Investigational Site, Valencia, Spain|1199.15.46005 Boehringer Ingelheim Investigational Site, Linköping, Sweden|1199.15.46001 Boehringer Ingelheim Investigational Site, Lund, Sweden|1199.15.46002 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1199.15.46004 Boehringer Ingelheim Investigational Site, Umeå, Sweden|1199.15.46003 Boehringer Ingelheim Investigational Site, Uppsala, Sweden|1199.15.38006 Boehringer Ingelheim Investigational Site, Cherkasy, Ukraine|1199.15.38005 Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Ukraine|1199.15.38004 Boehringer Ingelheim Investigational Site, Donetsk, Ukraine|1199.15.38002 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|1199.15.38003 Boehringer Ingelheim Investigational Site, Lviv, Ukraine|1199.15.44006 Boehringer Ingelheim Investigational Site, Derby, United Kingdom|1199.15.44007 Boehringer Ingelheim Investigational Site, Dundee, United Kingdom|1199.15.44003 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom|1199.15.44001 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom|1199.15.44005 Boehringer Ingelheim Investigational Site, London, United Kingdom|1199.15.44004 Boehringer Ingelheim Investigational Site, Nottingham, United Kingdom|1199.15.44002 Boehringer Ingelheim Investigational Site, Poole, United Kingdom|1199.15.44008 Boehringer Ingelheim Investigational Site, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01015118"
186,"NCT00744497","Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer","Completed","Has Results","Male","Phase 3","1930","Industry","Interventional","October 2008","August 2012","July 2015","September 1, 2008","February 6, 2014","October 17, 2016","University Of South Alabama / Mitchell Cancer Institute, Mobile, Alabama, United States|Southern Cancer Center, Mobile, Alabama, United States|Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Compassionate Cancer Care Medical Group, Inc., Corona, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Compassionate Cancer Care Medical Group Inc, Riverside, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Va San Diego Healthcare System, San Diego, California, United States|Edward Alexson, Md, Inc., Santa Ana, California, United States|Connecticut Oncology Group, Middletown, Connecticut, United States|Va Connecticut Healthcare System, West Haven, Connecticut, United States|Gwinnett Hospital System Inc., Lawrenceville, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Fort Wayne Medical Oncology And Hematology Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Maine Center For Cancer Medicine, Scarborough, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|New York Oncology Hematology, Pc, Albany, New York, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Samuel S. Stratton Vamc, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Piedmont Hematology Oncology Associates, Pllc, Winston-salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Mid Ohio Oncology/Hematology, Inc,Dba, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Regional Hemetology Oncology, Pc, Langhorne, Pennsylvania, United States|Upmc Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Associates In Hematology & Oncology, P.C., Upland, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Cancer Centers Of The Carolinas, Greenville, South Carolina, United States|Boston Baskin Cancer Foundation, Memphis, Tennessee, United States|Cancer Specialists Of South Texas, Pa, Corpus Christi, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Providence Regional Cancer System, Lacey, Washington, United States|University Of Washington, Seattle, Washington, United States|Dean Hematology And Oncology Clinic, Madison, Wisconsin, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Ramos Mejia, Buenos Aires, Argentina|Local Institution, Cipolletti, Rio Negro, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordaba, Argentina|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Lismore, New South Wales, Australia|Local Institution, Port Macquarie, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Douglas, Queensland, Australia|Local Institution, Milton, Queensland, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Ringwood, Victoria, Australia|Local Institution, Fremantle, Western Australia, Australia|Local Institution, Salvador, Bahia, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Santo Andre, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Abbottsford, British Columbia, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Owen Sound, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Thunder Bay, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Rimouski, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Regina, Saskatchewan, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Brno, Czech Republic|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Praha 2, Czech Republic|Local Institution, Praha 8, Czech Republic|Local Institution, Turku, Finland|Local Institution, Vaasa, Finland|Local Institution, Avignon, France|Local Institution, Besancon Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Paris, France|Local Institution, St Genis Laval, France|Local Institution, Strasbourg, France|Local Institution, Aachen, Germany|Local Institution, Berlin, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Kirchheim, Germany|Local Institution, Markkleeberg, Germany|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Kecskemet, Hungary|Local Institution, Zalaegerszeg, Hungary|Local Institution, Trivandrum, Kerala, India|Local Institution, Mumbai, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Ahmedabad, India|Local Institution, Jaipur, India|Local Institution, Kolkata, India|Local Institution, Kolkatta, India|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Arezzo, Italy|Local Institution, Genova, Italy|Local Institution, Lecce, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Roma, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Tijuana, Baja California, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Huixquilucan, Estado De Mexico, Mexico|Local Institution, Toluca, Estado De Mexico, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Mexico, Queretaro, Mexico|Local Institution, Stavanger, Norway|Local Institution, Callao, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Bialystok, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Baia Mare, Romania|Local Institution, Cluj Napoca, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Bloemfontein, Free State, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Gauteng, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Gijon, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Kungalv, Sweden|Local Institution, Sundsvall, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Cardiff, Glamorgan, United Kingdom|Local Institution, London, Middlesex, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Leeds, West Yorkshire, United Kingdom|Local Institution, Essex, United Kingdom","https://ClinicalTrials.gov/show/NCT00744497"
187,"NCT02023697","Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone","Completed","Has Results","Male","Phase 2","391","Industry","Interventional","March 10, 2014","March 1, 2017","August 9, 2018","December 30, 2013","July 12, 2018","September 18, 2018","Scottsdale, Arizona, United States|New Haven, Connecticut, United States|Fort Myers, Florida, United States|Bethesda, Maryland, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|East Setauket, New York, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Adelaide, South Australia, Australia|Melbourne, Victoria, Australia|Box Hill, Australia|Darlinghurst, Australia|Westmead, Australia|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto do Câncer do Estado de São Paulo, São Paulo, Sao Paulo, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer, São Paulo, Sao Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Sao Paulo, Brazil|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Santiago, Chile|Chomutov, Czechia|Praha 5, Czechia|Nantes, France|Vandoeuvre les Nancy, France|Villejuif Cedex, France|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Dresden, Sachsen, Germany|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Meldola, Emilia-Romagna, Italy|Roma, Lazio, Italy|Torino, Piemonte, Italy|Arezzo, Toscana, Italy|Busan, Busan Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Hospitalet de Llobregat, Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Madrid, Spain|Pamplona, Spain|Göteborg, Sweden|Karlstad, Sweden|Sundsvalls, Sweden|Umeå, Sweden|Taipei City, Taipei, Taiwan|Guishan Township, Taoyuan, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Bebington, Merseyside, United Kingdom|Taunton, Somerset, United Kingdom|Northwood, United Kingdom","https://ClinicalTrials.gov/show/NCT02023697"
188,"NCT01057810","Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer","Completed","Has Results","Male","Phase 3","837","Industry","Interventional","July 2010","April 2015","July 2015","January 27, 2010","August 18, 2016","August 18, 2016","Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Desert Hematology Oncology, Rancho Mirage, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|George Washington University, Washington, District of Columbia, United States|Lynn Cancer Institute Center For Hematology-Oncology, Boca Raton, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Md Anderson Cancer Center Orlando, Orlando, Florida, United States|Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Gwinnett Hospital System Inc., Lawrenceville, Georgia, United States|Straub Clinic And Hospital, Honolulu, Hawaii, United States|University Of Chicago, Chicago, Illinois, United States|Cancer Care Specialists Of Central Illinois, Decatur, Illinois, United States|Goshen Center For Cancer Care, Goshen, Indiana, United States|Hutchinson Clinic, Pa, Hutchinson, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|University Of Maryland, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|North Shore Hematology/Oncology Associates, P.C., East Setauket, New York, United States|Goshen Medical Associates, Goshen, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Suny Upstate Medical University, Syracuse, New York, United States|Novant Health Oncology Specialists, Winston Salem, North Carolina, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Kaiser Permanente Oncology/Hematology, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke'S Hospital & Health Network Laboratory, Bethlehem, Pennsylvania, United States|Cancer Center Of The Carolinas, Greenville, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Ashford, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte - Mg, Minas Gerais, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Kingston, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Temuco, Araucania, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Bucaramanga, Colombia|Local Institution, Medellin, Colombia|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Praha 5, Czech Republic|Local Institution, Praha 8, Czech Republic|Local Institution, Herlev, Denmark|Local Institution, Kobenhavn O, Denmark|Local Institution, Bordeaux, France|Local Institution, Clermont-ferrand, France|Local Institution, Marseille Cedex 9, France|Local Institution, Pointe A Pitre, France|Local Institution, Poitiers, France|Local Institution, Villejuif Cedex, France|Local Institution, Aachen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Marktredwitz, Germany|Local Institution, Munich, Germany|Local Institution, Wesel, Germany|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Gyula, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Mexico, Queretaro, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Sittard-geleen, Netherlands|Local Institution, Kristiansand, Norway|Local Institution, Gdansk, Poland|Local Institution, Koscierzyna, Poland|Local Institution, Krakow, Poland|Local Institution, Kutno, Poland|Local Institution, Lublin, Poland|Local Institution, Poznan, Poland|Local Institution, Slupsk, Poland|Va Caribbean Healthcare System, San Juan, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-napoca, Cluj County, Romania|Local Institution, Timisoara,timis County, Romania|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Adana, Turkey|Local Institution, Bornova, Izmir, Turkey|Local Institution, Gaziantep, Turkey|Local Institution, Kocaeli, Turkey|Local Institution, Kocaeli, Turkey|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom","https://ClinicalTrials.gov/show/NCT01057810"
189,"NCT00712881","Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer","Completed","No Results Available","Female","Phase 2","126","Industry","Interventional","October 2008","September 2015","December 2015","July 10, 2008","null","February 9, 2016","Teva Investigational Site 16, Kufstein, Austria|Teva Investigational Site 15, Wien, Austria|Teva Investigational Site 9, Brussels, Belgium|Teva Investigational Site 29, Yvoir, Belgium|Teva Investigational Site 4, Clichy Cedex, France|Teva Investigational Site 5, Nancy, France|Teva Investigational Site 33, Reims, France|Teva Investigational Site 8, Vandoeuvre-Les-Nancy CEDEX, France|Teva Investigational Site 30, Aachen, Germany|Teva Investigational Site 11, Dusseldorf, Germany|Teva Investigational Site 25, Dusseldorf, Germany|Teva Investigational Site 32, Essen, Germany|Teva Investigational Site 34, Lorrach, Germany|Teva Investigational Site 14, Munchen, Germany|Teva Investigational Site 27, München, Germany|Teva Investigational Site 20, Napoli, Italy|Teva Investigational Site 23, Roma, Italy|Teva Investigational Site 21, Verona, Italy|Teva Investigational Site 26, Barcelona, Spain|Teva Investigational Site 3, Barcelona, Spain|Teva Investigational Site 1, Lleida, Spain|Teva Investigational Site 2, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00712881"
190,"NCT00904839","BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer","Completed","Has Results","All","Phase 2","128","Industry","Interventional","May 2009","January 2012","January 2012","May 20, 2009","February 4, 2015","February 4, 2015","1199.51.32002 Boehringer Ingelheim Investigational Site, Bonheiden, Belgium|1199.51.32005 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1199.51.32006 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1199.51.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1199.51.3306A Boehringer Ingelheim Investigational Site, Nice Cedex 2, France|1199.51.3306B Boehringer Ingelheim Investigational Site, Nice Cedex 2, France|1199.51.3306C Boehringer Ingelheim Investigational Site, Nice Cedex 2, France|1199.51.3306D Boehringer Ingelheim Investigational Site, Nice Cedex 2, France|1199.51.3301A Boehringer Ingelheim Investigational Site, Paris, France|1199.51.3301B Boehringer Ingelheim Investigational Site, Paris, France|1199.51.3301C Boehringer Ingelheim Investigational Site, Paris, France|1199.51.3301D Boehringer Ingelheim Investigational Site, Paris, France|1199.51.3307A Boehringer Ingelheim Investigational Site, Reims Cedex, France|1199.51.3307B Boehringer Ingelheim Investigational Site, Reims Cedex, France|1199.51.3307C Boehringer Ingelheim Investigational Site, Reims Cedex, France|1199.51.3308B Boehringer Ingelheim Investigational Site, Saint Herblain, France|1199.51.3308C Boehringer Ingelheim Investigational Site, Saint Herblain, France|1199.51.3308A Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France|1199.51.3308D Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France|1199.51.3308E Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France|1199.51.3305A Boehringer Ingelheim Investigational Site, Toulouse cedex 3, France|1199.51.3305B Boehringer Ingelheim Investigational Site, Toulouse cedex 3, France|1199.51.3305E Boehringer Ingelheim Investigational Site, Toulouse Cedex 3, France|1199.51.3305C Boehringer Ingelheim Investigational Site, Toulouse Cedex, France|1199.51.3305D Boehringer Ingelheim Investigational Site, Toulouse Cedex, France|1199.51.3302A Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1199.51.3302B Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1199.51.3302C Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1199.51.3302D Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1199.51.3302E Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1199.51.49001 Boehringer Ingelheim Investigational Site, Celle, Germany|1199.51.49002 Boehringer Ingelheim Investigational Site, Dresden, Germany|1199.51.49003 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau, Germany|1199.51.49004 Boehringer Ingelheim Investigational Site, Halle/Saale, Germany|1199.51.49006 Boehringer Ingelheim Investigational Site, Mainz, Germany|1199.51.49008 Boehringer Ingelheim Investigational Site, Schwäbisch Hall, Germany|1199.51.39002 Boehringer Ingelheim Investigational Site, Ancona, Italy|1199.51.39001 Boehringer Ingelheim Investigational Site, Genova, Italy|1199.51.39004 Boehringer Ingelheim Investigational Site, Macerata, Italy|1199.51.39005 Boehringer Ingelheim Investigational Site, Reggio Emilia, Italy|1199.51.39003 Boehringer Ingelheim Investigational Site, Udine, Italy|1199.51.34006 Boehringer Ingelheim Investigational Site, Alicante, Spain|1199.51.34005 Boehringer Ingelheim Investigational Site, Barakaldo, Spain|1199.51.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1199.51.34007 Boehringer Ingelheim Investigational Site, La Coruña, Spain|1199.51.34003 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.51.34004 Boehringer Ingelheim Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00904839"
191,"NCT01326000","A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer","Completed","No Results Available","All","Phase 2","169","Industry","Interventional","April 2011","December 2013","December 2013","March 30, 2011","null","February 6, 2015","Encinitas, California, United States|Highland, California, United States|La Jolla, California, United States|La Verne, California, United States|LaJolla, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Diego, California, United States|Harvey, Illinois, United States|Skokie, Illinois, United States|Skokie, Illinois, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Winston-salem, North Carolina, United States|Sayre, Pennsylvania, United States|Greenville, South Carolina, United States|Memphis, Tennessee, United States|Newcastle, New South Wales, Australia|Port Macquarie, New South Wales, Australia|Adelaide, South Australia, Australia|Box Hill, Victoria, Australia|East Bentleigh, Victoria, Australia|Frankston, Victoria, Australia|Bruxelles, Belgium|Bruxelles, Belgium|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|Bordeaux, France|Brest, France|Lille, France|Paris, France|Saint Herblain, France|Toulouse, France|Essen, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Herne, Germany|Regensburg, Germany|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Udine, Friuli-Venezia Giulia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Olsztyn, Poland|Szczecin, Poland|Sabadell, Barcelona, Barcelona, Spain|Santander, Cantabria, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain|Aberdeen, United Kingdom|Belfast, United Kingdom|Bournemouth, United Kingdom|Cardiff, United Kingdom|Dorchester, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Northwood, United Kingdom|Romford, United Kingdom|Weston Super Mare, United Kingdom","https://ClinicalTrials.gov/show/NCT01326000"
192,"NCT00839332","A Study for Participants With Pancreatic Cancer","Completed","Has Results","All","Phase 1|Phase 2","157","Industry","Interventional","February 2009","February 2013","December 2013","February 9, 2009","April 17, 2018","April 17, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Post Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fargo, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danville, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hampton, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Green Bay, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heilbronn, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nürnberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ancona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendola, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hospitalet De Llobregat, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain","https://ClinicalTrials.gov/show/NCT00839332"
193,"NCT01441596","Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases","Completed","Has Results","Female","Phase 2","121","Industry","Interventional","October 2011","February 2014","August 2014","September 27, 2011","February 25, 2015","September 7, 2015","1200.67.10106 Boehringer Ingelheim Investigational Site, Bakersfield, California, United States|1200.67.10105 Boehringer Ingelheim Investigational Site, Fullerton, California, United States|1200.67.10001 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|1200.67.10108 Boehringer Ingelheim Investigational Site, Santa Barbara, California, United States|1200.67.10003 Boehringer Ingelheim Investigational Site, Lake Success, New York, United States|1200.67.10004 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States|1200.67.11004 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1200.67.11003 Boehringer Ingelheim Investigational Site, Greenfield Park, Quebec, Canada|1200.67.11002 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1200.67.35801 Boehringer Ingelheim Investigational Site, Helsinki, Finland|1200.67.35802 Boehringer Ingelheim Investigational Site, Tampere, Finland|1200.67.35803 Boehringer Ingelheim Investigational Site, Turku, Finland|1200.67.33009 Boehringer Ingelheim Investigational Site, Caen Cedex, France|1200.67.33010 Boehringer Ingelheim Investigational Site, Clermont-Ferrand cedex 1, France|1200.67.33008 Boehringer Ingelheim Investigational Site, Lille Cedex, France|1200.67.33001 Boehringer Ingelheim Investigational Site, Lyon Cedex 08, France|1200.67.33004 Boehringer Ingelheim Investigational Site, Marseille Cedex 09, France|1200.67.33011 Boehringer Ingelheim Investigational Site, Nice Cedex 02, France|1200.67.33002 Boehringer Ingelheim Investigational Site, Paris Cedex 05, France|1200.67.33003 Boehringer Ingelheim Investigational Site, Paris, France|1200.67.33012 Boehringer Ingelheim Investigational Site, Saint Cloud, France|1200.67.33005 Boehringer Ingelheim Investigational Site, Saint Herblain Cedex, France|1200.67.49002 Boehringer Ingelheim Investigational Site, Erlangen, Germany|1200.67.49008 Boehringer Ingelheim Investigational Site, Essen, Germany|1200.67.49005 Boehringer Ingelheim Investigational Site, Hannover, Germany|1200.67.49006 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|1200.67.49007 Boehringer Ingelheim Investigational Site, MÃ¼nchen, Germany|1200.67.49003 Boehringer Ingelheim Investigational Site, Oldenburg, Germany|1200.67.49004 Boehringer Ingelheim Investigational Site, TÃ¼bingen, Germany|1200.67.39001 Boehringer Ingelheim Investigational Site, Modena, Italy|1200.67.39002 Boehringer Ingelheim Investigational Site, Reggio Emilia, Italy|1200.67.82001 Boehringer Ingelheim Investigational Site, Goyang, Korea, Republic of|1200.67.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1200.67.82003 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1200.67.82004 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1200.67.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.67.34006 Boehringer Ingelheim Investigational Site, CÃ³rdoba, Spain|1200.67.34005 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat, Spain|1200.67.34003 Boehringer Ingelheim Investigational Site, Madrid, Spain|1200.67.34004 Boehringer Ingelheim Investigational Site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01441596"
194,"NCT00882180","Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement","Completed","No Results Available","All","Phase 1","41","Industry","Interventional","March 2009","July 2011","August 2011","April 16, 2009","null","August 24, 2011","TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Hospital Virgen del Rocio, Seville, Andalucia, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00882180"
195,"NCT01652482","Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)","Completed","No Results Available","All","Phase 2","135","Industry","Interventional","October 2012","November 2014","November 2014","July 30, 2012","null","November 2, 2016","Bakersfield, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Luis Obispo, California, United States|Santa Barbara, California, United States|Aurora, Colorado, United States|Orange Park, Florida, United States|Harvey, Illinois, United States|Paducah, Kentucky, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Jefferson City, Missouri, United States|Las Vegas, Nevada, United States|Philadelphia, Pennsylvania, United States|Kirkland, Washington, United States|Seattle, Washington, United States|Darlinghurst, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|St. Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Waratah, New South Wales, Australia|Wollongong, New South Wales, Australia|Herston, Queensland, Australia|Southport, Queensland, Australia|Adelaide, South Australia, Australia|Frankston, Victoria, Australia|Bruxelles, Belgium|Charleroi, Belgium|Haine-Saint-Paul, Belgium|Leuven, Belgium|Liège, Belgium|Creteil, France|Lyon, France|Paris, France|Villejuif, France|Dresden, Germany|München, Germany|München, Germany|Stuttgart, Germany|Trier, Germany|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Orbassano, Piemonte, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Auckland, New Zealand|Christchurch, New Zealand|Dunedin, New Zealand|Tauranga, New Zealand|Brasov, Romania|Bucharest, Romania|Bucuresti, Romania|Iasi, Romania|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Aberdeen, United Kingdom|London, United Kingdom|Oxford, United Kingdom|Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01652482"
196,"NCT01045304","Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","Completed","No Results Available","Female","Phase 2","163","Industry","Interventional","February 2010","March 2011","November 2012","January 11, 2010","null","January 14, 2014","Sanofi-Aventis Investigational Site Number 036002, Parkville, Australia|Sanofi-Aventis Investigational Site Number 036001, Perth, Australia|Sanofi-Aventis Investigational Site Number 036003, Westmead, Australia|Sanofi-Aventis Investigational Site Number 056001, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056002, Leuven, Belgium|Sanofi-Aventis Investigational Site Number 250005, Besancon Cedex, France|Sanofi-Aventis Investigational Site Number 250003, Bordeaux, France|Sanofi-Aventis Investigational Site Number 250002, Dijon, France|Sanofi-Aventis Investigational Site Number 250006, Paris Cedex 05, France|Sanofi-Aventis Investigational Site Number 250004, Paris, France|Sanofi-Aventis Investigational Site Number 250001, Toulouse, France|Sanofi-Aventis Investigational Site Number 380004, Genova, Italy|Sanofi-Aventis Investigational Site Number 380001, Milano, Italy|Sanofi-Aventis Investigational Site Number 380002, Modena, Italy|Sanofi-Aventis Investigational Site Number 380003, Udine, Italy|Sanofi-Aventis Investigational Site Number 528001, Rotterdam, Netherlands|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724004, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724001, Málaga, Spain|Sanofi-Aventis Investigational Site Number 724003, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01045304"
197,"NCT01254279","Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen","Completed","No Results Available","Male","Phase 3","984","Industry","Interventional","December 2010","December 2014","December 2014","December 6, 2010","null","January 21, 2015","Investigational Site Number 036004, Box Hill, Australia|Investigational Site Number 036020, Campbelltown, Australia|Investigational Site Number 036001, Camperdown, Australia|Investigational Site Number 036002, Camperdown, Australia|Investigational Site Number 036011, Douglas, Australia|Investigational Site Number 036019, Nambour, Australia|Investigational Site Number 036023, North Adelaide, Australia|Investigational Site Number 036008, Parkville, Australia|Investigational Site Number 036005, Perth, Australia|Investigational Site Number 036003, Port Macquarie, Australia|Investigational Site Number 036025, Randwick, Australia|Investigational Site Number 036009, South Brisbane, Australia|Investigational Site Number 036022, South Brisbane, Australia|Investigational Site Number 036017, Southport, Australia|Investigational Site Number 036012, St Leonards, Australia|Investigational Site Number 036010, Sydney, Australia|Investigational Site Number 036013, Sydney, Australia|Investigational Site Number 036014, Sydney, Australia|Investigational Site Number 036016, Tweed Heads, Australia|Investigational Site Number 036024, Wendouree, Australia|Investigational Site Number 036007, Westmead, Australia|Investigational Site Number 036015, Wodonga, Australia|Investigational Site Number 040-004, Linz, Austria|Investigational Site Number 040-005, Salzburg, Austria|Investigational Site Number 040-003, Vienna, Austria|Investigational Site Number 040-002, Wien, Austria|Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056007, Bruxelles, Belgium|Investigational Site Number 056003, Haine St Paul, Belgium|Investigational Site Number 056005, Liège, Belgium|Investigational Site Number 056004, Ottignies, Belgium|Investigational Site Number 056001, Roeselare, Belgium|Investigational Site Number 056006, Tournai, Belgium|Investigational Site Number 070003, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070001, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070002, Zenica, Bosnia and Herzegovina|Investigational Site Number 100004, Plovdiv, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100003, Sofia, Bulgaria|Investigational Site Number 100002, Sofia, Bulgaria|Investigational Site Number 124012, Kitchener, Canada|Investigational Site Number 124009, Laval, Canada|Investigational Site Number 124004, London, Canada|Investigational Site Number 124007, Moncton, Canada|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124011, Montreal, Canada|Investigational Site Number 124010, Quebec, Canada|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124006, Winnipeg, Canada|Investigational Site Number 191-001, Zagreb, Croatia|Investigational Site Number 203001, Brno, Czech Republic|Investigational Site Number 208-001, Cph Ø, Denmark|Investigational Site Number 208-002, Herlev, Denmark|Investigational Site Number 208-003, Odense, Denmark|Investigational Site Number 246002, Helsinki, Finland|Investigational Site Number 246001, Seinäjoki, Finland|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348002, Szolnok, Hungary|Investigational Site Number 348003, Szombathely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 356004, Chennai, India|Investigational Site Number 356006, Gurgaon, India|Investigational Site Number 356001, New Delhi, India|Investigational Site Number 356002, New Delhi, India|Investigational Site Number 356005, Trivandrum, India|Investigational Site Number 372004, Cork, Ireland|Investigational Site Number 372003, Dublin 24, Ireland|Investigational Site Number 372001, Dublin 7, Ireland|Investigational Site Number 372002, Dublin 7, Ireland|Investigational Site Number 380-001, Arezzo, Italy|Investigational Site Number 380-011, Aviano, Italy|Investigational Site Number 380-025, Bari, Italy|Investigational Site Number 380-007, Bergamo, Italy|Investigational Site Number 380-015, Bologna, Italy|Investigational Site Number 380-021, Fano, Italy|Investigational Site Number 380-012, Firenze, Italy|Investigational Site Number 380-003, Genova, Italy|Investigational Site Number 380-005, Genova, Italy|Investigational Site Number 380-014, Lecce, Italy|Investigational Site Number 380-023, Messina, Italy|Investigational Site Number 380-018, Milano, Italy|Investigational Site Number 380-022, Milano, Italy|Investigational Site Number 380-006, Napoli, Italy|Investigational Site Number 380-010, Napoli, Italy|Investigational Site Number 380-027, Napoli, Italy|Investigational Site Number 380-004, Orbassano, Italy|Investigational Site Number 380-017, Padova, Italy|Investigational Site Number 380-002, Parma, Italy|Investigational Site Number 380-009, Roma, Italy|Investigational Site Number 380-008, Roma, Italy|Investigational Site Number 380-024, Rozzano, Italy|Investigational Site Number 380-020, San Giovanni Rotondo, Italy|Investigational Site Number 380-013, Sassari, Italy|Investigational Site Number 380-016, Taormina, Italy|Investigational Site Number 398001, Almaty, Kazakhstan|Investigational Site Number 398003, Shymkent, Kazakhstan|Investigational Site Number 442001, Niederkorn, Luxembourg|Investigational Site Number 458002, Georgetown, Malaysia|Investigational Site Number 458001, Kuala Lumpur, Malaysia|Investigational Site Number 458003, Kuching, Malaysia|Investigational Site Number 484002, Durango, Mexico|Investigational Site Number 484006, Irapuato, Mexico|Investigational Site Number 484005, Toluca, Mexico|Investigational Site Number 484001, Zapopan, Mexico|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 616-001, Gdansk, Poland|Investigational Site Number 620002, Coimbra, Portugal|Investigational Site Number 620003, Lisboa, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620001, Porto, Portugal|Investigational Site Number 620005, Setúbal, Portugal|Investigational Site Number 642001, Bucharest, Romania|Investigational Site Number 642002, Cluj-Napoca, Romania|Investigational Site Number 642003, Timisoara, Romania|Investigational Site Number 688001, Belgrade, Serbia|Investigational Site Number 688002, Belgrade, Serbia|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 703001, Bratislava, Slovakia|Investigational Site Number 703002, Kosice, Slovakia|Investigational Site Number 724018, Barcelona, Spain|Investigational Site Number 724019, Barcelona, Spain|Investigational Site Number 724023, Castellón de la Plana, Spain|Investigational Site Number 724020, Córdoba, Spain|Investigational Site Number 724025, Elche, Spain|Investigational Site Number 724017, Granada, Spain|Investigational Site Number 724006, Guadalajara, Spain|Investigational Site Number 724011, L'Hospitalet de Llobregat, Spain|Investigational Site Number 724002, La Coruña, Spain|Investigational Site Number 724010, León, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724012, Madrid, Spain|Investigational Site Number 724007, Madrid, Spain|Investigational Site Number 724008, Manresa, Spain|Investigational Site Number 724021, Málaga, Spain|Investigational Site Number 724009, Oviedo, Spain|Investigational Site Number 724022, Pamplona, Spain|Investigational Site Number 724005, San Cristóbal de La Laguna - Sta. Cruz de Tenerife, Spain|Investigational Site Number 724016, Santander, Spain|Investigational Site Number 724015, Santiago de Compostela, Spain|Investigational Site Number 724024, Sevilla, Spain|Investigational Site Number 724004, Terrassa, Spain|Investigational Site Number 724013, Valencia, Spain|Investigational Site Number 724014, Valencia, Spain|Investigational Site Number 724001, Zaragoza, Spain|Investigational Site Number 752-002, Umeå, Sweden|Investigational Site Number 752-001, Uppsala, Sweden|Investigational Site Number 005, Kaohsiung Hsien,, Taiwan|Investigational Site Number 004, Taichung, Taiwan|Investigational Site Number 002, Taipei, Taiwan|Investigational Site Number 003, Taipei, Taiwan|Investigational Site Number 001, Tao Yuan Hsien, Taiwan|Investigational Site Number 826011, Birmingham, United Kingdom|Investigational Site Number 826002, Bristol, United Kingdom|Investigational Site Number 826003, Glasgow, United Kingdom|Investigational Site Number 826013, Leeds, United Kingdom|Investigational Site Number 826009, London, United Kingdom|Investigational Site Number 826012, Manchester, United Kingdom|Investigational Site Number 826005, Nottingham, United Kingdom|Investigational Site Number 826008, Preston, United Kingdom|Investigational Site Number 826001, Sutton, United Kingdom|Investigational Site Number 826007, Torquay, United Kingdom|Investigational Site Number 826006, Whitechurch, United Kingdom|Investigational Site Number 826004, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01254279"
198,"NCT00778102","A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.","Completed","Has Results","All","Phase 2","80","Industry","Interventional","October 2008","October 2013","October 2013","October 23, 2008","August 7, 2015","November 2, 2016","Wien, Austria|Bordeaux, France|Creteil, France|Le Mans, France|Lille, France|Lyon, France|Montpellier, France|Villejuif, France|San Sebastian, Guipuzcoa, Spain|Palma de Mallorca, Islas Baleares, Spain|Santiago de Compostela, La Coruña, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|London, United Kingdom|Manchester, United Kingdom|Sutton, United Kingdom|Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT00778102"
199,"NCT01571284","Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen","Completed","Has Results","All","Phase 3","781","Industry","Interventional","May 30, 2012","January 31, 2017","January 31, 2017","April 5, 2012","February 27, 2018","April 17, 2018","Investigational Site Number 840-002, Muscle Shoals, Alabama, United States|Investigational Site Number 840-008, Corona, California, United States|Investigational Site Number 840-007, Fountain Valley, California, United States|Investigational Site Number 840-004, Riverside, California, United States|Investigational Site Number 840-006, Indianapolis, Indiana, United States|Investigational Site Number 840-011, Metairie, Louisiana, United States|Investigational Site Number 840-001, Rockville, Maryland, United States|Investigational Site Number 840-010, Howell, New Jersey, United States|Investigational Site Number 840-012, Albuquerque, New Mexico, United States|Investigational Site Number 840-009, Farmington, New Mexico, United States|Investigational Site Number 840-003, Lake Success, New York, United States|Investigational Site Number 840-005, Middletown, Ohio, United States|Investigational Site Number 056010, Aalst, Belgium|Investigational Site Number 056015, Arlon, Belgium|Investigational Site Number 056004, Bonheiden, Belgium|Investigational Site Number 056001, Edegem, Belgium|Investigational Site Number 056012, Gent, Belgium|Investigational Site Number 056009, Haine-Saint-Paul, Belgium|Investigational Site Number 056003, Liège, Belgium|Investigational Site Number 056007, Liège, Belgium|Investigational Site Number 056014, Loverval, Belgium|Investigational Site Number 056013, Turnhout, Belgium|Investigational Site Number 056002, Verviers, Belgium|Investigational Site Number 056011, Yvoir, Belgium|Investigational Site Number 008, Brasília, Brazil|Investigational Site Number 009, Curitiba, Brazil|Investigational Site Number 012, Fortaleza, Brazil|Investigational Site Number 006, Passo Fundo, Brazil|Investigational Site Number 003, Porto Alegre, Brazil|Investigational Site Number 002, Rio de Janeiro, Brazil|Investigational Site Number 011, Salvador, Brazil|Investigational Site Number 013, Sao Jose do Rio Preto, Brazil|Investigational Site Number 001, São Paulo, Brazil|Investigational Site Number 004, São Paulo, Brazil|Investigational Site Number 005, São Paulo, Brazil|Investigational Site Number 124002, Calgary, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124005, Montreal, Canada|Investigational Site Number 124004, Ottawa, Canada|Investigational Site Number 124006, Québec, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152003, Santiago, Chile|Investigational Site Number 203005, Brno, Czechia|Investigational Site Number 203003, Olomouc, Czechia|Investigational Site Number 203001, Ostrava, Czechia|Investigational Site Number 203002, Praha 2, Czechia|Investigational Site Number 203004, Praha 5, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 208001, Cph Ø, Denmark|Investigational Site Number 208003, Hillerød, Denmark|Investigational Site Number 208002, Odense C, Denmark|Investigational Site Number 246001, Oulu, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 276-016, Aschaffenburg, Germany|Investigational Site Number 276-010, Augsburg, Germany|Investigational Site Number 276-011, Berlin, Germany|Investigational Site Number 276-012, Erlangen, Germany|Investigational Site Number 276-009, Frankfurt am Main, Germany|Investigational Site Number 276-013, Frankfurt am Main, Germany|Investigational Site Number 276-004, Halle, Germany|Investigational Site Number 276-007, Krefeld, Germany|Investigational Site Number 276-003, Lebach, Germany|Investigational Site Number 276-019, Leipzig, Germany|Investigational Site Number 276-008, Ludwigsburg, Germany|Investigational Site Number 276-018, Magdeburg, Germany|Investigational Site Number 276-014, Magdeburg, Germany|Investigational Site Number 276-006, Moers, Germany|Investigational Site Number 276-001, München, Germany|Investigational Site Number 276-002, München, Germany|Investigational Site Number 276-015, Northeim, Germany|Investigational Site Number 276-017, Velbert, Germany|Investigational Site Number 276-005, Weiden/Oberpfalz, Germany|Investigational Site Number 276-020, Wolfsburg, Germany|Investigational Site Number 372002, Dublin 24, Ireland|Investigational Site Number 372004, Galway, Ireland|Investigational Site Number 372001, Wilton, Ireland|Investigational Site Number 376002, Haifa, Israel|Investigational Site Number 376001, Jerusalem, Israel|Investigational Site Number 376005, Petach Tikva, Israel|Investigational Site Number 376003, Tel Aviv, Israel|Investigational Site Number 376004, Tel Hashomer, Israel|Investigational Site Number 380-005, Ancona, Italy|Investigational Site Number 380-029, Bergamo, Italy|Investigational Site Number 380-021, Bologna, Italy|Investigational Site Number 380-004, Brescia, Italy|Investigational Site Number 380-007, Candiolo, Italy|Investigational Site Number 380-012, Catania, Italy|Investigational Site Number 380-019, Catanzaro, Italy|Investigational Site Number 380-023, Firenze, Italy|Investigational Site Number 380-001, Genova, Italy|Investigational Site Number 380-014, Meldola, Italy|Investigational Site Number 380-016, Messina, Italy|Investigational Site Number 380-013, Milano, Italy|Investigational Site Number 380-015, Milano, Italy|Investigational Site Number 380-025, Milano, Italy|Investigational Site Number 380-022, Napoli, Italy|Investigational Site Number 380-028, Novara, Italy|Investigational Site Number 380-017, Padova, Italy|Investigational Site Number 380-002, Pisa, Italy|Investigational Site Number 380-008, Reggio Emilia, Italy|Investigational Site Number 380-024, Roma, Italy|Investigational Site Number 380-010, Roma, Italy|Investigational Site Number 380-011, Roma, Italy|Investigational Site Number 380-006, San Giovanni Rotondo, Italy|Investigational Site Number 380-026, Sassari, Italy|Investigational Site Number 380-020, Terni, Italy|Investigational Site Number 380-009, Torino, Italy|Investigational Site Number 380-003, Udine, Italy|Investigational Site Number 380-018, Verona, Italy|Investigational Site Number 1, Beirut, Lebanon|Investigational Site Number 484002, Mexico DF, Mexico|Investigational Site Number 484009, Mexico DF, Mexico|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484010, México, D.F., Mexico|Investigational Site Number 528001, Hoofddorp, Netherlands|Investigational Site Number 528002, Zwolle, Netherlands|Investigational Site Number 578002, Bergen, Norway|Investigational Site Number 578001, Oslo, Norway|Investigational Site Number 630-001, Rio Peidras, Puerto Rico|Investigational Site Number 643003, Kazan, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643006, Moscow, Russian Federation|Investigational Site Number 643009, Saint-Petersburg, Russian Federation|Investigational Site Number 724016, Alicante, Spain|Investigational Site Number 724008, Barakaldo, Spain|Investigational Site Number 724012, Cáceres, Spain|Investigational Site Number 724002, Córdoba, Spain|Investigational Site Number 724013, Donostia, Spain|Investigational Site Number 724014, L'Hospitalet de Llobregat, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724015, Madrid, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724004, Málaga, Spain|Investigational Site Number 724010, Sabadell, Spain|Investigational Site Number 724011, Santander, Spain|Investigational Site Number 724006, Santiago de Compostela, Spain|Investigational Site Number 724001, Valencia, Spain|Investigational Site Number 724009, Valencia, Spain|Investigational Site Number 724007, Zaragoza, Spain|Investigational Site Number 752_002, Jönköping, Sweden|Investigational Site Number 752_001, Växjö, Sweden|Investigational Site Number 764005, Bangkok,TH, Thailand|Investigational Site Number 764002, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 764008, Bangkok, Thailand|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764006, Bangkok, Thailand|Investigational Site Number 764009, Chiang Mai, Thailand|Investigational Site Number 764004, Khon Kaen, Thailand|Investigational Site Number 764010, Laksi, Thailand|Investigational Site Number 764007, Lopburi, Thailand|Investigational Site Number 792-06, Adana, Turkey|Investigational Site Number 792-01, Ankara, Turkey|Investigational Site Number 792-09, Ankara, Turkey|Investigational Site Number 792-08, Ankara, Turkey|Investigational Site Number 792-02, Capa, Turkey|Investigational Site Number 792010, Edirne, Turkey|Investigational Site Number 792-05, Gaziantep, Turkey|Investigational Site Number 792012, Istanbul, Turkey|Investigational Site Number 792-03, Istanbul, Turkey|Investigational Site Number 792-04, Istanbul, Turkey|Investigational Site Number 792-007, Izmir, Turkey|Investigational Site Number 792011, Izmir, Turkey|Investigational Site Number 826005, Dudley, United Kingdom|Investigational Site Number 826011, Hull, United Kingdom|Investigational Site Number 826008, Leicester, United Kingdom|Investigational Site Number 826007, London, United Kingdom|Investigational Site Number 826012, London, United Kingdom|Investigational Site Number 826003, Maidstone,, United Kingdom|Investigational Site Number 826009, Manchester, United Kingdom|Investigational Site Number 826004, Newcastle upon tyne, United Kingdom|Investigational Site Number 826006, Northwood, United Kingdom|Investigational Site Number 826002, Southampton, United Kingdom|Investigational Site Number 826001, Sutton, United Kingdom|Investigational Site Number 826010, Taunton, United Kingdom","https://ClinicalTrials.gov/show/NCT01571284"
200,"NCT00822809","CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers","Completed","No Results Available","All","Phase 3","230","Industry","Interventional","December 2008","November 2010","April 2011","January 14, 2009","null","October 3, 2012","Study Site, Several, France|Study site, Several, Germany|Study Site, Several, Italy|Study Site, Several, Spain","https://ClinicalTrials.gov/show/NCT00822809"
201,"NCT00979134","Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours","Completed","No Results Available","All","Phase 1","979","Industry","Interventional","October 2009","February 2014","March 2015","September 17, 2009","null","June 26, 2015","Research Site, Stanford, California, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Pierre Benite Cedex, France|Research Site, Villejuif Cedex, France|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Köln, Germany|Research Site, Napoli, Italy|Research Site, Rozzano, Italy|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Badajoz, Spain|Research Site, Majadahonda, Spain|Research Site, Valencia, Spain|Research Site, Birmingham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00979134"
202,"NCT01244191","Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer","Completed","No Results Available","All","Phase 3","1048","Industry","Interventional","November 2010","August 2013","November 2016","November 19, 2010","null","May 9, 2017","Tucson, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Oxnard, California, United States|Rancho Mirage, California, United States|Rancho Mirage, California, United States|Santa Monica, California, United States|Aurora, Colorado, United States|Boulder, Colorado, United States|Colorado Springs, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Denver, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Lone Tree, Colorado, United States|Longmont, Colorado, United States|Parker, Colorado, United States|Thornton, Colorado, United States|Newark, Delaware, United States|Fort Myers, Florida, United States|Miami Beach, Florida, United States|Pensacola, Florida, United States|Atlanta, Georgia, United States|Austell, Georgia, United States|Carrollton, Georgia, United States|Cartersville, Georgia, United States|Douglasville, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Carmel, Indiana, United States|Fishers, Indiana, United States|Goshen, Indiana, United States|Greenfield, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|Grand Island, Nebraska, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|East Orange, New Jersey, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|Goshen, New York, United States|Latham, New York, United States|New York, New York, United States|The Bronx, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Kettering, Ohio, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Springfield, Oregon, United States|Tualatin, Oregon, United States|Harrisburg, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Easley, South Carolina, United States|Greenville, South Carolina, United States|Greenville, South Carolina, United States|Greenville, South Carolina, United States|Spartanburg, South Carolina, United States|Bartlett, Tennessee, United States|Chattanooga, Tennessee, United States|Germantown, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Southaven, Tennessee, United States|Austin, Texas, United States|Austin, Texas, United States|Austin, Texas, United States|Austin, Texas, United States|Cedar Park, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Kyle, Texas, United States|Round Rock, Texas, United States|Round Rock, Texas, United States|San Marcos, Texas, United States|Salt Lake City, Utah, United States|Arlington, Virginia, United States|Fairfax, Virginia, United States|Gainesville, Virginia, United States|Leesburg, Virginia, United States|Midlothian, Virginia, United States|Richmond, Virginia, United States|Winchester, Virginia, United States|Woodbridge, Virginia, United States|Seattle, Washington, United States|Vancouver, Washington, United States|Vancouver, Washington, United States|Yakima, Washington, United States|Rosario, Santa Fe, Argentina|Buenos Aires, Argentina|Cordoba, Argentina|Rio Negro, Argentina|San Miguel de Tucuman, Argentina|Tucuman, Argentina|Greenslopes, Queensland, Australia|Camperdown, Australia|Kogarah, Australia|Perth, Australia|St. Leonards, Australia|Wollongong, Australia|Woodville, Australia|Salzburg, Austria|Wels, Austria|Brasschaat, Belgium|Brussels, Belgium|Duffel, Belgium|Salvador, BA, Brazil|Rio de Janeiro, RJ, Brazil|Passo Fundo, RS, Brazil|Passo Fundo, RS, Brazil|Porto Alegre, RS, Brazil|Joinville, Santa Catarina, Brazil|Joinville, SC, Brazil|Ijui, Brazil|Porto Alegre, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|London Ontario, Canada|Montreal, Canada|Quebec, Canada|Surrey, BC, Canada|Toronto, Canada|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Ostrava, Czechia|Pardubice, Czechia|Praha, Czechia|Usti nad Labem, Czechia|Herlev, Denmark|Naestved, Denmark|Odense, Denmark|Besancon, France|Brest, France|Caen Cedex, France|Grenoble, France|Lille, France|Marseille Cedex, France|Paris Cedex, France|Paris, France|Pierre Benite, France|Rennes Cedex, France|Saint-Priest en Jarez, France|Strasbourg Cedex, France|Toulouse Cedex, France|Tours Cedex, France|Villejuif, France|Bad Berka, Germany|Berlin, Germany|Berlin, Germany|Erfurt, Germany|Essen, Germany|Esslingen, Germany|Gauting, Germany|Grobhansdorf, Germany|Halle, Germany|Hamburg, Germany|Hannover, Germany|Karlsruhe, Germany|Kassel, Germany|Koln, Germany|Leverkusen, Germany|Lowenstein, Germany|Mainz, Germany|Mannheim, Germany|Munchen, Germany|Munchen, Germany|Munchen, Germany|Porta Westfalica, Germany|Rheine, Germany|Villingen-Schwenningen, Germany|Deszk, Hungary|Gyula, Hungary|Matrahaza, Hungary|Szekesfehervar, Hungary|Szolnok, Hungary|Ancona, Italy|Avellino, Italy|Aviano, Italy|Bari, Italy|Catania, Italy|Cremona, Italy|Cuneo, Italy|Firenze, Italy|Livorno, Italy|Milano, Italy|Modena, Italy|Monza, Italy|Napoli, Italy|Novara, Italy|Orbassano, Italy|Padova, Italy|Palermo, Italy|Parma, Italy|Perugia, Italy|Roma, Italy|Rozzano, Italy|Sassari, Italy|Sondalo, Italy|Sora, Italy|Torino, Italy|Mexico, DF, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Monterrey, Nuevo Leon, Mexico|Oaxaca, Mexico|Oaxaca, Mexico|Enschede, ER, Netherlands|Helmond, HA, Netherlands|Amsterdam, Netherlands|Arequipa, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Bystra, Poland|Krakow, Poland|Lublin, Poland|Olsztyn, Poland|Opole, Poland|Poznan, Poland|Poznan, Poland|Prabuty, Poland|Rzeszow, Poland|Szczecin, Poland|Torun, Poland|Walbrzych, Poland|Cluj-Napoca, Romania|Craiova, Romania|Oradea, Romania|Chelyabinsk, Russian Federation|Irkutsk, Russian Federation|Izhevsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novgorod, Russian Federation|Novosibirsk, Russian Federation|Pyatigorsk, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tula, Russian Federation|Tuymen, Russian Federation|Alicante, Spain|Barakaldo (Bilbao), Spain|Barcelona, Spain|Barcelona, Spain|Coruna, Spain|Coruna, Spain|La Laguna, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Manresa, Spain|Oviedo, Spain|Palma de Mallorca, Spain|Sabadell, Spain|Santiago de Compostela, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Vigo-Pontevedra, Spain|Zaragoza, Spain|Linkoping, Sweden|Lund, Sweden|Guildford, Surrey, United Kingdom|Aberdeen, United Kingdom|Glasgow, United Kingdom|Londin, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom|Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01244191"
203,"NCT00791778","Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer","Completed","Has Results","All","Phase 2","246","Industry","Interventional","November 2008","July 2011","December 2012","November 17, 2008","November 30, 2012","September 28, 2015","La Jolla, California, United States|Jacksonville, Florida, United States|Augusta, Georgia, United States|Scarborough, Maine, United States|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|La Louviere, Belgium|Leuven, Belgium|Wilrijk, Belgium|Hamilton, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Jyväskylä, Finland|Kuopio, Finland|ANGERS cedex 9, France|Caen Cedex 5, France|Lyon Cedex, France|Tours, France|Villejuif, France|Berlin, Germany|Hong Kong, Hong Kong|HongKong, Hong Kong|Meldola, Forlì, Italy|Campobasso, Italy|Milano, Italy|Roma, Italy|Roma, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Isehara, Kanagawa, Japan|Shimotsuke, Tochigi, Japan|Koto-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Sowon, Korea, Republic of|Den Haag, Netherlands|Maastricht, Netherlands|Bialystok, Poland|Gdynia, Poland|Krakow, Poland|Lublin, Poland|Poznan, Poland|Poznan, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Sabadell, Barcelona, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain","https://ClinicalTrials.gov/show/NCT00791778"
204,"NCT00833248","Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","Completed","Has Results","Male","Phase 3","246","Industry","Interventional","April 2009","September 2011","September 2011","February 2, 2009","September 27, 2012","October 4, 2012","Alabama Research Center, Birmingham, Alabama, United States|Urology Centers of Alabama, Homewood, Alabama, United States|Alaska Urological Association, Anchorage, Alaska, United States|Arizona Urologic Specialists, Tuscon, Arizona, United States|Orange County Urology, Lagua Hills, California, United States|Tri-Valley Urology Medical Group, Murrieta, California, United States|Connecticut Clinical Research Center, Middlebury, Connecticut, United States|South Florida Medical Research, Aventura, Florida, United States|DCT -Celebration, LLC dba Discovery Clinical Trials, Celebration, Florida, United States|Pinellas Urology Inc., St. Petersburg, Florida, United States|Palm Beach Urology Associates, Wellington, Florida, United States|Summit Research Institute, Bloomington, Indiana, United States|Northeast Indiana Research, Fort Wayne, Indiana, United States|Urology Center Research Institute, Englewood, New Jersey, United States|Urology Group of New Mexico, Albuquerque, New Mexico, United States|Premier Medical Group of Hudson, Columbia, New York, United States|University Urology Associates, New York, New York, United States|Urology Associates, Nashville, Tennessee, United States|Urology of Virginia, Norfolk, Virginia, United States|Hopital Jean Minjoz, Besancon, France|Institut Bergonié, Bordeaux Cedex, France|Centre Francois Baclesse, Caen, France|CHU Henri Mondor, Creteil, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital de la Timone, Marseille, Cedex 5, France|CRLC Val d'Aurelle Oncology Radiotherapy, Montpellier, France|Hôpital Tenon, Paris, France|Hôpital Saint Louis, Radiotherapy Departement, Paris, France|Clinique Francheville, Perigueux, France|CHU La Milétrie, Oncology Radiotherapy, Poitiers, France|Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France|Institut de Cancérologie de la Loire, Saint Priest en Jarez, France|Clinique Saint Brieuc, St Brieuc Cedex, France|Centre Paul Strauss, Strassbourg, France|Centre de radiologie Saint Louis, Toulon, France|Clinique du Parc, Toulouse, France|IGR, Villejuif, France|Charité-Universitätsmedizin, Campus Benjamin Franklin Klinik für Urologie, Berlin, Germany|Städtisches Klinikum Braunschweig, Braunschweig, Germany|Universitätsklinikum Dresden, Klinik und Poliklinik für Urologie, Dresden, Germany|Universitätsklinikum Ulm, Klinik für Strahlentherapie und Radioonkologie, Ulm, Germany|General University Hospital of Alexandroupolis, Alexandroupolis, Greece|General Hospital of Athens, ""Sismanogleio"", University of Athens, Marouse, Athens, Greece|University General Hospital of Loannina, Medical School, Loannina, Greece|University General Hospital of Patras, Patras, Greece|Albert Schweitzer Ziekenhuis, Ioc., Dordwijk, Dordrecht, Netherlands|Groene Hart Ziekenhuis, urology, Gouda, Netherlands|Franciscus Gasthuis, Dept. urology, Rotterdam, Netherlands|Maastad Ziekenhuis, Ioc. Clara, Rotterdam, Netherlands|Vlietland Ziekenhuis, Dept. urology, Schiedam, Netherlands|St. Elisabeth Ziekenhuis Tilburg, Tilburg, Netherlands|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Fundación IVO, Valencia, Spain|Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom|Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom|Oncology Royal United Hospital Bath NHS Trust, Bath, United Kingdom|Addenbrooke's Hospital, Oncology Centre, Cambridge, United Kingdom|St. James' University Hospital, Leeds, United Kingdom|The Royal Marsden NHS, Foundation Trust, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Southhampton General Hospital, Cancer Care Directorate, Southhampton Oncology Centre, Southhampton, United Kingdom|Velindre Hospital, Cardiff University, Whitchurch, United Kingdom","https://ClinicalTrials.gov/show/NCT00833248"
205,"NCT00976911","AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer","Completed","Has Results","Female","Phase 3","361","Industry","Interventional","October 2009","July 2014","July 2014","September 15, 2009","February 25, 2015","February 25, 2015","Bruxelles, Belgium|Edegem, Belgium|Leuven, Belgium|Namur, Belgium|Banja Luka, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Herlev, Denmark|Herning, Denmark|København, Denmark|Odense, Denmark|Kuopio, Finland|Oulu, Finland|Avignon, France|Bordeaux, France|Bordeaux, France|Bordeaux, France|Brive La Gaillarde, France|Caen, France|Clermont Ferrand, France|Colmar, France|Grenoble, France|La Roche Sur Yon, France|La Source, France|Le Chesnay, France|Le Mans, France|Lille, France|Lyon, France|Metz Tessy, France|Mont-de-marsan, France|Montpellier, France|Mougins, France|Nancy, France|Nantes, France|Nice, France|Nimes, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Perigueux, France|Reims CEDEX, France|Rouen, France|Saint Brieuc, France|Saint Herblain, France|Saint Nazaire, France|St Cloud, France|Strasbourg, France|Thonon Les Bains, France|Toulouse, France|Vandoeuvre Les Nancy, France|Berlin, Germany|Berlin, Germany|Düsseldorf, Germany|Düsseldorf, Germany|Erlangen, Germany|Essen, Germany|Essen, Germany|Frankfurt, Germany|Hamburg, Germany|Hannover, Germany|Hildesheim, Germany|Kassel, Germany|Kiel, Germany|Krefeld, Germany|Lübeck, Germany|Mannheim, Germany|Muenchen, Germany|Nuernberg, Germany|Offenbach, Germany|Recklinghausen, Germany|Rostock, Germany|Solingen, Germany|Stuttgart, Germany|Tübingen, Germany|Ulm, Germany|Wiesbaden, Germany|Athens, Greece|Aviano, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Bergamo, Lombardia, Italy|Mantova, Lombardia, Italy|Milano, Lombardia, Italy|Amersfoort, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Nieuwegein, Netherlands|Utrecht, Netherlands|Oslo, Norway|Trondheim, Norway|Lisboa, Portugal|Porto, Portugal|Sabadell, Barcelona, Barcelona, Spain|Santander, Cantabria, Spain|Palma de Mallorca, Islas Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Cordoba, Spain|Lerida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Murcia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Linkoeping, Sweden|Umea, Sweden|Uppsala, Sweden|Örebro, Sweden|Adana, Turkey|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Kocaeli, Turkey","https://ClinicalTrials.gov/show/NCT00976911"
206,"NCT01068483","Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients","Completed","No Results Available","All","Phase 1","107","Industry","Interventional","November 2008","September 2011","August 2012","February 15, 2010","null","April 11, 2013","Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4), Nashville, Tennessee, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Barcelona, Cataluna, Spain","https://ClinicalTrials.gov/show/NCT01068483"
207,"NCT00638690","Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy","Completed","Has Results","Male","Phase 3","1195","Industry","Interventional","May 2008","August 2010","October 2012","March 19, 2008","May 16, 2013","April 30, 2014","Birmingham, Alabama, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Duarte, California, United States|Los Angeles, California, United States|Marina Del Rey, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Bristol, Connecticut, United States|New Haven, Connecticut, United States|Stamford, Connecticut, United States|Boca Raton, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Galesburg, Illinois, United States|Indianapolis, Indiana, United States|Westwood, Kansas, United States|Wichita, Kansas, United States|Marrero, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Robbinsdale, Minnesota, United States|St. Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Box 302, New York, United States|East Setauket, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Stony Brook, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Virgiania Beach, Virginia, United States|Seattle, Washington, United States|Adelaide, Australia|Camperdown, Australia|Footscray, Australia|Geelong, Australia|Heidelberg, Australia|Herston, Australia|Hobart, Australia|Hornsby, Australia|Kogarah, Australia|Kurralta Park, Australia|Liverpool, Australia|Milton, Australia|Parkville, Australia|Perth, Australia|Subiaco, Australia|Wodonga, Australia|Wollongong, Australia|Linz, Austria|Salzburg, Austria|Wien, Austria|Antwerpen, Belgium|Bonheiden, Belgium|Bruxelles, Belgium|Gent, Belgium|Hasselt, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada|Calgary Ab, Canada|London, Canada|Angers Cedex 01, France|Caen, France|Cannes, France|Dijon, France|Lyon, France|Paris, France|Saint Herblain, France|Vandoeuvre Les Nancy Cedex, France|Villejuif N/A, France|Aachen, Germany|Berlin, Germany|Dresden, Germany|Hamburg, Germany|Homburg/Saar, Germany|Pecs, Hungary|Szombathely, Hungary|Cork, Ireland|Dublin 7, Ireland|Dublin, Ireland|Nijmegen, Netherlands|Badalona, Spain|Barcelona, Spain|Madrid, Spain|Belfast, United Kingdom|Birmingham, United Kingdom|Cambridge, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Northwood, United Kingdom|Oxford, United Kingdom|Sutton, United Kingdom|Whitchurch, United Kingdom","https://ClinicalTrials.gov/show/NCT00638690"
208,"NCT00841828","Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","Completed","Has Results","Female","Phase 2|Phase 3","102","Other|Industry","Interventional","February 2009","December 2011","December 2013","February 11, 2009","November 2, 2018","November 2, 2018","Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Xarxa Asistencial de Manresa, Manresa, Barcelona, Spain|Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain|Hospital del Espíritu Santo, Santa Coloma De Gramenet, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Onkologikoa, Donostia-San Sebastián, Guipuzcoa, Spain|Hospital Xeral Cíes, Vigo, Pontevedra, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital General Yagüe, Burgos, Spain|Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain|Complejo Hospitalario Universitario Reina Sofía, Córdoba, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00841828"
209,"NCT01666977","Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer","Completed","No Results Available","All","Phase 1|Phase 2","36","Industry","Interventional","August 2012","November 2015","November 2015","August 17, 2012","null","June 3, 2016","Research Site, Fayetteville, Arkansas, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, Pleasant Hill, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Peoria, Illinois, United States|Research Site, Paducah, Kentucky, United States|Research Site, Hannover, New Hampshire, United States|Research Site, Bronx, New York, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Greenville, South Carolina, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Bruxelles, Belgium|Research Site, Hamilton, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Málaga, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01666977"
210,"NCT01271920","Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab","Completed","No Results Available","All","Phase 2","45","Industry","Interventional","September 2010","October 2013","October 2013","January 7, 2011","null","February 23, 2017","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Novartis Investigative Site, Dijon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Tuebingen, Germany|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01271920"
211,"NCT01928459","Phase 1b Trial of BGJ398/BYL719 in Solid Tumors","Completed","No Results Available","All","Phase 1","62","Industry","Interventional","October 2013","August 2016","August 2016","August 26, 2013","null","August 22, 2017","H. Lee Moffitt Cancer Center & Research Institute Moffitt 4, Tampa, Florida, United States|University of Michigan Comprehensive Cancer Center SC, Ann Arbor, Michigan, United States|Karmanos Cancer Institute Dept of Onc, Detroit, Michigan, United States|Washington University School of Medicine Onc Dept, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center Onc Dept, New York, New York, United States|Vanderbilt University Medical Center Dept of Onc, Nashville, Tennessee, United States|Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bellinzona, Switzerland","https://ClinicalTrials.gov/show/NCT01928459"
212,"NCT01399684","A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer","Completed","No Results Available","All","Phase 2","127","Industry","Interventional","November 2011","February 2014","February 2014","July 22, 2011","null","August 26, 2016","Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Bakersfield, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Pasadena, California, United States|San Luis Obispo, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Jacksonville, Florida, United States|Ocala, Florida, United States|Port Saint Lucie, Florida, United States|Lawrenceville, Georgia, United States|Marietta, Georgia, United States|Harvey, Illinois, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Las Vegas, Nevada, United States|Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|South Brisbane, Queensland, Australia|Woodville South, South Australia, Australia|Footscray, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Bruxelles, Belgium|Bruxelles, Belgium|Leuven, Belgium|Gdansk, Poland|Krakow, Poland|Poznan, Poland|Warszawa, Poland|Santander, Cantabria, Spain|Barcelona, Spain|Barcelona, Spain|Sevilla, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01399684"
213,"NCT00769067","A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen","Completed","Has Results","All","Phase 2","188","Industry","Interventional","November 2008","October 2010","August 2014","October 8, 2008","August 21, 2015","October 7, 2015","Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Agajanian Institute of Oncology and Hematology, Montebello, California, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Wittingham Cancer Center @ Norwalk Hospital, Norwalk, Connecticut, United States|Medical Oncology & Hematology, P.C., Waterbury, Connecticut, United States|Winship Cancer Institute at Grady Health Systems, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Augusta Oncology Associates, P.C., Augusta, Georgia, United States|Augusta Oncology Associates, PC, Augusta, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Georgia Cancer Specialists, Decatur, Georgia, United States|The Longstreet Cancer Center, Gainesville, Georgia, United States|Central Georgia Cancer Care, P.C., Macon, Georgia, United States|Northwest Georgia Oncology Center, Marietta, Georgia, United States|Central Georgia Cancer Care, P.C., Warner Robins, Georgia, United States|Kootenai Cancer Center at Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Center for Blood and Cancer Disorders, Bethesda, Maryland, United States|Associates in Oncology/Hematology, PC, Rockville, Maryland, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|The West Clinic, Memphis, Tennessee, United States|Oncology/Hematology Associates, Clarksburg, West Virginia, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|St. Vincent's Hospital, Fitzroy, Victoria, Australia|The Andrew Love Cancer Centre,, Geelong, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita, Porto Alegre, RS, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|FUNDACAO PIO XII Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP, Sao Paulo, SP, Brazil|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Department of Clinical Oncology, Shatin, New Territories, Hong Kong|Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea, Republic of|SamsungMedicalCenter,SungkyunkwanUnivSchoolofMedicine,Div. of Hematology-Oncology, Dep. of Medicine, Seoul, Korea, Republic of|Medex spolka cywilna, Chrzanow, Poland|¿KardioDent¿, Krakow, Poland|""Vesalius"" Sp. z o.o., Krakow, Poland|Zaklad Rentgena i USG Wyrobek spolka jawna, Krakow, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland|Niepubliczny Zaklad Opieki Zdrowotnej AVI Centrum Medyczne, Warszawa, Poland|Ponce School of Medicine / CAIMED Center, Ponce, Puerto Rico|National Cancer Centre, Singapore, Singapore|Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Teresa Herrera, La Coruña, Spain|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Chest Department, Taipei, Taiwan|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT00769067"
214,"NCT02806648","A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)","Completed","No Results Available","All","Phase 2","21","Other","Interventional","May 2015","July 2017","January 2018","June 20, 2016","null","January 23, 2018","H.U.C de Asturias, Oviedo, Asturias, Spain|ICO, L'Hospitalet de Llobregat, Barcelona, Spain|C. H. de Navarra, Pamplona, Navarra, Spain|H. Vall d´Hebron, Barcelona, Spain|H. Castellon, Castelló, Spain|H U Ramón y Cajal, Madrid, Spain|H. 12 Octubre, Madrid, Spain|H.U.La Paz, Madrid, Spain|H.U.Virgen del Rocio, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02806648"
215,"NCT00652366","A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer","Completed","Has Results","All","Phase 2","467","Industry","Interventional","May 2008","February 2012","February 2012","April 3, 2008","February 11, 2015","February 11, 2015","Buenos Aires, Argentina|Florencio Varela, Argentina|Rosario, Argentina|Santa Fe, Argentina|Canberra, Australian Capital Territory, Australia|Liverpool, New South Wales, Australia|St. Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Ballarat, Victoria, Australia|Frankston, Victoria, Australia|Salzburg, Austria|Wien, Austria|Antwerpen, Belgium|Bruxelles, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Salvador, BA, Brazil|Belo Horizonte, MG, Brazil|Ijui, RS, Brazil|Santo Andre, SP, Brazil|Sao Paulo, SP, Brazil|Mississauga, Ontario, Canada|Toronto, Ontario, Canada|Zagreb, Croatia|Herlev, Denmark|Hillerod, Denmark|København, Denmark|Angers, France|Besancon, France|Brest, France|Paris, France|St-Priest-En-Jarez, France|Berlin, Germany|Bochum, Germany|Bonn, Germany|Esslingen, Germany|Halle, Germany|Hamburg, Germany|Hamm, Germany|Kaiserslautern, Germany|Leipzig, Germany|Marburg, Germany|Muenchen, Germany|Mönchengladbach, Germany|Saarbruecken, Germany|Trier, Germany|Ulm, Germany|Heraklion, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Zerifin, Israel|Chieti, Abruzzo, Italy|Napoli, Campania, Italy|Pordenone, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Orbassano, Piemonte, Italy|San Giovanni Rotondo, Puglia, Italy|Firenze, Toscana, Italy|Vilnius, Lithuania|Vilnius, Lithuania|Distrito Federal, Mexico|Gliwice, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Brasov, Romania|Bucuresti, Romania|Cluj Napoca, Romania|Sibiu, Romania|Belgrade, Serbia|Sremska Kamenica, Serbia|Singapore, Singapore|Singapore, Singapore|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Taipei, Taiwan|Taipei, Taiwan|London, United Kingdom|Salisbury, United Kingdom","https://ClinicalTrials.gov/show/NCT00652366"
216,"NCT02259582","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 2","82","Industry","Interventional","February 2015","April 7, 2017","April 7, 2017","October 8, 2014","August 20, 2018","August 20, 2018","Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|University of California, San Francisco, San Francisco, California, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Ocala Oncology Center, Ocala, Florida, United States|Edward H. Kaplan MD & Associates, Skokie, Illinois, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Broome Oncology, LLC, Binghamton, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hematology Oncology Associates of Rockland, Nyack, New York, United States|Gaston Hematology & Oncology, Gastonia, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Texas Oncology-Sherman, Sherman, Texas, United States|Compass Oncology, Vancouver, Washington, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|North Coast Cancer Institute Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Royall Brisbane & Women's Hospital, Herston, Queensland, Australia|Icon Cancer Foundation, Milton, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Monash Health, Monash Cancer Centre-Moorabbin, Bentleigh East, Victoria, Australia|St. John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Ziekenhuisnetwerk Antwerpen- Koningin Paola Kinderzickenhuis, Antwerpen, Belgium|Grand Hopital de Charleroi- Site Notre-Dame, Charleroi, Belgium|Centre Hospitalier Jolimont-Lobbes, La Louviere, Belgium|CHR de Ia Citadelle, Liege, Belgium|Azienda Ospedaliera Istituti Ospitalieri, Cremona, Lombardia, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Smilow Cancer Hospital at Yale-New Haven, Aviano, Pordenone, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Nuestra Senora de Sonsoles, Avila, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Institute Catalan de Oncologia (ICO L'Hospitalet), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Madrid Universitario Sanchinarro, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02259582"
217,"NCT00875979","A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab","Completed","Has Results","All","Phase 1|Phase 2","67","Industry","Interventional","May 2009","August 2011","August 2011","April 6, 2009","July 18, 2013","December 24, 2013","Boca Raton, Florida, United States|Deerfield Beach, Florida, United States|Maywood, Illinois, United States|Indianapolis, Indiana, United States|Wichita, Kansas, United States|Rockville, Maryland, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Bruxelles, Belgium|Vancouver, British Columbia, Canada|Montreal, Quebec, Canada|Paris, France|Villejuif, France|Köln, Germany|Aviano, Italy|Milano, Italy|Barcelona, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT00875979"
218,"NCT01168973","A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy","Completed","Has Results","All","Phase 3","1253","Industry","Interventional","December 2010","December 2013","August 2016","July 23, 2010","December 29, 2014","August 11, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sedona, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alhambra, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Duarte, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fullerton, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Long Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northridge, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Redondo Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Barbara, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterbury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lawrenceville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Savannah, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloomington, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cedar Rapids, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Overland Park, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashland, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Sterling, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baton Rouge, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chevy Chase, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danvers, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Framingham, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newton, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joplin, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Henderson, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reno, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lebanon, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portsmouth, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fargo, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Abington, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingston, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Abilene, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amarillo, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beaumont, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., El Paso, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Worth, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lewisville, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., McAllen, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mesquite, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midland, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odessa, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sugar Land, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Webster, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Christiansburg, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfax, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newport News, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lacey, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wenatchee, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Córdoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rioja, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucumain, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grimmenstein, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wels, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barretos, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belo Horizonte, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goiania, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moncton, New Brunswick, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grenoble, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Soden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bielefeld, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gerlingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Großhansdorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villingen-Schwenningen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kifissia, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyula, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matrahaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nyiregyhaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pécs, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szekesfehervar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cuttack, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Safed, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel-Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Novara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palermo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arnhem, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harderwijk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., S-Hertogenbosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zwolle, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grafton, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oslo, Norway|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tromsø, Norway|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glucholazy, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Opole, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Otwock, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Palmas De Gran Canaria, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mataró, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo De Alarcon, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eskilstuna, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linkoping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Basel, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bern, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fribourg, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Luzern, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zurich, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neihu Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cottingham, East Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Preston, Lancashire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wythenshawe, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scunthorpe, North Lincolnshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coventry, West Midlands, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands, United Kingdom","https://ClinicalTrials.gov/show/NCT01168973"
219,"NCT00707304","Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer","Completed","No Results Available","All","Phase 3","742","Industry","Interventional","November 2008","March 2011","August 2012","June 30, 2008","null","August 21, 2012","Desert Oasis Cancer Center, Casa Grande, Arizona, United States|Arizona Oncology Associates, Tucson, Arizona, United States|University of Colorado Hospital, Aurora, Colorado, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Cancer Care & Hematology Specialists of Chicagoland, Niles, Illinois, United States|Central Indiana Cancer Centers, Greenfield, Indiana, United States|Kansas City Cancer Center, LLC, Overland Park, Kansas, United States|NCI, CCR, The Waren Grant Magnuson Clinical Center, Bethesda, Maryland, United States|Newland Medical Associates, Southfield, Michigan, United States|Minnesota Oncology and Hematology, PA, Minneapolis, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|NH Oncology-Hematology, PA, Hooksett, New Hampshire, United States|Montefiore Medical Center, Bronx, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Alamance Regional Medical Center, Burlington, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|Legacy Pharma Research, Bismarck, North Dakota, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Kaiser Group Health, Portland, Oregon, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Cancer Care Northwest, Spokane, Washington, United States|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Townsville Hospital, Townsville, Queensland, Australia|The Queen Elisabeth Hospital, Woodville South, South Australia, Australia|Epworth Healthcare, Richmond, Victoria, Australia|DDODIU-Plovdiv, EOOD, Aleksandur Stamboliyski, Plovdiv, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria|DDODIU-Plovdiv, EOOD, Plovdiv, Bulgaria|DDODIU - Sofia District EOOD, Sofia, Bulgaria|UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Hôtel-Dieu de Lévis, Lévis, Quebec, Canada|Gerald Bronfman Centre for Clinical Research in Oncology, Montreal, Quebec, Canada|Fakultni nemocnice Na Bulovce, Budinova, Praha, Czech Republic|Institut Onkologie a Rehabilitace Na Plesi, Nova Ves pod Plesi, Czech Republic|Vitkovicka nemocnice a.s., Ostrava, Czech Republic|Fakultni Nemocnice Ostrava, Ostrava, Czech Republic|Pardubicka krajska nemocnice, a.s., Pardubice, Czech Republic|Fakultni Nemocnice Kralovske Vinohrady, Praha, Czech Republic|Fakultni nemocnice v Motole, s.p., Praha, Czech Republic|Oblastni nemocnice Pribram, a.s., Pribram, Czech Republic|Nemocnice Tabor, a.s., Tabor, Czech Republic|Hopital Cardiologique, Chru Lille, Lille, Cedex, France|CHU Pontchaillou, Rennes, Cedex, France|CRLCC René Gauducheau, Saint-herblain, Cedex, France|CLCC Paul Strauss, Strasbourg, Cedex, France|Hopital Larrey, Toulouse, Cedex, France|Centre Catherine de Sienne, Eric Tabarly, Nantes, France|CHU Angers, Angers cedex, France|Hopital Morvan, Brest, France|Centre Francois Baclesse, Caen Cedex, France|Centre d'Oncology de Gentilly, Cedex, France|Centre Hospitalier du Mans, Le Mans Cedex, France|Centre Léon Berard, Lyon, France|Hopital Sainte Marguerite, Marseille Cedex 9, France|Hôpital Saint-Antoine, Paris, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, France|Hopital Maison Blanche, Reims, France|CHU de Nancy, Hopital de Brabois, Vandoeuvre les Nancy, France|Praxis fuer interdisziplinaere Onkologie, Freiburg, BW, Germany|Universitaetsklinikum Mannheim, Mannheim, BW, Germany|Universitaetsklinikum Erlangen - PS, Erlangen, BY, Germany|Asklepios Fachkliniken Muenchen-Gauting, Gauting, BY, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, BY, Germany|Gemeinschaftspraxis fuer Haematologie Onkologie, Wiesbaden, HE, Germany|Universitaetsklinikum Goettingen, Goettingen, NI, Germany|St. Johannes Hospital - PS, Dortmund, NW, Germany|Krankenhaus Grosshansdorf, Woehrendamm, SH, Germany|Staedt. Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, ST, Germany|Zentralklinik Bad Berka, Bad Berka, TH, Germany|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Germany|General Hospital of Chania 'Ag. Georgios', Mournies, Crete, Greece|University Hospital of Larissa, Mezourlo, Larissa, Greece|University General Hospital of Patras, Rion, Patras, Greece|General Hospital of Athens ""Sotiria"", Athens, Greece|University Hospital of Heraklio, Crete, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Miskolc Megyei Jogu Varos Onkormanyzat Miskolci Egeszsegugyi, Csabai kapu, Miskolc, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Seregelyesi, Szekesfehervar, Hungary|Semmelweis Egyetem, Budapest, Hungary|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Szabolcs-Szatmar Bereg Megyei Josa Andras Oktato Korhaz, Nyiregyháza, Hungary|Torokbalinti Tudogyogyintezet, Torokbalint, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|King George Hospital, Vishakhapattanam, Andhhra Pradesh, India|Apollo Hospital, Hyderabad, Andhra Pradesh, India|Indo-American Cancer Institute and Research Center, Hyderabad, Andhra Pradesh, India|Kidwai Institute of Oncology, Bangalore, Karnataka, India|M. S. Ramaiah Memorial Hospital, Bangalore, Karnataka, India|A.J. Medical College Hosptial, Mangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|P.D. Hinduja Nat. Hospital & Med. Research Centre, Mumbai, Maharashtra, India|Kaushalya Medical Foundation Trust Hospital, Mumbai, Maharashtra, India|Cancer Care Clinic, Nagpur, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Searoc Cancer Hospital, Jaipur, Rajasthan, India|Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India|Dr. Kamakshi Memorial Hospital Pvt Ltd, Chennai, Tamilnadu, India|Christian Medical College Hospital, Vellore, Tamilnadu, India|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Ancona, AN, Italy|Istituto per la Ricerca e la Cura del Cancro, Candiolo, Candiolo/TO, Italy|Ospedale Versilia, Lido di Camaiore, LU, Italy|Istituto Nazionale Tumori, Milano, MI, Italy|Azienda Ospedaliera San Gerardo, Monza, MI, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma,, RM, Italy|Ospedale Mater Salutis, Legnago, VR, Italy|CRO Centro di Riferimento Oncologico di Aviano, Aviano, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy|Chonnam National University Hwasun Hospital, Hwasun up, Chonnam, Korea, Republic of|National Cancer Center, Ilsandong-gu, Goyang, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do,, Korea, Republic of|Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|Korea University Anam Hospital, Seongbuk-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|The Catholic University of Korea St. Vincent's Hospital, Paldal-gu, Suwon Gyeonggi-do, Korea, Republic of|Dr. Anna Levcenko GP and Internist Practice, Daugavpils, Latvia|Piejuras Hospital, Liepaja, Latvia|Riga Eastern Clinical University Hospital, Riga, Latvia|P. Stradina Clinical University Hospital, Riga, Latvia|Nilai Cancer Institute (NCI Cancer Hospital), Negeri Sembilan, Darul Khusus, Malaysia|Lam Wah Ee Hospital, Pulau Pinang, Georgetown,, Malaysia|Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Manila Doctors Hospital, Manila, Philippines|Lung Center of the Philippines, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Akademickie Centrum Kliniczne - Szpital AM w Gdansku, Gdansk, Poland|Nzoz Vesalius, Krakow, Poland|Miedziowe Centrum Zdrowia S.A., Lubin, Poland|NZOZ Olsztynski Osr. Onkologiczny ""Kopernik"" Sp.z o.o, Olsztyn, Poland|Specjalistyczny Szpital im. Prof. A. Sokolowskiego, Szczecin, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Str. Republicii nr. 34-36, Cluj-Napoca, Romania|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"", Baia Mare, Romania|Spitalul Judetean de Urgenta Braila, Braila, Romania|S.C. Ianuli Med Consult S.R.L., Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Judetean de Urgenta ""Sf. Ioan cel Nou"" Suceava, Suceava, Romania|Oncology Dispensary #2 of Krasnodar Region, Dagomysskaya str., Sochi, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|SHI Altay Regional Oncology Dispensary, Barnaul, Russian Federation|CCH #2 n.a. N. A. Semashko of LLC ""Russian Railways"", Moscow, Russian Federation|City Clinical Hospital #1, Novosibirsk, Russian Federation|Perm Territorial Oncology Dispensary, Perm, Russian Federation|SEIHPE ""Saint Petersburg SMU RosZdrav n.a. I.I.Pavlov"", St. Petersburg, Russian Federation|National Cancer Centre, Hospital Drive, Singapore|Parkway Cancer Centre, Mount Elizabeth, Singapore|Medical Oncology Centre, Napier Road, Singapore|John Hopkins Singapore International Medical Centre, Singapore, Singapore|H Mutua de Terrassa, Barcelona, Spain|HU Virgen de las Nieves, Granada, Spain|Fundacion Jimenez Diaz, Madrid, Spain|HGU La Paz, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung,, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Linkou Branch, Toayuan, Taiwan|Gazi University Medical Faculty, Ankara, Turkey|Gaziantep University Medical Faculty, Gaziantep, Turkey|Istanbul Bilim University Medical Fac., Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Bristol Haematology & Oncology Centre, Bristol, Brist, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, Gt Lon, United Kingdom|Christie Hospital, Manchester, Gt Man, United Kingdom|Southampton General Hospital, Southampton, Hants, United Kingdom|Castle Hill Hospital, Cottingham Hull, Hull, United Kingdom|University Hospital of South Manchester NHS Foundation Trust Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom|Singleton Hospital, Swansea,, S Glam,, United Kingdom|University Hospital of North Staffordshire, Stoke on Trent, Staffs, United Kingdom|Wolverhampton New Cross Hospital, Wolverhampton, Staffs, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Strath, United Kingdom|Ninewells Hospital, Dundee, Tays, United Kingdom|University Hospital of Coventry and Warwickshire, Coventry, Warwks, United Kingdom","https://ClinicalTrials.gov/show/NCT00707304"
220,"NCT01605227","Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","Completed","Has Results","Male","Phase 3","1028","Industry","Interventional","July 2012","September 2014","March 2015","May 24, 2012","March 14, 2018","March 14, 2018","Birmingham, Alabama, United States|Anchorage, Alaska, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Jonesboro, Arkansas, United States|Duarte, California, United States|Highland, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Montebello, California, United States|Orange, California, United States|Palo Alto, California, United States|Rancho Mirage, California, United States|Saint Helena, California, United States|San Marcos, California, United States|Vallejo, California, United States|Aurora, Colorado, United States|New Haven, Connecticut, United States|Southington, Connecticut, United States|Miami Beach, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Titusville, Florida, United States|Wellington, Florida, United States|West Palm Beach, Florida, United States|Athens, Georgia, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Galesburg, Illinois, United States|Niles, Illinois, United States|Ames, Iowa, United States|Sioux City, Iowa, United States|Wichita, Kansas, United States|Hazard, Kentucky, United States|Louisville, Kentucky, United States|Brewer, Maine, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Methuen, Massachusetts, United States|Detroit, Michigan, United States|Wyoming, Michigan, United States|Minneapolis, Minnesota, United States|Jefferson City, Missouri, United States|Springfield, Missouri, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|Lawrenceville, New Jersey, United States|Albany, New York, United States|Garden City, New York, United States|New York, New York, United States|Pinehurst, North Carolina, United States|Bismarck, North Dakota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Bryn Mawr, Pennsylvania, United States|Hershey, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Greenville, South Carolina, United States|Chattanooga, Tennessee, United States|Amarillo, Texas, United States|Bedford, Texas, United States|Houston, Texas, United States|Laredo, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Fairfax, Virginia, United States|Newport News, Virginia, United States|Spokane, Washington, United States|Green Bay, Wisconsin, United States|Albury, New South Wales, Australia|Concord, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Kogarah, New South Wales, Australia|Port Macquarie, New South Wales, Australia|Randwick, New South Wales, Australia|Wahroonga, New South Wales, Australia|Westmead, New South Wales, Australia|South Brisbane, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Kurralta Park, South Australia, Australia|Hobart, Tasmania, Australia|Bentleigh East, Victoria, Australia|Box Hill, Victoria, Australia|Wodonga, Victoria, Australia|Perth, Western Australia, Australia|Linz, Austria|Salzburg, Austria|Wein, Austria|Wien, Austria|Aalst, Belgium|Bonheiden, Belgium|Brussels, Belgium|Brussels, Belgium|Brussels, Belgium|Gent, Belgium|Hasselt, Belgium|Leuven, Belgium|Liège, Belgium|Roeselare, Belgium|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Miramichi, New Brunswick, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Owen Sound, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Angers, France|Besançon, France|Bordeaux, France|Caen, France|Clermont Ferrand, France|Dijon, France|La Roche sur Yon, France|Le Mans, France|Lille, France|Lyon Cedex 08, France|Marseille, France|Nancy, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Pierre Benite, France|Rennes, France|Saint Herblain, France|Strasbourg, France|Suresnes, France|Villejuif Cedex, France|Aachen, Germany|Aachen, Germany|Berlin, Germany|Berlin, Germany|Braunschweig, Germany|Dresden, Germany|Dusseldorf, Germany|Frankfurt am Main, Germany|Freiburg, Germany|Furth, Germany|Gütersloh, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Homburg, Germany|Kassel, Germany|Kempen, Germany|Kirchheim, Germany|Koln, Germany|Mannheim, Germany|Munchen, Germany|Munster, Germany|Nurtingen, Germany|Offenburg, Germany|Traunstein, Germany|Tubingen, Germany|Weiden, Germany|Wuppertal, Germany|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Ancona, Italy|Arezzo, Italy|Aviano, Italy|Brindisi, Italy|Cremona, Italy|Genova, Italy|Livorno, Italy|Meldola, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Novara, Italy|Orbassano, Italy|Padova, Italy|Pavia, Italy|Pisa, Italy|Pordenone, Italy|Ravenna, Italy|Rimini, Italy|Roma, Italy|Roma, Italy|Rozzano, Italy|Terni, Italy|Torino, Italy|Verona, Italy|Amsterdam, Netherlands|Groningen, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Zwolle, Netherlands|Ponce, Puerto Rico|Málaga, Andalucía, Spain|Sevilla, Andalucía, Spain|Oviedo, Asturias, Spain|Palma de Mallorca, Baleares, Spain|La Laguna, Canarias, Spain|Badalona, Cataluña, Spain|Barcelona, Cataluña, Spain|Barcelona, Cataluña, Spain|Barcelona, Cataluña, Spain|Barcelona, Cataluña, Spain|Barcelona, Cataluña, Spain|L'Hospitalet de Llobregat, Cataluña, Spain|Manresa, Cataluña, Spain|Elche, Comunidad Valenciana, Spain|Valencia, Comunidad Valenciana, Spain|A Coruña, Galicia, Spain|Santiago de Compostela, Galicia, Spain|Madrid, Madrid, Communidad De, Spain|Madrid, Madrid, Communidad De, Spain|Madrid, Madrid, Communidad De, Spain|Madrid, Madrid, Communidad De, Spain|Madrid, Madrid, Communidad De, Spain|Majadahonda, Madrid, Communidad De, Spain|Pamplona, Navarra, Spain|Gotenborg, Sweden|Malmo, Sweden|Orebro, Sweden|Stockholm, Sweden|Umea, Sweden|Uppsala, Sweden|Vaxjo, Sweden|Aberdeen, United Kingdom|Bath, United Kingdom|Birmingham, United Kingdom|Brighton, United Kingdom|Bristol, United Kingdom|Cambridge, United Kingdom|Cardiff, United Kingdom|Cottingham, United Kingdom|Edinburgh, United Kingdom|Inverness, United Kingdom|Lancaster, United Kingdom|Leeds, United Kingdom|London, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Northwood, United Kingdom|Plymouth, United Kingdom|Sheffield, United Kingdom|Southampton, United Kingdom|Sutton, United Kingdom|Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01605227"
221,"NCT00633464","Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer","Completed","Has Results","Female","Phase 2","79","Industry","Interventional","June 2008","September 2010","May 2011","March 12, 2008","April 24, 2012","March 10, 2016","Local Institution, Graz, Austria|Local Institution, Wien, Austria|Local Institution, Brno, Czech Republic|Local Institution, Prague 5, Czech Republic|Local Institution, Praha 2, Czech Republic|Local Institution, Bayonne, France|Local Institution, Dijon Cedex, France|Local Institution, Lyon, France|Local Institution, Paris Cedex 13, France|Local Institution, Saint Brieuc, France|Local Institution, Saint Herblain Cedex, France|Local Institution, Toulouse Cedex, France|Local Institution, Thessaloniki, Greece|Local Institution, Napoli, Italy|Local Institution, Gdansk, Poland|Local Institution, Olsztyn, Poland|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00633464"
222,"NCT01847274","A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer","Completed","No Results Available","Female","Phase 3","597","Industry|Other","Interventional","June 2013","June 2016","June 2016","May 6, 2013","null","December 13, 2016","Phoenix, Arizona, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Orange, California, United States|San Francisco, California, United States|Stanford, California, United States|New Haven, Connecticut, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Morristown, New Jersey, United States|Farmington, New Mexico, United States|New Hyde Park, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Oklahoma City, Oklahoma, United States|Abington, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|San Antonio, Texas, United States|The Woodlands, Texas, United States|Vancouver, Washington, United States|Graz, Austria|Innsbruck, Austria|Wien, Austria|Edegem, Antwerpen, Belgium|Leuven, Vlaams Brabant, Belgium|Kortrijk, Belgium|Liège, Belgium|Calgary, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Aalborg, Denmark|Copenhagen, Denmark|Herlev, Denmark|Odense, Denmark|Besancon, France|Lille, France|Montpellier, France|Nice, France|St Brieuc, France|St Herblain Cedex, France|Strasbourg, France|Dresden, Sachsen, Germany|Berlin, Germany|Düsseldorf, Germany|Essen, Germany|Göttingen, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Kiel, Germany|München, Germany|Ulm, Germany|Budapest, Hungary|Miskolc, Hungary|Szolnok, Hungary|Rehovot, HaMerkaz, Israel|Haifa, Hefa, Israel|Holon, Israel|Jerusalem, Israel|Kefar-Saba, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Monza, Lombardia, Italy|Aviano, Italy|Brescia, Italy|Catania, Italy|Milano, Italy|Pisa, Italy|Roma, Italy|Bergen, Norway|Oslo, Norway|Bialystok, Podlaskie, Poland|Gdansk, Pomorskie, Poland|Gdansk, Poland|Lodz, Poland|Poznan, Poland|Oviedo, Asturias, Spain|Barcelona, Spain|Madrid, Spain|Palma de Mallorca, Spain|Linkoeping, Sweden|Lund, Sweden|Stockholm, Sweden|Bangor, Gwynedd, United Kingdom|Birmingham, United Kingdom|Kent, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Somerset, United Kingdom|Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01847274"
223,"NCT01493713","Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer","Completed","No Results Available","All","Phase 4","83","Other","Interventional","November 16, 2011","December 8, 2014","December 18, 2017","December 16, 2011","null","February 16, 2018","Hospital de Donostia, San Sebastián, Guipúzcoa, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain|Hospital Son Llatzer, Palma de Mallorca, Mallorca, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clìnic, Barcelona, Spain|Complejo Hospitalario Xeral Calde, Lugo, Spain|Hospital Universitario Arnau de Vilanova de Lleida, Lérida, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complejo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital de Sabadell, Sabadell, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01493713"
224,"NCT01478373","Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib","Completed","Has Results","All","Phase 2","39","Industry","Interventional","January 2012","July 2014","July 2014","November 23, 2011","August 10, 2015","April 27, 2016","Novartis Investigative Site, HUS, Finland|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01478373"
225,"NCT02441946","A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer","Completed","Has Results","Female","Phase 2","224","Industry","Interventional","August 2015","August 16, 2016","February 12, 2018","May 12, 2015","January 30, 2018","April 17, 2018","Comprehensive Blood and Cancer Center, Bakersfield, California, United States|University of California-San Diego, La Jolla, California, United States|SMO TRIO -Translational Research, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Cancer Care Associates Medical Group, Redondo Beach, California, United States|Sansum Medical Research Foundation, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Monica, California, United States|Stanford University, Stanford, California, United States|SMO Pharmatech Oncology Inc, Denver, Colorado, United States|St Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Memorial Regional Hospital/Joe Dimaggio Childrens Hospital, Hollywood, Florida, United States|Oncology and Radiation Associates, Miami, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Kaiser Foundation Hospitals, Honolulu, Hawaii, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|Nebraska Hematology-Oncology, Lincoln, Nebraska, United States|Weill Cornell Medical College, New York, New York, United States|St. Charles Health System, Bend, Oregon, United States|The West Clinic, Germantown, Tennessee, United States|Millennium Oncology, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Columbia Basin Hematology & Oncology, Kennewick, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Hasselt, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Namur, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Yvoir, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Esslingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Furth, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Ludwigsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Tubingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Piacenza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Daegu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Gangnam-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seodaemun-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongbuk-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Songpa-gu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Ulsan-si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Badajoz, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Lleida, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Malaga, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT02441946"
226,"NCT01461057","A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer","Completed","Has Results","All","Phase 2","30","Industry","Interventional","December 6, 2011","March 1, 2015","October 31, 2017","October 27, 2011","June 27, 2016","August 9, 2018","Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Masaryk Memorial Cancer Institute; Oncological Clinic, Brno, Czechia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultní Nemocnice V Motole; Radioterapeuticko-Onkologicke Oddeleni, Praha 5, Czechia|University Hospital Na Bulovce; Institut of Radiation Oncology, Praha 8, Czechia|Hopital Morvan, Brest, France|CRLCC Val dAurelle Paul Lam, Montpellier cedex 5, France|Hopital Robert Debre; DERMATOLOGIE, Reims, France|Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo., Berlin, Germany|Klinikum Braunschweig; Medizinische Klinik III; Klinik für Hämatologie und Onkologie, Braunschweig, Germany|Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie, Frankfurt, Germany|Klinikum Mannheim III. Medizinische Klinik, Mannheim, Germany|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|A.O. Universitaria Pisana; Oncologia, Pisa, Toscana, Italy|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, Korea, Republic of|Yonsei Medical Center; Dept. of Medicine , Division of Hemato-Oncology, Seoul, Korea, Republic of|Asan Medical Center; Medical Oncology, Seoul, Korea, Republic of|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, Netherlands|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01461057"
227,"NCT01424566","A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer","Completed","Has Results","All","Phase 3","406","Industry","Interventional","June 29, 2012","July 10, 2015","December 28, 2015","August 29, 2011","April 23, 2018","April 23, 2018","East Melbourne, Australia|Parkville, Australia|Shumen, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Lunen, Germany|Stadtroda, Germany|Wetzlar, Germany|Budapest, Hungary|Deszk, Hungary|Komárom, Hungary|Nyíregyháza, Hungary|Szikszó, Hungary|Bangalore, India|Jaipur, India|Pune, India|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Ramat Gan, Israel|Zerifin, Israel|Garbagnate Milanese, Italy|Piacenza, Italy|Torino, Italy|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Bydgoszcz, Poland|Czeladź, Poland|Gdansk, Poland|Gliwice, Poland|Klodzko, Poland|Opole, Poland|Ostrowiec Swietokrzyski, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wloclawek, Poland|Alba Iulia, Romania|Baia Mare, Romania|Braila, Romania|Bucuresti, Romania|Focșani, Romania|Oradea, Romania|Satu Mare, Romania|Sibiu, Romania|Suceava, Romania|Cadiz, Spain|Granada, Spain|Madrid, Spain|Salamanca, Spain|Sevilla, Spain|Changhua City, Taiwan|Taichung, Taiwan|Tainan City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bury Saint Edmunds, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom","https://ClinicalTrials.gov/show/NCT01424566"
228,"NCT00699751","A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","Completed","Has Results","Male","Phase 3","921","Industry","Interventional","June 2008","July 2011","February 2014","June 18, 2008","May 7, 2014","May 27, 2016","Los Angeles, California, United States|Roseville, California, United States|Tampa, Florida, United States|New Orleans, Louisiana, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Philadelphia, Pennsylvania, United States|Liverpool, New South Wales, Australia|Randwick, New South Wales, Australia|St Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Wahroonga, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Toowoomba, Queensland, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Hobart, Tasmania, Australia|Fitzroy, Victoria, Australia|Nedlands, Western Australia, Australia|Kortrijk, Belgium|Ottignies, Belgium|Salvador, Bahia, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Barretos, Sao Paulo, Brazil|Piracicaba, Sao Paulo, Brazil|Belo Horizonte, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Brno, Czech Republic|Chomutov, Czech Republic|Olomouc, Czech Republic|Ostrava, Czech Republic|Plzen - Bory, Czech Republic|Praha 4, Czech Republic|Usti nad Labem, Czech Republic|La Roche Sur Yon, France|Montbeliard, France|Saint Cloud, France|Ulm, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Chai Wan, Hong Kong|Hong Kong, Hong Kong|Hongkong, Hong Kong|Kowloon, Hong Kong|Beer Sheva, Israel|Kfar Saba, Israel|Tel Aviv, Israel|Zrifin, Israel|Meldola, Forlì, Italy|Candiolo, Torino, Italy|Bergamo, Italy|Milano, Italy|Reggio Emilia, Italy|Alkmaar, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Bergen, Norway|Bodø, Norway|Kristiansand, Norway|Oslo, Norway|Oslo, Norway|Tromsø, Norway|Trondheim, Norway|Ålesund, Norway|Bydgoszcz, Poland|Gliwice, Poland|Kielce, Poland|Krakow, Poland|Luiblin, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Singapore, Singapore|Singapore, Singapore|Banska Bystrica, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Martin, Slovakia|Presov, Slovakia|Trnava, Slovakia|Santiago de Compostela, A Coruña, Spain|Alcorcón, Madrid, Spain|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Pamplona, Spain|Valencia, Spain|Zaragoza, Spain|Göteborg, Sweden|Jönköping, Sweden|Kalmar, Sweden|Malmö, Sweden|Sandviken, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Umeå, Sweden|Romford, Essex, United Kingdom|Leicester, Leicestershire, United Kingdom|Bebington, Merseyside, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Taunton, Somerset, United Kingdom|Ipswich, Suffolk, United Kingdom|Guildford, Surrey, United Kingdom|Sutton, Surrey, United Kingdom|Coventry, Warwickshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Belfast, United Kingdom|Brighton, United Kingdom|Bristol, United Kingdom|Cardiff, United Kingdom|Derby, United Kingdom|Hull, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Northwood, United Kingdom|Plymouth, United Kingdom|Sheffield, United Kingdom|Southampton, United Kingdom|Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00699751"
229,"NCT01970540","Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors","Completed","No Results Available","All","Phase 1","122","Industry","Interventional","May 25, 2011","August 9, 2017","August 9, 2017","October 28, 2013","null","August 23, 2017","Hospital Universitari Vall D'Hebron, Barcelona, Spain|Centro Oncológico Md Anderson International España, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|UCLH (University College London Hospitals), London, United Kingdom","https://ClinicalTrials.gov/show/NCT01970540"
230,"NCT01332656","Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel","Completed","No Results Available","Female","Phase 2","154","Industry","Interventional","May 2011","July 2014","July 2014","April 11, 2011","null","December 21, 2015","Investigational Site Number 840007, Burbank, California, United States|Investigational Site Number 840001, New Haven, Connecticut, United States|Investigational Site Number 840202, Fort Meyers, Florida, United States|Investigational Site Number 840009, Atlanta, Georgia, United States|Investigational Site Number 840002, Boston, Massachusetts, United States|Investigational Site Number 056002, Haine-Saint-Paul, Belgium|Investigational Site Number 056005, Kortrijk, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 056003, Namur, Belgium|Investigational Site Number 203003, Novy Jicin, Czech Republic|Investigational Site Number 203002, Olomouc, Czech Republic|Investigational Site Number 203001, Praha 2, Czech Republic|Investigational Site Number 203004, Zlin, Czech Republic|Investigational Site Number 250006, Bordeaux, France|Investigational Site Number 250004, Caen Cedex 05, France|Investigational Site Number 250001, Lyon, France|Investigational Site Number 250002, Paris Cedex 4, France|Investigational Site Number 250003, Villejuif, France|Investigational Site Number 276001, München, Germany|Investigational Site Number 380004, Genova, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380001, Roma, Italy|Investigational Site Number 616002, Krakow, Poland|Investigational Site Number 616004, Poznan, Poland|Investigational Site Number 616003, Rybnik, Poland|Investigational Site Number 616005, Warszawa, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643003, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643004, Saint-Petersburg, Russian Federation|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804005, Donetsk, Ukraine|Investigational Site Number 804004, Kharkov, Ukraine|Investigational Site Number 804002, Lviv, Ukraine","https://ClinicalTrials.gov/show/NCT01332656"
231,"NCT00856375","NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer","Completed","No Results Available","All","Phase 2","83","Industry","Interventional","December 2008","July 2014","December 2014","March 5, 2009","null","February 25, 2015","Pivotal Research Centers, Peoria, Arizona, United States|East Valley Hematology and Oncology Medical Center, Burbank, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente Oncology Clinical Trials, Vallejo, California, United States|University Hematology Oncology, Inc, Centralia, Illinois, United States|Louisville Oncology, Louisville, Kentucky, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Zale Berstein, MD, Buffalo, New York, United States|Center for Biomedical Research - Oncology, Knoxville, Tennessee, United States|ZNA Middelheim, Antwerp, Belgium|Chefarzt der Klinik fur Gastroenterologie/GI-Onkologie, Celle, Germany|Studienzentrale, St. Vicentius Kliniken gAG-Studienzentrale, Karlsruhe, Germany|MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad, Andra Pradesh, India|Hemato-Oncology Clinic Ahmedabad PVT. Ltd Vedanta, Ahmedabad, Gujarat, India|M.S. Ramaiah Memorial Hospital-Gokula Metropolis Clinical Research Centre, Bangalore, Karnatak, India|Rajalakshmi Multispecialty Hospital, Bangalore, Karnatak, India|Amrita Institute of Medical Sciences and Reserach Centre-Dept of Oncology, Kochi, Kerata, India|Shatabdi Superspeciality Hospital, Mumbai, Maharashtra, India|Chittaranjan National Cancer Institute, Kolkata, West Benagal, India|B.P.Poddar Hospital and Medical Research Ltd., Kolkata, West Bengal, India|Hospital General Universitario de Elche, Elche, Spain|Hospital Ramon y Cajal, Madrid, Spain|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00856375"
232,"NCT01362296","An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer","Completed","Has Results","All","Phase 2","134","Industry","Interventional","September 2011","September 2012","September 2013","May 30, 2011","May 26, 2014","July 11, 2014","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Athens, Georgia, United States|GSK Investigational Site, Coeur d'Alene, Idaho, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, St Louis, Missouri, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Marseille cedex 20, France|GSK Investigational Site, Paris Cedex 15, France|GSK Investigational Site, Paris Cedex 20, France|GSK Investigational Site, Paris cedex 5, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Toulouse Cedex 9, France|GSK Investigational Site, Villejuif, France|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Heraklion, Crete, Greece|GSK Investigational Site, Neo Faliro, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Székesfehérvár, Hungary|GSK Investigational Site, Törökbálint, Hungary|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Maastricht, Netherlands|GSK Investigational Site, Zwolle, Netherlands|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT01362296"
233,"NCT00986440","Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy","Completed","No Results Available","All","Phase 2","86","Industry","Interventional","July 2009","January 2013","January 2013","September 30, 2009","null","April 14, 2015","Fakulti nemocnice Brno, Brno, Czech Republic|Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Nemocnice Znojmo, p.o., Oddeleni radiacni a klinicke onkologie, Znojmo, Czech Republic|Hopitaux civils de colmar, Colmar, Cedex, France|Hopital Edouard Herriot, Lyon, Cedex, France|Service d'Oncologie Medicale, Rennes, Cedex, France|Centre Hospitalier Prive Saint Gregoire, Saint Grégoire, France|Onkologische Praxis Donauwörth, Donauwörth, Germany|Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin, Halle, Germany|Klinikum rechts der Isar, München, Germany|Institute for Cancer Research and Treatment - IRCC, Candiolo, Torino, Italy|Ospedale San Martino, Genova, Italy|Unita Operativa di Oncologia Medica, Lecce, Italy|Policlinico Santa Maria alle Scotte, Siena, Italy|Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Udine, Italy|Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie w Bialymstoku, Bialystok, Poland|Wojewodzki Szpital Specjalistyczny, Bytom, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Gliwice, Poland|VESALIUS Sp. z o.o., Krakow, Poland|NZOZ ONKOLOG s.c., Warszawa, Poland|Medical Radiological Research Centre, Obninsk, Kaluga, Russian Federation|Kazan State Medical University, Kazan, Tatarstan, Russian Federation|Russian Oncology Research Centre n.a. Blokhin, RAMS, Moscow, Russian Federation|Central Clinical Hospital #1, Moscow, Russian Federation|NUZ Semashko Central Clinical Hospital, Moscow, Russian Federation|St-Petersburg State Institution of Public Health, St Petersburg, Russian Federation|Federal State Institution of Healthcare Clinical Hospital # 122 n.a.L.G Sokolov, St-Petersburg, Russian Federation|Tula Regional Oncology dispensary, Tula, Russian Federation|H.Clinic I Provincial de Barcelona, Barcelona, Villaroel, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital Mútua de Terrassa, Terrassa (Barcelona), Spain|Volyn regional oncology dispensary, Lutsk, Volyn, Ukraine|Kyiv City Oncology Hospital, Kiev, Ukraine|Sumy Regional Oncology Center, Sumy, Ukraine|Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|St.Bartholomew's Hospital, London, United Kingdom|UCLH Cancer Clinical Trials Unit, London, United Kingdom|Christie Hospital, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00986440"
234,"NCT01658436","BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.","Completed","Has Results","All","Phase 2","31","Industry","Interventional","November 2012","July 2015","July 2015","August 7, 2012","May 2, 2016","May 2, 2016","Indiana University SC, Indianapolis, Indiana, United States|Dana Farber Cancer Institute GastrointestionalCancer Clinic, Boston, Massachusetts, United States|Montefiore Medical Center SC-2, Bronx, New York, United States|Ohio State Comprehensive Cancer Center/James Cancer Hospital SC, Columbus, Ohio, United States|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01658436"
235,"NCT02604342","Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib","Completed","Has Results","All","Phase 3","107","Industry","Interventional","November 3, 2015","January 26, 2017","August 13, 2018","November 13, 2015","February 26, 2018","October 23, 2018","GHdC Site Notre Dame, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|MBAL Serdika EOOD, Sofia, Bulgaria|Centre Francois Baclesse, Caen, France|Hopital Bichat Claude Bernard ; Service de Pneumologie, Paris, France|Hopital Du Haut Leveque; Service Des Maladies Respiratoires, Pessac, France|Hopital Foch; Pneumologie, Suresnes, France|Hopital Sainte Musse; Pneumologie, Toulon, France|Hopital Larrey; Pneumologie, Toulouse, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Zentralklinik Bad Berka GmbH; Abteilung Onkologie und Hämatologie, Bad Berka, Germany|Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, Germany|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Pius-Hospital; Klinik fuer Haematologie und Onkologie, Oldenburg, Germany|Queen Elizabeth Hospital; Clinical Oncology, Hong Kong, Hong Kong|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Semmelweis Egyetem X; Pulmonologiai Klinika, Budapest, Hungary|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Campania, Italy|AORN Ospedali dei Colli Ospedale Monaldi; UOC Pneumologia ad indirizzo Oncologico, Napoli, Campania, Italy|Istituto Nazionale Tumori Fondazione G. Pascale; U.O.C. Oncologia Medica Toraco Polmonare, Napoli, Campania, Italy|Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|POLICLINICO RODOLICO, U.O. di Oncologia Medica, Catania, Sicilia, Italy|A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii, Pisa, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Korea University Guro Hospital; Oncology, Seoul, Korea, Republic of|Oslo Universitetssykehus HF; Radiumhospitalet, Oslo, Norway|Medical University of Gdansk, Gdansk, Poland|Hospital Geral; Servico de Pneumologia, Coimbra, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|CHVNG/E_Unidade 1; Servico de Pneumologia, Vila Nova De Gaia, Portugal|FSBI""National Medical Research Center of Oncology named after N.N.Petrov"" MHRF, St Petersburg, Leningrad, Russian Federation|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|Main Military Clinical Hospital named after N.N. Burdenko, Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|FNsP F. D. Roosevelta Banska Bystrica, II.Ocna klinika SZU, Banska Bystrica, Slovakia|Vychodoslovensky onkologicky ustav, Kosice, Slovakia|Hospital Universitario de Torrejon, Torrejon de Ardoz, Madrid, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, Ankara, Turkey","https://ClinicalTrials.gov/show/NCT02604342"
236,"NCT00719212","Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer","Completed","Has Results","Female","Phase 2","61","Other","Interventional","January 2009","May 2013","May 2013","July 21, 2008","December 1, 2015","January 11, 2016","Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St Jude Heritage Healthcare, Fullerton, California, United States|Wilshire Oncology Medical Group Inc, La Verne, California, United States|LAC/USC Medical Center, Los Angeles, California, United States|University of Southern California/ Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|North Valley Hematology/ Oncology Medical Group, Northridge, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Central Hematology Oncology Medical Group Inc., Pasadena, California, United States|University of Colorado, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|St Joseph Mercy Health System, Ann arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Comprehensive Cancer Centre of Nevada, Henderson, Nevada, United States|Tom Baker Centre, Calgary, Canada|Juravinski Cancer Center, Hamilton, Canada|CHUM Hôpital Notre Dama, Montreal, Canada|Jewish General Hospital, Montreal, Canada|Centre Hospitalier Départemental Les Oudairies, La Roche Sur Yon, France|Centre Léon Berard, Lyon, France|Clinique Hartmann, Neuilly sur Seine, France|Institut Curie, Paris, France|Institut Gustave Roussy, Villejuif, France|Charité Campus Benjamin Franklin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany|Cork University Hospital, Cork, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|St Jame's Hospital, Dublin, Ireland|Waterford Regional Hospital, Waterford, Ireland|Kaplan Medical Center, Rehovot, Israel|Hospital Universitario de Tenerife, La Laguna (Santa Cruz de Tenerife), Spain|Hospital U 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Macarena de Sevilla, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT00719212"
237,"NCT01285609","Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin","Completed","Has Results","All","Phase 3","1289","Industry","Interventional","January 16, 2011","June 9, 2015","August 22, 2017","January 28, 2011","June 23, 2016","September 19, 2018","Sharp Memorial Hospital, San Diego, California, United States|Va Connecticut Healthcare System, West Haven, Connecticut, United States|Local Institution, Boca Raton, Florida, United States|Integrated Community Oncology Network, Jacksonville, Florida, United States|Quincy Medical Group, Quincy, Illinois, United States|Presence Medical Group Hematology Oncology, Skokie, Illinois, United States|Local Institution, Springfield, Illinois, United States|St. Francis Hospital & Health Centers, Indianapolis, Indiana, United States|Floyd Memorial Cancer Center Of Indiana, New Albany, Indiana, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Local Institution, Ypsilanti, Michigan, United States|University Of Kansas Cancer Center, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Clinical Research Alliance, Inc., Lake Success, New York, United States|Durham Va Medical Center (111g), Durham, North Carolina, United States|Carolina Biooncology Institute, Huntersville, North Carolina, United States|Novant Health Oncology Specialists, Lexington, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Oklahoma Oncology And Hematology, Pc Dba, Tulsa, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|Wjb Dorn Va Medical Center, Columbia, South Carolina, United States|Cancer Center Of The Carolinas, Greenville, South Carolina, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Thompson Oncology Group, Knoxville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Local Institution, Quilmes, Buenos Aires, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Wodonga, Victoria, Australia|Local Institution, Graz, Austria|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Aalst, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose dos Campos, SAO Paulo, Brazil|Local Institution, Porto Alegre, Brazil|Local Institution, Ribeirao Preto, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Oshawa, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Shantou, Guangdong, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Santiago, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Pereira, Risaralda, Colombia|Local Institution, Ostrava, Poruba, Czechia|Local Institution, Prague 2, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Pribram V-Zdabor, Czechia|Local Institution, Usti Nad Labem, Czechia|Local Institution, Znojmo, Czechia|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Hillerod, Denmark|Local Institution, Naestved, Denmark|Local Institution, Odense, Denmark|Local Institution, Caen Cedex 05, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre-les-nancy, France|Local Institution, Bad Berka, Germany|Local Institution, Bochum, Germany|Local Institution, Darmstadt, Germany|Local Institution, Dresden, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshandsdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Local Institution, Lubeck, Germany|Local Institution, Mainz, Germany|Local Institution, Muenchen, Germany|Local Institution, Neumunster, Germany|Local Institution, Regensburg, Germany|Local Institution, Tuebingen, Germany|Local Institution, Ulm, Germany|Local Institution, Villingen-Schwenningen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, New Territories, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Deszk, Hungary|Local Institution, Farkasgyepu, Hungary|Local Institution, Gyula, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Nyiregyhaza, Hungary|Local Institution, Pecs, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Szolnok, Hungary|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Beer Sheva, Israel|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Nahariya, Israel|Local Institution, Petah-Tikva, Israel|Local Institution, Rehovot, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Tel-aviv, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Benevento, Italy|Local Institution, Bologna, Italy|Local Institution, Lido Di Camaiore, Italy|Local Institution, Lucca, Italy|Local Institution, Monza, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Siena, Italy|Local Institution, Sondrio, Italy|Local Institution, Terni, Italy|Local Institution, Treviglio, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Fukuoka, Japan|Local Institution, Matsuyama, Ehime, Japan|Local Institution, Osakasayama-city, Japan|Local Institution, Sapporo Hokkaido, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Takatsuki, Japan|Local Institution, Tokyo, Japan|Local Institution, Cheonju-si, Chungcheongbuk-do, Korea, Republic of|Local Institution, Goyang-si, Gyeonggi-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Kangnam-gu, Korea, Republic of|Local Institution, Seoul, Seodaemungu, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Breda, Netherlands|Local Institution, Harderwijk, Netherlands|Local Institution, Hertogenbosch, Netherlands|Local Institution, Nieuwegein, Netherlands|Local Institution, Trujillo, LA Libertad, Peru|Local Institution, Arequipa, Peru|Local Institution, Cercado, Peru|Local Institution, Lima, Peru|Local Institution, Elblag, Poland|Local Institution, Gdansk- Zaspa, Poland|Local Institution, Gdansk, Poland|Local Institution, Grudziadz, Poland|Local Institution, Olsztyn, Poland|Local Institution, Otwock, Poland|Local Institution, Poznan, Poland|Local Institution, Szczecin, Poland|Local Institution, Torun, Poland|Local Institution, Warsaw, Poland|Local Institution, Sao Martinho Do Bispo, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Santa Maria Da Feira, Portugal|Local Institution, Vila Nova De Gaia, Portugal|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Cluj Napoca, Romania|Local Institution, Sibiu, Romania|Local Institution, Suceava, Romania|Local Institution, Timisoara, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pyatigorsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, St-Peterburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Tula, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Vereeniging, Gauteng, South Africa|Local Institution, Panorama,cape Town, Western CAPE, South Africa|Local Institution, Rondebosch, Western CAPE, South Africa|Local Institution, Cape Town, South Africa|Local Institution, Durban, South Africa|Local Institution, Barakaldo, Vizcaya, Spain|Local Institution, Benidorm-alicante, Spain|Local Institution, Castellon, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Manresa, Spain|Local Institution, Ourense, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Ávila, Spain|Local Institution, Gothenburg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Umea, Sweden|Local Institution, Basel, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Changhua City, Taiwan|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung County, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Bangkok, Tungpayathai, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Chiang Mai, Thailand|Local Institution, Songkhla, Thailand|Local Institution, Dundee, Angus/forfarshire, United Kingdom|Local Institution, Truro, Cornwall, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Nottingham, United Kingdom|Local Institution, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01285609"
238,"NCT00490646","A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer","Completed","Has Results","Female","Phase 2","50","Industry","Interventional","February 2008","June 2011","November 2011","June 25, 2007","July 18, 2012","March 10, 2016","Local Institution, Caen, France|Local Institution, Grenoble, France|Local Institution, St Priest En Jarez, France|Local Institution, Toulouse, France|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Pireaus, Greece|Local Institution, Bologna, Italy|Local Institution, Brescia, Italy|Local Institution, Modena, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Sora, Italy|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Izmir, Turkey|Local Institution, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT00490646"
239,"NCT00626106","QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer","Completed","No Results Available","Female","Phase 2","156","Industry","Interventional","March 2008","July 2010","August 2011","February 29, 2008","null","October 27, 2016","Research Site, Chandler, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Concord, California, United States|Research Site, Duarte, California, United States|Research Site, Montebello, California, United States|Research Site, San Francisco, California, United States|Research Site, Sylmar, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Denville, New Jersey, United States|Research Site, High Point, North Carolina, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, American Fork, Utah, United States|Research Site, Tacoma, Washington, United States|Research Site, Waratah, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Vancouver, British Columbia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Lyon, France|Research Site, Montpellier Cedex 5, France|Research Site, Nice Cedex 2, France|Research Site, Paris Cedex 5, France|Research Site, Reims Cedex, France|Research Site, Saint Herblain, France|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Hannover, Germany|Research Site, MÃ¼nchen, Germany|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Madrid, Spain|Research Site, Chur, Switzerland|Research Site, Luzern 16, Switzerland|Research Site, Zurich, Switzerland|Research Site, Derby, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Peterborough, United Kingdom","https://ClinicalTrials.gov/show/NCT00626106"
240,"NCT01487785","Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients","Completed","No Results Available","All","Phase 1","18","Industry","Interventional","March 2012","July 2014","July 2014","December 7, 2011","null","January 26, 2016","Massachusetts General Hospital Dept. of Mass General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center MSKCC - SC, New York, New York, United States|University of Utah / Huntsman Cancer Institute Huntsman UT, Salt Lake City, Utah, United States|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Liverpool, United Kingdom","https://ClinicalTrials.gov/show/NCT01487785"
241,"NCT01500720","Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer","Completed","Has Results","All","Phase 2","179","Industry","Interventional","March 2012","April 2014","April 2014","December 28, 2011","April 13, 2015","April 13, 2015","Investigational Site Number 840007, Muscle Shoals, Alabama, United States|Investigational Site Number 840005, Omaha, Nebraska, United States|Investigational Site Number 840006, Lebanon, New Hampshire, United States|Investigational Site Number 840003, Middletown, Ohio, United States|Investigational Site Number 840001, Philadelphia, Pennsylvania, United States|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124002, Oshawa, Canada|Investigational Site Number 124004, Rimouski, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 250005, Brest, France|Investigational Site Number 250004, Caen Cedex, France|Investigational Site Number 250006, La Tronche, France|Investigational Site Number 250002, Lille, France|Investigational Site Number 250003, Saint-Herblain Cedex, France|Investigational Site Number 250007, Villejuif Cedex, France|Investigational Site Number 276003, Großhansdorf, Germany|Investigational Site Number 276006, Löwenstein, Germany|Investigational Site Number 300005, Athens, Greece|Investigational Site Number 300003, Athens, Greece|Investigational Site Number 300001, Heraklion, Greece|Investigational Site Number 300002, Thessaloniki, Greece|Investigational Site Number 300004, Thessaloniki, Greece|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348003, Törökbálint, Hungary|Investigational Site Number 380001, Genova, Italy|Investigational Site Number 380002, Livorno, Italy|Investigational Site Number 380005, Novara, Italy|Investigational Site Number 380004, Parma, Italy|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 578001, Oslo, Norway|Investigational Site Number 578003, Stavanger, Norway|Investigational Site Number 578002, Trondheim, Norway|Investigational Site Number 616004, Gdansk, Poland|Investigational Site Number 616003, Lublin, Poland|Investigational Site Number 616002, Poznan, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 642003, Cluj Napoca, Romania|Investigational Site Number 642005, Cluj-Napoca, Romania|Investigational Site Number 642001, Craiova, Romania|Investigational Site Number 642002, Timisoara, Romania|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643005, St-Petersburg, Russian Federation|Investigational Site Number 643006, Tula, Russian Federation|Investigational Site Number 643003, Yaroslavl, Russian Federation|Investigational Site Number 724002, Badalona, Spain|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724005, Málaga, Spain|Investigational Site Number 724001, Valencia, Spain|Investigational Site Number 804002, Dnipropetrovsk, Ukraine|Investigational Site Number 804004, Donetsk, Ukraine|Investigational Site Number 804001, Lviv, Ukraine","https://ClinicalTrials.gov/show/NCT01500720"
242,"NCT01881230","Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)","Completed","Has Results","Female","Phase 2|Phase 3","191","Industry","Interventional","September 26, 2013","October 28, 2016","October 28, 2016","June 19, 2013","March 8, 2018","April 3, 2018","Ironwood Cancer and Research Center, Chandler, Arizona, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Arizona Cancer Research Alliance, Scottsdale, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Pacific Cancer Medical Center Inc, Anaheim, California, United States|California Cancer Associates for Research and Excellence cCARE, Escondido, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Wilshire Oncology Medical Group, Inc, La Verne, California, United States|Translational Research Management, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Redwood Regional Medical Group, INC, Santa Rosa, California, United States|Center for Hematology-Oncology, Boca Raton, Florida, United States|Memorial Breast Cancer Center, Hollywood, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Joliet Oncology-Hematology Associates, Ltd, Joliet, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|University of South Alabama Mitchell Cancer Institute, Lafayette, Louisiana, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, PC, Bethesda, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Midwest Physicians Group, Kansas City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|New Hampshire Oncology Hematology, Hooksett, New Hampshire, United States|Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Hematology Oncology Associates of CNY, East Syracuse, New York, United States|NYU Langone Arena Oncology, Lake Success, New York, United States|Clinical Research Alliance, New York, New York, United States|Alamance Regional Medical Cancer Center, Burlington, North Carolina, United States|University of Cincinnatti, Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Mark H Zangmeister Center, Columbus, Ohio, United States|Toledo Community Oncology Program, Toledo, Ohio, United States|Cancer Centers of Southwest Oklahoma, Lawton, Oklahoma, United States|North Bend Medical Center, Coos Bay, Oregon, United States|Northwest Cancer Specialists, P.C. - Hoyt, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Texas Oncology, PA, Dallas, Texas, United States|Texas Oncology, PA- Dallas, Dallas, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|UT Physicians General Medicine, Houston, Texas, United States|Cancer Care Centers of South Texas - Loop, San Antonio, Texas, United States|Texas Oncology P.A.- Tyler, Tyler, Texas, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Delta Hematologyoncology Associates, Portsmouth, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Medical Oncology Associates, Spokane, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Columbia St Marys Cancer Center, Milwaukee, Wisconsin, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Frankston Hospital Oncology Research, Frankston, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Universitaetsklinik Innsbruck, Innsbruck, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|Medizinische Universitat Wien, Vienna, Austria|Centro de Oncologia Da Bahia, Salvador, Bahia, Brazil|Liga Paranaense de Combate Ao Cancer, Curitiba, Paraná, Brazil|Instituto Nacional de Cancer - INCA, Rio De Janerio, Rio De Janeiro, Brazil|Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil|Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú, Jau/SP, São Paulo, Brazil|ONCOCLINIC Clinica de Oncologia LTDA, Fortaleza, Brazil|Instituto Ribeiraopretano de Combate Ao Cancer, Ribeirao Preto, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP, Ribeirao Preto, Brazil|Hospital Bruno Born, Rio Grande Do Sul, Brazil|Hospital de Base Da Faculdade de Medicina de, Sao Jose Do Rio Preto, Brazil|Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira, Sao Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Brazil|Instituto Brasileiro de Controle Do Cancer IBCC, São Paulo, Brazil|Ottawa General Hospital, Ottawa, Ontario, Canada|CHUM - Notre Dame, Montreal, Quebec, Canada|Hospital du Saint Scarement Sacrement Laboratory, Quebec City, Quebec, Canada|CSSS de Rimouski Neigette, Rimouski, Quebec, Canada|Alan Blair Cancer Centre at Pasqua Hosptial, Regina, Saskatchewan, Canada|Centre Jean Perrin, Clermont-Ferrand, France|Sankt Gertrauden-Krankenhaus, Berlin, Germany|Facharztpraxis fur Gynakologie und Geburtshilfe, Bonn, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Praxis fur interdisziplinare Onkologie & Hamatologie, Freiburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Frauenarzte am Bahnhofsplatz, Hildesheim, Germany|Schwerpunktpraxis fur Gynakologische Onkologie, Köln, Germany|LMU Klinikum der Universitat, München, Germany|Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Germany|Universitatsklinikum Ulm, Ulm, Germany|University of Athens Medical school - Regional General Hospital, Athens, Greece|IASO General, Athens, Greece|Metropolitan Hospital, Faliro, Greece|University General Hospital of Heraklion, Heraklion, Greece|University General Hospital of Patras, Rio Patras, Greece|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant' Anna, Ferrara, Italy|IRCCS AziendaOspedaliera Universitaria San Martino, Genova, Italy|Presidio Ospedaliero della Misericordia, Grosseto, Italy|Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte, Messina, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Istituto Oncologico Veneto, Padova, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Universitario A Gemelli, Roma, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy|Hospital Espirito Santo, Evora, Portugal|Hospital Da Luz, Lisboa, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Instituto Portugues de Oncologia do Porto, Francisco Gentil, Porto, Portugal|Clinic Barcelona Hospital Universitari, Barcelona, Spain|Hospital Universitario Vall D`Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Onkologikoa - Kutxaren Institutu Onkologikoa, San Sebastian, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Royal United Hospital, Bath, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The East and North Hertfordshire NHS Trust, Middlesex, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield South Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT01881230"
243,"NCT00728390","A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks","Completed","No Results Available","All","Phase 1","74","Industry","Interventional","July 2008","August 2011","January 2013","August 5, 2008","null","October 8, 2013","Pfizer Investigational Site, Amherst, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Villejuif, France|Pfizer Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00728390"
244,"NCT00615056","A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen","Completed","Has Results","All","Phase 2","171","Industry","Interventional","March 2008","March 2011","April 2012","February 14, 2008","April 20, 2012","April 19, 2013","Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Antioch, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Pleasant Hill, California, United States|Pfizer Investigational Site, San Leandro, California, United States|Pfizer Investigational Site, Santa Monica, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Bonita Springs, Florida, United States|Pfizer Investigational Site, Bradenton, Florida, United States|Pfizer Investigational Site, Cape Coral, Florida, United States|Pfizer Investigational Site, Cape Coral, Florida, United States|Pfizer Investigational Site, Englewood, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Fort Myers, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Naples, Florida, United States|Pfizer Investigational Site, Port Charlotte, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Venice, Florida, United States|Pfizer Investigational Site, Venice, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Ringgold, Georgia, United States|Pfizer Investigational Site, Dubuque, Iowa, United States|Pfizer Investigational Site, Crestview Hills, Kentucky, United States|Pfizer Investigational Site, Paducah, Kentucky, United States|Pfizer Investigational Site, Paducah, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, New Albany, Mississippi, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Fairfield, Ohio, United States|Pfizer Investigational Site, Hamilton, Ohio, United States|Pfizer Investigational Site, Chattanooga, Tennessee, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Gallatin, Tennessee, United States|Pfizer Investigational Site, Germantown, Tennessee, United States|Pfizer Investigational Site, Hermitage, Tennessee, United States|Pfizer Investigational Site, Hixson, Tennessee, United States|Pfizer Investigational Site, Lebanon, Tennessee, United States|Pfizer Investigational Site, Murfreesboro, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Paris, Tennessee, United States|Pfizer Investigational Site, Smyrna, Tennessee, United States|Pfizer Investigational Site, Union City, Tennessee, United States|Pfizer Investigational Site, Corpus Christi, Texas, United States|Pfizer Investigational Site, Mechanicsville, Virginia, United States|Pfizer Investigational Site, Midlothian, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Levis, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Montpellier, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Villejuif, France|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Kashiwa, Chiba, Japan|Pfizer Investigational Site, Suntougun, Shizuoka, Japan|Pfizer Investigational Site, Chuo-ku, Tokyo, Japan|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Jeollanam-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, L'hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00615056"
245,"NCT01000480","A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer","Completed","Has Results","All","Phase 2","90","Industry","Interventional","October 2009","January 2013","July 2013","October 23, 2009","January 1, 2014","April 2, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hemer, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lübeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nürnberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avellino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orbassano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sabadell, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain","https://ClinicalTrials.gov/show/NCT01000480"
246,"NCT00686959","Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 3","598","Industry","Interventional","September 2008","October 2014","November 2014","May 30, 2008","November 26, 2015","June 28, 2016","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Duarte, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fountain Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thomasville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quincy, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Albany, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Westwood, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairhaven, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fargo, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Longview, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odessa, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Marcos, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sugar Land, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morgantown, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Launceston, Tasmania, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antwerp, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gilly, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haine-St.- Paul, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Namur, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turnhout, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barretos, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newmarket, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jinan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sichuan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayonne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pierre Benite, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hemer, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rheine, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Ireland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., S-Hertogenbosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lisbon, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Maria Da Feira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vila Franca De Xira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alicante, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elche, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hospitalet De Llobregat, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Majadahonda, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terrassa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fatih, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melikgazi, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umuttepe, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edgbaston, Birmingham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edinburgh, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00686959"
247,"NCT00531960","A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.","Completed","Has Results","All","Phase 2","124","Industry","Interventional","January 2008","January 2010","January 2010","September 19, 2007","November 11, 2014","November 11, 2014","East Bentleigh, Victoria, Australia|Geelong, Victoria, Australia|Leuven, Belgium|Bayonne, France|Dijon, France|Le Mans, France|Marseille, France|Paris, France|Strasbourg, France|Vandoeuvre-les-nancy, France|Aviano, Friuli-Venezia Giulia, Italy|Milano, Lombardia, Italy|Ancona, Marche, Italy|Lido Di Camaiore, Toscana, Italy|Bundang City, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Kaunas, Lithuania|Vilnius, Lithuania|'s Hertogenbosch, Netherlands|Amsterdam, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Heerlen, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Lodz, Poland|Lublin, Poland|Otwock, Poland|Bucuresti, Romania|Cluj Napoca, Romania|Timisoara, Romania|Singapore, Singapore|Alicante, Spain|Barcelona, Spain|La Coruña, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Sevilla, Spain|Changhua, Taiwan|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Dudley, United Kingdom|Guildford, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00531960"
248,"NCT01493843","Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer","Completed","No Results Available","All","Phase 2","501","Industry","Interventional","January 20, 2012","March 30, 2016","March 30, 2016","December 16, 2011","null","April 25, 2017","Alabama Oncology, Birmingham, Alabama, United States|Highlands Oncology Group, Rogers, Arkansas, United States|cCare, Encinitas, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Desert Hematology Oncology Group, Rancho Mirage, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|Southern CA Permanente Med Grp, San Diego, California, United States|Kaiser Permanente, San Francisco, California, United States|K. Permanente - Santa Clara, Santa Clara, California, United States|Stockton Hema Onc Med Grp Inc, Stockton, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|K. Permanente - Walnut Creek, Walnut Creek, California, United States|Hematology Oncology PC; Bennett Cancer Center, Stamford, Connecticut, United States|Lynn Regional Cancer Center West, Boca Raton, Florida, United States|Florida Cancer Specialists - Fort Myers (Colonial Center Dr), Fort Myers, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Peachtree Hematology & Oncology Consultants, Pc, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Hematology-Oncology of Indiana, Pc, Indianapolis, Indiana, United States|Franklin Square Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Dana Farber Cancer Inst., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Wayne State University; Hemat/Onc, 4HW CRC, Detroit, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Va Sierra Nevada Health Care System, Reno, Nevada, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|Piedmont Hematology Oncology Associates, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Univ Hosp Case Medical Center, Cleveland, Ohio, United States|Center for Biomedical Research LLC, Knoxville, Tennessee, United States|The Sarah Cannon Research Inst, Nashville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Wellmonth Physician Services, Bristol, Virginia, United States|Blue Ridge Cancer Care - Roanoke, Roanoke, Virginia, United States|VA Puget Sound Health Care Sys, Seattle, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Clinica Universitaria Reina Fabiola, Cordoba, Argentina|Instituto FIDES, La Plata, Argentina|Isis Centro Especializado de Luces; Oncology, Santa Fe, Argentina|Royal Prince Alfred Hospital; Sydney Cancer Centre, Camperdown, New South Wales, Australia|St Vincent'S Hospital, Darlinghurst, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Flinders Medical Centre; Medical Oncology, Bedford Park, South Australia, Australia|Royal Hobart Hospital; Medical Oncology, Hobart, Tasmania, Australia|Footscray Hospital, Footscray, Victoria, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia|Centro de Oncologia da Bahia - CENOB, Salvador, BA, Brazil|Clinica de Tratamento e Pesquisa Oncologica - Oncotek, Brasilia, DF, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Liga Norte Riograndense Contra O Câncer, Natal, RN, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Instituto de Oncologia de Sorocaba - CEPOS, Sorocaba, SP, Brazil|Mcgill University - Royal Victoria Hospital; Oncology, Montreal, Quebec, Canada|Hopital du Sacre-Coeur, Montreal, Quebec, Canada|Clinica Santa Maria, Santiago, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Instituto Oncologico del sur, Temuco, Chile|Hospital Clinico Vina del Mar, Viña del Mar, Chile|Hopital Morvan, Brest, France|Clinique Victor Hugo; Radiotherapie, Le Mans, France|Clinique Catherine de Sienne; Service de cancérologie, Nantes, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Centre Hospitalier de Villefranche sur Saone, Villefranche-sur-Saone, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Zentralklinik Bad Berka GmbH; Abteilung Onkologie und Hämatologie, Bad Berka, Germany|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Krankenhaus Grosshansdorf;Pneumologie & Thoraxchirurgie, Grosshansdorf, Germany|St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie, Karlsruhe, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Medizinische Klinik, Pneumologie, Mainz, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, Regensburg, Germany|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie, Villingen-Schwenningen, Germany|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary|Koch Robert Korhaz, Edeleny, Hungary|Veszprem Megyei Onkormanyzat Tudogyogyintezet, Farkasgyepu, Hungary|Vas Megyei Markusovszky Korhaz ; Pulmonology, Szombathely, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Zala Megyei Korhaz; Dept of Pulmonary Medicine, Zalaegerszeg, Hungary|Shaare Zedek Medical Center; Oncology Dept, Jerusalem, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Ausl Di Bologna-Ospedale Bellaria;U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico, Orbassano, Piemonte, Italy|A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U., Verona, Veneto, Italy|Amphia Ziekenhuis, Breda, Netherlands|Catharina-ziekenhuis; Longgeneeskunde en Tuberculose, Eindhoven, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Regional Oncology Center, Chelyabinsk, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|City Oncology Hospital; Chemotherapy Dept, Nizhny Novgorod, Russian Federation|Leningrad Regional Clinical Hospital, St Petersburg, Russian Federation|Rsrch Onc Inst of Rosmed Tech; n.a. prof. N.N. Petrov; Dept of Surgery, St. Petersburg, Russian Federation|Hospital Nuestra Señora de Sonsoles; servicio de Oncologia, Avila, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Kiev City Clinical Oncology Center, Kiev, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, Ukraine|State Oncology Regional Treatment-Diagnostic Center; Chemotherapy Department, Lviv, Ukraine|Crimean Republican Institute; Oncology Clin Dispensary; Chemotherapy Dept, Simferopol, Ukraine|Sumy Reg. Clin. Oncological Dispensary; Thoracall Department, Sumy, Ukraine|Zaporizhzhia Regional Clinical Oncology Dispensary; Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine|Royal Surrey County Hospital; St. Lukes Cancer Centre, Guildford, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01493843"
249,"NCT00789373","A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 3","939","Industry","Interventional","November 2008","June 2010","November 2017","November 11, 2008","July 18, 2011","March 1, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wendouree, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genk, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gilly, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sint Niklaas, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Espoo, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avignon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans Cedex 1, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre-Les-Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gerlingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Großhansdorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neo Faliro, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bhopal, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patna, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avellino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aviano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reggio Emilia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Udine, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ede, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harderwijk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heerlen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lisbon, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vila Franca De Xira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manresa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sabadell, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaragoza, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bornova, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sihhiye, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zeytinburnu, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, West Midlands, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom","https://ClinicalTrials.gov/show/NCT00789373"
250,"NCT01351415","A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","Completed","Has Results","All","Phase 3","485","Industry","Interventional","June 25, 2011","June 25, 2016","June 25, 2016","May 10, 2011","September 18, 2017","September 18, 2017","USA Mitchell Cancer Institute, Mobile, Alabama, United States|Palo Verde Hema/Onc, Glendale, Arizona, United States|Arizona Center for Cancer Care, Glendale, Arizona, United States|Clopton Clinic, Jonesboro, Arkansas, United States|East Valley Hematology ; Oncology Medical Group, Burbank, California, United States|California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States|Scripps Clinic; Hematology & Oncology, La Jolla, California, United States|Sutter Cancer Center, Sacramento, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|The Hospital of Central CT, New Britain, Connecticut, United States|Eastern Ct Hema/Onco Assoc; Dept of Oncology, Norwich, Connecticut, United States|Lynn Cancer Institute - West, Boca Raton, Florida, United States|Baptist - MD Anderson Cancer Center, Jacksonville, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Cancer Care Centers of Brevard, Rockledge, Florida, United States|Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States|Summit Cancer Care PC, Savannah, Georgia, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr, Evanston, Illinois, United States|Joliet Oncology Hematology Associates, Ltd., Joliet, Illinois, United States|Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States|W. Suburban Ctr for Cncer Care, River Forest, Illinois, United States|St. Francis Medical Group, Indianapolis, Indiana, United States|Oncology Hematology Associates of Southwest Indiana, Newburgh, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|Cancer Center of Kansas, Wichita, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Jewish Cancer Care, Louisville, Kentucky, United States|Hematology/Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Louisiana Oncology Associates, Lafayette, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|York Hospital, York, Maine, United States|Anne Arundel Health System Research Instit-Annapolis Oncology Ctr, Annapolis, Maryland, United States|Tufts Medical Center; Neely Cancer Center, Boston, Massachusetts, United States|Ann Arbor Hematology Oncology, Ann Arbor, Michigan, United States|Henry Ford Hospital; Hematology Oncology, Detroit, Michigan, United States|Cancer & Hematology Center of West Michigan, Grand Rapids, Michigan, United States|Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States|St Joseph Oncology, Saint Joseph, Missouri, United States|Heartland CCOP/Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Stony Brook Univ Cancer Ctr; Medical Oncology Clinic, Stony Brook, New York, United States|Carolina Oncology Specialists, PA - Hickory, Hickory, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Mid Ohio Onc Hematology Inc, Columbus, Ohio, United States|Dayton Clinical Oncology Prog, Dayton, Ohio, United States|Signal Point Clinical; Research Center, LLC, Middletown, Ohio, United States|Toledo Hospital; CCOP Toledo, Toledo, Ohio, United States|Bay Area Hospital, Coos Bay, Oregon, United States|St. Lukes Hospital and Health Network, Bethlehem, Pennsylvania, United States|Hematology & Oncology Assoc; North Eastern Pennsylvania, Dunmore, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|University of Pennsylvania; Radiation Oncology, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Lankenau Hospital, Wynnewood, Pennsylvania, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|West Clinic, Germantown, Tennessee, United States|University of Tennessee Medical Center Cancer Institute, Knoxville, Tennessee, United States|Unv of TX SW Med Cntr; Hematology/Onc, Dallas, Texas, United States|Delta Hematology/ Oncology Associates, Portsmouth, Virginia, United States|Blue Ridge Cancer Care - Roanoke, Roanoke, Virginia, United States|Medical Oncology Associates, Spokane, Washington, United States|Fox Valley Hema and Onc SC, Appleton, Wisconsin, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|UNI OF WISCONSIN SCHOOL OF MEDICINE; GI Oncology Research Group, Paul P Carbone Cancer Center, Madison, Wisconsin, United States|Inst. Alexander Fleming; Oncology Dept, Buenos Aires, Argentina|Centro Oncologico Infinito; Oncologia, La Pampa, Argentina|Hospital Privado de Comunidad; Oncology, Mar Del Plata, Argentina|Sanatorio Parque de Rosario, Rosario, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|Clínica Viedma, Viedma, Rio Negro, Argentina|LKH Hohenems; Abteilung für Pulmologie, Hohenems, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, Innsbruck, Austria|Lkh Natters; Abt. Für Atemwegs- & Lungenkrankheiten, Natters, Austria|A.Ö. LKH; Abt. für Lungenkrankheiten, Steyr, Austria|Klinikum Wels-Grieskirchen; Lungenabt., Wels, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Krankenhaus Der Stadt Wien Lainz; V. Medizinische Abt., Wien, Austria|SMZ - Baumgartner Hohe, Pavilion Leopold; 1.Interne Lungenabteilung, Onkologische Tagesklinik, Wien, Austria|Clin. Europe (Ste Elisabeth), Bruxelles, Belgium|Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia, BA, Brazil|Centro de Pesquisa Clínica- Instituto do Câncer do Ceará- ICC, Fortaleza, CE, Brazil|Sociedade beneficente de senhoras Hospital Sirio Libanes, Brasilia, DF, Brazil|Centro de Estudos e Pesquisas Oncologicas - CESPO, Brasilia, DF, Brazil|Instituto de Câncer de Brasília, Taguatinga, DF, Brazil|Clinicas Oncologicas Integradas - COI, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|Nordsjællands Hospital, Hillerød, Onkologisk Afdeling, Hillerod, Denmark|Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire, Aix En Provence, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Hospitalier Intercommunal; Service de Pneumologie, Creteil, France|Hopital Nord Ouest;Unite 2c, Gleize, France|Centre Oscar Lambret, Lille, France|Hopital Calmette; Pneumologie, Lille, France|Hopital Louis Pradel; Cardiologie B, Lyon, France|Hôpital Saint Joseph; Oncologie Medicale, Marseille, France|Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique, Marseille, France|Centre Antoine Lacassagne, Nice, France|Ch Lyon Sud; Chir Onc Gyne Sct Jules Courmont, Pierre Benite, France|CH Rene Dubos; Oncologie, Pontoise, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Institut de Cancérologie de Loire, St-Priest-En-Jarez, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Hia Sainte Anne; Pneumologie, Toulon, France|Hopital Sainte Musse; Pneumologie, Toulon, France|Clinique Pasteur; Pneumologie, Toulouse, France|Chi De La Haute Saone De Vesoul; Pneumologie, Vesoul, France|Zentralklinik Bad Berka GmbH; Pneumologie, Bad Berka, Germany|Praxis Dr. med. David Borquez, Bergisch Gladbach, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie, Frankfurt, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, Germany|LungenClinic Großhansdorf, Großhansdorf, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin I, Halle (Saale), Germany|Universitaetsklinikum des Saarlandes; Innere Medizin V, Homburg/Saar, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie, Karlsruhe, Germany|Robert-Koch-Klinik; Pneumologie, Leipzig, Germany|Praxis Christian Geßner, Leipzig, Germany|Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik, Minden, Germany|Ludwig-Maximilians Uni Klinik Innenstadt; Medizinische Klinik, Muenchen, Germany|Pius-Hospital; Klinik fuer Haematologie und Onkologie, Oldenburg, Germany|Sotiria Hospital, Athens, Greece|Metropolitan Hospital; 2Nd Oncology Clinic, Piraeus, Greece|General Hospital of Thessaloniki Papanikolaou; Uni Pneumonology Dept., Thessaloniki, Greece|Diavalkaniko Hospital, Thessaloniki, Greece|Citta Ospedaliera; Divisione Oncologia Medica, Avellino, Campania, Italy|IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A, Napoli, Campania, Italy|Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica, Roma, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica, Saronno, Lombardia, Italy|A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii, Pisa, Toscana, Italy|Aichi Cancer Center Hospital; Respiratory Medicine, Aichi, Japan|National Cancer Center Hospital East; Thoracic Oncology, Chiba, Japan|National Hospital Organization Shikoku Cancer Center; Thoracic Oncology, Ehime, Japan|National Hospital Organization Kyushu Cancer Center, Thoracic Oncology, Fukuoka, Japan|Hyogo Cancer Center; Thoracic Oncology, Hyogo, Japan|Kanagawa Cardiovascular and Respiratory Center; Respiratory Medicine, Kanagawa, Japan|Yokohama Municipal Citizen'S Hospital; Respiratory, Kanagawa, Japan|Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan|Okayama University Hospital; Respiratory and Allergy Medicine, Okayama, Japan|OSAKA CITY GENERAL HOSPITAL;Medical Oncology, Osaka, Japan|Osaka International Cancer Institute; Thoracic Oncology, Osaka, Japan|Shizuoka Cancer Center; Thoracic Oncology, Shizuoka, Japan|National Cancer Center Hospital; Thoracic Medical Oncology, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Respiratory Medicine, Tokyo, Japan|American University of Beirut - Medical Center, Beirut, Lebanon|Hotel Dieu de France; Oncology, Beirut, Lebanon|Middle East Inst. of Health; Oncology, Beirut, Lebanon|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Hospital Central Sur de Alta Especialidad Petróleos Mexicanos, Mexico City, Mexico|Centro Médico Abc the American British Cowdray Medical Center, I.A.P. - Centro de Cáncer, Mexico City, Mexico|Amphia Ziekenhuis; Afdeling Longziekten, Breda, Netherlands|Leyenburg Hospital; Pulmonology, Den Haag, Netherlands|Catharina Ziekenhuis; Dept of Lung Diseases, Eindhoven, Netherlands|Ziekenhuis St Jansdal; Dept of Lung Diseases, Harderwijk, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Antonius Ziekenhuis; Dept of Lung Diseases, Nieuwegein, Netherlands|College of Medicine & Sciences, Sultan Qaboos University Hospital, Muscat, Oman|Fnsp Fdr Banska Bystrica; Dep of Pneumology&Ftizeology, Banska Bystrica, Slovakia|FNsP Bratislava, Nemocnica Ruzinov, Bratislava, Slovakia|Vychodoslovensky onkologicky ustav, Kosice, Slovakia|Inst. of Tb & Respiratory Diseases; Dep. of Oncology, Nitra, Slovakia|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, Spain|Hospital General Univ. de Alicante; Servicio de Oncologia, Alicante, Spain|Centro Oncologico MD Anderson International Espana, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario Dr. Peset; Servicio de Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Tawam Hospital; Medical Oncology Department, Al Ain, United Arab Emirates","https://ClinicalTrials.gov/show/NCT01351415"
251,"NCT02289833","A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","Completed","Has Results","All","Phase 2","49","Industry","Interventional","December 15, 2014","October 25, 2016","July 26, 2018","November 13, 2014","November 22, 2017","September 11, 2018","Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie, Berlin, Germany|Kaiserswerther Diakonie Florence Nightingale-Krankenh. Tagesklinik f.Onkologie, Düsseldorf, Germany|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Azienda Ospedaliera Univ Parma; Dept Oncologia Medica, Parma, Emilia-Romagna, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Medical University of Gdansk, Gdansk, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, Poland|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia, Zaragoza, Spain|CHUV; Departement d'Oncologie, Lausanne, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT02289833"
252,"NCT01456325","A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)","Completed","No Results Available","All","Phase 3","494","Industry","Interventional","January 2012","January 2016","January 2016","October 20, 2011","null","November 2, 2016","Chandler, Arizona, United States|Hayward, California, United States|Modesto, California, United States|Oakland, California, United States|Orange, California, United States|Roseville, California, United States|Sacramento, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|San Jose, California, United States|Santa Clara, California, United States|South San Francisco, California, United States|Vallejo, California, United States|Walnut Creek, California, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Chicago, Illinois, United States|Urbana, Illinois, United States|Bettendorf, Iowa, United States|Sioux City, Iowa, United States|Louisville, Kentucky, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Ann Arbor, Michigan, United States|Duluth, Minnesota, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Reno, Nevada, United States|Farmington, New Mexico, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bristol, Virginia, United States|Roanoke, Virginia, United States|La Plata, Argentina|Quilmes, Argentina|Santa Fe, Argentina|Camperdown, New South Wales, Australia|Waratah, New South Wales, Australia|Chermside, Queensland, Australia|Adelaide, South Australia, Australia|Parkville, Victoria, Australia|Bruxelles, Belgium|Gent, Belgium|Gilly (Charleroi), Belgium|Liège, Belgium|Namur, Belgium|Salvador/BA, BA, Brazil|Lajeado, RS, Brazil|Novo Hamburgo, RS, Brazil|Jau, SP, Brazil|Sao Paulo, SP, Brazil|Sorocaba, SP, Brazil|Saint John, New Brunswick, Canada|Sault Ste Marie, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Temuco, Chile|Cakovec, Croatia|Dubrovnik, Croatia|Pula, Croatia|Zagreb, Croatia|Besancon, France|Caen, France|Grenoble, France|Limoges, France|Marseille, France|Montpellier, France|Paris, France|Poitiers, France|Saint Herblain, France|Suresnes, France|Vandoeuvre-les-nancy, France|Bad Berka, Germany|Berlin, Germany|Grosshansdorf, Germany|Hamburg, Germany|Heidelberg, Germany|Karlsruhe, Germany|Mainz, Germany|München, Germany|Oldenburg, Germany|Regensburg, Germany|Ulm, Germany|Villingen-Schwenningen, Germany|Pokfulam, Hong Kong|Shatin, Hong Kong|Edeleny, Hungary|Miskolc, Hungary|Szombathely, Hungary|Cork, Ireland|Dublin, Ireland|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Aviano, Friuli-Venezia Giulia, Italy|Genova, Liguria, Italy|Milan, Lombardia, Italy|Monza, Lombardia, Italy|Rozzano, Lombardia, Italy|Ancona, Marche, Italy|Orbassano, Piemonte, Italy|Lido Di Camaiore, Toscana, Italy|Perugia, Umbria, Italy|Aichi, Japan|Chiba, Japan|Ehime, Japan|Fukuoka, Japan|Fukuoka, Japan|Hyogo, Japan|Hyogo, Japan|Kanagawa, Japan|Kyoto, Japan|Miyagi, Japan|Miyagi, Japan|Okayama, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan|Shizuoka, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Yamaguchi, Japan|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Groningen, Netherlands|Maastricht, Netherlands|Lima, Peru|Lima, Peru|Lima, Peru|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Ivanovo, Russian Federation|Krasnodar, Russian Federation|Omsk, Russian Federation|Saint-Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Kragujevac, Serbia|Bloemfontein, South Africa|Johannesburg, South Africa|Sandton, South Africa|Sabadell, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain|Changhua, Taiwan|Kaohsiung, Taiwan|Taipei, Taiwan|Cherkassy, Ukraine|Chernivtsi, Ukraine|Dnipropetrovsk, Ukraine|Sumy, Ukraine|Zaporizhzhya, Ukraine|Belfast, United Kingdom|Grimsby, United Kingdom|Leicester, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01456325"
253,"NCT01185847","A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer","Completed","No Results Available","All","Phase 2","90","Industry","Interventional","November 2010","September 2012","September 2012","August 20, 2010","null","January 1, 2016","Charleroi, Belgium|Leuven, Belgium|Liège, Belgium|Caen, France|Marseille, France|Saint Herblain, France|Toulouse, France|Bad Berka, Germany|Gauting, Germany|Grosshansdorf, Germany|Heidelberg, Germany|Köln, Germany|Mainz, Germany|Mannheim, Germany|Milano, Lombardia, Italy|Milan, Lombardia, Italy|Ancona, Marche, Italy|Lido Di Camaiore, Toscana, Italy|Livorno, Toscana, Italy|Perugia, Umbria, Italy|Lodz, Poland|Otwock, Poland|Warszawa, Poland|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Sevilla, Spain|London, United Kingdom","https://ClinicalTrials.gov/show/NCT01185847"
254,"NCT01297491","Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer","Completed","Has Results","All","Phase 2","63","Industry","Interventional","May 2011","October 2014","October 2014","February 16, 2011","February 2, 2016","March 11, 2016","Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States|Arizona Oncology Associates Tucson (Rudasill & La Cholla), Phoenix, Arizona, United States|Mayo Clinic - Arizona Mayo Scottsdale AZ, Scottsdale, Arizona, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr., Los Angeles, California, United States|University of California at San Diego, Moores Cancer Ctr SC, San Diego, California, United States|University of Colorado Univ CO, Aurora, Colorado, United States|Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer, Greenwood Village, Colorado, United States|H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt, Tampa, Florida, United States|Emory University School of Medicine/Winship Cancer Institute Emory 2, Atlanta, Georgia, United States|Rush University Medical Center SC, Chicago, Illinois, United States|University of Chicago Medical Center Unvi Chi, Chicago, Illinois, United States|University of Kansas Cancer Center Univ of KS, Kansas City, Kansas, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Fallon Clinic at Worcester Medical Center Fallon Clinic Worcester Med, Worcester, Massachusetts, United States|Karmanos Cancer Institute Wayne St Karmanos, Detroit, Michigan, United States|Washington University School of Medicine Washington University (16), St. Louis, Missouri, United States|Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2), Morristown, New Jersey, United States|Overlook Hospital - Carol G Simon Cancer Center Carol G Simon, Summit, New Jersey, United States|Roswell Park Cancer Institute Rosewell, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center Sloan Kettering, NY, New York, United States|Duke University Medical Center Duke 2, Durham, North Carolina, United States|MetroHealth Medical Center Dept.ofMetroHealthMedCtr.(2), Cleveland, Ohio, United States|University of Oklahoma Health Sciences Center Dept. of Oklahoma Univ. HSC, Oklahoma City, Oklahoma, United States|Northwest Cancer Specialists Compass Oncology -BKM, Portland, Oregon, United States|University of Pittsburgh Medical Center SC-2, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina MUSC, Charleston, South Carolina, United States|Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas, United States|Texas Oncology South Texas Oncology, Dallas, Texas, United States|U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office, Dallas, Texas, United States|Virginia Oncology Associates VOA - Lake Wright (2), *see Various Departments*, Virginia, United States|University of Wisconsin Univ WIsc 2, Madison, Wisconsin, United States|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Libramont, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Florianopolis, SC, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Marseille cedex 20, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Gauting, Germany|Novartis Investigative Site, Grosshansdorf, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Recklinghausen, Germany|Novartis Investigative Site, Hongkong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Deszk, Hungary|Novartis Investigative Site, Mátraháza, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Kurashiki, Okayama, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Mataro, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01297491"
255,"NCT01634061","Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients","Completed","No Results Available","Male","Phase 1","43","Industry","Interventional","September 2012","July 2015","July 2015","July 6, 2012","null","September 14, 2015","Cedars Sinai Medical Center SC, Los Angeles, California, United States|Hackensack University Medical Center Hackensack Univ, Hackensack, New Jersey, United States|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01634061"
256,"NCT01360554","ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 3","878","Industry","Interventional","June 16, 2011","September 30, 2013","September 14, 2015","May 25, 2011","May 24, 2017","May 24, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Northwest Alabama Cancer Center, Florence, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|University of South Alabama Medical Center, Mobile, Alabama, United States|Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Ironwood physicians P C dba Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Gilbert, Arizona, United States|Desert Oncology Associates dba Ironwood Cancer and Research Centers, Mesa, Arizona, United States|Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Mesa, Arizona, United States|Highlands Oncology Group PA, Fayetteville, Arkansas, United States|Highlands Oncology Group, PA, Rogers, Arkansas, United States|Central Hematology Oncology Medical Group Inc., Alhambra, California, United States|UCLA Hematology Oncology-Alhambra, Alhambra, California, United States|City of Hope, Duarte, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Drug Management Only, Los Angeles, California, United States|Drug Managerrent Only:, Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Administrative Address: UCLA Hematology Oncology-Clinical Research Unit (CRU), Los Angeles, California, United States|Drug Shipment Address: Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States|Regulatory Management Only:, Los Angeles, California, United States|Regulatory Management:, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|TORI Central Administration, Los Angeles, California, United States|Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, United States|UCLA/Pasadena Healthcare Hematology-Oncology, Pasadena, California, United States|Central Hematology Oncology Medical Group, Inc., Pasadena, California, United States|Cancer Care Associates Medical Group Inc., Redondo Beach, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|UCLA Hematology Oncology-Parkside, Santa Monica, California, United States|UCLA Hematology Oncology-Santa Monica, Santa Monica, California, United States|UCLA Santa Monica Medical Center & Orthopedic Hospital, Santa Monica, California, United States|City of Hope South Pasadena Cancer Center, South Pasadena, California, United States|UCLA/Santa Clarita Valley Cancer Center, Valencia, California, United States|UCLA Cancer Center, Westlake Village, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Florida Hospital, Orlando, Florida, United States|Cancer Institute of Florida, Orlando, Florida, United States|Hematology and Oncology Consultants, P.A., Orlando, Florida, United States|Investigational Drug Services, Florida Hospital, Orlando, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Austell, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Carrollton, Georgia, United States|Northwest Georgia Oncology Centers, PC, Cartersville, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Atlanta Cancer Care, Decatur, Georgia, United States|Georgia Cancer Specialists, Decatur, Georgia, United States|The Cancer Center at DeKalb Medical, Decatur, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Douglasville, Georgia, United States|Suburban Hematology-Oncology Associates, P.C., Duluth, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Oncology Specialists of North Georgia, LLC, Gainesville, Georgia, United States|The Longstreet Clinic Cancer Center, Gainesville, Georgia, United States|Suburban Hematology-Oncology Associates, P.C., Lawrenceville, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Suburban Hematology-Oncology Associates, P.C., Snellville, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Ingalls Memorial Hospital - In-Patient Pharmacy, Harvey, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Monroe Medical Associates, Harvey, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Monroe Medical Associates, Tinley Park, Illinois, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Monroe Medical Associates, Munster, Indiana, United States|Cedar Valley Medical Specialists, P.C., Waterloo, Iowa, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|University Medical Center, Inc., Louisville, Kentucky, United States|University Medical Center, Inc, Louisville, Kentucky, United States|Baptist Hospital East, Louisville, Kentucky, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer Institute at Farmington Hills, Farmington Hills, Michigan, United States|North Mississippi Hematology and Oncology Associates, Ltd., Starkville, Mississippi, United States|North Mississippi Hematology and Oncology Associates, Ltd.,, Tupelo, Mississippi, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine-IDS Pharmacy, Saint Louis, Missouri, United States|Siteman Cancer Center-St. Peters, Saint Peters, Missouri, United States|Dartmouth-Hitchcock Medical Center /Mary Hitchcock Memorial Hospital, Lebanon, New Hampshire, United States|Oncology and Hematology Specialists, P.A., Denville, New Jersey, United States|Stony Brook University-Cancer Center, Stony Brook, New York, United States|Carolina Oncology Specialists PA, Hickory, North Carolina, United States|Carolina Oncology Specialists PA, Lenoir, North Carolina, United States|Mercy clinic oklahoma communities, Inc. - Mercy clinic oncology/Hematology - Norman, Norman, Oklahoma, United States|Mercy Physicians of Oklahoma-Communities, Inc. - Mercy Clinic Oncology/Hematology - McAuley, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City - Oncology Infusion, Oklahoma City, Oklahoma, United States|Good Samaritan Hospital Samaritan Ambulatory Infusion Services, Corvallis, Oregon, United States|Samaritan Hematology & Oncology Consultants, Corvallis, Oregon, United States|Samaritan Pharmacy Services, Corvallis, Oregon, United States|Samaritan North Lincoln Hospital, Lincoln City, Oregon, United States|Samaritan Pacific Communities Hospital, Newport, Oregon, United States|Guthrie Clinic, Limited, Sayre, Pennsylvania, United States|Robert Packer Hospital, Sayre, Pennsylvania, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Kadlec Medical Center, Richland, Washington, United States|Outpatient Imaging Center, Richland, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Sozialmedizinisches Zentrum Baumgartner Hoehe - Otto Wagner Spital und Pflegezentrum, Vienna, Austria|Institut Jules Bordet, Brussels, Belgium|Laboratoire de la Porte de Hall, Brussels, Belgium|Grand Hopital de Charleroi Oncologie-Hematologie, Charleroi, Belgium|CHU Ambroise Parre- Service Biologie Clinique, Mons, Belgium|Heilig Hart Ziekenhuis Roeselare-Menen, Roeselare, Belgium|Tumour Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Union Hospital, Tongji Medical College of Huazhong University of Science & Technology/Cancer Center, Wuhan, Hubei, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Shanghai Pulmonary Hospital, Shanghai, China|Aalborg Sygehus Syd, Aalborg, Denmark|Helsingin yliopistollinen sairaala, Meilahden kolmiosairaala, keuhkosairauksien poliklinikka, Helsinki, Finland|Satakunnan keskussairaala/Keuhkosairauksien osasto A4, Pori, Finland|Centre Georges Francois Leclerc, Dijon, France|Hopital Albert Michallon, Grenoble cedex 09, France|Hôpital Paris Saint Joseph, Paris, France|CHU de Poitiers, Poitiers Cedex, France|Institut de Cancerologie de lOuest - Rene Gauducheau, Saint Herblain cedex, France|Universitaetsklinikum Aachen, Aachen, Germany|Asklepios Fachkliniken Muenchen-Gauting, Gauting, Germany|Lungenfachklinik Immenhausen, Immenhausen, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet, Mainz, Germany|Krankenhaus Bethanien, Medizinische Klinik III, Moers, Germany|University Hospital of Larissa, Larissa, Thessaly, Greece|Sotiria General Hospital of Athens, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|Semmelweis Egyetem Pulmonologiai Klinika, Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Veszprem Megyei Onkormanyzat Tudogyogyintezete, Farkasgyepu, Hungary|Pandy Kalman Megyei Korhaz, Aktiv Tudogyogyaszat, Gyula, Hungary|Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft., Nyiregyhaza, Hungary|Zala Megyei Korhaz, Pulmonologiai Osztaly, Zalaegerszeg-Pozva, Hungary|Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|Tata Memorial Centre, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharastra, India|St Vincent's University Hospital, Dublin, Leinster, Ireland|Beaumont Hospital, Dublin, Leinster, Ireland|St. James Hospital, Dublin, Ireland|Oncology Department, Waterford, Ireland|Aichi cancer center central hospital /Thoracic Oncology, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-city, Ehime, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kanazawa University Hospital, Kanazawa city, Ishikawa, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Kurashiki Central Hospital, Kurashiki, Okayama, Japan|Okayama University Hospital, Okayama-city, Okayama, Japan|National Hospital Organization Kinki-chuo Chest Medical Center, Sakai-Shi, Osaka-fu, Japan|Osaka City General Hospital Department of Clinical Oncology, Osaka-city, Osaka, Japan|Kinki University Hospital, Osakasayama-shi, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|National Hospital Organization, Yamaguchi-Ube Medical Center, Ube-shi, Yamaguchi, Japan|National Hp. Org. Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center/Department of Thoracic Oncology, Fukuoka, Japan|Kyushu University Hospital Respiratory Medicine, Fukuoka, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Clinical Trial Center, Seoul, Korea, Republic of|Asan Medical Center, Department of Oncology, Seoul, Korea, Republic of|Oaxaca Site Management Organization, Oaxaca, Mexico|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Mazowieckie, Poland|Zoz All-Medi, Otwock, Mazowieckie, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Mazowieckie, Poland|Nukleomed, Warsaw, Mazowieckie, Poland|City Hospital #2 Krasnodar Multi-Field Diagnostic and Treatment Association, Krasnodar, Krasnodarskij Kraj, Russian Federation|Oncology Center # 2, Sochi, Krasnodarskij Kraj, Russian Federation|Federal State Healthcare Clinical Hospital #101 of the Federal Biomedical Agency, Pyatigorsk, Stavropolskij Kraj, Russian Federation|Pyatigorsk Oncology Center, Pyatigorsk, Russian Federation|Clinic of Hospital Surgery, Saint-Petersburg, Russian Federation|Military Medical Academy n.a. S.M.Kirov, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|St.-Petersburg State Medical University I.P.Pavlov of Roszdrav, Saint-Petersburg, Russian Federation|Research Institute of Pulmonology, Saint-Petersburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|Univerzitna Nemocnica Bratislava, Klinika pneumologie a ftizeologie I- Oddelenie klinickej onkologie, Bratislava, Slovakia|Specializovana nemocnica sv. Svorada Zobor, n.o., Nitra, Slovakia|Fakultna nemocnica s poliklinikou, Nove Zamky, Slovakia|WCR: Wits Clinical Research, Parktown,Johannesburg, Gauteng, South Africa|GVI Oncology Clinical Research Unit, Kraaifontein, Western Cape, South Africa|Department of Oncotherapy, Bloemfontein, South Africa|GVI Oncology, Port Elizabeth, South Africa|Hospital General Universitario de Elche - Edificio UIAE, Elche, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Provincial de Castellon - Servicio de Oncologia, Castellón, Castellon, Spain|HOSPITAL DE LA SANTA CREU I SANT PAU - Pharmacy, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - AGDAC, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - Anatomia Patológica, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - Diagnostic per la Imatge i Med. Nuclear, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - Hospital de Día, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Provincial de Castellon (Farmacia), Castellon, Spain|Hospital Universitario 12 de Octubre-Radiology, Madrid, Spain|Hospital Universitario 12 de Octubre01, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario Virgen del Rocio. Hospital General Planta Baja. Servicio de Oncologia., Sevilla, Spain|KPE/Onkologikliniken, Karlstad, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Kantonsspital Aarau, Aarau, Switzerland|Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland|Hopitaux Universitaires de Geneve, Geneve 14, Switzerland|Ospedale Regionale di Locarno La Carita, Locarno, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Kent Oncology Centre, Maidstone, Kent, United Kingdom|New Cross Hospital - Royal Wolverhampton Hospital NHS Trust, Wolverhampton, West Midlands, United Kingdom|North Middlesex NHS Trust, Edmonton, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Cancer Clinical Trials Unit, London, United Kingdom|Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Lung and Melanoma Research Team, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01360554"
257,"NCT02161770","Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment","Completed","No Results Available","All","Phase 1","30","Industry","Interventional","December 22, 2014","May 16, 2017","August 22, 2017","June 12, 2014","null","September 26, 2017","Research Site, San Diego, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Detroit, Michigan, United States|Research Site, Cleveland, Ohio, United States|Research Site, San Antonio, Texas, United States|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Angers Cedex 9, France|Research Site, Marseille Cedex 20, France|Research Site, Pierre Benite Cedex, France|Research Site, Rennes, France|Research Site, Saint Herblain, France|Research Site, Toulouse, France|Research Site, Seoul, Korea, Republic of|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT02161770"
258,"NCT01887886","A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation","Completed","No Results Available","All","Phase 3","10","Industry","Interventional","December 2013","February 2015","February 2015","June 27, 2013","null","November 2, 2016","Bakersfield, California, United States|Fullerton, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Luis Obispo, California, United States|Fort Myers, Florida, United States|Orlando, Florida, United States|Saint Petersburg, Florida, United States|Chicago, Illinois, United States|Marrero, Louisiana, United States|Metairie, Louisiana, United States|St. Louis, Missouri, United States|Canton, Ohio, United States|Nashville, Tennessee, United States|Caen, France|Lyon, France|Nantes, France|Grosshansdorf, Germany|Oldenburg, Germany|Villingen-Schwenningen, Germany|Ehime, Japan|Okayama, Japan|Yamaguchi, Japan|Gwangju, Korea, Republic of|Suwon-si,, Korea, Republic of|Tanjung Bungah, Malaysia|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT01887886"
259,"NCT01903993","A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - ""POPLAR""","Completed","Has Results","All","Phase 2","287","Industry","Interventional","August 6, 2013","November 19, 2015","August 31, 2018","July 19, 2013","May 23, 2017","October 16, 2018","Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Centers - Colorado Springs (Circle), Lone Tree, Colorado, United States|Ocala Oncology Center, Ocala, Florida, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|New England Cancer Specialists, Scarborough, Maine, United States|Karmanos Cancer Institute.., Detroit, Michigan, United States|Billings Clinic; Research Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States|The Valley Hospital, Paramus, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Broome Oncology - Binghamton, Binghamton, New York, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Center for Biomedical Research LLC, Knoxville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology, P.A. - Fort Worth, Fort Worth, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|UZ Leuven Gasthuisberg, Leuven, Belgium|Chr de La Citadelle, Liège, Belgium|Cite de La Sante de Laval; Hemato-Oncologie, Laval, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital Gabriel Montpied; Service de Pneumologie, Clermont-ferrand, France|Hôpital Nord Michallon; Pneumologie, La Tronche, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll; Pneumologie, St Brieuc, France|Hopital Larrey; Pneumologie, Toulouse, France|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, Regensburg, Germany|Citta Ospedaliera; Divisione Oncologia Medica, Avellino, Campania, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System; Pharmacy, Seoul, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdańsk, Poland|Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii, Lodz, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, Poland|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Universitetssjukhuset Linköping; Lungmedicinkliniken, Linköping, Sweden|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, Turkey|Royal Free Hospital; Dept of Oncology, London, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Charing Cross Hospital; Medical Oncology., London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01903993"
260,"NCT01204749","TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer","Completed","No Results Available","Female","Phase 3","919","Industry","Interventional","November 2010","March 2013","December 2016","September 17, 2010","null","December 15, 2016","Research Site, Phoenix, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Englewood, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, Hollywood, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Boise, Idaho, United States|Research Site, Peoria, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Metairie, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Brightwaters, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Bendigo, Victoria, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, ItajaÃ-, Santa Catarina, Brazil|Research Site, Ribeirao Preto, SÃ£o Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, Gabrovo, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Temuco, CautÃ-n, Chile|Research Site, Valparaiso, ValparaÃ-so, Chile|Research Site, Zagreb, Croatia|Research Site, Brno, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Amiens, France|Research Site, Angers, France|Research Site, Avignon Cedex 2, France|Research Site, Bayonne, France|Research Site, Besancon Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Lille Cedex, France|Research Site, Lyon, France|Research Site, Marseille cedex 05, France|Research Site, Marseille Cedex 09, France|Research Site, Marseille, France|Research Site, Montpellier Cedex 5, France|Research Site, Nancy, France|Research Site, Nantes Cedex 2, France|Research Site, Nice cedex 2, France|Research Site, OrlÃ©ans cedex 2, France|Research Site, Paris cedex 15, France|Research Site, PÃ©rigueux cedex, France|Research Site, Reims Cedex, France|Research Site, Saint GrÃ©goire cedex, France|Research Site, Saint Herblain, France|Research Site, Strasbourg, France|Research Site, Villejuif cedex, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Kefar Sava, Israel|Research Site, Tel Hashomer, Israel|Research Site, Tel-Aviv, Israel|Research Site, Benevento, Italy|Research Site, Catania, Italy|Research Site, Cosenza (CS), Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Potenza, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Nagoya-city, Aichi, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kure-city, Hiroshima, Japan|Research Site, Sapporo-city, Hokkaido, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Morioka-city, Iwate, Japan|Research Site, Niigata-city, Niigata, Japan|Research Site, Osakasayama-city, Osaka, Japan|Research Site, Hidaka-Shi, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Yonago-city, Tottori, Japan|Research Site, Kurume-city, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Johor Bahru, Johor, Malaysia|Research Site, Kota Bahru, Kelantan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Coimbra, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Suceava, Romania|Research Site, Targu Mures, Romania|Research Site, Ivanovo, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Ljubljana, Slovenia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kraaifontein, Western Cape, South Africa|Research Site, Observatory, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, CÃ³rdoba, AndalucÃ-a, Spain|Research Site, Huelva, AndalucÃ-a, Spain|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Sevilla, AndalucÃ-a, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Salamanca, Castilla LeÃ³n, Spain|Research Site, Badalona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Elche, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, San SebastiÃ¡n, PaÃ-s Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, UmeÃ¥, Sweden|Research Site, Uppsala, Sweden|Research Site, Baden, Switzerland|Research Site, Bellinzona, Switzerland|Research Site, Chur, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Zurich, Switzerland|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01204749"
261,"NCT01519804","A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer","Completed","No Results Available","All","Phase 2","108","Industry","Interventional","April 2012","January 2014","September 2015","January 27, 2012","null","September 2, 2016","Huntsville, Alabama, United States|Scottsdale, Arizona, United States|Bakersfield, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Northridge, California, United States|Sacramento, California, United States|San Luis Obispo, California, United States|Santa Barbara, California, United States|Stanford, California, United States|Grand Junction, Colorado, United States|Boynton Beach, Florida, United States|Orlando, Florida, United States|Weston, Florida, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Harvey, Illinois, United States|Fort Wayne, Indiana, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Muncie, Indiana, United States|Metairie, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Hickory, North Carolina, United States|Cleveland, Ohio, United States|Middletown, Ohio, United States|Bend, Oregon, United States|Pittsburgh, Pennsylvania, United States|Seattle, Washington, United States|Buenos Aires, Argentina|La Rioja, Argentina|Santa Rosa, Argentina|Grenoble, France|Lyon, France|Paris, France|Rennes, France|Berlin, Germany|Göttingen, Germany|Halle (Saale), Germany|Immenhausen, Germany|München, Germany|Münster, Germany|Afula, Israel|Ashkelon, Israel|Tel Aviv, Israel|Zerifin, Israel|Avellino, Campania, Italy|Napoli, Campania, Italy|Udine, Friuli-Venezia Giulia, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Riga, Latvia|Pamplona, Navarra, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Aberdeen, United Kingdom|Birmingham, United Kingdom|Bournemouth, United Kingdom|Leeds, United Kingdom","https://ClinicalTrials.gov/show/NCT01519804"
262,"NCT00961415","AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 3","376","Industry","Interventional","August 2009","May 2011","May 2011","August 19, 2009","February 22, 2016","February 22, 2016","Beziers, France|Bordeaux, France|Bron, France|Caen, France|Caen, France|Clermont-ferrand, France|Creteil, France|GAP, France|Gleize, France|La Source, France|La Tronche, France|Lille, France|Limoges, France|Lyon, France|Marseille, France|Nancy, France|Nimes, France|Paris, France|Paris, France|Paris, France|Perpignan, France|Pierre Benite, France|Reims, France|Saint Priest En Jarez, France|Strasbourg, France|Toulon, France|Tours, France|Augsburg, Germany|Bad Berka, Germany|Berlin, Germany|Bonn, Germany|Ebensfeld, Germany|Frankfurt, Germany|Freiburg, Germany|Gauting, Germany|Grosshansdorf, Germany|Halle (Saale), Germany|Hamburg, Germany|Immenhausen, Germany|Karlsruhe, Germany|Leipzig, Germany|Minden, Germany|Muenchen, Germany|Oldenburg, Germany|Alexandroupolis, Greece|Napoli, Campania, Italy|Aviano, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Novara, Piemonte, Italy|Lecce, Puglia, Italy|Sassari, Sardegna, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Bundang City, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amersfoort, Netherlands|Amsterdam, Netherlands|Breda, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Haarlem, Netherlands|Hertogenbosch, Netherlands|Nieuwegein, Netherlands|Rotterdam, Netherlands|Sittard-Geleen, Netherlands|Zaandam, Netherlands|Balashikha, Russian Federation|Irkutsk, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation|Palma de Mallorca, Islas Baleares, Spain|Las Palmas de Gran Canaria, Las Palmas, Spain|La Laguna, Tenerife, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Gävle, Sweden|Linköping, Sweden|Lund, Sweden|Uppsala, Sweden|Zürich, Switzerland|Antalya, Turkey|Izmir, Turkey|Al Ain, United Arab Emirates","https://ClinicalTrials.gov/show/NCT00961415"
263,"NCT00760929","A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).","Completed","No Results Available","All","Phase 2","167","Industry","Interventional","November 2008","June 2010","June 2010","September 26, 2008","null","November 2, 2016","Beverly Hills, California, United States|New Port Richey, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Highland Park, Illinois, United States|Joliet, Illinois, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Hickory, North Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Richmond, Virginia, United States|St. Leonards, New South Wales, Australia|Adelaide, South Australia, Australia|Terrace Gardens, South Australia, Australia|Frankston, Victoria, Australia|Nedlands, Western Australia, Australia|Brussel, Belgium|Bruxelles, Belgium|Charleroi, Belgium|Edegem, Belgium|Leuven, Belgium|Liège, Belgium|Oshawa, Ontario, Canada|La Tronche, France|Lyon, France|Paris, France|Paris, France|Paris, France|Paris, France|Saint Herblain, France|Toulouse, France|Bad Berka, Germany|Berlin, Germany|Essen, Germany|Grosshansdorf, Germany|Halle (Saale), Germany|Hamburg, Germany|Heidelberg, Germany|Herne, Germany|Leverkusen, Germany|Mannheim, Germany|Muenchen, Germany|Oldenburg, Germany|Dublin, Ireland|Reggio Emilia, Emilia-Romagna, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Orbassano, Piemonte, Italy|Perugia, Umbria, Italy|Gdansk, Poland|Krakow, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|La Coruña, Spain|Madrid, Spain|Malaga, Spain|Guildford, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00760929"
264,"NCT00558272","Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease","Completed","Has Results","All","Phase 2","139","Industry","Interventional","February 2008","January 2010","August 2012","November 14, 2007","June 27, 2011","May 27, 2013","Research Site, Pleasant Hill, California, United States|Research Site, Sacramento, California, United States|Research Site, Middlebury, Connecticut, United States|Research Site, Aventura, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Arhus N, Denmark|Research Site, Frederica, Denmark|Research Site, Herlev, Denmark|Research Site, Holstebro, Denmark|Research Site, Kristiansand, Norway|Research Site, Oslo, Norway|Research Site, Lisboa, Portugal|Research Site, Barcelona, Cataluna, Spain|Research Site, Lerida, Cataluna, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Uppsala, Sweden|Research Site, Cardiff, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00558272"
265,"NCT00867009","A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 2","113","Industry","Interventional","April 2009","May 2011","September 2014","March 23, 2009","May 16, 2012","June 15, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salzburg, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wels, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuebingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bari, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palermo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Potenza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Treviso, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., S-Hertogenbosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lleida, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reus, Spain","https://ClinicalTrials.gov/show/NCT00867009"
266,"NCT02913443","A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)","Completed","No Results Available","All","Phase 1","18","Industry","Interventional","December 20, 2016","October 24, 2017","October 24, 2017","September 23, 2016","null","October 19, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|Institut Gustave Roussy, Villejuif, France|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02913443"
267,"NCT00700180","A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.","Completed","Has Results","All","Phase 2","303","Industry","Interventional","September 2008","September 2012","September 2012","June 18, 2008","September 25, 2014","September 25, 2014","St. Leonards, New South Wales, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Box Hill, Victoria, Australia|Fitzroy, Victoria, Australia|Antwerpen, Belgium|Liege, Belgium|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Ostrava, Czech Republic|Praha, Czech Republic|Odense, Denmark|Paris, France|Rouen, France|Bad Berka, Germany|Grosshansdorf, Germany|Hamburg, Germany|Oldenburg, Germany|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Edeleny, Hungary|Sopron, Hungary|Szombathely, Hungary|Torokbalint, Hungary|Milano, Italy|Milan, Italy|Orbassano, Italy|Roma, Italy|Den Haag, Netherlands|Enschede, Netherlands|Hoorn, Netherlands|Nieuwegein, Netherlands|Rotterdam, Netherlands|Poznan, Poland|Warszawa, Poland|Zabrze, Poland|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|St Petersburg, Russian Federation|Barakaldo, Vizcaya, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Changhua, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Aberdeen, United Kingdom|Chelmsford, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT00700180"
268,"NCT01280201","Pazopanib as Single Agent in Advanced NETs","Completed","No Results Available","All","Phase 2","44","Other","Interventional","December 2010","April 2013","November 2015","January 20, 2011","null","August 18, 2016","Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01280201"
269,"NCT01104584","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","Completed","Has Results","All","Phase 3","460","Industry","Interventional","May 2010","September 2011","January 2012","April 15, 2010","November 11, 2014","November 11, 2014","Tucson, Arizona, United States|Oakland, California, United States|Englewood, Colorado, United States|Chicago, Illinois, United States|New York, New York, United States|Columbus, Ohio, United States|Providence, Rhode Island, United States|San Antonio, Texas, United States|Tacoma, Washington, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Erlangen, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Göttingen, Niedersachsen, Germany|Göttingen, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Mumbai, Maharashtra, India|Delhi, India|Mumbai, India|Eindhoven, EJ, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Bydgoszcz, Poland|Gliwice, Poland|Krakow, Poland|Szczecin, Poland|Warszawa, Poland|Sabadell, Barcelona, Spain|Alzira, Valencia, Spain|Barcelona, Spain|Cordoba, Spain|Girona, Spain|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taizung, Taiwan","https://ClinicalTrials.gov/show/NCT01104584"
270,"NCT02374099","Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant","Completed","No Results Available","Female","Phase 2","97","Industry","Interventional","March 13, 2015","December 13, 2016","November 21, 2017","February 27, 2015","null","July 9, 2018","Ironwood Cancer and Research Center, Chandler, Arizona, United States|Virginia G Piper Cancer Center, Scottsdale, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University of Kansas Hospital, Westwood, Kansas, United States|Henry Ford Health System, Detroit, Michigan, United States|Clinical Research Alliance, New York, New York, United States|Medical Oncology Associates, Spokane, Washington, United States|Grand Hopital de Charleroi, Charleroi, Belgium|AZ Groeninge, Kortrijk, Belgium|Clinique Sainte Elisabeth - Service d'Oncologie, Namur, Belgium|GasthuisZusters Antwerpen, Wilrijk, Belgium|Centre Regional de lutte contre le cancer Paul Papin, Angers, France|Institut Bergonie, Borddeaux Cedex, France|Hopital Pitie Salpetriere, Paris, France|Centre Rene Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique, Saint Herblain, France|Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany|Hamatologisch Onkologische Praxis Eppendorf, Hamburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|TU München - Klinikum rechts der Isar, München, Germany|Policlinico S. Orsola - Malpighi, Bologna, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Istituto Nazionale Dei Tumori, Milano, Italy|IEO- Istituto Europeo di Oncologia, Milano, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Umberto I, Roma, Italy|Policlinico Universitario A Gemelli, Roma, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall D Hebron, Barcelona, Spain|Complejo Universitario La Coruna, La Coruna, Spain|Hospital General Gregorio Maranon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario Virgen de La Victoria, Malaga, Spain|Hospital Virgen del Rocio, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02374099"
271,"NCT01289041","BKM120 as Second-line Therapy for Advanced Endometrial Cancer","Completed","Has Results","Female","Phase 2","71","Industry","Interventional","February 2011","March 2014","March 2014","February 3, 2011","April 10, 2015","April 10, 2015","St. Joseph's Hospital & Medical Center St Joseph's, Phoenix, Arizona, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Morristown Memorial Hospital MMH, Morristown, New Jersey, United States|Carolinas HealthCare Systems Blumenthal Cancer Center, Charlotte, North Carolina, United States|University of Oklahoma Health Sciences Center OU Health, Oklahoma City, Oklahoma, United States|Sarah Cannon Research Institute SCRI (2), Nashville, Tennessee, United States|Texas Oncology, P.A. Austin, Bedford, Texas, United States|South Texas Oncology and Hematology, PA South Tex Onc, San Antonio, Texas, United States|Cancer Care Northwest CC Northwest- Spokane South(3), Spokane, Washington, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Le Mans Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01289041"
272,"NCT01379534","A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer","Completed","Has Results","Female","Phase 2","53","Industry","Interventional","November 2011","March 2014","March 2014","June 23, 2011","March 31, 2015","May 20, 2015","University of South Alabama / Mitchell Cancer Institute Univ South Alabama, Mobile, Alabama, United States|St. Jude Heritage Medical Group St Jude, Fullerton, California, United States|USC/Kenneth Norris Comprehensive Cancer Center USC 2, Los Angeles, California, United States|Cedars Sinai Medical Center TKI258A2211 (SC), Los Angeles, California, United States|University of California at Los Angeles UCLA 3, Los Angeles, California, United States|Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer, Greenwood Village, Colorado, United States|Florida Hospital Cancer Institute FL Hosp, Orlando, Florida, United States|Indiana University Health Goshen Center for Cancer IU Simon Cancer, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics SC, Iowa City, Iowa, United States|Dana Farber Cancer Institute SC, Boston, Massachusetts, United States|Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, United States|Hope A Woman's Cancer Center, Asheville, North Carolina, United States|Duke University Medical Center Duke3, Durham, North Carolina, United States|Community Oncology Research Network, Chattanooga, Tennessee, United States|The West Clinic SC, Memphis, Tennessee, United States|Texas Oncology, P.A. Austin, Bedford, Texas, United States|Texas Oncology, P.A. Tex Onc (3), Bedford, Texas, United States|Texas Oncology, P.A. SC, Fort Worth, Texas, United States|South Texas Oncology and Hematology, PA South Tex Onc, San Antonio, Texas, United States|Virginia Oncology Associates VOA - Lake Wright, *see Various Departments*, Virginia, United States|Cancer Care Northwest SC, Spokane, Washington, United States|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Málaga, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT01379534"
273,"NCT01923168","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women","Completed","Has Results","Female","Phase 2","340","Industry","Interventional","March 11, 2014","July 7, 2017","July 8, 2017","August 15, 2013","September 14, 2018","September 14, 2018","University of Alabama at Birmingham/ Kirklin Clinic Univ AL - PI, Birmingham, Alabama, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Los Angeles Hematology/Oncology Medical Group Onc Dept., Los Angeles, California, United States|University of California at Los Angeles UCLA SC, Los Angeles, California, United States|University of California San Francisco BYL719A2201 - SC, San Francisco, California, United States|Emory University School of Medicine/Winship Cancer Institute SC, Atlanta, Georgia, United States|Mercy Medical Center Medical Oncology & Hematology, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Johns Hopkins Med. BYL719A2201, Baltimore, Maryland, United States|Dana Farber Cancer Institute BYL719A2201, Boston, Massachusetts, United States|Mayo Clinic - Rochester BYL719A2201 - SC, Rochester, Minnesota, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Duke University Medical Center Duke University Medical Center, Durham, North Carolina, United States|Northwest Cancer Specialists Vancouver Loc, Portland, Oregon, United States|Vanderbilt Ingram Cancer Center Vanderbilt Health 100 Oaks, Nashville, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas, Texas, United States|Texas Oncology Texas Oncology - Sammons, Dallas, Texas, United States|Texas Oncology Houston Memorial City SC, Houston, Texas, United States|Cancer Care Centers of South Texas HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|Cancer Therapy & Research Center UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, United States|Virginia Oncology Associates SC, Norfolk, Virginia, United States|Seattle Cancer Care Alliance SC-3, Seattle, Washington, United States|Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, United States|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Dornbirn, Vorarlberg, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Villach, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Sint Niklaas, Belgium|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Koto-ku, Tokyo, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, San Sebastián, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01923168"
274,"NCT01246440","Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission","Completed","No Results Available","Female","Phase 2","39","Other|Industry","Interventional","June 2010","February 2014","December 2014","November 23, 2010","null","August 11, 2016","Institut Català d'Oncologia de Girona, Girona, Barcelona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Madrdi, Spain|Hospital Universitario Fundación Alcorcon, Alcorcon, Madrid, Spain|Hospital de la Vall d'Hebron, Barcelona, Spain|Hospital Gregorio Marañon, Madrid, Spain|M.D. Anderson, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Son Dureta, Mallorca, Spain|Hospital Jose Maria Morales Meseguer, Murcia, Spain|Hospital Universitario de Valdecilla, Santander, Spain|Hosptial Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01246440"
275,"NCT01788566","A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer","Completed","Has Results","All","Phase 2","61","Industry","Interventional","March 2013","August 2014","December 2015","February 11, 2013","June 27, 2016","June 27, 2016","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deerfield Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Farmington Hills, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamilton, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durango, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eindhoven, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Majadahonda, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT01788566"
276,"NCT00617669","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer","Completed","Has Results","Male","Phase 3","1494","Industry","Interventional","January 2008","May 2011","July 2011","February 18, 2008","May 31, 2012","September 10, 2012","Research Site, Greenbrae, California, United States|Research Site, San Diego, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, PORTUGALt St. Lucie, Florida, United States|Research Site, Rockville, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Santa Fe, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Fortaleza, Ceara/ LA, Brazil|Research Site, Goiania, Goias/ LA, Brazil|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas GERMANYais, Brazil|Research Site, Curitiba, Parana/ Brazil, Brazil|Research Site, Londrina, PR, Brazil|Research Site, PORTUGALto Alegre, Rio Grande do Sul/ LA, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Ribeirao Preto, Sao Paulo/ LA, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, CZECHOSLOVAKIA Republic, Czech Republic|Research Site, Jablonec nad Nisou, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague 2, Czech Republic|Research Site, Prague 6, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Seinajoki, Finland|Research Site, La Roche sur Yon, FRANCEnce, France|Research Site, Marseille, FRANCEnce, France|Research Site, Paris, FRANCEnce, France|Research Site, Reims, FRANCEnce, France|Research Site, Villejuif, FRANCEnce, France|Research Site, Paris, France|Research Site, Saint Herblain, France|Research Site, Hannover, GERMANYmany, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Emmendingen, Germany|Research Site, Kirchheim-Teck, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Muenster, Germany|Research Site, Tuebingen, Germany|Research Site, Wuppertal, Germany|Research Site, Budapest, HUNGARYary, Hungary|Research Site, Gyor, HUNGARYary, Hungary|Research Site, Miskolc, HUNGARYary, Hungary|Research Site, Ny Regyh Za, HUNGARYary, Hungary|Research Site, Szeged, HUNGARYary, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkota, West Bengal, India|Research Site, Delhi, India|Research Site, New Delhi, India|Research Site, Genoa, Italy|Research Site, Lugo (RA), Italy|Research Site, Rome, Italy|Research Site, Cheongju, Chungbuk, Korea, Republic of|Research Site, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Nowon-gu, Seoul, Korea, Republic of|Research Site, Seodaemun-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Nijmegen, Netherlands|Research Site, Cercado de Arequipa, Arequipa, Peru|Research Site, Cercado, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lublin, POLANDand, Poland|Research Site, Swidnica, POLANDand, Poland|Research Site, Warszaa, POLANDand, Poland|Research Site, Koscierzyna, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, PORTUGALtugal, Portugal|Research Site, PORTUGALto, PORTUGALtugal, Portugal|Research Site, Bucharest, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, RUSSIAsia, Russian Federation|Research Site, Izhevsk, RUSSIAsia, Russian Federation|Research Site, Kursk, RUSSIAsia, Russian Federation|Research Site, Sochi, RUSSIAsia, Russian Federation|Research Site, Voronezh, RUSSIAsia, Russian Federation|Research Site, Belgrade, SERBIAbia, Serbia|Research Site, Beograd, SERBIAbia, Serbia|Research Site, Nis, SERBIAbia, Serbia|Research Site, Panorama, Cape Town, South Africa|Research Site, TyGERberg, Cape Town, South Africa|Research Site, Overport, Durban, South Africa|Research Site, Bloemfontein, South Africa|Research Site, PORt Elizabeth, South Africa|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, Locarno, Switzerland|Research Site, Sursee, Switzerland|Research Site, Kaohsiung, TAIWANwan, Taiwan|Research Site, TAIWANpei, TAIWANwan, Taiwan|Research Site, Reading, Berkshire, United Kingdom|Research Site, Westgate Road, Newcastle Upon Tyne, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00617669"
277,"NCT01130337","A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer","Completed","Has Results","All","Phase 2","36","Industry","Interventional","July 2010","June 2014","June 2014","May 26, 2010","October 1, 2015","October 1, 2015","Elche, Alicante, Spain|Oviedo, Asturias, Spain|Santander, Cantabria, Spain|San Sebastian, Guipuzcoa, Spain|Palma de Mallorca, Islas Baleares, Spain|Vigo, Pontevedra, Spain|La Laguna, Tenerife, Spain|Barakaldo, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Burgos, Spain|Cordoba, Spain|Granada, Spain|La Coruña, Spain|Leon, Spain|Lerida, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Orense, Spain|Sevilla, Spain|Sevilla, Spain|Toledo, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01130337"
278,"NCT01513083","A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function","Completed","No Results Available","All","Phase 1","28","Industry","Interventional","February 2012","September 2014","September 2014","January 20, 2012","null","November 2, 2016","Fort Myers, Florida, United States|Detroit, Michigan, United States|Portland, Oregon, United States|Nashville, Tennessee, United States|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Marseille, France|Paris, France|Toulouse, France|Catanzaro, Calabria, Italy|Udine, Friuli-Venezia Giulia, Italy|Barcelona, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01513083"
279,"NCT01703481","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma","Completed","No Results Available","All","Phase 1","188","Industry","Interventional","June 15, 2012","July 5, 2017","July 5, 2017","October 10, 2012","null","December 21, 2017","Birmingham, Alabama, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Santa Monica, California, United States|Denver, Colorado, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Goshen, Indiana, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Tyler, Texas, United States|Fairfax, Virginia, United States|Bordeaux, France|Caen Cedex 05, France|Dijon, France|Lyon, France|Marseille, France|Saint Herblain Cedex, France|Villejuif, France|Badalona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Pamplona, Spain|Sevilla, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01703481"
280,"NCT00819780","PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors","Completed","Has Results","All","Phase 2","285","Industry","Interventional","April 24, 2009","May 30, 2012","July 7, 2016","January 9, 2009","August 6, 2014","August 29, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Berkeley, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Fountain Valley, California, United States|Research Site, La Verne, California, United States|Research Site, Orange, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Alpharetta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Post Falls, Idaho, United States|Research Site, Gurnee, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Danville, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Lambertville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Mountain Lakes, New Jersey, United States|Research Site, Sparta, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, East Setauket, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, White River Junction, Vermont, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Vancouver, Washington, United States|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Libramont, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Magdeburg, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, Passau, Germany|Research Site, Regensburg, Germany|Research Site, WÃ¼rzburg, Germany|Research Site, Alba (CN), Italy|Research Site, Fano, Italy|Research Site, Genova, Italy|Research Site, Mantova, Italy|Research Site, Udine, Italy|Research Site, Varese, Italy|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Elche, Comunidad, Spain|Research Site, A CoruÃ±a, Galicia, Spain|Research Site, San SebastiÃ¡n De Los Reyes, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00819780"
281,"NCT00628251","Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer","Completed","Has Results","Female","Phase 2","97","Industry","Interventional","July 30, 2008","September 15, 2009","September 19, 2018","March 5, 2008","June 3, 2016","October 31, 2018","Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, East Melbourne, Australia|Research Site, Melbourne, Parkville, Australia|Research Site, Randwick, Australia|Research Site, Leuven, Belgium|Research Site, Köln, Germany|Research Site, München, Germany|Research Site, Haifa, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel Aviv, Israel|Research Site, Szczecin, Poland|Research Site, Barcelona, Spain|Research Site, Hospitalet deLlobregat, Spain|Research Site, Lund, Sweden|Research Site, Cambridge, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT00628251"
282,"NCT01045057","Clinical Feasibility of New Tracheoesophageal Puncture Set","Completed","Has Results","All","Phase 1|Phase 2","27","Industry","Interventional","December 2009","March 2011","April 2011","January 8, 2010","February 10, 2015","February 27, 2015","University Hospital Leuven, Leuven, Belgium|Bundeswehr Krankenhaus, Ulm, Germany|Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|Hospital de la Santa Creu I Sant Pau Universitat Autònoma de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01045057"
283,"NCT01183780","A Study in Second Line Metastatic Colorectal Cancer","Completed","Has Results","All","Phase 3","1072","Industry","Interventional","December 2, 2010","July 17, 2014","June 20, 2016","August 18, 2010","July 15, 2015","July 11, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sedona, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Duarte, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Escondido, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rancho Cucamonga, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterbury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boynton Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Port Saint Lucie, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Titusville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thomasville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harvey, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peoria, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warrenville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goshen, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muncie, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cherry Hill, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hackensack, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morristown, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hudson, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jamaica, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bend, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingston, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Willow Grove, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Abilene, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arlington, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beaumont, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denton, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flower Mound, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Worth, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garland, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., McAllen, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odessa, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Round Rock, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sugar Land, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Temple, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waco, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Webster, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfax, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newport News, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winchester, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane Valley, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucumain, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randwick, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Leonards, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wodonga, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woolloongabba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford Park, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elizabeth Vale, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krems, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bonheiden, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haine-St.- Paul, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Itajai, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Jose Do Rio Preto, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pardubice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Copenhagen, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odense, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Chaussee Saint Victor, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Balingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bamberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lübeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mönchengladbach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Weiden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ioannina, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kecskemet, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel-Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macerata, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reggio Emilia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gifu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tochigi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anyang, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deventer, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eindhoven, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sittard - Geleen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ljubljana, Slovenia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sabadell, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT01183780"
284,"NCT01057589","A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer","Completed","Has Results","All","Phase 2","66","Industry","Interventional","February 2010","February 2012","October 2012","January 27, 2010","March 19, 2013","September 18, 2013","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Herblain, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cardiff, South Glamorgan, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom","https://ClinicalTrials.gov/show/NCT01057589"
285,"NCT00885755","A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer","Completed","Has Results","Female","Phase 2","33","Industry","Interventional","August 13, 2009","February 18, 2013","February 18, 2013","April 22, 2009","October 5, 2015","March 29, 2018","Royal Prince Alfred Hospital; Medical Oncology, Camperdown, New South Wales, Australia|Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia|Eastern Health Breast Cancer Research, East Ringwood, Victoria, Australia|Border Medical Oncology; Murray Valley Private Hospital, Wodonga, Victoria, Australia|Mount Medical Center, Perth, Western Australia, Australia|Royal Perth Hospital; Department of Medical Oncology, Perth, Western Australia, Australia|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Karolinska Hospital; Oncology - Radiumhemmet, Stockholm, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Hull Royal Infirmary, Hull, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00885755"
286,"NCT01815294","A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer","Completed","No Results Available","All","Phase 1","54","Industry","Interventional","May 2013","December 2014","December 2014","March 21, 2013","null","December 4, 2015","Nashville, Tennessee, United States|San Antonio, Texas, United States|Brussel, Belgium|Wilrijk, Belgium|Barcelona, Spain|Madrid, Spain|Valencia, Spain|London, United Kingdom","https://ClinicalTrials.gov/show/NCT01815294"
287,"NCT00678535","Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer","Completed","Has Results","All","Phase 3","904","Industry","Interventional","June 2008","March 2012","February 2013","May 15, 2008","May 16, 2013","July 21, 2014","Research site, Rosario, Argentina|Research site, Coburg VIC, Australia|Research site, Frankston, VIC, Australia|Research site, Perth, Australia|Research site, Graz, Austria|Research site, Kufstein, Austria|Research site, Steyr, Austria|Research Site, Wien, Austria|Research Site, Zams, Austria|Research Site, Bonheiden, Belgium|Research Site, Bruxelles, Belgium|Research site, Verviers, Belgium|Research site, Campinas, Brazil|Research site, Ijui, Brazil|Research site, Jaú, Brazil|Research site, Porto Alegre, Brazil|Research site, Salvador, Brazil|Research site, Santo André, Brazil|Research site, Sâo Paulo, Brazil|Research site, Pleven, Bulgaria|Research site, Plovdiv, Bulgaria|Research site, Rousse, Bulgaria|Research site, Sofia, Bulgaria|Research site, Reñaca, Chile|Research site, Santiago, Chile|Research site, Temuco, Chile|Research site, Valparaiso, Chile|Research site, Beijing, China|Research site, Guangzhou, China|Research site, Hefei, China|Research site, Nanjing, China|Research site, Shanghai, China|Research site, Shenyang, China|Research Site, Brno, Czech Republic|Research Site, Hradec Králové, Czech Republic|Research site, Prague 5, Czech Republic|Research site, Besancon, France|Research site, Clermont Ferrand Cedex 1, France|Research site, La Roche sur Yon, France|Research site, Marseille, France|Research site, Paris 14, France|Research site, Rennes, France|Research Site, Berlin, Germany|Research site, Bielefeld, Germany|Research site, Braunschweig, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research site, Esslingen, Germany|Research site, Frankfurt, Germany|Research Site, Giessen, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research site, Köln, Germany|Research site, Ludwigshafen, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research site, Offenbach, Germany|Research Site, Regensburg, Germany|Research site, Schweinfurt, Germany|Research Site, Schwäbisch Hall, Germany|Research site, Stuttgart, Germany|Research Site, Timisoara, Germany|Research Site, Troisdorf, Germany|Research site, Ulm, Germany|Research site, Weiden, Germany|Research Site, Weilheim, Germany|Research site, Ioannina, Greece|Research site, Thessaloniki, Greece|Research site, Hong Kong, Hong Kong|Research site, Budapest, Hungary|Research site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Tatabanya, Hungary|Research site, Haifa, Israel|Research site, Jerusalem, Israel|Research site, Petach Tiqva, Israel|Research site, Ramat Gan, Israel|Research site, Tel Aviv, Israel|Research site, Ancona, Italy|Research site, Bologna, Italy|Research site, Milano, Italy|Research site, Napoli, Italy|Research site, Roma, Italy|Research site, Rozzano (Milano), Italy|Research site, Chiba, Japan|Research site, Ehime, Japan|Research site, Hokkaido, Japan|Research site, Koto-ku, Japan|Research site, Nagoya, Japan|Research site, Osaka, Japan|Research site, Saitama, Japan|Research site, Shizuoka, Japan|Research site, Tochigi, Japan|Research site, Tokyo, Japan|Research site, Yokohama, Japan|Research site, Anyang, Korea, Republic of|Research site, Daegu, Korea, Republic of|Research site, Inchon-si, Korea, Republic of|Research site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research site, Gdańsk, Poland|Research site, Lublin, Poland|Research site, Opole, Poland|Research site, Wroclaw, Poland|Research site, Sana Maria da Feira, Portugal|Research site, Baia-Mare, Romania|Research Site, Bucharest, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Iasi, Romania|Research site, Timisoara, Romania|Research site, Kazan, Russian Federation|Research site, Moscow, Russian Federation|Research site, Obninsk, Russian Federation|Research site, Saint-Petersburg, Russian Federation|Research Site, Alicante, Spain|Research site, El Palmar-Murcia, Spain|Research site, Lugo, Spain|Research site, Pamplona, Spain|Research Site, Santander, Spain|Research site, Seville, Spain|Research Site, Valencia, Spain|Research site, Changhua, Taiwan|Research site, Kaohsiung County, Taiwan|Research site, Kaohsiung, Taiwan|Research site, Taichung City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research site, Taoyuan, Taiwan|Research site, Guildford, United Kingdom|Research site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00678535"
288,"NCT01449370","Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer","Completed","Has Results","All","Phase 1","125","Industry","Interventional","October 2011","July 2015","January 2016","October 10, 2011","March 9, 2017","March 9, 2017","Boston, Massachusetts, United States|Detroit, Michigan, United States|Dallas, Texas, United States|Barcelona, Spain|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01449370"
289,"NCT02009631","A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors","Completed","No Results Available","All","Phase 1","45","Industry","Interventional","November 2013","December 2014","December 2014","December 12, 2013","null","November 20, 2017","Site Reference ID/Investigator# 116015, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 116016, San Antonio, Texas, United States|Site Reference ID/Investigator# 117320, Groningn, Netherlands|Site Reference ID/Investigator# 117336, Maastricht, Netherlands|Site Reference ID/Investigator# 117517, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02009631"
290,"NCT02033551","A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors","Completed","No Results Available","All","Phase 1","47","Industry","Interventional","December 2013","September 2016","September 2016","January 13, 2014","null","September 27, 2016","Site Reference ID/Investigator# 117416, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 117415, San Antonio, Texas, United States|Site Reference ID/Investigator# 117337, Groningen, Netherlands|Site Reference ID/Investigator# 117338, Maastricht, Netherlands|Site Reference ID/Investigator# 117451, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02033551"
291,"NCT00560235","Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors","Completed","Has Results","All","Phase 1|Phase 2","138","Industry","Interventional","March 2008","March 2010","October 2012","November 19, 2007","February 28, 2014","October 28, 2015","Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Rochester, Minnesota, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Brisbane, Queensland, Australia|Pfizer Investigational Site, Parkville, Victoria, Australia|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Providencia, Santiago, RM, Chile|Pfizer Investigational Site, Lille Cedex, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Villejuif, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Freiburg, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Muenster, Germany|Pfizer Investigational Site, Jerusalem, Israel|Pfizer Investigational Site, Petach Tikva, Israel|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Esplugues de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Sutton, Surrey, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Oxford, United Kingdom|Pfizer Investigational Site, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT00560235"
292,"NCT01363947","Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer","Completed","No Results Available","All","Phase 1","87","Industry","Interventional","June 14, 2011","June 3, 2016","June 3, 2016","June 2, 2011","null","June 7, 2017","HonorHealth Research Institute - Pima Center, Scottsdale, Arizona, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Sarah Cannon Research Inst., Nashville, Tennessee, United States|Univ of Texas SW Medical Ctr, Dallas, Texas, United States|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01363947"
293,"NCT01124864","A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.","Completed","Has Results","All","Phase 2","153","Industry","Interventional","October 2010","August 2014","August 2014","May 17, 2010","March 2, 2016","March 2, 2016","University of California at Los Angeles UCLA - Santa Monica, Los Angeles, California, United States|Maryland Oncology Hematology, P.A. Dept. of Assoc. Onc/Hem, Rockville, Maryland, United States|Dana Farber Cancer Institute DFCI, Boston, Massachusetts, United States|St. Luke's Hospital and Health Network St Luke's, Bethlehem, Pennsylvania, United States|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Marseille cedex 20, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT01124864"
294,"NCT01143753","A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","45","Industry","Interventional","July 27, 2010","June 30, 2012","May 2, 2017","June 14, 2010","null","July 28, 2017","Royal Adelaide Hospital; Oncology, Adelaide, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia|Rigshospitalet, Onkologisk Klinik, København Ø, Denmark|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01143753"
295,"NCT01158079","Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment","Completed","No Results Available","All","Phase 1","7","Industry","Interventional","July 2010","August 2012","September 2012","July 8, 2010","null","October 12, 2012","TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Hospital Virgen del Rocio, Seville, Andalucia, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01158079"
296,"NCT00984282","Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer","Completed","Has Results","All","Phase 3","417","Industry","Interventional","October 15, 2009","August 31, 2012","August 30, 2017","September 25, 2009","December 10, 2013","September 13, 2018","Los Angeles, California, United States|Stanford, California, United States|New Haven, Connecticut, United States|Atlanta, Georgia, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States|Wien, Austria|Bruxelles - Brussel, Belgium|Sofia, Bulgaria|Guangzhou, Guangdong, China|Beijing, China|Beijing, China|Chengdu, China|Hangzhou, China|Shanghai, China|Shanghai, China|Tianjin, China|Odense C, Denmark|Angers, France|Bordeaux, France|Caen, France|LILLE cedex, France|Lyon, France|MARSEILLE cedex, France|Paris, France|Villejuif, France|Erlangen, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Napoli, Campania, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Catania, Sicilia, Italy|Pisa, Toscana, Italy|Siena, Toscana, Italy|Perugia, Umbria, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Koto-ku, Tokyo, Japan|Asan Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daejeon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Groningen, Netherlands|Leiden, Netherlands|Gliwice, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Obninsk, Russian Federation|Riyadh, Saudi Arabia|Majadahonda, Madrid, Spain|Barcelona, Spain|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Aberdeen, Aberdeenshire, United Kingdom|Cardiff, United Kingdom|Glasgow, United Kingdom|Leeds, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT00984282"
297,"NCT01868022","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling","Completed","No Results Available","All","Phase 1","65","Industry","Interventional","October 9, 2013","October 24, 2017","October 24, 2017","June 4, 2013","null","April 24, 2018","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Peoria, Illinois, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Koebenhavn Oe, Denmark|GSK Investigational Site, Marseille Cedex 5, France|GSK Investigational Site, Toulouse Cedex 9, France|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Arkhangelsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Pyatigorsk, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Vsevolozhsk, Russian Federation|GSK Investigational Site, Badajoz, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Leicester, Leicestershire, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT01868022"
298,"NCT00993655","Randomized Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer","Completed","Has Results","Female","Phase 2","275","Other|NIH","Interventional","September 2009","March 2016","July 2016","October 12, 2009","August 10, 2017","August 10, 2017","Mercy-Springfield, Springfield, Missouri, United States|CoxHealth, Springfield, Missouri, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Univ of Utah (Huntsman Cancer Institute), Salt Lake City, Utah, United States|Northwest CCOP - Multicare Health System, Tacoma, Washington, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada|BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada|Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Thunder Bay Regional Health Science Centre, Thunder Bay, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University - Dept. Oncology, Montreal, Quebec, Canada|CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Instituto Catalan de Oncologia - L'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Fundacion Alcorcon, Alcorcon, Madrid, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Corporacio Sanitaria Clinic, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Centro Oncologico MD Anderson - Madrid, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Fundacion Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|The Clatterbridge Center for Oncology - Liverpool, Wirral, Bebington, United Kingdom|Mount Vernon Hospital - Middlesex, Middlesex, Northwood, United Kingdom|Wexham Park Hospital, Berkshire, Slough, United Kingdom|St. George's Hospital - London, London, Tooting, United Kingdom|The Christie Hospital - Manchester, Manchester, Withington, United Kingdom|The Western General Hospital - Edinburgh, Edinburgh, United Kingdom|St. James University Hospital - Leeds, Leeds, United Kingdom|Liverpool Women's Hospital - Liverpool, Liverpool, United Kingdom|St. Bartholomew's Hospital - London, London, United Kingdom|The Royal Marsden Hospital - London, London, United Kingdom|The Hammersmith Hospital - London, London, United Kingdom|University College London Hospital - London, London, United Kingdom|St Marys Hospital - Manchester, Manchester, United Kingdom|The Churchill Hospital - Oxford, Oxford, United Kingdom|The Derriford Hospital - Plymouth, Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT00993655"
299,"NCT02317016","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer","Completed","Has Results","All","Phase 1","44","Industry","Interventional","March 10, 2015","July 11, 2015","May 22, 2018","December 15, 2014","July 14, 2016","July 31, 2018","Research Site, Fairfax, Virginia, United States|Research Site, Bordeaux Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Montpellier, France|Research Site, Rennes, France|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02317016"
300,"NCT01301716","A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors","Completed","No Results Available","All","Phase 1","75","Industry","Interventional","September 2011","August 2014","August 2014","February 23, 2011","null","November 2, 2016","Los Angeles, California, United States|Tampa, Florida, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01301716"
301,"NCT00842348","Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour","Completed","Has Results","All","Phase 3","89","Industry","Interventional","February 2009","December 2015","December 2015","February 12, 2009","February 17, 2017","February 17, 2017","Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|UZ Antwerpen, Antwerpen, Belgium|UCL Saint Luc, Bruxelles, Belgium|Fakultni nemocnice Na Bulovce, Prague, Czech Republic|General faculty, Praha, Czech Republic|Hôpital Beaujon, Clichy, France|CAC Oscar Lambret, Lille, France|Hôpital Edouard Herriot, Lyon, France|Hôpital R. Debré, Reims, France|Centro di Refierimiento Oncologica, Aviano, Italy|INSCT, Milano, Italy|University of Naples, Naples, Italy|Azienda San Giovanni Battista, Torino, Italy|Centrum Diagnostyczno-Lecznicze ""Gammed"", Warszawa, Poland|Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny, Warszawa, Poland|Narodny onkologicky ustav, Bratislava, Slovakia|Hospital Vall d'Hebron, Barcelona, Spain|Institut Catala Oncologia, Barcelona, Spain|University Hospital Wales, Cardiff, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James Hospital, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|QMC, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00842348"
302,"NCT01391533","Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors","Completed","No Results Available","All","Phase 1","72","Industry","Interventional","July 2011","April 2016","April 2016","July 12, 2011","null","April 13, 2016","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250001, Villejuif, France|Investigational Site Number 380004, Bologna, Italy|Investigational Site Number 380002, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01391533"
303,"NCT00705016","Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Completed","Has Results","All","Phase 1|Phase 2","184","Industry","Interventional","October 2008","September 2011","June 2013","June 25, 2008","April 30, 2014","April 30, 2014","Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Antwerp, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem (Antwerp), Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Lille cedex, France|Research Site, Montpellier, France|Research Site, Nice, France|Research Site, Toulouse, France|Research Site, Tours, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Villejuif, France|Research Site, Aachen, Germany|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Jena, Germany|Research Site, Leipzig, Germany|Research Site, Rostock, Germany|Research Site, Stuttgart, Germany|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, La Spezia, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Gliwice, Poland|Research Site, Warsaw, Poland|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Velencia, Spain|Research Site, Basel, Switzerland|Research Site, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT00705016"
304,"NCT01324479","Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","131","Industry","Interventional","February 29, 2012","July 4, 2017","July 4, 2017","March 29, 2011","null","March 23, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|University of Chicago Medical Center SC, Chicago, Illinois, United States|Karmanos Cancer Institute Wayne St Karmanos, Detroit, Michigan, United States|Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States|University of Texas/MD Anderson Cancer Center Dept of Onc, Houston, Texas, United States|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, La Tronche, France|Novartis Investigative Site, LILLE Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Utrecht, The Netherlands, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan|Novartis Investigative Site, Songkla, Thailand","https://ClinicalTrials.gov/show/NCT01324479"
305,"NCT01524978","A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers","Completed","Has Results","All","Phase 2","208","Industry","Interventional","April 12, 2012","October 28, 2016","October 28, 2016","February 2, 2012","November 20, 2017","November 20, 2017","Arizona Oncology, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, United States|Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Tianjin Cancer Hospital, Tianjin, China|Institut Bergonie; Oncologie, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Georges François Leclerc, Dijon, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut Paoli-Calmettes; Oncologie Medicale 1, Marseille Cedex 09, France|Centre Rene Gauducheau, Saint Herblain, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Klinik der Uni zu Koeln; Klinik I für Innere Medizin; Onkologie, Köln, Germany|Universitätsklinikum Mannheim, Tagestherapiezentrum, Interdisziplinäres Tumorzentrum, Mannheim, Germany|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Royal Marsden Hospital; Dept of Medicine, London, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01524978"
306,"NCT01688206","A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","Completed","No Results Available","All","Phase 1","132","Industry","Interventional","October 31, 2012","December 2, 2016","March 12, 2018","September 19, 2012","null","October 5, 2018","Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Institut Bergonie; Oncologie, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut Curie; Oncologie Medicale, Paris, France|ICO - Site René Gauducheau, Saint Herblain, France|Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01688206"
307,"NCT01253681","Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer","Completed","No Results Available","Female","Phase 1","27","Industry","Interventional","November 2010","October 2012","January 2015","December 3, 2010","null","October 14, 2015","Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01253681"
308,"NCT00707889","Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer","Completed","No Results Available","All","Phase 2","159","Industry","Interventional","October 2008","May 2012","May 2012","July 1, 2008","null","May 15, 2013","Site Reference ID/Investigator# 11341, Chapel Hill, North Carolina, United States|Site Reference ID/Investigator# 20801, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 8360, Nashville, Tennessee, United States|Site Reference ID/Investigator# 18581, Bedford Park, Australia|Site Reference ID/Investigator# 23443, Herston, Australia|Site Reference ID/Investigator# 18023, Bonheiden, Belgium|Site Reference ID/Investigator# 23646, Brussels, Belgium|Site Reference ID/Investigator# 18026, Leuven, Belgium|Site Reference ID/Investigator# 18022, Roeselare, Belgium|Site Reference ID/Investigator# 26662, Jau, Brazil|Site Reference ID/Investigator# 24245, Porto Alegre, Brazil|Site Reference ID/Investigator# 23265, Barrie, Canada|Site Reference ID/Investigator# 21083, Edmonton, Canada|Site Reference ID/Investigator# 22465, Ottawa, Canada|Site Reference ID/Investigator# 22141, Nachod, Czech Republic|Site Reference ID/Investigator# 22289, Heraklion, Greece|Site Reference ID/Investigator# 22286, Thessaloniki, Greece|Site Reference ID/Investigator# 22287, Thessaloniki, Greece|Site Reference ID/Investigator# 18281, Seoul, Korea, Republic of|Site Reference ID/Investigator# 18283, Seoul, Korea, Republic of|Site Reference ID/Investigator# 18282, Seoul, Korea, Republic of|Site Reference ID/Investigator# 20281, Wellington South, New Zealand|Site Reference ID/Investigator# 20141, Olsztyn, Poland|Site Reference ID/Investigator# 17946, Warsaw, Poland|Site Reference ID/Investigator# 38284, Warsaw, Poland|Site Reference ID/Investigator# 23908, Aveiro, Portugal|Site Reference ID/Investigator# 22324, Coimbra, Portugal|Site Reference ID/Investigator# 23724, Faro, Portugal|Site Reference ID/Investigator# 23964, Lisbon, Portugal|Site Reference ID/Investigator# 23303, Baia Mare, Romania|Site Reference ID/Investigator# 23302, Brasov, Romania|Site Reference ID/Investigator# 17962, Bucharest, Romania|Site Reference ID/Investigator# 17964, Bucharest, Romania|Site Reference ID/Investigator# 23304, Bucharest, Romania|Site Reference ID/Investigator# 17961, Cluj Napoca, Romania|Site Reference ID/Investigator# 23305, Craiova, Romania|Site Reference ID/Investigator# 24422, Moscow, Russian Federation|Site Reference ID/Investigator# 25063, Moscow, Russian Federation|Site Reference ID/Investigator# 25065, Moscow, Russian Federation|Site Reference ID/Investigator# 24423, Moscow, Russian Federation|Site Reference ID/Investigator# 22809, A Coruna, Spain|Site Reference ID/Investigator# 22807, Barcelona, Spain|Site Reference ID/Investigator# 22804, Madrid, Spain|Site Reference ID/Investigator# 22801, Madrid, Spain|Site Reference ID/Investigator# 22803, Pamplona Navarra, Spain|Site Reference ID/Investigator# 22800, Santander, Spain","https://ClinicalTrials.gov/show/NCT00707889"
309,"NCT01849666","A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy","Completed","No Results Available","All","Phase 1","2","Industry","Interventional","September 2013","April 2014","April 2014","May 8, 2013","null","November 2, 2016","Brussels, Belgium|Edegem, Belgium|Gent, Belgium|Wilrijk, Belgium|Helsinki, Finland|Heidelberg, Germany|Mainz, Germany|Amsterdam, Netherlands|Maastricht, Netherlands|Utrecht, Netherlands|Pamplona, Navarra, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01849666"
310,"NCT01851824","A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy","Completed","No Results Available","All","Phase 1","9","Industry","Interventional","August 2013","June 2014","June 2014","May 13, 2013","null","November 2, 2016","Wodonga, New South Wales, Australia|Buxtehude, Germany|Essen, Germany|Mannheim, Germany|Crete, Greece|Thessaloniki, Greece|Budapest, Hungary|Amsterdam, Netherlands|Maastricht, Netherlands|Utrecht, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Lisboa, Portugal|Porto, Portugal|Belgrade, Serbia|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01851824"
311,"NCT01289821","First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib","Completed","Has Results","All","Phase 2","54","Industry","Interventional","February 2011","March 2012","June 2014","February 4, 2011","September 4, 2013","March 15, 2017","Chicago, Illinois, United States|Concord, New South Wales, Australia|Woodville South, South Australia, Australia|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Stuttgart, Baden-Württemberg, Germany|Oldenburg, Niedersachsen, Germany|Herne, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Napoli, Campania, Italy|Genova, Liguria, Italy|Ancona, Marche, Italy|Santander, Cantabria, Spain|Barcelona, Spain|Madrid, Spain|Glasgow, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01289821"
312,"NCT00609518","A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 2","111","Industry","Interventional","February 2008","October 2009","June 2010","February 7, 2008","November 15, 2010","December 28, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bankstown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingswood Penrith, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Redcliffe, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toluca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo De Alarcon, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain","https://ClinicalTrials.gov/show/NCT00609518"
313,"NCT01482377","A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin","Completed","No Results Available","All","Phase 1","145","Industry","Interventional","December 2011","February 2016","February 2016","November 30, 2011","null","January 27, 2017","Rigshospitalet, Onkologisk Klinik, København Ø, Denmark|National Cancer Center, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed, Rotterdam, Netherlands|Utrecht University Medical Centre; Dept of Medical Oncology and UPC, Utrecht, Netherlands|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01482377"
314,"NCT01086254","SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer","Completed","No Results Available","All","Phase 2","119","Industry","Interventional","May 2010","December 2011","December 2011","March 15, 2010","null","September 24, 2013","Sanofi-Aventis Investigational Site Number 250002, Caen Cedex, France|Sanofi-Aventis Investigational Site Number 250003, Marseille Cedex 09, France|Sanofi-Aventis Investigational Site Number 250004, Toulouse, France|Sanofi-Aventis Investigational Site Number 250001, Villejuif, France|Sanofi-Aventis Investigational Site Number 276003, Essen, Germany|Sanofi-Aventis Investigational Site Number 276002, Gauting, Germany|Sanofi-Aventis Investigational Site Number 276001, Großhansdorf, Germany|Sanofi-Aventis Investigational Site Number 380003, Livorno, Italy|Sanofi-Aventis Investigational Site Number 380001, Orbassano, Italy|Sanofi-Aventis Investigational Site Number 380002, Rozzano, Italy|Sanofi-Aventis Investigational Site Number 724001, Badalona, Spain|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 826001, Newcastle Upon Tyne, United Kingdom|Sanofi-Aventis Investigational Site Number 826002, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01086254"
315,"NCT00880308","Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","103","Industry","Interventional","March 2009","July 2013","July 2013","April 13, 2009","null","December 30, 2014","University of Pittsburgh Medical Center SC, Pittsburgh, Pennsylvania, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, United States|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Leicester, United Kingdom","https://ClinicalTrials.gov/show/NCT00880308"
316,"NCT00942968","Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer","Completed","Has Results","All","Phase 4","338","Industry","Interventional","June 2009","March 2012","June 2013","July 21, 2009","February 24, 2017","February 24, 2017","Arizona Cancer Center, Tuscon, Arizona, United States|Bay Area Cancer Research Group, Pleasant Hill, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of CT Health Center, Farmington, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Georgetown University Hospital-Lombardi Cancer Ctr, Washington, District of Columbia, United States|Halifax Health, Daytona Beach, Florida, United States|Atlanta Institute for Medical Research, Decatur, Georgia, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Bringham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital K-15, Detroit, Michigan, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University, Medical Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|MidDakota Clinic, Bismarck, North Dakota, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Vermont Cancer Center at Fletcher Allen Health Care, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|LKH Graz Univrsitatstklinik fur Innere Medizin, Graz, Austria|Medizinische Universitat Innsbruck Studienambulanz Hamatologie, Innsbruck, Austria|KH d. Elizabethinen Linz GmbH Servicestelle fur klin. Studien und Universitare Angelegenheiten, Linz, Austria|KH der Barmherzigen Schwestern, Linz, Austria|Dialysestation Landesklinkum St.Poelten, St. Poelten, Austria|Medizinische Universitat Wien, Vienna, Austria|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Health Research Institute, Ottawa, Ontario, Canada|University Health Network-Toronto General Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Gelre Ziekenhuizen-Locatie Apeldoorn, Apeldoorn, Netherlands|Orbis Medisch Centrum, Sittard-Geleen, Sittard-Geleen, Netherlands|Hospital clinic i Provincial de Agencia de Ensayos Clinicos, Barcelona, Spain|Hospital General Santa Maria del Rosell, Caragena (Murcia), Spain|Hospital Virgen de la Arrixaca, El Palmar (Murcia), Spain|Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Universitaria de Navarra, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT00942968"
317,"NCT01091168","Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer","Completed","No Results Available","Female","Phase 3","594","Industry","Interventional","September 2009","January 2013","January 2013","March 23, 2010","null","October 13, 2016","Buenos aires, Argentina|Quilmes, Argentina|Rosario, Argentina|San Martin, Argentina|Tucuman, Argentina|Graz, Austria|Salzburg, Austria|Vienna, Austria|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Vitebsk, Belarus|Brussels, Belgium|Haine Saint Paul, Belgium|Yvoir, Belgium|Angers, France|Brest, France|Clermont Ferrand, France|Dijon, France|Grenoble, France|Le Mans, France|Lille, France|Limoges, France|Lorient, France|Montpellier, France|Nancy, France|Nantes, France|Nice, France|Paris, France|Pontoise, France|Reims, France|Rouen, France|Saint Brieuc, France|Saint Priest en Jarez, France|Strasbourg, France|Berlin, Germany|Dortmund, Germany|Essen, Germany|Mainz, Germany|Munich, Germany|Trier, Germany|Ancona, Italy|Aviano, Italy|Bolzano, Italy|Brindisi, Italy|Frattamaggiore, Italy|Macerata, Italy|Orbassano, Italy|Lisboa, Portugal|Arkhangelsk, Russian Federation|Engels, Russian Federation|Moscow, Russian Federation|Ryazan, Russian Federation|Saratov, Russian Federation|St Petersburg, Russian Federation|Stavropol, Russian Federation|Tambov, Russian Federation|Ufa, Russian Federation|Volgograd, Russian Federation|Duran, South Africa|Durban, South Africa|Johannesburg, South Africa|Pretoria, South Africa|A coruna, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Khmelnitskyy, Ukraine|Kyiv, Ukraine|Burnley, United Kingdom|Cornwall, United Kingdom|Derby, United Kingdom|Glasgow, United Kingdom|Ipswich, United Kingdom|Preston, United Kingdom|Worthing, United Kingdom","https://ClinicalTrials.gov/show/NCT01091168"
318,"NCT01273493","A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction","Completed","No Results Available","All","Phase 1","15","Industry","Interventional","December 2010","April 2014","April 2014","January 10, 2011","null","February 15, 2016","Scottsdale, Arizona, United States|Detroit, Michigan, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Tacoma, Washington, United States|Edegem, Belgium|Wilrijk, Belgium|Edmonton, Alberta, Canada|Barcelona, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01273493"
319,"NCT01387269","Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)","Completed","Has Results","All","Phase 3","484","Industry","Interventional","July 2011","January 2014","February 2015","July 4, 2011","July 11, 2017","October 27, 2017","Fullerton, California, United States|Glendale, California, United States|La Jolla, California, United States|Riverside, California, United States|Orange City, Florida, United States|Quincy, Illinois, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Northport, New York, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Brest, Belarus|Lesnoy, Belarus|Minsk, Belarus|Antwerpen, Belgium|Brussels, Belgium|Genk, Belgium|Liege, Belgium|Edmonton, Alberta, Canada|Sault Ste. Marie, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Benesov, Czechia|Brno, Czechia|Hlucin, Czechia|Liberec, Czechia|Nymburk, Czechia|Lyon Cedex, France|Villejuif cedex, France|Berlin, Germany|Grosshansdorf, Germany|Halle, Germany|Minden, Germany|Budapest, Hungary|Placenza, Italy|Rozzano, Italy|Amsterdam, Netherlands|Goes, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Grudziadz, Poland|Katowice, Poland|Krakow, Poland|Lublin, Poland|Ekaterinburg, Russian Federation|St. Petersburg, Russian Federation|Belgrade, Serbia|Sremska Kamenica, Serbia|Golnik, Slovenia|Ljubljana, Slovenia|Barcelona, Spain|Cordoba, Spain|Sevilla, Spain|Valencia, Spain|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Zaporizhzhya, Ukraine","https://ClinicalTrials.gov/show/NCT01387269"
320,"NCT01685060","LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib","Completed","Has Results","All","Phase 2","140","Industry","Interventional","November 26, 2012","March 29, 2016","March 29, 2016","September 13, 2012","May 8, 2017","June 19, 2017","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|City of Hope National Medical Center Dept of Oncology 2, Duarte, California, United States|University of California at Los Angeles Reg-5, Los Angeles, California, United States|University of California at San Diego, Moores Cancer Ctr SC, San Diego, California, United States|Stanford University Medical Center Stanford Cancer Center(2), Stanford, California, United States|University of Colorado Hospital SC, Aurora, Colorado, United States|Emory University School of Medicine/Winship Cancer Institute Dept of Oncology, Atlanta, Georgia, United States|University of Chicago Medical Center SC, Chicago, Illinois, United States|University of Kansas Cancer Center DeptofUofKansas CancerCenter-2, Kansas City, Kansas, United States|Cancer Center of Kansas Dept of CCK, Wichita, Kansas, United States|Maryland Oncology Hematology, P.A. SC, Rockville, Maryland, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Levine Cancer Institute SC 1, Charlotte, North Carolina, United States|Sarah Cannon Research Institute Drug Ship - 4, Nashville, Tennessee, United States|U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office, Dallas, Texas, United States|Seattle Cancer Care Alliance SC-1, Seattle, Washington, United States|University of Wisconsin Univ Wisc 2, Madison, Wisconsin, United States|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Marseille cedex 20, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01685060"
321,"NCT02154776","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.","Completed","No Results Available","Female","Phase 1","13","Industry","Interventional","June 27, 2014","October 26, 2016","October 26, 2016","June 3, 2014","null","July 23, 2018","University of California at Los Angeles UCLA SC, Los Angeles, California, United States|Horizon Oncology Center SC, Lafayette, Indiana, United States|Medical University of South Carolina SC, Charleston, South Carolina, United States|South Texas Accelerated Research Therapeutics SC, San Antonio, Texas, United States|University of Utah / Huntsman Cancer Institute SC-3, Salt Lake City, Utah, United States|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02154776"
322,"NCT01545947","Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","All","Phase 1","76","Industry","Interventional","May 2012","December 2014","December 2014","March 7, 2012","null","November 8, 2016","Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|NYU School of Medicine, New York, New York, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital Virgen del RocíoServicio de Hematologia, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01545947"
323,"NCT00902291","A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer","Completed","No Results Available","All","Phase 2","205","Industry","Interventional","April 2009","April 2012","April 2012","May 15, 2009","null","September 14, 2015","University of California San Diego Medical Center, La Jolla, California, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|University of Miami, Miami, Florida, United States|Medical Oncology LLC, Baton Rouge, Louisiana, United States|Annapolis Oncology Center, Annapolis, Maryland, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|Virginia G. Piper Cancer Center, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Regional Oncology Center, Syracuse, New York, United States|Kaiser Permanente Northwest Region Oncology Hematology, Portland, Oregon, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Baptist Regional Cancer Center, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Div. of Medical Oncology, Nashville, Tennessee, United States|Alan B. Pearson Regional Cancer Center Lynchburg Hematology Oncology Clinic, Lynchburg, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Chu Estaing, Clermont-Ferrand, France|Centre Jean Bernard, Oncologie médicale, Le Mans Cedex, France|Centre Régional de Lutte Contre le Cancer-Centre Oscar Lambret, Lille, France|Hôpital du Haut Lèvêque, Service d'Hepato Gastroentérologie, Pessac, France|Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France|Hôpital Charles Nicolle, Rouen, France|State Institution of Healthcare ""Arkhangelsk Regional Clinical Oncology Dispensary"", Arkhangelsk, Russian Federation|Regional Oncology Dispensary, Ivanovo, Russian Federation|Clinical Oncology Dispensary of Republic of Tatarstan, Kazan, Russian Federation|State Healthcare Institution ""Leningrad Regional Oncologic Dispensary"", Kuzmolovo, Russian Federation|Non-state Healthcare Institution N.A. Semashko Central Clinical Hospital #2 of JSC ""Russian Railway"", Moscow, Russian Federation|Medical Radiology Research Center of Russian Medical Academy, Obninsk, Russian Federation|State Healthcare Institution of Omsk Region ""Clinical Oncologic Dispensary"", Omsk, Russian Federation|State Educational Institution ""S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"", Saint Petersburg, Russian Federation|Saint Petersburg State Healthcare Institution ""Municipal Clinical Oncology Dispensary"", St. Petersburg, Russian Federation|Hospital Clinic i Provincial de Barcelona, Servicio de Oncologia, Barcelona, Spain|Madrid, Spain|Hospital Virgen de la Salud, Servicio Oncologia, Toledo, Spain","https://ClinicalTrials.gov/show/NCT00902291"
324,"NCT01183858","A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)","Completed","Has Results","All","Phase 3","315","Industry","Interventional","October 2010","October 2013","February 2014","August 18, 2010","February 23, 2015","August 19, 2015","Beijing, China|Changchun, China|Chengdu, China|Fuzhou, China|Guangzhou, China|Nanjing, China|Nanning, China|Shanghai, China|Shanghai, China|Shenyang, China|Tianjin, China|Wuhan, China|Hillerod, Denmark|København, Denmark|Naestved, Denmark|Roskilde, Denmark|Cairo, Egypt|Cairo, Egypt|Caen, France|Limoges, France|Marseille, France|Paris, France|Paris, France|Paris, France|Pontoise, France|Berlin, Germany|Berlin, Germany|Essen, Germany|Gauting, Germany|Grosshansdorf, Germany|Hannover, Germany|Hannover, Germany|Immenhausen, Germany|Lostau, Germany|München, Germany|Nürnberg, Germany|Rheine, Germany|Villingen-Schwenningen, Germany|Wuerselen, Germany|Wuppertal, Germany|Amsterdam, Netherlands|Breda, Netherlands|Nieuwegein, Netherlands|Zwolle, Netherlands|Sabadell, Barcelona, Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Sevilla, Spain|Valencia, Spain|Baden, Switzerland|Basel, Switzerland|Bern, Switzerland|Fribourg, Switzerland|Ankara, Turkey|Ankara, Turkey|Eskisehir, Turkey|Gaziantep, Turkey|Izmir, Turkey|Izmir, Turkey|Konya, Turkey","https://ClinicalTrials.gov/show/NCT01183858"
325,"NCT01337765","Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients","Completed","No Results Available","All","Phase 1","29","Industry","Interventional","July 2011","March 2013","March 2013","April 19, 2011","null","February 12, 2016","Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States|University of Texas/MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Barcelona, Cataluña, Spain","https://ClinicalTrials.gov/show/NCT01337765"
326,"NCT01454089","A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer","Completed","No Results Available","All","Phase 2","183","Industry","Interventional","October 2011","November 2014","November 2014","October 18, 2011","null","October 7, 2016","City of Hope National Medical Center, Duarte, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Radiological Associates of Sacramento, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, United States|Urology Cancer Center and GU Research Network, Omaha, Nebraska, United States|Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States|Monter Cancer Center, Lake Success, New York, United States|Columbia University Medical Center, New York, New York, United States|Texas Oncology, P.A., Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Center, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health, Oshawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM-Hospital Notre Dame, Montreal, Quebec, Canada|Centre Hospitalier Régional et Universitaire - Hôpital, Bretonneau Tours, Centre, France|Institute Jean Godinot, Reims, Champagne-Ardenne, France|Centre Hospitalier Universitaire de Rouen, Rouen, Haute-Normandie, France|Centre Hospitalier Universitaire, Institut Gustave Roussy, Villejuif Cedex, Ile-de-france, France|Centre Paul Papin, Angers Cedex 9, Pays De La Loire, France|Medicale Centre René Gauducheau, St. Herblain Cedex, Pays de la Loire, France|Institut Paoli Calmettes, Marseille Cedex 9, Provence Alpes Cote D'Azur, France|Centre Antoine Lacassagne, Nice, Provence Alpes Cote d'Azur, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany|Klinikum Rechts der Isar der Technischen Universität, München, Bayern, Germany|Johann-Wolfgang-Goethe-Universität Frankfurt, Frankfurt, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Niedeersachen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Universitätsklinikum Magdeburg A.ö.R., Magdeburg, Sachsen-Anhalt, Germany|Universitätsklinikum Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thuringen, Germany|Universitätsklinikum Mainz, Mainz, Germany|Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy|Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy|Unità Operativa di Oncologia Medica, Roma, Italy|Akademicki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Dolnoslaskie, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Kujawsko-Pomorskie, Poland|NZOZ Europejskie Centrum Zdrowia Otwock, Otwock, Mazowieckie, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Warszawa, Mazowieckie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Warminski-Mazurskie, Poland|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Institut Català D'Oncologia, Hospital Duran i Reynals, Madrid, Spain|Instituto Valenciano de Oncología-Fundación (IVO-FINCIVO), Valencia, Spain","https://ClinicalTrials.gov/show/NCT01454089"
327,"NCT02481934","Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma","Completed","Has Results","All","Phase 1","5","Other","Interventional","March 2013","July 2016","October 2016","June 25, 2015","December 5, 2016","April 17, 2017","Hospital Universitario 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02481934"
328,"NCT00764621","Health Economic Evaluation of Primovist-enhanced Liver MRI","Completed","No Results Available","All","Phase 4","360","Industry","Interventional","October 2008","September 2010","November 2010","October 2, 2008","null","November 4, 2014","Graz, Austria|Wien, Austria|Wien, Austria|Karlsruhe, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Dortmund, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Candiolo, Torino, Italy|Ancona, Italy|Bologna, Italy|Brescia, Italy|Chieti, Italy|Napoli, Italy|Seoul,, Korea, Korea, Republic of|Gyeunggi-do, South Korea, Korea, Republic of|Hwasun, Korea, Republic of|Jeonbuk, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Leiden, Netherlands|Utrecht, Netherlands|Santa Cruz de Tenerife, Canarias, Spain|Barcelona, Spain|Sevilla, Spain|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Basel, Basel-Stadt, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Genève, Switzerland|Luzern, Switzerland|Bangkok, Thailand|Songkhla, Thailand","https://ClinicalTrials.gov/show/NCT00764621"
329,"NCT01986166","A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS","Completed","No Results Available","All","Phase 1","23","Industry","Interventional","November 2013","January 2016","January 2016","November 18, 2013","null","July 18, 2016","San Francisco, California, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Detroit, Michigan, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Barcelona, Spain|Madrid, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01986166"
330,"NCT01189929","A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer","Completed","No Results Available","All","Phase 1","57","Industry","Interventional","August 2010","December 2016","December 2016","August 27, 2010","null","January 25, 2017","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Austin Hospital, Heidelberg, Victoria, Australia|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|START Madrid, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01189929"
331,"NCT01395914","Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)","Completed","Has Results","All","Phase 3","513","Industry","Interventional","July 2011","June 2014","February 2015","July 18, 2011","July 11, 2017","September 14, 2017","Corona, California, United States|Fountain Valley, California, United States|Fullerton, California, United States|Glendale, California, United States|La Jolla, California, United States|Riverside, California, United States|Washington, D.C., District of Columbia, United States|Orange City, Florida, United States|Quincy, Illinois, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Lake Success, New York, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Sylvania, Ohio, United States|West Reading, Pennsylvania, United States|Charleston, South Carolina, United States|Falls Church, Virginia, United States|Prairiewood, New South Wales, Australia|Adelaide, Australia|East Bentleigh, Australia|Victoria, Australia|Brest, Belarus|Lesnoy, Belarus|Minsk, Belarus|Antwerpen, Belgium|Brussels, Belgium|Genk, Belgium|Gent, Belgium|Liege, Belgium|Edmonton, Alberta, Canada|Sault Ste Marie, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Benesov, Czechia|Brno, Czechia|Hlucin, Czechia|Liberec, Czechia|Nymburk, Czechia|Lyon Cedex, France|Villejuif cedex, France|Grosshansdorf, Germany|Halle, Germany|Budapest, Hungary|Kassai, Hungary|Beer-Sheva, Israel|Petach Tikvah, Israel|Tel-Hashomer, Israel|Zerifin, Israel|Piacenza, Italy|Bydgoszcz, Poland|Grudziadz, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Szczecin, Poland|Warszawa, Poland|Ekaterinburg, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Belgrade, Serbia|Sremska Kamenica, Serbia|Ljubljana, Slovenia|Barcelona, Spain|Sevilla, Spain|Valencia, Spain|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine","https://ClinicalTrials.gov/show/NCT01395914"
332,"NCT02364999","A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC","Completed","Has Results","All","Phase 3","719","Industry","Interventional","April 20, 2015","May 8, 2017","December 22, 2017","February 18, 2015","June 27, 2018","August 23, 2018","Southern Cancer Center, PC, Daphne, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Beaver Medical Group, L.P., Highland, California, United States|Cancer Center of Central Connecticut, New Britain, Connecticut, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Holy Cross Hospital Resource Center, Silver Spring, Maryland, United States|Maryland Oncology & Hematology, PA, Silver Spring, Maryland, United States|Holy Cross Hospital, Hospital Pharmacy, Silver Spring, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Maryland Oncology & Hematology, PA, Wheaton, Maryland, United States|St. Joseph's Regional Medical Center, Paterson, New Jersey, United States|Millennium Oncology, Houston, Texas, United States|Millennium Oncology, Kingwood, Texas, United States|Millennium Oncology, Shenandoah, Texas, United States|Millennium Oncology, The Woodlands, Texas, United States|Epic Pharmacy, Lismore, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Cardiac Services, John Flynn Private Hospital -, Tugun, Queensland, Australia|South Coast Radiology, John Flynn Private Hospital, Tugun, Queensland, Australia|Austin Health - Olivia Newton - John Cancer & Wellness Centre, Heidelberg, Victoria, Australia|Western Health, Sunshine Hospital, St Albans, Victoria, Australia|Hospital Santa Izabel / Santa Casa de Misericordia da Bahia, Salvador, Bahia, Brazil|Oncoclinic (Clinica de Oncologia e Atendimento de Urgencia Ltda), Fortaleza, Ceara, Brazil|COT - Centro Oncologico do Triangulo Ltda, Uberlandia, Minas Gerais, Brazil|Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner, Curitiba, Parana, Brazil|Hospital Bruno Born (Sociedade Beneficencia e Caridade de Lajeado), Lajeado, RIO Grande DO SUL, Brazil|Oncosinos (Lessa Ferreira Servicos Oncologicos Ltda), Novo Hamburgo, RIO Grande DO SUL, Brazil|Hospital da Cidade de Passo Fundo - HCPF, Passo Fundo, RIO Grande DO SUL, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre - ISCMPA, Porto Alegre, RIO Grande DO SUL, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre - Hospital Santa Rita, Porto Alegre, RIO Grande DO SUL, Brazil|Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RIO Grande DO SUL, Brazil|Instituto Joinvillense de Hematologia e Oncologia SS Ltda - Clinica de Hematologia e Oncologia, Joinville, Santa Catarina, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto -, Sao Jose do Rio Preto, SAO Paulo, Brazil|Instituto de Oncologia de Sorocaba - ONCO Clinicas Especializadas SC Ltda, Sorocaba, SAO Paulo, Brazil|Instituto COI de Pesquisa, Educacao e Gestao - COI Clinicas Barra Da Tijuca, Rio de Janeiro, Brazil|lnstituto do Cancer do Estado de Sao Paulo - Octavio Frias de -, Sao Paulo, Brazil|Instituto de Assistencia Medica ao Servidor Publico Estadual - IAMSPE/HSPE-FMO, Sao Paulo, Brazil|Complex Oncological Center Shumen EOOD, Shumen, Bulgaria|Instituto Clinico Oncologico del Sur (ICOS), Temuco, Region DE LA Araucania, Chile|Bradford Hill Centro de Investigaciones Clinicas, Santiago, Region Metropolitana, Chile|Centro Internacional de Estudios Clinicos (CIEC), Santiago, Region Metropolitana, Chile|Fresenius Kabi Chile, Therapia i.v., Santiago, Region Metropolitana, Chile|Instituto Clínico Oncológico del Sur (ICOS), Temuco, Región DE LA Araucanía, Chile|Centro de Investigaciones Clinicas Vina del Mar Ltda., Vina del Mar, V Region, Chile|University Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|Nemocnice na Plesi s.r.o, Nova Ves pod Plesi, Czechia|Nemocnice Novy Jicin a.s, Novy Jicin, Czechia|Lekarna Agel Novy Jicin, Novy Jicin, Czechia|Nemocnice Pelhrimov p.o, Radioterapeuticke oddeleni, Pelhrimov, Czechia|Lekarna Oblastni nemocnice Pribram, Pribram, Czechia|Centre Hospitalier General De Mont De Marsan, Mont De Marsan Cedex, France|Centre Hospitalier Montbeliard, Montbeliard, France|L'hopital prive du Confluent S.A.S., Nantes Cedex, France|Hopital d'instruction des armees Sainte Anne, Toulon Cedex 9, France|Klinikum Bayreuth GmbH, Bayreuth, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|Viereck-Apotheke, Berlin, Germany|Vivantes GmbH Apotheke des Humboldt-Klinikums, Berlin, Germany|Vivantes Klinikum Spandau, Berlin, Germany|Staedtisches Klinikum Braunschweig gGmbH Apotheke, Braunschweig, Germany|Staedtisches Klinikum Braunschweig gGmbH Institut fuer Roentgendiagnostik und Nuklearmedizin, Braunschweig, Germany|Staedtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Fachkrankenhaus Coswig GmbH, Coswig, Germany|Apotheke Johannstadt Sven Ullrich e.K., Dresden, Germany|Klinikum Esslingen GmbH, Esslingen a.N., Germany|Radiologie Nuklearmedizin Adickesallee, Frankfurt am Main, Germany|St. Elisabethen - Krankenhaus, Frankfurt am Main, Germany|Sued-Apotheke, Frankfurt am Main, Germany|Asklepios Fachkliniken Muenchen Gauting, Gauting, Germany|Johannes-Apotheke, Groebenzell, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH - Apotheke, Halle (Saale), Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH - Institut fuer Radiologie, Halle (Saale), Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle (Saale), Germany|Zytoservice Deutschland GmbH, Hamburg, Germany|Katholisches Marienkrankenhaus gGmbH, Hamburg, Germany|Institut fuer Diagnostische und Interventionelle Radiologie, Hannover, Germany|Medizinische Hochschule Hannover Zentralapotheke, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum des Saarlandes - Klinik fuer Diagnostische und Interventionelle Radiologie, Homburg/Saar, Germany|Universitaetsklinikum des Saarlandes - Klinik fuer Innere Medizin V - Pneumologie, Allergologie,, Homburg/Saar, Germany|Universitaetsklinikum des Saarlandes, Apotheke, Homburg/Saar, Germany|Vincentius-Diakonissen-Kliniken gAG Karlsruhe, Karlsruhe, Germany|Vincentius-Diakonissen-Kliniken gAG Klinik fuer Diagnostische und Interventionelle Radiologie, Karlsruhe, Germany|Vincentius-Diakonissen-Kliniken gAG Zentralapotheke, Karlsruhe, Germany|Institut Fuer Versorgungsforschung In Der Onkologie, Koblenz, Germany|Radiologisches Institut Koblenz, Koblenz, Germany|Sonnenschein Apotheke, Koblenz, Germany|Hirsch-Apotheke, Leer, Germany|Onkologie UnterEms, Leer, Germany|Zentrum fuer Radiologie und Nuklearmedizin am Johannisplatz (ZRN Leipzig), Leipzig, Germany|Arkana Apotheke OHG, Leipzig, Germany|POIS Leipzig GbR, Pneumologisch/onkologisch/internistisches Studienzentrum, Leipzig, Germany|Onkologie Moers GbR, Moers, Germany|Friedrich-Ebert-Krankenhaus Neumuenster, Neumuenster, Germany|University Hospital of Heraklion, Heraklion, Crete, Greece|Univ. of Athens Hosp. of Chest Diseases of Athens ''Sotiria'', Athens, Greece|General Oncology Hospital of Kifissia ""Ag. Anargiroi"", Athens, Greece|University General Hospital Of Patras, Patras, Greece|Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece|European Inter-Balkan Medical Centre, Thessaloniki, Greece|Thermi Clinic S.A, Thessaloniki, Greece|Gen.Hospital ""G. Papanikolaou"", Thessaloniki, Greece|Semmelweis Egyetem Klinikai Pulmonologiai Klinikai Gyogyszertar, Budapest, Hungary|Semmelweis Egyetem, Pulmonologiai Klinika, Budapest, Hungary|Csongrad Megyei Mellkasi Betegsegek Szakkorhaza, Deszk, Hungary|Veszprem Megyei Tudogyogyintezet, Farkasgyepu, Hungary|Petz Aladar Megyei Oktato Korhaz, Pulmonologiai Osztaly, Gyor, Hungary|Matrai Gyogyintezet Pulmonologiai Osztaly, Matrahaza, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet, Megyei Onkologiai Kozpont, Szolnok, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|Mahatma Gandhi Cancer Hospital And Research Institute, Visakhapatnam, Andhra Pradesh, India|HealthCare Global Enterprises Limited, Bangalore, Karnataka, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Sahyadri Clinical Research and Development Center (A Unit of Sahayadri hospitals Limited), Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Institute of Respiratory Diseases, SMS Medical College & Hospital, Jaipur, Rajasthan, India|UOC Oncologia, Treviglio, BG, Italy|Oncologia Medica, Fondazione Poliambulanza Instituto Ospedaliero, Brescia, BS, Italy|UO Oncologia Medica, Catania, CT, Italy|Unita di Oncologia Toracica, Meldola, FC, Italy|UOC di Oncologia Medica, Lido di Camaiore, LU, Italy|UOSD Pneumologia Oncologica - Padiglione Flaiani, Roma, RM, Italy|S.C. Oncologia Medica-Presidio Ospedaliero Sondrio, Sondrio, SO, Italy|UOC Oncologia Medica, Legnago, VR, Italy|National Hospital Organization Hirosaki National Hospital, Hirosaki, Aomori, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|National Hospital Organization Himeji Medical Center, Himeji, Hyogo, Japan|National Hospital Organization Mito Medical Center, Higashi-ibaraki-gun, Ibaraki, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|National Hospital Organization Mie Chuo Medical Center, Tsu, MIE, Japan|National Hospital Organization Sendai Medical Center, Sendai, Miyagi, Japan|National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, Japan|Saiseikai Fukuoka General Hospital, Fukuoka, Japan|National Hospital Organization Kochi National Hospital, Kochi, Japan|National Hospital Organization Oita Medical Center, Oita, Japan|Japanese Red Cross Okayama Hospital, Okayama, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|VHS Medical Center, Seoul, Gangdong-gu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Nilai Medical Centre, Nilai, Negeri Sembilan, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Penang, Malaysia|Penang Adventist Hospital, Penang, Malaysia|Klinisch Chemisch en Hematologisch Laboratorium (KCHL), Arnhem, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Ziekenhuis De Gelderse Vallei, Ede, Netherlands|Elkerliek Ziekenhuis, Helmond, Netherlands|Cebu Doctors' University Hospital, Cebu City, Cebu, Philippines|Davao Doctors Hospital, Davao City, Davao DEL SUR, Philippines|Wojewodzki Szpital Zespolony w Elblagu, Elblag, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Kopernika w Lodzi,, Lodz, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc w Olsztynie, Olsztyn, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii im.Eugenii i Janusza Zeylandow, Poznan, Poland|MRUKMED. Lekarz Beata Madej Mruk i Partner. Sp. p. Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Samodzielny Publiczny Wojewodzki Szpital Zespolony w Szczecinie Szpital Wojewodzki w, Szczecin-Zdunowo, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Obserwacyjno-Zakazny, Torun, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Wojskowy Instytut Medyczny, Klinika Onkologii, Warszawa, Poland|Wojewodzki Szpital Chorob Pluc im. dr Alojzego Pawelca, Wodzislaw-Slaski, Poland|SPAD Imaging International S.R.L, Craiova, Dolj, Romania|SC Cardio-Center SRL, Craiova, Dolj, Romania|SC Oncolab SRL, Oncologie, Craiova, Jud Dolj, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Cardiologie, Targu-Mures, Mures, Romania|Spitalul Clinic Judetean Mures, radiologie si imagistica medicala, Targu-Mures, Mures, Romania|Spitalul Clinic Judetean Mures, sectia Clinica de Oncologie Medicala, Targu-Mures, Mures, Romania|S.C. Oncocenter Oncologie Clinica SRL, Timisoara, Timis, Romania|Medisprof, Cluj Napoca, Romania|Spitalul Clinic Municipal, Cluj-Napoca, Romania|SC Hiperdia SA, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta ""Sf Apostol Andrei"" Constanta Clinica Oncologie Medicala, Constanta, Romania|Centrul Medical Pozimed, SC Pozitron Medical Investigation SRL, Constanta, Romania|S.C. Centrul de Oncologie Sf. Nectarie S.R.L., Oncologie Medicala, Craiova, Romania|SC Radiotherapy Center Cluj SRL, Jud Cluj, Romania|Hiperdia Timisoara, Cardiologie, Timisoara, Romania|Hiperdia Timisoara, Radiologie si imagistica medicala, Timisoara, Romania|Dr's Grineva Private Clinic, Sochi, Krasnodar Region, Russian Federation|SHI Oncology Dispensary #2 of Health Department of Krasnodar Region, Sochi, Krasnodar Region, Russian Federation|""SAHI of Moscow """"Moscow City Oncology Hospital #62 of Health Department of Moscow"""""", P/o Stepanovskoe, Moscow Region, Russian Federation|""RBHI """"Kursk Regional Clinical Oncology Dispensary"""" of Healthcare Committee of Kursk Region"", Kislino Steading Of Kursk Region, Ryshkovskiy Village Council, Russian Federation|SBHI of Stavropol Region ""Essentuki Central City Hospital"", Essentuki, Stavropol Region, Russian Federation|Federal State Budgetary Institution of Healthcare ""Clinical Hospital #, Lermontov, Stavropol Region, Russian Federation|SBHI of Stavropol Region ""Pyatigorsk Oncology Dispensary"", Pyatigorsk, Stavropol Region, Russian Federation|Stavropol Krai State Budget Healthcare Institute ""Stavropol Regional Oncology Clinic"", Stavropol, Stavropol Region, Russian Federation|S.G. Primushko Republican Clinical Oncology Dispensary, Izhevsk, Udmurt Republic, Russian Federation|SBHI of Vladimir Region ""Regional Clinical Oncology Dispensary"", Vladimir, Vladimir Region, Russian Federation|State Budget Healthcare Institution of Arkhangelsk Region, Arkhangelsk, Russian Federation|Evimed Llc, Chelyabinsk, Russian Federation|Chelyabinsk Regional Hospital, Chelyabinsk, Russian Federation|SBHI ""Chelyabinsk Regional Clinical Hospital"", Chelyabinsk, Russian Federation|""SBHI """"Chelyabinsk Regional Clinical Oncology Dispensary"""""", Chelyabinsk, Russian Federation|Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Russian Federation|MRT-Expert, LLC, Chelyabinsk, Russian Federation|Road Clinical Hospital on the station Chelyabinsk of OJSC ""RZD"", Chelyabinsk, Russian Federation|SBHI ""Regional clinical hospital #2"" of MoH of Krasnodar Region, Krasnodar, Russian Federation|FSBI ""N.N.Blokhin Russian Cancer Research Center"" RAMS, Moscow, Russian Federation|P.A.Hertsen Moscow Oncology Research Institute - Branch of the National Medical Radiological, Moscow, Russian Federation|Privolzhskiy District Medical Center of Federal Biomedical Agency, Nizhniy Novgorod, Russian Federation|SBHI NR Clinical Diagnostic Center, Nizhniy Novgorod, Russian Federation|SBHI of NNR Nizhniy Novgorod Regional Oncology Dispensary, Nizhniy Novgorod, Russian Federation|SBHI of NNR Nizhniy Novgorod Regional Oncology Dispensary, Nizhniy Novgorod, Russian Federation|""Budgetary Healthcare Institution of Omsk Region """"Clinical Oncology Dispensary"""""", Omsk, Russian Federation|SBEI HPE RyazSMU of MoH of Russia based on SBI of Ryazan Region, Ryazan, Russian Federation|SPb SBHI ""City Clinical Oncology Dispensary"", Saint Petersburg, Russian Federation|FSBI 'Scientific-Research Oncology Institute n.a. N.N.Petrov' of MoH of RF, Saint-Petersburg, Russian Federation|Saratov scientific research institute of traumatology and orthopedics, Saratov, Russian Federation|NHI Road clinical hospital at the st. Saratov II of OJSC Russian Railways, Saratov, Russian Federation|Clinical hospital n.a. S.R. Mirotvortseva of SSMU, Saratov, Russian Federation|Limited Liability Company ""Common health"", Sochi, Russian Federation|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Amanzimtoti Oncology Centre, Amanzimtoti, Kwa-zulu Natal, South Africa|Drs Schnetler, Corbett and Partners Inc, Cape Town, Western CAPE, South Africa|Dr Lior Sareli Inc, Cape Town, Western CAPE, South Africa|Cape Town Oncology Trials (Pty) Ltd, Kraaifontein, Western CAPE, South Africa|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Servicio de Oncologia, Madrid, Spain|Consorcio Hospital Universitario General De Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chulalongkorn University, Patumwan, Bangkok, Thailand|Chiangrai Prachanukroh Hospital, Muang, Chiang RAI, Thailand|Chula Clinical Research Center, Bangkok, Thailand|Clinical Research Center, Phramongkutklao Hospital, Bangkok, Thailand|Medical Oncology Unit, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand|Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital,, Bangkok, Thailand|Prachachuen Imaging Center Co., Ltd., Bangkok, Thailand|Oncology Unit, Department of Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand|Baskent Universitesi Tip Fakultesi Adana Hastanesi, Adana, Turkey|Cukurova Universitesi Tip Fakultesi Balcali Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Diskapi Yildirim Beyazit Egitim ve Arastirma Hastanesi, Ankara, Turkey|Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Turkey|Yildirim Beyazit Universitesi Tip Fakultesi Ataturk Egitim ve Arastirma Hastanesi, Ankara, Turkey|Yedikule Gogus Hastaliklari ve Gogus Cerrahisi, Istanbul, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Turkey|Iyitem Goruntuleme ve Tani Merkezi, Istanbul, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari, Istanbul, Turkey|Prof Dr Nuri Tenekeci Tani Merkezi, Istanbul, Turkey|Euromed Goruntuleme ve Tani Merkezi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi lc Hastaliklari Anabilim Dali, Izmir, Turkey|LLC ""Medical clinic ""INNOVACIA"", chemotherapy department, Lyutizh, KYIV Region, Ukraine|""Municipal Institution """"Chernivtsi Regional Clinical Oncology Dispensary"""",, Chernivtsi, Ukraine|MI 'City Dnipropetrovsk Multi-field Clin. Hospital #4 of DRC', Dep.-nt of Chemotherapy;, Dnipropetrovsk, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"",, Kharkiv, Ukraine|MI 'Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council', Kryvyi Rih, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine|Poltava Reg. Clinical Oncology Dispensary of PRC, thoracic department, SHEI of Ukr., Poltava, Ukraine|""RMI """"Sumy Reg. Clin. Oncology Dispensary"""". oncothoracic dep.-nt. Surny State Univ.,, Sumy, Ukraine|""Central City Clinical Hospital, City Oncology Center, SHEI """"Uzhhorod National University"""", Uzhhorod, Ukraine|Vinnytsia Regional Clinical Oncology Dispensary, Vinnytsia, Ukraine","https://ClinicalTrials.gov/show/NCT02364999"
333,"NCT00817518","A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","145","Industry","Interventional","January 2009","December 2014","December 2014","January 6, 2009","null","September 2, 2015","Marseille, France|Paris, France|Paris, France|Villejuif, France|Essen, Germany|Amsterdam, Netherlands|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Cambridge, United Kingdom|London, United Kingdom|Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT00817518"
334,"NCT01454934","A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 3","540","Industry","Interventional","September 2011","July 2015","May 2, 2016","October 19, 2011","March 1, 2017","September 1, 2017","Los Angeles, California, United States|Pleasant Hill, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Washington, D.C., District of Columbia, United States|Port Saint Lucie, Florida, United States|Decatur, Illinois, United States|Southfield, Michigan, United States|Lebanon, New Hampshire, United States|Lake Success, New York, United States|Portland, Oregon, United States|Spokane, Washington, United States|Madison, Wisconsin, United States|Herston, Queensland, Australia|Frankston, Victoria, Australia|Strasbourg, Bas Rhin, France|Marseille Cedex 20, Bouches-du-Rhone, France|Marseille Cedex 9, Bouches-duRhone, France|Bordeaux, Gironde, France|Toulouse Cedex 9, Haute Garonne, France|Limoges, Haute Vienne, France|Rennes Cedex 9, Ille et Vilaine, France|Saint Herblain, Loire Atlantique, France|Lille, Nord, France|Paris Cedex 12, Paris, France|Pierre Benite cedex, Rhone, France|Villejuif cedex, Val de Marne, France|Aschaffenburg, Bayern, Germany|Gauting, Bayern, Germany|Muenchen, Bayern, Germany|Essen, Nordrhein Westfalen, Germany|Koeln, Nordrhein Westfalen, Germany|Recklinghausen, Nordrhein Westfalen, Germany|Mainz, Rheinland Pfalz, Germany|Halle, Sachsen Anhalt, Germany|Hong Kong, Hong Kong|Lido di Camaiore, Lucca, Italy|Monza, Milano, Italy|Aviano, Pordenone, Italy|Cremona, Italy|Milano, Italy|Siena, Italy|Nagoya-shi, Aichi-Ken, Japan|Kashiwa-shi, Chiba-Ken, Japan|Fukuoka-shi, Fukuoka-Ken, Japan|Hiroshima-shi, Hiroshima-Ken, Japan|Sapporo-shi, Hokkaido, Japan|Kobe-shi, Hygo-Ken, Japan|Akashi-shi, Hyogo-ken, Japan|Sendai-shi, Miyagi-Ken, Japan|Nigata-shi, Nigata-Ken, Japan|Kurashiki-shi, Okayama-Ken, Japan|Habinko-shi, Osaka-Fu, Japan|Osaka-shi, Osaka-Fu, Japan|Osakasayama-shi, Osaka-Fu, Japan|Sunto-gun, Shizuoka-Ken, Japan|Chuo-ku, Tokyo-to, Japan|Koto-ku, Tokyo-To, Japan|Ube-shi, Yamaguchi-Ken, Japan|Kitaadachi-gun, Japan|Seongnam-si, Gyeonggi-do, Korea, Republic of|Suwon, Gyeonggi-do, Korea, Republic of|Seoul, Korea, Korea, Republic of|Gdansk, Poland|Mrozy, Poland|Otwock, Poland|Sczedin, Poland|Warsazawa, Poland|Barnaul, Russian Federation|Novosibirsk, Russian Federation|Saint Petersburg, Russian Federation|Singapore, Singapore|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|Pamplona, Navarra, Spain|Barcelona, Spain|Madrid, Spain|Taichung, Taiwan|Tainan, Taiwan|Taipei City, Taiwan|Taipei, Taiwan|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Sutton, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT01454934"
335,"NCT00785785","A Study of Nilotinib Versus Imatinib in GIST Patients","Completed","Has Results","All","Phase 3","644","Industry","Interventional","March 2009","October 2014","October 2014","November 5, 2008","April 7, 2016","June 16, 2016","Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States|Northern Arizona Hematology/Oncology Associates, P.C. Dept. of No. AZ Hem-Onc, Flagstaff, Arizona, United States|City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(4), Duarte, California, United States|City of Hope National Medical Center Regulatory Document, Duarte, California, United States|University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (2), La Jolla, California, United States|University of California at Los Angeles GI Oncology Program, Los Angeles, California, United States|Stanford University Medical Center Stanford Cancer Center, Stanford, California, United States|University of Colorado Dept. of Univ. of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer, Greenwood Village, Colorado, United States|Washington Hospital Center Wash Hospital, Washington, District of Columbia, United States|Ocala Oncology Center Dept. of Ocala Oncology Center, Ocala, Florida, United States|Kootenai Medical Center Dept.ofKootenai Med.Ctr., Coeur d'Alene, Idaho, United States|Northwestern University Clinical Research Office (2), Chicago, Illinois, United States|Dana Farber Cancer Institute Centerfor Sarcoma&BoneOncology, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(6), Ann Arbor, Michigan, United States|Minnesota Oncology Hematology, P.A. SC, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester Division of Hematology, Rochester, Minnesota, United States|New York Oncology Hematology, P.C. NYOH Amsterdam, Troy, New York, United States|New York Oncology Hematology, P.C. NYOH@AlbanyMedicalCenter(2), Troy, New York, United States|University of Pennsylvania Medical Center CAMN107G2301, Philadelphia, Pennsylvania, United States|Vanderbilt Univeristy Ingram Cancer Ctr., Nashville, Tennessee, United States|Texas Oncology, P.A. Tex Onc (2), Bedford, Texas, United States|Texas Oncology Wichita Falls, Dallas, Texas, United States|University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3), Dallas, Texas, United States|University of Texas/MD Anderson Cancer Center Dept. of MD Anderson (13), Houston, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler, Texas, United States|University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(3), Salt Lake City, Utah, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Uberlândia, MG, Brazil|Novartis Investigative Site, Florianopolis, SC, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Pereira, Colombia|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Århus C, Denmark|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Chambray-lès-Tours, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille Cedex 05, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Niigata-city, Niigata, Japan|Novartis Investigative Site, Kurashiki, Okayama, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Gifu, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Toyama, Japan|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, León, Guanajuato, Mexico|Novartis Investigative Site, Chihuahua, Mexico|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Kraków, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Craiova, Dolj, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Kazan, Tatarstan Republic, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Umeå, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Khon Kaen, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Balcova / Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kartal, Turkey|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Newcastle-upon-Tyne, United Kingdom|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela","https://ClinicalTrials.gov/show/NCT00785785"
336,"NCT01496742","A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","Completed","No Results Available","All","Phase 2","259","Industry","Interventional","April 2012","November 2015","November 2015","December 21, 2011","null","September 23, 2016","Huntsville, Alabama, United States|Scottsdale, Arizona, United States|Bakersfield, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Northridge, California, United States|San Luis Obispo, California, United States|Santa Barbara, California, United States|Stanford, California, United States|Grand Junction, Colorado, United States|Boynton Beach, Florida, United States|Hollywood, Florida, United States|Orlando, Florida, United States|Lawrenceville, Georgia, United States|Marietta, Georgia, United States|Harvey, Illinois, United States|Fort Wayne, Indiana, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Muncie, Indiana, United States|Metairie, Louisiana, United States|Minneapolis, Minnesota, United States|Las Vegas, Nevada, United States|New York, New York, United States|Hickory, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Middletown, Ohio, United States|Bend, Oregon, United States|Portland, Oregon, United States|Seattle, Washington, United States|Buenos Aires, Argentina|La Rioja, Argentina|Santa Rosa, Argentina|Grenoble, France|Paris, France|Paris, France|Rennes, France|Göttingen, Germany|Halle (Saale), Germany|Immenhausen, Germany|München, Germany|Münster, Germany|Afula, Israel|Ashkelon, Israel|Holon, Israel|Tel Aviv, Israel|Zerifin, Israel|Avellino, Campania, Italy|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Orbassano, Piemonte, Italy|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Riga, Latvia|Kuala Lumpur, Malaysia|Negeri Sembilan, Malaysia|Penang, Malaysia|Pulau Pinang, Malaysia|Tanjung Bungah, Malaysia|Aguascalientes, Mexico|Chihuahua, Mexico|Leon, Mexico|CEBU City, Philippines|Davao City, Philippines|Pasig City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Pamplona, Navarra, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Aberdeen, United Kingdom|Birmingham, United Kingdom|Bournemouth, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01496742"
337,"NCT01836328","Conversion From Parenteral to Oral Methadone.","Completed","No Results Available","All","Phase 3","44","Other","Interventional","August 2011","June 2015","June 2015","April 19, 2013","null","March 16, 2016","Institut Català D'Ncologia. Hospital Duran Y Reynals, L'hospitalet de Llobregat, Barcelona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Universitario La Paz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01836328"
338,"NCT01042925","Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen","Completed","No Results Available","Female","Phase 1|Phase 2","42","Industry","Interventional","February 2010","December 2012","December 2012","January 6, 2010","null","June 3, 2016","Investigational Site Number 1537, Los Angeles, California, United States|Investigational Site Number 1238, Fort Meyers, Florida, United States|Investigational Site Number 1138, Boston, Massachusetts, United States|Investigational Site Number 1330, Detroit, Michigan, United States|Investigational Site Number 1151, Bronx, New York, United States|Investigational Site Number 1150, New York, New York, United States|Investigational Site Number 1214, Nashville, Tennessee, United States|Investigational Site Number 1246, Nashville, Tennessee, United States|Investigational Site Number 3413, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01042925"
339,"NCT01013740","Lapatinib in Combination With Vinorelbine","Completed","Has Results","Female","Phase 2","112","Industry","Interventional","November 25, 2009","August 21, 2012","March 1, 2016","November 16, 2009","July 18, 2013","May 31, 2017","Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Santiago, RegiÃ³n Metro De Santiago, Chile|Novartis Investigative Site, Santiago, RegiÃ³n Metro De Santiago, Chile|Novartis Investigative Site, ViÃ±a del Mar, ValparaÃ-so, Chile|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, NÃ®mes cedex 9, France|Novartis Investigative Site, Saint-Cloud, France|Novartis Investigative Site, Rheinfelden, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, MÃ¼nchen, Bayern, Germany|Novartis Investigative Site, Bad Nauheim, Hessen, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Chemnitz, Sachsen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion,Crete, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Ancona, Marche, Italy|Novartis Investigative Site, Torino, Piemonte, Italy|Novartis Investigative Site, Brindisi, Puglia, Italy|Novartis Investigative Site, Catania, Sicilia, Italy|Novartis Investigative Site, Catania, Sicilia, Italy|Novartis Investigative Site, Verona, Veneto, Italy|Novartis Investigative Site, Monterrey, Nuevo LeÃ³n, Mexico|Novartis Investigative Site, Oaxaca, Mexico|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Belgrad, Serbia|Novartis Investigative Site, Sremska Kamenica, Serbia|Novartis Investigative Site, Fuenlabrada (Madrid), Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Marbella, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Reus, Spain|Novartis Investigative Site, Segovia, Spain|Novartis Investigative Site, Vigo (Pontevedra), Spain|Novartis Investigative Site, Zamora, Spain","https://ClinicalTrials.gov/show/NCT01013740"
340,"NCT01471210","Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","Completed","No Results Available","All","Phase 1","124","Industry","Interventional","February 2012","April 2016","April 2016","November 15, 2011","null","April 19, 2017","Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|University Of Chicago, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Creteil Cedex, France|Local Institution, Lille Cedex, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Villejuif Cedex, France|Local Institution, Essen, Germany|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Local Institution, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT01471210"
341,"NCT01240655","A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","76","Industry","Interventional","April 2011","January 2015","January 2015","November 15, 2010","null","September 2, 2016","Dana Farber Cancer Institute SC, Boston, Massachusetts, United States|University of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, North Carolina, United States|Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2), Nashville, Tennessee, United States|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT01240655"
342,"NCT01516736","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","Completed","Has Results","Female","Phase 3","308","Industry","Interventional","March 2012","August 2013","December 2013","January 25, 2012","June 28, 2017","August 30, 2017","Sandoz Investigational Site, Hot Springs, Arkansas, United States|Sandoz Investigational Site, Jonesboro, Arkansas, United States|Sandoz Investigational Site, Corona, California, United States|Sandoz Investigational Site, Wichita, Kansas, United States|Sandoz Investigational Site, Mount Sterling, Kentucky, United States|Sandoz Investigational Site, Detroit, Michigan, United States|Sandoz Investigational Site, Bismarck, North Dakota, United States|Sandoz Investigational Site, Eugene, Oregon, United States|Sandoz Investigational Site, Germantown, Tennessee, United States|Sandoz Investigational Site, Newport News, Virginia, United States|Sandoz Investigational Site, Tucuman, Argentina|Sandoz Investigational Site, Temuco, Chile|Sandoz Investigational Site, Chennai, India|Sandoz Investigational Site, Delhi, India|Sandoz Investigational Site, Gujarat, India|Sandoz Investigational Site, Hyderabad, India|Sandoz Investigational Site, Karamsad, India|Sandoz Investigational Site, Lucknow, India|Sandoz Investigational Site, Maharashtra, India|Sandoz Investigational Site, Mangalore, India|Sandoz Investigational Site, Mumbai, India|Sandoz Investigational Site, Pradesh, India|Sandoz Investigational Site, Surat, India|Sandoz Investigational Site, Vadodara, India|Sandoz Investigational Site, Vellore, India|Sandoz Investigational Site, Visakhapatnam, India|Sandoz Investigational Site, Kelantan, Malaysia|Sandoz Investigational Site, Nilai, Malaysia|Sandoz Investigational Site, Penang, Malaysia|Sandoz Investigational Site, Penang, Malaysia|Sandoz Investigational Site, San Juan, Puerto Rico|Sandoz Investigational Site, San Juan, Puerto Rico|Sandoz Investigational Site, Arkhangelsk, Russian Federation|Sandoz Investigational Site, Bashkortostan, Russian Federation|Sandoz Investigational Site, Bryansk, Russian Federation|Sandoz Investigational Site, Kazan, Russian Federation|Sandoz Investigational Site, Krasnoyarsk, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Omsk, Russian Federation|Sandoz Investigational Site, Orel, Russian Federation|Sandoz Investigational Site, Orenburg, Russian Federation|Sandoz Investigational Site, Rostov-na-Donu, Russian Federation|Sandoz Investigational Site, St Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, Tomsk, Russian Federation|Sandoz Investigational Site, Vladimir, Russian Federation|Sandoz Investigational Site, Barcelona, Spain|Sandoz Investigational Site, Madrid, Spain|Sandoz Investigational Site, Santiago de Compostela, Spain|Sandoz Investigational Site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01516736"
343,"NCT01454180","Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets","Completed","No Results Available","All","Phase 2","31","Other|Industry","Interventional","October 2011","October 2011","December 2014","October 18, 2011","null","October 9, 2015","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01454180"
344,"NCT00862784","A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer","Completed","Has Results","All","Phase 2","48","Industry","Interventional","April 2009","April 2011","August 2011","March 17, 2009","June 17, 2014","June 17, 2014","ImClone Investigational Site, Ottawa, Ontario, Canada|ImClone Investigational Site, Toronto, Ontario, Canada|ImClone Investigational Site, Montreal, Quebec, Canada|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Santander, Spain|ImClone Investigational Site, Seville, Spain|ImClone Investigational Site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00862784"
345,"NCT00917384","Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma","Completed","Has Results","All","Phase 3","355","Industry","Interventional","August 2009","July 2012","December 2015","June 10, 2009","October 16, 2014","February 3, 2017","ImClone Investigational Site, Bakersfield, California, United States|ImClone Investigational Site, La Jolla, California, United States|ImClone Investigational Site, Redlands, California, United States|ImClone Investigational Site, Chicago, Illinois, United States|ImClone Investigational Site, New Orleans, Louisiana, United States|ImClone Investigational Site, Boston, Massachusetts, United States|ImClone Investigational Site, Omaha, Nebraska, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, West Reading, Pennsylvania, United States|ImClone Investigational Site, Providence, Rhode Island, United States|ImClone Investigational Site, Charleston, South Carolina, United States|ImClone Investigational Site, Knoxville, Tennessee, United States|ImClone Investigational Site, Memphis, Tennessee, United States|ImClone Investigational Site, Houston, Texas, United States|ImClone Investigational Site, Buenos Aires, Argentina|ImClone Investigational Site, Capital Federal, Argentina|ImClone Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|ImClone Investigational Site, Ciudada Autonoma, Argentina|ImClone Investigational Site, Cordoba, Argentina|ImClone Investigational Site, Rosario, Argentina|ImClone Investigational Site, Wodonga, New South Wales, Australia|ImClone Investigational Site, Hobart, Tasmania, Australia|ImClone Investigational Site, East Melbourne, Victoria, Australia|ImClone Investigational Site, Perth, Western Australia, Australia|ImClone Investigational Site, Bedford Park, Australia|ImClone Investigational Site, St. Leonards, Australia|ImClone Investigational Site, Woodville, Australia|ImClone Investigational Site, Sarajevo, Bosnia and Herzegovina|ImClone Investigational Site, Barretos, Brazil|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Brasilia, Brazil|ImClone Investigational Site, Curitiba, Brazil|ImClone Investigational Site, Curitiba, Brazil|ImClone Investigational Site, Florianopolis, Brazil|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Lajeados, Brazil|ImClone Investigational Site, Londrina, Brazil|ImClone Investigational Site, Passo Fundo, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Sao Paulo, Brazil|ImClone Investigational Site, Edmonton, Alberta, Canada|ImClone Investigational Site, Montreal, Quebec, Canada|ImClone Investigational Site, Sherbrooke, Quebec, Canada|ImClone Investigational Site, Concepcion, Chile|ImClone Investigational Site, La Serena, Chile|ImClone Investigational Site, Santiago, Chile|ImClone Investigational Site, Monteria, Colombia|ImClone Investigational Site, Osijek, Croatia|ImClone Investigational Site, Pula, Croatia|ImClone Investigational Site, Slavonski Brod, Croatia|ImClone Investigational Site, Zagreb, Croatia|ImClone Investigational Site, Brno, Czech Republic|ImClone Investigational Site, Hradec Kralove, Czech Republic|ImClone Investigational Site, Liberec, Czech Republic|ImClone Investigational Site, Nova Ves pod Plesi, Czech Republic|ImClone Investigational Site, Olomouc, Czech Republic|ImClone Investigational Site, Pardubice, Czech Republic|ImClone Investigational Site, Prague, Czech Republic|ImClone Investigational Site, Praha 10, Czech Republic|ImClone Investigational Site, Praha 2, Czech Republic|ImClone Investigational Site, Pribram, Czech Republic|ImClone Investigational Site, Alexandria, Egypt|ImClone Investigational Site, Cairo, Egypt|ImClone Investigational Site, Guatemala, Guatemala|ImClone Investigational Site, Guatemala, Guatemala|ImClone Investigational Site, Hyderabad, Andh Prad, India|ImClone Investigational Site, Hyderabad, Andh Prad, India|ImClone Investigational Site, New Delhi, Delhi, India|ImClone Investigational Site, Bangalore, Karna, India|ImClone Investigational Site, Bangalore, Karna, India|ImClone Investigational Site, Cochin, Kerala, India|ImClone Investigational Site, Thiruvananthapuram, Kerala, India|ImClone Investigational Site, Trivandrum, Kerala, India|ImClone Investigational Site, Chennai, Kilpauk, India|ImClone Investigational Site, Bhopal, Madh Prad, India|ImClone Investigational Site, Indore, Madh Prad, India|ImClone Investigational Site, Mumbai, Mahara, India|ImClone Investigational Site, Nashik, Mahara, India|ImClone Investigational Site, Pune, Mahara, India|ImClone Investigational Site, Chennai, Tamilnadu, India|ImClone Investigational Site, Chennai, Tamilnadu, India|ImClone Investigational Site, Kolkata, W Bengal, India|ImClone Investigational Site, Kolkata, W Bengal, India|ImClone Investigational Site, Bangalore, India|ImClone Investigational Site, Chennai, India|ImClone Investigational Site, Hyderabad, India|ImClone Investigational Site, Hyderabad, India|ImClone Investigational Site, Kolkata, India|ImClone Investigational Site, Mumbai, India|ImClone Investigational Site, Mumbai, India|ImClone Investigational Site, Pune, India|ImClone Investigational Site, West Bengal, India|ImClone Investigational Site, Jakarta, Indonesia|ImClone Investigational Site, Jakarta, Indonesia|ImClone Investigational Site, Jakarta, Indonesia|ImClone Investigational Site, Sumatera Utara, Indonesia|ImClone Investigational Site, West Java, Indonesia|ImClone Investigational Site, Aviano, Italy|ImClone Investigational Site, Bologna, Italy|ImClone Investigational Site, Brescia, Italy|ImClone Investigational Site, Cremona, Italy|ImClone Investigational Site, Lido di Camaiore, Italy|ImClone Investigational Site, Lucca, Italy|ImClone Investigational Site, Meldola, Italy|ImClone Investigational Site, Mirano, Italy|ImClone Investigational Site, Noale, Italy|ImClone Investigational Site, Potenza, Italy|ImClone Investigational Site, Rimini, Italy|ImClone Investigational Site, Udine, Italy|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Beirut, Lebanon|ImClone Investigational Site, Floriana, Malta|ImClone Investigational Site, Floriana, Malta|ImClone Investigational Site, Aguascelientes, Mexico|ImClone Investigational Site, Christchurch, New Zealand|ImClone Investigational Site, Cebu City, Philippines|ImClone Investigational Site, Pasig City, Philippines|ImClone Investigational Site, Gdansk, Poland|ImClone Investigational Site, Krakow, Poland|ImClone Investigational Site, Olsztyn, Poland|ImClone Investigational Site, Baia Mare, Romania|ImClone Investigational Site, Cluj Napoca, Romania|ImClone Investigational Site, Cluj Napoca, Romania|ImClone Investigational Site, Suceava, Romania|ImClone Investigational Site, Chelyabinsk, Russian Federation|ImClone Investigational Site, Kursk, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Pyatigorsk, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, Cape Town, South Africa|ImClone Investigational Site, Alcorcon, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Elche, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Santander, Spain|ImClone Investigational Site, Sevilla, Spain|ImClone Investigational Site, Kaohsiung, Taiwan|ImClone Investigational Site, Taichung County, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Bangkok, Thailand|ImClone Investigational Site, Chiang Mai, Thailand|ImClone Investigational Site, Rajathevee District, Thailand|ImClone Investigational Site, Adana, Turkey|ImClone Investigational Site, Gaziantep, Turkey|ImClone Investigational Site, Istanbul, Turkey|ImClone Investigational Site, Izmir, Turkey|ImClone Investigational Site, Bebington, Wirral, United Kingdom|ImClone Investigational Site, London, United Kingdom|ImClone Investigational Site, Sutton, United Kingdom|ImClone Investigational Site, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00917384"
346,"NCT00694382","Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy","Completed","No Results Available","All","Phase 3","3212","Industry","Interventional","June 2008","November 2010","November 2010","June 10, 2008","null","January 23, 2013","Investigational Site Number 840006, Birmingham, Alabama, United States|Investigational Site Number 840007, Casa Grande, Arizona, United States|Investigational Site Number 840060, Tucson, Arizona, United States|Investigational Site Number 840050, Fountain Valley, California, United States|Investigational Site Number 840072, Fullerton, California, United States|Investigational Site Number 840037, Indian Wells, California, United States|Investigational Site Number 840069, La Verne, California, United States|Investigational Site Number 840009, Long Beach, California, United States|Investigational Site Number 840001, Oceanside, California, United States|Investigational Site Number 840011, Rancho Mirage, California, United States|Investigational Site Number 840029, West Covina, California, United States|Investigational Site Number 840005, Norwich, Connecticut, United States|Investigational Site Number 840064, Torrington, Connecticut, United States|Investigational Site Number 840038, Woodbridge, Connecticut, United States|Investigational Site Number 840052, Washington, District of Columbia, United States|Investigational Site Number 840025, Washington, District of Columbia, United States|Investigational Site Number 840074, Clearwater, Florida, United States|Investigational Site Number 840019, Jacksonville, Florida, United States|Investigational Site Number 840051, Rockledge, Florida, United States|Investigational Site Number 840073, Sarasota, Florida, United States|Investigational Site Number 840070, Roswell, Georgia, United States|Investigational Site Number 840016, Park Ridge, Illinois, United States|Investigational Site Number 840028, Quincy, Illinois, United States|Investigational Site Number 840008, Skokie, Illinois, United States|Investigational Site Number 840033, Goshen, Indiana, United States|Investigational Site Number 840010, Indianapolis, Indiana, United States|Investigational Site Number 840014, Louisville, Kentucky, United States|Investigational Site Number 840048, Mount Sterling, Kentucky, United States|Investigational Site Number 840047, Metairie, Louisiana, United States|Investigational Site Number 840032, Ruston, Louisiana, United States|Investigational Site Number 840042, Bethesda, Maryland, United States|Investigational Site Number 840066, Easton, Maryland, United States|Investigational Site Number 840059, Tupelo, Mississippi, United States|Investigational Site Number 840024, Rochester, New York, United States|Investigational Site Number 840031, Syracuse, New York, United States|Investigational Site Number 840020, Durham, North Carolina, United States|Investigational Site Number 840021, Durham, North Carolina, United States|Investigational Site Number 840026, High Point, North Carolina, United States|Investigational Site Number 840046, Bismarck, North Dakota, United States|Investigational Site Number 840003, Middletown, Ohio, United States|Investigational Site Number 840022, Sylvania, Ohio, United States|Investigational Site Number 840075, East Providence, Rhode Island, United States|Investigational Site Number 840067, Beaumont, Texas, United States|Investigational Site Number 840004, El Paso, Texas, United States|Investigational Site Number 840034, Houston, Texas, United States|Investigational Site Number 840035, Sugar Land, Texas, United States|Investigational Site Number 840063, Kennewick, Washington, United States|Investigational Site Number 840018, Tacoma, Washington, United States|Investigational Site Number 032006, Buenos Aires, Argentina|Investigational Site Number 032003, Capital Federal, Argentina|Investigational Site Number 032004, Rosario, Argentina|Investigational Site Number 032005, San Miguel De Tucuman, Argentina|Investigational Site Number 032007, Tucuman, Argentina|Investigational Site Number 036004, Adelaide, Australia|Investigational Site Number 036002, Bedford Park, Australia|Investigational Site Number 036001, Box Hill, Australia|Investigational Site Number 036009, Lismore, Australia|Investigational Site Number 036007, Perth, Australia|Investigational Site Number 036006, Ringwood East, Australia|Investigational Site Number 036008, Westmead, Australia|Investigational Site Number 036003, Woodville, Australia|Investigational Site Number 036005, Woolloongabba, Australia|Investigational Site Number 040002, Graz, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040004, Wien, Austria|Investigational Site Number 112002, Gomel, Belarus|Investigational Site Number 112003, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 112004, Vitebsk, Belarus|Investigational Site Number 056008, Bonheiden, Belgium|Investigational Site Number 056011, Brussels, Belgium|Investigational Site Number 056005, Gent, Belgium|Investigational Site Number 056010, Haine-Saint-Paul, Belgium|Investigational Site Number 056006, Kortrijk, Belgium|Investigational Site Number 056009, Liège, Belgium|Investigational Site Number 056004, Merksem, Belgium|Investigational Site Number 056003, Oostende, Belgium|Investigational Site Number 056012, Ottignies, Belgium|Investigational Site Number 056002, Sint Niklaas, Belgium|Investigational Site Number 076002, Belo Horizonte, Brazil|Investigational Site Number 076022, Curitiba, Brazil|Investigational Site Number 076015, Curitiba, Brazil|Investigational Site Number 076012, Florianopolis, Brazil|Investigational Site Number 076001, Fortaleza, Brazil|Investigational Site Number 076009, Goiania, Brazil|Investigational Site Number 076007, Goiania, Brazil|Investigational Site Number 076016, Goiania, Brazil|Investigational Site Number 076024, Ijui, Brazil|Investigational Site Number 076003, Joinville, Brazil|Investigational Site Number 076010, Londrina, Brazil|Investigational Site Number 076026, Passo Fundo, Brazil|Investigational Site Number 076027, Passo Fundo, Brazil|Investigational Site Number 076023, Porto Alegre, Brazil|Investigational Site Number 076020, Porto Alegre, Brazil|Investigational Site Number 076014, Salvador, Brazil|Investigational Site Number 076018, Salvador, Brazil|Investigational Site Number 076011, Santo Andre, Brazil|Investigational Site Number 076006, Sao Jose Dos Campos, Brazil|Investigational Site Number 076008, Sao Paulo, Brazil|Investigational Site Number 076017, Sao Paulo, Brazil|Investigational Site Number 076004, Taguatinga, Brazil|Investigational Site Number 100001, Rousse, Bulgaria|Investigational Site Number 100003, Varna, Bulgaria|Investigational Site Number 124008, Greenfield Park, Canada|Investigational Site Number 124007, Kelowna, Canada|Investigational Site Number 124010, Moncton, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124002, Ottawa, Canada|Investigational Site Number 124009, Owen Sound, Canada|Investigational Site Number 124006, Rimouski, Canada|Investigational Site Number 124013, Saint John, Canada|Investigational Site Number 124001, Sherbrooke, Canada|Investigational Site Number 124012, Victoria, Canada|Investigational Site Number 124011, Weston, Canada|Investigational Site Number 152002, Temuco, Chile|Investigational Site Number 156014, Beijing, China|Investigational Site Number 156008, Beijing, China|Investigational Site Number 156022, Beijing, China|Investigational Site Number 156031, Changchun, China|Investigational Site Number 156021, Chengdu, China|Investigational Site Number 156019, Chongqing, China|Investigational Site Number 156003, Dalian, China|Investigational Site Number 156025, Guangzhou, China|Investigational Site Number 156026, Hangzhou, China|Investigational Site Number 156030, Nanning, China|Investigational Site Number 156029, Qingdao, China|Investigational Site Number 156024, Shanghai, China|Investigational Site Number 156028, Shanghai, China|Investigational Site Number 156020, Shanghai, China|Investigational Site Number 156011, Shanghai, China|Investigational Site Number 156013, Shantou, China|Investigational Site Number 156012, Suzhou, China|Investigational Site Number 156004, Xi'An, China|Investigational Site Number 156009, Xi'An, China|Investigational Site Number 156027, Yinchuan, China|Investigational Site Number 170010, Bogota, Colombia|Investigational Site Number 170005, Manizales, Colombia|Investigational Site Number 170002, Medellin, Colombia|Investigational Site Number 170006, Medellin, Colombia|Investigational Site Number 170007, Medellín, Colombia|Investigational Site Number 170008, Monteria, Colombia|Investigational Site Number 170004, Pereira, Colombia|Investigational Site Number 191006, Pula, Croatia|Investigational Site Number 191005, Rijeka, Croatia|Investigational Site Number 191007, Varazdin, Croatia|Investigational Site Number 191003, Zadar, Croatia|Investigational Site Number 191008, Zagreb, Croatia|Investigational Site Number 191001, Zagreb, Croatia|Investigational Site Number 191004, Zagreb, Croatia|Investigational Site Number 203004, Hradec Kralove, Czech Republic|Investigational Site Number 203008, Kolin, Czech Republic|Investigational Site Number 203007, Nova Ves Pod Plesi, Czech Republic|Investigational Site Number 203003, Praha 5, Czech Republic|Investigational Site Number 208001, Herlev, Denmark|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 246001, Turku, Finland|Investigational Site Number 250002, Antibes, France|Investigational Site Number 250010, Colmar, France|Investigational Site Number 250020, Gap, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250025, Lille Cedex, France|Investigational Site Number 250012, Lille Cedex, France|Investigational Site Number 250003, Lyon, France|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250024, Montpellier Cedex, France|Investigational Site Number 250006, Paris Cedex 10, France|Investigational Site Number 250027, Paris Cedex 10, France|Investigational Site Number 250004, Paris Cedex 14, France|Investigational Site Number 250021, Reims, France|Investigational Site Number 250019, Rouen, France|Investigational Site Number 250017, Saint Gregoire, France|Investigational Site Number 250014, Vandoeuvre Les Nancy, France|Investigational Site Number 276012, Augsburg, Germany|Investigational Site Number 276025, Berlin, Germany|Investigational Site Number 276016, Berlin, Germany|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276029, Berlin, Germany|Investigational Site Number 276004, Bochum, Germany|Investigational Site Number 276014, Dresden, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276030, Essen, Germany|Investigational Site Number 276005, Frankfurt Am Main, Germany|Investigational Site Number 276032, Gauting, Germany|Investigational Site Number 276038, Halle/Saale, Germany|Investigational Site Number 276034, Halle, Germany|Investigational Site Number 276037, Hamburg, Germany|Investigational Site Number 276007, Hannover, Germany|Investigational Site Number 276006, Köln, Germany|Investigational Site Number 276020, Leer, Germany|Investigational Site Number 276010, Leipzig, Germany|Investigational Site Number 276017, Magdeburg, Germany|Investigational Site Number 276011, Mannheim, Germany|Investigational Site Number 276003, Minden, Germany|Investigational Site Number 276021, München, Germany|Investigational Site Number 276019, München, Germany|Investigational Site Number 276015, München, Germany|Investigational Site Number 276013, Neumünster, Germany|Investigational Site Number 276022, Oldenburg, Germany|Investigational Site Number 276035, Paderborn, Germany|Investigational Site Number 276031, Passau, Germany|Investigational Site Number 276023, Rosenheim, Germany|Investigational Site Number 276008, Singen, Germany|Investigational Site Number 276024, Westerstede, Germany|Investigational Site Number 300004, Athens, Greece|Investigational Site Number 300003, Heraklion, Greece|Investigational Site Number 300002, Thessaloniki, Greece|Investigational Site Number 344001, Hong Kong, Hong Kong|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348009, Budapest, Hungary|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348010, Farkasgyepu, Hungary|Investigational Site Number 348001, Gyula, Hungary|Investigational Site Number 348012, Mátraháza, Hungary|Investigational Site Number 348003, Sopron, Hungary|Investigational Site Number 348008, Szikszó, Hungary|Investigational Site Number 348011, Szolnok, Hungary|Investigational Site Number 348007, Zalaegerszeg, Hungary|Investigational Site Number 356006, Bangalore, India|Investigational Site Number 356008, Bangalore, India|Investigational Site Number 356009, Bhopal, India|Investigational Site Number 356018, Chennai, India|Investigational Site Number 356020, Chennai, India|Investigational Site Number 356019, Coimbatore, India|Investigational Site Number 356015, Hyderabad, India|Investigational Site Number 356025, Hyderabad, India|Investigational Site Number 356011, Jaipur, India|Investigational Site Number 356014, Kochi, India|Investigational Site Number 356003, Kolkata, India|Investigational Site Number 356013, Kolkata, India|Investigational Site Number 356017, Kolkata, India|Investigational Site Number 356005, Madurai, India|Investigational Site Number 356016, Miraj, India|Investigational Site Number 356001, Mumbai, India|Investigational Site Number 356023, Nagpur, India|Investigational Site Number 356002, New Delhi, India|Investigational Site Number 356004, Pune, India|Investigational Site Number 356024, Pune, India|Investigational Site Number 356012, Vishakhapatnam, India|Investigational Site Number 360002, Bandung, Indonesia|Investigational Site Number 360001, Denpasar, Indonesia|Investigational Site Number 360004, Medan, Indonesia|Investigational Site Number 372004, Dublin 7, Ireland|Investigational Site Number 372003, Dublin, Ireland|Investigational Site Number 372002, Dublin, Ireland|Investigational Site Number 376003, Jerusalem, Israel|Investigational Site Number 376004, Kfar Saba, Israel|Investigational Site Number 376001, Nahariya, Israel|Investigational Site Number 376006, Petah-Tikva, Israel|Investigational Site Number 376007, Tzrifin, Israel|Investigational Site Number 380005, Castellanza, Italy|Investigational Site Number 380014, Cattolica, Italy|Investigational Site Number 380007, Cesena, Italy|Investigational Site Number 380015, Cremona, Italy|Investigational Site Number 380009, Faenza, Italy|Investigational Site Number 380012, Lecce, Italy|Investigational Site Number 380006, Lugo, Italy|Investigational Site Number 380001, Meldola, Italy|Investigational Site Number 380011, Parma, Italy|Investigational Site Number 380020, Perugia, Italy|Investigational Site Number 380013, Ravenna, Italy|Investigational Site Number 380016, Rimini, Italy|Investigational Site Number 380004, Sondrio, Italy|Investigational Site Number 380010, Sora, Italy|Investigational Site Number 380008, Taormina, Italy|Investigational Site Number 380019, Terni, Italy|Investigational Site Number 380003, Treviglio, Italy|Investigational Site Number 380017, Udine, Italy|Investigational Site Number 410008, Daegu, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410009, Seoul, Korea, Republic of|Investigational Site Number 410004, Suwon, Korea, Republic of|Investigational Site Number 428002, Liepaja, Latvia|Investigational Site Number 428003, Riga, Latvia|Investigational Site Number 428001, Riga, Latvia|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 458001, Kota Kinabalu, Malaysia|Investigational Site Number 458003, Kuala Lumpur, Malaysia|Investigational Site Number 458004, Penang, Malaysia|Investigational Site Number 458005, Penang, Malaysia|Investigational Site Number 484002, Acapulco, Mexico|Investigational Site Number 484006, Aguascalientes, Mexico|Investigational Site Number 484007, Durango, Mexico|Investigational Site Number 484008, Mérida, Mexico|Investigational Site Number 484012, Puebla, Mexico|Investigational Site Number 484003, Toluca, Mexico|Investigational Site Number 484010, Xalapa, Mexico|Investigational Site Number 528006, Den Haag, Netherlands|Investigational Site Number 528004, Groningen, Netherlands|Investigational Site Number 528005, Helmond, Netherlands|Investigational Site Number 528001, Hoofddorp, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 578001, Oslo, Norway|Investigational Site Number 604012, Arequipa, Peru|Investigational Site Number 604004, Callao, Peru|Investigational Site Number 604011, Callao, Peru|Investigational Site Number 604001, Cercado, Peru|Investigational Site Number 604002, Chiclayo, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604003, Lima, Peru|Investigational Site Number 616009, Bialystok, Poland|Investigational Site Number 616008, Bielsko-Biala, Poland|Investigational Site Number 616006, Gliwice, Poland|Investigational Site Number 616004, Krakow, Poland|Investigational Site Number 616003, Lubin, Poland|Investigational Site Number 616019, Olsztyn, Poland|Investigational Site Number 616021, Otwock, Poland|Investigational Site Number 616010, Poznan, Poland|Investigational Site Number 616001, Prabuty, Poland|Investigational Site Number 616014, Rybnik, Poland|Investigational Site Number 616005, Rzeszow, Poland|Investigational Site Number 616013, Torun, Poland|Investigational Site Number 616018, Warszawa, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616015, Wroclaw, Poland|Investigational Site Number 620003, Aveiro, Portugal|Investigational Site Number 620009, Guimarães, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620008, Matosinhos, Portugal|Investigational Site Number 620007, Porto, Portugal|Investigational Site Number 620002, Setúbal, Portugal|Investigational Site Number 642004, Brasov, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642001, Cluj Napoca, Romania|Investigational Site Number 642006, Cluj-Napoca, Romania|Investigational Site Number 642010, Iasi, Romania|Investigational Site Number 642003, Suceava, Romania|Investigational Site Number 642008, Timisoara, Romania|Investigational Site Number 643024, Berdsk, Russian Federation|Investigational Site Number 643006, Chelyabinsk, Russian Federation|Investigational Site Number 643001, Kazan, Russian Federation|Investigational Site Number 643004, Krasnoyarsk, Russian Federation|Investigational Site Number 643010, Obninsk, Russian Federation|Investigational Site Number 643005, Omsk, Russian Federation|Investigational Site Number 643022, Pyatigorsk, Russian Federation|Investigational Site Number 643023, Rostov-On-Don, Russian Federation|Investigational Site Number 643020, Saratov, Russian Federation|Investigational Site Number 643019, Smolensk, Russian Federation|Investigational Site Number 643021, Sochi, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643015, St-Petersburg, Russian Federation|Investigational Site Number 643011, St-Petersburg, Russian Federation|Investigational Site Number 643009, St.Petersburg, Russian Federation|Investigational Site Number 643008, Tomsk, Russian Federation|Investigational Site Number 643016, Tula, Russian Federation|Investigational Site Number 643018, Tyumen, Russian Federation|Investigational Site Number 643012, Ufa, Russian Federation|Investigational Site Number 643007, Vladivostok, Russian Federation|Investigational Site Number 643017, Voronezh, Russian Federation|Investigational Site Number 643003, Yaroslavl, Russian Federation|Investigational Site Number 688002, Belgrade, Serbia|Investigational Site Number 688004, Belgrade, Serbia|Investigational Site Number 688007, Kragujevac, Serbia|Investigational Site Number 688005, Nis, Serbia|Investigational Site Number 703003, Trnava, Slovakia|Investigational Site Number 705003, Golnik, Slovenia|Investigational Site Number 705002, Maribor, Slovenia|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 724008, Barakaldo, Spain|Investigational Site Number 724010, Barakaldo, Spain|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724006, Islas Baleares, Spain|Investigational Site Number 724011, Lérida, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724007, Madrid, Spain|Investigational Site Number 724013, Madrid, Spain|Investigational Site Number 724012, Madrid, Spain|Investigational Site Number 724005, Orense, Spain|Investigational Site Number 724003, Puerto De Sagunto, Spain|Investigational Site Number 724002, Valencia, Spain|Investigational Site Number 752003, Göteborg, Sweden|Investigational Site Number 752005, Mora, Sweden|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 752001, Växjö, Sweden|Investigational Site Number 756006, Aarau, Switzerland|Investigational Site Number 756004, Winterthur, Switzerland|Investigational Site Number 158004, Changhua, Taiwan|Investigational Site Number 804008, Cherkasy, Ukraine|Investigational Site Number 804009, Chernivtsi, Ukraine|Investigational Site Number 804002, Dnipropetrovsk, Ukraine|Investigational Site Number 804006, Donetsk, Ukraine|Investigational Site Number 804005, Krivoy Rog, Ukraine|Investigational Site Number 804001, Lutsk, Ukraine|Investigational Site Number 804010, Lviv, Ukraine|Investigational Site Number 804011, Sumy, Ukraine|Investigational Site Number 804004, Ternopil, Ukraine|Investigational Site Number 826016, Bangor, United Kingdom|Investigational Site Number 826010, Brighton, United Kingdom|Investigational Site Number 826015, Coventry, United Kingdom|Investigational Site Number 826013, Dundee, United Kingdom|Investigational Site Number 826007, Hull, United Kingdom|Investigational Site Number 826002, Lincoln, United Kingdom|Investigational Site Number 826017, Lincoln, United Kingdom|Investigational Site Number 826005, Manchester, United Kingdom|Investigational Site Number 826004, Norwich, United Kingdom|Investigational Site Number 826009, Peterborough, United Kingdom|Investigational Site Number 826011, Portsmouth, United Kingdom|Investigational Site Number 826001, Shrewsbury, United Kingdom|Investigational Site Number 826014, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT00694382"
347,"NCT02520752","A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","37","Industry","Interventional","December 10, 2015","January 30, 2017","September 12, 2017","August 13, 2015","null","July 12, 2018","Emory University School of Medicine/Winship Cancer Institute SC-2, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Dijon Cedex, Cote D Or, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02520752"
348,"NCT00863746","A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).","Completed","Has Results","All","Phase 3","703","Industry","Interventional","April 2009","March 2012","April 2013","March 18, 2009","July 30, 2013","January 19, 2015","Fayetteville, Arkansas, United States|Stanford, California, United States|Philadelphia, Pennsylvania, United States|Ramos Mejía, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Córdoba, Argentina|Córdoba, Argentina|Santa Fé, Argentina|Graz, Austria|Linz, Austria|Wien, Austria|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Genk, Belgium|Brasilia, Distrito Federal, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Santo André, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Guangzhou, China|Shanghai, China|Shanghai, China|Caen, France|Dijon, France|La Roche Sur Yon Cedex, France|La Tronche, France|Lille, France|Lyon Cedex, France|Saint Herblain, France|Tours, France|Heidelberg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Gauting, Bayern, Germany|München, Bayern, Germany|Kassel, Hessen, Germany|Köln, Nordrhein-Westfalen, Germany|Großhansdorf, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Hamburg, Germany|Athens, Greece|Heraklion, Greece|Thessaloniki, Greece|Shatin, N.T, Hong Kong|Hongkong, Hong Kong|Kowloon, Hong Kong|Budapest, Hungary|Budapest, Hungary|Edeleny, Hungary|Farkasgyepu, Hungary|Torokbalint, Hungary|Zalaegerszeg, Hungary|Mumbai, Maharashtra, India|Pune, Maharashtra, India|Kerala, India|Bandung, Indonesia|Jakarta, Indonesia|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Zrifin, Israel|Rozzano, Milano, Italy|Monza, Monza-Brianza, Italy|Orbassano, Torino, Italy|Avellino, Italy|Genova, Italy|Livorno, Italy|Parma, Italy|Perugia, Italy|Roma, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Akashi, Hyogo, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Itabashi-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Fukuoka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Nieuwegein, Netherlands|Zwolle, Netherlands|Lahore, Punjab, Pakistan|Karachi, Sindh, Pakistan|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|San Borja, Peru|Cebu City, Philippines|Manila, Philippines|Metro Manila, Philippines|Quezon City, Philippines|Kielce, Poland|Krakow, Poland|Olsztyn, Poland|Rzeszow, Poland|Szczecin, Poland|Warszawa, Poland|Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Singapore, Singapore|Singapore, Singapore|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Prietoria, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cruces/Barakaldo, Bilbao, Spain|Orense, Ourense, Spain|Barcelona, Spain|Barcelona, Spain|Lleida, Spain|Lugo, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Zamora, Spain|Falun, Sweden|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Songkhla, Thailand|Ankara, Turkey|Instanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kocaeli, Turkey|Bristol, Avon, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Greater Manchester, Manchester, United Kingdom|Sutton, Surrey, United Kingdom|Leeds, West Yorkshire, United Kingdom|Aberdeen, United Kingdom|London, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT00863746"
349,"NCT00820222","Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer","Completed","Has Results","Female","Phase 3","546","Industry","Interventional","April 14, 2009","June 11, 2012","March 22, 2018","January 12, 2009","March 15, 2013","June 14, 2018","Novartis Investigative Site, Goodyear, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Greenbrae, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Santa Barbara, California, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Coral Springs, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Warrenville, Illinois, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Great Falls, Montana, United States|Novartis Investigative Site, Voorhees, New Jersey, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Sint-Niklaas, Belgium|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Angers cedex 9, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bayonne cedex, France|Novartis Investigative Site, Besancon, France|Novartis Investigative Site, Caen Cedex 05, France|Novartis Investigative Site, Colmar, France|Novartis Investigative Site, Dechy, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Paris cedex 13, France|Novartis Investigative Site, Reims Cedex, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Saint Priest En Jarez Cedex, France|Novartis Investigative Site, Saint-Gregoire, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Vannes, France|Novartis Investigative Site, Ravensburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Eggenfelden, Bayern, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Landshut, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Wuerzburg, Bayern, Germany|Novartis Investigative Site, Potsdam, Brandenburg, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Bottrop, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duisburg, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Goch, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Herne, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuerselen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Speyer, Rheinland-Pfalz, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Brandenburg, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, N. Kifisia, Athens, Greece|Novartis Investigative Site, Neo Faliro, Greece|Novartis Investigative Site, Patra, Greece|Novartis Investigative Site, Peiraius, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Tatabanya, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Bologna, Emilia-Romagna, Italy|Novartis Investigative Site, Bologna, Emilia-Romagna, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Rimini, Emilia-Romagna, Italy|Novartis Investigative Site, Udine, Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Treviglio (BG), Lombardia, Italy|Novartis Investigative Site, Fermo (AP), Marche, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Lido Di Camaiore (LU), Toscana, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Perugia, Umbria, Italy|Novartis Investigative Site, Varese, Italy|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Bytom, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Moscow Region, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhniy Novgorod, Russian Federation|Novartis Investigative Site, Obninsk, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tver, Russian Federation|Novartis Investigative Site, Velikiy Novgorod, Russian Federation|Novartis Investigative Site, Voronezh, Russian Federation|Novartis Investigative Site, Vsevolozhsk, Russian Federation|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Caceres, Spain|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Jerez (Cadiz), Spain|Novartis Investigative Site, La Coruna, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiangmai, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Edinburgh, Midlothian, United Kingdom|Novartis Investigative Site, Birmingham, West Midlands, United Kingdom|Novartis Investigative Site, Aberdeen, United Kingdom|Novartis Investigative Site, Burton on Trent, United Kingdom|Novartis Investigative Site, Cottingham, Hull, United Kingdom|Novartis Investigative Site, Huddersfield, United Kingdom|Novartis Investigative Site, Ipswich, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Maidstone, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Peterborough, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom|Novartis Investigative Site, Wolverhampton, United Kingdom|Novartis Investigative Site, Worthing, United Kingdom","https://ClinicalTrials.gov/show/NCT00820222"
350,"NCT01862081","A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer","Completed","No Results Available","All","Phase 1","80","Industry","Interventional","July 16, 2013","June 9, 2017","June 9, 2017","May 24, 2013","null","November 28, 2017","Florida Cancer Specialists - Tampa (Dr. MLK Blvd), Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, P.A; Baylor Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A. - Fort Worth, Fort Worth, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy, Leuven, Belgium|Princess Margaret Hospital, Toronto, Ontario, Canada|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01862081"
351,"NCT02004106","A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors","Completed","No Results Available","All","Phase 1","110","Industry","Interventional","December 31, 2013","August 31, 2016","August 31, 2016","December 6, 2013","null","March 6, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rigshospitalet, Onkologisk Klinik, København Ø, Denmark|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands|Clinica Universitaria de Navarra; Servicio de oncología, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|CHUV; Departement d'Oncologie, Lausanne, Switzerland|Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT02004106"
352,"NCT00865709","Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects","Completed","Has Results","All","Phase 2","198","Industry","Interventional","March 2009","January 2011","February 2012","March 19, 2009","March 20, 2012","December 11, 2014","Wichita, Kansas, United States|Metairie, Louisiana, United States|Brockton, Massachusetts, United States|Burlington, Massachusetts, United States|Dallas, Texas, United States|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Castelfranco Veneto, Treviso, Italy|Genova, Italy|Macerata, Italy|Palermo, Italy|Pordenone, Italy|Torino, Italy|Udine, Italy|Verona, Italy|Bialystok, Poland|Elblag, Poland|Gdansk, Poland|Gdynia, Poland|Krakow, Poland|Krakow, Poland|Olsztyn, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Alba Iulia, Romania|Baia Mare, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Craiova-Dolj, Romania|Iasi, Romania|Oradea, Romania|Suceava, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Astrakhan, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Ivanovo, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Khabarovsk, Russian Federation|Krasnodar, Russian Federation|Kursk, Russian Federation|Magnitogorsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Pjatygorsk, Russian Federation|Rostov-on-Don, Russian Federation|Samara, Russian Federation|Sochi, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tula, Russian Federation|Ulyanovsk, Russian Federation|Vladimir, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation|L'Hospitalet de Llobregat, Barcelona, Spain|Manresa, Barcelona, Spain|Santander, Cantabria, Spain|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankovsk, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Krivoy Rog, Ukraine|Lugansk, Ukraine|Lviv, Ukraine|Mariupol, Ukraine|Sumy, Ukraine|Uzhgorod, Ukraine|Bristol, Avon, United Kingdom|Liverpool, Merseyside, United Kingdom|Northwood, Middlesex, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Aberdeen, United Kingdom|Belfast, United Kingdom|Glasgow, United Kingdom|Hull, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Portsmouth, United Kingdom","https://ClinicalTrials.gov/show/NCT00865709"
353,"NCT00841191","A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors","Completed","No Results Available","All","Phase 1|Phase 2","84","Industry","Interventional","March 2009","April 2011","April 2011","February 11, 2009","null","May 14, 2014","Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Brussel, Belgium|Wilrijk, Belgium|Caen, France|Lyon, France|Villejuif, France|Barcelona, Spain|Madrid, Spain|Birmingham, United Kingdom|Edinburgh, United Kingdom|Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00841191"
354,"NCT01927341","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors","Completed","No Results Available","All","Phase 1|Phase 2","90","Industry","Interventional","November 2013","October 2015","null","August 22, 2013","null","April 4, 2017","University of California at Los Angeles Dept of Onc, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center Oncology Dept, NY, New York, United States|Array BioPharma Investigative Site, Leuven, Belgium|Array BioPharma Investigative Site, Toronto, Ontario, Canada|Array BioPharma Investigative Site, Toulouse Cedex 9, France|Array BioPharma Investigative Site, Milano, MI, Italy|Array BioPharma Investigative Site, Amsterdam, Netherlands|Array BioPharma Investigative Site, Barcelona, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT01927341"
355,"NCT00994123","A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 1|Phase 2","162","Industry","Interventional","February 2010","November 2014","June 2015","October 14, 2009","August 22, 2016","August 22, 2016","Birmingham, Alabama, United States|Tucson, Arizona, United States|Loma Linda, California, United States|Sacramento, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Lafayette, Indiana, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Buffalo, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Edmonton, Alberta, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Heidelberg, Mannheim, Germany|Bad Berka, Germany|Frankfurt, Germany|Heidelberg, Germany|Lungenklinik, Germany|Ulm, Germany|Seoul, Gangnam-gu, Korea, Republic of|Seoul, Seodaemun-gu, Korea, Republic of|Barcelona, Spain|Madrid, Spain|Malaga, Spain|Guishan, Taoyuan County, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Tainan City, Taiwan|Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00994123"
356,"NCT01345682","LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","Completed","Has Results","All","Phase 3","483","Industry","Interventional","January 5, 2012","March 15, 2014","December 6, 2016","May 2, 2011","April 14, 2015","February 15, 2018","1200.43.00113 Boehringer Ingelheim Investigational Site, Harvey, Illinois, United States|1200.43.00106 Boehringer Ingelheim Investigational Site, Peoria, Illinois, United States|1200.43.00110 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|1200.43.00107 Boehringer Ingelheim Investigational Site, Omaha, Nebraska, United States|1200.43.00105 Boehringer Ingelheim Investigational Site, Stony Brook, New York, United States|1200.43.00102 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|1200.43.00103 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|1200.43.00109 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|1200.43.05401 Boehringer Ingelheim Investigational Site, Ciudad Autonoma de Bs As, Argentina|1200.43.05402 Boehringer Ingelheim Investigational Site, Santa Fe, Argentina|1200.43.05403 Boehringer Ingelheim Investigational Site, Villa Dominico, Argentina|1200.43.04303 Boehringer Ingelheim Investigational Site, Leoben, Austria|1200.43.04305 Boehringer Ingelheim Investigational Site, Salzburg, Austria|1200.43.04301 Boehringer Ingelheim Investigational Site, Wien, Austria|1200.43.03202 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1200.43.03203 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1200.43.03204 Boehringer Ingelheim Investigational Site, Gent, Belgium|1200.43.03201 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1200.43.05504 Boehringer Ingelheim Investigational Site, Barretos, Brazil|1200.43.05505 Boehringer Ingelheim Investigational Site, Jau, Brazil|1200.43.05507 Boehringer Ingelheim Investigational Site, Passo Fundo, Brazil|1200.43.05503 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|1200.43.05502 Boehringer Ingelheim Investigational Site, Rio de Janeiro, Brazil|1200.43.05501 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|1200.43.05506 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|1200.43.04202 Boehringer Ingelheim Investigational Site, Olomouc, Czechia|1200.43.04203 Boehringer Ingelheim Investigational Site, Prague 2, Czechia|1200.43.04201 Boehringer Ingelheim Investigational Site, Prague 8, Czechia|1200.43.04501 Boehringer Ingelheim Investigational Site, København Ø, Denmark|1200.43.03304 Boehringer Ingelheim Investigational Site, Avignon Cedex 9, France|1200.43.03306 Boehringer Ingelheim Investigational Site, Clermont-Ferrand cedex 1, France|1200.43.03312 Boehringer Ingelheim Investigational Site, Dijon Cedex, France|1200.43.03303 Boehringer Ingelheim Investigational Site, Lille Cedex, France|1200.43.03301 Boehringer Ingelheim Investigational Site, Lyon Cedex, France|1200.43.03302 Boehringer Ingelheim Investigational Site, Montpellier cedex 5, France|1200.43.03307 Boehringer Ingelheim Investigational Site, Nice cedex 2, France|1200.43.03314 Boehringer Ingelheim Investigational Site, Paris Cedex 05, France|1200.43.03305 Boehringer Ingelheim Investigational Site, Poitiers, France|1200.43.03316 Boehringer Ingelheim Investigational Site, Rouen Cedex 1, France|1200.43.03309 Boehringer Ingelheim Investigational Site, Saint Herblain Cedex, France|1200.43.03310 Boehringer Ingelheim Investigational Site, Vandoeuvre les Nancy cedex, France|1200.43.03317 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1200.43.04903 Boehringer Ingelheim Investigational Site, Aachen, Germany|1200.43.04902 Boehringer Ingelheim Investigational Site, Berlin, Germany|1200.43.04909 Boehringer Ingelheim Investigational Site, Dresden, Germany|1200.43.04901 Boehringer Ingelheim Investigational Site, Essen, Germany|1200.43.04905 Boehringer Ingelheim Investigational Site, Hamburg, Germany|1200.43.04906 Boehringer Ingelheim Investigational Site, Hannover, Germany|1200.43.04908 Boehringer Ingelheim Investigational Site, Jena, Germany|1200.43.04904 Boehringer Ingelheim Investigational Site, Leipzig, Germany|1200.43.04907 Boehringer Ingelheim Investigational Site, Mannheim, Germany|1200.43.03004 Boehringer Ingelheim Investigational Site, Haidari, Greece|1200.43.03005 Boehringer Ingelheim Investigational Site, Heraklion, Greece|1200.43.03002 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|1200.43.97201 Boehringer Ingelheim Investigational Site, Haifa, Israel|1200.43.97203 Boehringer Ingelheim Investigational Site, Petach Tikva, Israel|1200.43.97204 Boehringer Ingelheim Investigational Site, Tel Hashomer, Israel|1200.43.03909 Boehringer Ingelheim Investigational Site, Aosta, Italy|1200.43.03908 Boehringer Ingelheim Investigational Site, Cagliari, Italy|1200.43.03901 Boehringer Ingelheim Investigational Site, Confreria (CN), Italy|1200.43.03907 Boehringer Ingelheim Investigational Site, Milano, Italy|1200.43.03903 Boehringer Ingelheim Investigational Site, Napoli, Italy|1200.43.03905 Boehringer Ingelheim Investigational Site, Palermo, Italy|1200.43.03902 Boehringer Ingelheim Investigational Site, Savona, Italy|1200.43.03904 Boehringer Ingelheim Investigational Site, Taormina (ME), Italy|1200.43.03906 Boehringer Ingelheim Investigational Site, Venezia, Italy|1200.43.03910 Boehringer Ingelheim Investigational Site, Viterbo, Italy|1200.43.08106 Boehringer Ingelheim Investigational Site, Aichi, Nagoya, Japan|1200.43.08103 Boehringer Ingelheim Investigational Site, Chiba, Kashiwa, Japan|1200.43.08108 Boehringer Ingelheim Investigational Site, Ehime, Matsuyama, Japan|1200.43.08111 Boehringer Ingelheim Investigational Site, Hyogo, Akashi, Japan|1200.43.08107 Boehringer Ingelheim Investigational Site, Hyogo, Kobe, Japan|1200.43.08109 Boehringer Ingelheim Investigational Site, Kanagawa, Isehara, Japan|1200.43.08114 Boehringer Ingelheim Investigational Site, Miyagi, Natori, Japan|1200.43.08110 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1200.43.08105 Boehringer Ingelheim Investigational Site, Shizuoka, Sunto-gun, Japan|1200.43.08102 Boehringer Ingelheim Investigational Site, Tochigi, Shimotsuke, Japan|1200.43.08113 Boehringer Ingelheim Investigational Site, Tokyo, Koto-ku, Japan|1200.43.08104 Boehringer Ingelheim Investigational Site, Tokyo, Meguro-ku, Japan|1200.43.08112 Boehringer Ingelheim Investigational Site, Tokyo, Minato-ku, Japan|1200.43.05202 Boehringer Ingelheim Investigational Site, Mexico, Mexico|1200.43.00704 Boehringer Ingelheim Investigational Site, Ivanovo, Russian Federation|1200.43.00706 Boehringer Ingelheim Investigational Site, Kurski, Russian Federation|1200.43.00709 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1200.43.00703 Boehringer Ingelheim Investigational Site, Omsk, Russian Federation|1200.43.00710 Boehringer Ingelheim Investigational Site, Pyatigorsk, Russian Federation|1200.43.00707 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1200.43.00705 Boehringer Ingelheim Investigational Site, Ufa, Russian Federation|1200.43.02703 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|1200.43.02704 Boehringer Ingelheim Investigational Site, Kraaifontein, Cape Town, South Africa|1200.43.02701 Boehringer Ingelheim Investigational Site, Parktown, Johannesburg, South Africa|1200.43.02702 Boehringer Ingelheim Investigational Site, Pretoria, South Africa|1200.43.03401 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.43.03404 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.43.03405 Boehringer Ingelheim Investigational Site, Girona, Spain|1200.43.03406 Boehringer Ingelheim Investigational Site, Málaga, Spain|1200.43.03402 Boehringer Ingelheim Investigational Site, Salamanca, Spain|1200.43.03403 Boehringer Ingelheim Investigational Site, Zaragoza, Spain|1200.43.04602 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|1200.43.04101 Boehringer Ingelheim Investigational Site, Basel, Switzerland|1200.43.04102 Boehringer Ingelheim Investigational Site, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT01345682"
357,"NCT01801111","A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment","Completed","Has Results","All","Phase 1|Phase 2","138","Industry","Interventional","June 20, 2013","October 24, 2014","October 27, 2017","February 28, 2013","May 26, 2016","November 2, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|UC Irvine Medical Center, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|UCLA Cancer Center; Premiere Oncology, A Medical Corporation, Santa Monica, California, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Hospital Cancer Inst, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Midwestern Regional Medical Center; Office of Research, Zion, Illinois, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Columbia University Medical Center; Department of Hematology/Oncology, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Texas Oncology, P.A., Dallas, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Townsville General Hospital, Douglas, Queensland, Australia|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|AZ Delta (Campus Wilgenstraat), Roeselare, Belgium|University Hospital Herlev, Herlev, Denmark|CHU Angers - Hôpital Hôtel Dieu, Angers, France|Hopital Morvan, Brest, France|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|CHU de Grenoble - Hôpital Nord; Service d'Oncologie Thoracique, Grenoble, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hôpital Nord - AP-HM Marseille#; Gastroenterology and Hepatology, Marseille cedex 20, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|ICO Rene Gauducheau; CEC, St Herblain, France|Nouvel Hopital Civil - CHU Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Larrey, Toulouse, France|Charité Campus Virchow-Klinikum; Department of Cardiology, Berlin, Germany|Diakonie Kaiserswerth; Florence-Nightingale-Krankenhaus, Düsseldorf, Germany|LungenClinic Großhansdorf, Großhansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikum Koeln-Merheim, Koeln, Germany|Mathias-Spital Rheine, Rheine, Germany|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Lazio, Italy|AO San Camillo Forlanini, Roma, Lazio, Italy|Ospedale San Raffaele, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Ospedale Versilia, Lido Di Camaiore, Toscana, Italy|Presidio Ospedaliero Campo di Marte, Lucca, Toscana, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Umbria, Italy|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System; Pharmacy, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Maastricht University Medical Centre; Afdeling Klinische Farmacie en Toxicologie, Maastricht, Netherlands|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin""; Chemotherapy Departement, Moskva, Moskovskaja Oblast, Russian Federation|National University Hospital; Investigational Medicine Unit, Singapore, Singapore|Johns Hopkins Singapore, Singapore, Singapore|Hospital General Univ. de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hosp Clinico Univ Lozano Blesa, Zaragoza, Spain|Karolinska, Stockholm, Sweden|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung Univ Hosp, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Royal Marsden Hospital;Dept of Haematology Oncology Research, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01801111"
358,"NCT01155453","A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients","Completed","No Results Available","All","Phase 1","113","Industry","Interventional","April 2010","November 2014","November 2014","July 1, 2010","null","June 21, 2016","University of California at Los Angeles Div. of Hematology/Oncology, Los Angeles, California, United States|University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8), Houston, Texas, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Bellinzona, Switzerland","https://ClinicalTrials.gov/show/NCT01155453"
359,"NCT01999673","Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer","Completed","No Results Available","All","Phase 3","582","Industry","Interventional","December 2013","March 2017","March 2017","December 3, 2013","null","April 21, 2017","Peregrine Pharmaceuticals Investigational Site, Huntsville, Alabama, United States|Peregrine Pharmaceuticals Investigational Site, Chandler, Arizona, United States|Peregrine Pharmaceuticals Investigational Site, Glendale, Arizona, United States|Peregrine Pharmaceuticals Investigational Site, Greenbrae, California, United States|Peregrine Pharmaceuticals Investigational Site, Los Angeles, California, United States|Peregrine Pharmaceuticals Investigational Site, Oceanside, California, United States|Peregrine Pharmaceuticals Investigational Site, Orange, California, United States|Peregrine Pharmaceuticals Investigational Site, West Hills, California, United States|Peregrine Pharmaceuticals Investigational Site, Fort Myers, Florida, United States|Peregrine Pharmaceuticals Investigational Site, Saint Petersburg, Florida, United States|Peregrine Pharmaceuticals Investigational Site, Tampa, Florida, United States|Peregrine Pharmaceuticals Investigational Site, Athens, Georgia, United States|Peregrine Pharmaceuticals Investigational Site, Savannah, Georgia, United States|Peregrine Pharmaceuticals Investigational Site, Chicago, Illinois, United States|Peregrine Pharmaceuticals Investigational Site, Indianapolis, Indiana, United States|Peregrine Pharmaceuticals Investigational Site, Marrero, Louisiana, United States|Peregrine Pharmaceuticals Investigational Site, Shreveport, Louisiana, United States|Peregrine Pharmaceuticals Investigational Site, Baltimore, Maryland, United States|Peregrine Pharmaceuticals Investigational Site, Frederick, Maryland, United States|Peregrine Pharmaceuticals Investigational Site, Boston, Massachusetts, United States|Peregrine Pharmaceuticals Investigational Site, Lincoln, Nebraska, United States|Peregrine Pharmaceuticals Investigational Site, Lebanon, New Hampshire, United States|Peregrine Pharmaceuticals Investigational Site, Albuquerque, New Mexico, United States|Peregrine Pharmaceuticals Investigational Site, Winston-Salem, North Carolina, United States|Peregrine Pharmaceuticals Investigational Site, Cincinnati, Ohio, United States|Peregrine Pharmaceuticals Investigational Site, Middletown, Ohio, United States|Peregrine Pharmaceuticals Investigational Site, Portland, Oregon, United States|Peregrine Pharmaceuticals Investigational Site, Hershey, Pennsylvania, United States|Peregrine Pharmaceuticals Investigational Site, Pittsburgh, Pennsylvania, United States|Peregrine Pharmaceuticals Investigational Site, Chattanooga, Tennessee, United States|Peregrine Pharmaceuticals Investigational Site, Knoxville, Tennessee, United States|Peregrine Pharmaceuticals Investigational Site, Nashville, Tennessee, United States|Peregrine Pharmaceuticals Investigational Site, Nashville, Tennessee, United States|Peregrine Pharmaceuticals Investigational Site, Abilene, Texas, United States|Peregrine Pharmaceuticals Investigational Site, Dallas, Texas, United States|Peregrine Pharmaceuticals Investigational Site, Dallas, Texas, United States|Peregrine Pharmaceuticals Investigational Site, Fort Worth, Texas, United States|Peregrine Pharmaceuticals Investigational Site, Temple, Texas, United States|Peregrine Pharmaceuticals Investigational Site, Seattle, Washington, United States|Peregrine Pharmaceuticals Investigational Site, Campbelltown, New South Wales, Australia|Peregrine Pharmaceuticals Investigational Site, Camperdown, New South Wales, Australia|Peregrine Pharmaceuticals Investigational Site, Tweed Heads, New South Wales, Australia|Peregrine Pharmaceuticals Investigational Site, Milton, Queensland, Australia|Peregrine Pharmaceuticals Investigational Site, Redcliffe, Queensland, Australia|Peregrine Pharmaceuticals Investigational Site, Elizabeth Vale, South Australia, Australia|Peregrine Pharmaceuticals Investigational Site, Toorak Gardens, South Australia, Australia|Peregrine Pharmaceuticals Investigational Site, Geelong, Victoria, Australia|Peregrine Pharmaceuticals Investigational Site, Wodonga, Victoria, Australia|Peregrine Pharmaceuticals Investigational Site, Antwerp, Belgium|Peregrine Pharmaceuticals Investigational Site, Bruxelles, Belgium|Peregrine Pharmaceuticals Investigational Site, Gent, Belgium|Peregrine Pharmaceuticals Investigational Site, Herstal, Belgium|Peregrine Pharmaceuticals Investigational Site, Liege, Belgium|Peregrine Pharmaceuticals Investigational Site, Mechelen, Belgium|Peregrine Pharmaceuticals Investigational Site, Namur, Belgium|Peregrine Pharmaceuticals Investigational Site, Marseille, Bouches-du-Rhone, France|Peregrine Pharmaceuticals Investigational Site, Caen, Calvados, France|Peregrine Pharmaceuticals Investigational Site, Brest, Finistere, France|Peregrine Pharmaceuticals Investigational Site, Nantes, Loire-Atlantique, France|Peregrine Pharmaceuticals Investigational Site, Nancy, Meurthe-et-Moselle, France|Peregrine Pharmaceuticals Investigational Site, Bayonne, Pyrenees-Atlantiques, France|Peregrine Pharmaceuticals Investigational Site, Rennes, France|Peregrine Pharmaceuticals Investigational Site, Saint Priest en Jarez, France|Peregrine Pharmaceuticals Investigational Site, Saint-Herblain, France|Peregrine Pharmaceuticals Investigational Site, Karlsruhe, Baden-Wuerttemberg, Germany|Peregrine Pharmaceuticals Investigational Site, Munchen, Bayern, Germany|Peregrine Pharmaceuticals Investigational Site, Immenhausen, Hessen, Germany|Peregrine Pharmaceuticals Investigational Site, Marburg, Hessen, Germany|Peregrine Pharmaceuticals Investigational Site, Koln, Nordrhein-Westfalen, Germany|Peregrine Pharmaceuticals Investigational Site, Erfurt, Thuringia, Germany|Peregrine Pharmaceuticals Investigational Site, Berlin, Germany|Peregrine Pharmaceuticals Investigational Site, Berlin, Germany|Peregrine Pharmaceuticals Investigational Site, Grosshansdorf, Germany|Peregrine Pharmaceuticals Investigational Site, Halle an der Saale, Germany|Peregrine Pharmaceuticals Investigational Site, Hamburg, Germany|Peregrine Pharmaceuticals Investigational Site, Kassel, Germany|Peregrine Pharmaceuticals Investigational Site, Mainz, Germany|Peregrine Pharmaceuticals Investigational Site, Munster, Germany|Peregrine Pharmaceuticals Investigational Site, Villingen-Schwenningen, Germany|Peregrine Pharmaceuticals Investigational Site, Patras, Achaia, Greece|Peregrine Pharmaceuticals Investigational Site, Neo Faliro, Athens, Greece|Peregrine Pharmaceuticals Investigational Site, Athens, Attiki, Greece|Peregrine Pharmaceuticals Investigational Site, Chania, Crete, Greece|Peregrine Pharmaceuticals Investigational Site, Heraklion, Irakleio, Greece|Peregrine Pharmaceuticals Investigational Site, Thermi, Thessaloniki, Greece|Peregrine Pharmaceuticals Investigational Site, Athens, Greece|Peregrine Pharmaceuticals Investigational Site, Larissa, Greece|Peregrine Pharmaceuticals Investigational Site, Thessaloniki, Greece|Peregrine Pharmaceuticals Investigational Site, Thessaloniki, Greece|Peregrine Pharmaceuticals Investigational Site, Budapest, Hungary|Peregrine Pharmaceuticals Investigational Site, Budapest, Hungary|Peregrine Pharmaceuticals Investigational Site, Gyor, Hungary|Peregrine Pharmaceuticals Investigational Site, Gyula, Hungary|Peregrine Pharmaceuticals Investigational Site, Szolnok, Hungary|Peregrine Pharmaceuticals Investigational Site, Torokbalint, Hungary|Peregrine Pharmaceuticals Investigational Site, Zalaegerszeg, Hungary|Peregrine Pharmaceuticals Investigational Site, Meldola, Forli-Cesena, Italy|Peregrine Pharmaceuticals Investigational Site, Lido di Camaiore, Lucca, Italy|Peregrine Pharmaceuticals Investigational Site, Taormina, Messina, Italy|Peregrine Pharmaceuticals Investigational Site, Monza, Monza Brianza, Italy|Peregrine Pharmaceuticals Investigational Site, Aviano, Pordenone, Italy|Peregrine Pharmaceuticals Investigational Site, Bergamo, Italy|Peregrine Pharmaceuticals Investigational Site, Cremona, Italy|Peregrine Pharmaceuticals Investigational Site, Genova, Italy|Peregrine Pharmaceuticals Investigational Site, Milan, Italy|Peregrine Pharmaceuticals Investigational Site, Turin, Italy|Peregrine Pharmaceuticals Investigational Site, Suwon, Gyeonggi-do, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Suwon, Gyonggi-do, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Busan, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Cheongju-si, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Incheon, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Seongnam, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Seoul, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Seoul, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Seoul, Korea, Republic of|Peregrine Pharmaceuticals Investigational Site, Brasov, Romania|Peregrine Pharmaceuticals Investigational Site, Cluj-Napoca, Romania|Peregrine Pharmaceuticals Investigational Site, Cluj-Napoca, Romania|Peregrine Pharmaceuticals Investigational Site, Ploiesti, Romania|Peregrine Pharmaceuticals Investigational Site, Suceava, Romania|Peregrine Pharmaceuticals Investigational Site, Turda, Romania|Peregrine Pharmaceuticals Investigational Site, Ekaterinburg, Russian Federation|Peregrine Pharmaceuticals Investigational Site, Kursk, Russian Federation|Peregrine Pharmaceuticals Investigational Site, Nizhny Novgorod, Russian Federation|Peregrine Pharmaceuticals Investigational Site, Obninsk, Russian Federation|Peregrine Pharmaceuticals Investigational Site, St. Petersburg, Russian Federation|Peregrine Pharmaceuticals Investigational Site, St. Petersburg, Russian Federation|Peregrine Pharmaceuticals Investigational Site, St. Petersburg, Russian Federation|Peregrine Pharmaceuticals Investigational Site, Yaroslavl, Russian Federation|Peregrine Pharmaceuticals Investigational Site, Badalona, Barcelona, Spain|Peregrine Pharmaceuticals Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|Peregrine Pharmaceuticals Investigational Site, Manresa, Barcelona, Spain|Peregrine Pharmaceuticals Investigational Site, Majadahonda, Madrid, Spain|Peregrine Pharmaceuticals Investigational Site, Pamplona, Navarra, Spain|Peregrine Pharmaceuticals Investigational Site, A Coruna, Spain|Peregrine Pharmaceuticals Investigational Site, Barcelona, Spain|Peregrine Pharmaceuticals Investigational Site, Barcelona, Spain|Peregrine Pharmaceuticals Investigational Site, Barcelona, Spain|Peregrine Pharmaceuticals Investigational Site, Madrid, Spain|Peregrine Pharmaceuticals Investigational Site, Madrid, Spain|Peregrine Pharmaceuticals Investigational Site, Madrid, Spain|Peregrine Pharmaceuticals Investigational Site, Madrid, Spain|Peregrine Pharmaceuticals Investigational Site, Malaga, Spain|Peregrine Pharmaceuticals Investigational Site, Valencia, Spain|Peregrine Pharmaceuticals Investigational Site, Valencia, Spain|Peregrine Pharmaceuticals Investigational Site, Kaohsiung City, Taiwan|Peregrine Pharmaceuticals Investigational Site, Putzu, Taiwan|Peregrine Pharmaceuticals Investigational Site, Taichung, Taiwan|Peregrine Pharmaceuticals Investigational Site, Taichung, Taiwan|Peregrine Pharmaceuticals Investigational Site, Tainan City, Taiwan|Peregrine Pharmaceuticals Investigational Site, Tainan, Taiwan|Peregrine Pharmaceuticals Investigational Site, Taipei, Taiwan|Peregrine Pharmaceuticals Investigational Site, Taipei, Taiwan|Peregrine Pharmaceuticals Investigational Site, Taipei, Taiwan|Peregrine Pharmaceuticals Investigational Site, Taoyuan, Taiwan|Peregrine Pharmaceuticals Investigational Site, Chernivtsi, Ukraine|Peregrine Pharmaceuticals Investigational Site, Dnipropetrovsk, Ukraine|Peregrine Pharmaceuticals Investigational Site, Khmelnytskyi, Ukraine|Peregrine Pharmaceuticals Investigational Site, Kyiv, Ukraine|Peregrine Pharmaceuticals Investigational Site, Lutsk, Ukraine|Peregrine Pharmaceuticals Investigational Site, Uzhgorod, Ukraine","https://ClinicalTrials.gov/show/NCT01999673"
360,"NCT00813605","QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma","Completed","No Results Available","All","Phase 2","155","Industry","Interventional","March 2009","January 2011","June 2012","December 23, 2008","null","October 27, 2016","Research Site, Beverly Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Maria, California, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Fishers, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Paducah, Kentucky, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Hudson, New York, United States|Research Site, New York, New York, United States|Research Site, High Point, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Roanoke, Virginia, United States|Research Site, Bordeaux Cedex, France|Research Site, Boulogne Billancourt, France|Research Site, Lille, France|Research Site, Lyon Cedex 08, France|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Kolkata, West Bengal, India|Research Site, Bangalore, India|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Gdansk, Poland|Research Site, Gliwice, Poland|Research Site, Opole, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00813605"
361,"NCT00790816","Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents","Completed","No Results Available","All","Phase 1","500","Industry","Interventional","October 2008","August 19, 2016","August 19, 2016","November 14, 2008","null","February 28, 2018","Novartis Investigative Site, Scottsdale, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain","https://ClinicalTrials.gov/show/NCT00790816"
362,"NCT01602406","Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer","Completed","No Results Available","All","Phase 1","64","Industry","Interventional","September 21, 2012","August 2, 2017","August 2, 2017","May 21, 2012","null","July 26, 2018","Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01602406"
363,"NCT01479465","Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma","Completed","No Results Available","All","Phase 2","266","Industry","Interventional","December 2011","October 2014","February 2015","November 24, 2011","null","March 30, 2015","Clearview Cancer Institute, Huntsville, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Central Hematology Oncology Medical Group, Inc., Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Providence Saint Joseph Medical Center-Disney Family Cancer Center, Burbank, California, United States|Wilshire Oncology Medical Group, Inc., Corona, California, United States|Saint Jude Heritage Healthcare, Fullerton, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Comprehensive Hematology Oncology Centers, Inc., Los Angeles, California, United States|TORI Network (Translational Oncology Research Intl), Los Angeles, California, United States|UCLA Community Oncology Practice, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Wilshire Oncology Medical Group, Inc., Pomona, California, United States|Cancer Care Associates Medical Group, Redondo Beach, California, United States|Pacific Shores Medical Group, Redondo Beach, California, United States|Sharp Health Care, San Diego, California, United States|San Jose Medical Group, San Jose, California, United States|Central Coast Medical Oncology Corp, Santa Maria, California, United States|Yale University Smilow Cancer Hospital, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Florida Cancer Specialists, Gainesville, Florida, United States|MD Anderson Cancer Center, Orlando, Florida, United States|Florida Cancer Specialists, St. Petersburg, Florida, United States|Peachtree Hematology Oncology Consultants, PC, Atlanta, Georgia, United States|Suburban Hematology Oncology Associates, PC, Lawrenceville, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Hematology and Oncology Associates at BridgePoint, Tupelo, Mississippi, United States|Saint Joseph Oncology, Inc., Saint Joseph, Missouri, United States|Montana Cancer Institute, Missoula, Montana, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York University Clinical Cancer Center, New York, New York, United States|Oncology Hematology Care, Inc., Cincinatti, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Oncology Hematology Care, Inc., Wilmington, Ohio, United States|Kaiser Permanente Northwest Region Oncology Hematology, Portland, Oregon, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Center for Cancer and Blood Disorders, PC, Fort Worth, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Scott & White Memorial, Temple, Texas, United States|The Center for Cancer and Blood Disorders, Weatherford, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Intermountain Healthcare, St. George, Utah, United States|Virginal Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Institute, Midlothian, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Centre Hospitalier Universitaire Estaing, Clermont Ferrand, Auvergne, France|Centre Eugène Marquis, Rennes Cedex, Bretagne, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Dept. de Cancerologie Digestive et Urologique, Lille Cedex, France|Centre Hospitalier Régional Universitaire Hôpital Saint Eloi, Montpellier Cedex 5, France|Centre Antoine Lacassagne, Nice Cedex 2, France|Institut Paoli Calmettes Centre Régional de Lutte Contre le Cancer, Rennes Cedex, France|Hôpital Trousseau - Service de Gastroenterologie, Tours, France|Universitätsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany|Universitätsklinikums Mannheim, Mannheim, Baden-Wuerttenberg, Germany|Ludwig-Maximilians-Universität München Klinikum Großhadern, München, Bayern, Germany|Universitätsklinikum Rostock, Rostock, Mecklenburg-Vorpommern, Germany|Klinikum Region Hannover GmbH, Krankenhaus Siloah, Hannover, Niedersachsen, Germany|Medizinische Universitätsklinik Bochum, Bochum, Nordrhein-Westfalen, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Krankenanstalt Mutterhaus der Borromäerinnen e.V., Trier, Rheinland-Pfalz, Germany|Universitätsklinikum Dresden, Dresden, Sachsen, Germany|Universitätsklinikum der Friedrich-Schiller-Universität Jena, Jena, Thuringen, Germany|Städtisches Klinikum Frankfurt-Höchst, Frankfurt, Germany|Katholisches Marienkrankenhaus gGmbH, Hamburg, Germany|University Magdeburg, Magdeburg, Germany|Ospedale Unico Versilia, Lido di Camaiore, Lucca, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza, Monza e Brianza, Italy|Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Reggio Nella Emilia, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale Niguarda Cà Granda, Milano, Italy|Ospedale Civile SS Annunziata ASL 1, Sassari, Italy|Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Spólka z o. o., Kraków, Malopolskie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|Olsztynski Osrodek Onkologiczny ""Kopernik"" sp. z o. o., Olsztyn, Warminsko-Mazurskie, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland|Centralny Szpital Kliniczny MSWiA, Warszawa, Poland|Centrum Onkologii - Instytut im Marii Sklodowskiej-Curie, Warszawa, Poland|State Institution of Healthcare ""Arkhangelsk Regional Clinical Oncology Dispensary"", Arkhangelsk, Russian Federation|Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan, Kazan, Russian Federation|Kursk Regional Oncologic Dispensary, Kursk, Russian Federation|Cancer Research Center n.a. Blokhin, Chemotherapy Dept., Moscow, Russian Federation|Non-State Institution of healthcare ""Central Clinical Hospital #1 OAO RZD"", Moscow, Russian Federation|State Institution ""Blokhin Cancer Research Centre RAMS"", Moscow, Russian Federation|Nizhny Novgorod City Oncology Dispensary, Nizhny Novgorod, Russian Federation|State Healthcare Institution of Omsk Region ""Clinical Oncologic Dispensary"", Omsk, Russian Federation|N.N.Petrov Research Institute of Oncology, Saint Petersburg, Russian Federation|Centro Oncológico Regional de Galicia, A Coruña, La Coruna, Spain|Hospital Nuestra Señora de Sonsoles, Avila, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Girona Doctor Josep Trueta, Gerona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Instituto de Investigación Sanitaria, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01479465"
364,"NCT00661609","A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer","Completed","Has Results","All","Phase 2","54","Industry","Interventional","May 2008","May 2009","December 2009","April 18, 2008","January 12, 2011","January 12, 2011","Research Site, Palo Alto, California, United States|Research Site, San Bernardino, California, United States|Research Site, Southington, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Scarborough, Maine, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Woonsocket, Rhode Island, United States|Research Site, Seattle, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Vancouver, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dusseldorf, Germany|Research Site, Munchen, Germany|Research Site, Munster, Germany|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Leeds, West Yorkshire, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT00661609"
365,"NCT00555919","ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer","Completed","No Results Available","Female","Phase 2","68","Industry","Interventional","March 2008","April 2010","March 2011","November 9, 2007","null","October 10, 2014","Graz, Austria|Innsbruck, Austria|Salzburg, Austria|Wien, Austria|Turku, Finland|Vaasa, Finland|Lille, France|Lyon Cedex, France|Montpellier, France|Nantes, France|Paris, France|Reims, France|Tübingen, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Frankfurt, Hessen, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Kiel, Schleswig-Holstein, Germany|Rozzano, Milano, Italy|Bialystok, Poland|Gdansk, Poland|Olsztyn, Poland|Poznan, Poland|Madrid, Spain|Göteborg, Sweden|Sundsvall, Sweden|Växjö, Sweden|St. Gallen, Sankt Gallen, Switzerland|Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00555919"
366,"NCT00929188","A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain","Completed","No Results Available","All","Phase 2","100","Industry","Interventional","October 2009","January 2015","January 2015","June 26, 2009","null","January 22, 2016","Birmingham, Alabama, United States|Tucson, Arizona, United States|Laguna Hills, California, United States|Montebello, California, United States|San Diego, California, United States|Miami, Florida, United States|Orlando, Florida, United States|Stockbridge, Georgia, United States|Anderson, Indiana, United States|Lexington, Kentucky, United States|Marrero, Louisiana, United States|Shreveport, Louisiana, United States|Farmington Hills, Michigan, United States|Flat Rock, North Carolina, United States|Cleveland, Ohio, United States|Orem, Utah, United States|Falls Church, Virginia, United States|Lille, France|Lyon, France|Suresnes, France|Toulouse, France|Villejuif, France|Bygdoszcz, Poland|Gdansk-Zaspa, Poland|Gdansk, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Almada N/A, Portugal|Coimbra, Portugal|Faro, Portugal|Lisboa, Portugal|Ponta Delgada, Portugal|Porto, Portugal|Setubal, Portugal|Barcelona N/A, Spain|Madrid, Spain|Palma De Mallorca, Spain|San Sebastián De Los Reyes, Spain|Terrasa Barcelona N/A, Spain","https://ClinicalTrials.gov/show/NCT00929188"
367,"NCT02626234","A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","32","Industry","Interventional","December 8, 2015","February 28, 2017","April 28, 2017","December 10, 2015","null","December 26, 2017","Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group, Atlanta, Georgia, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02626234"
368,"NCT01177397","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma","Completed","No Results Available","All","Phase 1|Phase 2","173","Industry","Interventional","July 20, 2010","November 15, 2016","December 9, 2016","August 9, 2010","null","November 14, 2017","Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Mayo Clinic Cancer Clinical Studies Unit, Rochester, Minnesota, United States|Billings Clinic, Billings, Montana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Cancer Institute - Bellevue Hospital, New York, New York, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Institut Claudius Regaud, Toulouse Cedex, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif, France|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Sarah Cannon Research Institute UK, London, United Kingdom|UCL Cancer Institute, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01177397"
369,"NCT00873353","Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients","Completed","No Results Available","All","Phase 2","32","Other","Interventional","March 2008","August 2008","August 2010","April 1, 2009","null","August 18, 2010","Hospital Arquitecto Marcide, Ferrol, La Coruña, Spain|Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain|Centro Oncológico de Galicia, La Coruña, Spain|Complejo Hospitalario Xeral Calde, Lugo, Spain|Complejo Hospitalario de Orense, Orense, Spain|Hospital do Meixoeiro, Vigo, Spain|Complejo Hospitalario Xeral Cies, Vigo, Spain|Hospital POVISA, Vigo, Spain","https://ClinicalTrials.gov/show/NCT00873353"
370,"NCT01685268","A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate","Completed","No Results Available","Male","Phase 1|Phase 2","49","Industry","Interventional","September 2012","July 2014","December 2014","September 14, 2012","null","September 8, 2016","University of California, Los Angeles Institute of Urologic Oncology, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Florida Cancer Specialists-Fort Myers, Fort Myers, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States|Center for Cancer & Blood Disorders, Bethesda, Maryland, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Clinical Research Alliance, Inc., Lake Success, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|Northwest Medical Specialists, PLLC, Tacoma, Washington, United States|Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada|Centro Integral Oncologico Clara Campal, Madrid, Spain|Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Velindre Cancer Center, Cardiff, United Kingdom|University of Surrey, Guildford, United Kingdom|Charing Cross Hospital, London, United Kingdom|Royal Marsden Foundation Trust Instute of Cancer Researrch, London, United Kingdom|The Christie Hospital NHS Trust, Manchester, United Kingdom|Nottingham University Hospitals, Nottingham, United Kingdom|University Hospital Southampton, Southampton, United Kingdom|Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01685268"
371,"NCT01478685","A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors","Completed","No Results Available","All","Phase 1","169","Industry","Interventional","November 2011","November 2015","November 2015","November 23, 2011","null","March 25, 2016","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|University of California, San Francisco, San Francisco, California, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Greenville Hospital, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Centre Georges Francois Leclerc, Dijon, France|Institut Curie, Paris, France|The Netherlands Cancer Instiute Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01478685"
372,"NCT01460420","Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation","Completed","No Results Available","All","Phase 1|Phase 2","49","Other","Interventional","November 2011","June 2017","June 29, 2017","October 26, 2011","null","July 6, 2017","Medizinische Klinik and Poliklinik II, University Hospital, Würzburg,, Germany|S Giovanni Battista Hospital, Torino, Italy|Azienda Ospedaliera Universitaria di Udine, Udine, Italy|Hospital Clinic i Provincial,, Barcelona,, Spain|Hospital Santa Creu I Sant Pau,, Barcelona,, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Gregorio Marañón,, Madrid, Spain|Hospital Clinico Universitario Salamanca,, Salamanca,, Spain|Hospital Universitario Virgen del Rocío,, Sevilla, Spain|Karolinska University Hospital, Huddinge, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT01460420"
373,"NCT00688623","RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe","Completed","No Results Available","All","Phase 2","73","Industry","Interventional","June 24, 2009","November 7, 2016","November 7, 2016","June 3, 2008","null","July 2, 2017","Novartis Investigative Site, Bad Berka, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Viagrande, CT, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Glasgow - Scotland, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00688623"
374,"NCT00879333","Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)","Completed","Has Results","All","Phase 3","656","Industry","Interventional","July 2009","January 2014","January 2014","April 10, 2009","April 6, 2015","November 3, 2015","Highlands Oncology Group DeptofHighlandsOncologyGrp(2), Fayetteville, Arkansas, United States|Loma Linda Oncology Medical Group Loma Linda, Redlands, California, United States|Henry Ford Hospital Dept. of Henry Ford Hospital, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(4), Dallas, Texas, United States|The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2), Fort Worth, Texas, United States|University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston, Texas, United States|University of Washington Cancer Care Seattle Cancer Alliance, Seattle, Washington, United States|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Canberra, Australian Capital Territory, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Kurralta Park, South Australia, Australia|Novartis Investigative Site, North Adelaide, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Footscray, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, North Vancouver, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shijiazhuang, Hebei, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Clermont Ferrand cedex 1, France|Novartis Investigative Site, Clichy, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Offenburg, Germany|Novartis Investigative Site, Trier, Germany|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Frattamaggiore, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Sagamihara, Kanagawa, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Takatsuki-city, Osaka, Japan|Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan|Novartis Investigative Site, Utsunomiya, Tochigi, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Jeonju-si, Jeollabuk-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, León, Guanajuato, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Auckland, New Zealand|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan|Novartis Investigative Site, Liouying Township, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, East Yorkshire, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00879333"
375,"NCT01363232","Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients","Completed","No Results Available","All","Phase 1","89","Industry","Interventional","August 2011","March 2014","December 18, 2017","June 1, 2011","null","January 23, 2018","Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States|Karmanos Cancer Institute Study Coordinator, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center MSKCC (2), New York, New York, United States|Cancer Centers of the Carolinas CCC Faris, Greenville, South Carolina, United States|University of Texas/MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States|Array BioPharma Investigative Site, Toronto, Ontario, Canada|Array BioPharma Investigative Site, Essen, Germany|Array BioPharma Investigative Site, Heidelberg, Germany|Array BioPharma Investigative Site, Utrecht, Netherlands|Array BioPharma Investigative Site, Singapore, Singapore|Array BioPharma Investigative Site, Barcelona, Catalunya, Spain|Array BioPharma Investigative Site, Bellinzona, Switzerland","https://ClinicalTrials.gov/show/NCT01363232"
376,"NCT01154140","A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung","Completed","Has Results","All","Phase 3","343","Industry","Interventional","January 13, 2011","November 30, 2013","November 30, 2016","June 30, 2010","January 5, 2015","November 6, 2017","Tower Cancer Research Foundation, Beverly Hills, California, United States|Tower Hematology Oncology Medical Group, Beverly Hills, California, United States|CCTAP, Fontana, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Loma Linda University Cancer Center (LLUCC)-Schuman Pavilion, Loma Linda, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|CCTAP, Los Angeles, California, United States|Kaiser Permanente Southern California, San Diego, California, United States|CCTAP, San Diego, California, United States|Georgetown University Hospital, Washington, D.C., District of Columbia, United States|Research Pharmacy, Georgetown University Medical Center, Washington, D.C., District of Columbia, United States|Lynn Cancer Institute Center for Hematology Oncology, Boca Raton, Florida, United States|Florida Hospital, Orlando, Florida, United States|Cancer Institute of Florida, Orlando, Florida, United States|Investigational Drug Services, Orlando, Florida, United States|Georgia Cancer Specialists, Athens, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Georgia Cancer Specialists, Decatur, Georgia, United States|Georgia Cancer Specialists, Macon, Georgia, United States|Georgia Cancer Specialists, Marietta, Georgia, United States|Georgia Cancer Specialists, Sandy Springs, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Al Fisher, Pharm D., Harvey, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Monroe Medical Associates, Harvey, Illinois, United States|Monroe Medical Associates, Tinley Park, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Lois and Eskenazi Hospital, Indianapolis, Indiana, United States|Monroe Medical Association, Munster, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Maine Center for Cancer Medicine, Biddeford, Maine, United States|Maine Center for Cancer Medicine, Brunswick, Maine, United States|Maine Center for Cancer Medicine, Sanford, Maine, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|Kresge Eye Institute, Bingham Farms, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Kresge Eye Institute, Detroit, Michigan, United States|Karmanos Cancer Institute at Farmington Hills, Farmington Hills, Michigan, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Center for Advanced Medicine Infusion Center Pharmacy, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hematology-Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|UNM Eye Clinic, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|NSLIJ Health System/Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|OHSU Knight Cancer Institute, Beaverton, Oregon, United States|OHSU Knight Cancer Institute, Gresham, Oregon, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|OHSU Knight Cancer Institute, Tualatin, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Vincent Armenio, East Providence, Rhode Island, United States|Pharma Resource, East Providence, Rhode Island, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Vanderbilt Oncology Pharmacy, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|UT Southwestern Medical Center - Simmons Cancer Center Pharmacy, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|UT Southwestern University Hospital - William P. Clements, Jr., Dallas, Texas, United States|UT Southwestern University Hospital - Zale Lipshy, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|The Royal Brisbane & Womens Hospital, Herston, Queensland, Australia|Parkhaven Medical Center, Hyde Park, Queensland, Australia|Department of Medical Oncology, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, Department of Haematology and Medical Oncology, East Melbourne, Victoria, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Klinikum Wels-Grieskirchen, Wels, Austria|UZ Antwerpen-Pneumologie, Edegem, Antwerp, Belgium|Grand Hopital de Charleroi -Site Notre Dame, Charleroi, Hainaut, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|Universitair Ziekenhuis Brussel / Medische Oncologie, Brussel, Belgium|Institut Jules Bordet, Centre des Tumeurs de l'ULB, Bruxelles, Belgium|Universitair Ziekenhuis Gent (U.Z. Gent), Gent, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Department of Pulmonary Diseases AZ Delta, Roeselare, Belgium|Instituto Nacional de Cancer - INCA, Rio de Janeiro, RJ, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, RS, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP, Sao Paulo, SP, Brazil|Fundacao Pio XII Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Centre (MUHC), Glen Site, Cedars Cancer Centre, Montreal, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Quebec (IUCPQ), Ste-Foy, Quebec, Canada|Instituto Clinico Oncologico del Sur, Temuco, Cautin, Chile|Instituto Nacional del Cancer, Santiago, RM, Chile|Hospital Clinico Universidad de Chile, Seccion de Oncologia, Independencia, Santiago, Rm, Chile|307 Hospital of PLA, Beijing, Beijing, China|Oncology Center, Guangdong General Hospital, Guangzhou, Guangdong, China|Union Hospital, Tongji Medical College of Huazhong University of Science & Technology/Cancer Center, Wuhan, Hubei, China|No.81 Hospital of the PLA, Nanjing, Jiangsu, China|Oncology Department, West China Hospital of Sichuan University, Chengdu, Sichuan, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|Shanghai Chest Hospital/Department of Pulmonary Medicine, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Shanghai Pulmonary Hospital/Dept. of Oncology, Shanghai, China|Helsingin yliopistollinen keskussairaala, Meilahden kolmiosairaala,Keuhkosairauksien poliklinikka, Helsinki, Finland|Satakunnan keskussairaala/Keuhkosairauksien osasto A4, Pori, Finland|Tampereen yliopistollinen sairaala, Tampere, Finland|Hopital Avicenne, Bobigny Cedex, France|CHU de Caen, Caen Cedex, France|CHU Grenoble, Grenoble Cedex, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon Cedex 08, France|APHM - Hopital Nord / Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille Cedex 20, France|Hopital Arnaud de Villeneuve / CHU de Montpellier, Montpellier, France|Hopital Tenon, Service de Pneumologie, Paris cedex 20, France|Nouvel Hopital Civil - HSU - Pôle de Pathologie Thoracique - Service de Pneumologie, Strasbourg, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Charite - Universitaetsmedizin Berlin, Campus Mitte, Berlin, Germany|Thoraxklinik am Universitaetsklinikum Heidelberg, Heidelberg, Germany|St.Vincentius-Kliniken Karlsruhe, Karlsruhe, Germany|UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Kliniken Maria Hilf GmbH, Moenchengladbach, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|HSK Dr.- Horst-Schmidt-Kliniken GmbH,, Wiesbaden, Germany|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong|The Gujarat Cancer & Research Institute (M.P Shah Cancer Hospital),, Ahmedabad,, Gujarat, India|Tata Memorial Centre, Tata Memorial Hospital,, Mumbai, Maharashtra, India|Aseptic Compounding Unit, Dublin, Ireland|Department of Medical Oncology, Dublin, Ireland|Struttura Operativa Complessa Oncologia Medica A Centro di Riferimento Oncologico, Aviano, Pordenone, Italy|Farmacia, Aviano (PN), Italy|Istituto dei tumori Giovanni Paolo II, Bari, Italy|Unità Operativa di Oncologia Medica Azienda USL Città di Bologna, Bologna, Italy|Azienda Ospedaliero-Universitaria ""Mater Domini"", Catanzaro, Italy|Unità Operativa di Farmacia - Campus Salvatore venuta, Catanzaro, Italy|Ospedale Civile Azienda USL Toscana Nord Ovest, Livorno, Italy|Unità Operativa Farmacia Ospedaliera PO di Livorno, Livorno, Italy|Fondazione IRCCS Istituto Nazionale Tumori, Struttura Complessa di Medicina Oncologica 1, Milano, Italy|Farmacia Istituto Europeo di Oncologia IRCCS, U.O. Farmacia, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale Niguarda Ca'Granda, Divisione Oncologia Medica Falck, Milano, Italy|A.O.R.N. Ospedale Dei Colli - Monaldi, Napoli, Italy|Farmacia, Napoli, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano (TO), Italy|S.C. Farmacia Ospedaliera , Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano (TO), Italy|Oncologia Medica, Azienda Ospedaliero- Universitaria di Parma, Parma, Italy|Farmacia Ospedaliera, Perugia, Italy|SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Perugia, Italy|IRCCS -Arcispedale S. Maria Nuova Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia, Italy|Istituto Regina Elena, Struttura Complessa Oncologia Medica A, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini-Padiglione Flaiani, Roma, Italy|Farmacia Interna, Roma, Italy|Unita Operativa, Oncologia Medica, Istituto di Medicina Interna e Geriatria, Roma, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Okayama University Hospital, Okayama-city, Okayama, Japan|Kinki University Hospital, Osakasayama-shi, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|National Hospital Organization Yamaguchi-Ube Medical Center, Ube-shi, Yamaguchi, Japan|National Hospital organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital Respiratory Medicine, Fukuoka, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Sungkyunkwan Univ. School of Medicine, Seoul, Korea, Republic of|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Instituto Nacional de Cancerologia, Mexico, D.f., Mexico|Jeroen Bosch Ziekenhuis, 's Hertogenbosch, NB, Netherlands|VUMC, Amsterdam, Netherlands|Academisch Ziekenhuis Maastricht / afdeling longziekten en tuberculose, Maastricht, Netherlands|Oslo universitetssykehus HF - Radiumhospitalet, Oslo, Norway|Clinica Anglo Americana/Centro de Investigacion Oncologia CAA, San Isidro, Lima, Peru|Centro Hospitalar e Universitario de Coimbra - Hospital Geral, Coimbra, Portugal|Instituto Português de Oncologia de Lisboa, Prof. Francisco Gentil E.P.E., Lisboa, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Pulido Valente, Lisboa, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Vila Nova de Gaia, Portugal|Russian Oncological Research Center N.N. Blokhin, Moscow, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|First Saint-Petersburg State Medical University n.a. I.P. Pavlov, Saint-Petersburg, Russian Federation|First Saint-Petersburg State Medical University n.a. I.P., Saint-Petersburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Parkway Cancer Centre, Singapore, Singapore|OncoCare Cancer Centre, Singapore, Singapore|University of Witwatersrand Oncology, Johannesburg, Gauteng, South Africa|Rondebosch Oncology Centre, Rondebosch Medical Centre, Cape Town, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Aragon, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Catalunya, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Universitario Virgen de La Victoria, Malaga, Spain|Universitaetsspital Basel, Basel, Switzerland|Luzerner Kantonsspital (LUKS), Luzern, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Chang Gung Medical Foundation, Kaohsiung Branch, Kaohsiung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Comprehensive Cancer Center, Taichung, Taiwan|Chang Gung Medical Foundation, LinKou Branch, Taoyuan, Taiwan|City Multiple-Discipline Clinical Hospital #4,, Dnipropetrovsk, Ukraine|City Multiple-Discipline Clinical Hospital #4, Dnipropetrovsk, Ukraine|Department of Oncology and Medical Radiology, SI ""DMA of MOH, Ukraine, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncologic Center/Department of Chemotherapy, Kyiv, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine|Addenbrooke's Hospital, Oncology Centre, Cambridge, Cambridgeshire, United Kingdom|Lister Hospital, Stevenage, Hertfordshire, United Kingdom|Queen Elizabeth II Hospital, Welwyn Garden City, Hertfordshire, United Kingdom|Spire Manchester Hospital, Manchester, Lancashire, United Kingdom|Mount Vernon Hospital, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|NHS Greater Glasgow and Clyde Health Board, Beatson West of Scotland Cancer Centre,, Glasgow, Scotland, United Kingdom|Ross Hall Hospital, Glasgow, Scotland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Christie Hospital NHS Foundation Trust, Department of Medical Oncology, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01154140"
377,"NCT01193257","Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer","Completed","No Results Available","Male","Phase 3","1099","Industry","Interventional","November 2010","September 2014","February 2016","September 1, 2010","null","January 18, 2017","Anchorage, Alaska, United States|Fort Smith, Arkansas, United States|Fountain Valley, California, United States|Los Angeles, California, United States|Riverside, California, United States|San Diego, California, United States|Fort Myers, Florida, United States|Port Saint Lucie, Florida, United States|Indianapolis, Indiana, United States|Jeffersonville, Indiana, United States|New Orleans, Louisiana, United States|Westminster, Maryland, United States|Detroit, Michigan, United States|Jefferson City, Missouri, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Albany, New York, United States|East Syracuse, New York, United States|Rochester, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Tualatin, Oregon, United States|Lancaster, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Greenville, South Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Amarillo, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Odessa, Texas, United States|Tyler, Texas, United States|Webster, Texas, United States|Salt Lake City, Utah, United States|Newport News, Virginia, United States|Kennewick, Washington, United States|Redcliffe, Queensland, Australia|Woodville South, South Australia, Australia|Hobart, Tasmania, Australia|Malvere, Victoria, Australia|Wodonga, Victoria, Australia|Brussels, Belgium|Kortijk, Belgium|Liege, Belgium|Namur, Belgium|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Moncton, New Brunswick, Canada|Brampton, Ontario, Canada|Newmarket, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Hradec Dralove, Czech Republic|Kromertz, Czech Republic|Modrice, Czech Republic|Praha, Czech Republic|Zlin, Czech Republic|Tallinn, Estonia|Oulu, Finland|Tampere, Finland|La Roche-sur-Yon, France|Le Mans, France|Lyon Cedex, France|Lyon, France|Marseille, France|Paris, France|Villejuif cedex, France|Patras, Greece|Miskolc, Hungary|Osztaly, Hungary|Novara, Italy|Rome, Italy|Eindhoven, Netherlands|Bielsko-Biala, Poland|Goczalkowice-Zdroj, Poland|Wroclaw, Poland|Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01193257"
378,"NCT01288573","A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone","Completed","No Results Available","All","Phase 1|Phase 2","46","Industry","Interventional","March 3, 2014","May 9, 2017","May 9, 2017","February 2, 2011","null","May 16, 2017","Investigational Site Number 51, Gent, Belgium|Investigational Site Number 81, Brno, Czechia|Investigational Site Number 82, Praha 5 - Motol, Czechia|Investigational Site Number 61, København Ø, Denmark|Investigational Site Number 42, Lyon, France|Investigational Site Number 43, Paris Cedex 05, France|Investigational Site Number 33, Frankfurt Am Main, Germany|Investigational Site Number 34, Freiburg, Germany|Investigational Site Number 35, Hamburg, Germany|Investigational Site Number 31, Hannover, Germany|Investigational Site Number 36, München, Germany|Investigational Site Number 83, Budapest, Hungary|Investigational Site Number 92, Petach Tikva, Israel|Investigational Site Number 91, Tel-Aviv, Israel|Investigational Site Number 21, Genova, Italy|Investigational Site Number 24, Milano, Italy|Investigational Site Number 23, Padova, Italy|Investigational Site Number 22, Roma, Italy|Investigational Site Number 26, Torino, Italy|Investigational Site Number 72, Amsterdam, Netherlands|Investigational Site Number 71, Rotterdam, Netherlands|Investigational Site Number 85, Krakow, Poland|Investigational Site Number 84, Wroclaw, Poland|Investigational Site Number 94, Barcelona, Spain|Investigational Site Number 93, Madrid, Spain|Investigational Site Number 11, Birmingham, United Kingdom|Investigational Site Number 13, Glasgow, United Kingdom","https://ClinicalTrials.gov/show/NCT01288573"
379,"NCT00790426","Phase II Study of TKI258 in Advanced Urothelial Carcinoma","Completed","No Results Available","All","Phase 2","44","Industry","Interventional","March 2010","April 2012","April 2012","November 13, 2008","null","May 2, 2016","University of California San Diego - Moores Cancer Center UCSD, La Jolla, California, United States|USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, United States|University Chicago Hospital CTKI258A2201, Chicago, Illinois, United States|Dana Farber Cancer Institute Dana 1230, Boston, Massachusetts, United States|Nevada Cancer Institute Nevada Cancer Institute, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering (2), New York, New York, United States|Duke University Medical Center Dept.ofDukeUniversityMedCtr(2), Durham, North Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Leeds, West Yorkshire, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00790426"
380,"NCT01450761","Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","Completed","Has Results","All","Phase 3","1351","Industry","Interventional","December 13, 2011","March 19, 2015","May 17, 2017","October 12, 2011","July 18, 2016","July 12, 2018","Genesis Cancer Center, Hot Springs, Arkansas, United States|Sutter Medical Center, Auburn, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Cancer Specialists, LLC, Jacksonville, Florida, United States|Lake City Cancer Care, Lake City, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Medical Oncology, LLC, Augusta, Georgia, United States|Straub Clinic And Hospital, Honolulu, Hawaii, United States|Quincy Medical Group, Quincy, Illinois, United States|Presence Medical Group Hematology Oncology, Skokie, Illinois, United States|SIU School Of Medicine, Springfield, Illinois, United States|St. Francis Medical Group Oncology And Hematology Specialist, Indianapolis, Indiana, United States|Floyd Memorial Cancer Center Of Indiana, New Albany, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Ashland Bellefonte Cancer Center, Ashland, Kentucky, United States|University Of Kentucky, Lexington, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|St Joseph Mercy Hospital, Ypsilanti, Michigan, United States|St. Luke'S Cancer Institute, Kansas City, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Regional Cancer Care Associates, LLC/Cherry Hill Division, Cherry Hill, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Durham Va Medical Center (111g), Durham, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology Hematology Care, Incorporated, Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Mid-Ohio Oncology/Hematology, Inc. Dba, Columbus, Ohio, United States|Signal Point Clinical Research Center, Llc, Middletown, Ohio, United States|Mercy Clinic Oklahoma Communities, Inc, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Kaiser Permanente, Portland, Oregon, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Associated in Oncology and Hematology, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|University Of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States|Joe Arrington Cancer Research And Treatment Center, Lubbock, Texas, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Argentina|Local Institution, Provincia De Sante Fe, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Chermside, Queensland, Australia|Local Institution, Townsville, Queensland, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Wodonga, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Centro, Joinville/sc, Brazil|Local Institution, Curitiba/PR, Brazil|Local Institution, Passo Fundo, RS, Brazil|Local Institution, Porto Alegre, RS, Brazil|Local Institution, Sao Paulo/SP, Brazil|Local Institution, SP, Brazil|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Vitacura, Santiago, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Local Institution, Santiago, Chile|Local Institution, Valparaiso, Chile|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nangjing, Jiangsu, China|Local Institution, Soochow, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Chengdu City, Sichuan, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou City, Zhejiang, China|Local Institution, Hangzhou City, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Cordoba, Colombia|Local Institution, Ostrava - Poruba, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Espoo, Finland|Local Institution, Helsinki, Finland|Local Institution, Turku, Finland|Local Institution, Caen, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre-les-nancy, France|Local Institution, Bad Berka, Germany|Local Institution, Bochum, Germany|Local Institution, Dresden, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Munchen, Germany|Local Institution, Oldenburg, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Kowloon, Hong Kong|Local Institution, Tuen Mun, New Territories, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Farkasgyepu, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Pecs, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Szolnok, Hungary|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Limerick, Ireland|Local Institution, Beer Sheva, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Zerifin, Israel|Local Institution, Livorno, Italy|Local Institution, Lucca, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori, Miyagi, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Takatsuki, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Fukoka, Japan|Local Institution, Fukuoka, Japan|Local Institution, Osaka, Japan|Local Institution, Oskaka, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Tokyo, Japan|Local Institution, Suwon, Gyeonggi-do, Korea, Republic of|Local Institution, Goyang-si, Gyeonggji-do, Korea, Republic of|Local Institution, Hwasun-eup, Hwasun-gun, Jeonnam, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Cheongju-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, San Luis Potosi, S.l.p., Mexico|Local Institution, 's-Hertogenbosch, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Eindhoven, Netherlands|Local Institution, Nieuwegein, Netherlands|Local Institution, Cercado, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Karkow, Poland|Local Institution, Katowice - Ochojec, Poland|Local Institution, Lublin, Poland|Local Institution, Otwock, Poland|Local Institution, Poznan, Poland|Local Institution, Torun, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Vila Nova De Gaia, Portugal|Local Institution, Cluj Napoca, Judetul CLUJ, Romania|Local Institution, Craiova, Judetul DOLJ, Romania|Local Institution, Bucuresti, Romania|Local Institution, Cluj, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Krasnodar, Russian Federation|Local Institution, Kursk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pyatigorsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Pretoria, South Africa|Local Institution, A Coruna, Galicia, Spain|Local Institution, Barcelona, Spain|Local Institution, Benidorm-alicante, Spain|Local Institution, Castellon, Spain|Local Institution, Lleida, Spain|Local Institution, Majadahonda, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Linkoping, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Basel, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Zuerich, Switzerland|Local Institution, Changhua City, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan County, Taiwan|Local Institution, Rachathewi, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Chiang Mai, Thailand|Local Institution, Songkhla, Thailand|Local Institution, Withington, Manchester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Sutton, United Kingdom|Local Institution, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01450761"
381,"NCT01702558","A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)","Completed","No Results Available","All","Phase 2","181","Industry","Interventional","December 31, 2014","May 31, 2017","May 31, 2017","October 8, 2012","null","April 18, 2018","Fundacion Investigar, Caba, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Hospital Erasto Gaertner, Curitiba, PR, Brazil|Instituto Oncologico de Ribeirao Preto - INORP, Ribeirao Preto, SP, Brazil|Faculdade de Medicina de Sao Jose do Rio Preto - FAMERP, Sao Jose do Rio Preto, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|ICO Paul Papin; Oncologie Medicale., Angers, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Institut Curie; Oncologie Medicale, Paris, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo., Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie, Bielefeld, Germany|Heinrich-Heine Universitätsklinik Düsseldorf, Düsseldorf, Germany|Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH, Fulda, Germany|Klinikum St. Georg gGmbH; Klinik fuer Gynaekologie und Geburtshilfe, Leipzig, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany|Philipps-Universität Marburg; Klinik für Innere Med.; Schwerpunkt Hämatologie/Onkologie/Immunologie, Marburg, Germany|Klinikum rechts der Isar der TU München; Frauenklinik & Poliklinik, München, Germany|Klinikum rechts der Isar der TU München; III. Medizinischen Klinik (Hämatologie/Onkologie), München, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Azienda usl 5 Di Pisa-Ospedale Di Pontedera;U.O. Oncologia, Pontedera, Toscana, Italy|Ospedale Sacro Cuore Don Calabria; U.O. Di Oncologia, Negrar, Veneto, Italy|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|State Inst. Of Healthcare Orenburg Regional Clinical Oncology Dis, Orenburg, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|City Oncology Dispensary, St Petersburg, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Clinical Centre Nis, Clinic for Oncology, Nis, Serbia|Mammacentrum sv. Agáty, Banská Bystrica, Slovakia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A, Bratislava, Slovakia|Fakultna nemocnica Trencín; Onkologicke odd., Trencin, Slovakia|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01702558"
382,"NCT02269943","Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma","Completed","Has Results","All","Phase 2","36","Industry","Interventional","February 13, 2015","April 20, 2017","April 20, 2017","October 21, 2014","June 1, 2018","August 1, 2018","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University, Montreal, Quebec, Canada|Institut Hospitalier Franco-Britannique, Levallois-Perret, France|Institut Curie, Paris, France|Institut Gustave Roussy, Villejuif Cedex, France|University General Hospital of Heraklion, Heraklion, Greece|Thermi Clinic, Thessaloniki, Greece|Istituto Nazionale Dei Tumori, Milano, Italy|National Cancer Center, Singapore, Singapore|Singapore Oncology Consultants, Singapore, Singapore|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Instituto Catalan de Oncologia-Hospital Duran, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Chang Gung Medical Foundation, Kaohsiung Memorial Hospital, Niao-Sung Hsiang Kaohsiung County, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Hopital Abderrahman Mami de Pneumo-Phtisiologie de l'Ariana, Ariana, Tunisia|Institut Salah Azaiez, Bab Saadoun, Tunisia|Hospital Habib Bourguiba, Sfax, Tunisia","https://ClinicalTrials.gov/show/NCT02269943"
383,"NCT01170663","A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma","Completed","Has Results","All","Phase 3","665","Industry","Interventional","December 2010","July 2013","February 2017","July 27, 2010","July 31, 2014","March 19, 2018","ImClone Investigational Site, Burbank, California, United States|ImClone Investigational Site, Los Angeles, California, United States|ImClone Investigational Site, San Francisco, California, United States|ImClone Investigational Site, Jacksonville, Florida, United States|ImClone Investigational Site, Miramar, Florida, United States|ImClone Investigational Site, Atlanta, Georgia, United States|ImClone Investigational Site, Honolulu, Hawaii, United States|ImClone Investigational Site, East Orange, New Jersey, United States|ImClone Investigational Site, Albuquerque, New Mexico, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, Chattanooga, Tennessee, United States|ImClone Investigational Site, Houston, Texas, United States|ImClone Investigational Site, Seattle, Washington, United States|ImClone Investigational Site, Buenos Aires, Argentina|ImClone Investigational Site, Caba, Argentina|ImClone Investigational Site, Rosario, Argentina|ImClone Investigational Site, Santa Fe, Argentina|ImClone Investigational Site, Bankstown, New South Wales, Australia|ImClone Investigational Site, Kogarah, New South Wales, Australia|ImClone Investigational Site, Liverpool, New South Wales, Australia|ImClone Investigational Site, Wollongong, New South Wales, Australia|ImClone Investigational Site, Southport, Queensland, Australia|ImClone Investigational Site, Kurralta Park, South Australia, Australia|ImClone Investigational Site, Coburg, Victoria, Australia|ImClone Investigational Site, Footscray, Victoria, Australia|ImClone Investigational Site, Frankston, Victoria, Australia|ImClone Investigational Site, Parkville, Victoria, Australia|ImClone Investigational Site, Graz, Austria|ImClone Investigational Site, Linz, Austria|ImClone Investigational Site, Steyr, Austria|ImClone Investigational Site, Vienna, Austria|ImClone Investigational Site, Bonheiden, Belgium|ImClone Investigational Site, Brugge, Belgium|ImClone Investigational Site, Brussels, Belgium|ImClone Investigational Site, Brussels, Belgium|ImClone Investigational Site, Edegem, Belgium|ImClone Investigational Site, Leuven, Belgium|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Caxias Do Sul, Brazil|ImClone Investigational Site, Dois Lajeados, Brazil|ImClone Investigational Site, Gavea, Brazil|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Itajai, Brazil|ImClone Investigational Site, Londrina, Brazil|ImClone Investigational Site, Passo Fundo, Brazil|ImClone Investigational Site, Porto Alegre-Rs, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Ribeirão Preto, Brazil|ImClone Investigational Site, Rio De Janeiro, Brazil|ImClone Investigational Site, Salvador, Brazil|ImClone Investigational Site, Sao Jose Rio Preto, Brazil|ImClone Investigational Site, Sorocaba, Brazil|ImClone Investigational Site, São Paulo, Brazil|ImClone Investigational Site, São Paulo, Brazil|ImClone Investigational Site, São Paulo, Brazil|ImClone Investigational Site, Sofia, Bulgaria|ImClone Investigational Site, Varna, Bulgaria|ImClone Investigational Site, Providencia, Chile|ImClone Investigational Site, Vina Del Mar, Chile|ImClone Investigational Site, Tallinn, Estonia|ImClone Investigational Site, Tallinn, Estonia|ImClone Investigational Site, Besancon, France|ImClone Investigational Site, Brest, France|ImClone Investigational Site, Clermont-Ferrand, France|ImClone Investigational Site, Marseille, France|ImClone Investigational Site, Montbeliard, France|ImClone Investigational Site, Montpellier, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Saint-Etienne, France|ImClone Investigational Site, Berlin, Germany|ImClone Investigational Site, Bielefeld, Germany|ImClone Investigational Site, Dresden, Germany|ImClone Investigational Site, Essen, Germany|ImClone Investigational Site, Frankfurt, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Heidelberg, Germany|ImClone Investigational Site, Leipzig, Germany|ImClone Investigational Site, Mainz, Germany|ImClone Investigational Site, Munich, Germany|ImClone Investigational Site, Recklinghausen, Germany|ImClone Investigational Site, Tuebingen, Germany|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Gyula, Hungary|ImClone Investigational Site, Kaposvar, Hungary|ImClone Investigational Site, Pecs, Hungary|ImClone Investigational Site, Szekesfehervar, Hungary|ImClone Investigational Site, Beer Sheva, Israel|ImClone Investigational Site, Haifa, Israel|ImClone Investigational Site, Holon, Israel|ImClone Investigational Site, Jerusalem, Israel|ImClone Investigational Site, Petah Tikva, Israel|ImClone Investigational Site, Tel Hashomer, Israel|ImClone Investigational Site, Tel-Aviv, Israel|ImClone Investigational Site, Ancona, Italy|ImClone Investigational Site, Bari, Italy|ImClone Investigational Site, Bergamo, Italy|ImClone Investigational Site, Catania, Italy|ImClone Investigational Site, Genova, Italy|ImClone Investigational Site, Milano, Italy|ImClone Investigational Site, Padova, Italy|ImClone Investigational Site, Pisa, Italy|ImClone Investigational Site, Torino, Italy|ImClone Investigational Site, Aichi, Japan|ImClone Investigational Site, Chiba, Japan|ImClone Investigational Site, Ehime, Japan|ImClone Investigational Site, Fukuoka, Japan|ImClone Investigational Site, Hokkaido, Japan|ImClone Investigational Site, Kochi, Japan|ImClone Investigational Site, Oita, Japan|ImClone Investigational Site, Osaka-Pref, Japan|ImClone Investigational Site, Osaka, Japan|ImClone Investigational Site, Saitama, Japan|ImClone Investigational Site, Shizuoka, Japan|ImClone Investigational Site, Tochigi, Japan|ImClone Investigational Site, Tokyo, Japan|ImClone Investigational Site, Incheon, Korea, Republic of|ImClone Investigational Site, Seongnam-Si, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Suwon-City, Korea, Republic of|ImClone Investigational Site, Suwon, Korea, Republic of|ImClone Investigational Site, Kaunas, Lithuania|ImClone Investigational Site, Klaipeda, Lithuania|ImClone Investigational Site, Juchitan, Mexico|ImClone Investigational Site, Nuevo Leon, Mexico|ImClone Investigational Site, Brzozow, Poland|ImClone Investigational Site, Bydgoszcz, Poland|ImClone Investigational Site, Gdansk, Poland|ImClone Investigational Site, Lodz, Poland|ImClone Investigational Site, Lublin, Poland|ImClone Investigational Site, Poznan, Poland|ImClone Investigational Site, Warsaw, Poland|ImClone Investigational Site, Aveiro, Portugal|ImClone Investigational Site, Coimbra, Portugal|ImClone Investigational Site, Evora, Portugal|ImClone Investigational Site, Porto, Portugal|ImClone Investigational Site, Santa Maria Da Feira, Portugal|ImClone Investigational Site, Baia Mare, Romania|ImClone Investigational Site, Bucharest, Romania|ImClone Investigational Site, Iasi, Romania|ImClone Investigational Site, Targu Mures, Romania|ImClone Investigational Site, Krasnodar, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Perm, Russian Federation|ImClone Investigational Site, Saint Petersburg, Russian Federation|ImClone Investigational Site, Ufa, Russian Federation|ImClone Investigational Site, Singapore, Singapore|ImClone Investigational Site, Avila, Spain|ImClone Investigational Site, Burgos, Spain|ImClone Investigational Site, Jerez De La Frontera, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Majadahonda, Spain|ImClone Investigational Site, Palma De Mallorca, Spain|ImClone Investigational Site, Sabadell, Spain|ImClone Investigational Site, Sevilla, Spain|ImClone Investigational Site, Changhua, Taiwan|ImClone Investigational Site, Kaohsiung, Taiwan|ImClone Investigational Site, Liouying/Tainan, Taiwan|ImClone Investigational Site, Taichung, Taiwan|ImClone Investigational Site, Tainan, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Maidstone, Kent, United Kingdom|ImClone Investigational Site, Guildford, Surrey, United Kingdom|ImClone Investigational Site, Sutton, Surrey, United Kingdom|ImClone Investigational Site, Wolverhampton, West Midlands, United Kingdom","https://ClinicalTrials.gov/show/NCT01170663"
384,"NCT02289898","Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma","Completed","Has Results","All","Phase 2","207","Industry","Interventional","April 20, 2015","May 2017","September 2017","November 13, 2014","August 8, 2018","August 8, 2018","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|City of Hope, Duarte, California, United States|Scripps Cancer Center, La Jolla, California, United States|University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States|Soulhern California Permanente Medical Group, San Marcos, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|University of Rochester, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kaiser Permanente NW Oncology Research, Portland, Oregon, United States|Thomas Jefferson University, Sydney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Joe Arrington Cancer Research Treatment Center, Lubbock, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Monash Medical Centre, Moorabbin, Bentleigh East, Victoria, Australia|Western Health (Sunshine Hospitals), St Albans, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|St. John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Hopital Erasme, Brussels, Brussels Capital, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|St Josephs Health Centre, Toronto, Ontario, Canada|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitari Germans Trias i Pujol - lnstituto Catalan d'Oncologia (!CO), Barcelona, Spain|Hospital General Universitario Gregorio Marafi6n, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Sarah Cannon Research Institute UK, London, United Kingdom","https://ClinicalTrials.gov/show/NCT02289898"
385,"NCT01527929","Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment","Completed","No Results Available","All","Phase 1","25","Industry","Interventional","April 2012","November 2013","November 2013","February 7, 2012","null","December 4, 2013","Investigational Site Number 056002, Bruxelles, Belgium|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 528001, Rotterdam, Netherlands|Investigational Site Number 528002, Utrecht, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 826001, Cambridge, United Kingdom","https://ClinicalTrials.gov/show/NCT01527929"
386,"NCT01772797","Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer","Completed","No Results Available","All","Phase 1","22","Industry","Interventional","June 2013","January 2016","January 2016","January 21, 2013","null","September 22, 2016","University of Colorado Dept. of Anschutz Cancer (3), Aurora, Colorado, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia, Pennsylvania, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT01772797"
387,"NCT01576666","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","120","Industry","Interventional","July 2012","April 2015","April 2015","April 12, 2012","null","February 22, 2016","Cedars Sinai Medical Center SC, Los Angeles, California, United States|University of California San Francisco UCSF (SC), San Francisco, California, United States|H. Lee Moffitt Cancer Center & Research Institute Moffitt 4, Tampa, Florida, United States|Dana Farber Cancer Institute Dana SC, Boston, Massachusetts, United States|Mayo Clinic - Rochester Division of Hematology, Rochester, Minnesota, United States|Duke University Medical Center Duke - Baker, Durham, North Carolina, United States|Willamette Valley Clinical Studies Williamette Valley Cancer, Eugene, Oregon, United States|Northwest Cancer Specialists Northwest Cancer, Portland, Oregon, United States|Fox Chase Cancer Center FCCC, Philadelphia, Pennsylvania, United States|Texas Oncology Midtown Texas Oncology, Dallas, Texas, United States|Sammons Cancer Center - Texas Oncology SC-2, Dallas, Texas, United States|University of Texas/MD Anderson Cancer Center SC-3, Houston, Texas, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01576666"
388,"NCT01189968","A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer","Completed","No Results Available","All","Phase 1","50","Industry","Interventional","September 2010","September 2016","September 2016","August 27, 2010","null","September 20, 2016","Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Auckland Hospital, Grafton, Auckland, New Zealand|Waikato Hospital, Hamilton, New Zealand|START Madrid, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01189968"
389,"NCT01525550","A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors","Completed","Has Results","All","Phase 4","106","Industry","Interventional","June 6, 2012","March 19, 2016","July 26, 2018","February 3, 2012","May 19, 2017","September 26, 2018","Univeristy of California, Orange, California, United States|Research Location and IP Shipment Address: Henry Ford Hospital, Detroit, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Cliniques Universitaires Saint-Luc, Gastroenterologie, Bruxelles, Brussels Gewest, Belgium|China-Japan Friendship Hospital, Beijing, Beijing, China|307 Hospital of PLA, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni poliklinika, Praha 2, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Czechia|Hôpital Beaujon, Clichy Cedex, France|Semmelweis Egyetem/II. Sz. Belgyogyaszati Klinika, Budapest, Hungary|Tata Memorial Hospital, Mumbai, Maharashtra, India|IEO Istituto Europeo di Oncologia, IRCCS, Milano, Italy|Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, Romania|Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie, Bucuresti, Romania|Narodny Onkologicky ustav, Bratislava, Slovakia|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Hospital Universitario Madrid Sanchinarro - Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain","https://ClinicalTrials.gov/show/NCT01525550"
390,"NCT00844649","Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas","Completed","Has Results","All","Phase 3","861","Industry","Interventional","March 2009","September 2012","April 2013","February 16, 2009","December 11, 2013","March 1, 2017","UAB Comprenhensive Cancer Center at University of Alabama, Birmingham, Alabama, United States|Clearview Cancer Institute Oncology Specialities, P.C., Huntsville, Alabama, United States|TGEN Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|Mayo Clinic-Scottsdale, Scottsdale, Arizona, United States|Northern Arizona Hematology and Oncology Associates-AOA, Sedona, Arizona, United States|Arizona Cancer Center, University of Arizona, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope, Duarte, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|UCLA, Los Angeles, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|University Cancer Institute, LLC, Boynton Beach, Florida, United States|Collaborative Research Group, Boynton Beach, Florida, United States|FL Cancer Specialist, Ft Myers, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Lake County Oncology and Hematology, Tavares, Florida, United States|Phoebe Putney Cancer Center, Albany, Georgia, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Piedmont Hospital Research Institute, Atlanta, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Atlanta Cancer Care, Atlanta, Georgia, United States|Cancer Care & Hemaotology Specialists of Chicagoland, Arlington Heights, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Cancer Care & Hematology Specialists of Chicagoland, Niles, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Orchard Research, Skokie, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Hutchinson Clinic, PA, Hutchinson, Kansas, United States|Owsley Brown Frazier Cancer Center, Louisville, Kentucky, United States|Hematology Oncology Clinic, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|Mercy Hospital Portland, ME, Portland, Maine, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|Sidney Kimmel Comphrensive Cancer Center, John Hopkins University, Baltimore, Maryland, United States|Center for Cancer & Blood Disorders, Bethesda, Maryland, United States|Lahey Clinic, Burlington, Massachusetts, United States|Cancer Center of Excellence/University of MA Medical School, Worcester, Massachusetts, United States|St. Mary's/ Duluth Clinic, Duluth, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States|St. John's Medical Research Institute, Springfield, Missouri, United States|Saint Louis University, St. Louis, Missouri, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Hem Onc Associates-NM, Albuquerque, New Mexico, United States|University of New Mexico, Albuquerque, New Mexico, United States|New York Oncology Hematology PC, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Arena Oncology Associates, PC, Lake Sucess, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Piedmont Hematology Oncology, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Mid Ohio Oncology/Hematology Inc, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Cancer Centers of SW OK, Lawton, Oklahoma, United States|University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Mercy Physicians of Oklahoma, Oklahoma City, Oklahoma, United States|Cancer Care Associates- Tulsa, Tulsa, Oklahoma, United States|St. Mary Medical Center Hem-Onc Group, PC, Langhorne, Pennsylvania, United States|University of Pittsburg Medical Center, Pittsburg, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Medical City Dallas-US Oncology, Dallas, Texas, United States|Texas Oncology, PA, Dallas, Texas, United States|Texas Oncology, PA/ Methodist Charlton Cancer Center, Dallas, Texas, United States|Texas Oncology Laboratories, Fort Worth, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|The University of Texas Medical School at Houston, Houston, Texas, United States|Texas Oncology- Plano East, Plano, Texas, United States|Texas Oncology, PA, Round Rock, Texas, United States|Texas Oncology-Round Rock, Round Rock, Texas, United States|South Texas Oncology and Hematology, P.A, San Antonio, Texas, United States|Texas Oncology, PA, Wichita Falls, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Fairfax-Northern Virginia Hematology-Oncology, P.C., Fairfax, Virginia, United States|Virginia Cancer Specialist, PC, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Health Services, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Evergreen Hematology & Oncology, Spokane, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Macarthur Cancer Therapy Center, Campbelltown, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Newcastle Hospital, Waratah, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Haemotology & Oncology Australasia (HOCA), Milton, Queensland, Australia|Haematology Oncology Clinics of Australasia-Gold Coast, Milton, Queensland, Australia|Adelaide Cancer Centre (T/A Ashford Cancer Ctr), Ashford, South Australia, Australia|Flinders Medical Center, Bedford Park, South Australia, Australia|Calvary North Adelaide Hospital, North Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Medical Oncology Unit, Bendigo Health, Bendigo, Victoria, Australia|Monash Medical Centre, East Bentleigh, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Peninsula Oncology Centre, Frankston, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Perth, Western Australia, Australia|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Landesklinikum St. Pölten, St. Pölten, Austria|Medizinische Universität Wien, Vienna, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Imelda VZW , Gastro-Enterology, Bonheiden, Belgium|Hôpital Erasme, Gastro-Enterology, Brussels, Belgium|AZ Groeninge - Campus Sint-Niklaas, Kortrijk, Belgium|H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BC Cancer Agency-Vancouver, Vancouver, British Columbia, Canada|The Royal Victoria Hospital-Barrie, Barrie, Ontario, Canada|Hopital du Sacre-Coeur, Montreal, Quebec, Canada|Centre Hospitalier de L'Universite de Montreal St-Luc, Montreal, Canada|Princess Margaret Hospital, Ontario, Canada|Hotel-Dieu de Quebec, Quebec, Canada|Centre Regional de lutte contre le cancer Paul Papin, Angers, France|Hôpital Saint Antoine, Paris, France|Hôpital Beaujon, Paris, France|Kliniken Essen-Mitte, Essen, Germany|Klinikum Freising, Freising, Germany|Praxis für Innere Medizin, Dr. Oettle Helmut, Friedrichshafen, Germany|LMU Klinikum der Universität, Munich, Germany|Klinikum Oldenburg, Oldenburg, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|I.R.C.C.S. ""Giovanni Paolo II"" - Istituto Oncologico, Bari, Italy|E. O. Ospedali Galliera, Struttura Complessa Oncologia Medica, Genova, Italy|Nazionale per la Ricerca sul Cancro, Genova, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Oncologia Medica Falck, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero universitaria Pisana, Pisa, Italy|Arcispedale Santa Maria Nuova, Unità Operativa di Oncologia Medica, Reggio Emilia, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Istituto Nazionale Tumori ""Regina Elena"", Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Foggia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Med Radiological Centre of the Russian Academy of Med Sciences, Obninsk, Kaluga Region, Russian Federation|Tatarstan Republican Onc Ctr, Kazan, Republic of Tatarstan, Russian Federation|Altai Territorial Oncological Center, Barnaul, Russian Federation|Chelyabinsk Regional Onc Ctr, Chelyabinsk, Russian Federation|Ivanovo Regional Oncology Center, Ivanovo, Russian Federation|Regional Oncological Center # 2, Magnitogorsk, Russian Federation|Moscow Municipal Onc Hosp #62, Moscow Region, Russian Federation|Moscow City Clinical Hosp #57 Chemotherapy Dept, Moscow, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|Russian Res Ctr of Radiology under the Fed Agency for Hi-Tech Med Care, Moscow, Russian Federation|Russian Research Ctr of Surgery n.a. B.V. Petrovskiy under the Russian Academy of Med Sciences, Moscow, Russian Federation|Central Clinical Hosp of the President of the Russian Federation, Moscow, Russian Federation|Semashko Central Hosp #2, Moscow, Russian Federation|Omsk Regional Onc Ctr, Omsk, Russian Federation|Orenburg Regional Onc Ctr, Orenburg, Russian Federation|Pyatigorsk Affiliate of Stavropol Regional Onc Ctr, Pyatigorsk, Russian Federation|St. Petersburg State Med Academy n.a.Mechnikov, St Petersburg, Russian Federation|Russian Research Ctr for Radiology and Surgical Technologies, St Petersburg, Russian Federation|Clinical Hosp # 122 n.a. L.G. Sokolov, St. Petersburg, Russian Federation|Leningrad Regional Clinical Hosp, St. Petersburg, Russian Federation|St. Petersburg City Onc Ctr, St. Petersburg, Russian Federation|Tula Regional Oncology Center, Tula, Russian Federation|Bashkortostan Republican Onc Ctr, Ufa, Russian Federation|Yaroslavl Regional Onc Ctr, Yaroslavl, Russian Federation|Hospital Vall D´Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Dnepropetrovsk City Hosp #4, Dnepropetrovsk, UK, Ukraine|Donetsk Regional Antitumor Ctr, Donetsk, UK, Ukraine|Kirovohrad Regional Oncology Center, Department of Chemotherapy, Kirovohrad, UK, Ukraine|National Institute of Cancer, Department of Tumors of Abdominal Cavity and Retroperitoneum, Kyiv, UK, Ukraine|Kyiv City Clinical Hospital #10, Center for Hepatic, Bile Duct and Pancreatic Surgery, Kyiv, UK, Ukraine|Volyn Regional Oncology Center Department of Oncochemotherapy, Lutsk, UK, Ukraine|Lviv Regional Diagnostics and Treatment and Diagnostics Onc Ctr, Lviv, UK, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Surgery Center, Zhytomyr, UK, Ukraine|Kharkov Regional Onc Ctr, Kharkov, Ukraine|Kherson Regional Onc Ctr, Kherson, Ukraine|Odessa Regional Onc Ctr, Odessa, Ukraine|Zaporizhia Medical Academy of Postgraduate Education, Zaporizhia, Ukraine","https://ClinicalTrials.gov/show/NCT00844649"
391,"NCT01004250","A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer","Completed","Has Results","All","Phase 2","109","Industry","Interventional","October 2009","November 2012","December 2013","October 29, 2009","December 25, 2013","May 21, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Copenhagen, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herlev, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coswig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lecce, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rozzano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trento, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaen, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo De Alarcon, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden","https://ClinicalTrials.gov/show/NCT01004250"
392,"NCT01178450","Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation","Completed","No Results Available","All","Phase 4","30","Other","Interventional","January 2010","September 2014","September 2014","August 10, 2010","null","April 28, 2015","Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelone, Spain|Hospital Clinic de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01178450"
393,"NCT01523171","Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","Completed","No Results Available","All","Phase 2","97","Industry","Interventional","April 2012","April 2014","April 2014","February 1, 2012","null","March 17, 2016","Investigational Site Number 840007, Phoenix, Arizona, United States|Investigational Site Number 840003, San Francisco, California, United States|Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840005, Atlanta, Georgia, United States|Investigational Site Number 840014, Chicago, Illinois, United States|Investigational Site Number 840001, Kansas City, Kansas, United States|Investigational Site Number 840017, Baltimore, Maryland, United States|Investigational Site Number 840013, Baltimore, Maryland, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840009, New York, New York, United States|Investigational Site Number 840018, New York, New York, United States|Investigational Site Number 840022, Cleveland, Ohio, United States|Investigational Site Number 840019, Middletown, Ohio, United States|Investigational Site Number 840024, Charleston, South Carolina, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 840015, Salt Lake City, Utah, United States|Investigational Site Number 040002, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Antwerpen, Belgium|Investigational Site Number 056003, Leuven, Belgium|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250003, Nimes Cedex 9, France|Investigational Site Number 250002, Paris Cedex 10, France|Investigational Site Number 250006, Paris Cedex 12, France|Investigational Site Number 250004, Toulouse, France|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276007, Leipzig, Germany|Investigational Site Number 276006, Magdeburg, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 276005, Ulm, Germany|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380002, Roma, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 528002, Amsterdam, Netherlands|Investigational Site Number 528003, Maastricht, Netherlands|Investigational Site Number 528001, Nijmegen, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Majadahonda, Spain|Investigational Site Number 724002, Salamanca, Spain|Investigational Site Number 826001, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01523171"
394,"NCT01337089","Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain","Completed","Has Results","All","Phase 3","660","Industry","Interventional","January 19, 2011","January 27, 2016","January 27, 2016","April 18, 2011","April 23, 2018","April 23, 2018","Phoenix, Arizona, United States|Phoenix, Arizona, United States|El Cajon, California, United States|Gilroy, California, United States|Glendale, California, United States|Santa Rosa, California, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Holiday, Florida, United States|Jacksonville, Florida, United States|Lynn Haven, Florida, United States|Miami, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Park, Florida, United States|Marietta, Georgia, United States|Newnan, Georgia, United States|Stockbridge, Georgia, United States|Woodlawn, Illinois, United States|Ashland, Kentucky, United States|Bossier City, Louisiana, United States|Shreveport, Louisiana, United States|Saint Louis Park, Minnesota, United States|Kansas City, Missouri, United States|Missoula, Montana, United States|Berlin, New Jersey, United States|New York, New York, United States|New York, New York, United States|Flat Rock, North Carolina, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Laredo, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Lacey, Washington, United States|Parkville, Australia|Bruxelles, Belgium|Gabrovo, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Benešov, Czechia|Jablonec Nad Nisou, Czechia|Most, Czechia|Nová Ves Pod Pleší, Czechia|Ostrava, Czechia|Plzen, Czechia|Sokolov, Czechia|Teplice, Czechia|České Budějovice, Czechia|České Budějovice, Czechia|Berlin, Germany|Frankfurt, Germany|Jena, Germany|Lunen, Germany|Stadtroda, Germany|Wetzlar, Germany|Wiesbaden, Germany|Deszk, Hungary|Komarom, Hungary|Miskolc, Hungary|Nyíregyháza, Hungary|Szekszard, Hungary|Szikszo, Hungary|Beer Sheva, Israel|Haifa, Israel|Ramat Gan, Israel|Zerifin, Israel|Garbagnate Milanese, Italy|Piacenza, Italy|Torino, Italy|Riga, Latvia|Rēzekne, Latvia|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Chihuahua, Mexico|Distrito Federal, Mexico|Białystok, Poland|Bielsko-Biala, Poland|Bydgoszcz, Poland|Czeladz, Poland|Częstochowa, Poland|Częstochowa, Poland|Działdowo, Poland|Gdansk, Poland|Gliwice, Poland|Klodzko, Poland|Opole, Poland|Ostrowiec Swietokrzyski, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wloclawek, Poland|Ponce, Puerto Rico|San Juan, Puerto Rico|Baia Mare, Romania|Baia Mare, Romania|Braila, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Constanţa, Romania|Craiova, Romania|Focsani, Romania|Iaşi, Romania|Oradea, Romania|Satu Mare, Romania|Sibiu, Romania|Suceava, Romania|Târgovişte, Romania|Granada, Spain|Taichung, Taiwan|Tainan City, Taiwan|Bury Saint Edmunds, United Kingdom|Bury, United Kingdom|Cheltenham, United Kingdom|Crumpsall, United Kingdom|Edinburgh, United Kingdom|Edinburgh, United Kingdom|Gorleston-on-Sea, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom|Plymouth, United Kingdom|Weston-super-Mare, United Kingdom|Withington, United Kingdom","https://ClinicalTrials.gov/show/NCT01337089"
395,"NCT01743469","A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers","Completed","Has Results","All","Phase 2","201","Industry","Interventional","December 2012","December 2014","April 2016","December 6, 2012","May 7, 2018","May 7, 2018","Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium|Ghent University Hospital, 1K12 IE, De Pintelaan 185, Gent, Belgium|Leuven cancer institute (LKI), Herestraat, Leuven, Belgium|Juravinski Cancer Centre, 699 Concession St, Hamilton, Ontario, Canada|London Health Sciences Center, 790 Commissoners Road East, London, Ontario, Canada|Sunnybrook, 2075 Bayview Avenue, Suite T2049, Toronto, Ontario, Canada|Princess Margaret, 610 University Avenue, Toronto, Ontario, Canada|Hospital Beaujon, 100 Blvd du Général Leclerc, Clichy, France|Centre Oscar Lambret, 3 rue Frédéric Combemale, Lille cedex, France|Bureau d'Etudes Cliniques du Centre Léon Bérard, 28, rue Laennec, Lyon, France|Hospital Saint-Antoine, 184 rue du Faubourg St Antoine, Paris, France|Hopital Europeen Georges-Pompidou, AP-HP, 20 Rue Leblanc, Paris, France|Centre Eugene Marquis, Avenue bataille Flandres Dunkerque, Rennes cedex, France|Centre René Gauducheau, Boulevard Jacques Monod, Saint Herblain, France|Institute Gustave-Roussy, 114 rue Edouard Vaillant, Villejuif, France|Hospital del mar, Paseo Maritimo 25-29, Barcelona, Spain|Hospital Gregorio Marañon, Dr. Esquerdo, 44-46, Madrid, Spain|MD Anderson Cancer Centre, Ctra. Colmenar Viejo Km. 9 100,, Madrid, Spain|Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, United Kingdom|Leicester General Hospital, Gwndolen Road, Leicester, United Kingdom|The Royal Marsden Hospital, Downs Rd, Sutton, London, United Kingdom|The Christie Hospital, Wilmslow Road, Withington, Manchester, United Kingdom|Freeman Hospital, Freeman Road, High Heaton, Newcastle-upon-Tyne, United Kingdom|Southampton General Hospital, Tremona Road, Shirley, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01743469"
396,"NCT01577173","A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck","Completed","No Results Available","All","Phase 2","122","Industry","Interventional","July 2012","June 2015","June 2015","April 13, 2012","null","November 2, 2016","Stanford, California, United States|Aurora, Colorado, United States|Miami, Florida, United States|Chicago, Illinois, United States|Paducah, Kentucky, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|St Joseph, Missouri, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Charleston, South Carolina, United States|Knoxville, Tennessee, United States|Madison, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Waratah, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Kurralta Park, South Australia, Australia|Melbourne, Victoria, Australia|Edegem, Belgium|Namur, Belgium|Pleven, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Clichy, France|Lyon, France|Villejuif, France|Berlin, Germany|Essen, Germany|Debrecen, Hungary|Gyor, Hungary|Szolnok, Hungary|Udine, Friuli-Venezia Giulia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Orbassano, Piemonte, Italy|Torino, Piemonte, Italy|Brasov, Romania|Cluj-Napoca, Romania|Cluj-Napoca, Romania|Timisoara, Romania|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Salamanca, Spain|Valencia, Spain|Coventry, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01577173"
397,"NCT00932451","An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Completed","Has Results","All","Phase 2","1069","Industry","Interventional","January 2010","March 2015","December 2015","July 3, 2009","June 9, 2016","January 13, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Tower Hematology Oncology Medical Group, Beverly Hills, California, United States|Moores UCSD Cancer Center, La Jolla, California, United States|UCSD Medical Center - La Jolla, La Jolla, California, United States|Drug Shipping Address: Ronald Reagen University of California-Los Angeles, Los Angeles, California, United States|Ronald Reagen University of California-Los Angeles Medical Center, Los Angeles, California, United States|UCLA Opthalmic Oncology Center, Los Angeles, California, United States|University of California-Los Angeles, Los Angeles, California, United States|University of California, Irvine-Medical Center, Orange, California, United States|University of California, Irvine-Pharmacy, Orange, California, United States|Stanford University-Cancer Center, Palo Alto, California, United States|UC Davis Cancer Center, Sacramento, California, United States|University of California Davis Medical Center, Sacramento, California, United States|UCSD Medical Center - Hillcrest, San Diego, California, United States|Santa Monica-UCLA Medical Center & Orthopaedic Hospital Clinical Laboratory, Santa Monica, California, United States|UCLA Hematology Oncology-Santa Monica, Santa Monica, California, United States|University of California-Los Angeles, Santa Monica, California, United States|Redwood Regional Medical Group Inc, Santa Rosa, California, United States|DRUG SHIPMENT: University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Lions Eye Institute, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Kaiser Permanente Colorado - Franklin, Denver, Colorado, United States|Kaiser Permanente Colorado - Rock Creek, Lafayette, Colorado, United States|Smilow Cancer Center at Yale New Haven, Oncology Pharmacy, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Michael and Dianne Bienes Cancer Center, Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Center of South Florida Foundation, Inc., Lake Worth, Florida, United States|Memorial Cancer Center (West), Pembroke Pines, Florida, United States|H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Clinic, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Winship Cancer Institution, Atlanta, Georgia, United States|Georgia Cancer Specialists - Administrative Annex, Atlanta, Georgia, United States|MCG Health Cancer Center Pharmacy, Augusta, Georgia, United States|MCG Health System Pharmacy (Drug Shipment Only), Augusta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Georgia Cancer Specialists-Stemmer, Decatur, Georgia, United States|Georgia Cancer Specialists-Macon, Macon, Georgia, United States|Georgia Cancer Specialists-Kennestone, Marietta, Georgia, United States|Georgia Cancer Specialists-Northside, Sandy Springs, Georgia, United States|OnCare Hawaii, Inc., Honolulu, Hawaii, United States|University of Hawaii - Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Hawaii Medical Center East, Honolulu, Hawaii, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center (Attn: J Pi PharmD / A. Patel Pharm D), Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Ingalls Memorial Hospital (Drug Shipment Only), Harvey, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Monroe Medical Associates, Harvey, Illinois, United States|Monroe Medical Associates, Tinley Park, Illinois, United States|Indiana University Hospital Clarian Health, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Ship drug to: Investigational Drug Services, Indianapolis, Indiana, United States|Wishard Memorial Hospital, Indianapolis, Indiana, United States|Springmill Medical Clinic, Indianopolis, Indiana, United States|Monroe Medical Associates, Munster, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|The Harry and Jeanette Cancer Research Building, Baltimore, Maryland, United States|National Institutes of Health National Cancer Institute, Bethesda, Maryland, United States|Massachusette General Hospital, Boston, Massachusetts, United States|Massachussetts General Hospital, Boston, Massachusetts, United States|Beth Isreal Deaconess Medical Center, Pharmacy FD B18, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Pharmacy, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer lnstitute at Farmington Hllls, Farmington Hills, Michigan, United States|Barnes-Jewish Hospital, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Siteman Cancer Center, St. Peters, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center/Mary Hitchcock Memorial Hospital, Lebanon, New Hampshire, United States|University of New Mexico Eye Clinic, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|NSLIJ Health System/Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavilion, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|IP Shipment: CUMC Research Pharmacy, New York, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians, Oneida, New York, United States|Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians, Oswego, New York, United States|SUNY Upstate Medical University, Regional Oncology Center, Syracuse, New York, United States|Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians, Syracuse, New York, United States|UNC Health Care, Chapel Hill, North Carolina, United States|UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Presbyterian Hospital Cancer Center, Charlotte, North Carolina, United States|Presbyterian Hospital Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists, Huntersville, North Carolina, United States|Presbyterian Hospital Matthews, Matthews, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Hospital East, Columbus, Ohio, United States|The Ohio State University Investigational Drug Services, Columbus, Ohio, United States|The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|James Care in Kenny, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vincent Armenio, MD, East Providence, Rhode Island, United States|Pharma Resource, East Providence, Rhode Island, United States|Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute (Administration), Nashville, Tennessee, United States|Sarah Cannon Research Institute (Pharmacy), Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt Cancer Clinic, Nashville, Tennessee, United States|The Vanderbilt Chemo Clinic, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|UT Southwestern Medical Center - Simmons Cancer Center Pharmacy, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Southwestern University Hospital - Zale Lipshy, Dallas, Texas, United States|UT Southwestern University Hospital - William P. Clements, Jr, Dallas, Texas, United States|The University of Texas, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Lisa Nakatsu, RPh (Drug Shipment Address), Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology, East Melbourne, Victoria, Australia|Department of Medical Oncology, Nedlands, Western Australia, Australia|Nucleo de Oncologia da Bahia, Salvador, Bahia, Brazil|Instituto Nacional do Câncer - INCA, Rio de Janeiro, RJ, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, RS, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Fundacao Hospital Amaral Carvalho, Jau, Sao Paulo, Brazil|Fundacao Pio XII Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP, Sao Paulo, SP, Brazil|Fundacao Antonio Prudente, Sao Paulo, SP, Brazil|UMHAT Tsaritsa Yoanna - ISUL, Sofia, Bulgaria|MBAL Voennomeditsinska Academia, MMA HAT Sofia, Sofia, Bulgaria|Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, Klinika po himioterapiya, Sofia, Bulgaria|MDOZS ""Dr. Marko Markov"", Otdelenie po onkoterapiya i paliativni grizhi, Varna, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Alberta Health Services, Holy Cross Site, Calgary, Alberta, Canada|Office of Dr. John McWhae, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. Georges-L. Dumont Regional Hospital, Moncton, New Brunswick, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Dr. Dana Blakolmer and Associates, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada|Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Jewish General Hospsital, Montreal, Quebec, Canada|St. Mary's Hospital Center, Montreal, Quebec, Canada|SUN Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Cancer Institute and Hospital Chinese Academy of Medical Sciences and PUMC, Internal 4 Department, Beijing, China|307 Hospital of PLA, Beijing, China|Guangdong General Hospital, Guangzhou, China|Shanghai Chest Hospital/Department of Pulmonary Medicine, Shanghai, China|Shanghai Chest Hospital, Shanghai, China|Zhongshan Hospital Fudan University / Respiratory Department, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Centre Francois Baclesse, Caen Cedex 05, France|Centre Georges-François Leclerc, Dijon, France|Hopital Albert Michallon, Grenoble Cedex 09, France|APHM - Hopital Nord / Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille Cedex 20, France|Centre Antoine Lacassagne, NICE Cedex 2, France|Hopital Tenon, Paris cedex 20, France|Hospital Cochin, Paris, France|Centre Rene Gauducheau / Service d'Oncologie Medicale, St Herblain Cedex, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Carl-Gustav-Carus Dresden, Dresden, Germany|Westdeutsches Tumorzentrum, Universitaetsklinikum Essen, Innere Klinik - Tumorforschung, Essen, Germany|Krankenhaus Grosshansdorf, Zentrum fuer Pneumologie und Thoraxchirurgie, Grosshansdorf, Germany|Ambulantes Krebszentrum Hamburg, Hamburg, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Klinikum der Universitaet zu Koeln, Klinik I fuer Innere Medizin, Koeln, Germany|Klinikum der Universitaet Muenchen, Medizinische Klink - Innenstadt, Pneumologie, Muenchen, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|HSK Dr.- Horst-Schmidt-Kliniken, Wiesbaden, Germany|University General Hospital of Heraklion/ Department of Clinical Oncology, Heraklion, Crete, Greece|General Hospital of Thessaloniki Georgios Papanikolaou, Lung Cancer Neoplasia Research Department, Exohi, Thessaloniki, Greece|General Hospital of Chest Diseases of Athens ""Sotiria"", Athens, Greece|Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong|Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Tuen Mun Hospital, Department of Clinical Oncology, Tuen Mun, New Territories, Hong Kong|Orszagos Koranyi TBC es Pulmonologiai Intezet, VI. Bronchologia, Budapest, Hungary|Semmelweis Egyetem Pulmonologia Intezet, Budapest, Hungary|Debreceni Egyetem Orvos - es Egeszsegtudomanyi Centrum, Tudogyogyaszati Klinika, Debrecen, Hungary|Veszprem Megyei Onkormanyzat Tudogyogyintezete, Farkasgyepu, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Pulmonologiai Osztaly, Szekesfehervar, Hungary|Pest Megyei Tudogyogyintezet, III. Osztaly, Torokbalint, Hungary|Aseptic Compounding Unit, Dublin, Ireland|Department of Medical Oncology, Dublin, Ireland|Department of Medical Oncology, Galway, Ireland|Merlin Park Imaging Centre, Galway, Ireland|Pharmacy Aseptic Services Unit, Galway, Ireland|Divisione di Oncologia Medica, Ospedale San Giuseppe Moscati, Citta' Ospedaliera, Avellino, Italy|S.C. Oncologia Medica, Firenze, Italy|Oncologia Medica A, Genova, Italy|Ospedale Versilia, Oncologia Medica, Lido di Camaiore (LU), Italy|Ospedale San Luca, Lucca, Italy|Dipartimento Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative, Milano, Italy|Farmacia Istituto Europeo di Oncologia, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale Niguarda Ca' Granda Dipartimento Oncologico, SC Divisione di Oncologia Medica Falk, Milano, Italy|Nuovo Ospedale San Gerardo, Monza, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano (TO), Italy|SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia, Italy|Unita' Operativa Complessa di Pneumologia Oncologica I, Padiglione Flaiani, Roma, Italy|Centro C.O.E.S., A.O. San Giovanni Battista Le Molinette, Torino, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kinki University Hospital, Osakasayama-shi, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National Kyushu Cancer Center/Department of Thoracic Oncology, Fukuoka, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Okayama University Hospital, Okayama, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|National Cancer Center, Center for Lung Cancer, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Sungkyunkwan Univ School of Medicine, Seoul, Korea, Republic of|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Pracownia Optyczna Bozena Lawrynowicz Optyk Dyplomowany, Olsztyn, Poland|Ars Medica, Olsztyn, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Olsztyn, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Zaklad Medycyny Nuklearnej, Olsztyn, Poland|Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii, Poznan, Poland|Zaklad Diagnostyki Obrazowej, Poznan, Poland|Republican Clinical Oncology Dispensary of the Ministry of Health of Tatarstan Republic, Kazan, Russian Federation|State Institution ""National Cancer Research Center named after N.N. Blokhin' RAMS"", Moscow, Russian Federation|Saint-Petersburg State Medical University named after I.P.Pavlov of Roszdrav, Saint-Petersburg, Russian Federation|Research Institute of Pulmonology, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain|Institut Catala D'Oncologia - Hospital Duran I Reynals, L'hospitalet de Llobregat, Barcelona, Spain|Consorcio Hospitalario Parc Tauli, Sabadell, Barcelona, Spain|Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain|Hospital Del Mar, Barcelona, Spain|Hospital General Universitari Vall D´Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Navarra, Pamplona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Karolinska Universitetssjukhuset, Onkologiska kliniken, Stockholm, Sweden|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Department of Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital, Chest Department, Taipei, Taiwan|Cancer and Haematology Centre,, Headington, Oxford, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Nuffield Health Wessex Hospital, Eastleigh, United Kingdom|Department of Oncology, London, United Kingdom|Kings College London at Guy's Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, United Kingdom|Somers Cancer Research Building, M824, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00932451"
398,"NCT00932893","An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","Completed","Has Results","All","Phase 3","347","Industry","Interventional","September 2009","March 2012","January 2016","July 3, 2009","June 6, 2013","January 2, 2017","University of Arkansas for Medical Research, Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Tower Hematology Oncology Medical Group, Beverly Hills, California, United States|UCSD Medical Center -La Jolla, La Jolla, California, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Drug Shipping Address: [IRB# 10-001530] Ronald Reagan UCLA, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|UCLA Ophthalmic Oncology Center, Los Angeles, California, United States|University of California-Los Angeles, Los Angeles, California, United States|Ship Drug To : Kevin Kong- University of California, Irvine-Pharmacy, Orange, California, United States|University of California, Irvine-Medical Center, Orange, California, United States|Stanford University-Cancer Center, Palo Alto, California, United States|UC Davis Cancer Center, Sacramento, California, United States|University of California Davis Medical Center, Sacramento, California, United States|UCSD Medical Center- Hillcrest, San Diego, California, United States|Santa Monica-UCLA Medical Center and Orthopaedic Hospital, Santa Monica, California, United States|University of California, Los Angeles, Santa Monica, California, United States|Redwood Regional Medical Group, Inc., Santa Rosa, California, United States|Drug Shipment: University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Colorado Denver (CTRC), Aurora, Colorado, United States|Unviersity of Colorado Hospital, Anschutz Cancer Pavilion, Aurora, Colorado, United States|Unviersity of Colorado Hospital, Anschutz Inpatient Pavilion, Aurora, Colorado, United States|Kaiser Permanente, Denver, Colorado, United States|Kaiser Permanente, Lafayette, Colorado, United States|Drug Shipping for Yale; C/O Thomas Ferencz, RPh, BCOP, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Clinical Trial Office, New Haven, Connecticut, United States|Yale Cancer Center, New Haven, Connecticut, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Center of South Florida Foundation, Inc., Lake Worth, Florida, United States|Memorial Cancer Institute (West), Pembroke Pines, Florida, United States|H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Clinic, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Winship Cancer Institution, Atlanta, Georgia, United States|Georgia Cancer Specialists-Administrative Annex, Atlanta, Georgia, United States|Georgia Cancer Specialists - Stemmer, Decatur, Georgia, United States|Georgia Cancer Specialists-Macon, Macon, Georgia, United States|Georgia Cancer Specialists-Kennestone, Marietta, Georgia, United States|Georgia Cancer Specialists, Sandy Springs, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Hawaii Medical Center East, Honolulu, Hawaii, United States|OnCare Hawaii, Inc., Honolulu, Hawaii, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Ingalls Memorial Hospital (Drug Shipment Only), Harvey, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Monroe Medical Associates, Harvey, Illinois, United States|Monroe Medical Associates, Tinley Park, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Ship Drug to: Investigational Drug Services, Indianapolis, Indiana, United States|Wishard Memorial Hospital, Indianapolis, Indiana, United States|Springmill Medical Clinic, Indianapolis, Indiana, United States|Monroe Medical Associates, Munster, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusette General Hospital, Boston, Massachusetts, United States|Massachussetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|DFCI/Pharmacy (Drug Shipment Only), Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Lawrence and Idell Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Siteman Cancer Center- West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, St. Louis, Missouri, United States|Washington University, School of Medicine, St. Louis, Missouri, United States|Siteman Cancer Center, St. Peters, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|NSLIJ Health System/Monter Cancer Center, Lake Success, New York, United States|Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavilion, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians, Oneida, New York, United States|Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians, Oswego, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians, Syracuse, New York, United States|Investigational Drug Service, Pharmacy Department, UNC Hospitals, Chapel Hill, North Carolina, United States|UNC Health Care, NC Cancer Hospital Infusion/lnpatient Pharmacy (CHIP), Chapel Hill, North Carolina, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Hospital East, Columbus, Ohio, United States|The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|James Care in Kenny, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center-Shadyside, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vincent Armenio, MD, East Providence, Rhode Island, United States|Pharma Resource, East Providence, Rhode Island, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Vanderbilt Cancer Clinic, Nashville, Tennessee, United States|The Vanderbilt Chemo Pharmacy, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|The University of Texas, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Investigational Drug Service, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Sydney Cancer Centre, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology, East Melbourne, Victoria, Australia|Department of Medical Oncology, Nedlands, Western Australia, Australia|Nucleo de Oncologia da Bahia, Salvador, BA, Brazil|Instituto Nacional de Câncer - INCA, Rio de Janeiro, RJ, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, RS, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Fundacao Hospital Amaral Carvalho, Jau, Sao Paulo, Brazil|Fundacao Pio XII Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Câncer de São Paulo ""Octavio Frias de Oliveira"" - ICESP, Sao Paulo, SP, Brazil|Fundacao Antonio Prudente, Sao Paulo, SP, Brazil|MDOZS Plovdiv EOOD; Parvo vatreshno himioterapevtichno otdelenie, Plovdiv, Bulgaria|UMBAL ""Tsaritsa Yoanna - ISUL"", Klinika po onkoterapiya, Sofia, Bulgaria|MBAL Voennomeditsinska Academia, MMA HAT Sofia, Sofia, Bulgaria|Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, Klinika po himioterapiya, Sofia, Bulgaria|MDOZS ""Dr. Marko Markov"", Otdelenie po onkoterapiya i paliativni grizhi, Varna, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Alberta Health Services, Holy Cross Site, Calgary, Alberta, Canada|Office of Dr. John McWhae, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. Georges-L. Dumont Regional Hospital, Moncton, New Brunswick, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|RSM Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Dr. Dana Blakolmer and Associates, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|St. Mary's Hospital Center, Montreal, Quebec, Canada|SUN Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Cancer Institute and Hospital Chinese Academy of Medical Sciences and PUMC, Beijing, China|307 Hospital of PLA, Beijing, China|Shanghai Chest Hospital/Department of Pulmonary Medicine, Shanghai, China|Shanghai Chest Hospital, Shanghai, China|Zhongshan Hospital Fudan University / Respiratory Department, Shanghai, China|Shanghai Pulmonary Hospital/Dept. of Oncology, Shanghai, China|Centre Francois Baclesse, Caen Cedex 05, France|Centre Georges-François Leclerc, DIJON Cedex, France|Hopital Albert Michallon, Grenoble Cedex 09, France|Pr Fabrice BARLESI, Marseille Cedex 20, France|Centre Antoine Lacassagne, NICE Cedex 2, France|Groupe Hospitalier Cochin, Paris Cedex 14, France|Hopital Tenon / Service de Pneumologie, Paris cedex 20, France|Centre Rene Gauducheau / Service d'Oncologie Medicale, St Herblain Cedex, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinik Carl-Gustav-Carus Dresden, Dresden, Germany|Westdeutsches Tumorzentrum, Universitaetsklinikum Essen, Innere Klinik - Tumorforschung, Essen, Germany|Krankenhaus Grosshansdorf, Zentrum fuer Pneumologie und Thoraxchirurgie, Grosshansdorf, Germany|MVZ Prof. Mathey, Pfrof. Schofer GmbH, Hamburg, Germany|Thoraxklinik am Universitaetsklinikum Heidelberg, Internistische Onkologie der Thoraxtumoren, Heidelberg, Germany|Klinikum der Universitaet zu Koeln, Klinik I fuer Innere Medizin, Koeln, Germany|Klinikum der Universitaet Muenchen, Medizinische Klink - Innenstadt, Pneumologie, Muenchen, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|HSK Dr.- Horst-Schmidt-Kliniken, Innere Medizin III Haematologie, Onkologie, Palliativmedizin, Wiesbaden, Germany|University General Hospital of Heraklion/ Department of Clinical Oncology, Heraklion, Crete, Greece|General Hospital of Thessaloniki Georgios Papanikolaou, Lung Cancer Neoplasia Research Department, Exohi, Thessaloniki, Greece|General Hospital of Chest Diseases of Athens ""Sotiria"", Athens, Greece|Tuen Mun Hospital, Department of Clinical Oncology, Tuen Mun, New Territories, Hong Kong|Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong|Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Orszagos Koranyi TBC és Pulmonologiai Intezet, VI. Bronchologia, Budapest, Hungary|Semmelweis Egyetem Pulmonologia Intezet, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Tudogyogyaszati Klinika, Debrecen, Hungary|Veszprem Megyei Onkormanyzat Tudogyogyintezete, Farkasgyepu, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Pulmonologiai Osztaly, Szekesfehervar, Hungary|Pest Megyei Tudogyogyintezet, III. Osztaly, Torokbalint, Hungary|Aseptic Compounding Unit, Dublin 8, Ireland|Department of Medical Oncology, Dublin 8, Ireland|Department of Medical Oncology, Galway, Ireland|Merlin Park Imaging Centre, Galway, Ireland|Pharmacy Aseptic Service Unit, Galway, Ireland|A.O. di Rilievo Nazionale e di Alta Specialita - S. G. Moscati, Avellino, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Oncologia Medica A, Genova, Italy|Ospedale Versilia, Oncologia Medica, Lido di Camaiore (LU), Italy|Ospedale San Luca, Lucca, Italy|Dipartimento Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative, Milano, Italy|Istituto Europeo di Oncologia IRCCS, Milano, Italy|Ospedale Niguarda Ca' Granda Dipartimento Oncologico, SC Divisione di Oncologia Medica Falk, Milano, Italy|Nuovo Ospedale San Gerardo, Monza, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano (TO), Italy|SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia, Italy|Unita' Operativa Complessa di Pneumologia Oncologica I, Padiglione Flaiani, Roma, Italy|Centro C.O.E.S., A.O. San Giovanni Battista Le Molinette, Torino, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Okayama University Hospital, Okayama-city, Okayama, Japan|Kinki University Hospital, Osakasayama-shi, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National Kyushu Cancer Center, Fukuoka, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|National Cancer Center, Center for Lung Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|Samsung MedicaCenter,SungkyunkwanUnivSchoolofMedicine,Div. of Hematology-Oncology, Dep. of Medicine, Seoul, Korea, Republic of|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Pracownia Optyczna Bozena Lawrynowicz Optyk Dyplomowany, Olsztyn, NAP, Poland|Centrum Medyczne Ars Medica, Olsztyn, NAP, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, NAP, Poland|Klinika Onkologii i Radioterapii, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Olsztyn, Poland|Centralna Izba Przyjec Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland|Pracownia Tomografii Komputerowej ""ALL MEDI"" Sp. z o.o., Otwock, Poland|Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii, Poznan, Poland|Zaklad Diagnostyki Obrazowej, Poznan, Poland|Lux Med. Sp.z o.o, Warszawa, Poland|Republican Clinical Oncology Dispensary of the Ministry of Health of Tatarstan Republic, Kazan, Russian Federation|State Institution ""National Cancer Research Center named after N.N. Blokhin' RAMS"", Moscow, Russian Federation|Research Institute of Pulmonology, Saint-Peterburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Saint-Petersburg State Medical University named after I.P.Pavlov of Roszdrav, Saint-Petersburg, Russian Federation|State Medical Institution ""Oncology Center #2"" of Healthcare Department of Krasnodar Region, Sochi, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain|Institut Catala Doncologia - Hospital Duran I Reynals, L'hospitalet de Llobregat, Barcelona, Spain|Consorcio Hospitalario Parc Tauli, Sabadell, Barcelona, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera (Materno-Infantil), A Coruña, Spain|Hospital Del Mar, Barcelona, Spain|Hospital General Universitari Vall D´Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Karolinska Universitetssjukhuset, Onkologiska kliniken, Stockholm, Sweden|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Department of Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital, Chest Department, Taipei, Taiwan|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|The Alexandra Hospital, Cheshire, United Kingdom|Nuffield Health Wessex Hospital, Eastleigh, United Kingdom|Royal Free Hospital, London, United Kingdom|Kings College London at Guy's Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, United Kingdom|Cancer and Haematology Centre,, Oxford, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00932893"
399,"NCT01677455","An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer","Completed","No Results Available","Female","Phase 2","51","Industry","Interventional","July 2012","April 2015","August 2015","September 3, 2012","null","November 5, 2015","Synta Pharmaceuticals Investigative Site, Birmingham, Alabama, United States|Synta Pharmaceuticals Investigative Site, Altanta, Georgia, United States|Synta Pharmaceuticals Investigative Site, Boston, Massachusetts, United States|Synta Pharmaceuticals Investigative Site, New York, New York, United States|Synta Pharmaceuticals Investigative Site, Durham, North Carolina, United States|Synta Pharmaceuticals Investigative Site, Columbus, Ohio, United States|Synta Pharmaceuticals Investigative Site, Philadelphia, Pennsylvania, United States|Synta Pharmaceutical Investigative Site, Houston, Texas, United States|Synta Pharmaceuticals Investigative Site, Cordoba, Argentina|Synta Pharmaceuticals Investigative Site, Rosario Santa Fe, Argentina|Synta Pharmaceuticals Investigative Site, Brussels, Belgium|Synta Pharmaceutical Investigative Site, Charleroi, Belgium|Synta Pharmaceuticals Investigative Site, Wilrijk, Belgium|Synta Pharmaceuticals Investigative Site, Sao Paulo, Brazil|Synta Pharmaceutical Investigative Site, Seoul, Gangnam-GU, Korea, Republic of|Synta Pharmaceuticals Investigative Site, Seoul, Jongno-Gu, Korea, Republic of|Synta Pharmacuetical Investigative Site, Seoul, Seodaemun-GU, Korea, Republic of|Synta Pharmaceuticals Investigative Site, Seoul, Songpa-Gu, Korea, Republic of|Synta Pharmaceuticals Investigative Site, Lima, Peru|Synta Pharmaceuticals Investigative Site, Barcelona, Spain|Synta Pharmaceutical Investigative Site, Edinburgh, United Kingdom|Synta Pharmaceutical Investigative Site, Glasgow, United Kingdom|Synta Pharmaceutical Investigative Site, Nottingham, United Kingdom|Synta Pharmaceuticals Investigative Site, Oxford, United Kingdom|Synta Pharmaceutical Investigative Site, Peterborough, United Kingdom","https://ClinicalTrials.gov/show/NCT01677455"
400,"NCT01482156","Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","46","Industry","Interventional","January 2012","February 2015","February 2015","November 30, 2011","null","November 20, 2015","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Washington University School of Medicine Washington University (16), St. Louis, Missouri, United States|Medical University of South Carolina SC, Charleston, South Carolina, United States|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Montellier cedex 5, France|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Auckland, New Zealand|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, High Heaton, Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT01482156"
401,"NCT00723957","A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer","Completed","Has Results","All","Phase 2","260","Industry","Interventional","December 2008","May 2010","August 2011","July 29, 2008","October 17, 2011","March 10, 2016","Scripps Cancer Center, La Jolla, California, United States|Uof Md,Greenebaum Cancer Ctr., Baltimore, Maryland, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Bankstown, New South Wales, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Poitiers, France|Local Institution, Strasbourg, France|Local Institution, Strasbourg, France|Local Institution, Bad Berka, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Ulm, Germany|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Sondrio, Italy|Local Institution, Terni, Italy|Local Institution, Goyang-Si, Gyeonggi-Do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Baracaldo (Vizcaya), Spain|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan Hsien, Taiwan","https://ClinicalTrials.gov/show/NCT00723957"
402,"NCT01529411","Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer","Completed","No Results Available","All","Phase 2","86","Other","Interventional","February 2012","February 2013","December 2014","February 8, 2012","null","December 18, 2014","Hospital General de Elda Virgen de la Salud, Elda, Alicante, Spain|ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO-Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Fundació Althaia, Manresa, Barcelona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain|Complejo Hosp. Univ. de Santiago de Compostela, Santiago de Compostela, Galicia, Spain|Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain|H. del Mar (Fundació Institut Mar d´Investigacions Mèdiques - FIMIM), Barcelona, Spain|H. Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|H. General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Clínica Universitaria de Navarra (CUN), Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|H. Universitario Virgen de la Macarena, Sevilla, Spain|H. Universitario Virgen del Rocío, Sevilla, Spain|IVO, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01529411"
403,"NCT00600821","A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.","Completed","Has Results","All","Phase 2","118","Industry","Interventional","April 2008","April 2011","October 2012","January 25, 2008","May 22, 2012","November 8, 2013","Pfizer Investigational Site, Baton Rouge, Louisiana, United States|Pfizer Investigational Site, Pittsfield, Massachusetts, United States|Pfizer Investigational Site, Columbus, Mississippi, United States|Pfizer Investigational Site, Corinth, Mississippi, United States|Pfizer Investigational Site, New Albany, Mississippi, United States|Pfizer Investigational Site, Oxford, Mississippi, United States|Pfizer Investigational Site, Southaven, Mississippi, United States|Pfizer Investigational Site, Tupelo, Mississippi, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Bartlett, Tennessee, United States|Pfizer Investigational Site, Germantown, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Lubbock, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Wenatchee, Washington, United States|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Tabor, Czech Republic|Pfizer Investigational Site, Usti nad Labem, Czech Republic|Pfizer Investigational Site, Caen Cedex 05, France|Pfizer Investigational Site, Paris Cedex 14, France|Pfizer Investigational Site, Pierre-Bénite, France|Pfizer Investigational Site, Bydgoszcz, Poland|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Gdynia, Poland|Pfizer Investigational Site, Torun, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Mataro, Barcelona, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Alicante, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Southampton, Hampshire, United Kingdom|Pfizer Investigational Site, Dundee, Scotland, United Kingdom|Pfizer Investigational Site, Leeds, Yorkshire, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT00600821"
404,"NCT02116803","An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective","Completed","Has Results","All","Phase 2|Phase 3","12","Industry","Interventional","May 28, 2014","November 28, 2016","November 28, 2016","April 17, 2014","February 1, 2018","March 1, 2018","Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain","https://ClinicalTrials.gov/show/NCT02116803"
405,"NCT03005392","Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia","Completed","No Results Available","All","Phase 1|Phase 2","24","Other","Interventional","June 2015","September 2015","March 2016","December 29, 2016","null","December 29, 2016","Claudia Delgado, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT03005392"
406,"NCT01110824","Prevention of Left Ventricular Dysfunction During Chemotherapy","Completed","No Results Available","All","Phase 3","90","Other","Interventional","April 2008","December 2011","March 2012","April 27, 2010","null","November 15, 2013","Hospital Clinic, Barcelona, Catalunya, Spain|Hospital Clinic, Barcelona, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT01110824"
407,"NCT00715182","A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer","Completed","No Results Available","All","Phase 1","87","Industry","Interventional","July 2008","July 2012","July 2012","July 15, 2008","null","January 17, 2013","Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00715182"
408,"NCT01449058","A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors","Completed","No Results Available","All","Phase 1","139","Industry","Interventional","March 2012","August 31, 2016","August 15, 2017","October 7, 2011","null","October 2, 2017","University of California San Diego - Moores Cancer Center Dept Onc, La Jolla, California, United States|H. Lee Moffitt Cancer Center & Research Institute H. Lee Moffitt SC, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Massachusetts General Hospital CCPO, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center Onc. Dept, New York, New York, United States|Montefiore Medical Center SC, The Bronx, New York, United States|University of Texas/MD Anderson Cancer Center Dept. of Onc., Houston, Texas, United States|University of Utah / Huntsman Cancer Institute Huntsman (3), Salt Lake City, Utah, United States|Array BioPharma Investigative Site, Parkville, Victoria, Australia|Array BioPharma Investigative Site, Villejuif Cedex, France|Array BioPharma Investigative Site, Milano, MI, Italy|Array BioPharma Investigative Site, Roma, RM, Italy|Array BioPharma Investigative Site, Barcelona, Catalunya, Spain|Array BioPharma Investigative Site, Barcelona, Catalunya, Spain|Array BioPharma Investigative Site, Bellinzona, Switzerland|Array BioPharma Investigative Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01449058"
409,"NCT01338831","Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer","Completed","No Results Available","All","Phase 1","73","Industry","Interventional","September 2011","March 2014","March 2014","April 20, 2011","null","March 1, 2017","Massachusetts General Hospital Mass Gen 3, Boston, Massachusetts, United States|Cancer Institute of New Jersey SC, New Brunswick, New Jersey, United States|Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson, Philadelphia, Pennsylvania, United States|University of Utah / Huntsman Cancer Institute Huntsman 3, Salt Lake City, Utah, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT01338831"
410,"NCT01520870","Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.","Completed","No Results Available","All","Phase 2","49","Other|Industry","Interventional","February 2012","April 2015","March 9, 2017","January 30, 2012","null","March 16, 2018","Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Institut Català D'Oncologia L'Hospitalet (Ico), L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario A Coruña, A Coruna, Coruña (A), Spain|Hospital Del Mar, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Complejo Hospitalario Regional Virgen de Las Nieves, Granada, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Complejo Hospitalario Universitario Insular-Materno Infantil, Palmas de Gran Canaria, Spain|Hospital Universitario Y Politécnico La Fe, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01520870"
411,"NCT00940498","Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors","Completed","Has Results","All","Phase 1","78","Industry","Interventional","January 2010","August 2011","October 2012","July 16, 2009","November 2, 2018","November 2, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Insitute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Hospital General Vall D'Hebron, Barcelona, Spain|King's College London, London, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00940498"
412,"NCT01437787","Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis","Completed","No Results Available","All","Phase 3","289","Industry","Interventional","December 2011","June 2014","June 2014","September 21, 2011","null","January 8, 2016","Investigational Site Number 840014, Scottsdale, Arizona, United States|Investigational Site Number 840001, La Jolla, California, United States|Investigational Site Number 840012, La Jolla, California, United States|Investigational Site Number 840006, Los Angeles, California, United States|Investigational Site Number 840013, Baton Rouge, Louisiana, United States|Investigational Site Number 840008, Rochester, Minnesota, United States|Investigational Site Number 840009, Newark, New Jersey, United States|Investigational Site Number 840002, Canton, Ohio, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 036001, Box Hill, Australia|Investigational Site Number 036005, Herston, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 036004, Tweed Heads, Australia|Investigational Site Number 036002, Wodonga, Australia|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056003, Antwerpen, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 076002, Jau, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076001, Rio De Janeiro, Brazil|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124002, Saint John, Canada|Investigational Site Number 250006, Marseille, France|Investigational Site Number 250005, Nantes Cedex 01, France|Investigational Site Number 250004, Nimes, France|Investigational Site Number 250002, Pierre Benite Cedex, France|Investigational Site Number 250007, Poitiers, France|Investigational Site Number 250003, Toulouse, France|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 276006, Aachen, Germany|Investigational Site Number 276007, Bonn, Germany|Investigational Site Number 276008, Dresden, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348001, Debrecen, Hungary|Investigational Site Number 348007, Györ, Hungary|Investigational Site Number 348006, Kecskemét, Hungary|Investigational Site Number 348003, Miskolc, Hungary|Investigational Site Number 372002, Dublin, Ireland|Investigational Site Number 372001, Galway, Ireland|Investigational Site Number 376003, Haifa, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380007, Bologna, Italy|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Pavia, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 410002, Bundang-Gu, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Klaipeda, Lithuania|Investigational Site Number 484001, Queretaro, Mexico|Investigational Site Number 616005, Brzozow, Poland|Investigational Site Number 616002, Gdansk, Poland|Investigational Site Number 616006, Lodz, Poland|Investigational Site Number 616010, Warszawa, Poland|Investigational Site Number 616003, Wroclaw, Poland|Investigational Site Number 620005, Coimbra, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620003, Porto, Portugal|Investigational Site Number 642003, Brasov, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643009, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643010, Nizhny Novgorod, Russian Federation|Investigational Site Number 643008, Petrozavodsk, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643005, St.-Petersburg, Russian Federation|Investigational Site Number 643007, Volgograd, Russian Federation|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 710003, Johannesburg, South Africa|Investigational Site Number 710002, Parktown, South Africa|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 752001, Stockholm, Sweden|Investigational Site Number 752002, Uddevalla, Sweden|Investigational Site Number 158002, Changhua, Taiwan|Investigational Site Number 158003, Kaohsiung, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 826006, Belfast, United Kingdom|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826004, Leeds, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826005, London, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826008, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826009, Oxford, United Kingdom|Investigational Site Number 826010, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01437787"
413,"NCT00594984","Phase I/II Combination With Irinotecan- Erbitux","Completed","No Results Available","All","Phase 1|Phase 2","38","Industry","Interventional","May 2008","December 2012","December 2012","January 16, 2008","null","November 4, 2015","Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Washington University, Saint Louis, Missouri, United States|Local Institution, Buenos Aires, Argentina|Local Institution, Odense C, Denmark|Local Institution, Meldola Fc, Italy|Local Institution, Milano, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Madrid, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden","https://ClinicalTrials.gov/show/NCT00594984"
414,"NCT01352273","MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations","Completed","No Results Available","All","Phase 1","69","Industry","Interventional","June 2011","September 2013","September 2013","May 11, 2011","null","February 12, 2016","H. Lee Moffitt Cancer Center & Research Institute Moffitt 4, Tampa, Florida, United States|Oregon Health & Science University OHSU 3, Portland, Oregon, United States|University of Utah / Huntsman Cancer Institute Huntman 2, Salt Lake City, Utah, United States|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT01352273"
415,"NCT00688753","RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe","Completed","Has Results","All","Phase 2","92","Industry","Interventional","July 2009","October 2014","October 2014","June 3, 2008","November 26, 2015","September 2, 2016","Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Otwock, Poland|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00688753"
416,"NCT02413008","A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting","Completed","No Results Available","Female","Phase 2","70","Industry|Other","Interventional","April 2015","February 10, 2017","February 10, 2017","April 9, 2015","null","April 13, 2017","For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., L´Hospitalet de Llobregat, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., A Coruña, Spain|For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Jaén, Spain|For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Madrid, Spain|For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Valencia, Spain|For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT02413008"
417,"NCT00890825","AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients","Completed","Has Results","All","Phase 2","88","Industry","Interventional","April 20, 2009","May 11, 2011","November 2, 2016","April 30, 2009","June 20, 2018","June 20, 2018","Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Boston, Massachusetts, United States|Research Site, Columbus, Ohio, United States|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Ijuí, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Ostrava, Czechia|Research Site, Praha 8, Czechia|Research Site, Znojmo, Czechia|Research Site, Brest Cedex, France|Research Site, Clermont Ferrand, France|Research Site, Dijon, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille, France|Research Site, Rennes Cedex 9, France|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Györ, Hungary|Research Site, Mosdós, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Törökbálint, Hungary|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Perugia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Mexico, Mexico|Research Site, Morelia, Mexico|Research Site, Zacatecas, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, A Coruña, Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Málaga, Spain","https://ClinicalTrials.gov/show/NCT00890825"
418,"NCT01285466","A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab","Completed","No Results Available","All","Phase 1","110","Industry","Interventional","January 2011","October 2014","October 2014","January 28, 2011","null","February 14, 2017","Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland","https://ClinicalTrials.gov/show/NCT01285466"
419,"NCT01390818","Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors","Completed","Has Results","All","Phase 1","146","Industry","Interventional","May 2011","April 2015","April 2015","July 11, 2011","March 7, 2017","March 7, 2017","Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|Merck Serono Research Site, Milan, Italy|Merck Serono Research Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01390818"
420,"NCT01046266","A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma","Completed","No Results Available","All","Phase 1","62","Industry","Interventional","November 2009","June 2012","June 2012","January 11, 2010","null","September 14, 2016","Toulouse, France|Villejuif, France|Milano, Lombardia, Italy|Nijmegen, Netherlands|Barcelona, Spain|Sevilla, Spain|London, United Kingdom","https://ClinicalTrials.gov/show/NCT01046266"
421,"NCT01420783","Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia","Completed","No Results Available","All","Phase 2","81","Industry","Interventional","October 2011","November 2012","May 2014","August 22, 2011","null","March 17, 2016","Investigational Site Number 840008, Scottsdale, Arizona, United States|Investigational Site Number 840004, La Jolla, California, United States|Investigational Site Number 840005, Los Angeles, California, United States|Investigational Site Number 840011, Palo Alto, California, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840007, Rochester, Minnesota, United States|Investigational Site Number 840003, St Louis, Missouri, United States|Investigational Site Number 840001, Houston, Texas, United States|Investigational Site Number 036001, Clayton, Australia|Investigational Site Number 036002, Kingswood, Australia|Investigational Site Number 036004, Kogarah, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 124002, Montreal, Canada|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124001, Vancouver, Canada|Investigational Site Number 250004, Brest, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 276004, Frankfurt Am Main, Germany|Investigational Site Number 276003, Mannheim, Germany|Investigational Site Number 380003, Bologna, Italy|Investigational Site Number 380001, Firenze, Italy|Investigational Site Number 380004, Orbassano, Italy|Investigational Site Number 410001, Seongnam, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 724004, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724002, Valencia, Spain|Investigational Site Number 826001, Belfast, United Kingdom|Investigational Site Number 826006, Birmingham, United Kingdom|Investigational Site Number 826003, London, United Kingdom|Investigational Site Number 826004, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01420783"
422,"NCT00768755","Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 1|Phase 2","180","Industry","Interventional","January 2009","March 2011","March 2012","October 8, 2008","March 30, 2012","October 28, 2015","Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Macon, Georgia, United States|Pfizer Investigational Site, Marietta, Georgia, United States|Pfizer Investigational Site, Sandy Springs, Georgia, United States|Pfizer Investigational Site, Bloomington, Illinois, United States|Pfizer Investigational Site, Peoria, Illinois, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, West Reading, Pennsylvania, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, East Providence, Rhode Island, United States|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Lido di Camaiore (LU), Italy|Pfizer Investigational Site, Orbassano (TO), Italy|Pfizer Investigational Site, Sunto-gun, Shizuoka, Japan|Pfizer Investigational Site, Lubin, Poland|Pfizer Investigational Site, Otwock, Poland|Pfizer Investigational Site, Pila, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Prabuty, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Bacau, Romania|Pfizer Investigational Site, Iasi, Romania|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Pyatigorsk, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, St.Petersburg, Russian Federation|Pfizer Investigational Site, Terrassa, Barcelona, Spain|Pfizer Investigational Site, Castellon, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Palma de Mallorca, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Basel, Switzerland|Pfizer Investigational Site, Basel, Switzerland|Pfizer Investigational Site, Bruderholz, Switzerland|Pfizer Investigational Site, Liestal, Switzerland|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Romford, Essex, United Kingdom|Pfizer Investigational Site, Northwood, Middlesex, United Kingdom|Pfizer Investigational Site, Bournemouth, United Kingdom|Pfizer Investigational Site, Brighton, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, Middlesex, United Kingdom|Pfizer Investigational Site, Poole, United Kingdom","https://ClinicalTrials.gov/show/NCT00768755"
423,"NCT02273167","Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.","Completed","Has Results","All","Phase 3","849","Industry","Interventional","October 2014","August 2015","August 2015","October 23, 2014","April 18, 2017","May 15, 2018","AZ Sint-Lucas, Brugge, Belgium|UZ Ghent, Ghent, Belgium|UZ Leuven, Leuven, Belgium|CHC- Clinique Saint-Joseph, Liège, Belgium|Hôpital Avicenne- Service de Gastro-Entérologie, Bobigny, France|Hôpital Hotel-Dieu, Nantes, France|Kliniken Essen-Mitte; Abteilung für Gastroenterologie, Essen, Germany|Klinikum der Friedrich Schiller Universität Jena, Jena, Germany|Praxis für Innere Medizin, Gastroenterologie und Allg. Medizin, Ludwigshafen, Germany|A.O.U. di Bologna - Policlinico S. Orsola-Malpighi, Bologna, Italy|Ospedale Valduce U.O. Gastroenterologia e Endoscopia, Como, Italy|P.O. Maresca OORR Area Vesuviana ASL, Naples, Italy|Centro di Riferimento Oncologico (C.R.O.) S.O.C Gastroenterologia, Pordenone, Italy|Pol. Univ. A. Gemelli U.O. di Endoscopia Digestiva Chirurgica, Roma, Italy|Uniwersytecki Szpital Kliniczny w Bialymstoku, Białystok, Poland|Gabinet Internistyczny dr n. med. Krzysztof Janik, Czestochowa, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych, Warsaw, Poland|Robert Petryka Gabinet Internistyczny, Warsaw, Poland|Lexmedica Durbajlo Hanna, Wrocław, Poland|NZOZ Centrum Medyczne-Szpital Swietej Rodziny, Łódź, Poland|Hospital General Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Ramon y Cajal - Ctra. De Colmenar km. 9, 100, Madrid, Spain|Lothian Health Board, Edinburgh, United Kingdom|Borders General Hospital, Melrose, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom|Royal Albert Edward Infirmary Department, Wigan, United Kingdom","https://ClinicalTrials.gov/show/NCT02273167"
424,"NCT00722553","Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder","Completed","Has Results","All","Phase 2","30","Industry","Interventional","July 2008","April 2011","September 2011","July 25, 2008","July 17, 2012","May 10, 2013","The University of Arizona Health Sciences Center, Tucson, Arizona, United States|Peachtree Hematology/Oncology Consultants, Atlanta, Georgia, United States|University of Rochester Cancer Center, Rochester, New York, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Centro de Terapia Radiante Cumbres (CAICI), Rosario, Santa Fe, Argentina|IONC (Instituto Oncológuci de Cordoba), Cordoba, Argentina|Algemeen Ziekenhuis Middelheim, Antwerp, Belgium|Institut Jules Bordet, Brussels, Belgium|CH Split Clinic of Oncology and Radiotherapy, Split, Croatia|CHU Zagreb University Hospital Center Rebro in Zagreb, Zagreb, Croatia|Clinic of Oncology and Nuclear Medicine, CH ""Sestre Milosrdnice"", Zagreb, Croatia|Institut Sainte Catherine, Avignon, France|Centre Oscar Lambret, Lille Cedex, France|Centre Hospitalier Rene Dubos, Pontoise, France|Hopital Foch, Suresnes, France|Institut Gustave Roussy, Villejuif Cedex, France|Ciutat Sanitari de Vall d'Hebron, Barcelona, Spain|Hospital Del Mar - Barcelona, Barcelona, Spain|Hospital Virgen del Rocio, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT00722553"
425,"NCT02381080","Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy","Completed","No Results Available","All","Phase 1","26","Industry","Interventional","May 19, 2015","June 24, 2016","June 24, 2016","March 6, 2015","null","June 26, 2017","N/a N/a, Canada|Moscow, Russian Federation|Petrozavodsk, Russian Federation|St. Petersburg, Russian Federation|Madrid, Spain|Pamplona, Spain","https://ClinicalTrials.gov/show/NCT02381080"
426,"NCT01232452","A Study in Non-Small Cell Lung Cancer","Completed","Has Results","All","Phase 2","172","Industry","Interventional","April 2011","January 2013","June 2016","November 2, 2010","June 12, 2018","June 12, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hackensack, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rioja, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Duffel, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barretos, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Jose Do Rio Preto, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oshawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clermont-Ferrand, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Braunschweig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grosshansdorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Yaakov, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel-Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orbassano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saronno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harderwijk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., S-Hertogenbosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palma De Mallorca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edirne, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zeytinburnu, Turkey","https://ClinicalTrials.gov/show/NCT01232452"
427,"NCT01227889","A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma","Completed","Has Results","All","Phase 3","251","Industry","Interventional","December 23, 2010","December 19, 2011","September 16, 2016","October 25, 2010","May 16, 2014","October 4, 2017","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Vallejo, California, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Southport, Queensland, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Marseille Cedex 5, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Paris cedex 18, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Reims, France|GSK Investigational Site, Villejuif, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Erlangen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Kassel, Hessen, Germany|GSK Investigational Site, Wiesbaden, Hessen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Ludwigshafen, Rheinland-Pfalz, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Erfurt, Thueringen, Germany|GSK Investigational Site, Gera, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Gyor, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Pecs, Hungary|GSK Investigational Site, Cork, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Udine, Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Rozzano (MI), Lombardia, Italy|GSK Investigational Site, Siena, Toscana, Italy|GSK Investigational Site, Terni, Umbria, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Brzozow, Poland|GSK Investigational Site, Konin, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Slupsk, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Stavropol, Russian Federation|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01227889"
428,"NCT02093598","POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus","Completed","No Results Available","All","Phase 2","10","Other","Interventional","May 2012","March 2014","March 2014","March 21, 2014","null","April 14, 2015","Barcelona, Spain|Madrid, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT02093598"
429,"NCT00616135","Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy","Completed","No Results Available","Female","Phase 4","71","Industry","Interventional","June 2008","November 2010","November 2010","February 15, 2008","null","May 17, 2011","Jules Bordet Institute of Cancer, Brussels, Belgium|Università degli Studi di Firenze, Florence, Italy|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Instituto Valenciano Oncologia, Valencia, Spain|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom","https://ClinicalTrials.gov/show/NCT00616135"
430,"NCT01585987","An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy","Completed","Has Results","All","Phase 2","143","Industry","Interventional","July 2012","July 2014","April 2015","April 26, 2012","November 18, 2015","May 17, 2016","Mount Sinai Medical Center, Miami Beach, Florida, United States|Nyu Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Local Institution, Montpellier Cedex, France|Local Institution, Nice Cedex 03, France|Local Institution, Rennes, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Mainz, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Firenze, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Saku-shi, Nagano, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Katowice, Ochojec, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Olsztyn, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT01585987"
431,"NCT02273141","Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.","Completed","Has Results","All","Phase 3","515","Industry","Interventional","November 2014","August 2015","August 2015","October 23, 2014","April 18, 2017","May 15, 2018","Charité - Campus Virchow Klinikum, Berlin, Germany|University Hospital Schleswig-Holstein, Kiel, Germany|An der Germania Brauerei 6, Münster, Germany|An der Germania Brauerei 6, Milan, Italy|Osp.San Raffaele U.O. Gastroenterologia, Milan, Italy|P.T.P.Nuovo Regina Margherita, Rome, Italy|Onze Lieve Vrouwe Gashuis, Amsterdam, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Radboud UMC, Nijmegen, Netherlands|Orbis Medisch Centrum, Sittard, Netherlands|Centrum Medyczne sw. Lukasza, Czestochowa, Poland|Instytut Medycyny Wsi im. Witolda Chodzki w, Lubliniec, Poland|Specjalistyczna Praktyka Lekarska dr med. Marek Horynski, Sopot, Poland|SPSK Nr 1 im. Prof. Tadeusza Sokolowskiego, Szczecin, Poland|Hospital de Vinalopó, Unidad de Endoscopia Digestiva, Elche, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario La Paz, Unidad Enfermedad Intestinal, Madrid, Spain|Department of Surgery, Raigmore Hospital, Inverness, United Kingdom|Derriford Hospital, Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT02273141"
432,"NCT00993499","Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib","Completed","Has Results","All","Phase 1","44","Industry","Interventional","October 2009","September 2014","September 2014","October 12, 2009","October 7, 2015","October 7, 2015","1200.70.34001 Boehringer Ingelheim Investigational Site, Badalona (Barcelona), Spain|1200.70.34008 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.70.34009 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.70.34006 Boehringer Ingelheim Investigational Site, Girona, Spain|1200.70.34007 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat (Barcelona), Spain|1200.70.34005 Boehringer Ingelheim Investigational Site, Majadahonda (Madrid), Spain|1200.70.34004 Boehringer Ingelheim Investigational Site, Valencia, Spain|1200.70.34002 Boehringer Ingelheim Investigational Site, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00993499"
433,"NCT01283516","A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase","Completed","Has Results","All","Phase 1","304","Industry","Interventional","January 2011","October 2013","May 2016","January 26, 2011","August 11, 2014","March 16, 2017","University of Colorado Colorado Univ, Aurora, Colorado, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center MSK, NY, New York, United States|Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia, Pennsylvania, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance SC, Seattle, Washington, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom","https://ClinicalTrials.gov/show/NCT01283516"
434,"NCT01285778","Vectibix for the Treatment of Anal Cancer","Completed","No Results Available","All","Phase 2","58","Other|Industry","Interventional","October 2010","March 24, 2017","March 24, 2017","January 28, 2011","null","May 16, 2018","Hospital Universitario Germans Trias i Pujol. Institut Català Oncologia, Badalona, Barcelona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain|Hospital Infanta Sofía, San Sebastian de los Reyes, Madrid, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall Hebron, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Virgen Blanca, León, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01285778"
435,"NCT02272413","Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer","Completed","No Results Available","All","Phase 3","671","Industry","Interventional","July 8, 2015","June 30, 2017","November 16, 2018","October 23, 2014","null","November 26, 2018","Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Lalita Pandit, M.D., Inc., Fountain Valley, California, United States|Southern California Oncology Research Alliance, Los Angeles, California, United States|Innovative Clinical Research, Inc., Whittier, California, United States|Ashland Bellefonte Cancer Center, Ashland, Kentucky, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Detroit Clinical Research Center, Owosso, Michigan, United States|Carolinas Cancer Care, Charlotte, North Carolina, United States|CENIT - Centro de Neurociencias, Investigacion y Tratamiento, Ciudad Autonoma Buenos Aires, Argentina|Sanatorio Delta, Rosario, Argentina|Sanatorio Parque, Rosario, Argentina|Centro Oncológico de Rosario, Rosario, Argentina|CPCO - Centro de Pesquisa Clinica em Oncologia, Cachoeiro de Itapemirim, Brazil|Hospital do Cancer do Ceara, Fortaleza, Brazil|Pronutrir, Fortaleza, Brazil|Hospital de Carida de de Ijui - CACON, Ijuí, Brazil|Hospital Bruno Born, Lajeado, Brazil|Hospital da Cidade de Passo Fundo, Passo Fundo, Brazil|Universidade de Caxias do Sul - IPCEM - Inst. de Pesq.clilni, Petrópolis, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo André, Brazil|Clinica de Oncologia de Sorocaba, Sorocaba, Brazil|ICAVC - Instituto do Cancer Arnaldo Vieira de Carvalho, São Paulo, Brazil|ICESP - Instituto do Cancer do Estado de Sao Paulo, São Paulo, Brazil|MHAT - Dobrich, AD, Dobrich, Bulgaria|UMHAT Georgi Stranski, Clinic of Paediatrics, Pleven, Pleven, Bulgaria|Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria|DCC 1 - Ruse, EOOD, Ruse, Bulgaria|MHAT Serdika, EOOD, Sofia, Sofia, Bulgaria|MHAT 'Tokuda Hospital Sofia', EAD, Sofia, Bulgaria|SHATOD 'Dr. Marko Antonov Markov'-Varna, EOOD, Varna, Bulgaria|Clínica Santa María, Santiago, Chile|Hospital Clínico San Borja Arriarán, Santiago, Chile|Centro Internacional de Estudios Clinicos - CIEC, Santiago, Chile|Instituto Clínico Oncológico del Sur - ICOS, Temuco, Chile|Hospital Clinico Viña del Mar, Viña del Mar, Chile|General Hospital Pula, Pula, Croatia|Clinical Hospital Centar Sestre Milosrdnice, Zagreb, Croatia|University Clinic for Pulmonary Diseases, Zagreb, Croatia|Alexandria University Hospital, Alexandria, Egypt|Ain Shams University Hospital, Cairo, Egypt|National Cancer Institute, Cairo University, Cairo, Egypt|Nasser Institute, Cairo, Egypt|Oncology Centre- Mansoura University, Mansoura, Egypt|Menofiya University Hospital, Monofia, Egypt|Gesundheitszentrum Wetterau gGmbH, Bad Nauheim, Germany|Athens Hospital of Chest Diseases ""Sotiria"", Athens, Greece|University General Hospital of Heraklion, Crete, Greece|University of Patras Medical School, Patras, Greece|Euromedica Kyanous Stavros General Hospital, Thessaloniki, Greece|Health Center of Thermi, Thessaloniki, Thessaloniki, Greece|Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece|National Koranyi TBC and Pulm. Internal Med. Clinic, Budapest, Hungary|Semmelweis Egyetem, Budapest, Budapest, Hungary|Pulmonology Institute of Veszprem County, Farkasgyepu, Farkasgyepu, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi G. Korhaz-Rendelointezet, Szolnok, Hungary|Markusovszky County Hospital, Szombathely, Szombathely, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|ASST di Cremona, Cremona, Italy|Osp. Umberto I, Lugo (RA), Italy|Istituto Scientifico Romagnolo, Meldola (FC), Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Aichi Medical University Hospital, Aichi, Nagakute, Japan|Aichi Cancer Center Aichi Hospital, Aichi, Okazaki, Japan|Tosei General Hospital, Aichi, Seto, Japan|Fujita Health University Hospital, Aichi, Toyoake, Japan|Aso Co.,Ltd Iizuka Hospital, Fukuoka, Iizuka, Japan|Gunma Prefectural Cancer Center, Gunma, Ota, Japan|Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Amagasaki, Japan|Itami City Hospital, Hyogo, Itami, Japan|Kobe City Medical Center General Hospital, Hyogo, Kobe, Japan|Ibaraki Prefectural Central Hospital, Ibaraki, Kasama, Japan|Kagawa Rosai Hospital, Kagawa, Marugame, Japan|Kitasato University Hospital, Kanagawa, Sagamihara, Japan|Yokohama City University Hospital, Kanagawa, Yokohama, Japan|Uji-Tokushukai Medical Center, Kyoto, Uji, Japan|Matsusaka City Hospital, Mie, Matsusaka, Japan|Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Miyazaki, Japan|Nara Hospital Kinki University Faculty of Medicine, Nara, Ikoma, Japan|Niigata Cancer Center Hospital, Niigata, Niigata, Japan|Kansai Medical University Hospital, Osaka, Hirakata, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka, Japan|Takatsuki Red Cross Hospital, Osaka, Takatsuki, Japan|Saitama Medical University International Medical Center, Saitama, Hidaka, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, Japan|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Nihon University Itabashi Hospital, Tokyo, Itabashi-ku, Japan|Japan Anti-Tuberculosis Association Fukujuji Hospital, Tokyo, Kiyose, Japan|Toranomon Hospital, Tokyo, Minato-ku, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St.Vincent's Hospital, Suwon-si, Korea, Republic of|Hospital Pulau Pinang, Georgetown Pulau Pinang, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Investigacion Biomedica para el Desarrollo de Farmacos, El Salto, Mexico|Unidad de Atencion Medica e Investigacion en Salud S.C., Merida, Mexico|Axis Heilsa S. de R.L. de C.V., Monterrey, Monterrey, Mexico|Clinical Medical Research S.C, Orizaba, Mexico|Hospital San Jose Querétaro, Queretaro, Mexico|Centro Hemato Oncológico Privado, Toluca, Mexico|Dr. Pablo O. Torre Memorial Hospital, Bacolod City, Philippines|Cebu Doctors Hospital, Cebu City, Philippines|Perpetual Succour Hospital (Cebu), Cebu City, Philippines|Manila Doctors Hospital, Manila, Philippines|Lung Center of the Philippines, Quezon City, Philippines|Wojewodzkie Centrum Szpitalne Kotliny Jeleniogorskiej, Jelenia Gora, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|Zofia Tarnowska domo Zamoyska,RegHosp.Cardiol.Dep,Tarnobrzeg, Tarnobrzeg, Poland|The Provincial Polyclinical Hospital in Torun, Torun, Poland|Onco.Cent. - Instit. of Maria Sklodowskiej-Curie, Warszawa, Poland|Magodent Sp. Z o.o., Warszawa, Poland|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Centro Hospitalar Lisboa Norte Hospital Pulido Valente, Lisboa, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião, Santa Maria da Feira, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Baia Mare Emergency County Hospital, Baia Mare, Romania|Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Cluj Napoca, Cluj Napoca, Romania|Spitalul Militar de Urgenta Dr.Papilian, Cluj-Napoca, Cluj-Napoca, Romania|S.C Oncocenter Oncologie Clinica S.R.L, Timisoara, Romania|SBIH of Arkhangelsk reg. ""Arkhangelsk Clin. Onc. Dispensary"", Arkhangelsk, Russian Federation|St.Auton.Heal.Inst.""Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"", Kazan, Russian Federation|RBIH ""Kursk regional clinical oncology dispensary"", Kursk, Russian Federation|FSBI ""N.N Blokhin Med.Res.Cent.Onc.""MoH of RF, Moscow, Russian Federation|BHI of Omsk region - Clinical Oncology Dispensary, Omsk, Russian Federation|SBIH of Stavropol territory ""Pyatigorsk Oncol. Dispensary"", Pyatigorsk, Russian Federation|GUZ Leningradskaya Regional Clin. Hospital, St. Petersburg, St. Petersburg, Russian Federation|1stPavlov St.Med.Univ.St.-Petersburg Res.Inst., St. Petersburg, Russian Federation|SPb SBIH ""City Clinical Oncological Dispensary"", St. Petersburg, Russian Federation|FSBI ""N.N. Petrov National Medical Research Center of Oncology"" of MoH of RF, St. Petersburg, Russian Federation|Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, Serbia|Clinical Center Bezanijska kosa, Belgrade, Belgrade, Serbia|Clinic of Pulmonary Diseases and Tuberculosis 'Knez Selo', Gornji Matejevac, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Inst. for Pulm. Diseases of Vojvodine, Clinic f. Pulm. Oncol, Sremska Kamenica, Serbia|GVI Cape Gate Oncology Centre, Cape Town, South Africa|Rondebosch Oncology Centre, Cape town, South Africa|GVI Oncology Outeniqua Unit, George, South Africa|West Rand Oncology Centre, Johannesburg, Johannesburg, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Hospital Infanta Cristina, Badajoz, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain|Songklanagarind Hospital, Hat Yai, Thailand|Ubonratchathani Cancer Hospital, Muang, Muang, Thailand|Udonthani Cancer Hospital, Muang, Muang, Thailand|Maharaj Nakorn Chiang Mai Hospital, Muang, Thailand|Lampang Hospital, Muang, Thailand|Naresuan University Hospital, Muang, Thailand|Akdeniz University Medical Faculty, Antalya, Turkey|Inonu Uni. Med. Fac., Battalgazi, Battalgazi, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Trakya Universitesi Tip Fakultesi, Edirne, Turkey|Gaziantep University, Gaziantep, Turkey|Bezmi Alem Foundation University Medical Faculty Hospital, Istanbul, Turkey|Yeditepe University Medical School Hospital, Istanbul, Turkey|Fatih University Faculty of Medicince, Istanbul, Istanbul, Turkey|CTPI Chernihiv Regional Oncological Dispensary, Chernihiv, Chernihiv, Ukraine|CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC, Dnipropetrovsk, Ukraine|CHI Kharkiv Regional Clinical Oncological Center, Kharkiv, Ukraine|Kherson Regional Oncologic Dispensary, Kherson, Kherson, Ukraine|Treatment-Diagnostic CTR of Private Enterprise, Kirovohrad, Kirovohrad, Ukraine|CI Kryvyi Rih Oncological Dispensary of DRC, Kryvyi Rih, Dnipropetrovsk, Ukraine|National Institute of Cancer, Kyiv, Ukraine|Medical and Preventive Treatment Inst. Volyn Regional, Lutsk, Lutsk, Ukraine|CI of LRC Lviv Onco.Reg.Treat.&Diag.Cent., Lviv, Ukraine|Poltava Regional Clinical Oncological Dispensary, Poltava, Poltava, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|CI of TRC Ternopil RC Oncological Dispensary Thoracic Dept, Ternopil, Ukraine|Uzhgorod National University, City Children's Clin. Hospital, Uzhgorod, Ukraine|Transcarpathian Reg Clin Oncological Dispensary, Uzhgorod, Uzhgorod, Ukraine|Vinnytsia Regional Clinical Oncological Dispensary, Vinnytsia, Ukraine|CI Zapor Reg Cl Oncological Dispensary of ZRC, Zhaporizhzhia, Zhaporizhzhia, Ukraine|Cheltenham General Hospital, Cheltenham, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Can Tho Oncology Hospital, Can Tho, Vietnam|Bach Mai hospital, Hanoi, Vietnam","https://ClinicalTrials.gov/show/NCT02272413"
436,"NCT01767467","Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers","Completed","Has Results","All","Phase 3","568","Industry","Interventional","March 1, 2013","January 7, 2016","January 6, 2017","January 14, 2013","May 25, 2017","June 5, 2018","GSK Investigational Site, Inverness, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Elkhart, Indiana, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Marshfield, Wisconsin, United States|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Hobart, Tasmania, Australia|GSK Investigational Site, Coburg, Victoria, Australia|GSK Investigational Site, Wodonga, Victoria, Australia|GSK Investigational Site, Antwerpen, Belgium|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Jette, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Montpellier cedex 5, France|GSK Investigational Site, Mulhouse, France|GSK Investigational Site, Nantes cedex 1, France|GSK Investigational Site, Pessac cedex, France|GSK Investigational Site, Périgueux cedex, France|GSK Investigational Site, Rouen cedex 1, France|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Meldola (FC), Emilia-Romagna, Italy|GSK Investigational Site, Udine, Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Novara, Piemonte, Italy|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Jellanamdo, Korea, Republic of|GSK Investigational Site, Jeonju, Korea, Republic of|GSK Investigational Site, Kyunggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Multan, Pakistan|GSK Investigational Site, Panama, Panama|GSK Investigational Site, Chorzow, Poland|GSK Investigational Site, Opole, Poland|GSK Investigational Site, Slupsk, Poland|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Petrozavodsk, Russian Federation|GSK Investigational Site, St'Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Móstoles, Madrid, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Eskilstuna, Sweden|GSK Investigational Site, Karlskrona, Sweden|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taoyuan Hsien, Taiwan|GSK Investigational Site, Ankara, Turkey|GSK Investigational Site, Ankara, Turkey|GSK Investigational Site, Orpington, Kent, United Kingdom|GSK Investigational Site, Airdrie, Lanarkshire, United Kingdom|GSK Investigational Site, Swindon, Wiltshire, United Kingdom|GSK Investigational Site, Bournemouth, United Kingdom|GSK Investigational Site, Headington, Oxford, United Kingdom|GSK Investigational Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01767467"
437,"NCT01652469","Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.","Completed","No Results Available","All","Phase 3","81","Other|Industry","Interventional","August 2012","December 2015","December 2015","July 30, 2012","null","January 25, 2016","Krankenhaus Hietzing, Wien, Austria|Institut Jules Bordet, Brussels, Belgium|Aarhus University Hospital, Aarhus, Denmark|University Hospital of Heraklion, Heraklion, Greece|National Institute of Oncology, Budapest, Hungary|St James's Hospital, Dublin, Ireland|Institution Rabin MC, Petah Tikwa, Israel|Tel-Aviv Medical Center, Tel-Aviv, Israel|Medical Oncology, Second University Naples, Naples, Italy|Vercelli Teaching Hospital, Vercelli, Italy|Free University Medical Center, Amsterdam, Netherlands|Hospital general de Alicante, Alicante, Spain|Hospital Clínic Barcelona, Barcelona, Spain|Institut Català d'Oncologia - L'Hospitalet, Barcelona, Spain|Ciudad Real General University Hospital, Ciudad Real, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Onkologikoa, Donostia, Spain|Hospital Severo Ochoa, Leganés, Spain|Hospital 12 de Octubre, Madrid, Spain|Carlos Haya Hospital, Malaga, Spain|Hospital Universitari Sant Joan, Reus, Spain|Hospital Arnau Vilanova Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|University Hospital Basel, Basel, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Fondation du centre Pluridisciplinaire d'Oncologie (CePO), Lausanne, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Onkologiezentrum Berner Oberland, Thun, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|University Hospital South Manchester, Manchester, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01652469"
438,"NCT01598077","A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer","Completed","No Results Available","All","Phase 1","54","Industry","Interventional","July 2012","March 2014","March 2014","May 15, 2012","null","April 23, 2014","University of Chicago Medical Center University of Chicago (16), Chicago, Illinois, United States|Massachusetts General Hospital SC-5, Boston, Massachusetts, United States|University of Texas/MD Anderson Cancer Center UT MD, Houston, Texas, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT01598077"
439,"NCT02213263","A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)","Completed","Has Results","All","Phase 3","394","Industry","Interventional","September 30, 2014","October 23, 2017","April 19, 2018","August 11, 2014","October 30, 2018","November 6, 2018","Pacific Cancer Medical Center, Inc., Anaheim, California, United States|The Oncology Institute of Hope and Innovation, Anaheim, California, United States|Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc., Corona, California, United States|The Oncology Institute of Hope and Innovation, Downey, California, United States|Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Global Cancer Research Institute (GCRI), Inc, Gilroy, California, United States|Saint Louise Regional Hospital Radiology Department (Radiology Only), Gilroy, California, United States|South Valley Imaging Center (Imaging Only), Gilroy, California, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, United States|The Oncology Institute of Hope and Innovation, Glendale, California, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, United States|The Oncology Institute of Hope and Innovation, Long Beach, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|The Oncology Institute of Hope and Innovation, Lynwood, California, United States|The Oncology Institute of Hope and Innovation, Montebello, California, United States|Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States|Torrance Health Association DBA, Torrance Memorial Physician, Network/Cancer Care Associates, Redondo Beach, California, United States|Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc., Riverside, California, United States|Global Cancer Research Institute, Inc., San Jose, California, United States|O'Connor Hospital, San Jose, California, United States|PET Imaging of San Jose (Imaging Only), San Jose, California, United States|The Oncology Institute of Hope and Innovation, Santa Ana, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|Innovative Clinical Research Institute (ICRI), Whittier, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Center-Lakewood (Laboratory), Lakewood, Colorado, United States|Rocky Mountain Cancer Centers (RMCC) - Lakewood - St Anthony, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Center Pueblo, Pueblo, Colorado, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Lewis Hall Singletary Oncology Center At John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Northwestern Medicine West Region, DeKalb, Illinois, United States|Cancer Center,Northwestern Medicine, West Region, Geneva, Illinois, United States|Cancer Center of Kansas, Chanute, Kansas, United States|Cancer Center of Kansas, Dodge City, Kansas, United States|Cancer Center of Kansas, El Dorado, Kansas, United States|Cancer Center of Kansas, Independence, Kansas, United States|Cancer Center of Kansas, Kingman, Kansas, United States|Cancer Center of Kansas, Liberal, Kansas, United States|Cancer Center of Kansas, McPherson, Kansas, United States|Cancer Center of Kansas, Newton, Kansas, United States|The University of Kansas Cancer Center, Overland Park, Kansas, United States|Cancer Center of Kansas, Parsons, Kansas, United States|Cancer Center of Kansas, Salina, Kansas, United States|Cancer Center of Kansas, Wellington, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Cancer Center Of Kansas, Winfield, Kansas, United States|PET/CT facility Seton Imaging Center, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Rcca Md Llc, Bethesda, Maryland, United States|Holy Cross Hospital Resource Center, Silver Spring, Maryland, United States|Holy Cross Hospital Hospital Pharmacy, Silver Spring, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Maryland Oncology Hematology, P.A., Wheaton, Maryland, United States|The University of Kansas Cancer Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center, Lee's Summit, Missouri, United States|Saint Francis Medical Center, Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Saint Francis Medical Center, Grand Island, Nebraska, United States|Saint Francis Medical Center, Saint Francis Cancer Treatment Center, Hastings, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|Vidant Medical Center Pharmacy, Greenville, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Toledo Clinic Cancer Center - Maumee, Maumee, Ohio, United States|Toledo Clinic Cancer Center - Toledo, Toledo, Ohio, United States|Toledo Clinic, Inc., Toledo, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|San Antonio Military Medical Center- Department of Pharmacy, Fort Sam Houston, Texas, United States|San Antonio Military Medical Center- Department of Radiology, Fort Sam Houston, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Investigational Products Center (I PC), Fort Worth, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|Millennium Oncology, Houston, Texas, United States|US Oncology Investigational Product centre (IPC),Drug Shipment Only, Irving, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|Millennium Oncology, Kingwood, Texas, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, United States|Millennium Oncology, Shenandoah, Texas, United States|Millennium Oncology, The Woodlands, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge Cancer Center, Yakima, Washington, United States|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Kepler Universitaetsklinikum GmbH, Linz, Austria|Kepler Universitaetsklinikum GmbH, Linz, Austria|SI 'Republican Research and Practice Centre of Oncology and Medical Radiology n.a. N.N. Alexandrov', Lesnoy, Minsk Region, Belarus|SI 'Republican Research and Practice Centre of Oncology and Medical Radiology n.a. N.N. Alexandrov', Lesnoy, Minsk Region, Belarus|Healthcare Institution ""Brest Regional Oncologic Dispensary"", Brest, Belarus|Healthcare Institution 'Minsk City Clinical Oncology Dispensary', Minsk, Belarus|SI Republican Research and Practice Centre of oncology and medical radiology n.a N.N Alexandrov, Republic Of Belarus, Belarus|Hopital Erasme, Brussels, Belgium|Nuclear Medicine Department, Brussels, Belgium|Grand Hopital de Charleroi-Site Notre-Dame, Charleroi, Belgium|PET/CT facility: Grand Hopital de Charleroi (GHdC) - site Notre-Dame, Charleroi, Belgium|Pharmacy Department: Grand Hopital de Charleroi (GHdC) - site Notre-Dame, Charleroi, Belgium|Pharmacy Department, Centre Hospitalier De Jolimont - Lobbes, La Louviere (Haine-Saint Paul), Belgium|Centre Hospitalier de Jolimont - Lobbes, La Louviere (Haine-Saint-Paul), Belgium|Radiology Department, La Louviere (Haine-Saint-Paul), Belgium|C.H.U. Ambroise Pare, Mons, Belgium|Pharmacy Department, CHU Ambroise Pare, Mons, Belgium|Hospital Santa Izabel - Setor de Bioimagem, Salvador, Bahia, Brazil|Hospital Santa Izabel / Santa Casa de Misericordia da Bahia, Salvador, Bahia, Brazil|Clinica Multimagem, Goiania, GO, Brazil|Hospital das Clinicas da Universidade Federal de Goias \ Centro de Pesquisa Clinica, Goiania, GO, Brazil|Centro de Imagens da Faculdade de Medicina - INCT Medicina Nuclear - PET/CT, Belo Horizonte, MG, Brazil|Unidade Funcional Apoio Diagnostico e terapeutica por Imagem do HC/UFMG - CT Scan, Belo Horizonte, MG, Brazil|Hospital das Clinicas Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Central de Misturas Intravenosas do Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital de Clinicas de Porto Alegre - Centro de Pesquisa Clinica, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Servico de Radiologia do Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|CDI - Centro de Diagnostico por Imagem do Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|InsCer - Instituto do Cerebro do Rio Grande do Sul - PUCRS, Porto Alegre, RS, Brazil|Uniao Brasileira de Educacao e Assistencia (UBEA) - Hospital Sao Lucas da PUCRS -, Porto Alegre, RS, Brazil|Fundacao Amaral Carvalho / Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil|Fundacao Amaral Carvalho / Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil|Unidade de Quimioterapia, Jaú, SAO Paulo, Brazil|Casa da Esperanca, Santo Andre, SAO Paulo, Brazil|Tecnolab, Sao Bernardo do Campo, SAO Paulo, Brazil|CEMEDI, Campinas, SP, Brazil|Instituto Radium, Campinas, SP, Brazil|CAEP - Centro Avancado de Estudos e Pesquisas LTDA, Campinas, SP, Brazil|Hospital e Maternidade Madre Theodora LTDA, Campinas, SP, Brazil|CENNI Oncologia, Campinas, SP, Brazil|Fundacao do ABC - FMABC/ Faculdade de Medicina ABC ( CEPHO - Centro de Estudos e Pesquisas de, Santo Andre, SP, Brazil|Hospital Bandeirantes, Sao Paulo, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP / Fundacao Faculdade de Medicina MEC MPAS, Sao Paulo, SP, Brazil|Casa de Saude Santa Marcelina (Centro de Pesquisa Santa Marcelina), Sao Paulo, SP, Brazil|IEP São Lucas (Pharmacy), São Paulo, SP, Brazil|IEP Sao Lucas - Instituto de Ensino e Pesquisa Sao Lucas / HEMOMED - Instituto de Oncologia e, Sao Paulo, Brazil|Fleury, Sao Paulo, Brazil|University Hospital Center Zagreb, Department of Nuclear Medicine and Radiation Protection, Zagreb, Croatia|University Hospital Center Zagreb, Department of Pathology and Cytology, Zagreb, Croatia|University Hospital Center Zagreb, Department of Radiology, Zagreb, Croatia|University Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|CHU Marseille Hopital de La Conception, Marseille, Marseille Cedex 05, France|CH de Mulhouse, Hopital Emile Muller, Mulhouse, Mulhouse Cedex, France|Hopital Duchenne Chu - Boulogne Sur Mer, Boulogne Sur Mer, NAP, France|Hopital Duchenne Chu - Boulogne Sur Mer, Boulogne Sur Mer, France|Centre Hospitalier De Bourg En Bresse, Bourg En Bresse Cedex, France|Hopital Morvan-CHU Brest- Service Hematologie Clinique, Brest, France|Centre Hospitalier Universitaire Cote de Nacre, Caen, France|Centre Hospitalier du Mans, Le Mans, France|Clinique de la Sauvegarde, Lyon, France|""LTD """"M. Zodelava's Hematology Centre"""""", Tbilisi, Georgia|LTD ""Research Institute of Clinical Medicine"", Tbilisi, Georgia|High Technology Medical Center, University Clinic, Tbilisi, Georgia|Charite - Universitaetsmedizin Berlin, Berlin, Germany|Charite - Universitatsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitaetsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany|Charite - Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany|Charite - Universitatsmedizin Berlin, Berlin, Germany|Klinikum Chemnitz gGmbH - Institut fuer Interventionelle Radiologie und Neuroradiologie, Chemnitz, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Klinikum Chemnitz gGmbH - Klinik fuer Nuklearmedizin, Chemnitz, Germany|Klinikum Chemnitz gGmbH - Zentralapotheke, Chemnitz, Germany|Universitaetsklinikum Essen (AoeR), Essen, Germany|Universitatsklinikum Essen (AoR), Essen, Germany|DokuSan Gesellschaft fuer Medizinische Studien mbH & Co. KG, Herne, Germany|Apotheke des St. Anna Hospital, Herne, Germany|EVK Eickel, Herne, Germany|Praxis im Koeln Triangle, Koeln, Germany|Gemeinschaftspraxis fuer Diagnostische Radiologie und Nuklearmedizin, Mutlangen, Germany|Kliniken Ostalb, Stauferklinikum Schwaebisch Gmuend, Zentrum fuer Innere Medizin, Mutlangen, Germany|Stauferklinikum Schwaebisch Gmuend, Apotheke, Mutlangen, Germany|Universitaetsmedizin Rostock, Rostock, Germany|Klinikum Stuttgart, Klinik fuer Nuklearmedizin, Stuttgart, Germany|Vinzenz von Paul Kliniken gGmbH, Stuttgart, Germany|Radiologie Rhein-Sieg, Troisdorf, Germany|Ueberoertliche Berufsausuebungsgemeinschaft Drs. med. Helmut Forstbauer, Troisdorf, Germany|Zentralapotheke, Troisdorf, Germany|Gen. Hosp. of Athens ""Evangelismos - Eye Hosp.- Polikliniki"", Athens, Greece|Gen. Hosp. of Athens ""Evangelismos-Eye Hosp. - Polikliniki"", Athens, Greece|Gen. Hosp. of Athens ""Evangelismos-Eye Hosp.-Polikliniki"", Athens, Greece|Gen.Hosp.of Athens ""Evangelismos-Eye Hosp.-polikiliniki"", Athens, Greece|General Hospital of Athens ""Evangelismos - Eye Hosp. - Polikliniki"", Athens, Greece|Bioiatriki S.A., Athens, Greece|Bioiatriki, Athens, Greece|General Hospital of Athens 'Laiko', Athens, Greece|""""""ATTIKON"""" Gen. Univ. Hosp"", Athens, Greece|""ATTIKON'' Gen. Univ. Hosp., Chaidari, Athens, Greece|Magnitiki Patron, Patras, Greece|University General Hospital of Patras, Patras, Greece|Super Scan Imaging Centre, Surat, Gujarat, India|Pathology Department, Unique Hospital Multispeciality & Research Institute, Surat, Gujarat, India|Zircon- BIC Imaging Centre, Surat, Gujarat, India|Mangalore Institute of Oncology, Mangalore, Karanataka, India|HealthCare Global Enterprises Limited, Bangalore, Karnataka, India|Kasturba Medical College and Hospital, Manipal, Karnataka, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Department of Radiology, Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Department of Radiology, Pune, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, Maharashtra, India|Ruby Hall clinic, Pune, Maharashtra, India|R.K. Birla Cancer Center, Sawai Man Singh Hospital, Jaipur, Rajasthan, India|Apollo Speciality Hospital, Chennai, Tamilnadu, India|Department of Radiology, Chennai, Tamilnadu, India|Global Hospitals, Hyderabad, Telangana, India|Vijaya Diagnostic Centre, Hyderabad, Telangana, India|N.R.S Medical College and Hospital, Kolkata, WEST Bengal, India|Spandan PET-CT Unit, Kolkata, WEST Bengal, India|Rajiv Gandhi Cancer Institute & Research Center (RGCIRC), New Delhi, India|U.O. di Ematologia e CTMO - Istituti Ospedalieri di Cremona, Cremona, CR, Italy|IRST - IRCCS U. O. Oncologia Medica, Meldola, FC, Italy|U.O. Ematologia 1 - IRCCS AOU San Martino-IST, Genova, GE, Italy|Unita di Ricerca Clinica, Monza, MB, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Unità semplice di Medicina Nucleare, Latina, NAP, Italy|Clinica Ematologica - A.O.U. Ospedali Riuniti di Ancona, Torrette Ancona, Palermo, Italy|Az Ospedaliera Santa Maria, Terni, PG, Italy|Medicina nucleare, Reggio Emilia, Reggio, Italy|Radiologia, Reggio Emilia, Reggio, Italy|SC Ematologia - SC Ematologia - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Reggio, Italy|""Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita """"Sapienza"""", Rome, Rome Rm, Italy|IRCSS A.O.U. San Martino - IST - UO Clinica Ematologica, Genova, Italy|SC Ematologia, Fondazione IRCCS Ist Nazionale dei Tumori, Milano, Italy|Padiglione 1, Torre delle medicine, 6 piano, Parma, Italy|Ematologia e Centro Trapianti - AZ Osp. Ospedali Riuniti Marche Nord (AORMN) - Presidio S. Salvatore, Pesaro, Italy|U.O. Ematologia Universitaria - Dip. Di Oncologia dei Trapianti - AOU Pisana, Pisa, Italy|Policlinico Universitario Campus Bio- Medico-U.O.C. di Ematologia Trapianto Cellule Staminali, Roma, Italy|East Nagoya Imaging Diagnosis Center, Nagoya, Aichi, Japan|Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|Akita University Hospital, Akita City, Akita, Japan|Chiba Cancer Center, Chiba-shi, Chiba, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka-shi, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, Japan|Kobe City Medical Center General Hospital, Kobe-City, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, Japan|Showa University Northern Yokohama Hospital, Yokohama-shi, Kanagawa-ken, Japan|Kochi Medical School Hospital, Okocho, Nankoku, Kochi, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto-shi, Kumamoto-ken, Japan|Uozumi Clinic, Kumamoto-shi, Kumamoto-ken, Japan|Sendai Kousei Hospital, Sendai-shi, Miyagi, Japan|National Hospital Organization Sendai Medical Center, Sendai-shi, Miyagi, Japan|Aizawa Hospital, Matsumoto-shi, Nagano, Japan|Nagano Red Cross Hospital, Nagano-shi, Nagano, Japan|National Hospital Organization Nagasaki Medical Center, Omura, Nagasaki, Japan|National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan|Hanwa Dai 2 Senboku Hospital, Naka-ku Sakai, Osaka, Japan|Osaka City University Hospital, Osaka-City, Osaka, Japan|Tokushima University Hospital, Tokushima-Shi, Tokushima, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, Japan|Showa University Hospital, Shinagawa-ku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, Japan|Yamagata University Hospital, Yamagata-Shi, Yamagata, Japan|Fukuoka Wajiro PET Diagnostic Imaging Clinic, Fukuoka, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|Musashimurayama Hospital, Tokyo, Japan|Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hammoud Hospital, University Medical Center, Saida, Southern Governate, Lebanon|Doctors Center Radiology, Beirut, Lebanon|Mount Lebanon Hospital, Beirut, Lebanon|Middle East Institute Of Health, El Metn, Lebanon|Ain Wazein Hospital, Mount Lebanon, Lebanon|Grupo Medico Camino S.C., Mexico City, Distrito Federal, Mexico|Imagenus, Mexico City, Distrito Federal, Mexico|Isos Pharmacorp, S.A. de C.V., Mexico City, Distrito Federal, Mexico|Vely Grupo Medico Quirurgico, S.A. de C.V., Cuautitlan Izacalli, Estado DE Mexico, Mexico|Phylasis Clinicas Research S. de R.L. de C.V., Cuautitlan Izcalli, Estado DE Mexico, Mexico|Centro Universitario de Imagen Diagnostica, Radiologia e Imagen del Hospital Universitario, Monterrey, Nuevo LEON, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|Cirurgia y Ginecobstetricia de Oaxaca, S.A de C.V., Oaxaca, Mexico|Oaxaca Site Management Organization S.C., Oaxaca, Mexico|Hospital Angeles Puebla, Puebla, Mexico|Cancerologia de Queretaro S.C., Queretaro, Mexico|Hospital Infantil Teleton de Oncologia, Queretaro, Mexico|Hospital San Jose Norte, Queretaro, Mexico|Instituto Nacional de Enfermedades Neoplasicas, Surquillo, Lima, Peru|Pet Scan Peru, Lima, Peru|Resocentro, Lima, Peru|University of Philippines Manila-Philippine General Hospital, Manila, Metro Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Klinika Nowotworow Ukladu Chlonnego Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland|Euromedic Wroclawskie Centrum Medyczne II, Wroclaw, Poland|Euromedic Wroclawskie Centrum Medyczne III, Wroclaw, Poland|Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, Wroclaw, Poland|Euromedic Wroclawskie Centrum Medyczne I, Wroclaw, Poland|Apteka Dolnoslaskiego Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, Wroclaw, Poland|Unidade Local de Saude de Matosinhos E.P.E. - Hospital Pedro Hispano S.A., Matosinhos, Porto, Portugal|Hospital de Braga, Braga, Portugal|Hospital CUF Descobertas, Lisboa, Portugal|CIMC, Porto, Portugal|Dr. Campos Costa Clinic, Porto, Portugal|Centro Hospitalar do Porto-Hospital de Santo Antonio E.P.E., Porto, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil E.P.E, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Vila Nova de Gaia, Portugal|Modern Radiology, PSC, Coto Laurel, Puerto Rico|Ad-Vance Medical Research, LLC, Ponce, Puerto Rico|Caribe MRI and CT, Ponce, Puerto Rico|Policlinica de Diagnostic Rapid, Hematologie, Brasov, Romania|Policlinica de Diagnostic Rapid SA, Brasov, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Hiperdia Ritmului, Bucuresti, Romania|Affidea Fundeni, Bucuresti, Romania|Affidea Romania SRL, Bucuresti, Romania|Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Laborator Radiologie si Imagistica Medicala, Cluj-Napoca, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Sectia Oncologie Medicala, Cluj-Napoca, Romania|Clinica de Hematologie-Institutul Oncologic, Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania|CT Clinic S.R.L., Cluj-Napoca, Romania|A.Tsyb Medical Radiological Research Centre -, Obninsk, Kaluga Region, Russian Federation|State Healthcare Institution Republican Oncology Dispensary, Saransk, Mordovian Republic, Russian Federation|""SBHI of NNR """"Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko"""""", Nizhniy Novgorod, Nizhniy Novgorod Region, Russian Federation|LLC MC ""MRT-Diagnostika"", Nizhniy Novgorod, Nizhniy Novgorod Region, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies"" of MoH of RF, Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies"", Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies, Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI 'Russian Research Centre of Radiology and Surgical Technologies, Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies n.a. A.M. Granov"" of MoH of RF, Saint-Petersburg, Pesochniy, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies named after academician, Saint-Petersburg, Pesochniy, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies, Saint-Petersburg, Pesochniy, Russian Federation|FSBI 'National Medical Oncology Research Centre n.a. N.N.Petrov', Saint-Petersburg, Pos.pesochny, Russian Federation|Branch office of LLC 'PET-Technology' at Ufa city, Ufa, Republic Bashkortostan, Russian Federation|State Budgetary Healthcare Institution ""Republican Clinical Oncology Dispensary of the Ministry, Ufa, Republic Bashkortostan, Russian Federation|Private medical institution ""Euromedservice"", Pushkin, Saint Petersburg, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies"" of MoH of RF, Pesochniy Town, Saint-petersburg, Russian Federation|Federal State-Financed Institution 'North-Caucasian Research and Clinical Center', Lermontov, Stavropol Region, Russian Federation|SBHI of Stavropol Region ""Pyatigorsk Interdistrict Oncology Dispensary, Pyatigorsk, Stavropol Region, Russian Federation|""State Budget Healthcare Institution """"Chelyabinsk Regional Clinical Center of Oncology, Chelyabinsk, Russian Federation|FSBSI 'N.N.Blokhin Russian Cancer Research Center' of MoH of RF, Moscow, Russian Federation|Russian Cancer Research Centre them N.N. Blokhin, Moscow, Russian Federation|LLC ""VitaMed"", Moscow, Russian Federation|SBHI of Moscow City Clinical Hospital n.a. S.P.Botkin of Healthcare Department of Moscow, Moscow, Russian Federation|Ramsay Diagnostics, Moscow, Russian Federation|State Budgetary Institution of Healthcare ""Leningrad Regional Clinical Hospital"", Saint Petersburg, Russian Federation|Dr. Berezin Medical Institute, Saint-Petersburg, Russian Federation|N.P. Bechtereva Institute of Human Brain of the Russian Academy of Sciences, Saint-Petersburg, Russian Federation|N.P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences, Saint-Petersburg, Russian Federation|Non-state healthcare institution ""Road Clinical Hospital of Joint Stock Company ""Russian Railways"", Saint-Petersurg, Russian Federation|Yaroslavl State Medical Academy, Yaroslavl, Russian Federation|GBUZ of Yaroslavl Region ""Regional Clinical Hospital"", Yaroslavl, Russian Federation|NIKSCH & PARTNERS t/a CAPITAL RADIOLOGY, Groenkloof, Gauteng, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Department of Medical Oncology, University of Pretoria, Steve Biko Academic Hospitals Complex, Pretoria, Gauteng, South Africa|Albert Alberts Stem Cell Transplant Centre, Pretoria, Gauteng, South Africa|Dr JN De Jong and Partners t/a East Rad, Pretoria, Gauteng, South Africa|NIKSCH & PARTNERS t/a CAPITAL RADIOLOGY, Pretoria, Gauteng, South Africa|Drs Sulman & Partners Specialist Radiologists, Rosebank, Gauteng, South Africa|Drs Bloch & Partners Incorporated, Sandton, Gauteng, South Africa|Hospital Parc Tauli, Sabadell, Barcelona, Spain|Onkologikoa, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Sanitas La Zarzuela, Aravaca, Madrid, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital do Meixoeiro Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario Universitario A Coruna, A Coruna, Spain|Hospital Modelo, A Coruna, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Quiron de Barcelona, IEC, Barcelona, Spain|CETIR, Centre Medic, Barcelona, Spain|Radiodiagnostic CETIR - Clinica del Pilar, Barcelona, Spain|Hospital Universitario Puerta del Mar, Cadiz, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario Sanitas La Moraleja, Madrid, Spain|Centro CIMES, Malaga, Spain|Hospital universitario Virgen de la Victoria, Malaga, Spain|Centro Mario Gallegos, Malaga, Spain|Complejo Hospitalario de Ourense. Hematología, Ourense, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|H. Quiron Zaragoza, Zaragoza, Spain|Hospital de Dia Quiron Zaragoza, Zaragoza, Spain|Universitatsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Apotheke, Spital STS AG, Thun, Switzerland|Onkologiezentrum Thun-Berner Oberland Spital Sts Ag, Thun, Switzerland|Kantonsapotheke Zuerich, Zuerich, Switzerland|UniversitaetsSpital Zuerich, Zuerich, Switzerland|Cardiology Unit,Department of Medicine, Faculty of Medicine, Ramathibodi Hospital,, Bangkok, Thailand|Department of Radiology, Ramathibodi Hospital, Bangkok, Thailand|National Cancer Institute, Bangkok, Thailand|Hacettepe Universitesi Tip Fakultesi Onkoloji Hastanesi, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eg. ve Aras., Ankara, Turkey|Ultramar Tibbi Gorunteleme Merkezi, Ankara, Turkey|Ultramar Tibbi Goruntuleme Merkezi, Ankara, Turkey|Integra Gurses Teshis Tedavi ve Saglik Hizmetleri A.S., Ankara, Turkey|Adnan Menderes University Medical Faculty, Aydin, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi, Gaziantep, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama, Gaziantep, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Ic Hastaliklari Anabilim Dali, Izmir, Turkey|EGE-RAD Bilgisayarli Tomografi Ozel Saglik Hizmetleri ve Malzemeleri Tic.Ltd.Sti., Izmir, Turkey|Erciyes Universitesi Tip Fakultesi Nukleer Tip Laboratuvari, Kayseri, Turkey|Erciyes Universitesi Tip Fakultesi Radyoloji Laboratuvari, Kayseri, Turkey|Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey|Inonu Universitesi Tip Fakultesi Turgut Ozal Tip Merkezi, Malatya, Turkey|Celal Bayar University Medical Faculty, Manisa, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Turkey|""Mediks-rey International Group"" LLC, Obukhiv District, KYIV Region, Ukraine|""MedX-rey International Group"" LLC, Obukhiv District, KYIV Region, Ukraine|""MedX-Ray International Group"" LLC, Obukhiv, KYIV Region, Ukraine|""Municipal Institution """"Chernivtsi Regional Clinical Oncology Center"""",, Chernivtsi, Ukraine|MI 'City Dnipropetrovsk Multi-field Clin. Hospital #4 of DRC',, Dnipropetrovsk, Ukraine|Municipal Non-Profit Enterprise ""Regional Oncology Centre"", Kharkiv, Ukraine|National Cancer Institute, Kyiv, Ukraine|""Central City Clinical Hospital, City Oncology Center, SHEI """"Uzhhorod National University"""", Chair, Uzhhorod, Ukraine|Podilskyy Regional Oncology Center, Chemotherapy Department, Vinnytsia, Ukraine|Municipal Establishment 'Zaporizhzhia Regional Clinical Oncology Dispensary', Zaporizhzhia, Ukraine|LLC ""Diaservis"", Zaporizhzhia, Ukraine|Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, Essex, United Kingdom|Cobalt Diagnostic Imaging, Cheltenham, Glos., United Kingdom|Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Positron Emission Tomography (PET) Centre, Newcastle upon Tyne, United Kingdom|City Hospitals Sunderland NHS Foundation Trust-Sunderland Royal Hospital, Sunderland, United Kingdom|Diagnostic Imaging, Sunderland, United Kingdom","https://ClinicalTrials.gov/show/NCT02213263"
440,"NCT01262482","Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment","Completed","No Results Available","All","Phase 2","41","Other","Interventional","October 2008","October 2011","December 2011","December 17, 2010","null","November 9, 2012","Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|H. Josep Trueta, Girona, Spain|Centro Oncológico M.D. Anderson Spain, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Althaia, Manresa, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital General de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01262482"
441,"NCT00656136","BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","Completed","Has Results","All","Phase 3","585","Industry","Interventional","April 2008","October 2013","October 2013","April 10, 2008","November 27, 2013","July 26, 2016","1200.23.038 Boehringer Ingelheim Investigational Site, Kingman, Arizona, United States|1200.23.046 Boehringer Ingelheim Investigational Site, Fayetteville, Arkansas, United States|1200.23.027 Boehringer Ingelheim Investigational Site, Anaheim, California, United States|1200.23.028 Boehringer Ingelheim Investigational Site, Berkeley, California, United States|1200.23.029 Boehringer Ingelheim Investigational Site, Modesto, California, United States|1200.23.045 Boehringer Ingelheim Investigational Site, Montebello, California, United States|1200.23.009 Boehringer Ingelheim Investigational Site, Orange, California, United States|1200.23.026 Boehringer Ingelheim Investigational Site, Palm Springs, California, United States|1200.23.024 Boehringer Ingelheim Investigational Site, North Miami Beach, Florida, United States|1200.23.020 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.23.013 Boehringer Ingelheim Investigational Site, Valhalla, New York, United States|1200.23.056 Boehringer Ingelheim Investigational Site, Salt lake City, Utah, United States|1200.23.039 Boehringer Ingelheim Investigational Site, Renton, Washington, United States|1200.23.050 Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|1200.23.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1200.23.32003 Boehringer Ingelheim Investigational Site, Gent, Belgium|1200.23.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1200.23.32005 Boehringer Ingelheim Investigational Site, Liège, Belgium|1200.23.32006 Boehringer Ingelheim Investigational Site, Namur, Belgium|1200.23.1002 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada|1200.23.1005 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1200.23.1009 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1200.23.1001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1200.23.1004 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1200.23.86001 Boehringer Ingelheim Investigational Site, Beijing, China|1200.23.86002 Boehringer Ingelheim Investigational Site, Beijing, China|1200.23.86003 Boehringer Ingelheim Investigational Site, Beijing, China|1200.23.86009 Boehringer Ingelheim Investigational Site, Chengdu, China|1200.23.86007 Boehringer Ingelheim Investigational Site, Guangzhou, China|1200.23.86008 Boehringer Ingelheim Investigational Site, Hangzhou, China|1200.23.86004 Boehringer Ingelheim Investigational Site, Shanghai, China|1200.23.86005 Boehringer Ingelheim Investigational Site, Shanghai, China|1200.23.86006 Boehringer Ingelheim Investigational Site, Shanghai, China|1200.23.3303A Boehringer Ingelheim Investigational Site, Besançon Cedex, France|1200.23.3303C Boehringer Ingelheim Investigational Site, Besançon Cedex, France|1200.23.3305A Boehringer Ingelheim Investigational Site, Caen Cedex 5, France|1200.23.3304A Boehringer Ingelheim Investigational Site, La Tronche, France|1200.23.3304B Boehringer Ingelheim Investigational Site, La Tronche, France|1200.23.3307A Boehringer Ingelheim Investigational Site, Lyon Cedex 4, France|1200.23.3301A Boehringer Ingelheim Investigational Site, Paris cedex 20, France|1200.23.3302A Boehringer Ingelheim Investigational Site, Paris, France|1200.23.3302B Boehringer Ingelheim Investigational Site, Paris, France|1200.23.3306A Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|1200.23.3306C Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|1200.23.49010 Zentralklinik Bad Berka GmbH, Bad Berka, Germany|1200.23.49002 Innere Klinik und Poliklinik (Tumorforschung), Essen, Germany|1200.23.49003 Asklepios Fachkliniken München-Gauting, Gauting, Germany|1200.23.49005 Krankenhaus Großhansdorf, Großhansdorf, Germany|1200.23.49008 Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany|1200.23.49004 Johannes Gutenberg-Universität Mainz, Mainz, Germany|1200.23.49001 Universitätsklinikum Mannheim, Mannheim, Germany|1200.23.49006 HSK, Dr. Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany|1200.23.85202 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1200.23.39003 Boehringer Ingelheim Investigational Site, Genova, Italy|1200.23.39007 Boehringer Ingelheim Investigational Site, Orbassano (TO), Italy|1200.23.39002 Boehringer Ingelheim Investigational Site, Perugia, Italy|1200.23.39004 Boehringer Ingelheim Investigational Site, Prato, Italy|1200.23.39008 Boehringer Ingelheim Investigational Site, Roma, Italy|1200.23.39001 Boehringer Ingelheim Investigational Site, Rozzano (MI), Italy|1200.23.82005 Boehringer Ingelheim Investigational Site, Gyeonggi-do, Korea, Republic of|1200.23.82006 Boehringer Ingelheim Investigational Site, Hwasun, Korea, Republic of|1200.23.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1200.23.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1200.23.82003 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1200.23.82004 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1200.23.31002 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands|1200.23.31001 Boehringer Ingelheim Investigational Site, Groningen, Netherlands|1200.23.31003 Boehringer Ingelheim Investigational Site, Helmond, Netherlands|1200.23.65001 Boehringer Ingelheim Investigational Site, Singapore, Singapore|1200.23.3405 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.23.3404 Boehringer Ingelheim Investigational Site, Cruces, Spain|1200.23.3401 Boehringer Ingelheim Investigational Site, Madrid, Spain|1200.23.3403 Boehringer Ingelheim Investigational Site, Madrid, Spain|1200.23.3406 Boehringer Ingelheim Investigational Site, Madrid, Spain|1200.23.3402 Boehringer Ingelheim Investigational Site, Valencia, Spain|1200.23.88604 Taichung Veterans General Hospital, Taichung, Taiwan|1200.23.88605 China Medical University Hospital, Taichung, Taiwan|1200.23.88606 National Cheng Kung University Hospital, Tainan, Taiwan|1200.23.88601 National Taiwan University Hospital, Taipei, Taiwan|1200.23.88602 Veterans General Hospital, Taipei, Taiwan|1200.23.88607 Tri-Service General Hospital, Taipei, Taiwan|1200.23.88603 Chang Gung Memorial Hosp-Linkou, Taoyuan, Taiwan|1200.23.66001 Boehringer Ingelheim Investigational Site, Chiangmai, Thailand|1200.23.66003 Boehringer Ingelheim Investigational Site, Pathumwan, Bangkok, Thailand|1200.23.66002 Boehringer Ingelheim Investigational Site, Songkla, Thailand|1200.23.4404 Boehringer Ingelheim Investigational Site, Dundee, United Kingdom|1200.23.4403 Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom|1200.23.4401 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom|1200.23.4405 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.23.4406 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT00656136"
442,"NCT00805194","LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer","Completed","Has Results","All","Phase 3","1314","Industry","Interventional","December 3, 2008","November 2, 2010","November 13, 2017","December 9, 2008","December 1, 2014","December 13, 2017","LKH-Univ. Klinikum Graz, Graz, Austria|KH St. Vinzenz, Zams, Int. Abtlg., Kufstein, Austria|AKH d. Stadt Linz, Pulmologie, Linz, Austria|Bobruisk Inter-distict, Bobruisk, Belarus|Brest Regional Clinical, Brest Region, Belarus|Gomel Regional Clinical, Gomel, Belarus|Scientific Research Minsk, Minsk Region, Belarus|Public Health Inst. Minsk City Clinical Oncology Dispensary, Minsk, Belarus|Mogilov Regional Oncological Dispensary, Mogilov, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Liège - HOSP CHR de la Citadelle, Liège, Belgium|Multiprofile Hospital for Active Treatment, Gabrovo, Bulgaria|Univ.Multiprofile Hospital ""Dr. Georgy Stranski"" EAD, Pleven, Pleven, Bulgaria|District Oncology Dispensary Plovdiv, Plovdiv, Bulgaria|Interdistrict Oncology Dispensary, Ruse, Ruse, Bulgaria|District Oncology Dispensary Shumen, Shumen, Bulgaria|Specialized Hospital for Active Treatment in Oncolcogy, Sofia, Bulgaria|307 Hospital of PLA, Beijing, China|Jilin Province Cancer Hospital, Changchun, China|First Hospital of Jilin University, Changchun, China|West China Hospital, Chengdu, China|Southwest Hospital, Chongqing, China|First Affiliated Hospital of Dalian Medical University, Dalian, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, China|Fujian Provincial Tumor Hospital, Fujian, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|Sir Run Run Shaw Hospital, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|The Third Affiliated Hospital of Harbin Medical University, Harbin, China|the 81th Hospital of PLA, Nanjing, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Tongji Hospital, Wuhan, China|Zhongshan Hospital Fudan University, Xuhui Area, Shanghai, China|Clinic for Lung Diseases 'Jordanovac', Zagreb, Zagreb, Croatia|Clinical Hospital Centar Sestre Milosrdnice, Zagreb, Croatia|University Hospital Brno, Brno, Czechia|St. Anna Hospital, 2nd Internal Department, Brno, Czechia|District Hospital Liberec, Liberec, Czechia|Institut onkologie a rehabilitace Na Plesi s.r.o., Nova Ves pod Plesi, Czechia|District Hospital Pribram, Oncology Centrum, Pribram, Czechia|Herlev Hospital, Herlev, Denmark|Odense Universitetshospital, Odense C, Denmark|HOP Croix Rousse, Pneumo, Lyon, Lyon Cedex 4, France|INS Paoli-Calmettes, Marseille Cedex 9, France|HOP Lyon Sud, Pierre Bénite cedex, France|CHU de Rouen - Hôpital de Bois Guillaume, ROUEN cedex, France|HOP Nord Laënnec, Saint Herblain cedex, France|Oncology Institute of the Loire, Saint-Priest en Jarez, France|HOP Civil, Strasbourg cedex, France|Sainte Anne Training hospital for the armies, Toulon Cedex 09, France|Amtel Hospital first Clinical LLC, Tbilisi, Georgia|National Centre of Oncology, Tbilisi, Georgia|Chemotherapy &amp;amp; Immunotherapy Clinic 'Medulla', Tbilisi, Tbilisi, Georgia|Gemeinschaftspraxis Dr. Brudler / Dr. Heinrich, Augsburg, Augsburg, Germany|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Evangelische Lungenklinik Berlin, Berlin-Buch, Germany|Universitätsklinikum Benjamin Franklin, Berlin, Berlin, Germany|HELIOS Klinikum Emil von Behring GmbH, Berlin, Germany|Krankenhaus Nordwest, Frankfurt, Frankfurt/Main, Germany|Klinikum Frankfurt Höchst GmbH, Frankfurt/Main, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Germany|Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany|Städisches Krankenhaus Martha-Maria, Halle/Saale, Halle/Saale, Germany|Allgemeines Krankenhaus Harburg, 21075 Hamburg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum Kassel GmbH, Kassel, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Köln, Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Praxis Dr. Gessner, Leipzig, Leipzig, Germany|Klinik, Löwenstein, Löwenstein, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Lübeck, Germany|Katholisches Klinikum St. Hildegardiskrankenhaus, Mainz, Mainz, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinik links der Isar, München, Ziemssenstr. 1, München, Germany|Klinikum rechts der Isar TU, München, Ismaninger Str. 22, München, Germany|Städt. Krankenhaus, München-Bogenhausen, München, Germany|Pius-Hospital, Oldenburg, Oldenburg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Dr. Horst-Schmidt-Kliniken, Wiesbaden, Wiesbaden, Germany|Evangelisches Krankenhaus, Witten, Witten, Germany|Athens Hospital of Chest Diseasea ""SOTIRIA"", Athens, Greece|University Hospital of Heraklion, University Pulmonology Cl, Heraklio, Greece|Iaso General Hospital, Holargos, Athens, Greece|Papageorgiou Hospital, 1st Cardiological Cl., Thessaloniki, Thessaloniki, Greece|General Hospital ""Papanikolaou"", Thessaloniki, Greece|Vedanta Institute of Medical Sciences, Ahmedabad, India|KIDWAI memoraial Institute of oncology, Bangalore, India|Rajalakshmi Multispeciality Hospital, Bangalore, India|Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, M.P., India|Apollo Hospital, Chennai, India|SEAROC cancer center,S.K.soni Hospital, Jaipur, Rajasthan, India|Birla Cancer Centre, Jaipur, India|Bhagwan Mahaveer Cancer Hospital & Research Center, Jawahar, Jaipur, India|B. P .Poddar Hospital & Medical Research Ltd., Kolkata, West Bengal, India|Kasturba Medical College and Hospital, Mangalore, India|Tata Memorial Centre, Mumbai, India|Shatabdi Superspeciality Hospital, Nashik, India|Sir Gangaram Hospital, New Delhi, India|Indraprastha Apollo Hospital, New Delhi, India|Rajiv Gandhi Cancer Institute and Clinical Research, New Delhi, India|Jehangir Hospital Oncology Department, Pune, Maharahtra, India|Regional Cancer Center, Trivandrum, Kerala, India|City Cancer Centre, Cancer Hospital & Research, Vijayawada, India|King George Hospital, Visakhapatnam, India|E. Wolfson Medical Center, Holon 58100, Holon, Israel|Hadassah medical organization, Jerusalem 91120, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|The Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Israel|Sourasky Medical Center, Tel-Aviv, Israel|Assaf Harofe Medical Center, Zerifin, Israel|Az. Ospedaliere Umberto I di Ancona, Ancona, Italy|Centro di riferimento Oncologico, Aviano, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|Fond. Poliambulanza Istituto, Brescia, Italy|Azienda Ospedaliera Careggi, Firenze, Italy|Ospedale Civile, Ivrea (TO), Italy|Istituto Scientifico Romagnolo, Meldola, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Azienda Sanitaria Ospedale S. Luigi Gonzaga, Orbassano, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Ospedale S.Maria della Misericordia, AO di Perugia, Perugia, Italy|Seoul Veterans Hospital, Gangdong-gu, Seoul, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Hospital of Lithuanian Univ.of HealthSciences Kauno Klinikos, Kaunas, Lithuania|Siauliu ligonine, Siauliai, Siauliai, Lithuania|Vilniaus Universiteto, Vilnius, Lithuania|Pulmonology Center in Bydgoszcz, Bydgoszcz, Poland|Regional Complex Hospital, Elblag, Poland|Institute of Tuberculosis & Pulmonology, III. Dept., Olsztyn, Olsztyn, Poland|Mazowieckiego Centrum, Otwock, Poland|Wielkopolski Center Pulmonology+Tuberculosis P-III, Poznan, Poznan, Poland|Regional Specialist Hospital, Slupsk, Poland|Independent Public Hospital in Suwalki, Suwalki, Poland|Specialist Hospital, Szczecin-Zdunowo, Szczecin, Poland|Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warszawa, Poland|IPO Porto Francisco Gentil, EPE, Oncology Dep., Coimbra, Portugal|IPO Lisboa Francisco Gentil, EPE, Lisboa, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|IPO Porto Francisco Gentil, EPE, Oncology Dep., Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|CHS, EPE - Hospital de São Bernardo, Setúbal, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Baia Mare Emergency County Hospital, Baia Mare, Romania|Spitalul Clinic Judetean de Urgenta Brasov, Brasov, Romania|Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', Bucuresti, Romania|Institutul Oncologic &quot;Prof. Dr. Ion Chiricuta&quot;, Cluj-Napoca, Romania|County Hospital ""Dr. Alex Simionescu"", Hunedoara, Romania|Centrul de Oncologie Medicala, Iasi, Romania|Emergency Clinical County Hospital &quot;Sf Spiridon&quot;, Iasi, Iasi, Romania|Onesti County Hospital, Onesti, Romania|Emergency County Hospital &quot;Sf.loan cel Nou&quot;, Suceava, Romania|Oncomed SRL, Timisoara, Romania|SBIH of Arkhangelsk reg. &quot;Arkhangelsk Clin. Onc. Dispensary&quot;, Arkhangelsk, Russian Federation|GLPU Cheliabinsky, Chelyabinsk, Russian Federation|GUZ Irkutsk Regional Oncology Dispensary, Irkutsk, Russian Federation|Republic Clinical Oncology Dispensary, Dept. Chemotherapy, Kazan, Russian Federation|RBIH ""Kursk regional clinical oncology dispensary"", Kursk, Russian Federation|GUZ Regional Oncology Dispensary, Magnitogorsk, Magnitogorsk, Russian Federation|FSBSI ""Russian Oncol. Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|SBIH of Stavropol territory &quot;Pyatigorsk Oncol. Dispensary&quot;, Pyatigorsk, Russian Federation|GUZ &quot;Regional Clinical Oncology Dispensary&quot;, Ryazan, Russian Federation|GUZ ""Oncological Dispesary #2"", Sochi, Russian Federation|GUZ Leningradskaya Regional Clin. Hospital, St. Petersburg, St. Petersburg, Russian Federation|First Pavlov State Medical University Saint Petersburg, St. Petersburg, Russian Federation|SPb SBIH &quot;City Clinical Oncological Dispensary&quot;, St. Petersburg, Russian Federation|Research Institute of Oncology n.a. Petrov, Diagnost. Dept., St. Petersburg, Russian Federation|GUZ Sverdlovsky Regional Oncology Dispensary, Yekaterinburg, Russian Federation|Faculty Hospital Trnava, Trnava, Slovakia|GVI oncology Medi Clinic, Cape Town, South Africa|Parklands Hospital, Durban, South Africa|Wits Donald Gordon Clinical Trial Site, Johannesburg, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Pretoria Academic Hospital, Pretoria, South Africa|Wilgers oncology, Pretoria, South Africa|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario de Elche, Elche, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera-Cádiz, Spain|Hospital La Princesa, Madrid, Spain|Hospital Quirónsalud Madrid, Pozuelo de Alarcon, Spain|Fundación Instituto Valenciano de Oncologia, Valencia, Spain|Servicio de Oncologia Radiotherapica, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden AG, Baden, Switzerland|Chernigiv Regional Oncology Centre, Chernigiv, Ukraine|Bukovynsk State Medical University, Chernivtsi, Ukraine|Chmelnytskyi Oblasnnyi Oncologichnyi Tsentr, Chmelnytskyi, Ukraine|City Clinical Hospital #4, Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine|Donetsk Regional Antitumor Centre, Donetsk, Ukraine|Kharkiv Medical Acadamy of Postgraduate education, Kharkiv, Ukraine|Kryvorizskyi regional communal clinical oncology centre, Kryvyi Rig, Ukraine|Odesa Regional Oncological Centre, Odesa, Ukraine|Ternopil regional communal clinical oncology centre, Ternopil, Ukraine|Uzhgorod National University, Oncology Centre, Uzhgorod, Ukraine|Vinnytsia Regional Clinical Oncological Dispensary, Vinnytsia, Ukraine|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Bristol Haematology & Onc. Ctr, Bristol, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Poole Hospital, Poole, United Kingdom","https://ClinicalTrials.gov/show/NCT00805194"
443,"NCT01085136","LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib","Completed","Has Results","All","Phase 3","1154","Industry","Interventional","February 2010","October 2013","January 2016","March 11, 2010","October 3, 2014","April 4, 2017","Boehringer Ingelheim Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|Boehringer Ingelheim Investigational Site, Kingswood, New South Wales, Australia|Boehringer Ingelheim Investigational Site, South Brisbane, Queensland, Australia|Boehringer Ingelheim Investigational Site, Box Hill, Victoria, Australia|Boehringer Ingelheim Investigational Site, Fitzroy, Victoria, Australia|Boehringer Ingelheim Investigational Site, Wodonga, Victoria, Australia|Boehringer Ingelheim Investigational Site, Salzburg, Austria|Boehringer Ingelheim Investigational Site, Aalst, Belgium|Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|Boehringer Ingelheim Investigational Site, Duffel, Belgium|Boehringer Ingelheim Investigational Site, La Louvière, Belgium|Boehringer Ingelheim Investigational Site, Liège, Belgium|Boehringer Ingelheim Investigational Site, Middelheim, Belgium|Boehringer Ingelheim Investigational Site, Ottignies, Belgium|Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|Boehringer Ingelheim Investigational Site, Beijing, China|Boehringer Ingelheim Investigational Site, Changchun, China|Boehringer Ingelheim Investigational Site, Chengdu, China|Boehringer Ingelheim Investigational Site, Fuzhou, China|Boehringer Ingelheim Investigational Site, Guangzhou, China|Boehringer Ingelheim Investigational Site, Hangzhou, China|Boehringer Ingelheim Investigational Site, Nanjing, China|Boehringer Ingelheim Investigational Site, Shanghai, China|Boehringer Ingelheim Investigational Site, Helsinki, Finland|Boehringer Ingelheim Investigational Site, Bayonne, France|Boehringer Ingelheim Investigational Site, Caen Cedex 5, France|Boehringer Ingelheim Investigational Site, Dijon, France|Boehringer Ingelheim Investigational Site, La Tronche, France|Boehringer Ingelheim Investigational Site, Lyon Cedex 08, France|Boehringer Ingelheim Investigational Site, Paris cedex 20, France|Boehringer Ingelheim Investigational Site, Paris, France|Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France|Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|Boehringer Ingelheim Investigational Site, Berlin, Germany|Boehringer Ingelheim Investigational Site, Essen, Germany|Boehringer Ingelheim Investigational Site, Esslingen, Germany|Boehringer Ingelheim Investigational Site, Gauting, Germany|Boehringer Ingelheim Investigational Site, Hamburg, Germany|Boehringer Ingelheim Investigational Site, Hannover, Germany|Boehringer Ingelheim Investigational Site, Heidelberg, Germany|Boehringer Ingelheim Investigational Site, Mainz, Germany|Boehringer Ingelheim Investigational Site, Münster, Germany|Boehringer Ingelheim Investigational Site, Budapest, Hungary|Boehringer Ingelheim Investigational Site, Pecs, Hungary|Boehringer Ingelheim Investigational Site, Törökbálint, Hungary|Boehringer Ingelheim Investigational Site, Chennai, India|Boehringer Ingelheim Investigational Site, Jaipur, India|Boehringer Ingelheim Investigational Site, Maharashtra, India|Boehringer Ingelheim Investigational Site, Mumbai, India|Boehringer Ingelheim Investigational Site, Nashik, Maharashtra, India|Boehringer Ingelheim Investigational Site, Kfar Saba, Israel|Boehringer Ingelheim Investigational Site, Petach Tikva, Israel|Boehringer Ingelheim Investigational Site, Tel Hashomer, Israel|Boehringer Ingelheim Investigational Site, Avellino, Italy|Boehringer Ingelheim Investigational Site, Aviano (PN), Italy|Boehringer Ingelheim Investigational Site, Bergamo, Italy|Boehringer Ingelheim Investigational Site, Genova, Italy|Boehringer Ingelheim Investigational Site, Milano, Italy|Boehringer Ingelheim Investigational Site, Monza (mi), Italy|Boehringer Ingelheim Investigational Site, Ravenna, Italy|Boehringer Ingelheim Investigational Site, Roma, Italy|Boehringer Ingelheim Investigational Site, Goyang, Korea, Republic of|Boehringer Ingelheim Investigational Site, Hwasun, Korea, Republic of|Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|Boehringer Ingelheim Investigational Site, Distrito Federal, Mexico|Boehringer Ingelheim Investigational Site, Maastricht, Netherlands|Boehringer Ingelheim Investigational Site, Nieuwegein, Netherlands|Boehringer Ingelheim Investigational Site, Arequipa, Peru|Boehringer Ingelheim Investigational Site, La Victoria, Peru|Boehringer Ingelheim Investigational Site, Gdansk, Poland|Boehringer Ingelheim Investigational Site, Olsztyn, Poland|Boehringer Ingelheim Investigational Site, Otwock, Poland|Boehringer Ingelheim Investigational Site, Warszawa, Poland|Boehringer Ingelheim Investigational Site, Obninsk, Russian Federation|Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|Boehringer Ingelheim Investigational Site, A Coruña, Spain|Boehringer Ingelheim Investigational Site, Barcelona, Spain|Boehringer Ingelheim Investigational Site, Madrid, Spain|Boehringer Ingelheim Investigational Site, Mataró, Spain|Boehringer Ingelheim Investigational Site, Málaga, Spain|Boehringer Ingelheim Investigational Site, Valencia, Spain|Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|Boehringer Ingelheim Investigational Site, Taichung, Taiwan|Boehringer Ingelheim Investigational Site, Tainan, Taiwan|Boehringer Ingelheim Investigational Site, Taipei, Taiwan|Boehringer Ingelheim Investigational Site, Taoyuan, Taiwan|Boehringer Ingelheim Investigational Site, Dnipropetrovks, Ukraine|Boehringer Ingelheim Investigational Site, Donetsk, Ukraine|Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|Boehringer Ingelheim Investigational Site, Kyiv, Ukraine|Boehringer Ingelheim Investigational Site, Brighton, United Kingdom|Boehringer Ingelheim Investigational Site, Dundee, United Kingdom|Boehringer Ingelheim Investigational Site, Exeter, United Kingdom|Boehringer Ingelheim Investigational Site, London, United Kingdom|Boehringer Ingelheim Investigational Site, Maidstone, United Kingdom|Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|Boehringer Ingelheim Investigational Site, Sutton, Surrey, United Kingdom|Boehringer Ingelheim Investigational Site, Truro, Cornwall, United Kingdom","https://ClinicalTrials.gov/show/NCT01085136"
444,"NCT01798056","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy","Completed","Has Results","All","Phase 3","237","Industry","Interventional","March 6, 2013","June 18, 2015","May 20, 2016","February 25, 2013","August 17, 2018","August 17, 2018","GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Praha 8, Czechia|GSK Investigational Site, Besançon cedex, France|GSK Investigational Site, Ferolles-Attilly, France|GSK Investigational Site, Lyon Cedex 08, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Nîmes cedex 9, France|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Badajoz, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Móstoles, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, San Sebastian de los Reyes, Spain|GSK Investigational Site, Cheltenham, Gloucestershire, United Kingdom|GSK Investigational Site, Woolwich, London, United Kingdom|GSK Investigational Site, Swindon, Wiltshire, United Kingdom|GSK Investigational Site, Exeter, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, York, United Kingdom","https://ClinicalTrials.gov/show/NCT01798056"
445,"NCT01950273","Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma","Completed","Has Results","All","Phase 1","95","Industry","Interventional","September 27, 2013","December 22, 2015","December 22, 2015","September 25, 2013","September 5, 2018","September 5, 2018","The Canberra Hospital, Canberra, Migration Data, Australia|AKH - Medical University of Vienna, Wien, Austria|Brussels - UNIV St-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Namur - HOSP Ste-Elisabeth, Namur, Belgium|Clinical Hospital Centre Zagreb, Zagreb, Croatia|University Hospital Brno, Brno, Czechia|University Hospital Ostrava, Ostrava-Poruba, Czechia|Vseobecna fakultni nemocnice V Praze, Praha 2, Czechia|INS Bergonié, Bordeaux cedex, France|HOP Morvan, Brest, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|HOP Haut-Lévêque, Pessac, France|Hôpital la Milétrie - CHU Poitiers, Poitiers, France|Gesundheitszentrum Wetterau gGmbH, Bad Nauheim, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Haemato-Onkologie Hamburg, Hamburg, Germany|Klinikum Kassel GmbH, Kassel, Germany|General Hospital of Athens ""G. Gennimatas"", Athens, Greece|Semmelweis University, 1st Dept. Internal Medicine, Budapest, Hungary|Auckland Clinical Studies Ltd, Auckland, New Zealand|Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warszawa, Poland|BHI of Omsk region - Clinical Oncology Dispensary, Omsk, Russian Federation|St. Petersburg GUZ City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Puerta del Mar, Cádiz, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Virgen del Rocío, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01950273"
446,"NCT01102608","Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma","Completed","No Results Available","All","Phase 2","32","Other","Interventional","March 2008","October 2011","December 2011","April 13, 2010","null","March 20, 2012","Grupo Espanol de Investigación en Sarcomas, Barcelona, España, Spain","https://ClinicalTrials.gov/show/NCT01102608"
447,"NCT02069704","Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients","Completed","No Results Available","All","Phase 1","142","Industry","Interventional","October 29, 2014","October 2015","June 2017","February 24, 2014","null","February 15, 2018","Hospital de Gastroenterologia ""Dr. Carlos Bonorino Udaondo"", Buenos Aires, Argentina|Instituto Oncológico de Rosario, Rosario, Argentina|Fundaçáo Pio XII - Hospital do Cancer de Barretos, Barretos, Brazil|Hospital Caridade, Ijui, Brazil|Hospital Sao Lucas da Pucrs, Porto Alegre, Brazil|Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC, São Paulo, Brazil|Hosp. A.C Camargo, São Paulo, Brazil|Instituto do Cancer del estado de S. Paulo (ICEPS ), São Paulo, Brazil|M S Patel Cancer Centre- Shree Krishna Hospital, Karamsad, Gujarat, India|Sri Ramachandra Hospital, Chennai, India|Tata Hospital, Mumbai, India|Central India Canter Research Institute, Nagpur, India|Curie Manavta Cancer Center, Nashik, India|Regional Cancer Center & Medical College, Thiruvananthapuram, India|Centro Oncológico Clara Campal, Madrid, Spain|Dnipropetrovsk City Multiple-discipline Clinical Hospital №4, Dnipropetrovsk, Ukraine|Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Danylo Halytskiy Lviv National Medical University, Lviv, Ukraine","https://ClinicalTrials.gov/show/NCT02069704"
448,"NCT00942162","A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma","Completed","Has Results","All","Phase 2","125","Industry","Interventional","August 14, 2009","June 27, 2012","April 1, 2015","July 20, 2009","September 7, 2018","September 7, 2018","GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Stuart, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Besançon cedex, France|GSK Investigational Site, Boulogne, France|GSK Investigational Site, Brest, France|GSK Investigational Site, Dijon, France|GSK Investigational Site, Grenoble, France|GSK Investigational Site, Marseille Cedex 5, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Rouen, France|GSK Investigational Site, Tours, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Nuernberg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Marburg, Hessen, Germany|GSK Investigational Site, Wiesbaden, Hessen, Germany|GSK Investigational Site, Buxtehude, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Ludwigshafen, Rheinland-Pfalz, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Quedlinburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Erfurt, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Cork, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Siena, Toscana, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Kraków, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00942162"
449,"NCT00803062","Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer","Completed","Has Results","Female","Phase 3","452","NIH","Interventional","April 2009","February 2013","February 2013","December 5, 2008","May 24, 2016","December 7, 2017","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Highlands Oncology Group PA - Fayetteville, Fayetteville, Arkansas, United States|Washington Regional Medical Center - Fayetteville, Fayetteville, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Roy and Patricia Disney Family Cancer Center, Burbank, California, United States|Mills - Peninsula Hospitals, Burlingame, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|California Cancer Center - North Fresno, Fresno, California, United States|Long Beach Memorial Medical Center-Todd Cancer Institute, Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Stanford Cancer Institute, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of California San Diego, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Olive View-University of California Los Angeles Medical Center, Sylmar, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|Colorado Gynecologic Oncology Group, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Exempla Saint Joseph Hospital, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program CCOP, Denver, Colorado, United States|Rocky Mountain Gynecologic Oncology PC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Washington Hospital Center, Washington, District of Columbia, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Florida Gynecologic Oncology, Fort Myers, Florida, United States|Memorial Healthcare System - Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Atlanta Regional CCOP, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|Georgia Regents University Medical Center, Augusta, Georgia, United States|Well Star Cobb Hospital, Austell, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Harbin Clinic Medical Oncology and Clinical Research, Rome, Georgia, United States|Memorial University Medical Center, Savannah, Georgia, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Oncare Hawaii Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Oncare Hawaii Inc-Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute of Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Mount Sinai Hospital Medical Center, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Saint Francis Hospital, Evanston, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Advocate Lutheran General Hospital., Park Ridge, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cadence Cancer Center in Warrenville, Warrenville, Illinois, United States|Saint Francis Hospital and Health Centers, Beech Grove, Indiana, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Franciscan Saint Francis Health-Indianapolis, Indianapolis, Indiana, United States|Gynecologic Oncology of Indiana, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|Saint Vincent Oncology Center, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium CCOP, South Bend, Indiana, United States|Michiana Hematology Oncology-PC Westville, Westville, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Hospital District Sixth of Harper County, Anthony, Kansas, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Kansas City CCOP, Prairie Village, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Main Office, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wichita CCOP, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Saint Elizabeth Medical Center South, Edgewood, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, United States|Doctors Carrol, Sheth, Raghavan, Louisville, Kentucky, United States|Pikeville Medical Center, Pikeville, Kentucky, United States|Hematology/Oncology Clinic LLP, Baton Rouge, Louisiana, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Highland Clinic, Shreveport, Louisiana, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Franklin Square Hospital Center, Baltimore, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium CCOP, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mid-Michigan Medical Center - Midland, Midland, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Michiana Hematology Oncology PC-Niles, Niles, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Providence Hospital, Southfield, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro-Minnesota NCI Community Oncology Research Program, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Phelps County Regional Medical Center, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Ozark Health Ventures LLC-Cancer Research for The Ozarks Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Montana Cancer Consortium CCOP, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Frontier Cancer Center and Blood Institute-Billings, Billings, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Center of Hope at Renown Medical Center, Reno, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey, United States|Jersey Shore Medical Center, Neptune City, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|UMDNJ - New Jersey Medical School, Newark, New Jersey, United States|The Women's Institute for Gynecologic Cancer and Special Pelvic Surgery, Phillipsburg, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|Virtua West Jersey Hospital Voorhees, Voorhees, New Jersey, United States|Southwest Gynecologic Oncology Associates Inc, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Women's Cancer Care Associates LLC, Albany, New York, United States|Island Gynecologic Oncology, Brightwaters, New York, United States|State University of New York Downstate Medical Center, Brooklyn, New York, United States|Queens Hospital Center, Jamaica, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore-LIJ Health System CCOP, Manhasset, New York, United States|Orange Regional Medical Center, Middletown, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|North Shore-LIJ Health System/Center for Advanced Medicine, New Hyde Park, New York, United States|Beth Israel Medical Center, New York, New York, United States|New York University Langone Medical Center, New York, New York, United States|Saint Luke's Roosevelt Hospital Center - Saint Luke's Division, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Montefiore Medical Center-Einstein Campus, The Bronx, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Hope Women's Cancer Centers-Asheville, Asheville, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Akron General Medical Center, Akron, Ohio, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus CCOP, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton CCOP, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Genesis HealthCare System, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Mainline Health CCOP, Wynnewood, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|South Carolina Oncology Associates PA, Columbia, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Cancer Centers of the Carolinas-Greer Medical Oncology, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Upstate Carolina CCOP, Spartanburg, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Black Hills Obstetrics and Gynecology, Rapid City, South Dakota, United States|Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, United States|Tennessee Oncology PLLC- Centennial Medical Center, Nashville, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University Medical Center Brackenridge, Austin, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|Zale Lipshy University Hospital, Dallas, Texas, United States|Clements University Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Baylor All Saints Medical Center at Fort Worth, Fort Worth, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Lyndon Baines Johnson General Hospital, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Methodist Hospital, Houston, Texas, United States|Saint Luke's Episcopal Hospital, Houston, Texas, United States|Veterans Administration Medical Center, Houston, Texas, United States|Wilford Hall Medical Center, Lackland Air Force Base, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|American Fork Hospital, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Intermountain Health Care, Salt Lake City, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Fletcher Allen Health Care-Medical Center, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|Providence - Saint Peter Hospital, Olympia, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|MultiCare Allenmore Hospital, Tacoma, Washington, United States|Northwest CCOP, Tacoma, Washington, United States|Saint Joseph Medical Center, Tacoma, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Mary's Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Saint Joseph's Hospital, Marshfield, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|D N Greenwald Center, Mukwonago, Wisconsin, United States|Oconomowoc Memorial Hospital-ProHealth Care Inc, Oconomowoc, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|Marshfield Clinic at James Beck Cancer Center, Rhinelander, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|Marshfield Clinic Cancer Care at Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Vince Lombardi Cancer Clinic, Two Rivers, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Vall d'Hebron University Hospital, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitario Gregorio Maranon, Madrid, Spain|M D Anderson International Spain, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Son Llatzer, Palma, Spain|Instituto Valenciano de Oncologia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00803062"
450,"NCT01715896","A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis","Completed","Has Results","All","Phase 2","215","Industry","Interventional","March 2013","November 2014","February 2015","October 29, 2012","October 31, 2016","October 31, 2016","Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Barranquilla, Colombia|Research Site, Praha 2, Czech Republic|Research Site, Uherske Hradiste, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Montpellier cedex 5, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Kfar-Saba, Israel|Research Site, Petach-Tikva, Israel|Research Site, Rehovot, Israel|Research Site, Merida, Mexico|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Viseu, Portugal|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Niska Banja, Serbia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice - Saca, Slovakia|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Malaga, Spain|Research Site, Birkenhead, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT01715896"
451,"NCT00743938","A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC","Completed","No Results Available","All","Phase 2","141","Industry","Interventional","March 2009","August 2010","June 2012","August 29, 2008","null","October 12, 2015","Yale University School Of Medicine, New Haven, Connecticut, United States|Hematology Oncology, P.C., Stamford, Connecticut, United States|Mass General Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Piedmont Hematology Oncology Associates, Pllc, Winston-salem, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Hema/Oncology Assoc. Of Nepa, Dunmore, Pennsylvania, United States|Cancer Center Of The Carolinas, Greenville, South Carolina, United States|Local Institution, Bahia Blanca, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Villejuif Cedex, France|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Otwock, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Vizcaya, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00743938"
452,"NCT00690430","Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","Completed","Has Results","All","Phase 3","186","Industry","Interventional","April 2008","April 2012","April 2012","June 4, 2008","July 30, 2013","July 30, 2013","Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, Arizona, United States|University of Arizona / Arizona Cancer Center, Tucson, Arizona, United States|Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|H. Lee Moffitt Cancer Center/University of South Florida Dept of H. Lee Moffit, Tampa, Florida, United States|Montefiore Medical Center MMC, Bronx, New York, United States|Mount Sinai School of Medicine Study Coordinator, New York, New York, United States|Duke University Medical Center Dept. of Duke Cancer Center(2), Durham, North Carolina, United States|St. Luke's Hospital and Health Network St. Luke's Cancer Network, Bethlehem, Pennsylvania, United States|MD Anderson Cancer Center/University of Texas Dept. of MD Anderson (9), Houston, Texas, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Clichy, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Nice Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Bad Berka, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Tromsø, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Gliwice, Slaskie, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Hospitalet de Llobregat, Cataluña, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Jönköping, Sweden|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Withington, Greater Manchester, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, Basingstoke, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00690430"
453,"NCT00688376","Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","Completed","No Results Available","All","Phase 3","300","Industry","Interventional","August 2008","June 2009","September 2009","June 2, 2008","null","September 23, 2009","Stanford, California, United States|Miami, Florida, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|New Brunswick, New Jersey, United States|Brooklyn, New York, United States|Great Neck, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Oklahoma City, Oklahoma, United States|Dallas, Texas, United States|Houston, Texas, United States|Road Runner Research Ltd., San Antonio, Texas, United States|Cordoba Capital, Provincia de Cordoba, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Sydney, New South Wales, Australia|Westmead, Sydney, New South Wales, Australia|Calgary, Alberta, Canada|Antonio Varas, Providencia Santiago, Chile|Santa Maria, Providencia Santiago, Chile|Vandoeurvre Les Nancy, France|Villejuif, France|Koeln, Germany|Amsterdam, Netherlands|Groningen, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Palma de Mallorca, Spain|Valencia, Spain|Sutton, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT00688376"
454,"NCT01593228","Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial","Completed","No Results Available","All","Phase 3","37","Industry","Interventional","May 2012","September 2016","September 2016","May 8, 2012","null","September 19, 2017","Investigational Site Number 840013, Birmingham, Alabama, United States|Investigational Site Number 840033, Santa Maria, California, United States|Investigational Site Number 840046, Vallejo, California, United States|Investigational Site Number 840008, Denver, Colorado, United States|Investigational Site Number 840027, Jacksonville, Florida, United States|Investigational Site Number 840063, Augusta, Georgia, United States|Investigational Site Number 840055, Tucker, Georgia, United States|Investigational Site Number 840039, Maywood, Illinois, United States|Investigational Site Number 840012, Indianapolis, Indiana, United States|Investigational Site Number 840025, Sioux City, Iowa, United States|Investigational Site Number 840030, Boston, Massachusetts, United States|Investigational Site Number 840001, Detroit, Michigan, United States|Investigational Site Number 840006, Minneapolis, Minnesota, United States|Investigational Site Number 840002, Jackson, Mississippi, United States|Investigational Site Number 840059, Saint Louis, Missouri, United States|Investigational Site Number 840004, Saint Louis, Missouri, United States|Investigational Site Number 840022, Las Vegas, Nevada, United States|Investigational Site Number 840017, Voorhees, New Jersey, United States|Investigational Site Number 840010, Albany, New York, United States|Investigational Site Number 840015, Charlotte, North Carolina, United States|Investigational Site Number 840060, Cincinnati, Ohio, United States|Investigational Site Number 840043, Cleveland, Ohio, United States|Investigational Site Number 840021, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840028, Memphis, Tennessee, United States|Investigational Site Number 840007, Austin, Texas, United States|Investigational Site Number 840003, El Paso, Texas, United States|Investigational Site Number 840019, Plano, Texas, United States|Investigational Site Number 840005, Norfolk, Virginia, United States|Investigational Site Number 840009, Vancouver, Washington, United States|Investigational Site Number 056002, Leuven, Belgium|Investigational Site Number 380002, Genova, Italy|Investigational Site Number 724001, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01593228"
455,"NCT00835978","Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer","Completed","Has Results","All","Phase 2","213","Industry","Interventional","August 2009","October 2012","February 2016","February 4, 2009","May 26, 2014","May 30, 2017","East Bay Medical Oncology/Hematology Medical Associates Inc., Antioch, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Bay Area Cancer Research Group, LLC, Pleasant Hill, California, United States|Diablo Valley Oncology and Hematology Medical Group Inc, Pleasant Hill, California, United States|East Bay Medical Oncology/Hematology Medical Associates Inc, Pleasant Hill, California, United States|East Bay Medical Oncology/Hematology Medical Associates Inc, San Leandro, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Investigational Drug Services, IUHSCC, Indianapolis, Indiana, United States|IU Health University Hospital, Indianapolis, Indiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|The University Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, James Cancer Hospital, Columbus, Ohio, United States|JamesCare in Kenny, Columbus, Ohio, United States|West Chester Hospital Medical Building, West Chester, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Texas Oncology, Sammons Cancer Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Masarykuv onkologicky ustav, Brno, CZE, Czechia|Fakultni nemocnice Olomouc Onkologicka klinika, Olomouc, Czechia|Fakultni nemocnice Na Bulovce, Praha 8, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice V Usti nad Labem, o.z., Usti nad Labem, Czechia|Universitaetsklinikum Duesseldorf, Duesseldorf, Germany|Klinikum der J. W. Goethe-Universitaet, Medizinische Klinik II, Frankfurt, Germany|Medizinische Hochschule Hannover, Abt. Haematologie, Haemostaseologie & Onkologie, Hannover, Germany|Eberhardt-Karls-Universitaet Tuebingen, Klinik fuer Urologie, Tuebingen, Germany|Klinikum Weiden Klinik fuer Urologie, Andrologie und Kinderurologie, Weiden, Germany|Nagoya University Hospital, Nagoya, Aichi, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Kinki University Hospital, Osakasayama, Osaka, Japan|Hamamatsu University School of Medicine, University Hospital, Hamamatsu-City, Shizuoka, Japan|National Cancer Center, Chuo-ku, Tokyo, Japan|Japanese Foundation For Cancer Research Cancer Institute Hospital, Koto-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Akita University Hospital, Akita, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu University Hospital, Fukuoka, Japan|Nagasaki University Hospital, Nagasaki, Japan|Tokushima University Hospital, Tokushima, Japan|Yamagata University Hospital, Yamagata, Japan|Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia, Obninsk, Kaluga Region, Russian Federation|State Healthcare Institution ""Leningrad Regional Oncology Dispensary"", Poselok Kuzmolovskiy, Vsevolozhskiy Region, Leningradskaya Oblast, Russian Federation|FSBSI ""N.N. Blokhin Russian Cancer Research Center"", Moscow, Russian Federation|FSBI""Russian Scientific Center of Roengenoradiology"" of the MH of RF, Moscow, Russian Federation|Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary', Saint-Petersburg, Russian Federation|Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary', Saint-Petersburg, Russian Federation|GBUZ ""Samara Regional Clinical Oncology Dispensary"", Samara, Russian Federation|Hospital de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00835978"
456,"NCT01019434","Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","Completed","No Results Available","All","Phase 2","111","Other|Industry","Interventional","October 2009","December 2013","March 2014","November 25, 2009","null","July 9, 2018","UZ Leuven, Leuven, Belgium|Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau, Nantes-Saint Herblain, France|CHU Pitie-Salpetriere AP-HP, Paris, France|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Ospedale Bellaria, Bologna, Italy|Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands|Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands|ICO Badalona - Hospital Germans Trias i Pujol, Badalona, Spain|Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland|Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|Western General Hospital, Edinburgh, United Kingdom","https://ClinicalTrials.gov/show/NCT01019434"
457,"NCT01389440","Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer","Completed","No Results Available","All","Phase 2","24","Other","Interventional","May 2011","November 2016","January 22, 2017","July 8, 2011","null","May 18, 2018","Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital del Mar, Barcelona, Spain|Institut Català d'Oncologia (ICO) de L'Hospitalet, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Santa Creu y Sant Pau, Hospital Sant Pau, Barcelona, Spain|Instituto Catalán de Oncología, Girona, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital la Fe de Valencia, Valencia, Spain|Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01389440"
458,"NCT01166542","Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers","Completed","No Results Available","All","Phase 3","167","Industry","Interventional","June 2010","April 2012","May 2014","July 21, 2010","null","November 5, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Providence Health and Services, Burbank, California, United States|Wilshire Oncology Medical Group, Corona, California, United States|BMS Physician Practice, A Medical Corporation DBA Medical Oncology Care Associates, Orange, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States|Emory University - Winship Cancer Institute, Altanta, Georgia, United States|Alexian Brothers Hospital Network, Elk Grove Village, Illinois, United States|Mary Bird Perkinds Cancer Center - Baton Rouge, Baton Rouge, Louisiana, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, United States|Mercy Cancer Center, Toledo, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Oncology- Sammons Cancer Center, Dallas, Texas, United States|Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|ZNA Middelheim, Antwerpen, Belgium|University Hospital Antwerp, Edegem, Belgium|Universitair Ziekenhuis Brussel, Jette, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Center, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Hopital Notre-Dame, Montreal, Quebec, Canada|Hopital Saint-André / Service d'Oncologie-Radiothérapie, Bordeaux, France|Centre Antoine Lacassagne / Oncologie Médicale, Nice, France|Institut Curie / Département d'Oncologie Médicale, Paris, France|UKE Hamburg, Hamburg, Germany|Attikon University Hospital, Athens, Greece|Fovarosi Onkormanyzat Uzsoki Utcai Kórház, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Szegedi Tudományegyetem, Szegedi, Hungary|Markusovszky Korhaz, Szombathely, Hungary|Ufficio Sperimentazioni Cliniche c/o S.C. Oncologia Medica, Cuneo, Italy|Fondazione IRCCS Istituto Nazionale del Tumori, Milan, Italy|Ospedale San Paolo - Oncologia Medica, Milan, Italy|University Hospital in Modena, Modena, Italy|Centrum Onkologii - Instytyt im.M.Skłodowskiej-Curie, Krakow, Poland|Szpital MSWiA - Centrum Onkologi, Olsztyn, Poland|Wielkopolskie Centrum Onkologii, Poznań, Poland|Wojewódzki Szpital Specjalistyczny im. M.Kopernika, Łódź, Poland|State Health Care Institution ""Arkhangelsk Regional Clinical Oncology Dispensary"", Arkhangelsk, Russian Federation|Regional State Health Care Institution ""Belgorod Oncology Dispensary"", Belgorod, Russian Federation|State Health Care Institution ""Chelyabinsk Regional Oncology Dispensary"", Chelyabinsk, Russian Federation|State Health Care Institution ""Republican Clinical Oncology Dispensary of Ministry of Health of the Republic of Tatarstan"", Kazan, Russian Federation|State Budgetary Health Care Institution ""Clinical Oncology Dispensary #1"" of Krasnodar Region Health Care Department, Krasnodar, Russian Federation|Regional Budgetary Health Care Institution ""Kursk Regional Oncology Dispensary"" of Health Care Committee of Kursk region, Kursk, Russian Federation|Federal State Budgetary Institution ""Medical Research Radiology Center"" of Ministry of Public Health and Social Development of Russian Federation, Obninsk, Obninsk, Russian Federation|Federal State Budgetary Institution ""Russian Research Centre of Radiology and Surgery technologies"" of Ministry of Public Health and Social Development of the Russian Federation, Saint Petersburg, Russian Federation|Federal State Budgetary Institution ""N. N. Petrov Oncology Research Institute"" of Ministry of Public Health and Social Development of the Russian Federation, Saint-Petersburg, Russian Federation|St.Petersburg State Health Care Institution City Clinical Oncology Dispensary"", Saint-Petersburg, Russian Federation|State Health Care Institution ""Oncology Dispensary №2"" of Krasnodar Region Health Care Department, Sochi, Russian Federation|State Health Care Institution ""Tula Regional Oncology Dispensary"", Tula, Russian Federation|State Budgetary Healthcare Institution ""Republic Clinical Oncology Dispensary Ministry of Health of Bashkortostan"", Ufa, Russian Federation|State Budgetary Health Care Institution of the Yaroslavl region ""Regional Clinical Oncological Hospital"", Yaroslavl, Russian Federation|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Hospital Vall D'Hebron, Barcelona, Spain|Instituto Catlan de Oncologia (ICO) - Hospital Duran i Reynals, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Instituto Catlan de Oncologia (ICO) - Hospital Germans Trias I Pujol, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital de Navarra, Pamplona, Spain|Beatson West of Scotland Cancer Center, Glasgow, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|St. James's University Hospital, Leeds, United Kingdom|Guy's and St. Thomas Hospital, London, United Kingdom|The Royal Marsden Cancer Center, Fulham Road branch, London, United Kingdom|The Royal Marsden Cancer Center, Sutton Branch, Sutton, United Kingdom|Musgrove Park Hospital, Taunton, United Kingdom|The Velindre Hospital, Whitchurch, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01166542"
459,"NCT01498354","Efficiency of Two Dimensional High Definition Versus Three Dimensional Endoscopic Systems in Transanal Endoscopic Surgery","Completed","No Results Available","All","Phase 3","36","Other","Interventional","August 2010","October 2010","February 2012","December 23, 2011","null","September 10, 2015","Corporacion Sanitaria Universitaria Parc Tauli, Sabadell, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01498354"
460,"NCT01574092","Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas","Completed","No Results Available","All","Phase 2","39","Other","Interventional","November 2009","June 2014","March 2015","April 10, 2012","null","August 24, 2015","Hospital Sant Joan De Déu, Esplugues de Llobregat, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01574092"
461,"NCT02111330","Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) ""After Multiple Oral Doses"" in Healthy Volunteers","Completed","No Results Available","All","Phase 1","16","Other|Industry","Interventional","March 2014","May 2014","May 2014","April 11, 2014","null","March 8, 2016","Palobiofarma S.L. (molecule owner), Mataró, Barcelona, Spain|CIM Sant Pau - I.I.B. Sant Pau, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02111330"
462,"NCT01691924","Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers","Completed","No Results Available","Male","Phase 1","56","Other|Industry","Interventional","October 2012","October 2013","October 2013","September 25, 2012","null","March 8, 2016","Palobiofarma S.L. (molecule owner), Mataró, Barcelona, Spain|Cim- Sant Pau, HSCSP, Barcelona, Catalunya/Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01691924"
463,"NCT01636284","A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer","Completed","No Results Available","All","Phase 2","16","Industry","Interventional","June 2012","June 2013","June 2013","July 10, 2012","null","January 20, 2016","Mayo Clinic, Scottsdale, Arizona, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Pusan National University Hospital, Pusan, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|University Clinic of Navarra, Navarra, Spain","https://ClinicalTrials.gov/show/NCT01636284"
464,"NCT00786838","A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram","Completed","Has Results","All","Phase 2","76","Industry","Interventional","October 2008","December 2009","December 2009","November 6, 2008","January 23, 2014","April 11, 2014","Miami, Florida, United States|Charlotte, North Carolina, United States|Philadelphia, Pennsylvania, United States|Tacoma, Washington, United States|Brussels, Belgium|Edegem, Belgium|Wilrijk, Belgium|Lyon, France|Marseille, France|Montpellier, France|Villejuif, France|Bangalore N/A, India|Pune, India|Seoul, Korea, Republic of|Moscow N/A, Russian Federation|Moscow, Russian Federation|St Petersburg N/A, Russian Federation|St-Petersburg, Russian Federation|Sanchinarro, Spain","https://ClinicalTrials.gov/show/NCT00786838"
465,"NCT01468688","A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients","Completed","No Results Available","All","Phase 1","60","Industry","Interventional","April 20, 2012","July 29, 2016","July 29, 2016","November 9, 2011","null","July 7, 2017","Dana Farber Cancer Institute SC (2), Boston, Massachusetts, United States|Seattle Cancer Care Alliance Onc, Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01468688"
466,"NCT02074657","""LANK-2"": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia","Completed","No Results Available","All","Phase 2","13","Other","Interventional","April 2014","September 2016","September 2016","February 28, 2014","null","December 20, 2016","Hospital 12 de Octubre, Madrid, Spain|Hospital Infantil Universitario La Paz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02074657"
467,"NCT01523587","LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy","Completed","Has Results","All","Phase 3","795","Industry","Interventional","March 5, 2012","October 21, 2013","December 27, 2017","February 1, 2012","November 21, 2014","October 10, 2018","Ironwood Cancer and Research Centers, Chandler, Arizona, United States|University of California, La Jolla, California, United States|Sutter Medical Group, Sacramento, California, United States|Boca Raton Reginl Hospital-Lynn Cancer Institute, Boca Raton, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Cancer Care of North Florida, PA, Lake City, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Orchard Healthcare Research Inc, Skokie, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|West Jefferson General Hospital and Cancer Clinic, Marrero, Louisiana, United States|Lahey Clinic, Burlington, Massachusetts, United States|Commonwealth Hematology-Oncology, PC, Lawrence, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montefiore Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Queens Medical Associates, Fresh Meadows, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Mid Ohio Oncology/Hematology, Inc, Columbus, Ohio, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oncology Hematology Associates of Norhtern Pennsylvania, PC, DuBois, Pennsylvania, United States|Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Cancer Center, Philadelphia, Pennsylvania, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Cancer Center of Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Paris Cancer Center (PCC), Texas Oncology, Paris, Texas, United States|Cancer Therapy and Research at UTHSCSA, San Antonio, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Blue Ridge Cancer Care, Christiansburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma de Bs As, Argentina|Instituto Oncologico de Cordoba, Cordoba, Argentina|Clínica Colombo S.A., Cordoba, Argentina|Centro Oncologico de Rosario, Rosario, Argentina|Centro Oncologico CAIPO, San Miguel de Tucuman, Argentina|Medical University of Innsbruck, Innsbruck, Austria|LKH Leoben, Leoben, Austria|AKH d. Stadt Linz, Pulmologie, Linz, Austria|SMZ Baumgartner Hoehe Otto Wagner Spital, Wien, Austria|BC Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|Centro Oncologico Antofagasta, Antofagasta, Chile|Instituto de Terapias Oncologicas Providencia, Providencia, Santiago, Chile|Centro Internacional de Estudios Clinicos - CIEC, Recoleta, Santiago De Chile, Chile|Orlandi Oncologia, Vitacura, Chile|Beijing Cancer Hospital, Beijing, China|Beijing Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Xiangya Hospital, Central South University, Changsha, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|the 81th Hospital of PLA, Nanjing, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Herlev Hospital, Herlev, Denmark|Næstved Sygehus, Næstved, Denmark|Odense Universitetshospital, Odense C, Denmark|HOP d'Angers, Angers, France|INS Bergonié, Bordeaux, France|HOP Côte de Nacre, Caen, France|HOP de Chauny, Chauny, France|HOP Gabriel-Montpied, Clermont Ferrand, France|HOP de Creteil, Pneumo, Creteil, Creteil, France|HOP Le Mans, Le Mans, France|CTR Oscar Lambret, Cancéro, Lille, Lille, France|HOP Calmette, Lille, France|HOP Nord, Marseille Cedex 20, France|INS Paoli-Calmettes, Marseille, France|HOP de Mulhouse, Onco, Mulhouse, Mulhouse, France|HOP Cochin, Paris, France|HOP Val de Grâce, Onco, Paris, Paris, France|INS Jean Godinot, Onco, Reims, Reims, France|HOP de Rennes, Pneumo, Rennes, Rennes, France|HOP Saint Quentin, Onco, Saint Quentin, Saint Quentin, France|HOP Civil, Strasbourg, France|HOP Foch, Suresnes, France|INS Gustave Roussy, Villejuif, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany|Klinikum Esslingen GmbH, Esslingen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Lungenklinik Hemer, Hemer, Germany|Universitätsklinikum Mannheim GmbH, Mannheim, Germany|Universitätsklinikum Münster, Münster, Germany|Mathias-Spital Rheine, Rheine, Germany|""Hippokratio"" Hospital of Athens, 2nd Internal Medicine Clin, Athens, Greece|General Hospital of Chest Diseases Sotiria, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|University Hospital of Larisa, Oncology Clinic, Larisa, Greece|General Hospital of Larissa, Larisa, Greece|Metropolitan Hospital, Oncology Clinic, Neo Faliro, Athens, Greece|General Hospital ""G. Papageorgiou"", Thessaloniki, Greece|National Koranyi TBC and Pulm. Internal Med. Clinic, Budapest, Hungary|Semmelweis University, Dept. Pulmonology, Budapest, Hungary|Institute of Chest Diseases Csongrad County,Dpt. Pulmonology, Deszk, Hungary|Pulmonology Institute of Veszprem County, Farkasgyepu, Farkasgyepü, Hungary|Aladar Petz County Teaching Hospital, Dept. Pulmonology, Györ, Hungary|Lung Hospital of Matra, Dept. Pulmonology, Matrahaza, Hungary|Josa Andras Korhaz, Nyiregyhaza, Nyiregyhaza, Hungary|University of Pecs, 1st internal Med. Dept., Pulmonology, Pecs, Hungary|Pest County Lung Hospital, Department No. 3, Törökbalint, Hungary|Vikram Hospital, Bangalore, India|V S Hospital, Chennai, India|Dr. Kamakshi Memorial Hospital, Chennai, India|Sri Ramachandra Medical College & Research Institute, Chennai, India|M.S. Patel Cancer Hospital, Karamsad, India|B. P .Poddar Hospital & Medical Research Ltd., Kolkata, West Bengal, India|Tata Memorial Hospital, Mumbai, India|Ruby Hall Clinic, Pune, India|St James's Hospital, Dublin 8, Ireland|P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna, Bologna, Italy|ASST di Cremona, Cremona, Italy|Spedali Riuniti di Livorno, Livorno, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedaliera di Parma, Parma, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Ospedale San Vincenzo, Taormina (ME), Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|A. O. S. Maria della Misericordia, Udine, Italy|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St.Vincent's Hospital, Suwon, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Instituto Nacional de Cancerologia, Mexico, Mexico|Hospital y Clínica OCA S. A. de C. V., Monterrey, Mexico|Centro Hemato-Oncologico Privado de Toluca S.A. de C.V., Toluca, Mexico|Jeroen Bosch Ziekenhuis-Hertogenbosch, 's-HERTOGENBOSCH, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Ethische Commissie Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|IPO Lisboa Francisco Gentil, EPE, Lisboa, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|National Cancer Centre, Singapore, Singapore|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Hospital A Coruña, A Coruña, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Malaga, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Chang Gung Memorial Hospital Chiayi, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital, Chiayi, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan, Taiwan|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Bursa, Turkey|Dicle Universitesi Tip Fakultesi, Diyarbakir, Turkey|Gaziantep Univ. Tip Fakultesi Tibbi Onkoloji Bilim Dali, Gaziantep, Turkey|Kartal Egitim Ve Arastirma Hastanesi, Istanbul, Turkey|Yedikule Gog. Hst. EAH, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali, Izmir, Turkey|Dr.Suat Seren EAH, Izmir, Turkey|Queen Elizabeth Hospital, Birmingham, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Harrogate District Hospital, Harrogate, United Kingdom|Royal Free Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Maidstone Hospital, Kent Oncology Centre, Maidstone, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Scarborough Hospital, Scarborough, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01523587"
468,"NCT02328885","Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation","Completed","No Results Available","All","Phase 1|Phase 2","20","Other","Interventional","July 2014","March 22, 2017","March 22, 2017","December 31, 2014","null","July 3, 2018","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Vall Hebron, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02328885"
469,"NCT00719264","Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer","Completed","Has Results","All","Phase 2","365","Industry","Interventional","November 12, 2008","December 31, 2011","April 15, 2013","July 21, 2008","May 7, 2014","March 20, 2017","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(3), Duarte, California, United States|USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, United States|University of California at Los Angeles Dept. of Hem/Oncology, Los Angeles, California, United States|Karmanos Cancer Institute Dept.of KarmanosCancerInst (5), Detroit, Michigan, United States|Nevada Cancer Institute Dept. of Nevada Cancer (3), Las Vegas, Nevada, United States|St. Luke's Hospital and Health Network St. Luke's Cancer Network, Bethlehem, Pennsylvania, United States|Las Colinas Hematology Oncology Grapevine, Irving, Texas, United States|Seattle Cancer Care Alliance Dept. of SCCA, Seattle, Washington, United States|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Prague, Czech Republic|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Strasbourg, Cedex, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, La Roche sur Yon Cedex, France|Novartis Investigative Site, Montellier cedex 5, France|Novartis Investigative Site, Nantes cedex 2, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen Cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Suresnes, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dessau, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catanzaro, CZ, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Trento, TN, Italy|Novartis Investigative Site, Negrar, VR, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Goyang, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Obninsk, Russia, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Jaen, Andalucía, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Balcova / Izmir, Turkey|Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Mecidiyekoy/Istanbul, Turkey|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00719264"
470,"NCT01900652","A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants","Completed","Has Results","All","Phase 2","111","Industry","Interventional","August 2013","February 2015","March 2016","July 16, 2013","June 25, 2018","June 25, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - San Diego, La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|UCLA, Santa Monica, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Georgetown University Medical Center IRB, Washington, District of Columbia, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Emory University, Atlanta, Georgia, United States|University of Iowa Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Columbia University, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Portland VA Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology PLLC, Chattanooga, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|MS Center at Evergreen, Kirkland, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Group Health, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mechelen, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roeselare, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zerifin, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orbassano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southampton, Hants, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wythenshawe, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Headington, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01900652"
471,"NCT01700413","Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia","Completed","No Results Available","All","Phase 2","48","Other","Interventional","October 2012","October 2013","April 2015","October 4, 2012","null","January 28, 2016","Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospitals Vall D'Hebron, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01700413"
472,"NCT00576758","GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma","Completed","Has Results","All","Phase 2","175","Industry","Interventional","January 2008","September 2011","March 2013","December 19, 2007","March 31, 2014","August 19, 2014","Los angeles, California, United States|Denver, Colorado, United States|Gainesville, Florida, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Cumberland, Maryland, United States|Hackensack, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Concord, North Carolina, United States|Columbus, Ohio, United States|Houston, Texas, United States|Seattle, Washington, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Innsbruck, Austria|Salzburg, Austria|Wien, Austria|Bruxelles, Belgium|Gent, Belgium|Mont-godinne, Belgium|Goiania, GO, Brazil|Porto Alegre, RS, Brazil|Piracicaba, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Kingston, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Rijeka, Croatia|Zagreb, Croatia|København, Denmark|Vejle, Denmark|Århus, Denmark|Athens, Greece|Thessaloniki, Greece|Bologna, Italy|Brescia, Italy|Milano, Italy|Milano, Italy|Novara, Italy|Pisa, Italy|Reggio Calabria, Italy|Rozzano, Italy|Amsterdam, Netherlands|Groningen, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Warszawa, Poland|Warszawa, Poland|Palma de Mallorca, Islas Baleares, Spain|La Coruna, La Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Sevilla, Spain|Valencia, Spain|Zaragoza, Spain|Huddinge, Sweden|Malmo, Sweden|St. Gallen, Switzerland|Zürich, Switzerland|Istanbul, Turkey|Izmir, Turkey|London, United Kingdom","https://ClinicalTrials.gov/show/NCT00576758"
473,"NCT01297777","Imatinib in KIT-negative Systemic Mastocytosis","Completed","No Results Available","All","Phase 4","10","Other","Interventional","January 2011","August 2015","August 2015","February 17, 2011","null","August 29, 2016","Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle, Toledo, Spain","https://ClinicalTrials.gov/show/NCT01297777"
474,"NCT00668148","A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma","Completed","Has Results","All","Phase 2","113","Industry","Interventional","July 2008","October 2010","February 2012","April 29, 2008","July 17, 2018","July 17, 2018","ImClone Investigational Site, Aurora, Colorado, United States|ImClone Investigational Site, Orlando, Florida, United States|ImClone Investigational Site, Metairie, Louisiana, United States|ImClone Investigational Site, Metairie, Louisiana, United States|ImClone Investigational Site, Detroit, Michigan, United States|ImClone Investigational Site, Saint Louis, Missouri, United States|ImClone Investigational Site, Columbus, Ohio, United States|ImClone Investigational Site, Brussels, Belgium|ImClone Investigational Site, Leuven, Belgium|ImClone Investigational Site, Wilrijk, Belgium|ImClone Investigational Site, Bordeaux, France|ImClone Investigational Site, Lyon, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Toulouse, France|ImClone Investigational Site, Dresden, Germany|ImClone Investigational Site, Mannheim, Germany|ImClone Investigational Site, Leiden, Netherlands|ImClone Investigational Site, Warsaw, Poland|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00668148"
475,"NCT00842712","Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)","Completed","Has Results","All","Phase 2","232","Industry","Interventional","February 2009","July 2013","July 2013","February 12, 2009","September 30, 2014","January 13, 2017","Research Site, Antwerpen (Edegem), Belgium|Research Site, Brasschaat, Belgium|Research Site, Brussel, Belgium|Research Site, Gosselies, Belgium|Research Site, Leuven, Belgium|Research Site, Mons, Belgium|Research Site, Liberec, Czech Republic|Research Site, Usti nach Labem, Czech Republic|Research Site, Bobigny, France|Research Site, Bordeaux, France|Research Site, Lille, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Nantes - Saint Herblain, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Strasbourg, France|Research Site, Vandoeuvre, France|Research Site, Aachen, Germany|Research Site, Berlin, Germany|Research Site, Darmstadt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Goch, Germany|Research Site, Halle-Dölau, Germany|Research Site, Hamburg, Germany|Research Site, Luebeck, Germany|Research Site, Mannheim, Germany|Research Site, Munic, Germany|Research Site, Offenbach, Germany|Research Site, Oldenburg, Germany|Research Site, Wiesbaden, Germany|Research Site, Dublin, Ireland|Research Site, Avellino, Italy|Research Site, Bologna, Italy|Research Site, Meldola, Italy|Research Site, Rome, Italy|Research Site, Lublin, Poland|Research Site, Otwock, Poland|Research Site, Poznan, Poland|Research Site, Warsaw, Poland|Research Site, Wodzislaw Slaski, Poland|Research Site, Baracaldo Vizcaya, Spain|Research Site, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00842712"
476,"NCT00908232","Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD","Completed","Has Results","All","Phase 2","163","Industry","Interventional","May 2008","August 2011","August 2011","May 25, 2009","June 8, 2012","January 15, 2015","Bordeaux, France|Le Mans Cedex 2, France|Lille Cedex, France|Tours Cedex 9, France|Duisburg, Germany|Essen, Germany|Frankfurt An Der Oder, Germany|Leipzig, Germany|München, Germany|Mÿnchen, Germany|Oldenburg, Germany|Ulm, Germany|Athens, Greece|Patra, Greece|Budapest, Hungary|Debrecen, Hungary|Miskolc, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius Lt, Lithuania|Bialystok, Poland|Katowice, Poland|Kraków, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Belgrade, Serbia|Nis, Serbia|Novi Sad, Serbia|Sremska Kamenica, Serbia|Barcelona, Spain|Madrid, Spain|Toledo, Spain|Valencia, Spain|Ankara, Turkey|Istambul, Turkey|Istanbul, Turkey|Izmir, Turkey|Bath, United Kingdom|Edinburgh, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT00908232"
477,"NCT01335685","Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma","Completed","Has Results","All","Phase 1|Phase 2","61","Industry","Interventional","June 27, 2011","December 29, 2016","December 29, 2016","April 14, 2011","January 23, 2018","January 23, 2018","Lebanon, New Hampshire, United States|Morgantown, West Virginia, United States|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Quebec, Canada|Brno, Czechia|Praha 2, Czechia|Badalona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|San Sebastian, Spain|Sevilla, Spain|Bournemouth, United Kingdom|Brighton, United Kingdom|Cambridge, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom|Uxbridge, United Kingdom","https://ClinicalTrials.gov/show/NCT01335685"
478,"NCT00960440","Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors","Completed","Has Results","All","Phase 3","399","Industry","Interventional","October 2009","March 2011","March 2011","August 17, 2009","January 10, 2013","January 10, 2013","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Farmington, Connecticut, United States|Pfizer Investigational Site, Trumbull, Connecticut, United States|Pfizer Investigational Site, Aventura, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Boise, Idaho, United States|Pfizer Investigational Site, Idaho Falls, Idaho, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Portland, Maine, United States|Pfizer Investigational Site, Cumberland, Maryland, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Tupelo, Mississippi, United States|Pfizer Investigational Site, Lebanon, New Hampshire, United States|Pfizer Investigational Site, Voorhees, New Jersey, United States|Pfizer Investigational Site, Rocky Mount, North Carolina, United States|Pfizer Investigational Site, Bethlehem, Pennsylvania, United States|Pfizer Investigational Site, Willow Grove, Pennsylvania, United States|Pfizer Investigational Site, Wyomissing, Pennsylvania, United States|Pfizer Investigational Site, Hixson, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Lubbock, Texas, United States|Pfizer Investigational Site, Vancouver, Washington, United States|Pfizer Investigational Site, Vancouver, Washington, United States|Pfizer Investigational Site, Vancouver, Washington, United States|Pfizer Investigational Site, Kogarah, New South Wales, Australia|Pfizer Investigational Site, Daw Park, South Australia, Australia|Pfizer Investigational Site, Heidelberg, Victoria, Australia|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Kortrijk, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Goiania, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Orleans Cedex 1, France|Pfizer Investigational Site, Orleans, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Erlangen, Germany|Pfizer Investigational Site, Frankfurt am Main, Germany|Pfizer Investigational Site, Halle, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Koeln, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Rheine, Germany|Pfizer Investigational Site, Wuerzburg, Germany|Pfizer Investigational Site, Croom, Co. Limerick, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Firenze, Italy|Pfizer Investigational Site, Jesi, Italy|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, San Juan, Puerto Rico|Pfizer Investigational Site, Santiago de Compostela, A Coruña, Spain|Pfizer Investigational Site, Merida, Badajoz, Spain|Pfizer Investigational Site, Bilbao, Bizkaia, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, Baracaldo, Vizcaya, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Niao Sung Hsiang, Kaohsiung County, Taiwan|Pfizer Investigational Site, Kweishan, Taoyuan County, Taiwan|Pfizer Investigational Site, Changhua, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan","https://ClinicalTrials.gov/show/NCT00960440"
479,"NCT02039947","Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain","Completed","No Results Available","All","Phase 2","127","Industry","Interventional","February 21, 2014","May 12, 2017","February 14, 2018","January 20, 2014","null","October 5, 2018","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Greenslopes, Queensland, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Boulogne-Billancourt, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Pierre-Benite cedex, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Toulouse cedex, France|Novartis Investigative Site, Villejuif cedex, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Gera, Thueringen, Germany|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Padova, Veneto, Italy|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Las Palmas De Gran Canaria, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT02039947"
480,"NCT00883753","An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy","Completed","Has Results","All","Phase 3","934","Industry","Interventional","March 2009","April 2012","April 2012","April 20, 2009","August 6, 2014","August 6, 2014","Canberra, Australian Capital Territory, Australia|Coffs Harbour, New South Wales, Australia|Kogarah, New South Wales, Australia|Cairns, Queensland, Australia|Adelaide, South Australia, Australia|Fitzroy, Victoria, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Edmonton, Alberta, Canada|Lethbridge, Alberta, Canada|Kelowna, British Columbia, Canada|Nanaimo, British Columbia, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Quispamsis, New Brunswick, Canada|St John's, Newfoundland and Labrador, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Windsor, Ontario, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Rimouski, Quebec, Canada|Sherbrooke, Quebec, Canada|St-eustache, Quebec, Canada|Trois-rivieres, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Bruntal, Czech Republic|Ostrava, Czech Republic|Praha, Czech Republic|Sokolov, Czech Republic|Uherske Hradiste, Czech Republic|Zlin, Czech Republic|Belfort, France|Caen, France|Cahors, France|Corbeil-essonnes, France|Dijon, France|La Rochelle, France|Lievin, France|Lomme, France|Lyon, France|Lyon, France|Marseille, France|Montivilliers, France|Montpellier, France|Mulhouse, France|Paris, France|Poitiers, France|Reims, France|Roubaix, France|St Brieuc, France|Strasbourg, France|Toulouse, France|Valence, France|Valenciennes, France|Heraklion, Greece|Budapest, Hungary|Eger, Hungary|Szeged, Hungary|Veszprem, Hungary|Arenzano, Italy|Legnano, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Monserrato, Italy|Novara, Italy|Palermo, Italy|Potenza, Italy|Roma, Italy|Roma, Italy|Siena, Italy|Varese, Italy|'S Hertogenbosch, Netherlands|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Arnhem, Netherlands|Bergen Op Zoom, Netherlands|Den Haag, Netherlands|Den Haag, Netherlands|Den Helder, Netherlands|Enschede, Netherlands|Gouda, Netherlands|Heerlen, Netherlands|Hilversum, Netherlands|Leeuwarden, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Roosendaal, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Schiedam, Netherlands|Spijkenisse, Netherlands|Vlissingen, Netherlands|Krakow, Poland|Poznan, Poland|Wroclaw, Poland|Almada, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Bucharest, Romania|Bucharest, Romania|Cluj-napoca, Romania|Jeddah, Saudi Arabia|Jeddah, Saudi Arabia|Jeddah, Saudi Arabia|Elche, Alicante, Spain|Elda, Alicante, Spain|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|La Coruna, La Coruña, Spain|Las Palmas De Gran Canaria, Las Palmas, Spain|La Laguna, Tenerife, Spain|Alicante, Spain|Almeria, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Caceres, Spain|Cordoba, Spain|Granada, Spain|Huesca, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Salamanca, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Barnsley, United Kingdom|Basingstoke, United Kingdom|Bournemouth, United Kingdom|Brighton, United Kingdom|Burton on Trent, United Kingdom|Bury St Edmonds, United Kingdom|Cambridge, United Kingdom|Cardiff, United Kingdom|Chelmsford, United Kingdom|Dudley, United Kingdom|Eastbourne, United Kingdom|Gillingham, United Kingdom|Harrogate, United Kingdom|Ipswich, United Kingdom|Liverpool, United Kingdom|Llantrisant, United Kingdom|Londonderry, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Middlesborough, United Kingdom|Newcastle Upon Tyne, United Kingdom|Nottingham, United Kingdom|Reading, United Kingdom|Salford, United Kingdom|Sheffield, United Kingdom|Southport, United Kingdom|Swindon, United Kingdom|Torquay, United Kingdom|Westcliffe-on-sea, United Kingdom|Wirral, United Kingdom|Worthing, United Kingdom","https://ClinicalTrials.gov/show/NCT00883753"
481,"NCT01350804","Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","Completed","Has Results","All","Phase 3","551","Industry","Interventional","September 2011","February 2015","February 2015","May 10, 2011","May 23, 2016","May 23, 2016","Novartis Investigative Site, Anniston, Alabama, United States|Novartis Investigative Site, Vestavia, Alabama, United States|Novartis Investigative Site, Freemont, California, United States|Novartis Investigative Site, Pomona, California, United States|Novartis Investigative Site, Upland, California, United States|Novartis Investigative Site, Van Nuys, California, United States|Novartis Investigative Site, Bridgeport, Connecticut, United States|Novartis Investigative Site, Aventura, Florida, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Hialeah, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Palm Harbor, Florida, United States|Novartis Investigative Site, Pembroke Pines, Florida, United States|Novartis Investigative Site, Pensacola, Florida, United States|Novartis Investigative Site, Plantation, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Coeur d'Alene, Idaho, United States|Novartis Investigative Site, Morton Grove, Illinois, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Bowling Green, Kentucky, United States|Novartis Investigative Site, Lexington, Kentucky, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Lansing, Michigan, United States|Novartis Investigative Site, Eagan, Minnesota, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Richmond Heights, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Jackson, Tennessee, United States|Novartis Investigative Site, Kingsport, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Carrollton, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Clarksburg, West Virginia, United States|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Russe, Bulgaria|Novartis Investigative Site, Sevlievo, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, St. John's, Newfoundland and Labrador, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, Trois-Rivieres, Quebec, Canada|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Bruntal, Czech Republic|Novartis Investigative Site, Ostrava, Czech Republic|Novartis Investigative Site, Uherske Hradiste, Czech Republic|Novartis Investigative Site, Zlin, Czech Republic|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Cahors, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Cottbus, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Gommern, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Osnabrück, Germany|Novartis Investigative Site, Zerbst, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Gyula, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Valeggio Sul Mincio, (vr), Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Mexicali, Baja California, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Culiacan, Sinaloa, Mexico|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Korolev, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Tula, Russian Federation|Novartis Investigative Site, Banska Bystrica, Slovak Republic, Slovakia|Novartis Investigative Site, Piestany, Slovakia|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01350804"
482,"NCT02406144","Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma","Completed","No Results Available","All","Phase 3","316","Other|Industry","Interventional","November 2014","September 2017","November 2017","April 2, 2015","null","November 30, 2017","Complejo Hospitalario Universitario de Santiago, A Coruña, Spain|Hospital Txagorritxu, Alava, Spain|Hospital General de Albacete, Albacete, Spain|Hospital Del Vinalopo, Alicante, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital de Cabueñes, Asturias, Spain|Hospital Universitario Central de Asturias, Asturias, Spain|Hospital Clinic, Barcelona, Spain|H.Universitari Germans Trias I Pujol de Badalona, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital de Sabadell (Parc Taulí), Barcelona, Spain|Hospital de Sant Joan de Déu, Barcelona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitari Mútua de Terrasa, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Ico L'Hospitalet, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Marqués de Valdecilla, Cantabria, Spain|Hospital General de Castellón, Castello, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Hospital de Especialidades de Jerez de La Frontera, Cádiz, Spain|Hospital Universitari Dr. Josep Trueta de Girona, Girona, Spain|Hospital de Gran Canaria Doctor Negrín, GRAN Canaria, Spain|Hospital Universitario Virgen de Las Nieves, Granada, Spain|Hospital Universitario Guadalajara, Guadalajara, Spain|Hospital Universitario Donostia, Guipúzcoa, Spain|Hospital Son Llatzer, Illes Balears, Spain|Hospital Universitari Son Espases, Illes Balears, Spain|Hospital San Pedro, La Rioja, Spain|Hospital de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Centro Oncológico Md Anderson International España, Madrid, Spain|Fundación Jiménez Díaz-Ute, Madrid, Spain|Hm Universitario San Chinarro, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Del Tajo, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Infanta Sofía, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Fundación Alcorcón, Madrid, Spain|Hospital Universitario Infanta Cristina, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Complejo Hospital Costa Del Sol (Ivcs), Malaga, Spain|Hospital General Universitario Santa Lucia, Murcia, Spain|Hospital J.M. Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, Spain|Clinica Universidad de Navarra, Navarra, Spain|Complejo Hospitalario de Navarra, Navarra, Spain|Complejo Hospitalario de Ourense, Ourense, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Santa Bárbara, Soria, Spain|Hospital Universitari Joan Xxiii de Tarragona, Tarragona, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital Nuestra Señora Del Prado, Toledo, Spain|Hospital Clínico Universitario Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|HOSPITAL CLíNICO UNIVERSITARIO DE VALLADOLID, Valladolid, Spain|Hospital Universitario Del Rio Hortega, Valladolid, Spain|Hospital de Cruces, Vizcaya, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT02406144"
483,"NCT01916252","Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old","Completed","No Results Available","All","Phase 3","460","Other|Industry","Interventional","September 2013","November 16, 2016","November 16, 2016","August 5, 2013","null","September 27, 2017","Hospital Durán i Reynals - ICO L´Hospitalet, L'Hospitalet, Barcelona, Spain|H. Althaia, Xarxa Asistencial de Manresa, Manresa, Barcelona, Spain|Hospital Esp. de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Son Espases (Son Dureta), Mallorca, Illes Balears, Spain|Hospital Son Llátzer, Palma de Mallorca, Illes Balears, Spain|Hospital de Gran Canaria Dr. Negrín, Palmas de Gran Canaria, Islas Canarias, Spain|Hospital Nuestra Señora del Prado, Talavera de la Reina, Madrid, Spain|Complejo Universitario de Toledo, Toledo, Madrid, Spain|Hospital General de Albacete, Albacete, Spain|Hospital Univ. Fundación de Alcorcón, Alcorcón, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Torrevieja Salud UTE, Alicante, Spain|Hospital del Tajo, Aranjuez, Spain|Hospital German Trias i Pujol, Badalona, Spain|Hospital de Cruces, Barakaldo, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Univ. Santa Lucía, Cartagena, Spain|Hospital General de Castellón, Castellón, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Hospital San Pedro de Alcántara (Complejo Hospitalario de Cáceres), Cáceres, Spain|Hospital del Vinalopó, Elche, Spain|Hospital de Fuenlabrada, Fuenlabrada, Spain|Hospital de Cabueñes, Gijón, Spain|H. Univ. de Girona Dr. Josep Trueta (ICO), Girona, Spain|Complejo Hosp. Virgen de las Nieves, Granada, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Severo Ochoa, Leganés, Spain|Hospital de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Centro Oncológico MD Anderson, Madrid, Spain|Fundación Jiménez Díaz-UTE, Madrid, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital General Univ. Gregorio Marañón, Madrid, Spain|Hospital Infanta Cristina, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Infanta Sofía, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain|Complejo Hospitalario Costa del Sol, Marbella, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Complejo Hospitalario Ourense, Orense, Spain|Hospital Universitario Central Asturias, Oviedo, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra (Hospital Virgen del Camino), Pamplona, Spain|Complejo Hospitalario Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Hospital Univ. Marqués de, Santander, Spain|Complejo Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|Complejo Hosp. Regional Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Santa Bárbara, Soria, Spain|H. Universitari de Tarragona Joan XXIII, Tarragona, Spain|Hospital Universitari Mutua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Hospital Universitario Río Hortega, Valladolid, Spain|Hospital de Txagorritxu, Vitoria, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01916252"
484,"NCT01218516","A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung","Completed","No Results Available","All","Phase 2","130","Industry","Interventional","April 2011","December 2012","November 2013","October 11, 2010","null","June 20, 2016","Ironwood Cancer and Research Center, Chandler, Arizona, United States|Arizona Center for Hematology Oncology, Glendale, Arizona, United States|Providence Health System, Beverly Hills, California, United States|Cancer Care Associates of Fresno Medical Group, Inc., Fresno, California, United States|Medical Oncology Hematology, Gilroy, California, United States|California Cancer Care, Inc., Greenbrae, California, United States|Moores University of California San Diego Cancer Center, La Jolla, California, United States|Wilshire Medical Oncology Group, La Verne, California, United States|Glendale Adventist Medical Center, Los Angeles, California, United States|Clinical Trials and Research Associates, Inc., Montebello, California, United States|North Country Oncology-Hematology, Oceanside, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|Hematology Oncology Associates, P.C., Stamford, Connecticut, United States|Center for Hematology-Oncology, Boca Raton, Florida, United States|Medical Specialists of the Palm Beaches, Deerfield Beach, Florida, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Cancer Care of North Florida, Lake City, Florida, United States|Florida Cancer Institute-New Hope, New Port Richey, Florida, United States|Ocala Oncology Center, PL, Ocala, Florida, United States|MD Anderson Cancer Center-Orlando, Orlando, Florida, United States|University Hematology Oncology, Inc., Centralia, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Kentucky Cancer Center, Hazard, Kentucky, United States|Baptist Health System, Inc., Lexington, Kentucky, United States|Christus Saint Frances, Cabrini Hospital, Cabrini Cancer Center, Alexandria, Louisiana, United States|Hematology and Oncology Specialists, LLC, Metairie, Louisiana, United States|National Cancer Institute, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Berkshire Hematology Oncology, PC, Pittsfield, Massachusetts, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|Queens Hospital Center, Jamaica, New York, United States|Syracuse Veterns Affairs Medical Center, Syracuse, New York, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|St. Luke's Cancer Center Associates, Bethlehem, Pennsylvania, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology - Bedford, Bedford, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Houston Cancer Institute, Houston, Texas, United States|Texas Oncology - Plano East, Plano, Texas, United States|Northwest Cancer Center, Sugar Land, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Delta Hematology Oncology Associates, PC, Portsmouth, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Rockwood Cancer Treatment Center, Spokane, Washington, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Cancer Team Bellin Health, Green Bay, Wisconsin, United States|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Southern Medical Day Oncology Care Centre, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital, Dept. of Medical Oncology, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Cancer Centre, Adelaide, South Australia, Australia|Flinders Medical Centre, Dept. of Oncology, Bedford Park, South Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Frankston Hospital, Oncology Day Unit, Frankston, Victoria, Australia|Epworth Healthcare, Richmond, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Royal Victoria Hospital, Barrie, Ontario, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montréal, Quebec, Canada|Universitätsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Klinik Löwenstein gGmbH, Löwenstein, Baden-wuerttemberg, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Bayern, Germany|Krankenhaus Nordwest GmbH, Frankfurt am Main, Hessen, Germany|Johannes-Wesling-Klinikum Minden, Minden, Nordrhein-westfalen, Germany|Städtisches Krankenhaus Martha-Maria Halle Dölau gGmbH, Halle, Sachsen-anhalt, Germany|HELIOS Klinikum Emil von Behring, Berlin, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Ospedale Unico Versilia, Lido di Camaiore, Lucca, Italy|Azienda Ospedaliero-Univesitaria ""San Luigi Gonzaga"", Orbassano, Torino, Italy|Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy|A.O. Seconda Università degli Studi di Napoli, Napoli, Italy|Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Dzieciecy, Torun, Kujawsko-pomorskie, Poland|Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie, Warszawa, Mazowieckie, Poland|Specjalistyczny Szpital im. Alfreda Sokolowskiego, Szczecin, Zachodniopomorskie, Poland|Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan, Kazan, Tatarstan, Russian Federation|Cancer Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|City Oncology Hospital # 62, Moscow, Russian Federation|Hospital Regional Carlos Haya, Málaga, Malaga, Spain|Hospital General Vall d'Hebron, Barcelona, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Germans Trías i Pujol, Barcelona, Spain|Fundación Jiménez Díaz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01218516"
485,"NCT01632150","Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","Completed","Has Results","All","Phase 2","51","Industry","Interventional","May 2012","October 2013","March 2016","July 2, 2012","February 26, 2016","April 14, 2017","Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, LaLaguna, S Cruz Tener, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Sevilla, Spain|Local Institution, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01632150"
486,"NCT01974752","Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)","Completed","Has Results","All","Phase 3","152","Industry","Interventional","April 2014","May 2015","October 2016","November 4, 2013","September 28, 2016","January 5, 2017","Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Atlanta, Georgia, United States|Research Site, Lutherville, Maryland, United States|Research Site, St. Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Olomouc, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Hus, Finland|Research Site, Nice Cedex 2, France|Research Site, Paris Cedex 5, France|Research Site, Heidelberg, Germany|Research Site, München, Germany|Research Site, Jerusalem, Israel|Research Site, Ramat Gan, Israel|Research Site, Leiden, Netherlands|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Glasgow, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT01974752"
487,"NCT01376401","Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma","Completed","No Results Available","All","Phase 2","60","Other|Industry","Interventional","July 2011","June 2014","December 2015","June 20, 2011","null","May 17, 2016","Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Clínic, Barcelona, Spain|Institut català d'Oncología, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|MD Anderson Internacional, Madrid, Spain|Hospital General Morales Messeguer, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01376401"
488,"NCT01237249","Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone","Completed","No Results Available","All","Phase 2","250","Other|Industry","Interventional","February 2011","August 2014","May 2016","November 9, 2010","null","January 18, 2017","H. Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Fundación Hospital Alcorcón, Alcorcón, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|H. Vall d'Hebron, Barcelona, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|ICO - Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Cruces, Bilbao, Spain|Hospital General de Castellón, Castellón, Spain|Hospital General, Ciudad Real, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Donostia, Donostia, Spain|Hospital Francesc Borja, Gandía, Spain|ICO - Josep Trueta, Girona, Spain|Hospital General de Guadalajara, Guadalajara, Spain|H. de Jerez, Jerez de la Frontera, Spain|Complejo Hospitalario León, Leon, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre. Madrid, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital de Madrid, S.A.- Norte Hospital General, Madrid, Spain|Hospital del Tajo, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Infanta Sofia, Madrid, Spain|Hospital la Paz, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|MD Anderson, Madrid, Spain|Althaia, Manresa, Spain|Hospital General Univeristario Morales Messeguer, Murcia, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Complejo Hospital Costa del Sol, Málaga, Spain|Hospital Nuestra Señora de Valme, Málaga, Spain|Hospital de la Diputación de Navarra, Navarra, Spain|Hospital de Gran Canaria Doctor Negrín, Palma de Gran Canaria, Spain|Complejo Asistencial Son Dureta, Palma de Mallorca, Spain|Hospital Virgen del Camino, Pamplona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hoaspital Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Nuestra Señora del Prado, Toledo, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínico de Valencia., Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Clinico Lozano Blesa, Zaragoza, Spain|Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01237249"
489,"NCT01369329","A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)","Completed","Has Results","All","Phase 3","769","Industry","Interventional","July 2011","June 2013","July 2013","June 8, 2011","December 7, 2016","December 7, 2016","Tucson, Arizona, United States|Little Rock, Arkansas, United States|La Jolla, California, United States|Los Angeles, California, United States|Redwood City, California, United States|San Carlos, California, United States|San Diego, California, United States|Lone Tree, Colorado, United States|New Haven, Connecticut, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Weston, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Macon, Georgia, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Clive, Iowa, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Chevy Chase, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Chesterfield, Michigan, United States|Novi, Michigan, United States|Troy, Michigan, United States|Rochester, Minnesota, United States|Ocean Springs, Mississippi, United States|Lees Summit, Missouri, United States|Urbana, Missouri, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Marlton, New Jersey, United States|Morristown, New Jersey, United States|Great Neck, New York, United States|New York, New York, United States|Rochester, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Beavercreek, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Bend, Oregon, United States|Springfield, Oregon, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|North Charleston, South Carolina, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|Tyler, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Chesapeake, Virginia, United States|Norfolk, Virginia, United States|Virginia Beach, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Bedford Park, Australia|Box Hill, Australia|Central Queensland M C, Australia|Concord, Australia|Garran, Australia|Liverpool, Australia|Malvern, Australia|Parkville, Australia|Innsbruck, Austria|St Poelten, Austria|Wien, Austria|Brussel, Belgium|Leuven, Belgium|Liege, Belgium|Rio De Janeiro, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Brandon, Manitoba, Canada|Winnipeg, Manitoba, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Montreal, Quebec, Canada|Hradec Kralove, Czech Republic|Usti Nad Labem, Czech Republic|Herlev, Denmark|Silkeborg, Denmark|Amiens Cedex 1, France|Caen, France|Lille, France|Marseille, France|Nantes Cedex 1, France|Paris Cedex 18, France|Paris, France|Pessac, France|Reims, France|Rouen, France|Toulouse, France|Berlin, Germany|Erlangen, Germany|Essen, Germany|Frankfurt, Germany|Freiburg, Germany|Halle, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Jena, Germany|Kiel, Germany|Lÿneburg, Germany|Mannheim, Germany|Minden, Germany|München, Germany|Münster, Germany|Regensburg, Germany|Tübingen, Germany|Ulm, Germany|Szekszard, Hungary|Akureyri, Iceland|Reykjavik, Iceland|Dublin 9, Ireland|Dublin, Ireland|Jerusalem, Israel|Tel Hashomer, Israel|Chikushino, Japan|Fukuoka, Japan|Hamamatsu, Japan|Kagoshima, Japan|Nishinomiya, Japan|Ohtsu, Japan|Oita, Japan|Osaka, Japan|Sakura, Japan|Sapporo, Japan|Tokyo, Japan|Yokkaichi, Japan|Seoul, Korea, Republic of|Amsterdam, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Grafton, New Zealand|Hamilton, New Zealand|Krakow, Poland|Lodz, Poland|Belgrade, Serbia|Nis, Serbia|Cape Town, South Africa|Overport, South Africa|Madrid, Spain|Sagunto, Spain|Birmingham, United Kingdom|Brighton, United Kingdom|Bristol, United Kingdom|Cambridge, United Kingdom|Cardiff, United Kingdom|Exeter, United Kingdom|Gloucester, United Kingdom|Harrow, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom|Nottinghamshirecc, United Kingdom|Oxford, United Kingdom|Shropshire, United Kingdom|South Shields, United Kingdom|Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01369329"
490,"NCT01818752","Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","Completed","Has Results","All","Phase 3","955","Industry","Interventional","July 8, 2013","July 15, 2016","November 4, 2016","March 26, 2013","August 1, 2017","October 3, 2018","California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States|Marin Cancer Care, Greenbrae, California, United States|Sutter Gould Medical Foundation, Modesto, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|UF Health Shands Cancer Hospital, Gainesville, Florida, United States|Evanston KelIogg Cancer Center, Evanston, Illinois, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Maimonides Cancer Center, Brooklyn, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Saint Francis Health System, Greenville, South Carolina, United States|Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States|Santee Hematology Oncology, Sumter, South Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Centro de educacion medica c investigacioncs clinicas ""Norberto Quimo' (CEMIC), Buenos Aires, Argentina|Sanatorio Britanico S.A., Santa Fe, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Local Health District, North Gosford, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Eastern Health - Box Hill Hospital, Box Hill, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Royal North Shore Hospital, Haematology Department, New South Wales, Australia|Medical University of Innsbruck, University Clinic for Internal Medicine V, Innsbruck, Austria|Elisabeth Linz Hospital, Linz, Austria|Vienna Wilhelminen Hospital, Vienna, Austria|ZNA, Stuivenberg, Antwerp, Antwerpen, Belgium|Saint Joseph Clinic Arlon, Department of Hematology, Arlon, Luxembourg, Belgium|CHR de La Citadelle (ENG: Citadelle Regional Hospital Center), Liège, Belgium|CHU Mont-Godinne, Yvoir, Belgium|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Hematology Clinic, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Oncology and Hematology Clinic, Plovdiv, Bulgaria|Military Medical Academy - Multiprofile Hospital for Active Treatment, Sofia, Hematology and Oncology Clinic, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Hematology Clinic, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Varna, Bulgaria|CSSS-Champlain-Charles LeMoyne, Greenfield Park, Quebec, Canada|Fujian Medical University Union Hospital, Fuzhou City, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|The First Affiliated Hospital of the Fourth Military Medical University of PLA, Xi'an City, Shanxi, China|The First Affiliated Hospital of College of Medicine, Zhejiang University - Dr. Jie Jin, Hangzhou, Zhejiang, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|307 Hospital of PLA, Beijing, China|Beijing Chao Yang Hospital, Capital Medical University, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, China|Institute on Hematology & Blood Diseases Hospital Chinese Academy of Medical Scicnces & Peking Union Medical University, Tianjin, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|University Hospital Brno, Department of Internal Hematology and Oncology, Brno, Czechia|University Hospital Brno, Hospital Pharmacy - Department of Dilution of Cytostasis, Brno, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital Olomouc, 3rd Clinic of Internal Medicine, Nephrology, Rheumatology and Endocrinology, Olomouc, Czechia|University Hospital Ostrava, Clinic of Hematooncology of UHO and MFUO, Ostrava, Czechia|University Hospital Kralovske Vinohrady - Internal Hematology Clinic, Prague, Czechia|General University Hospital Prague, 1st Department of Medicine - Department of Hematology, Prague, Czechia|CHU de Caen, Côte de Nacre, Caen Cedex 9, France|CHU Estaing, Clermont-Ferrand, France|UHC Dijon, Children's Hospital, Dijon, France|CHRU Hopital Huriez, Departement of Hematology, Lille Cedex, France|CHRU Lille Hôpital Claude Huriez, Lille, France|Paoli Calmettes Institute, Department ofHematology 2, Marseille cedex, France|Nantes University Hospital Center, Nantes Cedex 1, France|Centre Hospitalier Regional Universitaire de Nimes, Groupe Hospitalo-Universitaire Caremeau, Nimes cedex 9, France|Hopital Saini Louis, Service d'immuno-Hematologie, Paris, France|Hopital Saint Antoine, Paris, France|Hospital Necker, Paris, France|South Lyon Hospital Center, Pierre Bénite, cedex, France|Centre Hospitalier Lyon Sud, Service d'hématologie Clinique, Pierre Bénite, Cedex, France|Hopital Pontchaillou, Rennes Cedex 9, France|Hospital Purpan, Toulouse Cedex 9, France|CHU de Tours Hopital Bretonneau, Tours Cedex 1, France|Freiburg University Medical Center, Freiburg, Baden-Wuerttemberg, Germany|Ulm University Hospital, Center for Internal Medicine, Clinic of Internal Medicine III, Ulm, Baden-Wuerttemberg, Germany|Ludwig Maximilians University Hospital - Medical Clinic III, Munich, Bavaria, Germany|University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany|Johannes Gutenberg-University Mainz, Medical Clinic and Policlinic III, Mainz, Rhineland-Palatinate, Germany|Saarland University Hospital, Homburg / Saar, Saarland, Germany|Group Practice for Hematology and Oncology, Dresden, Germany|Stiftungsklinikum Mittelrhein GmbH, Clinic of Internal Medicine, Koblenz, Germany|Evangelismos Hospital, Athens, Attica, Greece|University of Athens, Alexandra Hospital, Athens, Greece|St. Istvan and St. Laszlo Hospital of Budapest, Department of Haematology and Stem-cell Transplant, Budapest, Hungary|National Institute of Oncology, Department of Oncology, Internal Medicine ""A"" and Hematology, Budapest, Hungary|University of Debrecen, Medical and Health Science Center, Institute for Medicine, Chair of Hematology, Debrecen, Hungary|Bekes County Pandy Kalman Hospital 1st Department of Internal Medicine, Hematology, Gyula, Hungary|Kaposi Mor County Teaching Hospital, 2nd Department of Internal Medicine, Hematology, Kaposvar, Hungary|Bacs-Kiskun County Teaching Hospital, II. Department of Internal Medicine, Kecskemet, Hungary|Medical Center of the University of Pecs, 1st Clinic for Internal Medicine, Pecs, Hungary|Soroka University Medical Center, Beer-Sheva, Israel|Rambam Medical Center, Department of Hematology, Haifa, Israel|Ein Kerem Hospital, Department of Hematology, Jerusalem, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|UO Clinica Ematologica, IRCCS A.O.U. San Martino, Genova, GE, Italy|A.O.U. San Luigi Gonzaga, Orbassano, TO, Italy|Ospedali Riuniti di Ancona Umberto I, G.M. Lancisi, G. Salesi, Ancona, Italy|Maggiore della Carita Hospital of Novara, Novara, Italy|Local NHS of Piacenza Hospital Guglielmo da Saliceto Department Oncology-Hematology, Unit of Hema, Piacenza, Italy|Ospedale S. Eugenio, Roma, Italy|Policlinico Universitario ""Umberto I"", Rome, Italy|AO Città della Salute e della Scienza di Torino, Division of Hematology, Torino, Italy|Nagoya City University Hospital, Nagoya, Aichi, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Kyushu University Hospital, Fukuoka, Fukuoka-Ken, Japan|National Hospitalization Organization Kyushu Cancer Center, Minami-ku, Fukuoka, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Sapporo Medical University Hospital, Sapporo-shi, Hokkaidou, Japan|National Hospital Organization Okayama Medical Center, Okayama-city, Okayama, Japan|Osaka University Hospital, Suita, Osaka, Japan|Japanese Red Cross Medical Center, Tokyo, Shibuya-ku, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto, Tokyo, Japan|National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa-city, Tokyo, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Tokushima Prefectural Central Hospital, Tokushima, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo Leon, Mexico|Fundacion Centro Oncologieo de Integracion Regional - COIR, Mendoza, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico|Consultorio Privado del Dr. Guillermo Jose Ruiz y Arguelles, Puebla, Mexico|Vrije Universiteit Medisch Centrum (VUMC), Department of Hematology, Amsterdam, Netherlands|St. Antonius Ziekenhuis, Department of Hematology, Nieuwegein, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Isala Clinics in Zwolle, Department of Oncology, Zwolle, Netherlands|North Shore Hospital, Auckland, New Zealand|Auckland City Hospital, Auckland, New Zealand|Canterbury Health Laboratories, Christchurch, New Zealand|Wellington Hospital, Wellington, New Zealand|Independent Public Healthcare Facility of the Ministry of Internal Affairs & Warminsko-Mazurskie Oncology Centre in Olsztyn, Olsztyn, OIsztyn, Poland|Independent Public Healthcare Facility Municipal Hospital Group, Department of Hematology, Chorzow, Slaskie, Poland|Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Katowice, Poland|Independent Public Healthcare Facility University Hospital, Krakow, Poland|Nicolaus Copernicus Memorial Provincial Specialist Hospital, Lodz, Poland|Independent Public Teaching Hospital No.1 in Lublin, Dept. of Hematology-Oncology, Lublin, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Department of Hematology, Torun, Poland|Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland|""Prof. Dr. Ion Chiricuta"" Institut of Oncology, Hematology Department, Cluj-Napoca, Cluj County, Romania|Iasi Regional Institute for Oncology, Medical Hematology Department, Iasi, Iasi County, Romania|Brasov County Emergency Clinical Hospital, Hematology Department, Brasov, Romania|Fundeni Clinical Institute, Hematology Department, Bucharest, Romania|Coltea Clinical Hospital, Hematology Department, Bucharest, Romania|Bucharest Emergency University Hospital, Hematology Department, Bucharest, Romania|Targu-Mures County Emergency Clinical Hospital, Clinic of Hematology and Bone Marrow Transplantation, Targu-Mures, Romania|State Medical Institution: Republican Hospital n a.V.A. Baranov, Department of Hematology, Petrozavodsk, Republic Of Karelia, Russian Federation|Arkhangelsk Regional Clinical Hospital, Department of internal diseases #2, Arkhangelsk, Russian Federation|State Medical Institution: First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia, Izhevsk, Russian Federation|Institution of the Russian Academy of Medical Sciences Russian Oncological Research Center n.a. N.N.Blokhin under the Russian Academy of Medical Sciences, Moscow, Russian Federation|City Clinical Hospital N.A.S.P. Botkin, Department of Bone Marrow Transplantation and Intensive Chemotherapy for Patients with Myeloproliferative Disorders, Moscow, Russian Federation|State Higher Educational Institution St. Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation|The Federal State Budget Institute The Nikiforov Russian Center of Emergency and Radiation Medicine the Ministry of Russian, Saint Petersburg, Russian Federation|Federal State Institution: Russian Research Institute of Hematology and Blood Transfusion under the Federal Agency for High-Tech Medical Care, St. Petersburg, Russian Federation|City Clinical Hospital #31, Department of Bone Marrow Transplantation and Intensive Chemotherapy for Patients with Myeloproliferative Disorders, St. Petersburg, Russian Federation|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Singapore Oncology Consultants, Gleneagles Hospital, Singapore, Singapore|OncoCare Cancer Center, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Hospital Universitari Germans Trias i Pujol, Badalona, Barselona, Spain|University Hospital of Navarra, Pamplona, Navarra, Spain|Hospital Clinic i Provincial Barcelona, Barcelona, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Universitario, Salamanca, Salamanca, Spain|Hospital Virgen del Rocio University, Sevilla, Spain|Universitari i Politècnic la Fe de Valencia Consulta Externa de Hematología, Valencia, Spain|Hospital Quiron Zaragoza, Zaragoza, Spain|University Hospital Center Vaudois, Lausanne, Switzerland|County Hospital Saint Gallen, Saint Gallen, Switzerland|Changhua Christian Hospital, Changhua, Taiwan|Kuohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Linkou, Tapei, Taiwan|Ege University Medical Faculty, Izmir, Bornova, Turkey|Ankara University Medical Faculty, Cebeci Research and Application Hospital, Hematology Department, Ankara, Cebeci, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, Pendik, Turkey|Cherkasy Regional Oncology Center, Cherkasy, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Hematology Centre, Dnipropetrovsk, Ukraine|Kharkiv Regional Clinical Oncology Center, Department of Hematology, Kharkiv, Ukraine|Khmelnytskyi Regional Hospital, Hematology Department, Khmelnytskyi, Ukraine|Kyiv Center for Bone Marrow Transplantation, Kyiv, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine|Poltava M.V. Sklifosovskyi Regional Clinical-Hospital, Poltava, Ukraine|A. Novak Zakarpattia Regional Clinical Hospital, Uzhgorod, Ukraine|M.I. Pyrohov Vinnytsya Regional Clinical Hospital, Hematology Department, Vinnitsya, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Hematology Center, Zhytomyr, Ukraine|Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom|Maidstone Hospital, Kent Oncology Centre, Maidstone, Kent, United Kingdom|Northwick Park Hospital, Harrow, Middlesex, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|University College London, Cancer Centre, London, United Kingdom|Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom|Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, United Kingdom|The Royal Wolverhampton Hospitals NHS Trust, New Cross Hospital, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01818752"
491,"NCT01568866","Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients","Completed","Has Results","All","Phase 3","929","Industry","Interventional","June 20, 2012","November 10, 2014","February 5, 2018","April 2, 2012","December 11, 2015","October 5, 2018","Providence St. Joseph Medical Center, Burbank, California, United States|UCSD Moore Cancer Center, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Central Coast Medical Oncology Group, Santa Maria, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|MAB Oncology/Hematology, Melbourne, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Hematology Oncology of Indiana, PC, Indianapolis, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Associates in Oncology/Hematology PC, Rockville, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Kansas, Kansas City, Missouri, United States|Hackensack University Medical Ctr, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Clinical Research Alliance Inc., New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Wake Forest University Health Sciences, Section on Hematology and Oncology, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Hematology/Oncology Associates of SC, Greenville, South Carolina, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|The Methodist Cancer Center, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St. Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia|Saint George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Haematology & Oncology Clinics of Australia, South Brisbane, Queensland, Australia|Haematology and Oncology Clinics of Australia at Chermside, South Brisbane, Queensland, Australia|Haematology and Oncology Clinics of Australia at Wesley, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Saint Vincent's Hospital, East Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sunshine Hospital, St. Albans, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universität Innsbruck, Innsbruck, Tyrol, Austria|Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Upper Austria, Austria|Wilhelminenspital der Stadt Wien, Wien, Vienna, Austria|Universitair Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Namur, Belgium|Universitair Ziekenhuis Gent, Ghent, Oost-vlaanderen, Belgium|Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium|Cliniques Universitaires Saint Luc, Brussels, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Liga Norte Riograndense Contra o Câncer, Natal, RIO Grande DO Norte, Brazil|Clínica de Oncologia de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, RIO Grande DO SUL, Brazil|Hemocentro Campinas-Unicamp, Campinas, SAO Paulo, Brazil|Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil|Instituto Centros Oncológicos Integrados de Educação e Pesquisa, Rio de Janeiro, Brazil|Instituto Nacional do Câncer-INCA, Rio de Janeiro, Brazil|Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil|Military Medical Academy Hospital for Active Treatment, Sofia, Sofiya, Bulgaria|Shato, Ead, Sofia, Sofiya, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"" EAD, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment, ""Sveta Marina'', Varna, Bulgaria|University of Alberta Hospital, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Kelowna, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Fakultní nemocnice Královské Vinohrady, Praha 10, Praha, Czechia|Fakultní nemocnice Olomouc, Olomouc, Severomoravsky KRAJ, Czechia|FN Ostrava, Ostrava, Severomoravsky KRAJ, Czechia|Fakultní nemocnice Hradec Králové, Hradec Kralové, Vychodocesky KRAJ, Czechia|Fakultní nemocnice Brno, Brno, Czechia|Všeobecná fakultní nemocnice v Praze, Praha, Czechia|Centre Hospitalier de la Cote Basque, Bayonne, Aquitaine, France|Centre Hospitalier Universitaire Brest, Brest Cedex, Bretagne, France|Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes Cedex 9, Bretagne, France|Hopital Hotel-Dieu - Service d'Hematologie, Nantes, Cedex 1, France|Centre Henri-Becquerel, Rouen Cedex 1, Haute-normandie, France|Centre Hospitalier de Versailles, Le Chesnay, Ile-de-france, France|Hôpital Saint Louis, Paris, Ile-de-france, France|Hôpital Saint-Antoine, Paris, Ile-de-france, France|Hôpital Claude Huriez, Lille Cedex, NORD Pas-de-calais, France|Hôpital Hôtel-Dieu, Nantes cedex 1, PAYS DE LA Loire, France|Institut Paoli Calmettes, Marseille Cedex 9, Provence Alpes COTE D'azur, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, Rhone-alpes, France|Universitätsklinik Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-wuerttemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-wuerttemberg, Germany|Medizinische Klinik der Universität Würzburg, Würzburg, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum Aachen, Aachen, Nordrhein-westfalen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Rheinland-pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg / Saar, Saarland, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany|Universitätsklinikum Carl Gustav Carus, Med. Klinik und Poliklinik I, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thuringen, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Alexandra General Hospital, Athens, Attica, Greece|Bács-Kiskun Megyei Kórház Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, Kecskemét, Bacs-kiskun, Hungary|Pécsi Tudományegyetem, Pécs, Baranya, Hungary|Szegedi Tudományegyetem, Szeged, Csongrad, Hungary|Debreceni Egyetem Klinikai Központ, Debrecen, Hajdu-bihar, Hungary|Egyesített Szent István és Szent László Kórház-Rendelointézet, Budapest, Hungary|Somogy Megyei Kaposi Mac okato Korhoz, Kaposvár, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Rambam Health Corp., Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel|IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture, Rionero in Vulture, Potenza, Italy|Azienda Ospedaliero-Univesitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|Azienda Ospedaliera Pisana Ospedale Santa Chiara, Pisa, Italy|Aienda Policknico Umberto I di Roma, Roma, Italy|Azienda Policknico Umberto l di Roma, Roma, Italy|Università Tor Vergata Ospedale Sant Eugenio, Roma, Italy|Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte, Siena, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Nagoya City University Hospital, Nagoya City, Aichi, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-city, Fukuoka, Japan|Ogaki Municipal Hospital, Ogaki City, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|National Hospital Organization Nishigunma National Hospital, Shibukawa, Gunma, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata-city, Niigata, Japan|Osaka University Hospital, Suita, Osaka, Japan|Saitama Medical Center, Kawagoe, Saitama, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital Of Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan|Toranornon Hospital, Shinagawa, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Social Insurance Kyoto Hospital of All Japan Federation of Social Insurance Associations, Kyoto, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Tokushima Prefectural Central Hospital, Tokushima, Japan|Japanese Red Cross Medical Center, Tokyo, Japan|Gachon University Gil Medical Center, Incheon, Gyeonggi-Do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Pusan National University Hospital, Busan, Gyeongsangnam-Do, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|North Shore Hospital, North Shore City, Auckland, New Zealand|Middlemore Hospital, Otahuhu, Auckland, New Zealand|Auckland City Hospital, Grafton, Aukland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Specjalistyczny Szpital Miejski im. Mikolaja Kopernika, Torun, Kujawsko-Pomorskie, Poland|Zamojski Szpital Niepubliczny Sp. z o.o., Zamosc, Lubelskie, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Malopolskie, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespól Szpitali Miejskich, Chorzów, Slaskie, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu, Poznan, Wielkopolskie, Poland|Spitalul Universitar de Urgenta Bucuresti, Bucharest, Bucuresti, Romania|Policlinica de Diagnostic Rapid SA, Compartiment Medical Oncologie-Hematologie, Brasov, Romania|Spitalul Clinic Judetean de Urgenta Brasov (Bumbea, Horia), Brasov, Romania|Institutul Clinic Fundeni, Bucuresti, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Republican Clinical Hospital #1, Izhevsk, Russian Federation|City Clinical Hospital n.a. S. P. Botkin, Moscow, Russian Federation|Non-state Healthcare Institution ""N.A. Semashko Central Clinical Hospital #2 of JSC ""Russian Railway, Moscow, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Clinical Hospital Number 31, Saint Petersburg, Russian Federation|Federal Almazov Medical Research Centre, Saint Petersburg, Russian Federation|FGU Russian Scientific Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation|First Saint Petersburg I.P. Pavlov State Medical University, Saint Petersburg, Russian Federation|GUZ Samara Regional Clinical Hospital n.a. M.I. Kalinin, Samara, Russian Federation|National University Cancer Institute, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Singapore Oncology Consultants, Singapore, Singapore|Univerzitná nemocnica Bratislava, Bratislava, Slovakia|Hospital Son Llàtzer, Palma de Mallorca, Baleares, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Institut Universitari Dexeus, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fé de Valencia, Valencia, Spain|Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-LinKou Branch, Tao-Yuan, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Bangkok Metropolis, Thailand|Ramathibodi Hospital, Bangkok, Bangkok Metropolis, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|City Hematology Center, Dnepropetrovsk, Dnipropretrovsk, Ukraine|Municipal Institution of Health Protection ""Clinical Hospital #8"", Kharkov, Kharkiv, Ukraine|Cherkassy Regional Oncology Center, Cherkassy, Ukraine|MI ""Dnipropetrovsk City Multifield Clinical Hospital #4"" of Dnipropetrovsk Regional Council"", City Hematology Center, Dnipropetrovsk, Ukraine|Institute of Urgent and Reparative Surgury of Ukraine Academy of Medical Sciences, Donetsk, Ukraine|Khmelnytsky Regional Clinical Hospital, Khmelnytsky, Ukraine|Khmelnytsky Regional Hospital, Department of Hematology, Khmelnytsky, Ukraine|National Institute of Cancer, Oncohematology Department, Kiev, Ukraine|Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine|Lviv Regional Oncology Dispensary, Lviv, Ukraine|Lviv State Oncology Regional Treatment-Prophylactic Center, Department of Chemotherapy, Lviv, Ukraine|Regional Clinical Hospital, Mykolayiv, Ukraine|Royal Free Hospital, London, England, United Kingdom|University College Hospital, London, England, United Kingdom|Manchester Royal Infirmary, Manchester, England, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|Churchill Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Royal Marsden Hospital, Surrey, England, United Kingdom|Royal Wolverhampton Hospitals Trust, Wolverhampton, England, United Kingdom","https://ClinicalTrials.gov/show/NCT01568866"
492,"NCT01478048","Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","Completed","Has Results","All","Phase 2","185","Industry","Interventional","November 30, 2011","May 30, 2014","April 21, 2017","November 23, 2011","January 26, 2016","May 21, 2018","Compassionate Cancer Res Grp, Corona, California, United States|Local Institution, Corona, California, United States|Local Institution, Long Beach, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Ucla Department Of Medicine, Los Angeles, California, United States|Medical Oncology Care Associates, Orange, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Local Institution, Vallejo, California, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Kaiser Permanente-Moanalua Medical Center, Honolulu, Hawaii, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Local Institution, Decatur, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Local Institution, Urbana, Illinois, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Local Institution, Hazard, Kentucky, United States|University Of Kentucky Markey Cancer Center, Lexington, Kentucky, United States|Pikeville Medical Center Leonard Lawson Cancer Center, Pikeville, Kentucky, United States|Cancer Center Of Acadiana, Lafayette, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|St. Agnes Hospital, Baltimore, Pennsylvania, United States|Cancer Care Associates, Bethlehem, Pennsylvania, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Penn State Hershey Cancer Inst, Hershey, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Local Institution, Greenville, South Carolina, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Local Institution, Fairfax, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Grenoble Cedex 9, France|Local Institution, Le Mans, France|Local Institution, Lille Cedex, France|Local Institution, Nantes, France|Local Institution, Paris 12, France|Local Institution, Toulouse, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Milano, Parma, Italy|Local Institution, Roma, Parma, Italy|Local Institution, Ancona, Italy|Local Institution, Bari, Italy|Local Institution, Bologna, Italy|Local Institution, Brescia, Italy|Local Institution, Firenze, Italy|Local Institution, Genova, Italy|Local Institution, Lecce, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Modena, Italy|Local Institution, Pescara, Italy|Local Institution, Ravenna, Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Rome, Italy|Local Institution, Torino, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Murcia, Spain|Local Institution, Salamanca, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Toledo, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01478048"
493,"NCT02092922","A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)","Completed","No Results Available","All","Phase 2","154","Industry","Interventional","May 2014","July 2016","September 5, 2017","March 20, 2014","null","October 6, 2017","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|University of California, San Francisco Medical Center, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Yale Comprehensive Cancer Center, New Haven, Connecticut, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Nebraska Hematology Oncology, P.C., Lincoln, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Mount Sinai Medical Center, New York, New York, United States|NY Presbyterian - Weill Cornell Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Institut Jules Bordet, Bruxelles, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|QEII Health Sciences Center, Halifax, Nova Scotia, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Centre Hospitalier Lyon-Sud, Bierre-Benite Cedex, France|Hopital Claude Huriez, Lille Cedex, France|Institut Paoli Calmettes, Marseille Cedex 9, France|CHU Hotel Dieu, Nantes Cedex, France|G.H.U Caremeau, Nimes Cedex 9, France|Institut Universitaire de Cancer, Toulouse, France|CHU tours-Hopital Bretonneau, Tours Cedex, France|CHU de Nancy - Hopital de Brabois, Vandoeuvre les Nancy, France|TU Dresden Medizinische Fakultat, Medizinische Klinik und Poliklinik I, Dresden, Germany|Asklepios Kliniken Hamburg GmbH, Hamburg, Germany|University Hospital Heidelberg, Heidelberg, Germany|University Hospital Leipzig, Leipzig, Germany|University of Tubingen, Tubingen, Germany|Julius Maximilians Universitat Wurzburg, Wurzburg, Germany|General Hospital of Athens ""Evangelismos"", Athens, Greece|University of Athens School of Medicine, Athens, Greece|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Quiron de Zaragoza, Zaragoza, Spain|Barts Health NHS Trust, London, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Southhampton General Hospital, Southhampton, United Kingdom|The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT02092922"
494,"NCT01324947","Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma","Completed","Has Results","All","Phase 3","74","Industry","Interventional","March 2011","July 2014","July 2014","March 29, 2011","July 30, 2015","December 12, 2016","Royal Adelaide Hospital - SA Pathology Haematology, Adelaide, Australia|Princess Alexandra Hospital - Haematology, Brisbane, Australia|Royal Prince Alfred Hospital - Institute of Haematology, Camperdown, Australia|Peter McCallum Cancer Institute - Directorate of Cancer Medicine, East Melbourne, Australia|Frankston Hospital-Peninsula Health - Oncology Day Unit, Frankston, Australia|The Alfred Hospital - Malignant Haematology & Stem Cell Transplantation, Melbourne, Australia|Calvary Mater Newcastle - Haematology, Waratah, Australia|Border Medical Oncology, Wodonga, Australia|Wollongong Hospital - Haematology, Wollongong, Australia|UZ Gent - Hematology, Gent, Belgium|University Hospital Leuven - Hematology, Leuven, Belgium|Cliniques Universitaires ULC de Mont-Godinne - Hematology, Yvoir, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Charles University Hospital - Internal Medicine, Prague, Czech Republic|Aalborg Sygemus - Haematology, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital - Hematology, Vejle, Denmark|CHU Angers - Service des maladies du sang, Angers, France|Centre Hospitalier de la côte basque - Hematologie, Bayonne, France|Centre Hospitalier Départemental Vendée - Onco-hematologie, La Roche, France|CHRU de Lille - Service des maladies du sang, Lille, France|Institut Paoli Calmette - Hematology 1, Marseille, France|CHU Hôtel-Dieu - Hematologie, Nantes, France|Hôpital Saint Louis - Immuno-hematologie, Paris, France|CHU Saint Antoine - Service des maladies du sang, Paris, France|CHRU - Hôpital du Haut Lévêque - Centre François Magendie Service des maladies du sang, Pessac, France|Centre Hospitalier Lyon sud - Hematologie, Pierre-Benite, France|CHRU Hôpital Purpan - Hematologie, Toulouse, France|Hôpital Bretonneau - Hématologie & Thérapie cellulaire, Tours, France|CHU Nancy - Hematologie, Vandoeuvre-les-Nancy, France|Universitatsklinikum Carl Gustav Carus-Medizinische Klinik und Poliklinik I, Dresden, Germany|Universitätsklinikum Essen, Klinik für Hämatologie Westdeutsches Tumorzentrum, Essen, Germany|Askepios Klinik Altona-Abteilung Hamatologie und Internistische Onkologie, Hamburg, Germany|Universitätsklinikum Heidelberg - Medizinische Klinik und Poliklinik V, Heidelberg, Germany|Universitätsklinikum Jena - Klinik fur Innere Medizin II-Hamatologie/Onkologie, Jena, Germany|Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik II, Leipzig, Germany|Universitätsklinikum Münster - Medizinische Klinik und Poliklinik A, Münster, Germany|Universitätsklinikum Tübingen - Medizinische Klinik und Poliklinik - Abteilung II, Tübingen, Germany|Universitätsklinikum Ulm - Klinik fur Innere Medizin III, Ulm, Germany|Universitätsklinikum Würzburg - Medizinische Klinik und Poliklinik II, Würzburg, Germany|University of Athens - Alexandra Hospital, Athens, Greece|Università degli Studi di Bologna - Policlinico S. Orsola - Hematology, Bologna, Italy|AO Universitaria San Martino - hematooncology, Genova, Italy|Fondazione ""G. Pascale"" - Hematology, Napoli, Italy|Ospedale San Luigi AO Luigi Gonzaga - Hematology, Orbassano, Italy|Universita degli Studi di Padova - Clinical & Experimental Medicine, Padova, Italy|Ospedale Guglielmo da Saliceto - hematooncology, Piacenza, Italy|Unità di Ematologia Arcispedale S. Maria Nuova - Haematology, Reggio Emilia, Italy|Policlinico Umberto I, Università ""La Sapienza"" di Roma - Hematology, Roma, Italy|A.O.U. San Giovanni Battista - Hematology, Torino, Italy|VUMC - Hematology, Amsterdam, Netherlands|Erasmus Medical Center - Hematology, Rotterdam, Netherlands|University Medical Center - Hematology, Utrecht, Netherlands|Hematological Research Center under the Russian Academy of Medical Sciences - Hematology & BMT, Moscow, Russian Federation|Moscow State Medical Institution Municipal Clinical Hospital n.a. S.P. Botkin - Hematology, Moscow, Russian Federation|Russian Research Institute of Hematology and Blood Transfusion - Hematology, St. Petersburg, Russian Federation|State Higher Educational Institution St. Petersburg State Medical University - Onco-hematology, St. Petersburg, Russian Federation|Hospital Germans Trias i Pujol - Hematology, Badalona, Spain|Hospital Clinic i Provincial de Barcelona - Hematology, Barcelona, Spain|Hospital de Donostia - Hematology, Guipúzcoa, Spain|Hospital de La Princesa - Hematology, Madrid, Spain|Hospital 12 de Octubre - Hematology, Madrid, Spain|Hospital de Salamanca - Hematology, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla - Hematology, Santander, Spain|Hospital La Fe - Hematology, Valencia, Spain|Sahlgrenska Hospital, University of Goteborg - Hematology, Goteborg, Sweden|Karolinska University Hospital Huddinge - Center of hematology, Stockholm, Sweden|Karolinska University Hospital-medicine, Stockholm, Sweden|Karolinska University Hospital Solna- medicine, Stockholm, Sweden|Overlakare Medocomcentrum - Hematology, Uppsala, Sweden|Inselspital, Institut für Medizinische Onkologie, Bern, Switzerland|Hôpitaux Universitaire de Genève - Oncologie, Genève, Switzerland|Klinik und Poliklinik für Onkologie - UniversitätsSpital Zürich, Zürich, Switzerland|Royal Bournemouth Hospital - Haematology, Bournemouth, United Kingdom|St James's University Hospital - Haematology, Leeds, United Kingdom|St Bartholomew's Hospital - Medical Oncology, London, United Kingdom|King's College Hospital - Haematology Clinical Trials, London, United Kingdom|Freeman Hospital - Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital - Centre for Clinical Haematology, Nottingham, United Kingdom|Derriford Hospital - Haematology, Plymouth, United Kingdom|Royal hallamshire Hospital - Haematology, Sheffield, United Kingdom|Royal Marsden NHS Foundation Trust - Haematology, Surrey, United Kingdom|Royal Wolverhampton Hospitals Trust - Research and Development, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01324947"
495,"NCT01311687","A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study","Completed","Has Results","All","Phase 3","455","Industry","Interventional","March 11, 2011","March 1, 2013","August 29, 2017","March 9, 2011","April 30, 2014","October 24, 2018","Mayo Clinic, Rochester, Minnesota, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Princess Alexandra Hospital, Brisbane, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Alfred hospital, Melbourne, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Calvary Mater Hospital, Waratah, Australia|Border Medical Oncology, Wodonga, Australia|Wollongong Hospital, Wollongong, Australia|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHU UCL Mont-Godinne-Dinant asbl, Yvoir, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|James Cancer Hospital, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Maisonneuve Rosemont, Montreal, Quebec, Canada|Royal Victoria Hospital McGill Department of Oncology(RVH), Montreal, Quebec, Canada|Sir Mortimer B. Davis - Jewish Genl, Montreal, Quebec, Canada|Charles University General Hospital, Praha 2, Czechia|Hæmatologisk afd. B Aalborg Sygehus Syd, Aalborg, Denmark|Aarhus University Hospital, Arhus C, Denmark|Odense Universitetshospital, Odense C, Denmark|Vejle Hospital, Vejle, Denmark|CHU d'Angers, Angers Cedex 01, France|Centre Hospitalier de la cote basque, Bayonne, France|Centre Hospitalier Departemental, La Roche sur Yon, France|CHRU de Lille FR, Lille, France|Institut Paoli-Calmettes, Marseille Cedex 9, France|CHRU Nantes, Nantes Cedex 1, France|Hopital Saint-Louis, Paris, Cedex 10, France|CHU Hôpital St-Antoine, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Hopital Bretonneau, Tours, France|Hopital Purpan, Tulouse Cedex 9, France|CHU Nancy, Vandoeuvre, France|Universitatsklinikum Carl Gustav Carus, Dresden, Germany|Universitatsklinikum Essen, Essen, Germany|Askepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitatsklinikum Jena, Jena, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|University of Tubingen, Tübingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Universitatsklinikum Wurzburg, Wuerzburg, Germany|Alexandra General Hospital of Athens, Athens, Greece|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Clinica Ematologica- A.O.U. San Martino, Genova, Italy|Oncoematologia, Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy|AOU San Luigi Gonzaga, Orbassano, Italy|Universita degli Studi di Padova, Padova, Italy|Hospital Clinic, Placenza, Italy|Servizio di Ematologia, A.O. - Arcispedale S.Maria Nuova, Reggio Emilia, Italy|Univerita La Sapienza Dipartimento di Biotecnologie Cellulari ed Ematologia, Rome, Italy|Azienda Ospedaliera San Giovanni Battista, Torino, Italy|VU University Medical Center, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|State Institution Hematological Research, Centre of Russian Academy of Medical Science, Moscow, Russian Federation|State Institution Moscow Regional Research Clinical Institute, Moscow, Russian Federation|State Educational Institution, Saint Petersburg State Medical University, Saint Petersburg, Russian Federation|St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital Clinic Provincial de Barcelona, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Donostia, San Sebastián (Guipuzcoa), Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital de la Fe, Valencia, Spain|Department of Hematology Hematology Centre, Göteborg, Sweden|University Hospital in Lund, Lund, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Overlakare Medocomcentrum, hematologi, Uppsala, Sweden|Medizinische Universitatsklinik, Berne, Switzerland|Hopitaux Universitaires de Geneve-HUG, Geneva, Switzerland|UniversitatSspital Zurich, Zürich, Switzerland|Royal Bournemouth Hospital, Bournemouth, United Kingdom|St James's University Hospital, Leeds, United Kingdom|St.Bartholomew's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Hallamshire HospitalSheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom|The Royal Marsden Hospital, Sutton-Surrey, United Kingdom|The Royal Wolverhampton Hospital NHS Trust, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01311687"
496,"NCT01302392","A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma","Completed","Has Results","All","Phase 3","315","Industry","Interventional","September 2010","July 2014","September 2015","February 24, 2011","August 4, 2015","May 2, 2017","Nedlands, Australia|Perth, Australia|Linz, Austria|Salzburg, Austria|Vienna, Austria|Arlon, Belgium|Brugge, Belgium|Brussels, Belgium|Roeselare, Belgium|Brno, Czechia|Hradec Kralov, Czechia|Olomouc, Czechia|Prague, Czechia|Lyon, France|Nantes, France|Nimes, France|Dresden, Germany|Giessen, Germany|Koblenz, Germany|Mainz, Germany|Muenchen, Germany|Ulm, Germany|Athens, Greece|Rio Patras, Greece|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Gyula, Hungary|Kaposvar, Hungary|Pecs, Hungary|Szeged, Hungary|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariva, Israel|Petah-Tikva, Israel|Sheba, Israel|Ancona, Italy|Novara, Italy|Roma, Italy|Torino, Italy|Incheon, Korea, Republic of|Seoul, Korea, Republic of|North Shore City, New Zealand|Gdansk, Poland|Lodz, Poland|Pila, Poland|Torum, Poland|Warsaw, Poland|Wroclaw, Poland|Zamosc, Poland|Moscow, Russian Federation|St. Petersburg, Russian Federation|Beograd, Serbia|Nis, Serbia|Bratislava, Slovakia|Barcelona, Spain|Guipuzcoa, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Valencia, Spain|Zaragoza, Spain|Uppsala, Sweden|Hampshire, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01302392"
497,"NCT01023308","Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma","Completed","Has Results","All","Phase 3","768","Industry","Interventional","December 2009","March 2013","July 2015","December 2, 2009","October 23, 2015","December 29, 2016","Arizona Oncology Associates Tucson (Carondelet & Wilmot), Phoenix, Arizona, United States|Rau, Subramanyam, Anaheim, California, United States|Bay Area Cancer Research, Concord, California, United States|Southern California Permanente Medical Group SC, Los Angeles, California, United States|Kaiser Permanente - California Southern Kaiser Permanente SCPMG, San Diego, California, United States|Kaiser Permanente Onc Dept, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|Stanford University Medical Center School of Medicine, Stanford, California, United States|Boca Raton Community Hospital SC, Boca Raton, Florida, United States|Medical Specialist of Palm Beaches, Lake Worth, Florida, United States|Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch, Miami Shores, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States|NorthWest Georgia Oncology Centers NW Georgia Oncology Centers PC, Marietta, Georgia, United States|Loyola University Medical Center, Marywood, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center, New Orleans, Louisiana, United States|St. Agnes Hospital Healthcare Cancer Center, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Newland Medical Associates, PC Newland Medical - Southfield, Southfield, Michigan, United States|Hubert H. Humphrey Cancer Center - Coon Rapids, Edina, Minnesota, United States|Minnesota Oncology Hematology, P.A. Minnesota Oncology-Hematology, Minneapolis, Minnesota, United States|Missouri Cancer Associates Dept.ofMissouriCancerAssoc., Columbia, Missouri, United States|East Orange VA Medical Center SC, East Orange, New Jersey, United States|Mount Kisco Medical Group, Mt. Kisco, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Legacy Pharma Research, Bismarck, North Dakota, United States|Dayton CCOP, Dayton, Ohio, United States|Signal Point Hematology Oncology, Inc., Middletown, Ohio, United States|Western Pennsylvania Cancer Institute /Western Penn Hospital Western Pann. Cancer Inst., Pittsburgh, Pennsylvania, United States|Pharma Resource, East Providence, Rhode Island, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt Univeristy SC, Nashville, Tennessee, United States|Cancer Center of the High Plains, Amarillo, Texas, United States|MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston, Texas, United States|Kadlec Clinic Hematology and Oncology SC, Kennewick, Washington, United States|Swedish Cancer Institute SC, Seattle, Washington, United States|St. Mary Medical Center, Walla Walla, Washington, United States|West Virginia University/ Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Brasilia, DF, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Nanning, Guangxi, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Olomouc, CZE, Czech Republic|Novartis Investigative Site, Brno - Bohunice, Czech Republic|Novartis Investigative Site, Prague 2, Czech Republic|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Odense, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Ålborg, Denmark|Novartis Investigative Site, Århus, Denmark|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Giza, Egypt|Novartis Investigative Site, HUS Helsinki, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Blois Cedex, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, LILLE Cedex, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Strasbourg cedex, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duisburg, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, New Territories, Hong Kong|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar-Sava, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Pagani, SA, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Ogaki-city, Gifu, Japan|Novartis Investigative Site, Shibukawa, Gunma, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Kure, Hiroshima, Japan|Novartis Investigative Site, Higashiibaraki-gun, Ibaraki, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Shibuya, Tokyo, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, San Luis Potosí, Mexico|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Fredrikstad, Norway|Novartis Investigative Site, Kristiansand, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Skien, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Salamanca, Castilla y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, La Laguna, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Luleå, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Fatih / Istanbul, Turkey|Novartis Investigative Site, Aberdeen, Scotland, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01023308"
498,"NCT03000452","A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","Completed","Has Results","All","Phase 2","18","Industry","Interventional","March 14, 2017","September 18, 2017","December 4, 2017","December 22, 2016","October 16, 2018","October 16, 2018","City of Hope Cancer Center, Duarte, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Kansas Hospital, Westwood, Kansas, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hosp, Morristown, New Jersey, United States|OHSU, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States|Universitaetsklinik Innsbruck, Innsbruck, Austria|Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria|Medizinische Universitat Wien, Vienna, Austria|Alexandra General Hospital of Athens, Athens, Greece|UMCU Utrecht, Utrecht, Netherlands|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Dr. Pesset, Valencia, Spain|Falu lasarett, Falun SE, Sweden|Helsingborg hospital, Helsingborg, Sweden|Lund University Hosptial, Lund, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT03000452"
499,"NCT01080391","Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma","Completed","Has Results","All","Phase 3","792","Industry","Interventional","July 14, 2010","June 16, 2014","December 5, 2017","March 4, 2010","July 8, 2015","October 3, 2018","Mayo Clinic, Scottsdale, Arizona, United States|Providence St. Joseph Medical Center, Burbank, California, United States|St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Stanford University, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|The University of Michigan - Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Clinical Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|The Don & Sybil Harrington Cancer Center, Amarillo, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medizinische Universitat Wien, Wien, Austria|Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie, Wien, Austria|Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg, Antwerpen, Belgium|AZ Sint-Jan AV, Brugge, Belgium|UZ Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|University Multiprofile Hospital for Active Treatment, ""Dr. Georgi Stranski"", Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Bulgaria|Military Medical Academy Multiprofile Hospital for Active Treatment, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|General Hospital, Health Sciences Centre, St John's, Newfoundland and Labrador, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada|Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada|University Hospital Brno, Department of Internal Medicine - Hematooncology, Brno, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital Olomouc, Olomouc, Czechia|University Hospital Kralovske Vinohrady - Prague, Praha 10, Czechia|General University Hospital Prague, Praha 2, Czechia|Hospital Antoine Beclere, Clamart, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Hopital Claude Huriez, Lille, France|CH de Mulhouse, Hopital Emile Muller, Mulhouse, France|CHU Nantes Hotel Dieu, Nantes, France|Hopital Saint-Antoine, Paris, France|Groupe Hospitalier Necker - Enfants Malades, Paris, France|Cancer Institut Universitaire de Toulouse-Oncopole (iUCT), Toulouse, France|Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France|University of Dusseldorf, Dusseldorf, Germany|Krankenhaus Nordwest, Frankfurt am Main, Germany|University of Hamburg-Eppendorf, Hamburg, Germany|Universitat Heidelberg, Heidelberg, Germany|Stiftungsklinikum Mittelrhein, Koblenz, Germany|LMU Klinikum der Universitat, Munchen, Germany|Universitatsklinikum Munster, Munster, Germany|Universitatsklinikum Wurzburg, Wurzburg, Germany|Alexandra Hospital, Athens, Greece|University General Hospital of Patras, Patras, Greece|St. Istvan and St. Laszlo Hospital of Budapest, Budapest, Hungary|University of Debrecen, Medical and Health Science Center, Debrecen, Hungary|Petz Aladar County Teaching Hospital, Gyor, Hungary|Bekes County Pandy Kalman Hospital, Gyula, Hungary|Kaposi Mor County Teaching Hospital, Kaposvar, Hungary|University of Pecs, Pecs, Hungary|University of Szeged, Albert Szent-Gyorgi Clinical Center, Szeged, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Ein Kerem, Jerusalem, Israel|Western Gailee Hospital - Nahariya, Nahariya, Israel|Rabin Medical Center, Petach Tikva, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Azienda Ospedallera Niguarda Ca Granda, Milano, Italy|Azienda Ospedllero Maggiore della Carita, Novara, Italy|Azienda Ospedaliera Pisana Ospendale Santa Chiara - Main, Pisa, Italy|Ospedale S. Eugenio, Roma, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Erasmus MC, Department of Haematology, Rotterdam, Netherlands|University Clinical Centre, Department of Hematologii Transplantologii, Gdansk, Poland|Samodzielny Publ. Szp. Wojewodzki w Gorzow Wlkp., Gorzow Wielkopolski, Poland|Independent Public Teaching Hospital of Medical University of Silesia in Katowice, Katowice, Poland|Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz, Lodz, Poland|Szpital Wojewwodzki im. dr Ludwika Rydygiera w Suwalkach, Suwalki, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland|Maria Sklodowska-Curie Institute of Oncology, Warszawa, Poland|Zamojski Non-Public Hospital, Zamosc, Poland|Fundeni Clinical Institute, ""Stefan Berceanu"" Center for Hematology and Bone Marrow Transplantation, Bucharest, Romania|Coltea Clinical Hospital, Bucharest, Romania|Bucharest University Emergency Hospital, Bucharest, Romania|Regional Institute of Iasi, Iasi, Romania|State Medical Institution Komi Republican Oncological Center, Syktyvkar, Komi Republic, Russian Federation|First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia, Izhevsk, Russian Federation|Federal State Budgetary Scientific Institution: N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation|Moscow State Medical Institution Municipal City Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|Federal State Budget Institution: Hematology Research Center under MoH, Moscow, Russian Federation|FSBI: Russian Research Institute of Hematology and Blood Transfusion under the Ferderal Agency for M&B, St. Petersburg, Russian Federation|State Higher Educational Institution: St Petersburg State Medical University n.a.I.P Pavlov, St. Petersburg, Russian Federation|SHEI: First St. Petersburg State Medical University N.a.I.P Pavlov under MoH, Clinic of Bone Marrow Transplant, St. Petersburg, Russian Federation|Federal State Budget Institute: Federal Almalov Medical Research Centre under Ministry of Healthcare, St. Petersburg, Russian Federation|Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Military Medical Academy, Clinic of Hematology, Belgrade, Serbia|Clinical Center Nis, Clinic of Hematology, Nis, Serbia|Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad, Serbia|Hospital Universitario Germans Trias i Pujol, Badalona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Donostia, San Sebastian, Spain|Hospital Universitario y Politeecnico La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Karolinska Universitetsjukhuset i Huddinge, Stockholm, Sweden|Karolinska Universitetssjukhuset Solna, Hematologiskt Centrum, Stockholm, Sweden|St. Bartholomew's Hospital, London, United Kingdom|Royal Free Hampstead, London, United Kingdom|St. Georges Hospital, London, United Kingdom|Nottingham University Hospitals (City Campus), Nottingham, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom|The Royal Wolverhampton Hospital NHS Trust, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01080391"
500,"NCT00689936","Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","Completed","Has Results","All","Phase 3","1623","Industry","Interventional","August 21, 2008","July 14, 2016","July 14, 2016","June 4, 2008","August 11, 2017","April 26, 2018","University of AL Birmingham, Birmingham, Alabama, United States|Cedar Sinai Medical Center Dept of Medicine, Los Angeles, California, United States|University of California, San Francisco- California, San Francisco, California, United States|Stanford University Stanford, Stanford, California, United States|Gainesville Heme Oncology Associates, Gainesville, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Integrated Community Oncology Network, Orange Park, Florida, United States|Gulf Coast Oncology, Saint Petersburg, Florida, United States|Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, United States|Southern Illinois Hematology Oncology, Centralia, Illinois, United States|Orchard Healthcare Research, Inc., Chicago, Illinois, United States|John H Stroger Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Ingalls Cancer Institute, Harvey, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Maine Center for Cancer Medicine Blood Disorders, Scarborough, Maine, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Billings Clinic, Billings, Montana, United States|Arena Oncology Associates, PC, Lake Success, New York, United States|Dakota Cancer Institute, Fargo, North Dakota, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kaiser Permanente Northwest Oncology Hematology, Portland, Oregon, United States|St. Luke's Hospital and Health Network, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Cancer Center, Collierville, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|University of Texas Medical Branch, Galveston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Fred Hutchinson Cancer Center, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre Divsion of Haematology Medical Oncology, E. Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|Geelong Hospital, Geelong, Australia|Gosford Hospital, Gosford, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Cabrini Hospital, Malvern, Australia|The Royal Melbourne Hospital, Parkville, Australia|Royal Perth Hospital, Perth, Australia|Gold Coast Hospital, Southport, Australia|Royal North Shore Hospital, St Leonards, Australia|Westmead Hospital, Wentworthville, Australia|Border Medical Oncology, Wodonga, Australia|Wollongong Hospital, Wollongong, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Hospital Leoben, Leoben, Austria|Hospital of Barmherzige Schwestern Linz, Linz, Austria|Hospital of Elisabethinen Linz, Linz, Austria|General Hospital Linz, Linz, Austria|MM-015. Salzburger Landkliniken, St. Johanns-Spital, Universitätsklinik fur Innere Medizin III, Salzburg, Austria|Hospital St. Polten, St. Pölten, Austria|Hospital of the Barmherzigen Bruder Vienna, Vienna, Austria|MM-015.Wihelminenspital, Vienna, Austria|MM-015. Medizinische Universität Wien, Vienna, Austria|Hospital Wels, Wels, Austria|Hospital Wiener Neustadt, Wiener Neustadt, Austria|ZNA Stuivenberg Centrumziekenhuis, Antwerpen, Belgium|Les Cliniques du Sud Luxembourg, Arlon, Belgium|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Hopital Erasme, Brussels, Belgium|AZ-VUB, Brussels, Belgium|Jules Bordet Institut, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|Virga Jesse Ziekenhuis, Hasselt, Belgium|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|H. Hartziekenhuis Roeselare-Menen vzw campus Wilgenstraat, Roeselare, Belgium|Cliniques Universitaires UCL de Mont-Godine, Yvoir, Belgium|University of Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Kelowna, British Columbia, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|BC Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada|Leukemia/BMT Program of BCDiv of Hem, Vancouver Gen Hosp, Vancouver, British Columbia, Canada|Vancouver Island Cancer Center, Victoria, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Science Centre, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Hospital Charles LeMoyne, Greenfield Park, Quebec, Canada|Hopital de la Cite-de-la-Sante, Laval, Quebec, Canada|Hotel-Dieu de Levis, Levis, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Hospital Maisonneuve - Rosemont, Montreal, Quebec, Canada|CHUM- Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Sir Mortimer B. Davis - Jewish Genl, Montreal, Quebec, Canada|CHUQ - Hotel-Dieu de QuebecHematology - Oncology, Quebec, Canada|Chaoyang Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|West China Hospital of Sichuan University, Chengdu, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, China|Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China|Clinique Claude BernardOncologie, Albi, France|CHU Sud, Amiens, France|CHRU Hopital du bocage, Angers cedex 01, France|CH Argenteuil Victor Dupouy, Argenteuil, France|Centre Hospitalier de la cote basque, Bayonne, France|Centre Hospitalier, Blois cedex, France|Hopital Avicenne, Bobigny Cedex, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital de Fleyriat, Bourg en Bresse cedex, France|Hopital Augustin Morvan, Brest cedex, France|Centre Francois Baclesse, Caen cedex 5, France|CHU, Caen, France|CH, Cannes Cedex, France|CH Rene Dubois, Cergy-Pontoise, France|Centre Hospitalier William Morey, Chalon/Saone Cedex, France|Hopital dinstruction des armees Percy, Clamart Cedex, France|Hopital Antoine Beclere, Clamart, France|Chu Estaing, Clermont Ferrand, France|CH Louis Pasteur, Colmar cedex, France|Hopital Henri Mondor, Creteil, France|CHRU Hopital du bocage, Dijon, France|Centre Hospitalier General, Dunkerque, France|CHRU, Grenoble cedex 09, France|Institut Prive de Cancerologie, Grenoble, France|Centre Hospitalier Departemental, La Roche -Sur-Yon cedex 9, France|CH, Le Chesnay Cedex, France|Hopital J MonodRhumato Nord, Le Havre, France|Kremlin Bicetre, Le Kremlin bicetre CDX, France|Centre Hospitalier, Le Mans cedex, France|Centre Jean Bernard, Le Mans, France|CHRU-Hopital Claude Huriez, Lille cedex, France|GH de Institut Catholique St Vincent, Lille, France|CH - Hôpital Dupuytren, Limoges Cedex 1, France|CHU Hopital Edouard Herriot, Lyon cedex, France|Centre Leon Berard, Lyon, France|Centre Hospitalier de Valence, Lyon, France|Institut Paoli-Calmettes, Marseille Cedex 9, France|Hopital de Mercy, METZ cedex 3, France|Clinique Pont de chaume Oncologie et Radiotherapie, Montauban cedex, France|CHU Montpellier - Hôpital Lapeyronie, Montpellier Cedex 5, France|Hopital Emile Muller, Mulhouse, France|CHRU - Hotel Dieu, Nantes, France|Centre Antoine Lacassagne Oncologie medicale et Hematologie, Nice cedex 1, France|Hopital de lArchet 1, Nice cedex 3, France|CH La Source, Orleans, France|Hopital Cochin, Paris Cedex 14, France|Hopital Saint Louis, Paris, France|Hopital Necker, Paris, France|CHU Hôpital St-Antoine, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|CU CHU Clemenceau, Poitiers cedex, France|Hopital R. Debre, Reims cedex, France|CHU Reims - Hôpital Maison Blanche, Reims, France|CHRU Hopital sud Medecine Interne, Rennes cedex 02, France|CHRU Hôpital de Pontchaillou, Rennes Cedex, France|CHG Rodez, Rodez, France|Centre Henri Becquerel, Rouen cedex, France|Centre Rene Huguenin, Saint Cloud, France|Institut de Cancerologie de Loire, St Priest en Jarez, France|Centre Hospitalier Yves Le Foll, St-Brieuc cedex 1, France|CHRU Hôpital de Hautepierre, Strasbourg, France|CHRU Hopital Purpan, Toulouse cedex 9, France|CHRU Hopital Bretonneau, Tours cedex, France|CHRU Hopital Trousseau, Tours, France|CHRU Hôpitaux de Brabois, Vandoeuvre Cedex, France|CH P. Chubert, Vannes cedex, France|Institut Gustave Roussy, Villejuif, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Dusseldorf, Germany|Universitatsklinikum Essen-, Essen, Germany|Staedtische Kliniken Frankfurt am Main Hochst, Frankfurt am Main, Germany|Universitatsklinikum Giessen, Giessen, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Askepios Klinik St. Georg, Hamburg, Germany|Universitatsklinikum Jena, Jena, Germany|Medizinische Klinik und Poliklinik II, Leipzig, Germany|Universitatsklinikum schleswig-Holstein, Lübeck, Germany|Poliklinik A, Muenster, Germany|Klinikum der Johann-Wolfgang-Goethe-Universtat, München, Germany|Medizinische Klinik III Klinikum der Universität München-Großhadern, München, Germany|Medizinische Fakultat der Universitat Rostock, Rostock, Germany|Zentrum F. Innere Medizin II Robert- Bosch-Krankenhaus GmBH, Stuttgart, Germany|Medizinische Klinik - Abteilung II, Tübingen, Germany|Klinik fur Innere Medizin III, Ulm, Germany|Alexandra Hospital, University of Athens, Athens, Greece|Attiko Hospital of Athens, Athens, Greece|Evangelismos Hospital of Athens, Athens, Greece|University of Athens, Athens, Greece|Metaxa Hospital Peiraias, Piraeus, Greece|Theagenio Anticancer Hospital of Thessaloniki, Thessaloniki, Greece|Adelaide and Meath Hospital, Dublin, Ireland|Mater Misercordiae Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Policlinico S. Orsola, Bologna, Italy|Oncologia Medica, Università della Magna Grecia, Catanzaro, Italy|Clinica Ematologica, A.O.U. San Martino di Genova, Genova, Italy|Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce, Lecce, Italy|Unità Operativa di Oncoematologia, Ospedale di Matera, Matera, Italy|U.O. di Ematologia e Trapianto di Midollo Osseo, Milano, Italy|Istituto Europeo di Oncologia - IEO, Milano, Italy|Presidio Ospedaliero A. Perrino, Milano, Italy|Policlinico di Modena, Modena, Italy|Oncoematologia, Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy|Casa di Cura La Maddalena, Divisione di Ematologia, Palermo, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, Italy|Ospedale Civile, Piacenza, Italy|A.O. Universitaria Ospedale S.Chiara Dip.Oncologia, Div. Ematologia, Pisa, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Istituto Nazionale Tumori Regina Elena, Struttura Complessa Ematologia ed Unita di Cellule Staminali, Roma, Italy|Azienda Policlinico Umberto I, Universita La Sapienzadi Roma, Rome, Italy|Ospedale Molinette, Torino, Italy|Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Daegu Catholic University Medical Center 3056-6, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejon, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Hwasun Chonnam National University Hospital, Hwasun-goon, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital 42, Jeonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Severance Hospital, Seongsanno, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul - Saint Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Wellington Hospital, Newtown, New Zealand|Hospital de Sao Marcos, Braga, Portugal|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Instituto Português de Oncologia Porto, Porto, Portugal|Hospital de Santo Antonio- Porto, Porto, Portugal|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Univ. Josep Trueta, Girona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Universitario Morales Messeguer, Murcia, Spain|Hospital Clinico Virgen de la Victoria, Málaga, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clinica Universitaria de Navarra,, Pamplona, Spain|Hospital Sant Pau, Reus, Spain|Hospital de Donosti, San Sebastian, Spain|Hospital Universtario Marques de Valdecilla, Santander, Spain|Hospital Clinico Santiago de Compostela, Santiago de Compostela, Spain|Hosptial La Fe, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Linkoping University Hospital, Linkoping, Sweden|Karolinska University HospitalSolna, Stockholm, Sweden|St. Görans Hospital, Stockholm, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Abteilung Onkologie Haematologie des Kantonsspitals Aarau, Aarau, Switzerland|UniversitatsSpital Basel, Basel, Switzerland|Inselsspital Bern, Berne, Switzerland|Kantonsspital Graubunden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland|Kantonsspital Munsterlingen, Münsterlingen (TG), Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|China Medical University Hospital, Taichung City, Taiwan|Veteran General Hospital - Taipei, Taipei, Taiwan|National Taiwan University Hospital, Tapei, Taiwan|Gwynedd Hospital, Bangor, United Kingdom|Royal United Hospital, Bath, United Kingdom|Belfast City Hospital Haematology Department, Belfast Northern Ireland, United Kingdom|Birminghman QE, Birmingham West Midlands, United Kingdom|Royal Bournemouth Hosp, Bournemouth Dorset, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|University Hospital of Wales - Cardiff, Cardiff, United Kingdom|The Beatson West of Scotland Centre, Glasgow, United Kingdom|Dept of Haematology St Bartholomews Hospital, London, United Kingdom|Guy's and St Thomas' Hospital - London, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Churchhill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth Crownhill Devon, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom|Pinderfields General Hospital, West Yorkshire, United Kingdom|New Cross Hospital- Wolverhampton, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00689936"
501,"NCT01822613","Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)","Completed","No Results Available","All","Phase 1","48","Industry","Interventional","July 26, 2013","June 3, 2016","June 3, 2016","April 2, 2013","null","June 1, 2017","University of Chicago Medical Center Dept of Onc, Chicago, Illinois, United States|Karmanos Cancer Institute Dept of Onc, Detroit, Michigan, United States|University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston, Texas, United States|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01822613"
502,"NCT00911859","A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients","Completed","Has Results","All","Phase 2","118","Industry","Interventional","June 2009","April 2013","April 2013","June 2, 2009","November 18, 2014","November 18, 2014","Boston, Massachusetts, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Adelaide, Australia|Melbourne, Australia|Bordeaux Cedex, France|Montpellier, France|Strasbourg, France|Ahmedabad, India|Calicut, India|Hyderabad N/A, India|Jaipur, India|Mumbai, India|Afula, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat-Gan, Israel|Seoul, Korea, Republic of|Bialystok, Poland|Chorzów, Poland|Gdynia, Poland|Lodz, Poland|Wroclaw, Poland|Baia Mare, Romania|Brasov, Romania|Iasi, Romania|Arkhangelsk, Russian Federation|Moscow N/A, Russian Federation|Nizhni Novgorod, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Barcelona, Spain|Madrid, Spain|Murcia N/A, Spain|Salamanca, Spain","https://ClinicalTrials.gov/show/NCT00911859"
503,"NCT01714726","Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.","Completed","No Results Available","All","Phase 2","121","Industry","Interventional","February 1, 2013","May 20, 2014","December 14, 2016","October 26, 2012","null","January 8, 2018","Precision Research Institute, LLC, Chula Vista, California, United States|Rocky Mountain Clinical Research, Lakewood, Colorado, United States|Borland Groover Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Gastroenterology Associates of Central Georgia, Macon, Georgia, United States|University Chicago Medical Center, Chicago, Illinois, United States|Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States|University of Michigan Health Care System, Ann Arbor, Michigan, United States|Troy Internal Medicine PC, Troy, Michigan, United States|Ehrhardt Clinical Research, LLC, Belton, Missouri, United States|Weill Medical College, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Charlotte Gastroenterology & Hepatology, Charlotte, North Carolina, United States|Consultants for Clinical Research Inc., Cincinnati, Ohio, United States|Zeidler Ledcor Centre, Edmonton, Alberta, Canada|GI Research Institute, Vancouver, British Columbia, Canada|Hotel Dieu Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Vaughan, Ontario, Canada|Hepato-Gastroenterologie HK, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava -, Ostrava-Poruba, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|CHU Amiens Picardie Service Hépato-gastroentérologie, Amiens Cedex 1, France|Hôpital Beaujon Service de Gastroentérologie et Assistance Nutritive, Clichy, France|Hôpital Charles Nicolle Service d'Hepato-Gastroentérologie1, Rue De Germont Pavillon Derocque, Rouen, France|Hôpital de Rangueil1 avenue du Professeur Jean Poulhès Service de Gastroentérologie et de Nutrition, Toulouse Cedex 9, France|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Praxis Dr. med. Constanze & Dr. med. Wolfgang Brandt Facharzt für Innere MedizinRudolf-Breitscheid-Str., Potsdam, Germany|Peterfy S. utcai Korhaz-Rend.Int es Baleseti Kozp., Budapest, Hungary|Szent János Kórház és Észak-budai Egyesített Kórházak, Budapest, Hungary|Vas Megyei Markusovszky Kórház Nonprofit Zrt., Budapest, Hungary|Azienda Ospedaliera Policlinico S. Orsola - Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Ii Università Degli Studi Di Napoli, Napoli, Italy|A.O. Policlinico Universitario ""Tor Vergata"", Roma, Italy|Università Cattolica del Sacro Cuore-Policlinico A. Gemelli Complesso Integrato Columbus, Roma, Italy|Istituto Clinico ""Humanitas"", Rozzano, Italy|Szpital Uniwersytecki nr 2 im. Jana Biziela w Bydgoszczy Centrum Endoskopii Zabiegowej, Bydgoszcz, Poland|Endoskopia Sp. z o. o. ul., Sopot, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, Poland|CEIC Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|CEIC Hospital Universitàrio de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Saint Pau Avda. Sant Antoni Mª Claret, Barcelona, Spain|Sabadell, H. Parc Taulí,Ap.Digestivo Aparatro DigestivoParc Taulí, Barcelona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01714726"
504,"NCT02115139","GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases","Completed","No Results Available","All","Phase 2","58","Other|Industry","Interventional","April 4, 2014","December 31, 2016","July 31, 2018","April 15, 2014","null","November 27, 2018","ICO Badalona, Badalona, Spain|H. Clinic de Barcelona, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|H. Insular de Canarias, Las Palmas de Gran Canaria, Spain|H. U. Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|H. Clínico de Santiago, Santiago de Compostela, Spain|H.U. Virgen Macarena, Sevilla, Spain|H. Virgen de la Salud, Toledo, Spain|H. General de Valencia, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02115139"
505,"NCT01985126","An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD","Completed","Has Results","All","Phase 2","124","Industry","Interventional","September 27, 2013","January 9, 2015","May 30, 2017","November 15, 2013","February 2, 2017","June 25, 2018","Duarte, California, United States|Los Angeles, California, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Detroit, Michigan, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Madison, Wisconsin, United States|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|Montreal, Quebec, Canada|Barcelona, Spain|Salamanca N/A, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01985126"
506,"NCT01385748","Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis","Completed","Has Results","All","Phase 2","183","Industry","Interventional","April 2010","October 2014","December 2014","June 30, 2011","August 9, 2017","November 28, 2017","21st Century Oncology of Arizona, Sun City, Arizona, United States|Compassionate Cancer Care Medical Group, Corona, California, United States|City of Hope, Duarte, California, United States|California Cancer Associates for Researche and Excellence, Fresno, California, United States|Compassionate Cancer Care Medical Group, Riverside, California, United States|Central Coast Medical Oncology Corp., Santa Maria, California, United States|Centura Health Research Center, Denver, Colorado, United States|University of Connectcut Health Center, Farmington, Connecticut, United States|AMPM Research Clinic, Miami, Florida, United States|Barbara Ann Karmonos Cancer Hospital, Detroit, Michigan, United States|Washington University School of medecine, Saint Louis, Missouri, United States|Billings Clinic Montana, Billings, Montana, United States|Winthrop University Hospital, Mineola, New York, United States|Montefiore Medical Center, The Bronx, New York, United States|Carolinas Medical Center- Carolinas Health Care System, Charlotte, North Carolina, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Penn State Hershey Cancer Institut, Hershey, Pennsylvania, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Hospital Jean Minjoz, Besançon, France|CHU Morvan, Brest, France|Centre François Baclesse, Caen, France|Clinique Pasteur, Evreux, France|Centre Oscar Lambret, Lille, France|Clinique Chénieux, Limoges, France|Clinique Hartmann, Neuilly-sur-Seine, France|CH Lyon Sud, Pierre-Bénite, France|CHU La Milétrie, Poitiers, France|CHP St gregoire, Saint gregoire, France|Centre de Cancérologie Etienne-Dolet, Saint-Nazaire, France|Hôpital Bretonneau, Tours, France|Institut Gustave Roussy, Villejuif, France|Universitatsklinikum Erlangen Strahlenklinik, Erlangen, Germany|Universitatsklinikum Essen, Essen, Germany|Universitatsklinikum Freiburg Klinik fur Strahlentherapie, Freiburg, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Paracelsius- Klinik, Osnabruck, Germany|Bács-Kiskun Megyei Kórház Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, Kecskemét, Nyíri u. 38, Hungary|Jósa András Oktatókórház Egészségügyi Szolgáltató Nonprofit Kft., Nyíregyháza, Szent István út 68, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc,, Szentpéteri kapu 72-76, Hungary|Szent Imre Kórház, Budapest, Tétényi út 12-16., Hungary|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de La princesa, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Puerta de Hierro Majadahonda, Madrid, Spain|Hospital Universitario Ramon y cajal, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital de Navarra, Pamplona, Spain|Centre Hospitalier Universitaire, Lausanne, Switzerland","https://ClinicalTrials.gov/show/NCT01385748"
507,"NCT01602224","A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)","Completed","Has Results","All","Phase 2","220","Industry","Interventional","July 2012","July 2014","July 2014","May 18, 2012","August 15, 2018","September 14, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fullerton, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Barbara, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grand Junction, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cedar Rapids, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashland, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Campinas, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nimes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bamberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ampelokipoi, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bari, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toluca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wroclaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neihu Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melikgazi, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sihhiye, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Headington, Oxford, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, Surrey, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01602224"
508,"NCT01203917","Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC","Completed","Has Results","All","Phase 4","1060","Industry","Interventional","September 2010","August 2012","June 2016","September 17, 2010","October 14, 2013","January 2, 2017","Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, ANGERS Cedex 9, France|Research Site, Saint Herblain Cedex, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Deszk, Hungary|Research Site, Edelény, Hungary|Research Site, Győr, Hungary|Research Site, Mosdós, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ancona, Italy|Research Site, Carpi, Italy|Research Site, Livorno, Italy|Research Site, Perugia, Italy|Research Site, Oslo, Norway|Research Site, Stavanger, Norway|Research Site, Trondheim, Norway|Research Site, Gdańsk, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Szczecin, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Lugo, Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Basel, Switzerland|Research Site, Chur, Switzerland|Research Site, Rapperswil-Jona, Switzerland|Research Site, Sursee, Switzerland|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Aberdeen, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Burnley, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01203917"
509,"NCT01721044","A Moderate to Severe Rheumatoid Arthritis Study","Completed","Has Results","All","Phase 3","527","Industry","Interventional","January 2013","June 2014","September 2014","November 2, 2012","January 18, 2018","January 18, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palo Alto, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Upland, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danbury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trumbull, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lewes, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boynton Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tamarac, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boise, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lansing, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freehold, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hartsdale, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethlehem, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wyomissing, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Myrtle Beach, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nassau Bay, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Webster, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesapeake, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Franklin, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Miguel De Tucuman, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maroochydore, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fitzroy, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mons, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frederiksberg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glostrup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odense, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orleans, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Würzburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kifissia, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Larissa, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashkelon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Yaakov, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Japan, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Luis Potosi, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ubbergen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nadarzyn, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caguas, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Vila Joiosa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fribourg, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lausanne, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zürich, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edirne, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Shields, Tyneside, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradford, West Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT01721044"
510,"NCT00708292","A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.","Completed","No Results Available","All","Phase 1|Phase 2","29","Industry","Interventional","July 2008","January 2011","January 2011","July 2, 2008","null","July 22, 2015","Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale, Arizona, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3), San Antonio, Texas, United States|Novartis Investigative Site, Melbourne, Australia|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00708292"
511,"NCT01191801","Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML","Completed","Has Results","All","Phase 3","711","Industry","Interventional","December 17, 2010","September 26, 2014","March 1, 2017","August 31, 2010","May 9, 2017","August 22, 2018","Moores UCSD Cancer Center, La Jolla, California, United States|UCLA Division of Hematology/Oncology, Los Angeles, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|HCA HealthONE - Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States|George Washington University-Medical Faculty Associates, Washington, District of Columbia, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Rush University Medical Center, Division of Hematology/Oncology, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Ellis Fischel Cancer Center, University of Missouri Health Care, Columbia, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|North Shore Long Island Jewish Health System, Lake Success, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|New York Medical College, Division of Oncology/Hematology, Valhalla, New York, United States|Mecklenburg Medical Group, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals fo Cleveland, Cleveland, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Family Cancer Center, Memphis, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|The University of Texas, M.D. Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Department of Medicine Section of Hematology/Oncology, West Virginia University Hospitals, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, United States|The Canberra Hospital, Garran, Australian Capital Territory, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Haematology Department, Gosford Hospital, Gosford, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Andrew Love Cancer Center, Geelong Hospital, Barwon Health, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Department of Clinical Haematology and BMT Service, Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Universitatsklinik Graz, Universitatsklinik fur Innere Medizin, Abteilung fur Hamatologie, Graz, Austria|University Hospital for Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria|Landeskrankenhaus Salzburg, Universitaetsklinik fur innere Medizin lll, Universitaetsklinikum der PMU, Salzburg, Austria|AKH Wien / MedUniWien Universtatsklinik fur Innere Medizin 1, Wien, Austria|ZNA Middleheim Lindendreef 1, Antwerpen, Belgium|ZNA Stuivenberg, Lange Beeldekensstraat 267, Antwerpen, Belgium|AZ St.-Jan Brugge-Oostende AV, Brugge, Belgium|Cliniques Universitaires Saint Luc, Brussels, Belgium|UZ Leuven, campus Gasthuisberg, Department of Haematology, Leuven, Belgium|H.-Hartziekenhuis Roeselare - Menen vzw, Roeselare, Belgium|Division of Hematology, Vancouver General Hospital, Vancouver, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada|Charles LeMoyne Hospital, Greenfield Park, Quebec, Canada|Fakultni nemocnice Kralovske Vinohrady, Oddeleni klinicke hematologie, Praha, Srobarova, Czechia|Fakultni nemocnice Brno, Interni hematoonkologicka klinika, Brno, Czechia|Fakultni nemocnice Hradec Kralove, 2. Interni klinika-oddeleni klinicke hematologie, Hradec Kralove, Czechia|CHU Lille, Service des maladies du sang, Hopital Huriez, Lille, Lille Cedex, France|CHU Angers, Service des maladies du sang, Angers Cedex 01, France|Hopital Avicenne- Departement Onco-hematologie, Bobigny, France|Hopital Mignot, Le Chesnay, France|Institut Paoli Calmettes, Marseille, France|CHU Nantes Hotel Dieu, Service d'hematologie clinique, Nantes, France|CHU de Bordeaux- Hopital Haut-Leveque, Centre Francois Magendle, Pessac, France|Centre Hospitalier Lyon Sud - Service d'Hematologie - Pavillon Marcel Berard - Bat. 1G - 1er etage, 165 Chemin du grand Revoyet, Pierre Benite, France|Service d'hematologie- Hopital Purpan- CHU de Toulouse, Toulouse, France|St. Johannes-Hospital, Duisburg, Germany|Klinikum Frankfurt am Main-Hochst, Department of Hematology and Oncology, Klinikum Frankfurt Academic Hospital of the University of Frankfurt, Frankfurt, Germany|Universitatsklinikum Hamburg-Eppendorf; ll. Medizinische Klinik und Poliklinik; Onkologie, Hamatologie und Knochenmarktransplantation, Hamburg, Germany|Medizinische Hochschule Hannover, Abteilung Hamatologie, Hannover, Germany|SLK-Kliniken Heilbronn GmbH, Medizinische Klinik, Heilbronn, Germany|Staedtisches Krankenhaus Kiel GmbH, Infektionsambulanz der 2. Medizinischen Klinik, Kiel, Germany|Klinikum St. Georg gGmbH; Klinik fur Internistische Onkologie/Hamatologie, Leipzig, Germany|University Hospital of Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen lll, Medizinische Klinik, Munich, Germany|University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary|Petz Aladar County Hospital, Gyor, Hungary|kaposi Mor Oktato Korhaz Belgyogyaszati Osztaly, Kaposvar, Hungary|Szegedi Tudomanyegyetem, 11. Belgyogyaszati Klinika, Szeged, Hungary|Ospedale ""A. Perrino"", U.O. Compessa di Ematologia, Brindisi, Italy|Azienda Ospedaliero-Universitaria Sant'Anna, Sezione di Ematologia, Dipartmento di Science Biomediche e Terapie Avanzate, Ferrara, Italy|Ospedaliera Universitaria San Martino di Genova, Genova, Italy|Ospedale ""Vito Fazzi"", U.O Ematologia, Lecce, Italy|AORN ""A. Cardarelli"", U.O.S.C. Ematologia con TMO, Napoli, Italy|Azienda Ospedaliero-Universitaria Maggiore Della Carita, Struttura Complessa Direzione Universitaria Ematologia, Novara, Italy|Fondazione IRCCS, Policlinico S. Matteo - Dipartimento di Ematologia, Pavia, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Dept. of Hematology, Asan Medical Center, Seoul, Korea, Republic of|Haematology Research, Auckland District Health Board, Auckland City Hospital, Grafton, Auckland, New Zealand|Canterbury Health Laboratories, Christchurch, New Zealand|Department of Haematology, Waikato Hospital, Hamilton, New Zealand|Regional Cancer Treatment Service, Palmerston North Hospital, Palmerston North, New Zealand|Uniwersyteckle Centrum Kliniczne, Gdansk, Poland|Klinika Hematologii i Chorob Rozrostowych Ukladu Krwiotworczego, Szpital Kliniczny Przemiemienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Centro Oncologico MD Anderson International Espana, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Sont Llatzer, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari Politecnic la Fe Hematology Department, Valencia, Spain|Blackpool Victoria Hospital, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom|Department of Haematology, University Hospital of Wales, Cardiff, United Kingdom|Queen's Centre for Oncology and Hematology, Castle Hill Hospital, Cottingham, United Kingdom|Leicester Royal Infirmary, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom|Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom|Department of Haematology, Guy's Hospital, London, United Kingdom|Central Manchester University Hospitals NHS Trust, Manchester Royal Infirmary, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01191801"
512,"NCT01939977","Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.","Completed","Has Results","All","Phase 4","148","Other|Industry","Interventional","January 2014","September 2015","December 2015","September 11, 2013","November 19, 2018","November 19, 2018","Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Del Mar, Barcelona, Spain|Fundació Puigvert-Iuna, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Puerta Del Mar, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Complexo Hospitalario Universitario A Coruna, La Coruna, Spain|Complejo Hospitalario Universitario de Canarias, Las Palmas De Gran Canaria, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen Del Rocío, Sevilla, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01939977"
513,"NCT02425878","Ulipristal Acetate 10 mg and Asisted Reproduction","Completed","No Results Available","Female","Phase 3","2","Other","Interventional","May 2015","May 2016","May 2016","April 24, 2015","null","August 30, 2016","IVI Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02425878"
514,"NCT01435343","Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia","Completed","No Results Available","All","Phase 1|Phase 2","55","Other","Interventional","July 2012","May 2016","December 2016","September 16, 2011","null","April 25, 2017","Hospital Universitari Germans Trials i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau., Barcelona, Spain|Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitari La Fe, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01435343"
515,"NCT01084837","Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure","Completed","No Results Available","All","Phase 2","60","Other","Interventional","March 2010","September 2012","December 2013","March 11, 2010","null","September 17, 2015","Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario, Salamanca, Spain|Hospital General, Segovia, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital La Fe, Valencia, Spain|Hospital Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01084837"
516,"NCT00840346","Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)","Completed","No Results Available","All","Phase 1|Phase 2","46","Other","Interventional","September 2009","May 2016","May 2016","February 10, 2009","null","May 17, 2016","Hospital Clinic y Provincial de Barcelona, Barcelona, Spain|Hospital Germans Trías i Pujol, Barcelona, Spain|Hospital Santa Creu y Sant Pau. Barcelona, Barcelona, Spain|Hospital 12 de Octubre. Madrid, Madrid, Spain|Hospital Clínico San Carlos. Madrid, Madrid, Spain|Hospital Ramón y Cajal. Madrid, Madrid, Spain|Hospital Morales Messeguer. Murcia, Murcia, Spain|Hospital Univ. La Fe de Valencia, Valencia, Spain|Hospital Lozano Blesa. Zaragoza, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00840346"
517,"NCT00651781","Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia","Completed","No Results Available","All","Phase 1|Phase 2","40","Other","Interventional","April 2008","January 2013","February 2013","April 3, 2008","null","February 28, 2013","Hospital Germans Trias I Pujol, Badalona, Spain|Hospital Clinic y Provincial de Barcelona, Barcelona, Spain|Hospital Santa Creu y Sant Pau.Barcelona, Barcelona, Spain|Hospital Vall d´hebron, Barcelona, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos., Madrid, Spain|Hospital Ramón y Cajal. Madrid, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital La Fe de Valencia, Valencia, Spain|Hospital Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00651781"
518,"NCT01453205","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","Completed","Has Results","All","Phase 2","187","Industry","Interventional","February 27, 2012","July 11, 2016","July 11, 2016","October 17, 2011","March 12, 2018","March 12, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Burbank, California, United States|Research Site, Palm Springs, California, United States|Research Site, Sylmar, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Westwood, Kansas, United States|Research Site, Hazard, Kentucky, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Fargo, North Dakota, United States|Research Site, Dayton, Ohio, United States|Research Site, Newark, Ohio, United States|Research Site, Sylvania, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, St. John, New Brunswick, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha, Czechia|Research Site, Bordeaux, France|Research Site, Le Mans, France|Research Site, Libourne Cedex, France|Research Site, Marseille, France|Research Site, Marseille, France|Research Site, Pessac, France|Research Site, Rouen, France|Research Site, Tours, France|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Mainz, Germany|Research Site, Muenchen, Germany|Research Site, Tuebingen, Germany|Research Site, Wuerzburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Aviv, Israel|Research Site, Gdynia, Poland|Research Site, Lublin, Poland|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, Cadiz, Spain|Research Site, Girona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Malaga, Spain|Research Site, Pamplona, Spain|Research Site, Salamanca, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kurupelit, Turkey|Research Site, Malatya, Turkey|Research Site, Talas, Turkey","https://ClinicalTrials.gov/show/NCT01453205"
519,"NCT00952588","Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients","Completed","Has Results","All","Phase 2|Phase 3","74","Industry","Interventional","July 2009","June 2011","June 2011","August 6, 2009","March 31, 2014","March 31, 2014","Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, New York, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Westmead, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Angers Cedex 01, France|Research Site, Clermont-ferrand, France|Research Site, Grenoble Cedex 09, France|Research Site, Lyon Cedex 03, France|Research Site, Marseille Cedex 09, France|Research Site, Nantes, France|Research Site, Duisburg, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Munster, Germany|Research Site, Villingen-schwenningen, Germany|Research Site, Bologna, BO, Italy|Research Site, Genova, GE, Italy|Research Site, Orbassano, TO, Italy|Research Site, Udine, UD, Italy|Research Site, Roma, Italy|Research Site, Nagoya, Aichi, Japan|Research Site, Yoshida-gun, Fukui, Japan|Research Site, Maebashi, Gunma, Japan|Research Site, Isehara, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Fukuoka, Japan|Research Site, Brasov, Romania|Research Site, Tg Mures, Romania|Research Site, Oviedo, Asturias, Spain|Research Site, Badalona(barcelona), Cataluna, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Brighton, United Kingdom|Research Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00952588"
520,"NCT02731287","Topical Timolol for Infantile Hemangioma in Early Proliferative Phase","Completed","No Results Available","All","Phase 2","70","Other","Interventional","March 2014","January 2017","March 2017","April 7, 2016","null","November 14, 2018","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Virgen del Rocío, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02731287"
521,"NCT00610272","Optimization of Radiotherapy in Treatment of Painful Bone Metastasis","Completed","No Results Available","All","Phase 3","650","Other","Interventional","January 2008","April 2012","August 2012","February 7, 2008","null","August 7, 2013","Centre Pierre et Marie Curie, Centre hospitalier universitaire Mustapha (CHU), Alger, Algeria|Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Misr Oncology Center (MOC), Cairo, Egypt|Tata Memorial Hospital, Mumbai, India|Institute of Oncology, University of Vilinius, Vilnius, Lithuania|Institute of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of|Instituto Nacional de Cancerología (INCAN), Ciudad de Mexico, Mexico|Institute of Oncology and Radiology, Belgrade, Serbia|Hospital Clinic Universidad de Barcelona, Barcelona, Spain|Hospital Son Dureta, Palma de Mallorca, Spain|Institut national de cancer Salah Azaiz, Tunis, Tunisia|Mount Vernon Cancer Centre, Northwood, United Kingdom","https://ClinicalTrials.gov/show/NCT00610272"
522,"NCT01864759","Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma","Completed","No Results Available","All","Phase 1","14","Other","Interventional","January 11, 2013","December 20, 2016","April 26, 2017","May 30, 2013","null","August 29, 2017","Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet del Llobregat, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01864759"
523,"NCT01575574","Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis","Completed","No Results Available","All","Phase 4","74","Other","Interventional","July 2012","July 2016","July 2016","April 11, 2012","null","August 23, 2016","Hospital Clinic of Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01575574"
524,"NCT00880269","Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)","Completed","Has Results","All","Phase 2","59","Industry","Interventional","August 2009","February 2012","February 2012","April 13, 2009","September 9, 2016","February 23, 2017","University of Chicago Medical Center Dept. of U. of Chicago Hosp(3), Chicago, Illinois, United States|Nebraska Methodist Hospital Nebraska Methodist Hospital(2), Omaha, Nebraska, United States|North Shore University Hospital North Shore Univ, Manhasset, New York, United States|Memorial Sloan Kettering Cancer Center Dept. of MSKCC (2), NY, New York, United States|Oregon Health Sciences University Dept. of OHSU (2), Portland, Oregon, United States|University of Texas Southwestern Medical Center Dept of Simmons Cancer Center, Dallas, Texas, United States|University of Texas/MD Anderson Cancer Center Dept of MD Anderson (14), Houston, Texas, United States|Novartis Investigative Site, Gosford, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Bobigny Cedex, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Paris Cedex 4, France|Novartis Investigative Site, Toulouse cedex 9, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Surquillo, Lima, Peru|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Balcova / Izmir, Turkey|Novartis Investigative Site, Aberdeen, Scotland, United Kingdom|Novartis Investigative Site, Leeds, West Yorkshire, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00880269"
525,"NCT02550249","Neoadjuvant Nivolumab in Glioblastoma","Completed","No Results Available","All","Phase 2","29","Other","Interventional","June 2015","March 2017","March 2017","September 15, 2015","null","April 11, 2017","Clinica Universidad de Navarra, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT02550249"
526,"NCT01303796","A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia","Completed","No Results Available","All","Phase 3","482","Industry","Interventional","October 1, 2011","December 15, 2016","July 31, 2017","February 25, 2011","null","October 31, 2018","University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|Scripps Cancer Center, La Jolla, California, United States|UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Shands Cancer Hospital at University of Florida, Gainesville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|St. Louis University Cancer Center, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth - Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, New Jersey, United States|Westchester Hematology Oncology Group, PC, Hawthorne, New York, United States|Beth Israel Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medizinische Universitaetsklinik, Innsbruck, Austria|Elisabethinen Krankenhaus, Linz, Austria|Krankenhaus der Barmherzigen Schwestern, Linz, Austria|Univ. Klinik fur Innere Medizin III LKH, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|AKH Wien, Wien, Austria|Hanusch Krankenhaus, Wien, Austria|Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerpen, Belgium|AZ Sint-Jan Brugge-Oostende, Brugge, Belgium|Universite Catholique de Louvain, Brussels, Belgium|Centre Hospitalier De Jolimont-Lobbes, La Louviere, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium|CHU d'Amiens Hopital Sud, Amiens, France|Centre Hospitalier de la Cote Basque, Bayonne, France|CHU de Lyon - Hopital Edouard Herriot, Lyon, France|Institut Paoli Calmettes, Marseille, France|CHRU De Montpellier Hopital St. Eloi, Montpellier, France|Centre Hospitalier De Mulhouse, Mulhouse, France|Hopital St Louis Universite Paris 7, Paris, France|Centre Hospitalier de Perigueux, Perigueux, France|Centre Hospitalier d'Annecy, Pringy, France|Centre Hospitalier de Saint-Brieuc Yves Ie Foll, St Brieuc, France|CHU de Strasbourg - Hopital Civil, Strasbourg, France|Strasbourg Oncologie Liberale, Strasbourg, France|CHU de Tours Hopital Bretonneau, Tours, France|Universitaetsklinikum Charite Berlin, Campus Benjamin Franklin, Berlin, Germany|Universitaetsklinikum Carl-Gustav-Carus Dresden, Dresden, Germany|St. Johannes Hospital, Duisburg, Germany|Klinikum Frankfurt Hoechst, Frankfurt, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|SLK Kliniken Heilbronn, Heilbronn, Germany|Klinikum St. Georg, Leipzig, Germany|Johannes Wesling Klinikum, Minden, Germany|TU Muenchen, Muenchen, Germany|Universitaetsklinikum Muenster, Muenster, Germany|University of Debrecen, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, Hungary|Kaposi Mor Oktato Korhaz, Kaposvár, Hungary|AOU Ospedali Riuniti Umberto I, Ancona, Italy|AO Ospedali Riuniti di Bergamo, Bergamo, Italy|Universita di Bologna Ist Ematologia Oncologia Medica Seragnoli, Bologna, Italy|AO Spedali Civili di Brescia, Brescia, Italy|Universita Cattolica del Sacro Cuore, Campobasso, Italy|AOU Careggi, Firenze, Italy|AOU San Martino IST, Genova, Italy|PO Vito Fazzi, Lecce, Italy|Ospedale San Raffaele, Milano, Italy|AORN Antonio Cardarelli, Napoli, Italy|Uni. Napoli Ospedale Federico lI, Napoli, Italy|AOU Maggiore della Carità di Novara, Novara, Italy|AOOR Villa Sofia Cervello di Palermo, Palermo, Italy|Policlinico San Matteo Di Pavia, Pavia, Italy|AOU San Luigi Gonzaga, Torino, Italy|Akademickie Centrum Kliniczne Szpital Akademii Medycznej w Gdansku, Gdansk, Poland|Wojewodzki Szpital Specjalistyczny, Legnica, Poland|Wojewódzki Szpital Specjalistyczny w Legnicy, Legnica, Poland|University of Lodz N. Copernicus Memorial Hospital, Lodz, Poland|IHT Instytut Hematologii I Transfuzjologii w Warszawie, Warsaw, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Wroclawiu, Wroclaw, Poland|Hospital Universitari Germans Trias i Pujol ICO Badalona, Badalona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital De La Santa Creu Sant Pau, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Canarias, La Laguna, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Clinico Universitario, Santiago de Compostela, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari ""La Fe"", Valencia, Spain|Sunderby Hospital, Luleå, Sweden|Skåne Universitetssjukhus Univ Hospital Lund, Lund, Sweden|Inselspital Bern, Bern, Switzerland|Kings College Hospital and Guys and St Thomas' Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01303796"
527,"NCT01418729","Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma","Completed","No Results Available","All","Phase 2","216","Other","Interventional","September 2011","December 2015","June 2017","August 17, 2011","null","September 20, 2017","Hospital Donostia, Instituto Biodonostia, San Sebastian, Gipuzkoa, Spain","https://ClinicalTrials.gov/show/NCT01418729"
528,"NCT01074047","Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)","Completed","Has Results","All","Phase 3","488","Industry","Interventional","June 1, 2010","January 22, 2014","July 25, 2016","February 24, 2010","February 26, 2015","August 29, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital, Fitzroy, Australia|Klinikum Wels-Grieskirchen GmbH, Wels, Upper Austria, Austria|Wilhelminenspital, I Medizinische Abt., Wien, Vienna, Austria|Landeskliniken Salzburg Saint Johanns-Spital, III Medizinische Abteilung, Salzburg, Austria|Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Namur, Belgium|Universitair Ziekenhuis Gent, Ghent, Oost-vlaanderen, Belgium|Algemeen Ziekenhuis Sint-Jan, Brugge, West-vlaanderen, Belgium|Centre Hospitalier de Jolimont-Lobbes, La Louvière, Belgium|University of Alberta Hospital, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal pavilion Notre Dame, Montreal, Quebec, Canada|Hopital du Sacre Coeur de Montréal, Montreal, Quebec, Canada|Tom Baker Cancer Centre, Calgary, Canada|Princess Margaret Hospital, Ontario, Canada|The Third Hospital of Peking University, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peoples Hospital of Jiangsu Province, Jiangsu, China|Shanghai Ruijin Hospital, Shanghai, China|Shanghai Changhai Hospital,the Second Military Medical University, Shanghai, China|West China Hospital,Sichuan University, Sichuan, China|Tianjin Blood Disease Hospital, Tianjin, China|Fakultni nemocnice Brno, Brno, Jihormoravsky Kraj, Czechia|Fakultni nemocnice Olomouc, hemato-onkologicka klinika, Olomouc, Olomoucký Kraj, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Praha, Czechia|Ustav hematologie a krevni transfuze, Praha 2, Praha, Czechia|Centre Hospitalier Régional Universitaire, Hôpital de Hautepierre, Strasbourg, Alsace, France|Hospital Avicenne, Service d'hematologie Clinique, Bobigny, ILE-DE-France, France|Hopital Percy Clamart, Clamart Cedex, Ile-de-france, France|Hôpital Saint Louis, Paris Cedex 10, Ile-de-france, France|Centre Hopitalier Universitaire Dupuytren, Limoges, Limousin Lorraine, France|Centre Hospitalier Universitaire de Toulouse, Toulouse Cedex 09, Midi-pyrénées, France|Centre Hospitalier Universitaire de Nice, Nice Cedex 3, Nice, France|CHRU d'Angers, Angers cedex 09, Pays de La Loire, France|Centre Hospitalier Universitaire Nantes, Hotel Dieu, Nantes Cedex 1, Pays de La Loire, France|Centre Hospitalier Universitaire d'Amiens, Groupe Hospitalier Sud, Amiens Cedex 1, Picardie, France|Hôpital de la Conception, Marseille, Provence Alpes Cote D'azur, France|Centre Hospitalier de la Cote Basque, Aquitaine, France|Centre Hospitalier Universitaire de Lyon-Hôpital Edouard Herriot, Lyon Cedex 03, France|Universitatsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-wuerttemberg, Germany|University of Rostock, Div. of Haematology and Oncology, Rostock, Mecklenburg-vorpommern, Germany|Heinrich-Heine-Universität Düsseldorf, Düesseldorf, Nordrhein-westfalen, Germany|Universitatsklinikum Essen, Zentrum fur Tumorforschung und Tumortherapie, Essen, Nordrhein-Westfallen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thueringen, Germany|Soroka Medical Center, Beer Sheva, Beersheva, Israel|Assaf Harofeh Medical Centre, Beer Yaakov, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center - Tel Hashomer, Heart Institute, Tel Hashomer, Israel|IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture, Rionero in Vulture, Potenza, Italy|Azienda Sanitaria Ospedaliera ""San Luigi Gonzaga"", Orbassano, Turin, Italy|Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria, Alessandria, Italy|Azienda Ospedaliera Universitaria - Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliera Policlinico di Bari, Bari, Italy|Azienda Ospedaliera Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|Azienda Policlinico Umberto I di Roma, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Udine, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|Yonsei University Health System, Seodaemun-gu, Seoul, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Saint Mary's Hospital Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Hospital at Guro, Seoul, Korea, Republic of|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Wroclaw, Dolnoslaskie, Poland|Dolnoslaskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku, Wroclaw, Dolnoslaskie, Poland|Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika, Lódz, Lodzkie, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland|Samodzielny Publiczny SK im. A. Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach, Katowice, Slaskie, Poland|Central City Hospital # 7, Ekaterinburg, Russian Federation|City Clinical Hospital n.a. S. P. Botkin, Moscow, Russian Federation|State Healthcare Institution ""Nizhny Novgorod N.A. Semashko Regional Clinical Hospital"", Nizhniy Novgorod, Russian Federation|Saint Petersburg State Academician I.P. Pavlov Medical University, Saint Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Son Dureta, Palma de Mallorca, Baleares, Spain|Hospital Son Llàtzer, Palma de Mallorca, Baleares, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Chang Gung Memorial Hospital, Kaohsiung, Niao-Sung Hsiang, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital Pei-Tou District, Taipei, Taiwan|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Barts and the London NHS Trust, London, United Kingdom|King's College Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01074047"
529,"NCT00989261","Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)","Completed","No Results Available","All","Phase 2","333","Industry","Interventional","November 2009","September 2012","September 2012","October 5, 2009","null","January 5, 2018","University of California, San Francisco, San Francisco, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Clinical Trials Center, Nashville, Tennessee, United States|The Vanderbuilt Clinic, Nashville, Tennessee, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Institut Paoli Calmettes Centre Regional de Lutte Contre le Cancer, Marseille, Cedex 9, France|Hematologie - CHU Purpan, Toulouse, Cedex, France|Centre Hospitalier Regional Universitaire, Hopital de Hautepierre, Alsace, France|Hopital Avicenne, Bobigny, France|Centre Hospitalier Universitaire d'Angers, d'Angers, France|Centre Hospitalier Universitaire Grenoble, Grenoble, France|Centre Hospitalier de Versailles, Le Chesnay, France|Hopital Claude Huriez, Lille, France|Centre Hospitalier Universitaire Limoges, Limoges, France|Hopital Edouard Herriot, Lyon, France|Hopital Saint-Antoine, Paris, France|Hopital Saint-Louis, Paris, France|Hopital Haut-Leveque, Pessac, France|Centre Henry Becquerel, Service d'Hematologie, Rouen, France|Centre Hospitalier Universitaire Brabois, Vandoeuvre les Nancy, France|Charite Campus Virchow Klinikum, Berlin, Germany|Charite, Campus Benjamin Franklin, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Unikliniksklinikum Carl Gustav Carus, Dresden, Germany|Uniklinik Essen, Westdeutsches Tumorzentrum, Essen, Germany|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany|Asklepios Klinik St Georg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitatsklinikum Jena, Jena, Germany|Universitatsklinikum Leipzig Selbstandige Abteilung fur Hamatologie, Leipzig, Germany|Universitatsklinikum Magdeburg, Magdeburg, Germany|Universitatsklinikum Mannheim, Mannheim, Germany|Philipps-Universitat Marburg, Marburg, Germany|Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany|Universitatsklinikum Munster, Munster, Germany|Universitatsklinikum Regensburg Abteilung fur Hamatologie, Regensburg, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany|Universitatsklinikum Tubingen, Tubingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Universitatsklinikum Wurzburg, Wurzburg, Germany|Instituto Di Ematologia ""L.Ea. Seragnoli"", Bologna, Italy|Unita Trapianti di Midollo Osseo per Adulti, Brescia, Italy|Presidio Ospedaliero ""A. Businco"" - Centro di Riferimento Oncologico Regionale, Cagliari, Italy|Azienda Ospedaliera-Universitaria Vittorio Emanuele-Ferrarotto, Catania, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Farmacia Ospidaliera, Orbassano, Italy|Ospedale Civile S. Maria delle Croci, Ravenna, Italy|Ospedale Sant Eugenio, Roma, Italy|Universita Degli Studi di Roma Tor Vergata, Roma, Italy|Azienda Ospedaliero Universitaria Senese, Siena, Italy|Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Clinica Ematologica, Udine, Italy|University Medical Center Groningen, Groningen, Netherlands|Utrecht University Medical Centre, Dept. of Hematology, Utrecht, Netherlands|Dolnoslaskie Centrum Transplantacji Komorkowych z, Wroclaw, Poland|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia del Hospital Universitari Germans, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Universitari de Girona, Girona, Spain|Hospital de la Princesa, Servicio de Hematologia, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario de Salamanca, Hospital Clinico, Servicio de Hematologia, Salamanca, Spain|Hospital La Fe, Servicio de Hematologia, Valencia, Spain|Addenbrook's Hospital, Cambridge, United Kingdom|Castle Hill Hospital, Cottingham, United Kingdom|Saint James University Hospital, Institute of Oncology, Leeds, United Kingdom|Hanmmersmith Hospital, Dept. of Hematology, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00989261"
530,"NCT01147939","Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)","Completed","No Results Available","All","Phase 3","381","Industry","Interventional","June 2010","February 2013","June 2013","June 22, 2010","null","September 27, 2013","Scripps Cancer Center Clinical Research, La Jolla, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|UCLA School of Medicine, Division of Hematology/Oncology, Los Angeles, California, United States|Rocky Mountain Blood and Bone Marrow Transplant Program, Denver, Colorado, United States|Shands at the University of Florida, Gainesville, Florida, United States|Winship Cancer Institute at Emory, Atlanta, Georgia, United States|The Blood and Marrow Transplant Group of GA, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|St. Francis Hospital and Health Center, Indianapolis, Indiana, United States|University of Iowa Hopsitals, Iowa City, Iowa, United States|LSU Health Sciences Center,, Shreveport, Louisiana, United States|Northern New Jersey Cancer Associates, Hackensack, New Jersey, United States|New York Presbyterian Hospital, Weill-Cornell Medical College, New York, New York, United States|Memorial Sloan-Kettering, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Health Sciences Section on Hematology and Oncology, Winston-Salem, North Carolina, United States|The Jewish Hospital, Cincinnati, Ohio, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|St. Francis Hospital, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Froedtert Hospital, Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal North Shore Hopsital, Sydney, New South Wales, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Box Hill Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium|UZ Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|University Hospital Antwerp, Edegem, Belgium|CHU Liège, Liège, Belgium|UCL Mont-Godinne, Yvoir, Belgium|Princess Margaret Hospital, Toronto, Ontario, Canada|CHU Limoges - Hôpital Dupuytren, Limoges, France|Hopital Edouard Herriot, Lyon, France|Institut J. Paoli and I. Calmettes, Marseilles, France|Centre Antoine Lacassagne, Nice, France|Hopital Saint Antoine, Paris, France|CHU de Bordeaux - Hopital Haut-Leveque, Pessac, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|Charité-Campus B. Franklin Med. Klinik Haematology, Berlin, Germany|Evangelische Kliniken Johanniter- und Waldkrankenhaus Bonn GmbH, Bonn, Germany|Heinrich-Heine Universität Düsseldorf, Klinik für Hämatologie/Onkolog. und Klin. Immunologie, Düsseldorf, Germany|III. Medizinische Klinik und Poliklinik;Hämatologie, Onkologie und Pneumologie, Mainz, Germany|Universitätsklinikum Münster, Medisinische Klinik & Poliklinik A, Münster, Germany|Universitätsklinikum Rostock, Rostock, Germany|Robert-Bosch-Krankenhaus, Abt.Hämatologie,Onkologie u.Palliativmedizin, Stuttgart, Germany|Universitätsklinikum Ulm, Klinik für Innere Medizin III, Comprehensive Cancer Center Ulm (CCCU), Ulm, Germany|St James's Hospital Dublin, Dublin, Ireland|University Hospital Galway, Galway, Ireland|A.O.U Careggi, Firenze, Italy|A.O San Martino, Genova, Italy|Fondazione San Raffaele del Monte Tabor, Milano, Italy|A.O. Cardarelli, Napoli, Italy|Hospital S. Maria delle Croci, Ravenna, Italy|Fondazion Policlin T Vergata, Roma, Italy|Haukeland Universitetssykehus, Bergen, Norway|Oslo University Hospital, Oslo, Norway|St Olavs Hospital, Trondheim, Norway|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw, Poland|Fundeni Clinical Institute ""Stefan Berceanu"" Center for Hematology and Bone Marrow Transplant, Bucharest, Romania|Oncology Institute ,,Ion Chiricuta"" Cluj Napoca , Hematology dept., Cluj Napoca, Romania|St. Spiridon"" University Hospital, Hematology Department, Iasi, Romania|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitari Son Dureta, Palma de Mallorca, Spain|Hospital de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario La Fé, Servicio de Hematología, Valencia, Spain|Gartnavel General Hospital: Beatson WOS Cancer Centre, Glasgow, Scotland, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Christie Hospital, Haematology and Transplant Day Unit, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01147939"
531,"NCT01102595","Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma","Completed","No Results Available","All","Phase 2","102","Other","Interventional","December 2009","October 2013","December 2014","April 13, 2010","null","August 26, 2015","Grupo Español de Investigacion en Neurooncologia, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01102595"
532,"NCT01100177","Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients","Completed","No Results Available","All","Phase 2","12","Other","Interventional","June 2009","December 2011","January 2012","April 8, 2010","null","March 11, 2013","Grupo Español de Investigacion en Neurooncologia, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01100177"
533,"NCT01006044","Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection","Completed","No Results Available","All","Phase 2","26","Other","Interventional","October 2009","August 2014","August 2014","November 2, 2009","null","September 3, 2014","Clínica Universidad de Navarra, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT01006044"
534,"NCT01337752","Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency","Completed","No Results Available","All","Phase 2","9","Industry","Interventional","January 2012","May 2013","May 2013","April 19, 2011","null","February 23, 2017","University Chicago Hospital Dept. of Univ of Chicago (2), Chicago, Illinois, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01337752"
535,"NCT01853228","A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia","Completed","No Results Available","All","Phase 2","17","Industry","Interventional","October 22, 2013","August 28, 2017","August 28, 2017","May 14, 2013","null","February 1, 2018","Gent, Belgium|Copenhagen Ø, Denmark|Paris, France|Toulouse Cedex 9, France|Vandoeuvre-Lès-Nancy, France|Essen, Germany|Hamburg, Germany|Hannover, Germany|Stuttgart, Germany|Rotterdam, Netherlands|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Birmingham, United Kingdom|Cambridge, United Kingdom|Glasgow, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01853228"
536,"NCT01338337","Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia","Completed","No Results Available","All","Phase 2","40","Other","Interventional","November 2010","December 2015","December 2015","April 19, 2011","null","January 26, 2016","Hospital General de Jerez, Jerez, Cádiz, Spain|Hospital Costa del Sol, Marbella, Malaga, Spain|Hospital Reina Sofía, Servicio de Hematología, Cordoba, Spain|Hospital Universitario San Cecilio, Granada, Spain|Hospital Virgen de las Nieves, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT01338337"
537,"NCT02080624","Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome","Completed","No Results Available","All","Phase 2","23","Other","Interventional","January 2011","September 2012","December 2012","March 6, 2014","null","March 6, 2014","Clinica Universidad de Navarra, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT02080624"
538,"NCT01684449","Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma","Completed","No Results Available","All","Phase 1|Phase 2","28","Other","Interventional","January 2010","May 2013","December 2013","September 13, 2012","null","October 27, 2015","H. Universitario de Canarias, Tenerife, Santa Cruz de Tenerife, Spain|H. Sant Pau, Barcelona, Spain|Institut Català d'Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain|H. La Paz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|H. Son Espases, Mallorca, Spain|Instituto Valenciano de Oncología, Valencia, Spain|H. Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01684449"
539,"NCT02063659","Telotristat Etiprate for Carcinoid Syndrome Therapy","Completed","Has Results","All","Phase 3","76","Industry","Interventional","March 11, 2014","March 29, 2016","March 29, 2016","February 14, 2014","September 25, 2017","February 26, 2018","Lexicon Investigational Site, Stanford, California, United States|Lexicon Investigational Site, Orlando, Florida, United States|Lexicon Investigational Site, Iowa City, Iowa, United States|Lexicon Investigational Site, Lexington, Kentucky, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Buffalo, New York, United States|Lexicon Investigational Site, New York, New York, United States|Lexicon Investigational Site, Philadelphia, Pennsylvania, United States|Lexicon Investigational Site, Kogara, New South Wales, Australia|Lexicon Investigational Site, St. Leonards, New South Wales, Australia|Lexicon Investigational Site, Herston, Queensland, Australia|Lexicon Investigational Site, East Melbourne, Victoria, Australia|Lexicon Investigational Site, Edegem, Belgium|Lexicon Investigational Site, Gent, Belgium|Lexicon Investigational Site, Yvoir, Belgium|Lexicon Investigational Site, Calgary, Alberta, Canada|Lexicon Investigational Site, Halifax, Nova Scotia, Canada|Lexicon Investigational Site, Clichy, France|Lexicon Investigational Site, Lille, France|Lexicon Investigational Site, Lyon, France|Lexicon Investigational Site, Marseille, France|Lexicon Investigational Site, Strasbourg, France|Lexicon Investigational Site, Villejuif, France|Lexicon Investigational Site, Bad Berka, Germany|Lexicon Investigational Site, Berlin, Germany|Lexicon Investigational Site, Hamburg, Germany|Lexicon Investigational Site, Heidelberg, Germany|Lexicon Investigational Site, Lubeck, Germany|Lexicon Investigational Site, Mainz, Germany|Lexicon Investigational Site, Marburg, Germany|Lexicon Investigational Site, Munich, Germany|Lexicon Investigational Site, Neuss, Germany|Lexicon Investigational Site, Jerusalem, Israel|Lexicon Investigational Site, Amsterdam, Noord-Holland, Netherlands|Lexicon Investigational Site, Amsterdam, Noord-Holland, Netherlands|Lexicon Investigational Site, Noord Brahant, Netherlands|Lexicon Investigative Site, Rotterdam, Netherlands|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Madrid, Spain|Lexicon Investigational Site, Madrid, Spain|Lexicon Investigational Site, Sevilla, Spain|Lexicon Investigational Site, Uppsala, Sweden|Lexicon Investigational Site, Basingstoke Hampshire, United Kingdom|Lexicon Investigational Site, Coventry, United Kingdom|Lexicon Investigational Site, London, United Kingdom|Lexicon Investigational Site, London, United Kingdom|Lexicon Investigational Site, London, United Kingdom|Lexicon Investigational Site, Manchester, United Kingdom|Lexicon Investigational Site, Newcastle upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT02063659"
540,"NCT01677910","TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","Completed","Has Results","All","Phase 3","135","Industry","Interventional","January 8, 2013","March 21, 2016","March 21, 2016","September 3, 2012","September 18, 2017","February 27, 2018","Lexicon Investigational Site, Mobile, Alabama, United States|Lexicon Investigational Site, Palo Alto, California, United States|Lexicon Investigational Site, San Francisco, California, United States|Lexicon Investigational Site, Orlando, Florida, United States|Lexicon Investigational Site, Iowa City, Iowa, United States|Lexicon Investigational Site, Lexington, Kentucky, United States|Lexicon Investigational Site, Kenner, Louisiana, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Omaha, Nebraska, United States|Lexicon Investigational Site, Buffalo, New York, United States|Lexicon Investigational Site, New York, New York, United States|Lexicon Investigational Site, Durham, North Carolina, United States|Lexicon Investigational Site, Philadelphia, Pennsylvania, United States|Lexicon Investigational Site, Fort Worth, Texas, United States|Lexicon Investigational Site, Houston, Texas, United States|Lexicon Investigational Site, McAllen, Texas, United States|Lexicon Investigational Site, Kogara, New South Wales, Australia|Lexicon Investigational Site, Saint Leanoards, New South Wales, Australia|Lexicon Investigational Site, Herston, Queensland, Australia|Lexicon Investigational Site, Fitzroy, Victoria, Australia|Lexicon Investigational Site, Freemantle, Western Australia, Australia|Lexicon Investigational Site, Woodville South, Australia|Lexicon Investigational Site, Edegem, Belgium|Lexicon Investigational Site, Gent, Belgium|Lexicon Investigational Site, Yvoir, Belgium|Lexicon Investigational Site, Calgary, Alberta, Canada|Lexicon Investigational Site, Halifax, Nova Scotia, Canada|Lexicon Investigational Site, Clichy, France|Lexicon Investigational Site, Lille, France|Lexicon Investigational Site, Lyon, France|Lexicon Investigational Site, Marseille, France|Lexicon Investigational Site, Strasbourg, France|Lexicon Investigational Site, Villejuif, France|Lexicon Investigational Site, Bad Berka, Germany|Lexicon Investigational Site, Berlin, Germany|Lexicon Investigational Site, Essen, Germany|Lexicon Investigational Site, Hamburg, Germany|Lexicon Investigational Site, Heidelberg, Germany|Lexicon Investigational Site, Lubeck, Germany|Lexicon Investigational Site, Mainz, Germany|Lexicon Investigational Site, Marburg, Germany|Lexicon Investigational Site, Munchen, Germany|Lexicon Investigational Site, Neuss, Germany|Lexicon Invetigational Site, Jerusalem, Israel|Lexicon Investigational Site, Bologna, Italy|Lexicon Investigational Site, Ferrara, Italy|Lexicon Investigational Site, Milan, Italy|Lexicon Investigational Site, Milan, Italy|Lexicon Investigational Site, Modena, Italy|Lexicon Investigational Site, Napoli, Italy|Lexicon Investigational Site, Orbassano, Italy|Lexicon Investigational Site, Perugia, Italy|Lexicon Investigational Site, Pisa, Italy|Lexicon Investigational Site, Rome, Italy|Lexicon Investigational Site, Amsterdam, Netherlands|Lexicon Investigational Site, Noord-Brahant, Netherlands|Lexicon Investigational Site, Noord-Holland, Netherlands|Lexicon Investigational Site, Zuid-Holland, Netherlands|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Madrid, Spain|Lexicon Investigational Site, Madrid, Spain|Lexicon Investigational Site, Seville, Spain|Lexicon Investigational Site, Lund, Sweden|Lexicon Investigational Site, Uppsala, Sweden|Lexicon Investigational Site, Basingstoke-Hampshire, United Kingdom|Lexicon Investigational Site, Coventry, United Kingdom|Lexicon Investigational Site, Glasgow, United Kingdom|Lexicon Investigational Site, Headington-Oxford, United Kingdom|Lexicon Investigational Site, London, United Kingdom|Lexicon Investigational Site, London, United Kingdom|Lexicon Investigational Site, London, United Kingdom|Lexicon Investigational Site, Manchester, United Kingdom|Lexicon Investigational Site, Newcastle upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT01677910"
541,"NCT02252263","A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma","Completed","No Results Available","All","Phase 1","44","Industry","Interventional","December 9, 2014","October 10, 2017","October 10, 2017","September 30, 2014","null","November 1, 2017","University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT02252263"
542,"NCT01615809","Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia","Completed","Has Results","All","Phase 2","32","Other","Interventional","October 2011","July 2013","July 2013","June 11, 2012","October 23, 2015","March 29, 2018","Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01615809"
543,"NCT01242774","Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)","Completed","No Results Available","All","Phase 1","46","Industry","Interventional","October 2010","May 2014","May 2014","November 17, 2010","null","May 6, 2015","Stanford University Medical Center Stanford U, Stanford, California, United States|Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital, Columbus, Ohio, United States|Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States|Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3, Nashville, Tennessee, United States|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Salamanca, Castilla y Leon, Spain|Novartis Investigative Site, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01242774"
544,"NCT00631371","Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects","Completed","Has Results","All","Phase 3","791","Industry","Interventional","April 2008","April 2012","April 2015","March 7, 2008","June 4, 2013","April 27, 2016","Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States|South County Hematology/Oncology, Chula Vista, California, United States|Cancer Center Oncology Medical Group, La Mesa, California, United States|UCLA Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|North County Oncology Medical Clinic, Oceanside, California, United States|Medical Oncology Associates - SD, San Diego, California, United States|Sharp Memorial Hospital Investigational Pharmacy, San Diego, California, United States|Sharp Rees-Stealy, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Pacific Hematology/Oncology Associates, San Francisco, California, United States|San Francisco Oncology Associates, San francisco, California, United States|Cohen & Hufford MD's INC, San Francisco, California, United States|The Jones Clinic, PC, New Albany, Mississippi, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Edmond Oncology Center, Edmond, Oklahoma, United States|OU Medical Center, Oklahoma City, Oklahoma, United States|OU Physician's Building, Oklahoma City, Oklahoma, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|The Jones Clinic, PC, Germantown, Tennessee, United States|The Vanderbilt Clinic, Nashville, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Centro Oncológico Rosario, Rosario, Santa Fé, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|ISIS Clinica Especializado, Santa Fe, Argentina|Mater Adult Hospital, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Cancer Care SA, Kurralta Park, Australia|Mater Private Hospital, South Brisbane, Australia|ZNA Middelheim, Antwerpen, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Jessa Ziekenhuis - campus Virga Jessa, Hasselt, Belgium|Cliniques Universitaires de Mont-Godinne UCL, Mont-Godinne, Belgium|Centro Goiano de Oncologia, Goiania, GO, Brazil|Centro Goiano de Oncologia - CGO, Goiania, GO, Brazil|ProCura - Centro Goiano de Pesquisa Clínica Ltda, Goiania, GO, Brazil|Clínica de Oncologia de Porto Alegre Sociedade Simples Ltda, Porto Alegre, Rio Grande do Sul, Brazil|Instituto Nacional de Cancer - INCA, Rio de Janeiro, RJ, Brazil|Associaçao Hospital de Caridade Ijui, Ijui, RS, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Clinica de Oncologia de Porto Alegre - Sociedade Simples Ltda., Porto Alegre, RS, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil|Instituto de Oncologia de Piracicaba S/S Ltda, Piracicaba, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira - ICESP, Sao Paulo, SP, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Instituto Nacional do Cancer - INCA, Rio de Janeiro, Brazil|Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Sante et de Services Sociaux de Rimouski - Neigette, Rimouski, Quebec, Canada|Instituto Nacional del Cancer, Santiago, Region Metropolitana / Chile, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Instituto Clinico Oncologico del Sur, Santiago, Chile|Oncologos del Occidente S.A, Pereira, Risaralda, Colombia|Oblastni nemocnice Jicin a s, Jicin, Ceska republika, Czech Republic|Masarykuv onkologicky ustav, Brno, Czech Republic|Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Krajska zdravotni, a.s., Usti nad Labem, Czech Republic|Centre Jean Perrin, Clermont-Ferrand, France|Clinique Sainte Marguerite, Hyères, France|Hopital Andre Mignot, Le Chesnay, France|Centre médical Oncogard, Nimes, France|CHU de Poitiers, Poitiers Cedex, France|CHU de Rouen, Rouen Cedex, France|Centre rené Gauducheau, Saint-Herblain-Nantes, France|Hopital Foch, Suresnes, France|Institut Gustave Roussy, Villejuif Cedex, France|Vivantes Klinikum am Urban, Neztwerk fuer Gesundheit GmbH, Berlin, Germany|Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany|Klinikum Region Hannover, Krankenhaus Siloah, Hannover, Germany|TU Muenchen, rechts der Isar, Muenchen, Germany|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Orszagos Onkologiai Intezet, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Josa Andras Oktato Korhaz Nonprofit Kft., Nyiregyhaza, Hungary|Szegedi Tudomanyegyetem, Urologiai Klinika, Szeged, Hungary|Veszprem Megyei Csolnoky Ferenc, Veszprem, Hungary|Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|Healthcare Global Enterprises Limited, Bangalore, Karnataka, India|Lakeshore Hospital & Research Center Limited, Kochi, Kerala, India|Jawaharlal Nehru Cancer Hospital, Department of Medical Oncology, Bhopal, Madhya Pradesh, India|Tata Memorial Center, Mumbai, Maharashtra, India|Tata Memorial Centre, Navi Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Searoc Cancer Centre, Jaipur, Rajasthan, India|Apollo Hospital, Chennai, Tamil Nadu, India|Regional Cancer Centre, Kerela, Trivandrum, India|Divisione di Urologia, Azienda Ospedaliera Policlinico Consorziale di Bari, Bari, Italy|Sezione di Oncologia Medica Centro di Ricerca Clinica, Chieti, Italy|Unità Operativa di Oncologia, Azienda Ospedaliera Policlinico di Modena, Modena, Italy|Farmacia del Comitato Etico Provinciale di Modena, Modena, Italy|Struttura Complessa di Oncologia Medica Ospedale Santa Maria della Misericordia, Perugia, Italy|IFO- Istituti Fisioterapici Ospitalieri, Roma, Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Yonsei University Health System-Severance Hospital, Seoul, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Aranda de la Parra, Leon, Guanajuato, Mexico|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpital Specjalistyczny im. L. Rydygiera Sp. z o.o., Krakow, Poland|Centrum Onkologii Ziemi Lubelskiej im. sw Jana z Dukli, Lublin, Poland|Szpital Kliniczny Przemienienia Panskiego UM im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland|Centrum Medyczne Ostrobramska NZOZ ""Magodent"", Warszawa, Poland|Wojskowy Instytut Medyczny, Pracownia Badan Cynnosciowych Ukladu Oddechowego, Klinika Chorob Wewnetr, Warszawa, Poland|Wojskowy Intsytut Medyczny, Zaklad Diagnostyki Laboratoryjnej CSK MON, Warszawa, Poland|Wojskowy Intsytut Medyczny, Zaklad Medycyny Nuklearnej CSK MON, Warszawa, Poland|Hospital de San Joao, Porto, Portugal|Hospital de São João, Porto, Portugal|Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia, Obninsk, Kaluga region, Russian Federation|Leningrad Regional Oncology Dispensary, Saint-Petersburg, Leningradskaya oblast, Russian Federation|Republican Clinical Oncology Dispensary of Minzdrav of Tatarstan Republic, Kazan, Russian Federation|Chair of Radiology and Radiotherapy, Moscow, Russian Federation|N.N. Blokhin Russian Cancer Research Center, Department of Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation|N.N. Blokhin Russian Cancer Research Center, Department of Urology, Moscow, Russian Federation|Moscow Scientific Research Oncology Institute P.A. Herzen, Moscow, Russian Federation|Privolzhskiy District Medical Center of Federal Biomedical Agency, Nizhni Novgorod, Russian Federation|Scientific research Institute of Oncology N.N. Petrov, Pesochny, Saint-Petersburg, Russian Federation|City Hospital No.26, Saint-Petersburg, Russian Federation|City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|National Cancer Centre Singapore, Singapore, Singapore|Fakultna Nemocnica s poliklinikou F D Roosevelta, Banska Bystrica, Slovakia|Oddelenie funkcnej diagnostiky, Banska Bystrica, Slovakia|Klinika pneumologie a ftiziologie FNsP LFUK, Bratislava, Slovakia|Fakultna Nemocnica s poliklinikou akad L Derera, Bratislava, Slovakia|Klinica nuklcarncj mediciny, Martin, Slovakia|Klinika nuklearnej mediciny JLF UK a Martinskej fakultnej nemocnice, Martin, Slovakia|Klinika tuberkulozy a plucnych chorob UK JLF a Martinskej fakultnej nemocince, Martin, Slovakia|Nemocnica s poliklinikou Skalica, Skalica, Slovakia|KK MED, s.r.o., Zilina, Slovakia|MEDIVASA s.r.o., Zilina, Slovakia|Nemocnica s poliklinikou Zilina, Zilina, Slovakia|GVI Oncology Trial Unit, Kraaifontein, Cape Town, South Africa|Westridge Medical Centre, Mayville, Durban, South Africa|Pretoria Urology Hospital, Hatfield, Pretoria, South Africa|Panorama Medical Centre, Panorama, Cape Town, Western Cape, South Africa|University of the Witwatersrand Oncology, Parktown, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Dr. Fourie & Voges, Pretoria, South Africa|Institut Catala Doncologia, L'hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Sant Creu I Sant Pau, Barcelona, Spain|Hospital del mar de Barcelona, Barcelona, Spain|Hospital de Madrid Norte-Sanchinarro, Madrid, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Veterans General Hospital-Taipei, Taipei, ROC, Taiwan|Tri-Service General Hospital, Neihu, Tapei, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei TOC, Taiwan|Division of Oncology, Tao Yuan, Taiwan|Universitet, kafedra onkologyy, Chenivtsi, Ukraine|A.P Romodanov Itstitut nejrohirurhii, Chernovtsi, Ukraine|Uchbobo-naukovyi likuvalnyi kompleks DDMU im. M.Gor'kogo, Donetsk, Ukraine|Donetskyy Oblasyy protypukhlynnyy Tsenter, Donetsk, Ukraine|Donetske Obl. clinico-teritorial'ne medichne ob'yednannya, Donetsk, Ukraine|""State Institution """"Institute for Occupational Health of the, Kiev, Ukraine|R.E.Kavetsky Institute of experimental pathology, oncology and radiobiology NAS of Ukraine,Laborator, Kiev, Ukraine|A.P Romodanov Itstitut nejrohirurhii, Kiyv, Ukraine|Oblasnyy onkologychnyy dispanser, onkourologichne viddilennya, Ivano-Frankivskiy Derzhavniy Medichni, Medychna vul., Ivano-Frankivsk, Ukraine|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Christie Hospital, Withington, Manchester, United Kingdom|University of Leeds, Leeds, North Yorkshire, United Kingdom|Guy's Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00631371"
545,"NCT00663559","Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy","Completed","No Results Available","All","Phase 2","59","Other","Interventional","February 2008","August 2009","February 2010","April 22, 2008","null","December 18, 2014","Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Parc Taulí, Sabadell, Barcelona, Spain|Hospital CLINIC, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital de Jaén, Jaén, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00663559"
546,"NCT02049905","Phase 3 Study to Treat Patients With Soft Tissue Sarcomas","Completed","No Results Available","All","Phase 3","433","Industry","Interventional","January 2014","May 2017","May 2017","January 30, 2014","null","June 7, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Associates, PC, Phoenix, Arizona, United States|The University of Arizona, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, Denver, California, United States|City of Hope Medical Group, Duarte, California, United States|Samuel Oschin Cancer Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Stanford University Medical Center, Stanford, California, United States|U of CO Health Sciences Center, Aurora, Colorado, United States|Mayo Clinic, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Oncology Specialists, SC, Niles, Illinois, United States|Kansas City Cancer Center, Overland Park, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Center for Health and Healing, Portland, Oregon, United States|Jefferson Medical College, Philadelphia, Pennsylvania, United States|U of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Center, Hamilton, Ontario, Canada|McGill University, Montreal, Quebec, Canada|Instituto Clinico Oncologica del Sur (ICOS), Lago Puyehue, Temuco Cautin, Chile|Herlev Hospital, Herlev, Denmark|Institut Bergonie, Bordeaux Cedex, Aquitaine, France|Centre Georges Francois Leclerc, Dijon, Bourgogne, France|Hopital Rene Huguenin - Institut Curie, Saint-Cloud, Ile-de-France, France|Institut Gustave Roussy, Villejuif, Ile-de-France, France|Centre Leon Berard, Lyon, Rhone-Alpes, France|Centre Hospitalier Regional et Universitaire - Hospital Bretonneau, Centre, France|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Sharet Institute of Oncology Hadassah Ein Karem Medical Center, Ein Karem, Jerusalem, Israel|Rambam Medical Center, Haifa, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel-Heshomer, Israel|Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, Italy|Azienda Ospedaliero-Universitaria di Bologna-Policlinico S Orsola-Malpighi, Bologna, Italy|IRCCS Instituto Ortopedico Rizzoli, Bologna, Italy|Istituto Europeo di Oncologia Milano, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|Leiden Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands|Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland|State Institution ""Blokhin Cancer Research Centre RAMS"", Moscow, Russian Federation|City Oncology Hospital #2, Moscow, Russian Federation|Republican Clinical Oncologic Dispensary of Ministry of Health Republic Tatarstan, Tatarstan, Russian Federation|Hospital Universitario Son Espases, Palma de Mallorca, Baleares, Spain|Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Inst Catala D'Oncologia, Barcelona, Spain|Consorcio Hospitalario Provincial de Castellon, Castellon, Spain|Hospital Universitario La Paz, Madrid, Spain|Centro Integral Oncologico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid, Spain|Hospital San Carlos Madrid, Madrid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT02049905"
547,"NCT01440088","A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma","Completed","No Results Available","All","Phase 3","640","Industry|Other","Interventional","September 2011","December 2015","May 2016","September 26, 2011","null","June 2, 2016","Mayo Arizona, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|USC-Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Washington Cancer Institute, Washington, District of Columbia, United States|South Florida Center for Gynecologic Oncology, Boca Raton, Florida, United States|Mayo Clinic-Florida-Cancer Clinical Studies Unit, Jacksonville, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Midtown Campus, Atlanta, Georgia, United States|Kootenai Health - Kootenai Cancer Center, Coeur d`Alene, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Oncology Specialists, Park Ridge, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Health Care - University of Iowa Hospital, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute Center for Sarcoma and Bone Oncology, Boston, Massachusetts, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Mayo Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Montefiore, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center, NY, New York, United States|Carolinas Hematology-oncology Associates-Blumenthal Cancer Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Arthur G. James Cancer Hospital and Richard J Solove Research Institue, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburg Medical Center, Pittsburg, Pennsylvania, United States|MUSC - Hollings Cancer Center, Charleston, South Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Vermont, Burlington, Vermont, United States|Virginia Commonwealth Universtiy-Massey Cancer Center, Richmond, Virginia, United States|University of Washington Cancer Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Klinikum Graz, Graz, Austria|Univ. Klinik fur Innere Medizin I Internistische Onkologie Medizinische Universitat Innsbruck, Innsbruck, Austria|Allgemeines Krankenhaus Wien, Wien, Austria|Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg, Leuven, Belgium|Juravinski Cancer Centre at Hamilton Health Sciences - Department of Medicine, Hamilton, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Tom Baker Cancer Centre, Calgary, Canada|Cross Cancer Institute, Edmonton, Canada|Ottawa Health Research Institue, Ottawa, Canada|BCCA- Vancouver Cancer Centre - Division of Medical Oncology, Vancouver, Canada|Cancer Care Manitoba, Winnipeg, Canada|University Hospital Herlev at Copenhagen, Herlev, Copenhagen, Denmark|ICO Rene Gauducheau, Saint Herblain Cedex, Nantes, France|Institut Bergonie, Bordeaux, France|Departement d'Oncologie Medicale, Dijon, France|Centre Leon Berard, Lyon, France|Département d'Oncologie Moléculaire, Institut Paoli-Calmettes (IPC) and U119 Inserm, Marseille, France|Centre Antoine Lacassagne, Nice, France|CHU Strasbourg, Strasbourg, France|Institut Claudius Regaud, Toulouse Cedex, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Helios Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin-Brandenburg, Berlin, Germany|Universitätsklinikum Essen, Essen, Germany|Krankenhaus Nordwest GmbH, Frankfurt, Germany|Medizinische Hochschule Hannover (MHH) - Klinik fuer Haemonstaseologie, Onkologie und Stammzelltransplantation, Hannover, Germany|Div. of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, Germany|Wilhelm's University, Universitatsklinikum Muenster, Medizinische Klinik und Poliklinik A, Albert-Schweitzer-Campus 1, Munster, Germany|Magyar Honvedseg Honvedkorhaz, Onkologiai Osztaly, Budapest, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Megyei Onkologiai Kozpont, Szolnok, Hungary|Sharette Institute of Oncology, Hadassah-Hebrew University Medical Center, Hadassah Medical Org-Ein Karem, Kiryat Hadassah, Jerusalem, Israel|IRCCS Centro di Riferimento Oncologico-Struttura Operativa, Aviano, Pordenone, Italy|Fondazione del Piemonte per l'Oncologia, Instituto per la Ricerca e la Cura del cancro (I.R.C.C.), Dipartimento Oncologico, Direzione Operativa Oncologia Medica a Direzione Universitaria, Candiolo, Torino, Italy|Centro di Riferimento Oncologico (CRO), Aviano, Italy|Azienda Ospedaliera Garibaldi, Catania, Italy|Azienda Ospedaliero Universitaria-Policlinico Paolo Giacco, Palermo, Italy|ASL TO/2 di TORINO_Presidio Sanitario Gradenigo, S.C. di Oncologia, Torino, Italy|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Centrum Onkologii Instytut im M. Sklodowskiej-Curie, Krakow, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland|GUZ ""Regional Oncology Dispensay"", Kazan, Kazan, Russian Federation|ROTSN RAMS them. Н.Н.Блохина NN Blokhin, Moscow, Russian Federation|FGU Moscow Research Institute of Oncology named after P.A. Hertzen of Rosmedtechnology, Moscow, Russian Federation|H.U. Canarias, Hospital Universitario de Canarias. Servicio de Oncología Médica, Tenerife, Canarias, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Sant Joan de Deu, Department de Oncologia, Barcelona, Spain|Hospital Universitario Ramón y Cajal., Madrid, Spain|Universidad Complutense Madrid Facultad de Medicina - Hospital Universitario 12 de Octubre, Servicio de Oncologia Medica Hospital Universitario 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01440088"
548,"NCT01327885","Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma","Completed","Has Results","All","Phase 3","452","Industry","Interventional","March 2011","January 2015","August 2016","April 4, 2011","February 28, 2017","March 12, 2018","Tucson, Arizona, United States|Los Angeles, California, United States|Orange, California, United States|Santa Monica, California, United States|Stanford, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Post Falls, Idaho, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Urbana, Illinois, United States|Iowa City, Iowa, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Newark, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Burlington, Vermont, United States|Seattle, Washington, United States|Ciudad de Buenos Aires, Argentina|San Miguel de Tucuman, Argentina|San Salvador de Jujuy, Argentina|Camperdown, New South Wales, Australia|St Leonards, New South Wales, Australia|Woolloongabba, Queensland, Australia|Woodville South, South Australia, Australia|Nedlands, Western Australia, Australia|Graz, Austria|Salzburg, Austria|Wien, Austria|Bruxelles, Belgium|Leuven, Belgium|Liege, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|Florianopolis, Santa Catarina, Brazil|Barretos, Brazil|Curitiba, Brazil|Jau, Brazil|Porto Alegre, Brazil|Salvador, Brazil|Sao Paulo, Brazil|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czechia|Hradec kralove, Czechia|Novy Jicin, Czechia|Praha 5, Czechia|Herlev, Denmark|Angers, France|Bordeaux, France|Lyon, France|Marseille, France|Nantes, France|Paris, France|Poitiers, France|Saint-Priest en Jarez, France|Villejuif, France|Berlin, Germany|Dresden, Germany|Essen, Germany|Hannover, Germany|Koln, Germany|Mannheim, Germany|Tubingen, Germany|Haifa, Israel|Jerusalem, Israel|Ramat-Gan, Israel|Tel Aviv, Israel|Aviano, Pordenone, Italy|Candiolo, Italy|Milano, Italy|Monza, Italy|Padova, Italy|Rozzano (MI), Italy|Torino, Italy|Daejeon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Leiden, Netherlands|Christchurch, New Zealand|Gdansk, Poland|Gliwice, Poland|Warszawa, Poland|Cluj-Napoca, Romania|Craiova, Romania|Iasi, Romania|Sibiu, Romania|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|Singapore, Singapore|Palma de Mallorca, Baleares, Spain|Badalona, Cataluna, Spain|L'Hospitalet de Llobregat, Cataluna, Spain|Madrid, Comunidad De Madrid, Spain|Barcelona, Spain|Valencia, Spain|Hat Yai, Songkhla, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Pathum Wan, Thailand|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT01327885"
549,"NCT01611142","Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)","Completed","No Results Available","All","Phase 2","38","Industry","Interventional","April 2012","May 2015","May 2015","June 4, 2012","null","June 14, 2016","Aarhus University Hospital, Aarhus, Denmark|CHU Henri Mondor, Créteil Cedex, France|CHRU Lille, Lille Cedex, France|Hopital Saint-Louis, Paris, France|Centre Hospitaliser de Lyon Sud, Pierre Benite, France|Centre Henri Becquerel, Rouen, France|Università di Bologna, Bologna, Italy|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Universitair Medisch Centrum Groningen (UMCG), Groningen, Netherlands|Institut Catalá D`Oncologia, Hospital Duran y Reynals, Barcelona, Spain|Hospital Univesitario 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Guy's Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Cancer Research UK Centre/Southhampton General Hospital, SouthHampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01611142"
550,"NCT01168791","Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma","Completed","No Results Available","All","Phase 3","447","Industry","Interventional","July 2010","March 2013","March 2013","July 23, 2010","null","July 18, 2013","Birmingham, Alabama, United States|Arizona Oncology Associates, Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California, Los Angeles, Los Angeles, California, United States|Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|Pomona, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Medical Oncology Hematology Consultants, Newark, Delaware, United States|MedStar Research Institute, Washington, District of Columbia, United States|Washington, District of Columbia, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Indiana University Simon Cancer Center, Indiannapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Kansas City Cancer Center, Overland Park, Kansas, United States|New Orleans, Louisiana, United States|LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|St.Louis University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Saint Barnabas, West Orange, New Jersey, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|UC Cancer Institute, Cinncinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Bethelehem, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Pennsylvania Oncology/Hematology Associates, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburg, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Burlington, Vermont, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States|Bellin Cancer Center, Green Bay, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Ciudad de Buenos Aires, Argentina|Cordoba, Argentina|Ramos Mejia, Argentina|Instituto CAICI, Rosario, Argentina|Sante Fe, Argentina|North Adelaide Oncology, Adelaide, Australia|Royal Adelaide Hospital, Adelaide, Australia|Camperdown, Australia|East Melbourne, Australia|The Canberra Hospital, Garran, Australia|Garran, Australia|Kurralta Park, Australia|Nedlands, Australia|Prince of Wales Hospital, Randwick, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Antwerp, Belgium|Bruxelles, Belgium|Leuven, Belgium|Liege, Belgium|Institution name: Hospital de Câncer de Barretos - Fundação PIOXII, Barretos, Brazil|Belo Horizonte, Brazil|Santa Casa da Misericórdia de Curitiba, Curitiba, Brazil|Florianopolis, Brazil|Jau, Brazil|Hospital da Cidade de Passo Fundo, Passo Fundo, Brazil|Hospital das Clínicas de Porto Alegre, Porto Alegre, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Centro de Oncologia da Bahia, Salvador, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Santiago, Chile|Instituto Clínico Oncológico del Sur, Temuco, Chile|Vina del Mar, Chile|Bogota, Colombia|Medellin, Colombia|Monteria, Colombia|Angers, France|Bordeaux, France|Institut Paoli Calmettes, Marseilles, France|Marseille, France|Montpellier, France|Nice, France|Paris, France|Toulouse, France|Villejuif, France|HELIOS Klinikum Berlin Buch, Bad Sarrow, Germany|Hannover, Germany|Universitätsklinikum Köln, Koln, Germany|Mannheim, Germany|Tuebingen University Hospital, Tuebingen, Germany|Guatemala, Guatemala|Jaipur, India|Mumbai, India|Nasik, India|Pune, India|Secunderabad, India|Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Ramat-Gan, Israel|Tel Aviv, Israel|Candiolo, Italy|Humanitas Cancer Center, Rozzana, Italy|Ospedale Gradenigo Oncology, Torino, Italy|Centro Hemato Oncologico Paitilla, Panama, Panama|Medical and Research Center, Panama, Panama|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Gilwice, Poland|Centrum Onkologii Instytut, Warszawa, Poland|Bucharest, Romania|Cluj Napoca, Romania|Craiova, Romania|Moscow, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Singapore, Singapore|Badalona, Spain|Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Valencia, Spain|The Royal Marsden NHS Foundation Trust Sarcoma, London, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01168791"
551,"NCT00753688","Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy","Completed","Has Results","All","Phase 3","369","Industry","Interventional","October 2008","November 2010","December 2012","September 16, 2008","December 21, 2011","August 22, 2013","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Santa Monica, California, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Clevand, Ohio, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Woolloongabba, Queensland, Australia|GSK Investigational Site, Kurralta Park, South Australia, Australia|GSK Investigational Site, Hobart, Tasmania, Australia|GSK Investigational Site, Box Hill, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Herlev, Denmark|GSK Investigational Site, Bordeaux cedex, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Lyon Cedex 08, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Paris Cedex 5, France|GSK Investigational Site, Saint-Priest en Jarez, France|GSK Investigational Site, Vandoeuvre-Les-Nancy, France|GSK Investigational Site, Villejuif, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Bad Saarow, Brandenburg, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Rozzano (MI), Lombardia, Italy|GSK Investigational Site, Candiolo (TO), Piemonte, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Terni, Umbria, Italy|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Mie, Japan|GSK Investigational Site, Okayama, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Leiden, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Linköping, Sweden|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT00753688"
552,"NCT00796120","An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)","Completed","Has Results","All","Phase 3","121","Industry","Interventional","November 2008","August 2012","August 2014","November 24, 2008","September 16, 2014","December 10, 2015","Santa Monica, California, United States|Boston, Massachusetts, United States|Albuquerque, New Mexico, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Boreaux, France|Lille, France|Lyon, France|Paris, France|Villejuif, France|Bad Saarow, Germany|Köln, Germany|Mannheim, Germany|Barcelona, Spain|Palma De Mallorca N/A, Spain|Valencia N/A, Spain|Edinburgh, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00796120"
553,"NCT00699517","A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies","Completed","No Results Available","All","Phase 3","355","Industry","Interventional","June 2008","April 2013","April 2013","June 18, 2008","null","December 21, 2015","Investigational Site Number 840004, Santa Monica, California, United States|Investigational Site Number 840003, Orlando, Florida, United States|Investigational Site Number 840005, Maywood, Illinois, United States|Investigational Site Number 840002, Newark, New Jersey, United States|Investigational Site Number 840007, Philadelphia, Pennsylvania, United States|Investigational Site Number 840001, San Antonio, Texas, United States|Investigational Site Number 056001, Bruxelles, Belgium|Investigational Site Number 056004, Haine-Saint-Paul, Belgium|Investigational Site Number 056005, Liège, Belgium|Investigational Site Number 076007, Belo Horizonte, Brazil|Investigational Site Number 076008, Goiania, Brazil|Investigational Site Number 076003, Ijui, Brazil|Investigational Site Number 076004, Jau, Brazil|Investigational Site Number 076006, Novo Hamburgo, Brazil|Investigational Site Number 076002, Porto Alegre, Brazil|Investigational Site Number 076005, Porto Alegre, Brazil|Investigational Site Number 076009, Rio De Janeiro, Brazil|Investigational Site Number 250008, Bordeaux, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250004, Lille, France|Investigational Site Number 250001, Lyon Cedex 03, France|Investigational Site Number 250010, Marseille, France|Investigational Site Number 250006, Montpellier Cedex, France|Investigational Site Number 250007, Nice Cedex 02, France|Investigational Site Number 250005, Rennes, France|Investigational Site Number 250003, Saint Cloud, France|Investigational Site Number 250012, Saint Priest En Jarez, France|Investigational Site Number 250009, Saint-Herblain, France|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348002, Debrecen, Hungary|Investigational Site Number 356005, Bangalore, India|Investigational Site Number 356003, Hyderabad, India|Investigational Site Number 356004, New Delhi, India|Investigational Site Number 380001, Aviano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380004, Milano, Italy|Investigational Site Number 380002, Rozzano, Italy|Investigational Site Number 891001, Belgrade, Serbia|Investigational Site Number 891002, Sremska Kamenica, Serbia|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724003, Pamplona, Spain|Investigational Site Number 826001, Bebington, United Kingdom|Investigational Site Number 826003, Bristol, United Kingdom|Investigational Site Number 826002, Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT00699517"
554,"NCT01008358","Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma","Completed","No Results Available","All","Phase 2","20","Other|Industry","Interventional","December 2008","May 2012","May 2012","November 4, 2009","null","June 8, 2012","Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT01008358"
555,"NCT01915589","Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)","Completed","No Results Available","All","Phase 2","16","Industry","Interventional","September 16, 2013","October 8, 2014","October 8, 2014","August 5, 2013","null","June 14, 2017","Los Angeles, California, United States|Orange, California, United States|Washington, D.C., District of Columbia, United States|Miami, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Westwood, Kansas, United States|Louisville, Kentucky, United States|New York, New York, United States|Rochester, New York, United States|Dallas, Texas, United States|Galveston, Texas, United States|Seattle, Washington, United States|Graz, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Gent, Belgium|Leuven, Belgium|Praha 2, Czechia|CLERMONT-FERRAND Cedex 1, France|Creteil, France|Lille, France|Marseille, France|Montpellier Cedex, France|Vandoeuvre-les-nancy, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Shatin, Hong Kong|Budapest, Hungary|Debrecen, Hungary|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Kashiwa-shi, Chiba, Japan|Kobe, Hyogo, Japan|Moriguchi, Osaka, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Chuo-ku, Tokyo, Japan|Osaka, Japan|Shizuoka, Japan|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Santiago de Compostela, A Coruña, Spain|Barcelona, Catalunya, Spain|Alicante, Spain|Pontevedra, Spain|Valencia, Spain|Genève 14, Genève, Switzerland|Bern, Switzerland|Kaohsiung City, Taiwan|Tainan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Birmingham, West Midlands, United Kingdom","https://ClinicalTrials.gov/show/NCT01915589"
556,"NCT00838357","A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).","Completed","No Results Available","All","Phase 3","118","Industry","Interventional","September 2008","November 2010","November 2010","February 6, 2009","null","March 24, 2015","Hôpital du Haut Lévêque, Bordeaux, France|Hôpital Lyon Sud, Lyon, France|Institut Paoli Calmettes, Marseille, France|CHU Hotel-Dieu Université de Nantes, Nantes, France|Hôpital Saint-Louis, Paris, France|Institut Gustave Roussy, Villejuif, France|Charité - Campus Benjamin Franklin, Berlin, Germany|Klinikum der Universität zu Köln, Cologne, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum Nürnberg Nord, Nürnberg, Germany|Universitätsklinik Würzburg, Würzburg, Germany|L. & A. Seragnoli, University of Bologna, Bologna, Italy|Ospedale Ferrarotto, Catania, Italy|Azienda Ospedaliera S. Martino, Genova, Italy|VU Medisch Centrum, Amsterdam, Netherlands|Hospital Santa Creu y Sant Pau, Barcelona, Spain|Hospital Carlos-Haya, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital la Fe, Valencia, Spain|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Gartnavel Hospital, Glasgow, United Kingdom|St James's University Hospital, Leeds, United Kingdom|King's college Hospital, London, United Kingdom|Nottingham University NHS Trust, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00838357"
557,"NCT01271504","E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma","Completed","No Results Available","All","Phase 1|Phase 2","102","Industry","Interventional","April 2011","June 23, 2015","June 23, 2015","January 6, 2011","null","August 28, 2017","Tucson, Arizona, United States|Fort Myers, Florida, United States|Saint Petersburg, Florida, United States|Chapel Hill, North Carolina, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Nashville, Tennessee, United States|Brussels, Belgium|Bruxelles, Belgium|Leuven, Belgium|Rozzano, Milano, Italy|Modena, Italy|Pavia, Italy|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Lviv, Ukraine|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Glasgow, Strathclyde, United Kingdom","https://ClinicalTrials.gov/show/NCT01271504"
558,"NCT01014208","Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","Completed","Has Results","All","Phase 3","447","Industry","Interventional","March 2010","February 2014","November 2014","November 16, 2009","October 16, 2014","August 7, 2015","GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Westwood, Kansas, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Chaple Hill, North Carolina, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Yvoir, Belgium|GSK Investigational Site, Fuzhou, Fujian, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Jianan, Shandong, China|GSK Investigational Site, Hangzhou, Zhejiang, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Chengdu, China|GSK Investigational Site, Jiang Su Province, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Aarhus, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Szombathely, Hungary|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, James Street, Ireland|GSK Investigational Site, Petach-Tikva, Israel|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Akita, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Okayama, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokushima, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Jellanamdo, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Amersfoort, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Enschede, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Hoofddorp, Netherlands|GSK Investigational Site, Leiden, Netherlands|GSK Investigational Site, Maastricht, Netherlands|GSK Investigational Site, Nieuwegein, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Sittard-geleen, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Zwolle, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Chorzow, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Pozuelo de Alarcón/Madrid, Spain|GSK Investigational Site, Salamanca, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Blackpool, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cheltenham, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Headington, Oxford, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Northwood, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Southampton, United Kingdom|GSK Investigational Site, Whitchurch, Cardiff, United Kingdom|GSK Investigational Site, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01014208"
559,"NCT02102204","Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis","Completed","Has Results","All","Phase 3","902","Industry","Interventional","March 25, 2014","November 4, 2016","June 26, 2017","April 2, 2014","November 17, 2017","November 17, 2017","Research Site, Birmingham, Alabama, United States|Research Site, Alhambra, California, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Cudahy, California, United States|Research Site, Granada Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site, Simi Valley, California, United States|Research Site, Vacaville, California, United States|Research Site, Whittier, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Dublin, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Highland Park, Illinois, United States|Research Site, Merrillville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Brookhaven, Mississippi, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, College Point, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Mineola, New York, United States|Research Site, Rosedale, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Fairfax, Virginia, United States|Research Site, Hampton, Virginia, United States|Research Site, Mechanicsville, Virginia, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Prahan, Victoria, Australia|Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Baudour, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Roeselare, Belgium|Research Site, Tournai, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 6, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Fredericia, Denmark|Research Site, København, Denmark|Research Site, Caen, France|Research Site, La Tronche cedex, France|Research Site, Lille Cedex, France|Research Site, Marseille, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Reims Cedex, France|Research Site, Saint Priest en Jarez, France|Research Site, Saint-Ouen, France|Research Site, Aachen, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Langenhagen, Germany|Research Site, Minden, Germany|Research Site, München, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Wiesbaden, Germany|Research Site, Zwickau, Germany|Research Site, Alexandroupoli, Greece|Research Site, Larissa, Greece|Research Site, Nikaia, Piraeus, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Pecs, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szigetvar, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ashkelon, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Lecco, Italy|Research Site, Lucca, Italy|Research Site, Milano, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Pordenone, Italy|Research Site, Verona, Italy|Research Site, Riga, Latvia|Research Site, Alytus, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Ukmerge, Lithuania|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Hamilton, New Zealand|Research Site, Gdansk, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Sieradz, Poland|Research Site, Wadowice, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zabrze, Poland|Research Site, Zamosc, Poland|Research Site, Zyrardow, Poland|Research Site, Almada, Portugal|Research Site, Aveiro, Portugal|Research Site, Forte da Casa, Portugal|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Santo Tirso, Portugal|Research Site, Setubal, Portugal|Research Site, Vila Franca de Xira, Portugal|Research Site, Mitishi, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Lleida, Cataluña, Spain|Research Site, Torrevieja, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Badajoz, Extremadura, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Karlstad, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Trollhättan, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zurich, Switzerland|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT02102204"
560,"NCT01896232","Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet","Completed","Has Results","All","Phase 3","683","Industry","Interventional","August 13, 2013","November 12, 2014","January 8, 2015","July 11, 2013","March 27, 2017","October 17, 2018","Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Bakersfield, California, United States|Research Site, Chula Vista, California, United States|Research Site, Covina, California, United States|Research Site, Granada Hills, California, United States|Research Site, La Mesa, California, United States|Research Site, La Puente, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Gabriel, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Aurora, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Orange, Connecticut, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pinecrest, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Southgate, Michigan, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Sewell, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Mineola, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Fairfax, Virginia, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Feldkirch, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Genk, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Roeselare, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Novy Jicin, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Praha 6, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Trinec, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aalborg, Denmark|Research Site, Fredericia, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Boulogne sur Mer, France|Research Site, Lille Cedex, France|Research Site, Nouilly, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Saint Ouen, France|Research Site, Saint Priest en Jarez, France|Research Site, Saint-Ouen, France|Research Site, Sainte Foy les Lyon, France|Research Site, Aachen, Germany|Research Site, Coburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Magdeburg, Germany|Research Site, Mettmann, Germany|Research Site, Minden, Germany|Research Site, München, Germany|Research Site, Wiesbaden, Germany|Research Site, Zwickau, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Nikaia, Piraeus, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Pecs, Hungary|Research Site, Pecs, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szigetvar, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Cagliari, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Lecco, Italy|Research Site, Lucca, Italy|Research Site, Milano, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Pordenone, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Alytus, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kedainiai, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Siauliai, Lithuania|Research Site, Ukmerge, Lithuania|Research Site, Hamilton, New Zealand|Research Site, Papatoetoe, Auckland, New Zealand|Research Site, Takapuna, Auckland City, New Zealand|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Sieradz, Poland|Research Site, Wadowice, Poland|Research Site, Warsawa, Poland|Research Site, Warszawa, Poland|Research Site, Zabrze, Poland|Research Site, Zyrardow, Poland|Research Site, Almada, Portugal|Research Site, Aveiro, Portugal|Research Site, Estoril, Portugal|Research Site, Forte Da Casa, Portugal|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Santo Tirso, Portugal|Research Site, Setubal, Portugal|Research Site, Vila Franca de Xira, Portugal|Research Site, Mitishi, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Puerto Real, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Lleida, Cataluña, Spain|Research Site, Torrevieja, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Badajoz, Extremadura, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Galdakao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Trollhättan, Sweden|Research Site, Aarau, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zurich, Switzerland|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT01896232"
561,"NCT01785875","Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","Completed","Has Results","All","Phase 3","891","Industry","Interventional","July 2013","July 2015","July 2015","February 7, 2013","March 27, 2017","March 27, 2017","Research Site, Birmingham, Alabama, United States|Research Site, Pine Bluff, Arkansas, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Chula Vista, California, United States|Research Site, Cudahy, California, United States|Research Site, Fairfield, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Northridge, California, United States|Research Site, Norwalk, California, United States|Research Site, Ontario, California, United States|Research Site, Riverside, California, United States|Research Site, San Gabriel, California, United States|Research Site, Simi Valley, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Coral Springs, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pinecrest, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Evanston, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Merrillville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Brookhaven, Mississippi, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Carrboro, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Columbia, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Forth Worth, Texas, United States|Research Site, Grand Prairie, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Mansfield, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Alexandria, Virginia, United States|Research Site, Alexandria, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Hampton, Virginia, United States|Research Site, Mechanicsville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Baudour, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Roeselare, Belgium|Research Site, Tournai, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hradec Kralove, Czech Republic|Research Site, Novy Jicin, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 4 - Nusle, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Slavkov u Brna, Czech Republic|Research Site, Usti nad Orlici, Czech Republic|Research Site, Bordeaux Cedex, France|Research Site, Caen, France|Research Site, La Tronche cedex, France|Research Site, Marseille cedex 5, France|Research Site, Marseille, France|Research Site, Poitiers, France|Research Site, Reims Cedex, France|Research Site, Saint-Ouen, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Erfurt, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ashkelon, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Nahariya, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Pavia, Italy|Research Site, Verona, Italy|Research Site, Amsterdam, Netherlands|Research Site, Enschede, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zamosc, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Karlstad, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01785875"
562,"NCT01788046","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","Completed","Has Results","All","Phase 3","515","Industry","Interventional","March 12, 2013","April 14, 2014","May 9, 2014","February 11, 2013","March 27, 2017","August 31, 2018","Research Site, Mobile, Alabama, United States|Research Site, Azusa, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Chula Vista, California, United States|Research Site, Fairfield, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Norwalk, California, United States|Research Site, Riverside, California, United States|Research Site, Simi Valley, California, United States|Research Site, Denver, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Merrillville, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Fort Washington, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Brookhaven, Mississippi, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbia, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Rutland, Vermont, United States|Research Site, Alexandria, Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Westmead, New South Wales, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussel, Belgium|Research Site, Liege, Belgium|Research Site, Roeselare, Belgium|Research Site, Tournai, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, New Westminister, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Novy Jicin, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Caen, France|Research Site, Grenoble, France|Research Site, Marseille cedex 5, France|Research Site, Marseille, France|Research Site, Perpignan Cedex, France|Research Site, Erfurt, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Quartu Sant'Elena CA, Italy|Research Site, Amsterdam, Netherlands|Research Site, Enschede, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Gdansk, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Karlstad, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden","https://ClinicalTrials.gov/show/NCT01788046"
563,"NCT01785849","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis","Completed","Has Results","All","Phase 3","508","Industry","Interventional","March 12, 2013","May 22, 2014","June 12, 2014","February 7, 2013","March 27, 2017","September 3, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Pine Bluff, Arkansas, United States|Research Site, Azusa, California, United States|Research Site, Covina, California, United States|Research Site, Lakewood, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Northridge, California, United States|Research Site, Ontario, California, United States|Research Site, Panorama City, California, United States|Research Site, Sacramento, California, United States|Research Site, Whittier, California, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Meridian, Idaho, United States|Research Site, Evanston, Illinois, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Southgate, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Amherst, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Sumter, South Carolina, United States|Research Site, Columbia, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Grand Prairie, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mansfield, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Mechanicsville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Prahan, Victoria, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Baudour, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Praha 6, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Trinec, Czechia|Research Site, Nantes Cedex 01, France|Research Site, Poitiers, France|Research Site, Reims Cedex, France|Research Site, Saint-Ouen, France|Research Site, Salouel Cedex 1, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Kiel, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Pecs, Hungary|Research Site, Ashkelon, Israel|Research Site, Nahariya, Israel|Research Site, Tel Aviv, Israel|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, San Fermo Della Battaglia (CO), Italy|Research Site, Verona, Italy|Research Site, Bialystok, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01785849"
564,"NCT00977080","Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D","Completed","Has Results","All","Phase 4","272","Industry","Interventional","November 2009","May 2011","May 2011","September 15, 2009","June 20, 2012","June 20, 2012","Site Reference ID/Investigator# 22781, Tempe, Arizona, United States|Site Reference ID/Investigator# 24342, Chula Vista, California, United States|Site Reference ID/Investigator# 21142, Los Angeles, California, United States|Site Reference ID/Investigator# 22762, Los Angeles, California, United States|Site Reference ID/Investigator# 22758, Riverside, California, United States|Site Reference ID/Investigator# 21442, San Diego, California, United States|Site Reference ID/Investigator# 23688, Arvada, Colorado, United States|Site Reference ID/Investigator# 21370, Coral Springs, Florida, United States|Site Reference ID/Investigator# 25902, Hudson, Florida, United States|Site Reference ID/Investigator# 21146, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 26743, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 22788, Miami, Florida, United States|Site Reference ID/Investigator# 22722, Orlando, Florida, United States|Site Reference ID/Investigator# 23147, Tampa, Florida, United States|Site Reference ID/Investigator# 22778, Meridian, Idaho, United States|Site Reference ID/Investigator# 21369, Detroit, Michigan, United States|Site Reference ID/Investigator# 22786, Detroit, Michigan, United States|Site Reference ID/Investigator# 21144, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21443, St. Louis, Missouri, United States|Site Reference ID/Investigator# 21145, Omaha, Nebraska, United States|Site Reference ID/Investigator# 22505, Flushing, New York, United States|Site Reference ID/Investigator# 22759, Toledo, Ohio, United States|Site Reference ID/Investigator# 22796, Lancaster, Pennsylvania, United States|Site Reference ID/Investigator# 22770, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 22772, Aiken, South Carolina, United States|Site Reference ID/Investigator# 21147, Orangeburg, South Carolina, United States|Site Reference ID/Investigator# 22982, Houston, Texas, United States|Site Reference ID/Investigator# 21143, Houston, Texas, United States|Site Reference ID/Investigator# 22506, San Antonio, Texas, United States|Site Reference ID/Investigator# 22776, Bluefield, West Virginia, United States|Site Reference ID/Investigator# 22311, Brno, Czech Republic|Site Reference ID/Investigator# 22310, Jilemnice, Czech Republic|Site Reference ID/Investigator# 21624, Usti nad Labem, Czech Republic|Site Reference ID/Investigator# 22363, Aalborg, Denmark|Site Reference ID/Investigator# 23105, Copenhagen, Denmark|Site Reference ID/Investigator# 23909, Fredericia, Denmark|Site Reference ID/Investigator# 22462, Holstebro, Denmark|Site Reference ID/Investigator# 21748, Coburg, Germany|Site Reference ID/Investigator# 33268, Darmstadt, Germany|Site Reference ID/Investigator# 35903, Duesseldorf, Germany|Site Reference ID/Investigator# 21742, Frankfurt, Germany|Site Reference ID/Investigator# 21744, Heilbronn, Germany|Site Reference ID/Investigator# 21368, Luedenscheid, Germany|Site Reference ID/Investigator# 22362, Athens, Greece|Site Reference ID/Investigator# 38970, Thessaloniki, Greece|Site Reference ID/Investigator# 22322, Thessaloniki, Greece|Site Reference ID/Investigator# 22463, Thessaloniki, Greece|Site Reference ID/Investigator# 22323, Thessaloniki, Greece|Site Reference ID/Investigator# 39262, Thessaloniki, Greece|Site Reference ID/Investigator# 22312, Bergamo, Italy|Site Reference ID/Investigator# 21746, Genova, Italy|Site Reference ID/Investigator# 39180, Lucca, Italy|Site Reference ID/Investigator# 22314, Milan, Italy|Site Reference ID/Investigator# 21367, Pavia, Italy|Site Reference ID/Investigator# 21745, Pesaro, Italy|Site Reference ID/Investigator# 21842, Alkmaar, Netherlands|Site Reference ID/Investigator# 22309, Delft, Netherlands|Site Reference ID/Investigator# 21843, Dordrecht, Netherlands|Site Reference ID/Investigator# 38903, Beja, Portugal|Site Reference ID/Investigator# 38531, Faro, Portugal|Site Reference ID/Investigator# 22464, Lisbon, Portugal|Site Reference ID/Investigator# 23910, Vila Franca de Xira, Portugal|Site Reference ID/Investigator# 24643, Moscow, Russian Federation|Site Reference ID/Investigator# 24642, Moscow, Russian Federation|Site Reference ID/Investigator# 21361, Barcelona, Spain|Site Reference ID/Investigator# 21364, Cordoba, Spain|Site Reference ID/Investigator# 22366, L'Hospitalet, Barcelona, Spain|Site Reference ID/Investigator# 38343, Madrid, Spain|Site Reference ID/Investigator# 21362, Madrid, Spain|Site Reference ID/Investigator# 21363, Palma de Mallorca, Spain|Site Reference ID/Investigator# 22367, Pamplona, Spain|Site Reference ID/Investigator# 38462, Puerto de la Cruz, Spain|Site Reference ID/Investigator# 21365, Seville, Spain|Site Reference ID/Investigator# 23913, Linkoping, Sweden|Site Reference ID/Investigator# 23782, Stockholm, Sweden|Site Reference ID/Investigator# 22364, Uppsala, Sweden|Site Reference ID/Investigator# 23912, Birmingham, United Kingdom|Site Reference ID/Investigator# 21747, Coventry, United Kingdom|Site Reference ID/Investigator# 23102, London, United Kingdom|Site Reference ID/Investigator# 23104, London, United Kingdom|Site Reference ID/Investigator# 23103, Manchester, United Kingdom|Site Reference ID/Investigator# 41982, Omagh, Northern Ireland, United Kingdom|Site Reference ID/Investigator# 40222, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT00977080"
565,"NCT01957878","Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL","Completed","No Results Available","Female","Phase 2","239","Industry","Interventional","December 2013","October 2016","October 2016","October 8, 2013","null","December 2, 2016","Regionaal Ziekenhuis Heilig Hart Tienen Hospital, Tienen, Vlaams Brabant, Belgium|Centre for the Evaluation of Vaccination Vaccine & Infectious Disease Institute (VAXINFECTIO) Faculty of Medicine University of Antwerp Belgium, Antwerp, Belgium|Grand Hôpital de Charleroi Site Notre-Dame, Charleroi, Belgium|University Hospitals Leuven, Leuven, Belgium|Helsinki University Central Hospital, Helsinki, Finland|Kuopio University Hospital, Kuopio, Finland|Tampereen yliopistollinen sairaala Hospital, Tampere, Finland|CHU Amiens Hopital Sud, Amiens, France|Hôpital Saint Jacques, Besançon, France|GORH, CHU Estaing, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital Jeanne de Flandre CHU de Lille, Lille, France|CHU de Nîmes - Hopital Universitaire Caremeau, Nîmes, France|Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur (CIC BT505), Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU de Reims Institut Alix de Champagne, Reims, France|Hôpital de Hautepierre, Strasbourg, France|Charité - Universitätsmedizin Berlin Hospital, Berlin, Germany|Universitätsklinikum Erlangen Hospital, Erlangen, Germany|Elisabeth Krankenhaus Essen GmbH - Clinic/Outpatient Facility, Essen, Germany|Klinikum der Friedrich Schiller Universität Jena Hospital, Jena, Germany|LMU Klinikum der Universität- Hospital, München, Germany|Klinikum Wolfsburg Hospital, Wolfsburg, Germany|Center Gynaecological Oncology Amsterdam AMC, NKI-AVL, VUmc, Amsterdam, Netherlands|St. Antonius Ziekenhuis Hospital, Nieuwegein, Netherlands|Hospital Clinic Dept of Obstetrics and Gynecology C/ Villarroel Unidad de Ginecología Oncológica, Instituto Clínico de Ginecología y Obstetricia y Neonatología (ICGON), Hospital Clínic, Instituto de Investigaciones Biomédi, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall D Hebron, Barcelona, Spain|Institut Catala d'Oncologia L'Hopitalet de Llobregat, Barcelona, Spain|Clinica Ginecologica Ceoga, Clinic/Outpatient Facility, Lugo, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz de Madrid, Madrid, Spain|Hospital Universitario ""12 de Octubre"", Madrid, Spain|Hospital Regional Universitario Carlos Haya - Hospital Materno Infantil, Malaga, Spain|Hospital Sagrado Corazón de Sevilla, Sevilla, Spain|Dumfries and Galloway Royal Infirmary Hospital, Dumfries, United Kingdom|Liverpool - GUM - Liverpool Centre for Sexual Health, Liverpool, United Kingdom|St Mary's Hospital, London, United Kingdom|Academic O&G University of Manchester Research - St Mary's Hospital, Manchester, United Kingdom|The Centre for Immunology and Infection Hull York Medical School University of York, York, United Kingdom","https://ClinicalTrials.gov/show/NCT01957878"
566,"NCT02131662","Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap","Completed","Has Results","Female","Phase 2","309","Industry","Interventional","May 15, 2014","May 4, 2016","May 4, 2016","May 6, 2014","December 8, 2017","December 8, 2017","Mesa, Arizona, United States|Tucson, Arizona, United States|San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Southington, Connecticut, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Plantation, Florida, United States|South Miami, Florida, United States|Sandy Springs, Georgia, United States|Naperville, Illinois, United States|Newburgh, Indiana, United States|Marrero, Louisiana, United States|Lincoln, Nebraska, United States|Moorestown, New Jersey, United States|Neptune City, New Jersey, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Chattanooga, Tennessee, United States|Dallas, Texas, United States|Frisco, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Leuven, Belgium|Liege, Belgium|Pleven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Winnipeg, Manitoba, Canada|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Pointe-Claire, Quebec, Canada|Quebec, Canada|Ceske Budejovice, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Pisek, Czechia|Praha 2, Czechia|Praha, Czechia|Espoo, Finland|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Oulu, Finland|Karlsruhe, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|Geseke, Nordrhein-Westfalen, Germany|Bernburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Ilsede, Germany|Debrecen, Hungary|Debrecen, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szentes, Hungary|Matsudo, Chiba, Japan|Iizuka, Fukuoka, Japan|Koriyama, Fukushima, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kanazawa, Ishikawa, Japan|Omura, Nagasaki, Japan|Numazu, Shizuoka, Japan|Kita, Tokyo, Japan|Nakano-ku, Tokyo, Japan|Tacchikawa, Tokyo, Japan|Kumamoto, Japan|Nagano, Japan|Nesttun, Norway|Oslo, Norway|Sellebakk, Norway|Trondheim, Norway|Trondheim, Norway|Aravaca, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Göteborg, Sweden|Stockholm, Sweden|Uppsala, Sweden|Örebro, Sweden|Bern, Switzerland","https://ClinicalTrials.gov/show/NCT02131662"
567,"NCT01512173","Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo","Completed","No Results Available","All","Phase 2","82","Industry","Interventional","January 2012","May 2013","May 2013","January 19, 2012","null","October 30, 2014","CHU Bordeaux Hôpital Pellegrin-Enfants - Unité de Dermatologie pédiatrique, Bordeaux, France|Hôpital Saint Vincent de Paul - Dermatologie Pédiatrique, Lille, France|CHU Lyon Est Hôpital mère enfant - Consultation des angiomes, Lyon Bron, France|CHU Timone - Service de dermatologie, Marseille, France|Hôpital Mère-Enfant - Service de Néonatologie et Réanimation Pédiatrique, Nantes, France|CHU Necker enfants malades - Service de dermatologie, Paris, France|CHU Saint-Etienne Hôpital Nord - Service de dermatologie, Saint-Etienne, France|CHU Toulouse Hôpital des enfants - Département cardio-pédiatrique, Toulouse, France|Hôpital de Clocheville - Centre de Pédiatrie Gatien, Tours, France|Pomorskie Centrum Traumatologii im. M. Kopernika w Gdańsku Klinika Chirurgii i Urologii Dzieci i Młodzieży GUMed, Gdańsk, Poland|Uniwersytet Medyczny w Łodzi Klinika Chirurgii i Onkologii Dziecięcej, Lodz, Poland|Instytut ""Pomnik-Centrum Zdrowia Dziecka"", Klinika Onkologii, Warszawa, Poland|Hospital Sant Pau de Barcelona, Barcelona, Spain|Hospital Universitario Infantil Niño Jesús, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01512173"
568,"NCT01367665","STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma","Completed","No Results Available","All","Phase 2","1226","Industry","Interventional","July 1, 2011","June 14, 2017","June 14, 2017","June 7, 2011","null","August 30, 2017","Inst. de Oncologia Angel H. Roffo ; Servicio de Oncologia, Buenos Aires, Argentina|Premier Specialists, Kogarah, New South Wales, Australia|Skin and Cancer Foundation Australia, Westmead, New South Wales, Australia|CMAX A division of IDT Australia Limited, Adelaide, South Australia, Australia|Skin & Cancer Foundation, Carlton, Victoria, Australia|LKH Graz; Abteilung für allgemeine Dermatologie, Graz, Austria|LKH Salzburg; Universitätsklinik für Dermatologie, Salzburg, Austria|Landesklinikum St. Pölten, St. Pölten, Austria|Medizinische Universität Wien; Univ.Klinik für Dermatologie, Wien, Austria|UZ Leuven Gasthuisberg, Leuven, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|District Oncology Dispensary; Department for Oncology and Dermatology, Plovdiv, Bulgaria|National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic, Sofia, Bulgaria|Western Canada Dermatology Institute, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|London Regional Cancer Centre, London, Ontario, Canada|Dr. Nowell Solish Cosmetic Dermatology, Toronto, Ontario, Canada|Victoria Park MediSpa, Montreal, Quebec, Canada|Centre de Recherche Dermatologique du Quebec Metropolitain (CRDQ), Quebec, Canada|Inst. Nacional de Cancerologia; Clinica de Seno, Bogota, Colombia|Riesgo De Fractura; Rheumatology, Bogota, Colombia|Hemato Oncologos S.A., Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Reumalab Sas; Rheumatology, Medellin, Colombia|Clinical Hospital Sisters of Mercy, Zagreb, Croatia|Nemocnice Ceske Budejovice, Ceske Budejovice, Czechia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultní nemocnice Ostrava; Kožní oddělení, Ostrava, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni, Praha, Czechia|Herlev Hospital; Onkologisk afdeling, Herlev, Denmark|Helsinki University Central Hospital; Skin & Allergy Hospital, Helsinki, Finland|Kuopion yliopistollinen sairaala, Kuopio, Finland|Hopital Saint Andre CHU De Bordeaux; Dermatologie, Bordeaux, France|Hopital Ambroise Pare; Sce Dermatologie, Boulogne-billancourt, France|Chu Site Du Bocage;Dermatologie, Dijon, France|Hopital Claude Huriez; Sce Dermatologie, Lille, France|Hopital Timone Adultes; Dermatologie, Marseille, France|Hopital Saint Eloi; CHU de Montpellier; Svc de Dermatologie, Montpellier, France|Hopital Hotel Dieu Et Hme; Clinique Dermatologique, Nantes, France|Hopital Saint Louis; Dermatologie 1, Paris, France|Centre Hospitalier Lyon Sud; Dermatologie, Pierre Benite, France|Hôpital Larrey Université Paul Sabatier; Service Dermatologie, Toulouse, France|Institut Gustave Roussy; Comite 5, Villejuif, France|Charité Campus Mitte; Hauttumorcentrum Charité (HTCC); Klinik für Dermatologie, Venerologie und Alle, Berlin, Germany|Vivantes Klinikum Spandau, Berlin, Germany|Elbekliniken Buxtehude; Klinik für Dermatologie, Buxtehude, Germany|Klinikum Dortmund gGmbH Klinikzentrum Mitte, Dortmund, Germany|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Dermatologie, Dresden, Germany|Universitätsklinikum Düsseldorf; Hautklinik, Düsseldorf, Germany|HELIOS Klinikum Erfurt, Klinik für Hautkrankheiten und Allergologie, Erfurt, Germany|Universitätsklinikum Essen, Essen, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany|Universitätsklinikum Freiburg Universitäts-Hautklinik, Freiburg, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, Germany|Universitätsmedizin Greifswald; Klinik für MKG-Chirurgie und Plastische Operationen, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Klinik f.Dermatologie, Hamburg, Germany|Medizinische Hochschule Hannover; Klinik für Dermatologie, Allergologie und Venerologie, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum am Gesundbrunnen; Tumorzentrum, Heilbronn, Germany|Klinikum Kassel; Hautklinik, Kassel, Germany|UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie, Kiel, Germany|Klinik der Uni zu Köln; Klinik & Poliklinik fuer Dermatologie & Venerologie, Köln, Germany|Klinikum d.Stadt Ludwigshafen Hautklinik, Ludwigshafen, Germany|Uni Schleswig-Holstein; Klinik für Dermatologie, Allergologie und Venerologie (Hautklinik), Lübeck, Germany|Universitätsklinikum Magdeburg; Hautklinik; Klinik für Dermatologie und Venerologie, Magdeburg, Germany|Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, Mannheim, Germany|Universitätsklinikum Marburg Klinik f. Dermatologie, Marburg, Germany|Universitätsklinikum Münster; Klinik für Hautkrankheiten; Allgemeine Dermatologie und Venerologie, Muenster, Germany|Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie, München, Germany|Klinikum rechts der Isar der TU München; Klinik & Poliklinik für Dermatologie und Allergologie, München, Germany|Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie, Nürnberg, Germany|Klinikum Dorothea Ch.Erxleben; Klinik für Dermatologie und Allergologie, Quedlinburg, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany|Universitaets-Hautklinik Tuebingen, Tübingen, Germany|Universitätsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie, Würzburg, Germany|Laiko General Hospital; 1St Pathological Clinic, Athens, Greece|Andreas Syggros Hospital; 1st University Dermatology Clinic; Oncology Department, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University General Hospital of loannina; Dermatology and Venereal Diseases Clinic, Ioannina, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Debreceni Egyetem OEC; Borgyogyaszati Klinika, Debrecen, Hungary|Kaposi Mor Teaching Hospital, Kaposvár, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, Hungary|Cork University Hospital; Dermatology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland|Rambam Medical Center, Haifa, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel|Sheba Medical Center; Tel Hashomer, Ramat Gan, Israel|Ospedale San Salvatore (ASL-01); Dip. di Dermatologia U.O.S. di Dermatologia Oncol, L'Aquila, Abruzzo, Italy|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Policlinico Sant'Orsola Malpighi; U.O. Dermatologia, Bologna, Emilia-Romagna, Italy|I.R.S.T. Srl - Meldola - FC; Day Hospital Oncologico, Meldola, Emilia-Romagna, Italy|Azienda Ospedaliera Umberto I; Clinica Dermatologica, Roma, Lazio, Italy|Fondazione Ptv Policlinico Tor Vergata; Dermatologia, Roma, Lazio, Italy|Istituto Dermatologico San Gallicano IRCCS; Dermatologia Oncolgica, Roma, Lazio, Italy|Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Università di Brescia; Dipartimento di Dermatologia, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Farmacia, Rozzano, Lombardia, Italy|A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica, Ancona, Marche, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Ospedale Armando Businco; Dermatologia, Cagliari, Sardegna, Italy|Ospedale IOT- Palagi Dermatologia 2, Firenze, Toscana, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|National Cancer Institute, Vilnius, Lithuania|Hospital General de México, Mexico City, Mexico|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|LUMC; Dermatologie, Leiden, Netherlands|Maastricht University Medical Centre; Dermatologie, Maastricht, Netherlands|Erasmus MC; Dermatology, Rotterdam, Netherlands|Waitemata District Health; General Surgery, Takapuna, New Zealand|Oslo Universitetssykehus HF; Radiumhospitalet, Oslo, Norway|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdańsk, Poland|DERMED Centrum Medyczne; Sp zoo, Lodz, Poland|Centrum Diagnostyki Znamion, Poznan, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie; Klinika Onkologiczna, Warsaw, Poland|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Oncology Center Sf. Nectarie, Craiova, Romania|Spital Clinic Judetean Mures; Oncologie, Targu Mures, Romania|S.C. Life Search S.R.L; Medical Oncology Clinic, Timisoara, Romania|FSBI ""Scientific Research Institute of Oncology named after N.N.Petrov"" Ministry of Health of RF, St Petersburg, Leningrad, Russian Federation|Russian Cancer Research Center, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Fakultna Nemocnica Roosevelta, Banska Bystrica, Slovakia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Hospital Univ. Central de Asturias; Servicio de Dermatologia, Oviedo, Asturias, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Hospital de Gran Canaria Dr. Negrin; Servicio de Dermatologia, Las Palmas de Gran Canaria, Las Palmas, Spain|Fundacion Hospital de Alcorcon; Servicio de Dermatologia, Alcorcon, Madrid, Spain|Hospital Universitario del Sureste; Servicio de Dermatologia, Arganda del Rey, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Dermatologia, Pamplona, Navarra, Spain|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Dermatologia, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Dermatologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de dermatología, Barcelona, Spain|Hospital Reina Sofia; Servicio de dermatología, Cordoba, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, Spain|Hospital General Universitario de Guadalajara; Servicio de Dermatologia, Guadalajara, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Dermatologia, Murcia, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Dermatologia, Toledo, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Dermatologia, Zaragoza, Spain|Skånes Onkologiska Klinik, Universitetssjukhuset, Lund, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Universitätsspital Zürich; Dermatologische Klinik, Zürich, Switzerland|Ankara Numune Training and Research Hospital; Dermatology, Ankara, Turkey|Gazi Universitesi Tip Facultesi; Dept. of Dermatology, Ankara, Turkey|Istanbul Uni of Medicine Faculty; Oncology Dept, Istanbul, Turkey|Dokuz Eylul University Medicine Faculty; Dermatology, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, ANKARA, Turkey|Addenbrookes Hospital; Cambridge Cancer Trials Centre, S4 Box 279, Cambridge, United Kingdom|Western Infirmary; Division of Cardiovascular and Medical Sciences, Glasgow, United Kingdom|St Thomas Hospital, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Freeman Hospital; Northern Centre For Cancer Care, New Castle upon Tyne, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01367665"
569,"NCT01223027","Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma","Completed","Has Results","All","Phase 3","564","Industry","Interventional","March 2011","June 2014","June 2014","October 18, 2010","November 6, 2015","December 7, 2015","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5), La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai Medical Ctr. (SC), Los Angeles, California, United States|University of California at Los Angeles UCLA (4), Los Angeles, California, United States|Stanford University Medical Center Cancer Clinical Trials Office, Stanford, California, United States|Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States|Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Straub Clinic & Hospital Straub, Honolulu, Hawaii, United States|Moanalua Medical Center. Attn: Oncology Dept, Honolulu, Hawaii, United States|University of Kansas Cancer Center Univ of KS, Kansas City, Kansas, United States|University of Maryland Medical Center UMMC, Baltimore, Maryland, United States|Karmanos Cancer Institute Dept.of KarmanosCancerInst (5), Detroit, Michigan, United States|University of Minnesota Medical Center - Fairview Univ of MN, Minneapolis, Minnesota, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas, Nevada, United States|CINJ at Cooper University Hospital Cooper, Voorhees, New Jersey, United States|Memorial Sloan Kettering Cancer Center Dept. of MSKCC, NY, New York, United States|SUNY - Upstate Medical University Div. of Hematology-Oncology, Syracuse, New York, United States|New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Troy, New York, United States|Willamette Valley Clinical Studies Williamette Valley Cancer, Eugene, Oregon, United States|St. Luke's Hospital and Health Network St Luke's, Bethlehem, Pennsylvania, United States|Medical University of South Carolina -Hollings Cancer Center Med Univ SC, Charleston, South Carolina, United States|Cancer Centers of the Carolinas CC of C -Eastside, Greenville, South Carolina, United States|Sarah Cannon Research Institute SC - 3, Chattanooga, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Vanderbilt University Medical Center SC, Nashville, Tennessee, United States|Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (4), Dallas, Texas, United States|Texas Oncology Texas Onc - Austin, Dallas, Texas, United States|Texas Oncology Texas Oncology - Houston, Dallas, Texas, United States|University of Texas Southwestern Medical Center UTSW, Dallas, Texas, United States|Deke Slayton Cancer Center Deke Slayton Cancer Center (2), Webster, Texas, United States|Utah Cancer Specialists Dept.of Utah Cancer Spec. (3), Salt Lake City, Utah, United States|University of Virginia Health Systems Univ Virginia, Charlottesville, Virginia, United States|Rockwood Clinic Spokane Location, Spokane, Washington, United States|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Woodville, South Australia, Australia|Novartis Investigative Site, Footscray, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liège, Belgium|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Praha 5, Czech Republic|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Saint Priest en Jarez Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Suresnes, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy Cede, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Zrifin, Israel|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Toon-city, Ehime, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Obihiro, Hokkaido, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Matsumoto, Nagano, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Takatsuki-city, Osaka, Japan|Novartis Investigative Site, Hidaka, Saitama, Japan|Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Yamagata, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Meerssen, KR, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Ålesund, Norway|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Benidorm, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Las Palmas de Gran Canarias, Las Palmas de Gran Canaria, Spain|Novartis Investigative Site, Alcorcon, Madrid, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Sundsvall, Sweden|Novartis Investigative Site, Umeå, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bristol, Avon, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Colchester, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01223027"
570,"NCT01327053","A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma","Completed","Has Results","All","Phase 2","229","Industry","Interventional","June 29, 2011","June 28, 2013","December 22, 2017","April 1, 2011","November 23, 2015","August 7, 2018","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|University of California at Los Angeles UCLA 3, Los Angeles, California, United States|Stanford University Medical Center Stanford Univ 2, Stanford, California, United States|University of Colorado UC, Aurora, Colorado, United States|Washington Hospital Center Wash Hospital, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center & Research Institute Cutaneous Onc Dept, Tampa, Florida, United States|NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Study coordinator, Chicago, Illinois, United States|Dana Farber Cancer Institute DFCI - MA, Boston, Massachusetts, United States|Henry Ford Hospital Henry Ford, Detroit, Michigan, United States|Washington University School Of Medicine-Siteman Cancer Ctr Siteman, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2), Las Vegas, Nevada, United States|Hackensack University Medical Center Hackensack (SC), Hackensack, New Jersey, United States|New York University Medical Center SC-2, New York, New York, United States|Penn State University / Milton S. Hershey Medical Center Hershey Medical, Hershey, Pennsylvania, United States|University of Pittsburgh Medical Center UPMC, Pittsburgh, Pennsylvania, United States|Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas, United States|Texas Oncology Tex Onc 3, Dallas, Texas, United States|Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States|University of Texas/MD Anderson Cancer Center MD Anderson, Houston, Texas, United States|Texas Oncology Cancer Care & Research Center, Waco, Texas, United States|Texoma Cancer Center Texoma Cancer Center, Wichita Falls, Texas, United States|University of Utah / Huntsman Cancer Institute Huntsman/Univ UT, Salt Lake City, Utah, United States|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Waterloo, Ontario, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille Cedex 05, France|Novartis Investigative Site, Pierre-Benite Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Gera, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Stade, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Genève, Switzerland|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, High Heaton, Newcastle Upon Tyne, United Kingdom|Novartis Investigative Site, Yeovil, Somerset, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01327053"
571,"NCT01480479","Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma","Completed","No Results Available","All","Phase 3","745","Industry","Interventional","November 2011","November 2016","November 2016","November 29, 2011","null","January 16, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of Arizona Health Network, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope Cancer Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente, Redwood City Medical Center, Redwood City, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford Cancer Institute, Stanford University, Stanford, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale University Medical Center, New Haven, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Medical Center, Comprehensive Cancer Center, Miami Beach, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Atlanta Cancer Care, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Covenant Clinic / Iowa Spine and Brain Institute, Waterloo, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, PC, Bethesda, Maryland, United States|Dana-Farber Cancer Institute and Mass General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Edward W. Sparrow Hospital Association - Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary's of Michigan Medical Center/Field Neurosciences Institute, Saginaw, Michigan, United States|Allina Health, Abbott Northwestern Hospital, John Nasseff Neuroscience Institute, Minneapolis, Minnesota, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|New Jersey Neuroscience Institute, JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Dent Neurosciences Research Institute, Amherst, New York, United States|Montefiore Medical Center, Bronx, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|The Long Island Brain Tumor Center at Neurology Surgery, P.C., Great Neck, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Columbia University Medical Center - The Neurologic Institute of New York, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Brain and Spine Surgeons of New York, White Plains, New York, United States|The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|University Hospitals, Case Medical Center (Cleveland), Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Oncology & Hematology Care, Portland, Oregon, United States|Pacific Neurosurgical, Portland, Oregon, United States|Lehigh Valley Physician Group-Hematology-Oncology Associates, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|West Penn. Allegheny Health System, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina - Department of Neuroscience, Charleston, South Carolina, United States|University of Tennessee Medical Center - Knoxville, Knoxville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology Midtwon, Austin, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|The Methodist Neurological Institute, Houston, Texas, United States|University of Utah Department of Neurosurgery, Salt Lake City, Utah, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Virginia Healthcare System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Adult Hospital, Mater Misericordiae Health Services Brisbane Limited, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Calvary North Adelaide Hospital, North Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Epworth Healthcare, Richmond, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Liverpool Hospital, Liverpool, Australia|Medical University Innsbruck, Dept of Neurology, Anichstrabe 35, Innsbruck, Austria|Medizinische Universität Wien, Innere Medizin I, Onkologie, Vienna, Austria|Universitair Ziekenhuis Antwerpen, Edegem, Antwerp, Belgium|ZNA Middelheim, Antwerpen, Belgium|Ghent University Hospital, Ghent, Belgium|Hospital Mae de Deus-Centro de Pesquisa em Oncologia Clinica, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisas Clinicas da Fundação Dr Amaral Carvalho, Jaú, São Paulo, Brazil|Fundação Faculdade Regional de Medicina de de São José do Rio Preto - Hospital de Base, São José do Rio Preto, São Paulo, Brazil|Instituto Nacional do Cancer (INCA), Rio de Janeiro, Brazil|Hospital Albert Einstein, Sao Paulo, Brazil|Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiência/ Hospital São José, São Paulo, Brazil|Hospital A C Camargo, São Paulo, Brazil|Foothills Hospital Medical Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver Clinic, Vancouver, British Columbia, Canada|BC Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada|University of Manitoba-Cancer Care Manitoba, Winnipeg, Manitoba, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital, Regional Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|CHUS Hôpital Fleurimont, Shenbrooke, Quebec, Canada|CHUQ L'Hotel Dieu de Qujebec, Quebec, Canada|Fundacion Santa Fe, Bogota, Bogota D.C, Colombia|Hospital Ceske Budejovice, Ceske Budejovice, Czechia|Umiversity Hospital (Fakultni Nemocnice), Prague, Czechia|Hospital Na Homolce, Prague, Czechia|Multiscan s.r.o., Praha 5, Czechia|Masaryk´s Hospital Usti nad Labem, Usti nad Labem, Czechia|Institut de Cancerologie de I'Quest-Paul Papin, Angers, France|Institute Bergonie, Bordeaux, France|Centre Leon Berard de Lyon, Lyon, France|ICM Val d'Aurel Montpellier, Montpellier, France|Institut de Cancerologie de L'Quest-Center Rane Gauducheau, Nantes, France|Service de Neurologie-GH, Paris, France|Centre Eugene Marquis, Rennes, France|Institut de Cancerologie de l'ouest-Center Rene Gauducheau, St Herblain, France|Institut Gustave Roussy, Villejuif, France|Klinik und Poliklinik fur Neurologie der Universitat Regensburg, Regensburg, Bavaria, Germany|Strahlenklinik Universitatsklinikum Erlangen, Erlangen, Germany|Dr. Senchkenbergisches Institut fur Neuroonkologie, Frankfurt, Germany|University Hospital Hamburg Kopf und Neurozentrum, Hamburg, Germany|Universitaetsklinikum Heidelberg, Neurologische Klinik, IM Neuenheimer Feld 672, Heidelberg, Germany|University Medical Centre, Kiel, Germany|Universitaetsklinikum Muenster, Muenster, Germany|LMU Munich, Munich, Germany|NNA, Athens, Attiki, Greece|""HYGEIA"" Hospital, Marousi, District Of Attica, Greece|Országos Onkológiai Intézet Sugárterápiás Osztály, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum Onkológiai Intézet, Debrecen, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Sugárterápiás Osztály, Miskolc, Hungary|Pécsi Tudományegyetem Általános Orvostudományi Kar, Pécs, Hungary|Szegedi Tudományegyetem Onkoterápiás Klinika, Szeged, Hungary|Vas Megyei Markusovszky Lajos Általános Rehabilitációs és Gyógyfürdő Kórház, Egyetemi Oktatókórház Nonprofit Zrt, Szombathely, Hungary|City Cancer Centre, Vijayawada, Vijayawada, Andhra Pradesh, India|HCG - Bangalore Institute of Oncology, Bangalore, Bengaluru, Karnataka, India|Amrita Institute of Medical Sciences and Research Centre, Kochi, Kochi, Kerala, India|Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, Thiruvananthapuram, Kerala, India|Marathwada Regional Cancer Centre and Research Institute - Government, Aurangabad, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Andheri-West, Mumbai, India|Tata Memorial Hospital , Mumbai, Parel, Mumbai, India|Indraprastha Apollo Hospital, New Delhi, Jasola Viha, New Delhi, India|Sahyadri Hospitals Limited, Erandauame, Pune, India|Dr. Rai Memorial Medical Centre, Chennai, Chennai, Tamil Nadu, India|HCG Shanti Mukand Hospital - Curie Cancer Centre, Delhi, Delhi, India|Soroka University M.C., Beer-Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|SHEBA Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|UO Oncologie Medica Dipartimento Oncologico, Bologna, Italy|Fondazione IRCCS Instituto Neurologico Carlo Besta, Milano, Italy|Sacred Heart Catholic University, Rome, Italy|Universita e AO Citta delia Scienza, Universita Di Torino, Torino, Italy|Grupo Médico Camino S.C., Mexico, D.F, Mexico|Hospital Civil de Guadalajara ""Fray Antonio Alcalde"", Guadalajara, Jalisco, Mexico|Ensayos Clínicos y Medicina de Alta Especialidad, S.C., Culiacán, Sinaloa, Mexico|Servicios Medicos de Investigacion Clinica Sc, Durango, Mexico|Hospital Central ""Ignacio Morones Prieto"", San Luis Potosí, Mexico|Medisch Centrum Haaglanden, The Hague, Zuid Holland, Netherlands|VUMC, Amsterdam, Netherlands|Radboud University Nijmegen Medical Center, Nijmegen, Netherlands|Christchurch Hospital, Christchurch Central, Christchurch, New Zealand|Palmerston North Hospital, Roslyn, Palmerston North, New Zealand|Waikato Hospital, Regional Cancer Centre, Hamilton, Waikato District, New Zealand|Waikato Hospital, Regional Cancer Center, Hamilton, Waikato Distric, New Zealand|Hospital Almanzor Aguinaga Asenjo, Chiclayo, Peru|Instituto Oncologico Miraflores, Lima, Peru|Clinica Anglo Americana, Lima, Peru|Clinica Ricardo Palma, Lima, Peru|Oncosalud, Lima, Peru|Institut Catala d Oncologia, LaHospitalet De Lubregat, Catalonia, Spain|Dra. Sonia Del Barco Berron, ICO Girona Avda,, Franca, Girona, Spain|Hospital Clinic, Barcelona, Spain|ICO Badalona-Hospital Germans Trias i Pujol, Barcelonia, Spain|Hospital 12 de Octubre, Madrid, Spain|Kantonsspital Aarau Medizinische Onkologie Tellstrasse, Aarau, AG, Switzerland|CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, VD, Switzerland|Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland|Inselspital, Universitatsspital Bern, Universitatsklinik fur Medizinische Onkologie, Freiburgstrasse, Bern, Switzerland|Hopitaux Universitaires de Geneve-HUG-Centre d'Oncologie, Geneva, Switzerland|Brain Tumor Center, University Hospital Zurich, Zurich, Switzerland|National Cheng Kung University Hospital, Tainan City, Bei District, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan City - Yongkang District, Taiwan|Tri-Service General Hospital, Taipei city - Neihu District, Taiwan|Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Patumwan, Bankok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Amphoe Muang, Chiang Mai, Thailand|Songkhlanagarind Hospital, Hat Yai, Songkla, Thailand|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|The Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centrel, Glasgow, United Kingdom|Guy's and St Thomas' NHS, Westminister Bridge Road, London, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT01480479"
572,"NCT00824265","Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia","Completed","Has Results","All","Phase 3","365","Industry","Interventional","March 12, 2009","December 17, 2014","October 25, 2017","January 16, 2009","July 25, 2016","November 9, 2018","Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Clinton, Maryland, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Brasilia, Goiás, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigational Site, Porto Alegre, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigation Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigational Site, Sao Paulo, Brazil|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigational Site, Sofia, Bulgaria|Novartis Investigational Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, New Westminster, British Columbia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Lehrte, Niedersachsen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach-Rheydt, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigational Site, Hamburg, Germany|Novartis Investigational Site, Lubeck, Germany|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Vadodara, India|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Pavia, Lombardia, Italy|Novartis Investigative Site, Ascoli Piceno, Marche, Italy|Novartis Investigative Site, Alessandria, Piemonte, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Catania, Sicilia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Iasi, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei city, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigational Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Cherkasy, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Khmelnytskyi, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Makiivka, Ukraine|Novartis Investigational Site, Simferopil, Ukraine|Novartis Investigative Site, Vinnitsa, Ukraine|Novartis Investigational Site, Zhytomyr, Ukraine|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bradford, United Kingdom|Novartis Investigative Site, Burton on Trent, United Kingdom|Novartis Investigative Site, Cottingham, United Kingdom|Novartis Investigative Site, Dudley, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom|Novartis Investigative Site, Swindon, United Kingdom|Novartis Investigative Site, Truro, United Kingdom|Novartis Investigative Site, Uxbridge, United Kingdom","https://ClinicalTrials.gov/show/NCT00824265"
573,"NCT01915602","Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)","Completed","No Results Available","All","Phase 2","14","Industry","Interventional","September 27, 2013","July 29, 2015","February 8, 2017","August 5, 2013","null","May 15, 2017","La Jolla, California, United States|Washington, D.C., District of Columbia, United States|Fairway, Kansas, United States|Louisville, Kentucky, United States|Ann Arbor, Michigan, United States|New York, New York, United States|Cleveland, Ohio, United States|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Liege, Belgium|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Beijing, China|Beijing, China|Shanghai, China|Hradec Kralove, Czechia|Olomouc, Czechia|Praha 5, Czechia|Bordeaux, France|Caen Cedex, France|Clichy, France|Lille, France|Lyon, France|Marseille, France|Nice Cedex 3, France|Paris, France|Saint-priest-en-jarez, France|Vandoeuvre-les-nancy, France|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Zalaegerszeg, Hungary|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Nagoya, Aichi, Japan|Chiba-shi, Chiba, Japan|Fukuoka-shi, Fukuoka, Japan|Yokohama, Kanagawa, Japan|Osakasayama-shi, Osaka, Japan|Irima-gun, Saitama, Japan|Bunkyo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Singapore, Singapore|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Hospitalet de Llobregat, Barcelona, Spain|Vigo, Pontevedra, Spain|Madrid, Spain|Madrid, Spain|Bern, Switzerland|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Chiang Mai, Thailand|Khon Kaen, Thailand|Songkhla, Thailand|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Mersin, Turkey|Birmingham, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT01915602"
574,"NCT00903175","Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma","Completed","Has Results","All","Phase 2","471","Industry","Interventional","October 2009","May 2015","May 2015","May 18, 2009","June 28, 2016","November 8, 2016","University of Alabama at Birmingham/ Kirklin Clinic Comprehensive CancerCenter (1), Birmingham, Alabama, United States|University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst., Mobile, Alabama, United States|Highlands Oncology Group HighlandsOncGrp-Bentonville(2), Fayetteville, Arkansas, United States|University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5), La Jolla, California, United States|University of California at Los Angeles Dept. of UCLA (3), Los Angeles, California, United States|University of Colorado Dept. of Anschutz Cancer (2), Aurora, Colorado, United States|Norwalk Hospital Norwlak SC, Norwalk, Connecticut, United States|Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Ctr (2, Washington, District of Columbia, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|University of Miami SC, Miami, Florida, United States|MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando, Orlando, Florida, United States|University Cancer & Blood Center, LLC Dept of NE GCC (2), Athens, Georgia, United States|Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept.ofNorthwesternMemHospital, Chicago, Illinois, United States|Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3), Maywood, Illinois, United States|Crescent City Research Consortium, LLC SC, Metairie, Louisiana, United States|VA Maryland Health Care Dept.of GreenbaumCancerCent(7), Baltimore, Maryland, United States|Weinberg Cancer Institute at Franklin Square Hospital, Baltimore, Maryland, United States|Billings Clinic Dept of Billings Clinic(2), Billings, Montana, United States|Hackensack University Medical Center DeptofHackensackUniv.MedCtr., Hackensack, New Jersey, United States|Cooper Cancer Center, Voorhees, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center Dept. of MSKCC, NY, New York, United States|SUNY - Upstate Medical University Div. of Hematology-Oncology, Syracuse, New York, United States|University of North Carolina Dept. of LinbergerCancerCtr(3), Chapel Hill, North Carolina, United States|Levine Cancer Institute Oncology, Charlotte, North Carolina, United States|Duke University Medical Center Duke, Durham, North Carolina, United States|University of Oklahoma Health Sciences Center Dept of OHSC, Oklahoma City, Oklahoma, United States|St. Luke's Hospital and Health Network St Luke's Hospital (2), Bethlehem, Pennsylvania, United States|The West Clinic Dept. of the West Clinic, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2), Fort Worth, Texas, United States|East Texas Medical Center Cancer Institute, Tyler, Texas, United States|Utah Cancer Specialists Dept.of Utah Cancer Spec. (3), Salt Lake City, Utah, United States|Aurora Advanced Healthcare SC, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Woodville, South Australia, Australia|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Angers cedex 02, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy Cede, France|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Hongkong, Hong Kong|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Daejeon, Korea, Republic of|Novartis Investigative Site, Chihuahua, Mexico|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Lleida, Cataluna, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Bristol, Avon, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00903175"
575,"NCT01821391","Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses","Completed","No Results Available","All","Phase 3","131","Industry","Interventional","July 2013","January 2014","March 2014","April 1, 2013","null","September 12, 2014","Investigative site, Montpellier, France|Investigational site, Nantes, France|Investigational site, Nice, France|Investigational site, Paris, France|Investigative site, Rennes, France|Investigational site, Aachen, Germany|Investigational site, Berlin, Germany|Investigational site, Muenster, Germany|Investigational site, Recklinghausen, Germany|Investigational site, Assen, Netherlands|Investigational site, Maastricht, Netherlands|Investigational site, Nijmegen, Netherlands|Investigational site, Huesca, Spain|Investigational site, Madrid, Spain|Investigative site, Pamplona, Spain|Investigational site, Valencia, Spain|Investigational site, Karlskoga, Sweden|Investigational site, Norrköping, Sweden","https://ClinicalTrials.gov/show/NCT01821391"
576,"NCT00916409","Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)","Completed","No Results Available","All","Phase 3","700","Industry","Interventional","June 2009","December 2016","March 2017","June 9, 2009","null","April 10, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|University of California San Diego Moores Cancer Center (UCSD), La Jolla, California, United States|University of Southern California (USC), Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|University of Illinois at Chicago (UIC), Chicago, Illinois, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Maine Medical Center, Scarborough, Maine, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Division of Oncology, St. Louis, Missouri, United States|New Jersey Neuroscience Center - JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, Department of Neurosurgery, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|The Ohio State University Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Geisinger Health System, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor, Dallas, Texas, United States|Methodist Hospital, Houston, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston (UTHSC), Houston, Texas, United States|Scott and White Healthcare, Temple, Texas, United States|Memorial Hermann The Woodlands, The Woodlands, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States|University Hospital Graz, Graz, Austria|Medical University of Vienna, Vienna, Austria|SMZ-Süd/Kaiser-Franz-Josef-Spital, Vienna, Austria|Tom Baker Cancer Center, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton,, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Notre-Dame Hospital (CHUM), Montreal, Quebec, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|McGill - Gerald Bronfman Centre for Clinical Research in Oncology -, Montreal, Quebec, Canada|(CHUS) Centre Hospitalier Universitaire de Sherbrooke, Service de Neurochirurgie, Sherbrooke, Quebec, Canada|Na Homolce Hospital, Prague, Czech Republic|CHU Amiens Sud-Salouel, Amiens, France|CHU Angers, Angers, France|Hôpital Saint André Centre Hospitalier Universitaire (CHU) des Hôpitaux de Bordeaux, Bordeaux, France|Hospital of Neurology Pierre Wertheimer, Lyon, France|Group Hospitals Pitie-Salpetriere, Paris, France|Centre Hospitalo-Universitaire de Toulouse Purpan, Toulouse, France|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Medical University Heidelberg, Heidelberg, Germany|University Hospital of Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Az. Ospedaliero-Universitaria - Ospedali Riuniti, Ancona, Italy|Ospedale Lecco, Lecco, Italy|C. Besta Neurological Institute, Milan, Italy|Foundation Hospital Greater Policlinico, Milan, Italy|Istituti Fisioterapici Ospitalieri - Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Asan Medical Center, Asan, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital (CNUH), Daejeon, Korea, Republic of|Samsung Medical Center (SMC), Seoul, Korea, Republic of|Seoul National University Bundang Hospital (SNUBH), Seoul, Korea, Republic of|Seoul National University Hospital (SNUH), Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital (CMC Seoul), Seoul, Korea, Republic of|Yonsei University Severance Hospital (YUHS), Seoul, Korea, Republic of|Ajou University Hospital (AUH), Suwon, Korea, Republic of|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari de Bellvitge-ICO Duran i Reynals, Barcelona, Spain|Fundacion Jimenes Diaz, Madrid, Spain|Hospital 12 de Octubre, Servicio de Oncología Médica, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Karolinska Institute, Stockholm, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitätsSpital Zürich, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT00916409"
577,"NCT02314143","Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib","Completed","No Results Available","All","Phase 2","47","Industry","Interventional","November 13, 2013","January 19, 2017","January 19, 2017","December 11, 2014","null","September 26, 2017","GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Reims Cedex, France|GSK Investigational Site, Rennes Cedex, France|GSK Investigational Site, Villejuif cedex, France|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02314143"
578,"NCT02558894","Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma","Completed","Has Results","All","Phase 2","65","Industry","Interventional","November 16, 2015","June 15, 2017","June 15, 2017","September 24, 2015","August 2, 2018","August 2, 2018","Research Site, Tampa, Florida, United States|Research Site, New York, New York, United States|Research Site, Vancouver, British Columbia, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Friedrichshafen, Germany|Research Site, München, Germany|Research Site, Tuebingen, Germany|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Barcelona, Spain|Research Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02558894"
579,"NCT00748189","Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia","Completed","Has Results","All","Phase 3","447","Industry","Interventional","December 22, 2008","March 20, 2013","May 17, 2018","September 8, 2008","March 26, 2014","September 7, 2018","Novartis Investigative Site, Sedona, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Murrieta, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Ocoee, Florida, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Abilene, Texas, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Fort Worth, Texas, United States|Novartis Investigative Site, Midland, Texas, United States|Novartis Investigative Site, Odessa, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Webster, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Yakima, Washington, United States|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Haine-Saint-Paul, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Porto Alegre, Rio De Janeiro, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Hradec Kralove, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ulm, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Erlangen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Wuerzburg, Bayern, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Lehrte, Niedersachsen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach-Rheydt, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Ahmedabad, India|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Cork, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, James Street, Ireland|Novartis Investigative Site, Limerick, Ireland|Novartis Investigative Site, Tullamore, Ireland|Novartis Investigative Site, Waterford, Ireland|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Napoli, Campania, Italy|Novartis Investigative Site, Albano Laziale (Roma), Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Ascoli Piceno, Marche, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Bari, Puglia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Venezia - Mestre, Veneto, Italy|Novartis Investigative Site, Vicenza, Veneto, Italy|Novartis Investigative Site, Udine, Italy|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Taunton, Somerset, United Kingdom|Novartis Investigative Site, Sunderland, Tyne, United Kingdom|Novartis Investigative Site, Bath, United Kingdom|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Bradford, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Canterbury, Kent, United Kingdom|Novartis Investigative Site, Carshalton, United Kingdom|Novartis Investigative Site, Cornwall, United Kingdom|Novartis Investigative Site, Dudley, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Milton Keynes, United Kingdom|Novartis Investigative Site, Newcastle-upon-Tyne, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Peterborough, United Kingdom|Novartis Investigative Site, Rhyl, Denbighshire, United Kingdom|Novartis Investigative Site, Salford, United Kingdom|Novartis Investigative Site, Stoke on Trent, United Kingdom|Novartis Investigative Site, Swindon, United Kingdom|Novartis Investigative Site, Uxbridge, United Kingdom","https://ClinicalTrials.gov/show/NCT00748189"
580,"NCT01520922","Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)","Completed","Has Results","All","Phase 2","99","Industry","Interventional","March 2012","February 2013","November 2015","January 30, 2012","December 16, 2013","January 19, 2017","Novartis Investigative Site, Tuscon, Arizona, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, St. Petersburg, Florida, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Ogden, Utah, United States|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Hradec Kralove, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Modena, Emilia-Romagna, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Torino, Piemonte, Italy|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Majadahonda (Madrid), Spain","https://ClinicalTrials.gov/show/NCT01520922"
581,"NCT01826214","Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia","Completed","Has Results","All","Phase 2","70","Industry","Interventional","May 2013","May 2015","May 2015","April 8, 2013","May 20, 2016","August 30, 2016","Duke University Medical Center SC-5, Durham, North Carolina, United States|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Salamanca, Castilla y Leon, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01826214"
582,"NCT00692770","Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)","Completed","Has Results","All","Phase 3","1114","Industry","Interventional","August 15, 2008","November 29, 2013","November 28, 2014","June 6, 2008","December 1, 2014","August 8, 2018","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Ann Arbor, Michigan, United States|Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Pilar, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Camperdown, New South Wales, Australia|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Innsbruck, Austria|Linz, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Santiago de Chile, Santiago, Chile|Reñaca, Valparaíso, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanning, Guangxi, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Xi'an, Shanxi, China|Xi'an, Shanxi, China|Xi'an, Shanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijng, China|Chongqing, China|Dalian, China|Hefei, China|Shanghai, China|Shanghai, China|Tianjin, China|ANGERS cedex 09, France|Bondy, France|Bordeaux, France|Creteil, France|Lille, France|Lyon, France|Marseille, France|Nice, France|Paris, France|Paris, France|Rennes, France|Toulouse, France|Vandoeuvre-les-nancy, France|Villejuif, France|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg/Saar, Saarland, Germany|Halle/Saale, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Athens / Greece, Greece|Hong Kong, Hong Kong|Kwun Tong, Hong Kong|Shatin, Hong Kong|Benevento, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Palermo, Sicilia, Italy|Padova, Veneto, Italy|Kashiwa-shi, Chiba, Japan|Kanazawa, Ishikawa, Japan|Yokohama-shi, Kanagawa, Japan|Osakasayama-shi, Osaka, Japan|Suita, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Kumamoto, Japan|Kyoto, Japan|Okayama, Japan|Osaka, Japan|Tokushima, Japan|Goyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Jeollabuk-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|México, D.F., Distrito Federal, Mexico|Monterrey, Nuevo Leon, Mexico|México, D.F., Mexico|Auckland, New Zealand|Coimbra, Portugal|Bucharest, Romania|Cluj-Napoca, Romania|Iasi, Romania|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Oviedo, Asturias, Spain|Sabadell, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Catalunya, Spain|Majadahonda, Madrid, Spain|Badajoz, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Valladolid, Spain|Göteborg, Sweden|Stockholm, Sweden|Bern, Switzerland|Zürich, Switzerland|Changhua, Taiwan|Kaohsiung City, Taiwan|Kaohsung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Southampton, Hampshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT00692770"
583,"NCT01582061","An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.","Completed","Has Results","All","Phase 3","104","Industry","Interventional","August 16, 2011","January 26, 2017","January 26, 2017","April 20, 2012","June 19, 2018","June 19, 2018","Advanced Research, LLC, Peoria, Arizona, United States|St Josephs Hospital & Medical Center St Joes, Phoenix, Arizona, United States|University of California at Los Angeles UCLA Tiverton, Los Angeles, California, United States|LA Biomedical Research at Harbor UCLA Medical Center, Torrance, California, United States|Emory University School of Medicine, Atlanta, Georgia, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Diabetes and Endocrinology Associates, PC, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of New Mexico Hospital UNM, Albuquerque, New Mexico, United States|Mount Sinai School of Medicine, New York, New York, United States|Oregon Health and Science University OHSU 5, Portland, Oregon, United States|University of Pennsylvania Medical Center Univ Penn, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Mid South Endocrine Associates, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Prague 2, Czech Republic, Czechia|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Orense, Galicia, Spain|Novartis Investigative Site, Pontevedra, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand","https://ClinicalTrials.gov/show/NCT01582061"
584,"NCT00738582","An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma","Completed","No Results Available","All","Phase 2","89","Industry","Interventional","December 2008","June 2011","January 2014","August 20, 2008","null","December 11, 2015","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Diego, La Jolla, California, United States|UCLA Medical Hematology & Oncology, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Christiana Care Health System, Newark, Delaware, United States|Emory University School of Medicine, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins University--Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|NIH/National Cancer Institute, Bethesda, Maryland, United States|Columbia University Medical Center, New York, New York, United States|Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Hopital Laval, Quebec, PQ, Canada|HELIOS Klinikum Emil von Behring, Berlin, Germany|Asklepios Fachkliniken Müchen-Gauting, Gauting, Germany|Krankenhaus Großhansdorf, Großhansdorf, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Medizinsche Hochschule Hannover, Hannover, Germany|Fachklinik für Lungenerkrankungen Immenhausen, Immenhausen, Germany|Medizinische Klinik (Hämatologie/Onkologie), München, Germany|Medisch Spectrum Twente, Enschede, Netherlands|Erasmus MC, Rotterdam, Netherlands|H. de la Santa Creu i Sant Pau, Barcelona, Spain|H. Son Dureta, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Consorci Sanitari Parc Taulí, Sabadell Barcelona, Spain|H. Virgen del Rocío, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT00738582"
585,"NCT00790036","Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","Completed","Has Results","All","Phase 3","742","Industry","Interventional","July 24, 2009","June 15, 2016","June 15, 2016","November 13, 2008","July 12, 2017","July 12, 2017","Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (3), La Jolla, California, United States|USC/Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisMedicalCenter(4), Los Angeles, California, United States|University of Colorado Health, Colorado Springs, Colorado, United States|Denver Health & Hospital Authority CACZ885M2301, Denver, Colorado, United States|Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States|University Cancer Institute, Boynton Beach, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Columbus Regional, Columbus, Georgia, United States|Rush University Medical Center Div. of Hematology & Oncology, Chicago, Illinois, United States|Indiana University Hospital IU Cancer Center, Indianapolis, Indiana, United States|Tulane University Health Sciences Center Office of Clinical Research, New Orleans, Louisiana, United States|Lahey Clinic Dept of Lahey Clinic (3), Burlington, Massachusetts, United States|Mayo Clinic - Rochester Dept. of MayoClinic-Rochester, Rochester, Minnesota, United States|Washington University School of Medicine Div. of Medical Oncology, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center Dartmouth, Lebanon, New Hampshire, United States|Levine Cancer Institute Oncology, Charlotte, North Carolina, United States|Wake Forest University Baptist Medical Center Dept. of WFUHS, Winston-Salem, North Carolina, United States|University of Pittsburgh Medical Center SC-3, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States|Cancer Centers of the Carolinas Cancer Centers of Carolinas (3, Greenville, South Carolina, United States|University of Tennessee Cancer Institute SC-2, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD, Fort Worth, Texas, United States|University of Texas/MD Anderson Cancer Center Dept of MD Anderson (18), Houston, Texas, United States|Baylor College of Medicine Dept.of Baylor College of Med., Houston, Texas, United States|South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States|Texas A&M HealthSciencesCtr-Scott & White Memorial Hospital CenterForCancerPrevention&Care, Temple, Texas, United States|University of Vermont Office of Clinical Trials Res., Burlington, Vermont, United States|University of Virginia Health Systems SC-2, Charlottesville, Virginia, United States|Blue Ridge Research Center at Roanoke Neurological Center SC, Roanoke, Virginia, United States|Dean Health System, Madison, Wisconsin, United States|Waukesha Memorial Hospital Cancer Center Dept.ofWaukeshaMemorialHosp., Waukesha, Wisconsin, United States|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Douglas, Queensland, Australia|Novartis Investigative Site, Greenslopes, Queensland, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Mississauga, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Québec, Quebec, Canada|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Bucaramanga, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Brno - Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Mansoura, Egypt|Novartis Investigative Site, Amiens cedex1, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Saint Priest en Jarez Cedex, France|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Piacenza, PC, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Potenza, PZ, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Venezia, VE, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Matsuyama-city, Ehime, Japan|Novartis Investigative Site, Kure, Hiroshima, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Shinjuku-ku, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Lublin, Lubelskie, Poland|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N. Novgorod, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Dammam, Saudi Arabia|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Cadiz, Andalucía, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zürich, CH, Switzerland|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela","https://ClinicalTrials.gov/show/NCT00790036"
586,"NCT01029262","A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q","Completed","Has Results","All","Phase 3","239","Industry","Interventional","January 26, 2010","March 17, 2013","May 9, 2018","December 9, 2009","June 18, 2015","August 21, 2018","University of California at Los Angeles, Los Angeles, California, United States|Southern Illinois Hematology Oncology, Centralia, Illinois, United States|Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Adelaide Hospital Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Medizinische Universitat Innsbruck, Innsbruck, Austria|Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Austria|Universitatsklinik fur Innere Medizin Salzburg, Salzburg, Austria|Klinikum Wels-Grieskirchen GmbH, Weis, Austria|Wiener Gebietskrankenkasse-Hanusch-Krankenhaus, Wien, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Center Hospitalier Universitaire Ambroise Pare, Mons, Belgium|Cliniques Universitaires UCL de Mont-Godine, Namur, Belgium|Tom Baker Cancer Center, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnepeg, Manitoba, Canada|Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada|Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada|Maisonneuve Rosemont, Montreal, Quebec, Canada|McGill University, Dept. Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Vseobecna Fakultni Nemocnice v Praze, Prague, Czechia|Ustav hematologie a krevni transfuze, Praha, Czechia|CHU d'Angers, Angers, France|Hopital Avicenne, Bobigny Cedex, France|Hopital A. Michallon, La Tronche, France|CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France|Institut Paoli-Calmettes, Marseille cedex, France|Groupe hospitalier Cochin Saint-Vincent de Paul, Paris Cedex, France|BAG Freiberg-Richter, Jacobash, Illmer, Wolf, Dresden, Germany|Marien Hospital, Duesseldorf, Germany|Sankt Johannes Hospital Duisburg, Duisberg, Germany|Universitätsklinikum Düsseldorf, Düesseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum Mannheim der Universitat Heidelberg, Heidelberg, Germany|Universitat zu Koln, Köln, Germany|Universitatsklinikum Mannheim, Mannheim, Germany|TU München - Klinikum rechts der Isar, München, Germany|Rabin Medical Center, Petach-Tikva, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Az. Osp. SS.Antonio e Biagio - SC Ematologia, Alessandria, Italy|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|P.O. Ospedale Roberto Binaghi (UNI CA/ASL 8), Cagliari, Italy|Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Cardarelli, Naples, Italy|AOU San Luigi Gonzaga, Orbassano, Italy|IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture, Rionero in Vulture, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy|Azienda Policlinico Umberto I, Universita La Sapienzadi Roma, Roma, Italy|Policlinico Agostino Gemelli - Istituto di Ematologia, Roma, Italy|Policlinico Univeristario di Udine, Udine, Italy|Hiroshima University Hospital, Hiroshima, Japan|Tokai University School of Medicine, Isehara City, Kanagawa, Japan|Kameda General Hospital, Kamogawa, Japan|Kanazawa University Hospital, Kanazawa, Japan|Nagasaki Unversity Hospital, Nagasaki, Japan|National Hospital Organization Nagoya Medical Center, Nagoya, Japan|Osaka Red Cross Hospital, Osaka, Japan|Tohoku University Hospital, Sendai, Japan|Japanese Red Cross Medical Center, Shibuya, Japan|Jichi Medical University Hospital, Shimotsuke, Japan|Kanto Medical Center NTT EC, Shinagawa, Japan|Katedra i Klinika Hematologii i Transplantacji Szpiku - SLASKIEGO UNIWERSYTETU MEDYCZNEGO, Gdansk, Poland|Uniwersytet Medyczny w Lodzi, Lodz, Poland|Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warsaw, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal|Hospital Geral de Santo Antonio, Porto, Portugal|Hospital Clinic Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Gazi Universitesi Tip Fakltesi, Ankara, Turkey|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Istanbul Universitesi Istanbul, Istanbul, Turkey|Dokuz Eylul Universitesi Tip Faiultesi, Izimir, Turkey|Royal Bournemouth Hospital, Bournemouth, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom|King's College Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01029262"
587,"NCT01362140","Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","Completed","Has Results","All","Phase 3","147","Industry","Interventional","December 21, 2011","February 11, 2015","September 14, 2017","May 30, 2011","December 5, 2016","December 19, 2017","Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Brugge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Haine Saint Paul - La Louviere, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Ottignies, Belgium|Research Site, Roeselare, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Zlin, Czechia|Research Site, Avignon Cedex 9, France|Research Site, Bobigny cedex, France|Research Site, Caen, France|Research Site, Lyon Cédex 3, France|Research Site, Lyon, France|Research Site, Nantes Cedex 1, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 10, France|Research Site, Paris, France|Research Site, Pontoise Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Dresden, Germany|Research Site, Göttingen, Germany|Research Site, Hannover, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, Regensburg, Germany|Research Site, Rotenburg (Wümme), Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Alessandria, Italy|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Pesaro, Italy|Research Site, Pisa, Italy|Research Site, Reggio Calabria, Italy|Research Site, Rionero In Vulture PZ, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Udine, Italy|Research Site, Zaragoza, Aragón, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Basel, Switzerland|Research Site, Luzern, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT01362140"
588,"NCT00760877","Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)","Completed","Has Results","All","Phase 3","207","Industry","Interventional","June 2009","July 2015","July 2015","September 26, 2008","August 16, 2016","November 8, 2016","Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Québec, Quebec, Canada|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Lyon cedex 04, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT00760877"
589,"NCT02021110","Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease","Completed","No Results Available","All","Phase 2","34","Other","Interventional","December 2013","October 2015","October 2015","December 27, 2013","null","April 7, 2016","Radboud University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands|Academic Medical Centre Amsterdam, Amsterdam, Netherlands|Donostia University Hospital, San Sebastian, Spain","https://ClinicalTrials.gov/show/NCT02021110"
590,"NCT01056341","Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy","Completed","Has Results","All","Phase 2|Phase 3","512","Industry","Interventional","January 2010","May 2012","November 2013","January 26, 2010","June 24, 2014","December 10, 2015","University of California, Irvine, California, United States|Lucile Packard Children's Hospital, Redwood City, California, United States|Rady Children's Hospital, San Diego, California, United States|Miami Children's Hospital, Miami, Florida, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Cardinal Glennon Children's Hospital, St.Louis, Missouri, United States|State University of NY, Brooklyn, New York, United States|Oregon Health Sciences University, Portland, Oregon, United States|Dell Children's Medical center, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Eastern Clinical Research Unit - Box Hill Hospital, Box Hill, Australia|Royal Children's Hospital, Melbourne, Australia|Sydney Children's Hospital, Randwick, Australia|CHU St.Justine, Montreal, Canada|The Hospital for Sick Children, Toronto, Canada|Children Dermatology, Brno, Czech Republic|Clinic of Dermatovenerology, University, Prague, Czech Republic|Hôpital Pellegrin-Enfants, Bordeaux, France|Hôpital Femme Mère Enfant, Lyon, France|CHU Hôtel Dieu, Nantes, France|Hôpital Archet 2, Nice, France|Hôpital Armand Trousseau, Paris, France|Hôpital Necker Enfants malades, Paris, France|Hopital Robert Debre - Consultation de Dermatologie, Paris, France|Hopital Nord-CHU St Etienne, St-Etienne, France|Hôpital des enfants, Toulouse, France|Hôpital Clocheville, Tours, France|Universitätsklinikum Freiburg, Freiburg, Germany|Kinderkrankenhaus Wilhelmstift, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Kinderchirurgische Klinik Ludwig-Maximilians-Universität, München, Germany|Heim Pál Gyermekkórház,, Budapest, Hungary|University of Bari, Bari, Italy|Clinica Dermatologica, Milano, Italy|Vilnius University Children's Hospital, Vilnius, Lithuania|Hospital Infantil de Mexico Federico Gomez, Mexico CIty, Mexico|Auckland Dermatology, Auckland, New Zealand|Waikato Clinical Research 2008 Ltd., Hamilton, New Zealand|Clinica Internacional, Lima, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Instituto Nacional de Salud del Niño, Lima, Peru|Klinika Chirurgii i Urologii Dzieci i Mlodziezy Akademii Medycznej, Gdansk, Poland|University Children's Hospital, Krakow, Poland|Department of Pediatric Surgery and Oncology, Lodz, Poland|Klinika Onkologii, Centrum Zdrowia Dziecka, Warszawa, Poland|Spitalul Clinic Urgenta pentru Copii Grigore Alexandrescu, Bucharest, Romania|I.O.M.C Alfred Rusescu, Bucharest, Romania|Spitalul de Copii Dr. Victor Gomoiu, Bucharest, Romania|Spitalul Clinic de Urgenta pentu Copii Sf. Maria, Iasi, Romania|Spitalul de Urgenta Copii, Louis Turcanu, Timisoara, Romania|Medical University - Filatov Pediatric Hospital, Moscow, Russian Federation|Medical Pediatric Academy, St-Peterburg, Russian Federation|Neonatal Intensive Care Department, St-Peterburg, Russian Federation|Servicio de Dermatologia del Hospital Infantil, A Coruna, Spain|Hospital Sant Pau de Barcelona, Barcelona, Spain|Hospital Universitario Infantil Niño Jesús, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01056341"
591,"NCT01156857","PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata","Completed","No Results Available","Female","Phase 3","209","Industry","Interventional","July 2010","November 2011","February 2012","July 5, 2010","null","January 15, 2016","Medical University Graz, department of obstetrics and gynecology, Graz, Austria|Medical University Vienna, department of obstetrics and gynecology, Vienna, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|CHR de la citadelle, Liège, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium|Prywatna Klinika Polozniczo-Ginekologiczna, Bialystok, Poland|INVICTA Sp. Z o.o., Gdańsk, Poland|Private Practice, Katowice, Poland|Private Practice, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Klinika Ginekologii Onkologicznej i Ginekologii, Lublin, Poland|Private Practice, Warszawa, Poland|Private Practice, Warszawa, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie, Klinika Poloznictwa, Chorob Kobiecych i Ginekologii Onkologicznej, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, I Katedra i Klinika Ginekologii i Położnictwa, Wroclaw, Poland|Institut Universitari Dexeus Departamento de Ginecología, Barcelona, Spain|Hospital Universitario Hebron, gynecology department, Barcelona, Spain|Hospital Clinic i provincial de Barcelona, gynecology department, Barcelona, Spain|Hospital General de Ciudad Real Gynecology, Ciudad Real, Spain|Hospital Universitario de Guadalajara Consultas de Ginecología (Planta 0), Guadalajara, Spain|Clinica Ginecologica CEOGA, departamento de Ginecologia, Lugo, Spain|Private pratice, Madrid, Spain|Hospital universitario 12 de Octubre, departamento de ginecologia, Madrid, Spain|CHIP, Malaga, Spain","https://ClinicalTrials.gov/show/NCT01156857"
592,"NCT00740831","PGL4001 Versus GnRH-agonist in Uterine Myomas","Completed","Has Results","Female","Phase 3","301","Industry","Interventional","August 2008","January 2010","June 2010","August 25, 2008","November 16, 2012","December 17, 2012","Medical University Graz, Graz, Austria|Medical University of Innsbruck, Innsbruck, Austria|Landesklinikum Thermenregion Neunkirchen; Dept. For Gynecology, Neunkirchen, Austria|Medical University Vienna, Vienna, Austria|Hopital Erasme, Department of Obstetrics and Gynecology,, Brussels, Belgium|Clinique Universitaire St-Luc, Brussels, Belgium|CHR de la Citadelle, Liège, Belgium|Clinique Universitaire de Mont-Godinne, Yvoir, Belgium|Cabinet de Gynécologie Chirurgicale, Bordeaux, France|CHU de Clermont-Ferrand - Polyclinique Gynécologie-Obstétrique, Clermont Ferrand, France|Klinik für Gynäkologie und Geburtshilfe, Chemnitz, Germany|Private Practice, Frankfurt, Germany|Medizinische Hochschule Hannover, Frauenklinik, Abt. I für Frauenheilkunde und Geburtshilfe,, Hannover, Germany|Universitätsklinikum Köln Klinik und poliklinik für Frauenheilkunde und Geburtshilfe, Köln, Germany|Universität zu Lübeck, Klinik für Gynäkologie und Geburtshilfe, Lübeck, Germany|Poliklinik fur Frauenheilkunde und Geburtshilfe, Münster, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Ammerland-Klinik GmbH Frauenklinik, Westerstede, Germany|Soroka University Medical Center, Division of Obstetrics & Gynecology, Be'er Sheva, Israel|Hadassah University Hospital, Jerusalem, Israel|Hadassah University Hospital, Mount Scopus, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Western Galilee Hospital Nahariya, Nahariya, Israel|Rabin Medical Center, Helen Schneider Hospital for Women, Petach Tikva, Israel|Clinica Ostetrica e Ginecologica II - Università degli Studi di Bari, Bari, Italy|Clinica Obstetrica - Azienda Ospedaliera Universitaria di Cagliari, Cagliari, Italy|Azienda Ospedaliera S. Gerardo - U. O. Ostetricia e Ginecologia, Monza, Italy|Policlinico Universitario Federico II, Napoli, Italy|Universita di Padova-Dip scienze ginecologiche e della riproduzione umana, Padova, Italy|Clinica Ostetrica e Ginecologica - A. O. U. Policlinico Paolo Giaccone, Palermo, Italy|Policlinico Universitario ""Agostino Gemelli"", Roma, Italy|University Medical Center Utrecht, Gynecologist Reproductive Medicine and Surgery, Division for Reproductive Medicine, Utrecht, Netherlands|Prywatna Klinika Polozniczo-Ginekologiczna, Bialystok, Poland|INVICTA Sp. Z o.o., Gdańsk, Poland|Private Practice, Katowice, Poland|Samodzielny Publiczny Szpital Klinika Ginekologii Onkologicznej i Ginekologii, Lublin, Poland|Gabinet Lekarski Specjalistyczny ""Sonus"", Warszawa, Poland|Institut Universitari Dexeus, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Clínica Ginecológica CEOGA, Lugo, Spain|Private Practice, Madrid, Spain|Hospital Universitario Doce de Octubre, Madrid, Spain|Hospital Virgen de la Arrixaca Servicio de Ginecología Carretera Madrid-Cartagena, Murcia, Spain|Hospital Universitaris La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00740831"
593,"NCT01252069","PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)","Completed","No Results Available","Female","Phase 3","132","Industry","Interventional","January 2011","August 2013","January 2014","December 2, 2010","null","January 13, 2016","Medical University Vienna, department of obstetrics and gynecology, Vienna, Austria|Cliniques Universitaires Saint-Luc Gynécologie-Obstétrique, Bruxelles, Belgium|CHR de la Citadelle Gynécologie-Obstétrique, Liège, Belgium|Cliniques Universitaires UCL de Mont-Godinne Gynécologie-Obstétrique, Yvoir, Belgium|Prywatna Klinika Polozniczo-Ginekologiczna, Bialystok, Poland|INVICTA Sp. Z o.o., Gdańsk, Poland|Private practice, Katowice, Poland|Private practice, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Klinika Ginekologii Onkologicznej i Ginekologii, Lublin, Poland|Private Practice, Warszawa, Poland|Private practice, Warszawa, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie, Klinika Poloznictwa, Chorob Kobiecych i Ginekologii Onkologicznej, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, I Katedra i Klinika Ginekologii i Położnictwa, Wroclaw, Poland|Hospital Universitario Hebron, gynecology department, Barcelona, Spain|Clinica Ginecologica CEOGA, departamento de Ginecologia, Lugo, Spain|Private Practice, Madrid, Spain|HOSPITAL Universitario 12 de Octubre y Fundación de Investigación Biomédica Hospital 12 de Octubre Departamento de Ginecología, Madrid, Spain|CHIP (Complejo Hospitalario Integral Privado), Malaga, Spain","https://ClinicalTrials.gov/show/NCT01252069"
594,"NCT02465814","Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids","Completed","No Results Available","Female","Phase 2","120","Industry","Interventional","June 2015","October 2016","October 2016","June 9, 2015","null","November 22, 2016","Villach, Kärnten, Austria|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Wien, Austria|Tienen, Vlaams Brabant, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Pleven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brno, Czech Republic|Ceske Budejovice, Czech Republic|Olomouc, Czech Republic|Olomouc, Czech Republic|Pisek, Czech Republic|Plzen, Czech Republic|Praha 2, Czech Republic|Praha 8, Czech Republic|Praha, Czech Republic|Helsinki, Finland|Pori, Finland|Turku, Finland|Bernburg, Sachsen-Anhalt, Germany|Blankenburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Debrecen, Hungary|Debrecen, Hungary|Szentes, Hungary|Modena, Emilia-Romagna, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Vilnius, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Almere, Netherlands|Heerlen, Netherlands|Nieuwegein, Netherlands|Zwolle, Netherlands|Fredrikstad, Norway|Lørenskog, Norway|Nesttun, Norway|Stavanger, Norway|Bialystok, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Warszawa, Poland|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Aravaca, Madrid, Spain|Barcelona, Spain|Valencia, Spain|Valencia, Spain|Stockholm, Sweden|Stockholm, Sweden|Umeå, Sweden|Harrow, London, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Portsmouth, United Kingdom","https://ClinicalTrials.gov/show/NCT02465814"
595,"NCT00790400","Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)","Completed","Has Results","All","Phase 3","118","Industry","Interventional","April 2009","June 2011","November 2015","November 13, 2008","August 28, 2012","February 17, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Tuberous Sclerosis Center, Phoenix, Arizona, United States|Massachusetts General Hospital Massachussetts General Hospita, Boston, Massachusetts, United States|Minnesota Epilepsy Group, St. Paul, Minnesota, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|LeBonheur Childrens Medical Group SC-2, Memphis, Tennessee, United States|Novartis Investigative Site, Torono, Ontario, Canada|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Yamagata, Japan|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Brighton, East Sussex, United Kingdom|Novartis Investigative Site, Craigavon, Northern Ireland, United Kingdom|Novartis Investigative Site, Cardiff, Wales, United Kingdom|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00790400"
596,"NCT01642472","PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata","Completed","No Results Available","Female","Phase 3","64","Industry","Interventional","July 2012","March 2015","April 2015","July 17, 2012","null","January 8, 2016","Medical University Vienna, Vienna, Austria|Cliniques Universitaires Saint-Luc, Gynécologie-Obstétrique,, Brussels, Belgium|CHR de la Citadelle, Liège, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium|Prywatna Klinika Polozniczo-Ginekologiczna, Bialystok, Poland|INVICTA Sp. Z o.o., Gdańsk, Poland|Private practice, Katowice, Poland|Prywatny Gabinet Lekarski Ginekologia I Poloznictwo Ultrasonografia, Lodz, Poland|Specjalistyczny Gabinet Ginekologiczno-Polozniczy, Lublin, Poland|Gabinet Lekarski Specjalistyczny ""Sonus"", Warszawa, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie, Klinika Poloznictwa, Chorob Kobiecych i Ginekologii Onkologicznej, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, I Katedra i Klinika Ginekologii i Położnictwa, Wroclaw, Poland|Hospital Universitario Vall Hebrón (Gynecology department) Edificio Maternal, Barcelona, Spain|Clinica Ginecologica CEOGA, Lugo, Spain|Private Practice, Madrid, Spain|HOSPITAL Universitario 12 de Octubre y Fundación de Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01642472"
597,"NCT01246557","Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment","Completed","No Results Available","All","Phase 1|Phase 2","20","Other","Interventional","December 2009","April 2014","April 2014","November 23, 2010","null","April 4, 2014","Centro Médico Teknon, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Valle Hebron, Barcelona, Spain|Hospital Clinico Universitario de Barcelona, Barcelona, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01246557"
598,"NCT01987505","MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma","Completed","Has Results","All","Phase 3","140","Industry","Interventional","November 11, 2013","April 11, 2017","April 11, 2017","November 19, 2013","July 4, 2018","July 4, 2018","Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital General de Elda; Servicio de Hematologia, Elda, Alicante, Spain|Hospital de Granollers, Servicio de Hematología, Granollers, Barcelona, Spain|Hospital Mutua de Terrassa; Servicio de Hematologia, Terrassa, Barcelona, Spain|Hospital Son Llatzer; Servicio de Hematologia, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia, La Coruna, LA Coruña, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Hematologia, Santiago de Compostela, LA Coruña, Spain|Complejo Hospitalario San Millan - San Pedro; Servicio Hematologia, Logroño, LA Rioja, Spain|Complejo Asistencial de León, Servicio de Hematología, León, Leon, Spain|Hospital Universitario de Fuenlabrada; Servicio de Hematologia, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa; Servicio de Hematologia, Leganes, Madrid, Spain|Hosital Universitario de Mostoles;Servicio de Hematologia, Mostoles, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Hematologia, Pamplona, Navarra, Spain|Hospital de Navarra, Servicio de Hematología, Pamplona, Navarra, Spain|Complejo Hospitalario Universitario de Vigo; Servicio de Hematologia, Vigo, Pontevedra, Spain|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Basurto; Servicio de Hematologia, Bilbao, Vizcaya, Spain|Hospital de Galdakano; Servicio de Hematologia, Galdakao, Vizcaya, Spain|Complejo Hospitalario Torrecardenas; Servicio de Hematologia, Almeria, Spain|Hospital Universitario de Burgos, Servicio de Hematología, Burgos, Spain|Hospital General de Castellon; Servicio de Hematologia, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Hematologia, Cordoba, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Hematologia, Granada, Spain|Hospital Universitario de Gaudalajara; Hematología, Guadalajara, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Hematologia, Lerida, Spain|Hospital Infanta Leonor; Servicio de Hematologia, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Hematología, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio Hematologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Principe de Asturias; Servicio de Hematología, Madrid, Spain|Hospital Univ. Virgen de la Victoria, Malaga, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Hematologia, Murcia, Spain|Complejo Hospitalario de Pontevedra; Servicio de Hematologia, Pontevedra, Spain|Complejo Asistencial de Segovia, Segovia, Spain|Hospital Universitario Virgen Macarena; Servicio de Hematologia, Sevilla, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Hematologia, Sevilla, Spain|Hospital de Rio Hortega; Servicio de Hematologia, Valladolid, Spain","https://ClinicalTrials.gov/show/NCT01987505"
599,"NCT01195766","Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma","Completed","No Results Available","All","Phase 2","64","Other","Interventional","July 2010","September 2013","May 2015","September 6, 2010","null","February 24, 2016","Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Instituto Catalan de Oncologia, L'Hospitalet, Barcelona, Spain|Hospital Son Espases, Palma de Mallorca, Mallorca, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clinico de Valencia, Valencia, Spain|Hospital Rio Hortega, Valladolid, Spain","https://ClinicalTrials.gov/show/NCT01195766"
600,"NCT01133158","R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial","Completed","Has Results","All","Phase 2","61","Other","Interventional","July 2009","December 2013","July 2016","May 28, 2010","November 1, 2018","November 1, 2018","Complejo Hospitalario Universitario de Santiago, Santiago, A Coruña, Spain|Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital San Juan de Alicante, San Juan de Alicante, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital de Galdakao, Galdakao, Bilbao, Spain|Hospital Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital de Getafe, Getafe, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Son Llàtzer, Palma de Mallorca, Mallorca, Spain|Hospital Son Espases, Palma de Mallorca, Mallorca, Spain|Hospital Universitario Virgen de Arrixaca, El Palmar, Murcia, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, La Laguna, Tenerife, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d´Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital San Pedro Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital de Jaén, Jaén, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Complejo Hospitalario Carlos Haya, Málaga, Spain|Hospital de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Río Hortega, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Clínico de Zaragoza, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01133158"
601,"NCT01133977","E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma","Completed","Has Results","All","Phase 1|Phase 2","97","Industry","Interventional","April 2010","June 2014","November 2014","May 31, 2010","October 10, 2016","October 10, 2016","Hagerstown, Maryland, United States|Albany, New York, United States|Greenville, South Carolina, United States|Dallas, Texas, United States|Norfolk, Virginia, United States|Berlin, Germany|Berlin, Germany|Berlin, Germany|Heidelberg, Germany|Muenchen, Germany|Bari, Italy|Milan, Italy|Milian, Italy|Napoli, Italy|Siena, Italy|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Valenica, Spain|Dorset, United Kingdom|Glasgow, United Kingdom|Manchester, United Kingdom|Middlesex, United Kingdom|Oxford, United Kingdom|Southampton, United Kingdom|Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT01133977"
602,"NCT01514526","Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma","Completed","No Results Available","All","Phase 2","17","Other","Interventional","January 2012","July 2013","November 2016","January 23, 2012","null","April 25, 2017","Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain|Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01514526"
603,"NCT01564784","A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia","Completed","Has Results","All","Phase 3","327","Industry","Interventional","August 2, 2012","March 8, 2016","January 4, 2017","March 28, 2012","January 17, 2018","January 17, 2018","Investigational Drug Services - UC San Diego Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center - La Jolla, La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Children's Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles, Los Angeles, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA Drug Information/Investigation Drug, Los Angeles, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Rrmc, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|Children's Hospital of Orange County, Orange, California, United States|UC Irvine Medical Center, Orange, California, United States|Freidenrich Center for Translational Research (CTRU), Stanford University, Palo Alto, California, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, United States|Martha Hamilton, Investigational Drug Services, Dept of Pharmacy, Stanford, California, United States|Stanford Cancer Institute, Stanford, California, United States|Stanford University Hospital and Clinics, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Hospital, Cancer Center Infusion Center, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Smilow Cancer Center at Yale New Haven Hospital (Drug Shipment Address), New Haven, Connecticut, United States|Yale-New Haven Hospital & Smilow Cancer Center, New Haven, Connecticut, United States|Miami Children's Hospital, Miami, Florida, United States|MD Anderson Cancer Center Orlando - 5th Floor Investigational Pharmacy, Orlando, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Orlando Heart Health Institute, Orlando, Florida, United States|Orlando Regional Medical Center, Orlando, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Investigational Drug Service, Emory University Clinic, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents Medical Center Pharmacy, Georgia Regents University Cancer Center, Augusta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Medicine Developmental Therapeutics Institute, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Dept. of Pharmacy, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Hospital, Kansas City, Kansas, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Norton Cancer Institute, Suburban, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Oncology Investigational Drug Service, Baltimore, Maryland, United States|The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital (MGH), Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System-, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|UNM Cancer Center, Albuquerque, New Mexico, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, United States|NewYork-Presbyterian Hospital, New York, New York, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Stony Brook University Medical Center, The Cancer Center, Stony Brook, New York, United States|Division of Hematology/Oncology, Stony Brook University Hospital, Stony Brook, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|UNC Cancer Hospital Infusion Pharmacy, Chapel Hill, North Carolina, United States|UNC Hospitals - The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OU Medical Center Presbyterian Tower, Oklahoma City, Oklahoma, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|IDS-investigational drug pharmacy Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Penn State Milton S. Hershey Medical Center,, Hershey, Pennsylvania, United States|Drug Shipment/Storage Address (MUSC Investigational Drug Services), Charleston, South Carolina, United States|Hollings Cancer Center, Charleston, South Carolina, United States|MUSC Hospital, Charleston, South Carolina, United States|Parkland Health and Hospital System, Dallas, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Drug Shipment Address: UT Southwestern medical Center: Simmons Pharmacy, Dallas, Texas, United States|University of Texas Southwestern Universtiy Hospital - William P Clements Jr., Dallas, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|UT Southwestern University Hospital- Zale Lipshy, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|LDS Hospital, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|West Virginia University Hospitals Pharmaceutical Services, Morgantown, West Virginia, United States|West Virginia University Hospitals, Morgantown, West Virginia, United States|Sanatorio Allende, Cordoba, Argentina|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Eastern Clinical Research Unit, Box Hill Hospital, Box Hill, Victoria, Australia|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Guangdong General Hospital, Guangzhou, Guangdong, China|Henan Cancer Hostipal, Zhengzhou, Henan, China|The first hospital of jilin university, Changchun, Jilin, China|Beijing Chao-yang Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|The 307th Hospital of PLA, Beijing, China|Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences,, Tianjin, China|Interni Hematologicka a Onkologicka Klinika, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|HUS-Kuvantaminen, Helsinki, Finland|HYKS/Hematologian klinikka, Helsinki, Finland|CHU de Dijon-Hopital d'Enfants-Service d'hematologie Clinique, Dijon, France|C.H.U. de Grenoble, Hopital Albert Michallon, Grenoble Cedex 09, France|Hopital Universitaire Andre Mignot, Le Chesnay Cedex, France|CHU Dupuytren, Limoges Cedex, France|Institut Paoli-Calmettes, Marseille, France|Hôpital Saint-Louis, Paris Cedex 10, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez Cedex, France|Iuct - Oncopole, Toulouse Cedex 9, France|CHU Brabois- Service d'hematologie, Vandoeuvre-les-Nancy, France|Klinikum der Goethe Universitaet, Frankfurt, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln, Klinik I für Innere Medizin, Köln, Germany|Klinikum Rechts der Isar der TU München, Muenchen, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Egyesitett Szent Istvan és Szent Laszlo Korhaz-Rendelointezet;, Budapest, Hungary|Debreceni Egyetem Orvos-es Egeszsegtudomanyi Centrum II. Belgyogyaszati Klinika, Debrecen, Hungary|Azienda Ospedaliera Brotzu CTMO P.O. Businco, Cagliari, CA, Italy|Farmacia, Cagliari, CA, Italy|U.O. Radiodiagnostica, Cagliari, CA, Italy|IRST-Ematologia, Meldola (FC), FC, Italy|Istituto di Ematologia Seragnoli, Bologna, Italy|A.O.U. Vittorio Emanuele di Catania-Ospedale Ferrarotto, Catania, Italy|Pharmacy (Drug Shipment Only), Catania, Italy|Radiology (Radiology Only), Catania, Italy|U.O. di Ematologia Dip. Medicine Specialistiche A.O.U. Arcispedale Sant'Anna, Cona, Ferrara, Italy|Clinica Ematologica, Genova, Italy|Pharmacy (Drug Shipment ONLY), Genova, Italy|Pharmacy, Genova, Italy|Radiology Department (Radiology ONLY), Genova, Italy|Radiology Department, Genova, Italy|U.O. Ematologia 1, Genova, Italy|S.C. Pharmacy, Milano, Italy|S.C. Radiology, Milano, Italy|SC Ematologia, Milano, Italy|A.O. San Gerardo - Farmacia, Monza, Italy|A.O. San Gerardo di Monza, Monza, Italy|AORN ""A. Cardarelli"", Napoli, Italy|Pharmacy (Drug Shipment only), Napoli, Italy|RAdiology Department (RAdiology only), Napoli, Italy|Clinica Ematologica, Pavia, Italy|Radiologist Department, Ravenna, Italy|Servizio di Farmacia, Ravenna, Italy|U.O. Ematologia, Ospedale S. Maria delle Croci, Ravenna, Italy|Clinica Ematologica, Udine, Italy|Radiology (Radiology Only), Udine, Italy|SOC Pharmacy (Drug Shipment Only), Udine, Italy|Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|The Hospital of Hyogo College of Medicine, Nishinomiya-shi, Hyogo, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Osaka City University Hospital, Osaka-city, Osaka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Akita University Hospital, Akita, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Tokai University Hospital, Kanagawa, Japan|Chonnam National University, Hwasun Hospital, Hwasun-Gun, Jeonnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Erasmus Medical Center, Rotterdam, South Holland, Netherlands|Erasmus Medical Center, Rotterdam, South Holland, Netherlands|Klinika Hematologii i Transplantologii, Gdansk, Poland|Oddzial Hematologii, Klinika Hematologii, Regionalny Osrodek Onkologiczny Wojewodzki Szpital, Lodz, Poland|Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warsaw, Poland|Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, Wroclaw, Poland|National University Hospital/National University Cancer Institute Singapore (NCIS), Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Castille AND LION, Spain|Hospital Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital Son Llatzer, Palma de Mallorca, Mallorca, Spain|Hospital de la Santa Creu i Sant Pau(Nuevo Hospital), Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario Jose Maria Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Universitetssjukhus Lund, Hematologkliniken, Lund, Sweden|Hematology Center, Stockholm, Sweden|Chang Gung Medical Foundation, Kaohsiung Branch, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Department of Academic Oncology, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01564784"
604,"NCT01440374","A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia","Completed","Has Results","All","Phase 2","162","Industry","Interventional","September 2011","March 2015","December 2015","September 26, 2011","June 14, 2016","June 5, 2017","Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Hot Springs, Arkansas, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Stanford, California, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Voorhees, New Jersey, United States|Novartis Investigative Site, The Bronx, New York, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Ciudad AutÃ³noma de Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autónoma de Buenos Aires, Argentina|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Goiânia - GO, Goiás, Brazil|Novartis Investigative Site, GoiÃ¢nia - GO, GoiÃ¡s, Brazil|Novartis Investigative Site, Curitiba, Paraná, Brazil|Novartis Investigative Site, Curitiba, ParanÃ¡, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Barretos, SÃ£o Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, São Paulo, Brazil|Novartis Investigative Site, SÃ£o Paulo, Brazil|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha 2, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Goettingen, Niedersachsen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion, Crete, Greece|Novartis Investigative Site, Ioannina, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Chai Wan, Hong Kong|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvár, Hungary|Novartis Investigative Site, KaposvÃ¡r, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Cork, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, James Street, Ireland|Novartis Investigative Site, Limerick, Ireland|Novartis Investigative Site, Tallaght, Dublin, Ireland|Novartis Investigative Site, Tullamore, Ireland|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach-Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Bologna, Emilia-Romagna, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Alessandria, Piemonte, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Hwasun, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Monterrey, Nuevo LeÃ³n, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Chihuahua, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Oaxaca, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Torun, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Nizhniy Novgorod, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Granada, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Málaga, Spain|Novartis Investigative Site, MÃ¡laga, Spain|Novartis Investigative Site, Pozuelo de AlarcÃ³n/Madrid, Spain|Novartis Investigative Site, Pozuelo de Alarcón/Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taoyuan County, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Khon Kaen, Thailand|Novartis Investigative Site, Songkla, Thailand","https://ClinicalTrials.gov/show/NCT01440374"
605,"NCT00802555","Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)","Completed","No Results Available","All","Phase 1","21","Industry","Interventional","January 2009","December 2011","December 2011","December 5, 2008","null","July 12, 2012","Dallas, Texas, United States|Houston, Texas, United States|Bologna, Italy|Milano, Italy|Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00802555"
606,"NCT01200758","A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma","Completed","Has Results","All","Phase 3","410","Industry","Interventional","February 15, 2011","June 12, 2012","October 31, 2017","September 14, 2010","August 5, 2015","November 27, 2018","Gosford Hospital; Cancer Care Services, Gosford, New South Wales, Australia|Wollongong Hospital; Cancer Services, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Gold Coast Hospital; Haematology Department, Southport, Queensland, Australia|Queen Elizabeth Hospital; Haematology, Woodville South, South Australia, Australia|UZ Antwerpen, Edegem, Belgium|CHU Sart-Tilman, Liège, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept, Banja Luka, Bosnia and Herzegovina|University Clinical Center Sarajevo, Clinic for Hematology, Sarajevo, Bosnia and Herzegovina|University Clinical Centre Tuzla, Clinic for Oncology, Hematology and Radiotherapy, Tuzla, Bosnia and Herzegovina|Nucleo de Hematologia e Transplante de Medula Ossea de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Santa Casa de Misericordia de Sao Paulo; Hematologia e Hemoterapia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, Brazil|UMHAT Dr Georgi Stranski; Hematology, Pleven, Bulgaria|Umhat S. George; Hematology, Plovdiv, Bulgaria|Specialised Hospital For Treatment Of Hematological Diseases; Hematology, Sofia, Bulgaria|Mhat Sveta Marina; Dept. of Haematology, Varna, Bulgaria|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Cite de La Sante de Laval; Hemato-Oncologie, Laval, Quebec, Canada|Centre de sante et de services sociaux Rimouski Neigette, Rimouski, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie, Quebec, Canada|Fundacion Cardioinfantil, Bogota, Colombia|Centro Medico Imbanaco, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Oncólogos de Occidente, Pereira, Colombia|UHC Rijeka, Rijeka, Croatia|University Hospital Center Zagreb; Haematology Department, Zagreb, Croatia|Herlev Uni Hospital; Hæmatologisk Afdeling L 121, Herlev, Denmark|Rigshospitalet; Hæmatologisk Klinik, København Ø, Denmark|Odense Universitetshospital; Hæmatologisk Afdeling, Odense C, Denmark|Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium, Roskilde, Denmark|Vejle Hospital; Dept of Medicine, Division of Hematology, Vejle, Denmark|Aarhus Universitetshospital, Hæmatologisk Afdeling R, Århus, Denmark|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie, Bordeaux, France|Hopital Henri Mondor; Hematologie Clinique, Creteil, France|Chu Site Du Bocage;Hematologie Clinique, Dijon, France|Clinique Victor Hugo; Chimiotherapie, Le Mans, France|Institut J Paolii Calmettes; Onco Hematologie 1, Marseille, France|Hopital Saint Eloi; Hematologie Oncologie Medicale, Montpellier, France|Hopital Hotel Dieu Et Hme;Hopital De Jour, Nantes, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Hopital De Haut Leveque; Hematologie Clinique, Pessac, France|Ch Lyon Sud; Hemato Secteur Jules Courmont, Pierre Benite, France|Hopital De La Miletrie; Hematologie Et Oncologie Medicale, Poitiers, France|Hopital Bretonneau; Hematologie Therapie Cellulaire, Tours, France|M.Zodelava's Hematology Center, Tbilisi, Georgia|Mediclub, Tbilisi, Georgia|Institute of Hematology and Transfusiology, Tbilisi, Georgia|Chemotherapy and Immunotherapy Clinic Medulla, Tbilisi, Georgia|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie, Darmstadt, Germany|Gemeinschaftspraxis Dr. med. J. Mohm und Dr. med. G. Prange-Krex; Fachaerzte fuer Innere Medizin, Dresden, Germany|PIOH PD Dr. R. Schnell - Dr. H. Schulz - Dr. M. Hellmann, Frechen, Germany|Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik I, Giessen, Germany|Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik, Greifswald, Germany|Internistisch-Onkologische Gemeinschaftspraxis; Dres. Rohrberg, Hurtz, Schma usw., Halle, Germany|Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie, Hannover, Germany|St. Vincentius Kliniken Ag; Medizinische Klinik Abt. 2, Karlsruhe, Germany|UKSH Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Kiel, Germany|Gemeinschaftspraxis PD Dr. med. Marcel Reiser und Dr. med. Ildiko Kátay, Koeln, Germany|Onkologische Gemeinschaftspraxis, Magdeburg, Germany|Gemeinschaftspraxis Fr. Dr. med. Balser & Hr. Dr. med. Weidenbach, Marburg, Germany|Medizinisches Versorgungszentrum MOP, München, Germany|Praxis Dr.med. Jens Uhlig, Naunhof, Germany|Praxis Dr. Clemens Müller-Naendrup (Onkologische Schwerpunktpraxis im MVZ 2 GmbH), Olpe, Germany|Prosper-Hospital, Medizinische Klinik I, Recklinghausen, Germany|Praxis Dr. Fenchel, Saalfeld, Germany|Caritas Kilinik St. Theresia; Abt. Innere Medizin, Saarbruecken, Germany|Praxis für Hämatologie & Onkologie, Saarbruecken, Germany|Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine, Athens, Greece|Attiko Hospital; Haematology Clinic, Athens, Greece|Azienda Ospedaliera Ospedale S.Carlo; Ematologia, Potenza, Basilicata, Italy|A.O. Universitaria Federico II Di Napoli; Oncologia Ed Endocrinologia Clinica, Napoli, Campania, Italy|AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia, Reggio Emilia, Emilia-Romagna, Italy|Ospedale S. Eugenio; Divisione Di Ematologia, Roma, Lazio, Italy|Uni Degli Studi Di Genova; 1A Divisione Di Ematologia, Genova, Liguria, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia, Brescia, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia, Milano, Lombardia, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo, San Giovanni Rotondo, Puglia, Italy|Ospedale Ca Foncello; Ematologia, Treviso, Veneto, Italy|Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy|University Clinic for Hematology; HSCT Department, Skopje, Macedonia, The Former Yugoslav Republic of|University Clinic of Hematology Skopje, Hospital Care Department, Skopje, Macedonia, The Former Yugoslav Republic of|University Malaya Medical Center; Hematology Unit of Department of Internal Medicine, Kuala Lumpur, FED. Territory OF Kuala Lumpur, Malaysia|Ampang Hospital; Department of Haematology, Ampang, Malaysia|Sarawak General Hospital; Department of Radiotherapy, Oncology and Palliative care, Sarawak, Malaysia|Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico|Hospital General De Culiacan; Servicio De Hematologia, Culiacan, Mexico|Hospital Universitario Dr. Jose E. Gonzalez; Haematology, Monterrey, Mexico|Centro de Estudios Clinicos de Queretaro (CECLIQ), Queretaro, Mexico|Canterbury Health Laboratories; Haematology, Christchurch, New Zealand|Palmerston North Hospital; Regional Cancer Treatment Service, Palmerston North, New Zealand|Instituto;Oncologico Miraflores, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Hospital Maria Auxiliadora, Lima, Peru|Spitalul Clinic Judetean de Urgenta Brasov,Clinica de Hematologie, Brasov, Romania|Fundeni Clinical Inst. ; Hematology Dept, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta Sf. Spiridon Iasi, Clinica de Hematologie, Iasi, Romania|Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania|Spitalul Clinic municipal de Urgenta Timisoara; Clinica de Hematologie, Timisoara, Romania|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|Haematology Research Center; Haematology, Moscow, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|St. Petersburg State Medical University n.a. I.P. Pavlov; Hematology, transfusiology and transplanta, Saint-Petersburg, Russian Federation|Research Inst. of Hematology & Blood Transfusion ; Hematology, St Petersburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies; Dept of Radiology, St.Petersburg, Pesochny, Russian Federation|Institute of Hematology, Belgrade, Serbia|Clinical Center Vojvodine; Clinic for Hematology, Novi Sad, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|Singapore General Hospital; Department of Haematology, Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|St. Elisabeths Cancer Center, Bratislava, Slovakia|National Cancer Inst. ; Dept. of Chemotherapy, Bratislava, Slovakia|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|King Edward VIII; Department of Haematology, Congella, South Africa|Durban Oncology Center, Durban, South Africa|University of Witwatersrand/Johannesburg Hospital; Dept. of ocnology, Johannesburg, South Africa|Cancercare, Kraaifontein, South Africa|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Duran i Reynals; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario de la Princesa; Servicio de Hematologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Hematologia, Murcia, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|National Cancer Inst., Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey|Istanbul University Cerrahpasa Medical Faculty; Hematology Department, Istanbul, Turkey|Bilim University School of Medicine; Hematology, Istanbul, Turkey|Dokuz Eylul Uni ; Hematology, Izmir, Turkey|Ege Uni Medical School; Hematology, Izmir, Turkey|Ninewells Hospital & Medical School; Ward 34, Dundee, United Kingdom|Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom|Derriford Hospital; Department of Haematology, Plymouth, United Kingdom|Queen's Hospital; Oncology, Romford, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Pinderfields General Hospital; Dept of Haematology, Wakefield, United Kingdom|New Cross Hospital; Dept. Of Haematology, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01200758"
607,"NCT01547546","A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma","Completed","No Results Available","All","Phase 1","29","Industry","Interventional","April 2012","January 2015","January 2015","March 8, 2012","null","November 2, 2016","Los Angeles, California, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Houston, Texas, United States|Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01547546"
608,"NCT01466179","Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)","Completed","Has Results","All","Phase 2","225","Industry","Interventional","December 2011","October 2013","January 2017","November 7, 2011","January 22, 2015","August 18, 2017","City of Hope, Duarte, California, United States|University of California Los Angeles, Los Angeles, California, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Dana Farber Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Streets, Buffalo, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CHU d'Angers, Angers, France|Hôpital de l'hôtel Dieu, Nantes, France|Hôpital Saint Louis, Paris, France|CHU de Purpan, Toulouse, France|Charité - Campus Benjamin Franklin, Berlin, Germany|Klinikum der Goethe Universität, Medizinische Klinik II, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Universitätsklinikum Münster, Münster, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany|Julius-Maximilians-Universität, Medizinische Klinik und Poliklinik II, Würzburg, Germany|Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Antonio Cardarelli, Naples, Italy|Ospedali Riuniti ""Villa Sofia-Cervello"", Palermo, Italy|Università La Sapienza di Roma, Rome, Italy|Azienda Ospedaliero-Universitaria, Turin, Italy|Azienda Ospedaliera di Verona, Verona, Italy|ICO Hospital Germans Trias I Pujol, Badalona, Spain|Hospital Clínic Servei d´Hematologia, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|University Hospitals Bristol NHS, Bristol, United Kingdom|Royal Free Hampstead NHS Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01466179"
609,"NCT01115491","A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme","Completed","Has Results","All","Phase 2","32","Industry","Interventional","June 2010","July 2012","July 2012","May 4, 2010","December 8, 2014","December 8, 2014","Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Valencia, Spain","https://ClinicalTrials.gov/show/NCT01115491"
610,"NCT00937950","Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects","Completed","Has Results","Female","Phase 3","2022","Industry","Interventional","August 5, 2009","January 20, 2014","January 20, 2014","July 13, 2009","January 15, 2015","July 27, 2018","GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Bardstown, Kentucky, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, New Bern, North Carolina, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Carnegie, Pennsylvania, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pleasant Hills, Pennsylvania, United States|GSK Investigational Site, Wenatchee, Washington, United States|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Hobart, Tasmania, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Parkville, Victoria, Australia|GSK Investigational Site, Perth, Western Australia, Australia|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Campinas, Brazil|GSK Investigational Site, Curitiba, Brazil|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Langley, British Columbia, Canada|GSK Investigational Site, St. John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Truro, Nova Scotia, Canada|GSK Investigational Site, Beauport, Quebec, Canada|GSK Investigational Site, Gatineau, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Jyvaskyla, Finland|GSK Investigational Site, Kotka, Finland|GSK Investigational Site, Kouvola, Finland|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Lahti, Finland|GSK Investigational Site, Lappeenranta, Finland|GSK Investigational Site, Mikkeli, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Pori, Finland|GSK Investigational Site, Rauma, Finland|GSK Investigational Site, Seinajoki, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Vaasa, Finland|GSK Investigational Site, Karlsruhe, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ravensburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Rheinstetten, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Nordhausen, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Cavite, Philippines|GSK Investigational Site, Laguna, Philippines|GSK Investigational Site, Las Pinas City, Philippines|GSK Investigational Site, Los Banos, Laguna, Philippines|GSK Investigational Site, Makati City, Philippines|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Móstoles/Madrid, Spain|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Aberdeen, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00937950"
611,"NCT00825149","A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma","Completed","No Results Available","All","Phase 1","137","Industry","Interventional","February 2009","November 2015","November 2015","January 19, 2009","null","November 4, 2016","Kogarah, New South Wales, Australia|Sydney, New South Wales, Australia|Greenslopes, Queensland, Australia|Woolloongabba, Queensland, Australia|Kurralta Park, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Lille, France|Montpellier, France|Pierre Benite, France|Aschaffenburg, Germany|Freiburg, Germany|Göttingen, Germany|Heidelberg, Germany|Kiel, Germany|Köln, Germany|Muenchen, Germany|Ulm, Germany|Würzburg, Germany|Roma, Lazio, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Salamanca, Spain|Valencia, Spain|Leicester, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Plymouth, United Kingdom|Southampton, United Kingdom|Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT00825149"
612,"NCT01007292","A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment","Completed","No Results Available","All","Phase 2","43","Industry","Interventional","November 2009","March 2013","June 2015","November 4, 2009","null","October 19, 2015","Site US2778 John B. Amos Cancer Center, Columbus, Georgia, United States|Site US55 Loyola University Hospital - Maywood, Maywood, Illinois, United States|Site US9 Mount Sinai School of Medicine, New York, New York, United States|Site US2802 Mecklenburg Medical Group, Charlotte, North Carolina, United States|Site US2149 Gabrail Cancer Center Research, Canton, Ohio, United States|Site US402 University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States|Site FR1926 Institut Bergonie, Bordeaux-cedex, France|Site FR2700 Centre Antoine Lacassagne, Nice, France|Site FR476 Hopital Saint Louis, Paris, France|Site FR1889 Centre de Lutte Contre le Cancer - Centre Henri Becquerel, Rouen, France|Site FR1897 Hopital Bretonneau, Tours, France|Site ES1349 Hospital del Mar, Barcelona, Spain|Site ES1339 Hospital Universitario Ramon y Cajal, Madrid, Spain|Site ES2967 Hosptial Universitario Madrid Sanchinarro, Madrid, Spain|Site ES1346 Hospital Universitario de Salamanca, Salamanca, Spain|Site GB2702 Addenbrookes Hospital, Cambridge, United Kingdom|Site GB1928 St. Georges Hospital, London, United Kingdom|Site GB2624 The Christie NHS Foundation Trust, Manchester, United Kingdom|Site GB1903 Oxford Radcliffe Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01007292"
613,"NCT02478957","Treatment of Indolent Systemic Mastocytosis With PA101","Completed","No Results Available","All","Phase 2","41","Industry","Interventional","June 2015","March 2016","June 2016","June 23, 2015","null","September 29, 2016","Hopital Necker - Enfants Malades, Paris, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum Darmstadt, Darmstadt, Germany|University Medical Center Mainz, Mainz, Germany|Technical University München, Munich, Germany|University of Salerno, Salerno, Italy|University Medical Center of Groningen, Groningen, Netherlands|Hospital Universitario de Fuenlabrada, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02478957"
614,"NCT01755767","Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy","Completed","No Results Available","All","Phase 3","383","Industry","Interventional","December 27, 2012","March 28, 2017","March 28, 2017","December 24, 2012","null","March 30, 2018","Tucson, Arizona, United States|Los Angeles, California, United States|Orange, California, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Chicago, Illinois, United States|Westwood, Kansas, United States|New Orleans, Louisiana, United States|Scarborough, Maine, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Hackensack, New Jersey, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|Seattle, Washington, United States|Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Buenos Aires, Caba, Argentina|Pilar, Argentina|Camperdown, New South Wales, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Graz, Austria|Innsbruck, Austria|Linz, Austria|Wien, Austria|Brussels, Belgium|Ghent, Belgium|Leuven, Belgium|Liege, Belgium|Porto Alegre, RS, Brazil|Sao Paulo, SP, Brazil|Barretos, Brazil|Rio de Janeiro, Brazil|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Amiens Cedex 1, France|Bordeaux Cedex, France|Caen Cedex 09, France|Clichy, France|Creteil, France|Grenoble, France|Lille Cedex, France|Marseille Cedex 09, France|Montpellier, France|Paris Cedex 12, France|Paris Cedex, France|Reims Cedex, France|Rennes Cedex, France|Toulouse Cedex 09, France|Villejuif Cedex, France|Aachen, Germany|Berlin, Germany|Bonn, Germany|Duesseldorf, Germany|Essen, Germany|Frankfurt am Main, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Leipzig, Germany|Magdeburg, Germany|Mainz, Germany|Muenchen, Germany|Munich, Germany|Regensburg, Germany|Tuebingen, Germany|Ulm, Germany|Wuerzburg, Germany|Meldola, Forli-Cesena, Italy|Rozzano, Milano, Italy|Orbassano (TO), Torino, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Catania, Italy|Firenze, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Padova, Italy|Parma, Italy|Pavia, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Turin, Italy|Amsterdam, Netherlands|Auckland, New Zealand|Lisboa, Portugal|Porto, Portugal|Vila Real, Portugal|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Majadahonda, Madrid, Spain|Pamplona, Navarra, Spain|Alicante, Spain|Barcelona, Spain|Cordoba, Spain|Madrid, Spain|Sabadell, Spain|Santander, Spain|Valencia, Spain|Zaragoza, Spain|Gothenburg, Sweden|Stockholm, Sweden|Bern, Switzerland|Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT01755767"
615,"NCT01693068","Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma","Completed","Has Results","All","Phase 2","194","Industry","Interventional","December 5, 2012","July 4, 2015","October 24, 2016","September 26, 2012","January 5, 2018","January 5, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, San Francisco, California, United States|Research Site, Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Maywood, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Please contact the US Medical Information in, Rockland, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Morristown, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, Madison, Wisconsin, United States|Research Site, Adelaide, SA, Australia|Research Site, Albury/Wodonga, Australia|Research Site, Auchenflower, Australia|Research Site, Box Hill, Australia|Research Site, Greenslopes, Australia|Research Site, Herston, Australia|Research Site, Malvern, Australia|Research Site, North Sydney, Australia|Research Site, Prahran, Australia|Research Site, Wendouree, Australia|Research Site, Woodville South, Australia|Research site, Woolloongabba, Australia|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Bordeaux, France|Research Site, Brest, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nantes, France|Research Site, Paris, France|Research Site, Pierre Benite, France|Research Site, Rennes, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Buxtehude, Germany|Research site, Düsseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Kiel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research site, München, Germany|Research Site, Münster, Germany|Research Site, Plauen, Germany|Research Site, Tübingen, Germany|Research Site, Würzburg, Germany|Research Site, Jerusalem, Israel|Research Site, Ramat-Gan, Israel|Research Site, Tel-Aviv, Israel|Research Site, Bari, Italy|Research Site, Genova, Italy|Research Site, Meldola - FC, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Groningen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Hamilton, New Zealand|Research Site, Palmerston North, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, l'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Zürich, Switzerland|Research Site, Cambridge, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01693068"
616,"NCT01507168","A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma","Completed","No Results Available","All","Phase 2","186","Industry","Interventional","February 2012","August 2015","August 2015","January 10, 2012","null","November 2, 2016","Los Angeles, California, United States|Los Angeles, California, United States|Bethesda, Maryland, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|New York, New York, United States|New York, New York, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Seattle, Washington, United States|Bruxelles, Belgium|Gent, Belgium|Angers, France|Clichy, France|Grenoble, France|Marseille, France|Nice, France|Paris, France|Toulouse, France|Vandoeuvre-les-nancy, France|Villejuif, France|Berlin, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Heidelberg, Germany|Leipzig, Germany|Munich, Germany|Tübingen, Germany|Pokfulam, Hong Kong|Shatin, Hong Kong|Benevento, Campania, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Padova, Veneto, Italy|Chiba, Japan|Ishikawa, Japan|Kanagawa, Japan|Osaka, Japan|Tokyo, Japan|Tokyo, Japan|Busan, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Singapore, Singapore|Santander, Cantabria, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bebington, United Kingdom|London, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT01507168"
617,"NCT01307397","A Study of Vemurafenib in Participants With Metastatic Melanoma","Completed","Has Results","All","Phase 3","3219","Industry","Interventional","March 1, 2011","February 24, 2016","February 24, 2016","March 2, 2011","December 18, 2017","December 18, 2017","University ""Mother Theresa"" Hospital Center; Oncology Department, Tirana, Albania|Hospital Britanico; Oncologia, Buenos Aires, Argentina|Fundación CIDEA, Buenos Aires, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, Argentina|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Border Medical Oncology, Wodonga, New South Wales, Australia|Greenslopes Private Hospital; Gallipoli Research Centre, Greenslopes, Queensland, Australia|The Townsville Hospital; Townsville Cancer Centre, Townsville, Queensland, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, Australia|Geelong Hospital; Geelong Cardiology Practice, Geelong, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Landeskrankenhaus Feldkirch; Abteilung für Innere Medizin, Feldkirch, Austria|LKH Graz; Abteilung für allgemeine Dermatologie, Graz, Austria|LKH Innsbruck; Universitätsklinik für Dermatologie, Innsbruck, Austria|Krankenhaus der Elisabethinen Linz; Abteilung für Dermatologie, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|LKH Salzburg; Universitätsklinik für Dermatologie, Salzburg, Austria|Landesklinikum St. Pölten, St. Pölten, Austria|Medizinische Universität Wien; Univ.Klinik für Dermatologie, Wien, Austria|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|District Oncology Dispensary; Department for Oncology and Dermatology, Plovdiv, Bulgaria|National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic, Sofia, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Lion'S Gate Hospital, North Vancouver, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|St. Boniface General Hospital; Medicine, Winnipeg, Manitoba, Canada|QEII HSC; Oncology, Halifax, Nova Scotia, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|The Ottawa Hospital; Division of Infectious Diseases, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Chuq - Hopital Hotel Dieu de Quebec; Oncology, Quebec City, Quebec, Canada|Centro Javeriano de Oncología, Bogota, Colombia|Fundacion Santa Fe de Bogotá, Bogota, Colombia|Clínica Imbanaco; Oncology, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Clinical Hospital Sisters of Mercy, Zagreb, Croatia|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Faculty Hospital; Dialysis Unit, Ostrava, Czechia|1 Lekarska Fakulta Uni Karlovy; 3 Interni Klinika, Labor. Pro Endokrinologii A Metabolismus, Praha, Czechia|Faculty Hospital Kralovske Vinohrady; Oncology, Praha, Czechia|Aarhus Universitetshospital; Kræftafdelingen, Aarhus C, Denmark|Herlev Hospital; Onkologisk afdeling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense, Denmark|Hospital Regional Vicente Corral Moscoso, Servicio de Oncología, Cuenca, Ecuador|Hospital Abel Gilbert Ponton; Oncology, Guayaquil, Ecuador|Hospital Solca Portoviejo; Oncologia, Portoviejo, Ecuador|East Tallinn Central Hospital; Clinic of Internal Medicine, Tallinn, Estonia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, Estonia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Uniklinik RWTH Aachen; Klinik für Dermatologie und Allergologie - Hautklinik, Aachen, Germany|Klinikum Augsburg Süd; Klinik für Dermatologie und Allergologie, Augsburg, Germany|CAMPUS BENJAMIN FRANKLIN CharitéCentrum 14 Med.Klinik f.Hämatologie u.Onkologie, Berlin, Germany|St. Josef-Hospital Klinik f. Dermatologie u. Allergologie, Bochum, Germany|Elbekliniken Buxtehude; Klinik für Dermatologie, Buxtehude, Germany|DRK-Krankenhaus; Hautklinik, Chemnitz, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik und Poliklinik I, Dresden, Germany|Universitätsklinikum Düsseldorf; Hautklinik, Düsseldorf, Germany|HELIOS Klinikum Erfurt, Klinik für Hautkrankheiten und Allergologie, Erfurt, Germany|Universitätsklinikum Erlangen; Hautklinik, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik fuer Allgemein- und Viszeralchirurgie, Frankfurt, Germany|Uniklinikum Freiburg Dermatol, Freiburg, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, Germany|Universitätsmedizin Göttingen Georg-August-Universität Zentrum Dermatologie, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Klinik f.Dermatologie, Hamburg, Germany|Medizinische Hochschule; Hautklinik Linden, Hannover, Germany|Uni-Hautklinik, Heidelberg, Germany|Klinikum am Gesundbrunnen; Tumorzentrum, Heilbronn, Germany|Universitätsklinikum Jena; Klinik für Hautkrankheiten, Jena, Germany|Klinikum Kassel; Hautklinik, Kassel, Germany|UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie, Kiel, Germany|Klinik der Uni zu Köln; Klinik & Poliklinik fuer Dermatologie & Venerologie, Köln, Germany|Universitätsklinikum Leipzig Klinik f.Dermatologie Venerologie u.Allergologie, Leipzig, Germany|Klinikum d.Stadt Ludwigshafen Hautklinik, Ludwigshafen, Germany|Universitätsklinikum Schleswig-Holstein; Campus Lübeck, Lübeck, Germany|Universitätsklinikum Magdeburg; Hautklinik; Klinik für Dermatologie und Venerologie, Magdeburg, Germany|Johannes Gutenberg Unis-Klinik; Dept For Dermatology, Mainz, Germany|Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, Mannheim, Germany|Universitätsklinikum Marburg Klinik f. Dermatologie, Marburg, Germany|Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik, Minden, Germany|Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie, München, Germany|Staedtisches Krankenhaus Muenchen-Schwabing, Haematologie & Onkolgie, München, Germany|Universitätsklinikum Münster, Münster, Germany|Fachklinik Hornheide; Internistische Onkologie, Münster, Germany|Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie, Nürnberg, Germany|Klinikum Dorothea Ch.Erxleben; Klinik für Dermatologie und Allergologie, Quedlinburg, Germany|KLINIKUM VEST GmbH Knappschaftskrankenhaus Abt.Haut- Allergie- Venen- und Umwelterkrankungen, Recklinghausen, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany|Universitaets-Hautklinik Tuebingen, Tübingen, Germany|Wilhelm Fresenius Klinik; Klinik f. Dermatologie u. Allergologie, Wiesbaden, Germany|HELIOS Klinikum Barmen Zentrum Dermatologie Allergologie und Umweltmedizin, Wuppertal, Germany|Universitätsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie, Würzburg, Germany|Laiko General Hospital; 1St Pathological Clinic, Athens, Greece|Hospital Hygeia; 1St Oncology Dept., Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Metropolitan Hospital; Dept. of Oncology, Piraeus, Greece|Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Debreceni Egyetem OEC; Borgyogyaszati Klinika, Debrecen, Hungary|Pecsi Tudomanyegyetem AOK; Borgyogyaszati Klinika, Pecs, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, Hungary|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India|Chhatrapati Shahuji Maharaj Medical University; Department of Oncology, Lucknow, India|Regional Cancer Centre; Dept of Oncology, Trivandrum, India|Christian Med Clg & Hspt, Vellore, India|Cork Uni Hospital; Oncology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Waterford Regional Hospital; Department Of Medical Oncology, Waterford, Ireland|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Ranbam Health Care Campus; Oncology - Hafia, Hafia, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|AO Santa Maria Nuova; U.O. Day Hospital di Oncologi, Reggio Emilia, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, Italy|Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica, Roma, Lazio, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|Policlinico Le Molinette; Clinica Dermatologica, Torino, Piemonte, Italy|Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari, Bari, Puglia, Italy|Policlinico P. Giaccone; Istituto Di Oncologia, Clinica Medica 1, Palermo, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera S. Chiara; Dip di Onc,Trapianti e delle Nuove Tecnologie in Medicina, Pisa, Toscana, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hosp; Dept Internal Med Hem Onc, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Daugavpils Regional Hospital, Daugavpils, Latvia|Rigas Austrumu Kliniska Universitates slimnica, Latvijas Onkologijas centrs, Riga, Latvia|Klaipeda University Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center, Vilnius, Lithuania|University Clinic for Radiotherapy and Oncology Skopje; Department of skin malignancies, Skopje, Macedonia, The Former Yugoslav Republic of|Fundación Rodolfo Padilla Padilla, A.C.; Oncology, Leon, Mexico|Inst. Nacional de Cancerologia; Investigacion Clinica, Mexico City, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, Mexico|Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde, Amsterdam, Netherlands|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands|Tergooiziekenhuizen, Blaricum, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, Netherlands|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, Netherlands|UMC St Radboud; Interne Oncologie; Medical Oncology Department, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht; Inwendige Geneeskunde Afd., Utrecht, Netherlands|Haukeland Universitetshospital; Onkologisk Avd., Bergen, Norway|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Krakow, Poland|ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii;Wojska Polskiego 37, Olsztyn, Poland|NZOZ Med.-Polonia sp. z o.o., Poznań, Poland|Centrum Onkologii- Instytut; im. M.Skłodowskiej-Curie, Warszawa, Poland|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Institut of Oncology Al. Trestioreanu Bucharest; Oncology, Bucuresti, Romania|Medisprof SRL, Cluj-Napoca, Romania|S.C. Life Search S.R.L; Medical Oncology Clinic, Timisoara, Romania|FSBI ""Scientific Research Institute of Oncology named after N.N.Petrov"" Ministry of Health of RF, St Petersburg, Leningrad, Russian Federation|Regional Clinical Oncology Dispensary, Krasnodar, Russian Federation|Russian Cancer Research Center, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Stavropol Clinical Oncology Dispansary, Stavropol, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Clinical Center Bezanijska Kosa; Oncology, Belgrade, Serbia|Onkologicky ustav sv. Alzbety; Oddelenie ambulantnej chemoterapie, Bratislava, Slovakia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie E, Bratislava, Slovakia|POKO Poprad; Department of Oncology, Poprad, Slovakia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Universitas Annex, University of the Free State; Clinical Oncology, Bloemfontein, South Africa|Cape Town Oncology Trials, Cape Town, South Africa|Cancercare, Cape Town, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Sandton Oncology Centre, Sandton, South Africa|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, Las Palmas, Spain|Hospital Universitario de Santa Lucía; Servicio de Oncología Médica, Cartagena (Murcia), Murcia, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Xeral Cíes; Servicio de Oncologia, Vigo, Pontevedra, Spain|Hospital Universitario de Canarias (HUC), La Laguna (Tenerife), Tenerife, Spain|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Sahlgrenska Universitetssjukhuset; Onkology, Gothenburg, Sweden|Skånes Onkologiska Klinik, Universitetssjukhuset, Lund, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Universitaetsspital Basel; Onkologie, Basel, Switzerland|Inselspital Bern; Medizinische Onkologie, Bern, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|CHUV; Departement d'Oncologie, Lausanne, Switzerland|Kantonsspital St. Gallen; Onkologie/Hämatologie, St. Gallen, Switzerland|Universitätsspital Zürich; Dermatologische Klinik, Zürich, Switzerland|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, Turkey|Ankara Uni , Ibn-I Sina Hospital; Oncology Dept, Ankara, Turkey|Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey|Akdeniz University School of Medicine; General Surgery, Antalya, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, İZMİR, Turkey|Gaziantep University Medical Faculty, Medical Oncology Department, Gaziantep, Turkey|Kartal Training and Research Hospital;Medical Oncology Department, Istanbul, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, Turkey|American Hospital, Medical Oncology Department, Istanbul, Turkey|Dokuz Eylul Uni ; Medical Oncology, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, ANKARA, Turkey|Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Royal Surrey County Hospital; St. Lukes Cancer Centre, Guildford, United Kingdom|St James University Hospital, Leeds, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|Northern Centre for Cancer Care Freeman Hospital; Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne, United Kingdom|Mount Vernon Hospital; Centre For Cancer Treatment, Northwood, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, United Kingdom|Singleton Hospital; Oncology, Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT01307397"
618,"NCT01515189","Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab","Completed","Has Results","All","Phase 3","831","Industry","Interventional","February 17, 2012","February 6, 2016","August 17, 2017","January 24, 2012","March 24, 2017","September 13, 2018","The Angeles Clinic And Research Institute, Los Angeles, California, United States|University Of California Los Angeles, Los Angeles, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Fundacion Cidea, Buenos Aires, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Halfax, Nova Scotia, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Bordeaux, France|Local Institution, Dijon Cedex, France|Local Institution, Grenoble, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Reims Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Mainz, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Budapest, Hungary|Local Institution, Kaposvar, Hungary|Local Institution, Szeged, Hungary|Local Institution, Jerusalem, Israel|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, George, Western CAPE, South Africa|Local Institution, Rondebosch, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Navarra, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Umea, Sweden|Local Institution, Lausanne, Switzerland|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Glasgow, Scotland, Strathclyde, United Kingdom|Local Institution, London, Surrey, United Kingdom|Local Institution, Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT01515189"
619,"NCT00855218","A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).","Completed","Has Results","All","Phase 2","307","Industry","Interventional","March 2009","July 2011","February 2013","March 4, 2009","September 24, 2012","August 18, 2017","La Jolla, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Gainesville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Camperdown, New South Wales, Australia|St Leonards, New South Wales, Australia|Greenslopes, Queensland, Australia|Clayton, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Halifax, Nova Scotia, Canada|Toronto, Ontario, Canada|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Xi'an, Shannxi, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Creteil, France|Lille, France|Lyon Cedex, France|Lyon, France|Marseille, France|Paris, France|Paris, France|Vandoeuvre-les-nancy, France|Villejuif, France|Villejuif, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Jena, Thüringen, Germany|Berlin, Germany|Hamburg, Germany|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Palermo, Sicilia, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Verona, Veneto, Italy|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Santiago de Compostela, A Coruña, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|Badalona, Barcelona, Spain|Sabadell, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Catalunya, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|La Laguna, Santa Cruz de Tenerife, Spain|A Coruña, Spain|Alicante, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00855218"
620,"NCT00901901","Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","Completed","Has Results","All","Phase 3","732","Industry","Interventional","May 21, 2009","April 17, 2012","May 23, 2018","May 14, 2009","September 30, 2013","July 6, 2018","San Francisco, California, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Maywood, Illinois, United States|Westwood, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Rochester, New York, United States|Valhalla, New York, United States|Charlotte, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Herston, Queensland, Australia|Clayton, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Kortrijk, Belgium|La Louviere, Belgium|Leuven, Belgium|Liege, Belgium|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Floridablanca, Colombia|Medellín, Colombia|Bordeaux, France|Clichy, France|Creteil, France|La Roche Sur Yon, France|Lille, France|Lyon, France|Marseille, France|Paris, France|Pessac, France|Vandoeuvre-les-nancy, France|Villejuif, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Berlin, Germany|Athens, Greece|Larissa, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Shatin, Hong Kong|Beer Sheva, Israel|Haifa, Israel|Petah Tikva, Israel|Rehovot, Israel|Zrifin, Israel|Milano, Lombardia, Italy|Goyang-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Christchurch, New Zealand|Wellington South, New Zealand|Lima, Peru|Lima, Peru|Bydgoszcz, Poland|Gdansk, Poland|Gliwice, Poland|Warszawa, Poland|Barnaul, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Singapore, Singapore|Singapore, Singapore|Johannesburg, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Lugo, Spain|Madrid, Spain|Santander, Spain|Valencia, Spain|Valencia, Spain|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Sheffield, South Yorkshire, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT00901901"
621,"NCT01035229","Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.","Completed","Has Results","All","Phase 3","546","Industry","Interventional","April 2010","October 2013","October 2013","December 18, 2009","October 27, 2014","September 22, 2016","Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Compassionate Cancer Care Medical Group CCCMG, Fountain Valley, California, United States|University of California San Diego - Moores Cancer Center SC - 3, La Jolla, California, United States|California Pacific Medical Center California Pacific Med, San Francisco, California, United States|Rocky Mountain Cancer Centers RMCC - Denver-Midtown (4), Greenwood Village, Colorado, United States|Queen's Medical Center Queens Cancer Center, Honolulu, Hawaii, United States|The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU, Baltimore, Maryland, United States|Massachusetts General Hospital Dept. of Mass General Hospital, Boston, Massachusetts, United States|Midwest Cancer Care Physicians Research Medical Center, Kansas City, Missouri, United States|VA Sierra Nevada Health Care System Dept. of VA Sierra Nevada HCS, Reno, Nevada, United States|University of Rochester Medical Center Rochester, Rochester, New York, United States|Northwest Cancer Specialists Rose Quarter Cancer Center, Portland, Oregon, United States|St. Luke's Hospital and Health Network St. Luke's Cancer Network (2), Bethlehem, Pennsylvania, United States|Texas Cancer Center - Abilene, Abilene, Texas, United States|Methodist Charlton Cancer Center Methodist, Dallas, Texas, United States|University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3), Dallas, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio, San Antonio, Texas, United States|Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care, Roanoke, Virginia, United States|University of Washington Cancer Care SC, Seattle, Washington, United States|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Amiens cedex 1, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Caen Cedex9, France|Novartis Investigative Site, Chambray-lès-Tours, France|Novartis Investigative Site, Clermont Ferrand cedex 1, France|Novartis Investigative Site, Clichy, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex 04, France|Novartis Investigative Site, Marseille Cédex 5, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Nice Cedex 3, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen Cedex, France|Novartis Investigative Site, St Priest en Jarez Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Foggia, FG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Frattamaggiore, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Chiba-city, Chiba, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Iizuka-city, Fukuoka, Japan|Novartis Investigative Site, Gifu-shi, Gifu, Japan|Novartis Investigative Site, Ogaki-city, Gifu, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Liouying Township, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT01035229"
622,"NCT01815840","A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas","Completed","Has Results","All","Phase 2","229","Industry","Interventional","April 30, 2013","August 27, 2015","August 31, 2016","March 21, 2013","August 4, 2016","September 28, 2017","Dermatology Research Associate, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Skin Surgery Med Group, Inc, San Diego, California, United States|California Pacific Medical Center Research Institute, Santa Rosa, California, United States|Advanced Derm & Cosmetic Surg, Ormond Beach, Florida, United States|Skin and Cancer Associates and the Center for Cosmetic Enhancement, Plantation, Florida, United States|Emory University Clinic, Atlanta, Georgia, United States|Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States|Beverly Hospital;Oncology Center Pharmacy, Beverly, Massachusetts, United States|Saint Louis University School of Medicine; Department of Dermatology, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Long Island Skin Cancer and Dermatologic Surgery, Smithtown, New York, United States|Mariwalla Dermatology, West Islip, New York, United States|The Skin Surgery Center, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Dermatology and Laser Center of Charleston PA, Charleston, South Carolina, United States|LKH Innsbruck; Universitätsklinik für Dermatologie, Innsbruck, Austria|Medizinische Universität Wien; Univ.Klinik für Dermatologie, Wien, Austria|UBC Department of Dermatology & Skin Sciences, Vancouver, British Columbia, Canada|Dermetics, Burlington, Ontario, Canada|Innovaderm Research Inc., Montreal, Quebec, Canada|CHU Amiens - Hopital Sud, Amiens, France|Hopital Saint Andre CHU De Bordeaux; Dermatologie, Bordeaux, France|Chu Site Du Bocage;Dermatologie, Dijon, France|Hopital Dupuytren; Dermatologie, Limoges, France|Hopital Timone Adultes; Dermatologie, Marseille, France|Hopital Saint Eloi; CHU de Montpellier; Svc de Dermatologie, Montpellier, France|Hopital Hotel Dieu Et Hme; Clinique Dermatologique, Nantes, France|Hôpital Saint-Louis, Paris, France|Ch Francois Mitterrand; Medecine Oncologie, Pau, France|Hopital Nord ; Dermatologie, Saint-Etienne, France|Universitätsklinik Essen; Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Essen, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, Germany|Medizinische Hochschule Hannover; Klinik für Dermatologie, Allergologie und Venerologie, Hannover, Germany|UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie, Kiel, Germany|Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie, München, Germany|Fachklinik Hornheide; Dermatologie, Münster, Germany|Universitätsklinikum Tübingen Universitäts-Hautklinik, Tübingen, Germany|Ospedale San Salvatore (ASL-01); Dip. di Dermatologia U.O.S. di Dermatologia Oncol, L'Aquila, Abruzzo, Italy|Arcispedale Santa Maria Nuova; Dermatologia, Reggio Emilia, Emilia-Romagna, Italy|Università di Brescia; Dipartimento di Dermatologia, Brescia, Lombardia, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Ospedale IOT- Palagi Dermatologia 2, Firenze, Toscana, Italy|Hospital General de México, Mexico City, Mexico|Hospital General Dr. Manuel Gea Gonzalez; Dermatology, Mexico, Mexico|VU MEDISCH CENTRUM;Afdeling Dermatologie, Amsterdam, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|Maastricht University Medical Centre; Dermatologie, Maastricht, Netherlands|Blokhin Cancer Research Center; General Oncology Department, Moscow, Russian Federation|FSBI ""Russian Oncology Research Center n.a. N. N. Blokhin"" of Ministry of Health of the Russian Fed, Moscow, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Hospital Costa Del Sol; Servicio de Dermatologia, Málaga, Malaga, Spain|Hospital Clinic i Provincial; Servicio de Farmacia, Barcelona, Spain|Hospital General Universitario de Guadalajara; Servicio de Dermatologia, Guadalajara, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01815840"
623,"NCT01708174","A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)","Completed","Has Results","All","Phase 2","22","Industry","Interventional","May 6, 2013","October 5, 2016","October 5, 2016","October 16, 2012","June 14, 2017","August 11, 2017","Ann & Robert H. Lurie Children Dept of Oncology, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Dept Onc, Baltimore, Maryland, United States|Dana Farber Cancer Institute SC-7, Boston, Massachusetts, United States|Columbia University Medical Center- New York Presbyterian Dept of Oncology, New York, New York, United States|Cincinnati Children's Hospital Medical Center Division of Hema/Onco., Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh Dept of Oncology, Pittsburgh, Pennsylvania, United States|University of Texas/MD Anderson Cancer Center SC-3, Houston, Texas, United States|Seattle Cancer Care Alliance Dept Oncology, Seattle, Washington, United States|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Bordeaux, Aquitaine, France|Novartis Investigative Site, Angers Cedex 1, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Moskow, Russia, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Esplugues de Llobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom","https://ClinicalTrials.gov/show/NCT01708174"
624,"NCT01860638","A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma","Completed","No Results Available","All","Phase 2","296","Industry","Interventional","August 19, 2013","January 13, 2017","May 5, 2017","May 23, 2013","null","April 30, 2018","Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz, Austria|Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus; Innere Medizin mit Neuroonkologie, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Kaiser-Franz-Josef-Spital; Neurologische Abteilung, Wien, Austria|MBAL Serdika EOOD, Sofia, Bulgaria|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, Estonia|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Hopital Avicenne; Neurologie, Bobigny, France|Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Hopital Cote De Nacre; Unite Neurologie Generale, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille, France|Hôpital Central; Departement de Neuro-Oncologie, Nancy, France|Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France|Hopital Purpan, Toulouse Cedex 9, France|Agioi Anargyroi Anticancer Hospital; Radiotherapeutic Clinic, Kifisia, Greece|Hygeia Hospital, Marousi, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Ospedale Bellaria; U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia, Torino, Piemonte, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Riga East Clinical University hospital, Clinic Gailezers, Dept of Neurosurgery, Riga, Latvia|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital de Sao Joao; Servico de Oncologia, Porto, Portugal|Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania|Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-napoca, Romania|Spital Clinic Judetean Mures; Oncologie, Targu Mures, Romania|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hosp. Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Universitetssjukhuset; Onkologkliniken, Linkoeping, Sweden|Norrlands Universitetssjukhus; Cancer Centrum, Umea, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Adana City Hospital, Medical Oncology, Adana, Turkey|Baskent Universitesi Tıp Fakultesi; Ic Hastalıkları Anabilim Dalı Tıbbi Onkoloji Bilim Dalı, Ankara, Turkey|Dokuz Eylul Uni ; Medical Oncology, Izmir, Turkey|Kocaeli University Faculty of Medicine; Medical oncology, Izmit, Turkey|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital; Dept of Oncology, Cambridge, United Kingdom|University College Hospital; Department of Oncology, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01860638"
625,"NCT01140347","A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","Completed","Has Results","All","Phase 3","565","Industry","Interventional","October 2010","March 2014","March 2015","June 9, 2010","March 26, 2015","December 28, 2015","ImClone Investigational Site, Orange, California, United States|ImClone Investigational Site, San Francisco, California, United States|ImClone Investigational Site, New Haven, Connecticut, United States|ImClone Investigational Site, Jacksonville, Florida, United States|ImClone Investigational Site, New Orleans, Louisiana, United States|ImClone Investigational Site, Boston, Massachusetts, United States|ImClone Investigational Site, Worcester, Massachusetts, United States|ImClone Investigational Site, Ann Arbor, Michigan, United States|ImClone Investigational Site, St Louis, Missouri, United States|ImClone Investigational Site, Newark, New Jersey, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, Winston-Salem, North Carolina, United States|ImClone Investigational Site, Dayton, Ohio, United States|ImClone Investigational Site, Philadelphia, Pennsylvania, United States|ImClone Investigational Site, Charleston, South Carolina, United States|ImClone Investigational Site, Lubbock, Texas, United States|ImClone Investigational Site, Seattle, Washington, United States|ImClone Investigational Site, Milwaukee, Wisconsin, United States|ImClone Investigational Site, Bankstown, New South Wales, Australia|ImClone Investigational Site, Kogarah, New South Wales, Australia|ImClone Investigational Site, Liverpool Bc, New South Wales, Australia|ImClone Investigational Site, Kurralta Park, South Australia, Australia|ImClone Investigational Site, Prahran, Victoria, Australia|ImClone Investigational Site, Linz, Austria|ImClone Investigational Site, Salzburg, Austria|ImClone Investigational Site, Steyr, Austria|ImClone Investigational Site, Vienna, Austria|ImClone Investigational Site, Bonheiden, Belgium|ImClone Investigational Site, Brussels, Belgium|ImClone Investigational Site, Charleroi, Belgium|ImClone Investigational Site, Edegem, Belgium|ImClone Investigational Site, Leuven, Belgium|ImClone Investigational Site, Liège, Belgium|ImClone Investigational Site, Ottignies, Belgium|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Botucatu, Brazil|ImClone Investigational Site, Brasilia, Brazil|ImClone Investigational Site, Campinas, Brazil|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Ribeirao Preto, Brazil|ImClone Investigational Site, Rio De Janeiro, Brazil|ImClone Investigational Site, Salvador, Brazil|ImClone Investigational Site, Sao Jose Rio Preto, Brazil|ImClone Investigational Site, São Paulo, Brazil|ImClone Investigational Site, Plovdiv, Bulgaria|ImClone Investigational Site, Sofia, Bulgaria|ImClone Investigational Site, Varna, Bulgaria|ImClone Investigational Site, Ottawa, Ontario, Canada|ImClone Investigational Site, Brib, Czech Republic|ImClone Investigational Site, Hradec Kralove, Czech Republic|ImClone Investigational Site, Olomouc, Czech Republic|ImClone Investigational Site, Prague, Czech Republic|ImClone Investigational Site, Helsinki, Finland|ImClone Investigational Site, Amiens, France|ImClone Investigational Site, Angers, France|ImClone Investigational Site, Avignon, France|ImClone Investigational Site, Besancon, France|ImClone Investigational Site, Bordeaux, France|ImClone Investigational Site, Clermont-Ferrand, France|ImClone Investigational Site, La Roche Sur Yon, France|ImClone Investigational Site, Limoges, France|ImClone Investigational Site, Marseille, France|ImClone Investigational Site, Nice, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Poitiers, France|ImClone Investigational Site, Reims, France|ImClone Investigational Site, Saint-Etienne, France|ImClone Investigational Site, Berlin, Germany|ImClone Investigational Site, Bielefeld, Germany|ImClone Investigational Site, Bonn, Germany|ImClone Investigational Site, Düsseldorf, Germany|ImClone Investigational Site, Essen, Germany|ImClone Investigational Site, Frankfurt, Germany|ImClone Investigational Site, Freiburg, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Hannover, Germany|ImClone Investigational Site, Homburg, Germany|ImClone Investigational Site, Leipzig, Germany|ImClone Investigational Site, Magdeburg, Germany|ImClone Investigational Site, Munich, Germany|ImClone Investigational Site, Münster, Germany|ImClone Investigational Site, Tübingen, Germany|ImClone Investigational Site, Ulm, Germany|ImClone Investigational Site, Weiden, Germany|ImClone Investigational Site, Kowloon, Hong Kong|ImClone Investigational Site, Pokfulam, Hong Kong|ImClone Investigational Site, Shatin, Hong Kong|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Beer Sheva, Israel|ImClone Investigational Site, Petah Tiqva, Israel|ImClone Investigational Site, Tel Aviv, Israel|ImClone Investigational Site, Bari, Italy|ImClone Investigational Site, Benevento, Italy|ImClone Investigational Site, Bologna, Italy|ImClone Investigational Site, Genova, Italy|ImClone Investigational Site, Lecce, Italy|ImClone Investigational Site, Milano, Italy|ImClone Investigational Site, Modena, Italy|ImClone Investigational Site, Padova, Italy|ImClone Investigational Site, Palermo, Italy|ImClone Investigational Site, Pavia, Italy|ImClone Investigational Site, Rome, Italy|ImClone Investigational Site, Udine, Italy|ImClone Investigational Site, Chiba, Japan|ImClone Investigational Site, Fukuoka, Japan|ImClone Investigational Site, Hyogo, Japan|ImClone Investigational Site, Ishikawa, Japan|ImClone Investigational Site, Kanagawa, Japan|ImClone Investigational Site, Kochi, Japan|ImClone Investigational Site, Kyoto, Japan|ImClone Investigational Site, Miyagi, Japan|ImClone Investigational Site, Osaka-Pref, Japan|ImClone Investigational Site, Osaka, Japan|ImClone Investigational Site, Saga, Japan|ImClone Investigational Site, Tochigi, Japan|ImClone Investigational Site, Tokushima, Japan|ImClone Investigational Site, Tokyo, Japan|ImClone Investigational Site, Anyang, Korea, Republic of|ImClone Investigational Site, Incheon, Korea, Republic of|ImClone Investigational Site, Seodaemun-Gu, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Amsterdam, Netherlands|ImClone Investigational Site, Rotterdam, Netherlands|ImClone Investigational Site, Oslo, Norway|ImClone Investigational Site, Quezon City, Philippines|ImClone Investigational Site, Lisbon, Portugal|ImClone Investigational Site, Santa Maria Da Feira, Portugal|ImClone Investigational Site, Bucharest, Romania|ImClone Investigational Site, Cluj-Napoca, Romania|ImClone Investigational Site, Craiova, Romania|ImClone Investigational Site, Avila, Spain|ImClone Investigational Site, Girona, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Ourense, Spain|ImClone Investigational Site, Valencia, Spain|ImClone Investigational Site, Stockholm, Sweden|ImClone Investigational Site, Bern, Switzerland|ImClone Investigational Site, Changhua, Taiwan|ImClone Investigational Site, Kuei Shan Hsiang, Taiwan|ImClone Investigational Site, Liouying/Tainan, Taiwan|ImClone Investigational Site, Niaosung, Taiwan|ImClone Investigational Site, Taichung, Taiwan|ImClone Investigational Site, Tainan, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Bangkok, Thailand|ImClone Investigational Site, Hat Yai, Thailand","https://ClinicalTrials.gov/show/NCT01140347"
626,"NCT01950364","A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma","Completed","Has Results","All","Phase 1","20","Industry","Interventional","November 2013","October 2014","June 2015","September 25, 2013","February 9, 2016","May 11, 2016","Brussels, Belgium|Gent, Belgium|Vilnius, Lithuania|Barcelona, Spain|Madrid, Spain|Salamanca, Spain","https://ClinicalTrials.gov/show/NCT01950364"
627,"NCT01632228","A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma","Completed","No Results Available","All","Phase 2","135","Industry","Interventional","June 29, 2012","January 21, 2016","January 21, 2016","July 2, 2012","null","February 5, 2018","University of Alabama At Birmingham; Neuro-Oncology, Birmingham, Alabama, United States|Cedars Sinai Medical Center; Neurosurgery, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|USCF - Neurosurgery, San Francisco, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Florida Cancer Specialists - Englewood, Englewood, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|North Western Univ; Neurology, Chicago, Illinois, United States|Northshore University Health System; Cardiology, Evanston, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Hatton Research Institutes, Cincinnati, Ohio, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Baylor Research Inst., Dallas, Texas, United States|University of Virgina, Charlottesville, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance; Investigational Drug Service, Seattle, Washington, United States|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727, Toronto, Ontario, Canada|McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada|CHUS Hopital Fleurimont; CRC, Sherbrooke, Quebec, Canada|Hopital Avicenne; Neurologie, Bobigny, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Hopital Roger Salengro, Lille, France|Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille, France|Centre Val Aurelle Paul Lamarque; Medecine B3, Montpellier, France|Hôpital Central; Departement de Neuro-Oncologie, Nancy, France|Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Hopital Purpan, Toulouse Cedex 9, France|Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn, Germany|Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|Universitatsklinikum Hamburg-Eppendorf; Klinik und Poliklinik fur Neurochirurgie, Hamburg, Germany|Ärztehaus Velen, Ibbenbühren, Germany|Universitätsklinikum Köln, Köln, Germany|Klinikum der Johannes Gutenberg Uni Mainz; Studienz. Neurologie, Klinik und Poliklinik Neurologie, Mainz, Germany|Uni Klinikum München - Großhardern; Med. Klinik U. Poliklinik III - Abt. Onkologie u. Hämatologie, München, Germany|Pius-Hospital, Oldenburg, Germany|Ospedale Bellaria; U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|Presidio Ospedaliero Marconi Bufalini; U.O. di Oncologia, Cesena, Emilia-Romagna, Italy|A.O. Universitaria Di Parma; Oncologia Medica, Parma, Emilia-Romagna, Italy|Spedali Civili di Brescia, Brescia, Lombardia, Italy|Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milano, Lombardia, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Az. Osp. Pisana Ospedale S. Chiara; U.O. Di Reumatologia, Pisa, Toscana, Italy|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Clinic i Provincial; Servicio de Farmacia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|HUG; Oncologie, Geneve, Switzerland|Universitätsspital Zürich; Klinik für Neurologie, Zürich, Switzerland|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Nottingham City Hospital; David Evans Centre, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT01632228"
628,"NCT01673386","A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma","Completed","No Results Available","All","Phase 2","58","Industry","Interventional","July 2012","January 2014","January 2014","August 28, 2012","null","June 23, 2015","Los Angeles, California, United States|Albany, Georgia, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Shreveport, Louisiana, United States|Worcester, Massachusetts, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Charlestown, South Carolina, United States|Myrtle Beach, South Carolina, United States|San Antonio, Texas, United States|Madison, Wisconsin, United States|Antwerp, Belgium|Brussels, Belgium|Bordeaux, France|Caen, France|Lyon, France|Paris, France|Berlin, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Munich, Germany|Aviano, Italy|Pavia, Italy|Rome, Italy|Barcelona, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain|Glasgow, Scotland, United Kingdom|Swansea, Wales, United Kingdom|Cambridge, United Kingdom|London, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01673386"
629,"NCT00943826","A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma","Completed","Has Results","All","Phase 3","921","Industry","Interventional","June 29, 2009","February 28, 2013","September 9, 2015","July 22, 2009","May 20, 2013","September 25, 2017","University of Alabama At Birmingham; Neuro-Oncology, Birmingham, Alabama, United States|UCLA, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr, Evanston, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Hatton Research Institutes, Cincinnati, Ohio, United States|Sarah Cannon Cancer Center and Research Institute, Nashville, Tennessee, United States|University of Virgina, Charlottesville, Virginia, United States|Prince of Wales Hospital; Department of Medical Oncology, Randwick, New South Wales, Australia|North Shore Private Hospital; Northern Specialist Centre, St Leonards, New South Wales, Australia|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Princess AleXandra Hospital; Department of Medical Oncology, Woolloongabba, Queensland, Australia|Calvary North Adelaide; North Adeliade Oncology Centre, North Adelaide, South Australia, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|AZ Sint Lucas (Sint Lucas), Gent, Belgium|CHU Sart-Tilman, Liège, Belgium|AZ Delta (Campus Wilgenstraat), Roeselare, Belgium|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|BC Cancer Agency, Vancouver Clinic; Dept. of Medical Oncology, Vancouver, British Columbia, Canada|CancerCare Manitoba; Neuro-Oncology, Winnipeg, Manitoba, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario; Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital Regional Cancer Centre; Neuro-Oncology, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727, Toronto, Ontario, Canada|Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada|Chuq - Hopital Hotel Dieu de Quebec, Quebec City, Quebec, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd., Aalborg, Denmark|Righospitalet, Hæmatologisk Klinik, København Ø, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense, Denmark|Hopital Avicenne; Rhumatologie, Bobigny, France|Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France|Institut Bergonie; Gastro Enterologie Oncologie, Bordeaux, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, France|Hopital Beaujon; Oncologie, Clichy, France|Centre Georges François Leclerc, Dijon, France|Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille, France|Centre Val Aurelle Paul Lamarque; Medecine B3, Montpellier, France|Hôpital Central; Departement de Neuro-Oncologie, Nancy, France|Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Neurochirurgie, Dresden, Germany|Justus-Liebig-Universität Giessen; Neurochirurgische Klinik, Gießen, Germany|Universitatsklinikum Hamburg-Eppendorf; Klinik und Poliklinik fur Neurochirurgie, Hamburg, Germany|Universitatsklinikum Heidelberg; Abteilung Neuroonkologie, Heidelberg, Germany|Ärztehaus Velen, Ibbenbühren, Germany|Klinikum der Johannes Gutenberg Uni Mainz; Studienz. Neurologie, Klinik und Poliklinik Neurologie, Mainz, Germany|Uni Klinikum München - Großhardern; Med. Klinik U. Poliklinik III - Abt. Onkologie u. Hämatologie, München, Germany|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University Hospital of Larissa; Oncology, Larissa, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Dr Stephen Yau; Clinical oncology, Hong Kong, Hong Kong|Hong Kong Sanatorium & Hospital; Comprehensive Oncology Centre, Hong Kong, Hong Kong|Queen Mary Hospital; Microbiology Dept., Hong Kong, Hong Kong|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház; Neurosurgery, Miskolc, Hungary|Pécsi Tudományegyetem Áok; Onkoterapias Intezet, Pecs, Hungary|Rambam Medical Center; Oncology, Haifa, Israel|Hadassah Hebrew University Hospital; Leslie and Michael Gaffin Center for Neuro-Oncology, Jerusalem, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba MC; Pediatric Hematology Oncology, Tel Hashomer, Israel|Ausl Di Bologna-Ospedale Bellaria;U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|Ospedale Bufalini, Forli, Emilia-Romagna, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia, Torino, Piemonte, Italy|Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy|Ospedale di Treviso, Universita di Padova; Neurosurgery Dept, Treviso, Veneto, Italy|Hiroshima University Hospital; Neurosurgery, Hiroshima, Japan|Tsukuba University Hospital; Neurology, Ibaraki, Japan|Kumamoto University Hospital; Neurosurgery, Kumamoto, Japan|Kitano Hospital; Neurosurgery, Osaka, Japan|Saitama Medical University International Medical Center; Clinical and Medical Oncology, Saitama, Japan|National Cancer Center Hospital; Neurosurgery, Tokyo, Japan|Komagome Hospital; Neurosurgery, Tokyo, Japan|Kyorin University Hospital; Neurosurgery, Tokyo, Japan|Pusan National University Hospital; Neuro Sugery, Busan, Korea, Republic of|Kyungpook National University Hosital; Neuro Sugery, Daegu, Korea, Republic of|National Cancer Centre; Neurosurgery Dept, Goyang-si, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, Korea, Republic of|Asan Medical Center; Medical Oncology, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|Samsung Medical Center; Neurosurgery Department, Seoul, Korea, Republic of|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands|Catharina Ziekenhuis; Dept of Internal Medicin, Eindhoven, Netherlands|Utrecht University Medical Centre; Dept of Medical Oncology and UPC, Utrecht, Netherlands|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Christchurch Hospital; Dept of Oncology, Christchurch, New Zealand|Waikato Hospital; Regional Cancer Center, Hamilton, New Zealand|Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, Poland|Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii, Bydgoszcz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie; Klinika Neurochirurgii i Neurochirurgii Dzi, Lublin, Poland|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|IPO de Lisboa; Servico de Neurologia, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital de Sao Joao; Servico de Oncologia, Porto, Portugal|Institut Oncologic Prof. Dr. Alexandru Trestioreanu; Departament Radioterapie, Bucharest, Romania|Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-napoca, Romania|Spital Clinic Judetean Mures; Oncologie, Targu Mures, Romania|N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow, Russian Federation|Russian Research Oncology Center n.a. N.N. Blokhin of the RAMS; Department of Neurosurgery, Moscow, Russian Federation|Scientific Research Neurosurgery Institute; Dept. of Neurooncology, Moscow, Russian Federation|Institution of Higher Professional Learning Military; Neurooncology, St. Petersburg, Russian Federation|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Sahlgrenska Universitetssjukhuset; Jubileumskliniken, Göteborg, Sweden|Skånes University Hospital, Skånes Department of Onclology, Lund, Sweden|Norrlands Universitetssjukhus; Cancer Centrum, Umea, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|HUG; Oncologie, Geneve, Switzerland|Queen Elizabeth Medical Centre; Neurosurgery, Birmingham, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|The Royal Marsden NHS Foundation Trust; Oncology, London, United Kingdom|Northern Centre for Cancer Care;Oncology, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom|Queen's Hospital; Oncology, Romford, United Kingdom|Weston Park Hospital; Cancer Clinical Trials Centre, Sheffield, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|The Clatterbridge Cancer Ctr For Oncolgy, Wirral, United Kingdom","https://ClinicalTrials.gov/show/NCT00943826"
630,"NCT00908752","Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC","Completed","No Results Available","All","Phase 3","734","Industry","Interventional","July 20, 2009","September 28, 2012","January 26, 2018","May 27, 2009","null","March 5, 2018","Richard Finn, M.D., Los Angeles, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Montefiore Medical Center, Bronx, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Parkville, Victoria, Australia|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjing, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Angers, France|Local Institution, Bondy, France|Local Institution, Bordeaux, France|Local Institution, Clichy Cedex, France|Local Institution, Creteil Cedex, France|Local Institution, Grenoble, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 04, France|Local Institution, Marseille Cedex 05, France|Local Institution, Paris Cedex, France|Local Institution, Paris, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Hong Kong, Hong Kong|Local Institution, New Territories, Hong Kong|Local Institution, Genova, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Toyoake City, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Hiroshima City, Hiroshima, Japan|Local Institution, Kure-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kochi-shi, Kochi, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Tsu-shi, MIE, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-sayama City, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Toyama City, Toyama, Japan|Local Institution, Nishinomiya-shi, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Kyunggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Taegu, Korea, Republic of|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT00908752"
631,"NCT00936221","Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients","Completed","Has Results","All","Phase 2","385","Industry","Interventional","July 2009","November 2011","November 2014","July 9, 2009","December 9, 2015","March 14, 2016","Research Site, Aurora, Colorado, United States|Research Site, Boston, Massachusetts, United States|Research Site, Belo Horizonte, Brazil|Research Site, Ijuí, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Brno, Czech Republic|Research Site, Novy Jicin, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Lille Cedex, France|Research Site, Marseille, France|Research Site, Villejuif Cedex, France|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Hannover, Germany|Research Site, Kiel, Germany|Research Site, Tübingen, Germany|Research Site, Budapest, Hungary|Research Site, Györ, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Amsterdam, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Oslo, Norway|Research Site, Barcelona, Spain|Research Site, Houston, Spain|Research Site, Málaga, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Göteborg, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Zürich, Switzerland|Research Site, Cambridge, United Kingdom|Research Site, Chelmsford, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT00936221"
632,"NCT00864253","A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma","Completed","Has Results","All","Phase 3","529","Industry|Other","Interventional","April 2009","June 2012","February 2014","March 18, 2009","June 5, 2014","April 26, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|AZ Cancer Ctr, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Genesis Cancer Ctr - Hot Springs, Hot Springs, Arkansas, United States|University of Arkansa for Medical Sciences, Little Rock, Arkansas, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|San Diego Pacific Oncology and Hematology Associates, Encinitas, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|University of Southern California/Norris Cancer Center, Los Angeles, California, United States|University of CA Los Angeles, Los Angeles, California, United States|St. Mary's Medical Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|University of Miami Hospital and Clincs/SCCC, Miami, Florida, United States|Waren Billhartz Cancer Center, Maryville, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|IA Blood and Cancer Care, PLC, Cedar Rapids, Iowa, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|St. John's Medical Research, Springfield, Missouri, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Piedmont Hematology, Winston-Salem, North Carolina, United States|OH State University Arthur G. James Cancer Hospital, Columbus, Ohio, United States|Integris Cancer Institute of OK, Oklahoma City, Oklahoma, United States|St. Luke's Hospital & Health Network, Bethlehem, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Mary Crowley Research Center, Dallas, Texas, United States|Univ of TX MD Anderson Cancer Ctr, Houston, Texas, United States|Univ of TX Med School at Houston, Houston, Texas, United States|Covenant Health System DBA Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Hope Oncology, Richardson, Texas, United States|Utah Cancer Specialist, Salt Lake City, Utah, United States|Univ. of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington, United States|Evergreen Hematology & Oncology, Spokane, Washington, United States|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Sydney West Cancer Trials Centre/Westmead Hospital, Westmead, New South Wales, Australia|Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands Perth, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA Centre for the Southern Interior, Kelowna, British Columbia, Canada|BCCA, Centre for the Southern Interior, Kelowna, British Columbia, Canada|BC Cancer Agency-Fraser Valley Ctr., Surrey, British Columbia, Canada|BC Cancer Agency-Vancouver, Vancouver, British Columbia, Canada|BC Cancer Agency-Vancouver Island Ctr., Victoria, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Credit Valley Hospital, Missiauga, Ontario, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University Dept. of Oncology Clinical Research Program, Montreal, Quebec, Canada|Hopital Saint Andre' CHU de Bordeaux, Bordeaux, France|Centre Hospitaller Universitaire de Grenoble, Grenoble Cedex 09, France|CHRU Hopital Claude Huriez, Lile cedax, France|Hopital Dypuytren-CHU de Limoges, Limoges cedex, France|Centre Leon Berad, Lyon, France|Hopital Sainte Marguerite, Marseille Cedex 9, France|CHU Hopital Saint Eloi, Montepellier Cedex 5, France|Centre Regional Val d' Aurelle Paul Lamarque, Montpellier, France|Hopital de 1 Archet 2, Nice Cedex 3, France|Hopital Saint-Louis, Paris Cedex, France|Hopital Bichat, Paris, France|Groupe hospitalier Cochin-St. Vincent de Paul, Paris, France|Institut Gustave Roussy (IGR) Centre de Lutte Contre le Canc, Villejuif Cedex, France|Charite Universitaetsmedizin Berlin, Berlin, BE, Germany|Universitaetsklinkum Heidelberg, Heidelberg, BW, Germany|Universitaetsklinkum Heidelberg, Heidelber, BW, Germany|Universitaetsklinkum Tuebingen, Tuebingen, BW, Germany|Universitaetsklinkum Wuerzburg PS, Wuerzburg, BY, Germany|Universitaetsklinkum Hamburg-Eppendorf, Hamburg, HH, Germany|Univeritaetsklinkum Goettingen, Gottington, NI, Germany|Medizinische Hochschuke Hannover, Hannover, NI, Germany|St. Josef-Hospital, Bochum, NW, Germany|Universitaetsklinkum Essen, Essen, NW, Germany|Universitaetklinkum Koeln, Koln, NW, Germany|Universitaetsklinkum Schegwig-Holstein, Keil, SH, Germany|Universitaetsklinkum Dresden, Dresden, SN, Germany|UniversitawtsklinKum Jena, Jena, Strasse 35, Germany|Universitaesklinkum Leipzig, Leipzig, Germany|Universitaetsklinkum Mainz, Mainz, Germany|Istituto Tumori ""Giovanni Paolo II"", Bari, BA, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei T, Meldola, FC, Italy|IST-Istituto Nazionale per la Ricera sul Cancro, Genova, GE, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Istituto Nazionale Tumori, Milano, MI, Italy|IOV-Instituto Oncologico IRCCS, Padova, PD, Italy|Azienda Ospedaliera Universitaria Sense, Siena, SI, Italy|Ist. Naz. per lo studio e la cura dei tumori G. Pascale, Napoli, Italy|Ospedale S. Chiara, Pisa, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Rijnstate ziekenhuis Arnhem, Amhem, Netherlands|Erasmus MC ae"" Daniel den Hoed, Rotterdam, Netherlands|H Clinic i Provincial, Barcelona, Spain|H CLINIC I Provincial, Barcelona, Spain|H Clinico San Carlos, Madrid, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Spain|Broomfield Hospital, Chelmsford, Essex, United Kingdom|Velindre Hospital, Cardiff, Glam, United Kingdom|St. George's Hospital, London, GT Lon, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, Nott, United Kingdom|Singleton Hospital, Sothwest Wales Inst., Swansea, S Glam, United Kingdom|Univ Hospital of North Staffordshire, Stroke on Kent, Staffs, United Kingdom|Weston Park Hospital, Sheffield, Syorks, United Kingdom|Newcross Hospital, Wolverhampton, Wstmid, United Kingdom|Royal Marsden Hospital London, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00864253"
633,"NCT01346540","A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.","Completed","Has Results","All","Phase 1","16","Industry","Interventional","April 14, 2011","April 25, 2013","January 17, 2017","May 3, 2011","September 10, 2018","September 10, 2018","1199.82.39004 Boehringer Ingelheim Investigational Site, Milano, Italy|1199.82.3102 Boehringer Ingelheim Investigational Site, Maastricht, Netherlands|1199.82.3401 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1199.82.3406 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.82.3410 Boehringer Ingelheim Investigational Site, Málaga, Spain|1199.82.4401 Boehringer Ingelheim Investigational Site, London, United Kingdom|1199.82.4402 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01346540"
634,"NCT01229436","Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)","Completed","Has Results","All","Phase 3","254","Industry","Interventional","December 2010","October 2012","October 2012","October 27, 2010","March 17, 2014","March 17, 2014","Pfizer Investigational Site, Copenhagen, Denmark|Pfizer Investigational Site, Silkeborg, Denmark|Pfizer Investigational Site, Montpellier cedex 5, France|Pfizer Investigational Site, Nice, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Bad Neustadt, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Muenster, Germany|Pfizer Investigational Site, Nurnberg, Germany|Pfizer Investigational Site, Tubingen, Germany|Pfizer Investigational Site, Miskolc, Hungary|Pfizer Investigational Site, Sesto San Giovanni, Milano, Italy|Pfizer Investigational Site, Modena, Italy|Pfizer Investigational Site, Savona, Italy|Pfizer Investigational Site, Elche, Alicante, Spain|Pfizer Investigational Site, Hospitalet De Llobregat, Barcelona/ Spain, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Málaga, Spain|Pfizer Investigational Site, Malmö, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Derby, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Norwich, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01229436"
635,"NCT01442090","Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy","Completed","No Results Available","All","Phase 2","85","Industry","Interventional","October 2011","May 2013","July 2015","September 28, 2011","null","August 10, 2016","Fort Myers, Florida, United States|Saint Petersburg, Florida, United States|Boston, Massachusetts, United States|Las Vegas, Nevada, United States|New York, New York, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Bordeaux, France|Paris, France|Villejuif, France|Berlin, Germany|Hannover, Germany|München, Germany|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Leeds, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01442090"
636,"NCT01378975","A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases","Completed","Has Results","All","Phase 2","146","Industry","Interventional","July 2011","July 2015","July 2015","June 23, 2011","August 1, 2016","August 1, 2016","Los Angeles, California, United States|Aurora, Colorado, United States|Tampa, Florida, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Charlotte, North Carolina, United States|Dallas, Texas, United States|Seattle, Washington, United States|Wentworthville, New South Wales, Australia|Melbourne, Victoria, Australia|Toronto, Ontario, Canada|Bordeaux, France|Nice, France|Paris, France|Paris, France|Essen, Germany|Frankfurt, Germany|Kiel, Germany|Mannheim, Germany|Münster, Germany|Tübingen, Germany|Tel-Hashomer, Israel|Milano, Lombardia, Italy|Siena, Toscana, Italy|Amsterdam, Netherlands|Groningen, Netherlands|Pamplona, Navarra, Spain|Barcelona, Spain|Madrid, Spain|Northwood, United Kingdom","https://ClinicalTrials.gov/show/NCT01378975"
637,"NCT00858871","First Line Hepato Cellular Carcinoma (HCC)","Completed","No Results Available","All","Phase 3","1714","Industry","Interventional","May 2009","June 2012","September 2013","March 10, 2009","null","October 17, 2016","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Agajanian Institute Of Hematology And Oncology, Downey, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Va Ct Healthcare System, West Haven, Connecticut, United States|Medical Specialists Of Palm Beaches, Lake Worth, Florida, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|3912 Taubman Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Thomas Jefferson Univ., Philadelphia, Pennsylvania, United States|Mcguire Dvamc, Richmond, Virginia, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Concord, New South Wales, Australia|Local Institution, Westmead Nsw, New South Wales, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Prahan, Victoria, Australia|Local Institution, Liege, Belgium|Local Institution, Salvador - Ba, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Goiania, Goias, Brazil|Local Institution, Divinopolis, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, Rio Grande do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, London, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi An, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Brno, Czech Republic|Local Institution, Prague 5, Czech Republic|Local Institution, Praha 2, Czech Republic|Local Institution, Bordeaux, France|Local Institution, Clichy Cedex, France|Local Institution, Creteil Cedex, France|Local Institution, Grenoble Cedex 09, France|Local Institution, Lille, France|Local Institution, Lyon Cedex 04, France|Local Institution, Marseille Cedex 05, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Vandoeuvre Cedex, France|Local Institution, Berlin, Germany|Local Institution, Halle, Germany|Local Institution, Hamburg, Germany|Local Institution, Magdeburg, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Shatin, Hong Kong|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Kochi, Kerala, India|Local Institution, Trivandrum, Kerala, India|Local Institution, Pune, Maharashtra, India|Local Institution, Ahmedabad, India|Local Institution, Chennai, India|Local Institution, Coimbatore, India|Local Institution, Hyderabad, India|Local Institution, Kolkata, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Torrette -Ancona, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-Shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Tsu-shi, MIE, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-Sayama City, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-Ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shimonoseki-shi, Yamaguchi, Japan|Local Institution, Nishinomiya-shi, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Kyunggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Distrito Federal, Mexico|Local Institution, Gdansk, Poland|Local Institution, Gliwice, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Cape Town, Western Cape, South Africa|Local Institution, Observatory, Cape Town, Western Cape, South Africa|Local Institution, Rondebosch, Western Cape, South Africa|Local Institution, Santiago De Compostela, A Coruna, Spain|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan R.O.C., Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Bristol, Avon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT00858871"
638,"NCT01220271","A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma","Completed","No Results Available","All","Phase 1|Phase 2","75","Industry","Interventional","April 2011","August 2015","November 2016","October 13, 2010","null","February 16, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain","https://ClinicalTrials.gov/show/NCT01220271"
639,"NCT01197560","Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","Completed","Has Results","All","Phase 2|Phase 3","111","Industry","Interventional","September 1, 2010","July 4, 2013","April 5, 2018","September 9, 2010","August 20, 2014","September 10, 2018","Providence St Joseph Medical Center/Cancer Center, Burbank, California, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson Houston, Houston, Texas, United States|Royal Adelaide Hospital, Adelaide, Australia|Royal Brisbaine and Womens Hospital, Herston, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Innsbruck University Hospital, Innsbruck, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|University Hospital Hradec Kralove, Hradec Kralove 5, Czechia|Charles University, Praha, Czechia|ICH CHU Brest- C.H.U. MORAVAN, Brest Cedex 2, France|CHU de Grenoble-Hopital Albert Michallon, Grenoble, France|Chd -Vendee, La Roche Sur Yon, France|Centre Hospitalier Lyon Sud, Lyon, France|Institute Paoli-Calmette, Marsielle, France|Hotel Dieu, Nantes Cedex 1, France|Hôpital Saint Jean, Perpignan, France|CHRU-Hopital du Haut -Leveque, Pessac, France|CHU de Rennes Hopital de Pontchaillou, Rennes, France|University Hospital OF Toulouse Purpan, Toulouse, France|Hopital de Brabois Adultes, Vandoeuvre-les Nancy cedex, France|Istituto di Ematologica Istituto di Ematologica "" L.e. A. Seragnoli' Azienda Ospedaliera Universitaria Policlinico, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Clinica Ematologica, A.O.U. San Martino di Genova, Genova, Italy|IEO istituto Europeo di Oncologia, Miano, Italy|Universita Federico II di Napoli Nuovo Policlinico, Napoli, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Irccs/Crob, Rionero In Vulture (PZ), Italy|Policlinico Tor Vergata (Universta Tor Vergata), Roma, Italy|Azienda Ospedaliera di Perugai Ospedale S. Maria della Miseri, Terni, Italy|Hospital Universitari Vll D' Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Costa Del Sol, Marbella, Spain|CH de Orense, Ourense, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hosptial Clinico Universitario de Salamanca, Salamanca, Spain|Onkologiska kliniken, Umea, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Royal Bournemouth Hospital Haematology, Bournemouth, United Kingdom|Royal Devon and Exeter Hospital Haematology Department, Exeter, United Kingdom|St. James Institute of Oncology, Leeds, United Kingdom|Royal Mardsen Hospital - Fulham (Satellite Site), London, United Kingdom|The Christie Foundation Trust, I'st Floor, Haemotology Oncology Outpatients, Lymphoma Team, Manchester, United Kingdom|Derrford Hospital, Plymouth, United Kingdom|Southhampton University Hospital NHS Trust, Southhampton, United Kingdom|Royal Mardsen NHS Foundation Trust, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01197560"
640,"NCT02391545","A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)","Completed","No Results Available","All","Phase 1|Phase 2","55","Industry","Interventional","December 2014","January 2017","May 2017","March 18, 2015","null","May 4, 2018","Los Angeles, California, United States|Palo Alto, California, United States|Hackensack, New Jersey, United States|Rochester, New York, United States|Dallas, Texas, United States|Kortrijk, Belgium|Leuven, Belgium|Wilrijk, Belgium|Clermont-Ferrand, France|Marseille Cedex 05, France|Pessac, France|Rouen Cedex 1, France|Tours Cedex 01, France|Bologna, Italy|Varese, Italy|Badalona, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Leeds, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT02391545"
641,"NCT01374906","Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease","Completed","Has Results","All","Phase 3","150","Industry","Interventional","November 4, 2011","December 21, 2016","December 21, 2016","June 16, 2011","April 11, 2018","May 22, 2018","ClinTriCo, Phoenix, Arizona, United States|University of California at Los Angeles UCLA Tiverton, Los Angeles, California, United States|Harbor-UCLA Medical Center LA Biomed, Torrance, California, United States|Emory University School of Medicine/Winship Cancer Institute G2304 - C2301, Atlanta, Georgia, United States|Pituitary Center, Division of Endocrinology SC, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Mount Sinai School of Medicine Mt. Sinai Medical Center, New York, New York, United States|Oregon Health & Sciences University DeptofOregonHealth&Sciences(2), Portland, Oregon, United States|University of Pennsylvania - Clinical Studies Unit Unniv SC, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center CSOM230G2304, Nashville, Tennessee, United States|Swedish Medical Center Swedish, Seattle, Washington, United States|Medical College of Wisconsin MCW 2, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Jette, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, Caen Cedex9, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille Cédex 5, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Germering, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Nankoku-city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St.- Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Diskapi / Ankara, Ankara, Turkey|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Salford, Manchester, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01374906"
642,"NCT01632904","Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study","Completed","Has Results","All","Phase 3","110","Industry","Interventional","June 2012","March 2014","May 2016","July 3, 2012","April 7, 2015","November 14, 2017","Scottsdale, Arizona, United States|Fayetteville, Arkansas, United States|Burbank, California, United States|Glendale, California, United States|La Jolla, California, United States|Los Angeles, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Stamford, Connecticut, United States|Washington, D.C., District of Columbia, United States|Boynton Beach, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Niles, Illinois, United States|Springfield, Illinois, United States|Ames, Iowa, United States|Westwood, Kansas, United States|Alexandria, Louisiana, United States|Baltimore, Maryland, United States|Southfield, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Saint Louis, Missouri, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|East Orange, New Jersey, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|Albany, New York, United States|Armonk, New York, United States|Mineola, New York, United States|New York, New York, United States|Canton, Ohio, United States|Bethlehem, Pennsylvania, United States|Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Amarillo, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Garland, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Tyler, Texas, United States|Salt Lake City, Utah, United States|Alexandria, Virginia, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Antwerpen, Belgium|Brugge, Belgium|Aachen, Germany|Berlin, Germany|Freiburg, Germany|Hamburg, Germany|Stuttgart, Germany|Ulm, Germany|Galway, Ireland|Firenze, Italy|Reggio Calabria, Italy|Varese, Italy|Barcelona, Spain|Pamplona, Spain|Salamanca, Spain|Boston, United Kingdom|Leicester, United Kingdom|Nottingham, United Kingdom|West Bromwich, United Kingdom","https://ClinicalTrials.gov/show/NCT01632904"
643,"NCT01713946","A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","Completed","Has Results","All","Phase 3","366","Industry","Interventional","April 29, 2013","October 25, 2017","October 25, 2017","October 25, 2012","November 7, 2018","November 7, 2018","University of Alabama at Birmingham SC, Birmingham, Alabama, United States|TGen/APNNA, Phoenix, Arizona, United States|University of California at Los Angeles SC, Los Angeles, California, United States|Children's Hospital Oakland SC, Oakland, California, United States|Children's Hospital of Orange County SC, Orange, California, United States|Rady Children's Hospital SC, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Childrens Medical Center SC, Hartford, Connecticut, United States|University of Chicago SC - 2, Chicago, Illinois, United States|Kennedy Krieger Institute SC, Baltimore, Maryland, United States|Children's Hospital Boston SC, Boston, Massachusetts, United States|Minnesota Epilepsy Group - PA SC, Saint Paul, Minnesota, United States|Washington University School of Medicine SC-2, Saint Louis, Missouri, United States|Morristown Memorial Hospital SC-2, Morristown, New Jersey, United States|New York University Medical Center SC-3, New York, New York, United States|Cincinnati Children's Hospital Medical Center SC, Cincinnati, Ohio, United States|Oregon Health and Science University SC - 3, Portland, Oregon, United States|Children's Hospital of Philadelphia SC, Philadelphia, Pennsylvania, United States|LeBonheur Childrens Medical Group SC, Memphis, Tennessee, United States|Texas Scottish Rite Hospital for Children Texas Scottish, Dallas, Texas, United States|Texas Children s Hospital SC, Houston, Texas, United States|The University of Texas Medical School-Houston SC, Houston, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Jette, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Amiens Cedex 1, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Kehl-Kork, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Izumi-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, Japan|Novartis Investigative Site, Setagaya-ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Heeze, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Samara, Samara Region, Russian Federation|Novartis Investigative Site, Voronezh, Voronezh Region, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Sevilla, Andalucía, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Buckinghamshire, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, York, United Kingdom","https://ClinicalTrials.gov/show/NCT01713946"
644,"NCT00934544","Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial","Completed","Has Results","All","Phase 3","219","Industry","Interventional","July 2009","March 2015","March 2015","July 8, 2009","May 30, 2012","April 15, 2016","Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Antwerp, Belgium|Novartis Investigative Site, Antwerp, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, La Louvière, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Amiens cedex 1, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lens Cedex, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Poitiers Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt/M, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Tuebingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Pavia, (pv), Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Florence, Italy|Novartis Investigative Site, Orbassano, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT00934544"
645,"NCT01562977","Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL","Completed","No Results Available","All","Phase 2","82","Other","Interventional","April 2011","April 2015","April 2015","March 26, 2012","null","October 30, 2017","Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Duran i Reynals, Sabadell, Barcelona, Spain|Hospital SAS de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Dr. Jose Molina Orosa, Arrecife, Lanzarote, Spain|Fundación Hospital de Alcorcón, Alcorcón, Madrid, Spain|Hospital Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain|Hospital Virgen de Arrixaca, El Palmar, Murcia, Spain|Complejo Hospitalario de A Coruña, A Coruña, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital 12 Octubre, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Son Espasses, Palma de Mallorca, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Corporació Sanitari Parc Taulí, Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01562977"
646,"NCT01296256","Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).","Completed","No Results Available","All","Phase 2","60","Other","Interventional","May 2011","November 2015","November 2015","February 15, 2011","null","February 17, 2016","Complejo Hospitalario Universitario de Santiago, Santiago, A Coruña, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Son Llátzer, Palma de Mallorca, Mallorca, Spain|Hospital Universitario Virgen de Arrixaca, El Palmar, Murcia, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Tenerife, Spain|Hospital Vall d´Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|H. de la Santa Creu i Sant Pau, Barcelona, Spain|H.U. 12 de Octubre,, Madrid, Spain|H.U. Gregorio Marañón,, Madrid, Spain|H.U. La Paz, Madrid, Spain|H.U. La Princesa, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|H. Clínico Universitario de Salamanca, Salamanca, Spain|H. U. Marqués de Valdecilla., Santander, Spain|Hospital Clinico de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|H. La Fe, Valencia, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01296256"
647,"NCT01185262","Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia","Completed","No Results Available","All","Phase 1","25","Other|Industry","Interventional","April 2009","December 2012","September 2013","August 19, 2010","null","September 30, 2013","Hospital Universitario Reina Sofía, Córdoba, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01185262"
648,"NCT01015248","Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma","Completed","No Results Available","All","Phase 2","60","Other","Interventional","May 2009","December 2013","December 2013","November 18, 2009","null","September 7, 2016","Hospital Central de Asturias, Oviedo, Asturias, Spain|ICO-Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO-Hospital Durans i Reynals, Hospitalet de Llobregat, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Marqués de Valdecilla, Santander, Cantabria, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain|Hospital Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Son Llátzer, Palma de Mallorca, Mallorca, Spain|Clínica Universitaria Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, Sta. Cruz de Tenerife, Tenerife, Spain|Hospital del Mar, Barcelona, Spain|Hospital La Princesa, Madrid, Spain|Hospital MD Anderson, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Clínico de Zaragoza ""Lozano Blesa"", Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT01015248"
649,"NCT01397825","MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine","Completed","Has Results","All","Phase 1|Phase 2","45","Industry","Interventional","August 9, 2011","February 5, 2015","October 5, 2016","July 20, 2011","March 27, 2018","March 27, 2018","Tucson, Arizona, United States|Beverly Hills, California, United States|Burbank, California, United States|Miami, Florida, United States|Lexington, Kentucky, United States|Worcester, Massachusetts, United States|New York, New York, United States|Rochester, New York, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Germantown, Tennessee, United States|Memphis, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Burlington, Vermont, United States|Orbassano, Torino, Italy|Genova, Italy|Palermo, Italy|Roma, Italy|Madrid, Spain|Sevilla, Spain|Aberdeen, Grampian Region, United Kingdom|London, Greater London, United Kingdom|Southampton, Hampshire, United Kingdom|Birmingham, West Midlands, United Kingdom","https://ClinicalTrials.gov/show/NCT01397825"
650,"NCT00742027","Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma","Completed","No Results Available","All","Phase 2","129","Industry","Interventional","September 2008","August 2013","August 2013","August 27, 2008","null","January 20, 2016","City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(2), Duarte, California, United States|Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2), Atlanta, Georgia, United States|Georgia Regents University Cancer Clinical Research Unit, Augusta, Georgia, United States|Rush University Medical Center Divisionof Hem/Onc Research(2), Chicago, Illinois, United States|VA Maryland Health Care Dept.of GreenbaumCancerCent(5), Baltimore, Maryland, United States|Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, United States|Karmanos Cancer Institute Div.of Hematology/Oncology, Detroit, Michigan, United States|Mayo Clinic - Rochester Hematology, Rochester, Minnesota, United States|University of Pennsylvania Medical Center Dept of UPenn Med Ctr (3), Philadelphia, Pennsylvania, United States|University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, United States|The Methodist Hospital Cell & Gene Therapy Clinic, Houston, Texas, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, United States|West Virginia University/ Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Malvern, Victoria, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Be'er Sheva, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Selangor, Malaysia|Novartis Investigative Site, Auckland, New Zealand|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Withington, Greater Manchester, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00742027"
651,"NCT00646750","Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom","Completed","No Results Available","All","Phase 2","31","Other","Interventional","January 2008","February 2010","June 2012","March 28, 2008","null","February 15, 2016","H.U. Central de Asturias, Oviedo, Oviedo, Asturias, Spain|H.Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Alicante, Alicante, Spain|H. de la Santa Creu i Sant Pau, Barcelona, Spain|Instituto Catalán de Oncología,, Barcelona, Spain|H. Reina Sofía, Córdoba, Spain|Clínica Puerta de Hierro,, Madrid, Spain|H.U. 12 de Octubre,, Madrid, Spain|H.U. Gregorio Marañón,, Madrid, Spain|H.U. La Paz, Madrid, Spain|H.U. La Princesa, Madrid, Spain|M.D. Anderson Internacional, Madrid, Spain|H. Morales Messeguer, Murcia, Spain|H.U. Virgen de la Arrixaca, Murcia, Spain|H. Clínico Universitario de Salamanca, Salamanca, Spain|H.U. Marqués de Valdecilla, Santander, Spain|H.U. La Fe, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00646750"
652,"NCT02053610","CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)","Completed","Has Results","All","Phase 3","787","Industry|Other","Interventional","December 31, 2009","August 31, 2013","August 23, 2017","February 3, 2014","October 10, 2014","September 14, 2018","San Diego, California, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Green Bay, Wisconsin, United States|Waukesha, Wisconsin, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Rosario, Argentina|Adelaide, New South Wales, Australia|Gosford, New South Wales, Australia|Kogarah, New South Wales, Australia|Liverpool, New South Wales, Australia|St. Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Greenslopes, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Kurralta Park, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Graz, Austria|Innsbruck, Austria|Wien, Austria|Wien, Austria|Goiania, GO, Brazil|Belo Horizonte, MG, Brazil|Porto Alegre, RS, Brazil|Santo Andre, SP, Brazil|Sao Paulo, SP, Brazil|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Barrie, Ontario, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Rimouski, Quebec, Canada|Zagreb, Croatia|Brno, Czechia|Hradec Kralove, Czechia|Praha 2, Czechia|Aalborg, Denmark|København, Denmark|Odense, Denmark|Vejle, Denmark|Århus, Denmark|Cairo, Egypt|Tallinn, Estonia|Tartu, Estonia|Angers, France|Bobigny, France|Caen, France|Clermont Ferrand, France|Creteil, France|Le Mans, France|Lille, France|Lyon, France|Marseille, France|Montpellier, France|Nantes, France|Paris, France|Paris, France|Pessac, France|Pierre Benite, France|Poitiers, France|Reims, France|Rennes, France|Rouen, France|Toulouse, France|Tours, France|Vandoeuvre Les Nancy, France|Ahaus, Germany|Amberg, Germany|Ansbach, Germany|Bamberg, Germany|Berlin, Germany|Bonn, Germany|Bremen, Germany|Bremen, Germany|Bremen, Germany|Delitzsch, Germany|Detmold, Germany|Dresden, Germany|Dresden, Germany|Duisburg, Germany|Erlangen, Germany|Erlangen, Germany|Eschweiler, Germany|Essen, Germany|Essen, Germany|Esslingen, Germany|Frankfurt am Main, Germany|Frankfurt an der Oder, Germany|Frankfurt, Germany|Frechen, Germany|Freiburg, Germany|Giessen, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamm, Germany|Hannover, Germany|Heidelberg, Germany|Homburg/Saar, Germany|Kaiserslautern, Germany|Karlsruhe, Germany|Kempten, Germany|Kiel, Germany|Koblenz, Germany|Koeln, Germany|Kronach, Germany|Köln, Germany|Landshut, Germany|Lebach, Germany|Leer, Germany|Lemgo, Germany|Lörrach, Germany|Lüdenscheid, Germany|Magedburg, Germany|Mainz, Germany|Mannheim, Germany|Muenchen, Germany|Mutlangen, Germany|München, Germany|München, Germany|München, Germany|München, Germany|Neunkirchen/Saar, Germany|Nürnberg, Germany|Oldenburg, Germany|Porta Westfalica, Germany|Ravensburg, Germany|Recklinghausen, Germany|Regensburg, Germany|Regensburg, Germany|Rostock, Germany|Rüsselsheim, Germany|Saarbruecken, Germany|Sindelfingen, Germany|Stuttgart, Germany|Trier, Germany|Tübingen, Germany|Ulm, Germany|Villingen-Schwenningen, Germany|Weilheim, Germany|Wendlingen, Germany|Witten, Germany|Worms, Germany|Wuerzburg, Germany|Würzburg, Germany|Hong Kong, Hong Kong|Cosenza, Calabria, Italy|Ferrara, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Orbassano, Piemonte, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Messina, Sicilia, Italy|Terni, Umbria, Italy|Aguascalientes, Mexico|Culiacan, Mexico|Hermosillo, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Delftzijl, Netherlands|Enschede, Netherlands|Leeuwarden, Netherlands|Nieuwegein, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Bucharest, Romania|Bucuresti, Romania|Targu-mures, Romania|Kazan, Russian Federation|Nizhny Novgorod, Russian Federation|Penza, Russian Federation|Perm, Russian Federation|Rostov-na-donu, Russian Federation|UFA, Russian Federation|Bratislava, Slovakia|Oviedo, Asturias, Spain|Manresa, Barcelona, Spain|Sabadell, Barcelona, Spain|Jerez de La Frontera, Cadiz, Spain|Santander, Cantabria, Spain|San Sebastian, Guipuzcoa, Spain|La Coruna, LA Coruña, Spain|Santiago de Compostela, LA Coruña, Spain|Pamplona, Navarra, Spain|La Laguna, Tenerife, Spain|Gandia, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Jaen, Spain|Las Palmas, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Malaga, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Toledo, Spain|Toledo, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Aarau, Switzerland|Basel, Switzerland|Bern, Switzerland|Chur, Switzerland|Luzern, Switzerland|St. Gallen, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Khon Kaen, Thailand|Bournemouth, United Kingdom|Cambridge, United Kingdom|Canterbury, United Kingdom|Cardiff, United Kingdom|Cottingham, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|Leicester, United Kingdom|London, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT02053610"
653,"NCT01998880","CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)","Completed","Has Results","All","Phase 3","787","Industry|Other","Interventional","December 22, 2009","August 1, 2012","August 23, 2017","December 2, 2013","January 28, 2014","September 14, 2018","San Diego, California, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Green Bay, Wisconsin, United States|Waukesha, Wisconsin, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Rosario, Argentina|Adelaide, New South Wales, Australia|Gosford, New South Wales, Australia|Kogarah, New South Wales, Australia|Liverpool, New South Wales, Australia|St. Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Greenslopes, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Kurralta Park, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Graz, Austria|Innsbruck, Austria|Wien, Austria|Wien, Austria|Goiania, GO, Brazil|Belo Horizonte, MG, Brazil|Porto Alegre, RS, Brazil|Santo Andre, SP, Brazil|Sao Paulo, SP, Brazil|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Barrie, Ontario, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Rimouski, Quebec, Canada|Zagreb, Croatia|Brno, Czechia|Hradec Kralove, Czechia|Praha 2, Czechia|Aalborg, Denmark|København, Denmark|Odense, Denmark|Vejle, Denmark|Århus, Denmark|Cairo, Egypt|Tallinn, Estonia|Tartu, Estonia|Angers, France|Bobigny, France|Caen, France|Clermont Ferrand, France|Creteil, France|Le Mans, France|Lille, France|Lyon, France|Marseille, France|Montpellier, France|Nantes, France|Paris, France|Paris, France|Pessac, France|Pierre Benite, France|Poitiers, France|Reims, France|Rennes, France|Rouen, France|Toulouse, France|Tours, France|Vandoeuvre Les Nancy, France|Ahaus, Germany|Amberg, Germany|Ansbach, Germany|Bamberg, Germany|Berlin, Germany|Bonn, Germany|Bremen, Germany|Bremen, Germany|Bremen, Germany|Delitzsch, Germany|Detmold, Germany|Dresden, Germany|Dresden, Germany|Duisburg, Germany|Erlangen, Germany|Erlangen, Germany|Eschweiler, Germany|Essen, Germany|Essen, Germany|Esslingen, Germany|Frankfurt am Main, Germany|Frankfurt an der Oder, Germany|Frankfurt, Germany|Frechen, Germany|Freiburg, Germany|Giessen, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamm, Germany|Hannover, Germany|Heidelberg, Germany|Homburg/Saar, Germany|Kaiserslautern, Germany|Karlsruhe, Germany|Kempten, Germany|Kiel, Germany|Koblenz, Germany|Koeln, Germany|Kronach, Germany|Köln, Germany|Landshut, Germany|Lebach, Germany|Leer, Germany|Lemgo, Germany|Lörrach, Germany|Lüdenscheid, Germany|Magedburg, Germany|Mainz, Germany|Mannheim, Germany|Muenchen, Germany|Mutlangen, Germany|München, Germany|München, Germany|München, Germany|München, Germany|Neunkirchen/Saar, Germany|Nürnberg, Germany|Oldenburg, Germany|Porta Westfalica, Germany|Ravensburg, Germany|Recklinghausen, Germany|Regensburg, Germany|Regensburg, Germany|Rostock, Germany|Rüsselsheim, Germany|Saarbruecken, Germany|Sindelfingen, Germany|Stuttgart, Germany|Trier, Germany|Tübingen, Germany|Ulm, Germany|Villingen-Schwenningen, Germany|Weilheim, Germany|Wendlingen, Germany|Witten, Germany|Worms, Germany|Wuerzburg, Germany|Würzburg, Germany|Hong Kong, Hong Kong|Cagliari, Italy|Cosenza, Italy|Ferrara, Italy|Genova, Italy|Messina, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Orbassano, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Terni, Italy|Torino, Italy|Aguascalientes, Mexico|Culiacan, Mexico|Hermosillo, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Delftzijl, Netherlands|Enschede, Netherlands|Leeuwarden, Netherlands|Nieuwegein, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Bucharest, Romania|Bucuresti, Romania|Targu-mures, Romania|Kazan, Russian Federation|Nizhny Novgorod, Russian Federation|Penza, Russian Federation|Perm, Russian Federation|Rostov-na-donu, Russian Federation|UFA, Russian Federation|Bratislava, Slovakia|Oviedo, Asturias, Spain|Manresa, Barcelona, Spain|Sabadell, Barcelona, Spain|Jerez de La Frontera, Cadiz, Spain|Santander, Cantabria, Spain|San Sebastian, Guipuzcoa, Spain|La Coruna, LA Coruña, Spain|Santiago de Compostela, LA Coruña, Spain|Pamplona, Navarra, Spain|La Laguna, Tenerife, Spain|Gandia, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Jaen, Spain|Las Palmas, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Malaga, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Toledo, Spain|Toledo, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Aarau, Switzerland|Basel, Switzerland|Bern, Switzerland|Chur, Switzerland|Luzern, Switzerland|St. Gallen, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Khon Kaen, Thailand|Bournemouth, United Kingdom|Cambridge, United Kingdom|Canterbury, United Kingdom|Cardiff, United Kingdom|Cottingham, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|Leicester, United Kingdom|London, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01998880"
654,"NCT01905943","A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia","Completed","Has Results","All","Phase 3","979","Industry","Interventional","November 4, 2013","December 29, 2016","October 6, 2018","July 23, 2013","October 29, 2018","October 29, 2018","Hospital Iturraspe, Santa Fé, Argentina|Hospital Erasme; Neurologie, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|CHU Sart-Tilman, Liège, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept, Banja Luka, Bosnia and Herzegovina|University Clinical Center Sarajevo, Clinic for Hematology, Sarajevo, Bosnia and Herzegovina|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, SP, Brazil|Hospital Sirio Libanes; Centro de Oncologia, Sao Paulo, SP, Brazil|Hospital Estadual do Servidor Publico; Hematologia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP; Hematologia, Sao Paulo, SP, Brazil|Hospital Santa Marcelina;Oncologia, Sao Paulo, SP, Brazil|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Regional health authority A vitalite health network, Moncton, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie, Greenfield Park, Quebec, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|Centre de sante et de services sociaux Rimouski Neigette, Rimouski, Quebec, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie, Quebec, Canada|Cairo University Hospital Al Kasr El Ainy, Cairo, Egypt|National Cancer Institute, Cairo, Egypt|North Estonia Regional Hospital; Hematology, Tallinn, Estonia|Tartu Uni Hospital; Hematology - Oncology Clinic, Tartu, Estonia|Kuopio University Hospital, Kuopio, Finland|Tampere University Hospital; Hematology, Tampere, Finland|Turku Uni Central Hospital; Dept of Internal Medicine, Turku, Finland|Hotel Dieu; Medecine D, Angers, France|Ch Victor Dupouy; Hematologie, Argenteuil, France|Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie, Bordeaux, France|Hopital Augustin Morvan; Hematologie, Brest, France|Hopital Cote De Nacre; Hematologie Biologique, Caen, France|Chu Estaing; Hematologie Clinique Adultes, Clermont Ferrand, France|Hopital Henri Mondor; Hematologie Clinique, Creteil, France|Chu Site Du Bocage;Hematologie Clinique, Dijon, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France|Ch Du Mans; Medecine Hematologie Oncologie, Le Mans, France|Hopital Claude Huriez; Hematologie, Lille, France|Hopital Uni Ire Dupuytren; Hematologie, Limoges, France|Hopital Saint Eloi; Hematologie Oncologie Medicale, Montpellier, France|Hopital Emile Muller; Hematologie, Mulhouse, France|Hopital Hotel Dieu Et Hme;Hopital De Jour, Nantes, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Hopital Saint Antoine; Hematologie Clinique, Paris, France|Hopital Pitie Salpetriere; Hematologie Clinique, Paris, France|Hopital Saint Jean; Hematologie, Perpignan, France|Hopital De Haut Leveque; Hematologie Clinique, Pessac, France|Ch Lyon Sud; Hemato Secteur Jules Courmont, Pierre Benite, France|Centre Hospitalier René Dubos; Hematologie, Pontoise, France|Hopital Robert Debre; Hematologie Clinique, Reims, France|Centre Henri Becquerel; Hematologie, Rouen, France|Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll, St Brieuc, France|Hopital Bretonneau; Hematologie Therapie Cellulaire, Tours, France|Hämatologisch-onkologische Praxis Dr. med. - Brudler, - Heinrich, - Bangerter, Augsburg, Germany|BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Germany|Ev. Krankenhaus Essen Süd Zentrum f. Innere Medizin Klinik f. Hämatologie und Onkologie, Essen, Germany|Gemeinschaftspraxis; Prof. Dr. Michael Kiehl und Dr.med. Wolfgang Stein, Frankfurt an der Oder, Germany|Onkologisches Zentrum am Bethanien-Kankenhaus, Frankfurt, Germany|Dres.Andreas Ammon und Dirk Meyer, Göttingen, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Onkologische Gemeinschaftspraxis, Magdeburg, Germany|Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin, Mutlangen, Germany|Dres. Hans-Dieter Schick Dorothea Schick Burkhard Schmidt u.w., München, Germany|Gemeinschaftspraxis Dr. med. Holger Klaproth / Dr. med. Anca Astrid Cura, Neunkirchen/Saar, Germany|Dr. med. Joachim Zimber, Nürnberg, Germany|eps - early phase GmbH, Pößneck, Germany|Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, Germany|Schwerpunktpraxis & Tagesklinik f. Hämatologie & Onkologie Regensdorf / Schwandorf / Wörth, Regensburg, Germany|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Onkologische Schwerpunktpraxis Dres. Rudolf Schlag und Björn Schöttker, Würzburg, Germany|General Hospital of Athens Evangelismos; Hematology, Athens, Greece|Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine, Athens, Greece|Laiko General Hospital; Hematology Clinic, Athens, Greece|University Hospital of Ioannina; Hematology, Ioannina, Greece|Georgios Papanikolaou Hospital; Hematology Department, Thessaloniki, Greece|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Waterford Regional Hospital; Department Of Medical Oncology, Waterford, Ireland|Soroka Medical Center; Hematology Deptartment, Beer Sheva, Israel|Bnei-Zion Medical Center; Hematology Dept, Haifa, Israel|Hadassah Ein Karem Hospital; Haematology, Jerusalem, Israel|Kaplan Medical Center, Rehovot, Israel|Ichilov Sourasky Medical Center; Heamatology, Tel Aviv, Israel|Az. Osp. Pugliese; Divisione de Ematologia, Catanzaro, Calabria, Italy|Ospedale Cardarelli; Divisione Di Ematologia, Napoli, Campania, Italy|Arcispedale S. Anna; Sezione Di Ematologia, Ferrara, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Ematologia, Modena, Emilia-Romagna, Italy|AUSL di Piacenza - Ospedale ""Guglielmo da Saliceto"";U.O. Ematologia, Piacenza, Emilia-Romagna, Italy|Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia, Rimini, Emilia-Romagna, Italy|Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol, Roma, Lazio, Italy|Uni Degli Studi Di Genova; 1A Divisione Di Ematologia, Genova, Liguria, Italy|Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora, Milano, Lombardia, Italy|ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Struttura Complessa di Ematologia, Milano, Lombardia, Italy|Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad, Novara, Piemonte, Italy|Ospedale Molinette - Universita' Di Torino; Cliniche Universitarie Ematologia I, Torino, Piemonte, Italy|Azienda ospedaliera oo rr di foggi; Hematology, Foggia, Puglia, Italy|Ospedale Vito Fazzi; Div. Oncoematologia, Lecce, Puglia, Italy|Ospedale Oncologico A Businco-Cagliari; Ematologia Sez., Cagliari, Sardegna, Italy|ARNAS Garibaldi; Ematologia, Catania, Sicilia, Italy|Azienda USL 6 Livorno - P.O. Livorno; U.O. Ematologia Clinica, Livorno, Toscana, Italy|Uni Di Verona Policlinico G.B. Rossi; Divisione E Cattedra Di Ematologia, Verona, Veneto, Italy|Pusan University Hospital, Busan, Korea, Republic of|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, Korea, Republic of|RECUH, Oncology Centre of Latvia; Clinic of Chemotherapy and Heamatology, Riga, Latvia|Hospital of Lithuanian University of Health. Sciences Kaunas Clinics, Kaunas, Lithuania|Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center, Vilnius, Lithuania|University Clinic of Hematology Skopje, Hospital Care Department, Skopje, Macedonia, The Former Yugoslav Republic of|Hospital General De Culiacan; Servicio De Hematologia, Culiacan, Mexico|Hospital General de México; Haematology, Mexico City, Mexico|Centro Medico Nacional Sxxi - Imss; Haematology, Mexico City, Mexico|Hospital Universitario Dr. Jose E. Gonzalez; Haematology, Monterrey, Mexico|Centro de Estudios Clinicos de Queretaro (CECLIQ), Queretaro, Mexico|Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie, Lublin, Poland|Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Poland|Szpital Wojewodzki w Opolu, Oddzial Hematologii i Onkologii Hematologicznej, Opole, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddział Chorób Wewnetrznych/Hematologiczny, Slupsk, Poland|Hospital de Santa Maria; Servico de Hematologia e Transplantacao de Medula, Lisboa, Portugal|IPO do Porto; Servico de Onco-Hematologia, Porto, Portugal|Policlinica de Diagnostic Rapid, Brasov, Romania|Spitalul Clinic Judetean de Urgenta Brasov; Clinica de Hematologie, Brasov, Romania|Spitalul Clinic Coltea; Clinica de Hematologie, Bucuresti, Romania|Spitalul Clinic municipal de Urgenta Timisoara; Clinica de Hematologie, Timisoara, Romania|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Vladimirskiy Regional Scientific Research Inst. ; Hematology, Moscow, Russian Federation|Almazov Federal Heart, Blood and Endocrinilogy Centre; Hematology department, Saint-Petersburg, Russian Federation|Regional Oncology Center, Volgograd, Russian Federation|Institute of Hematology, Belgrade, Serbia|Clinic of Haematology Cc Nis, NIS, Serbia|Fakultna Nemocnica Roosevelta; Dept. of Haematology, Banska Bystrica, Slovakia|National Oncology Inst. ; Dept. of Haematology, Bratislava, Slovakia|Hospital Celje; Haematology Dept, Celje, Slovenia|Clinical Center Ljubljana; Haematology Dept, Ljubljana, Slovenia|Hospital Maribor; Haematology Dept, Maribor, Slovenia|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona, Barcelona, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain|Complejo Hospitalario San Millan - San Pedro; Servicio Hematologia, Logroño, LA Rioja, Spain|Hospital Quiron de Madrid; Servicio de Hematologia, Pozuelo de Alarcon, Madrid, Spain|Hospital San Pedro De Alcantara; Servicio de Hematologia, Caceres, Spain|Hospital Universitario Reina Sofia; Servicio de Hematologia, Cordoba, Spain|Hospital Infanta Leonor; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Hematología, Madrid, Spain|Complejo Hospitalario Universitario de Ourense, Servicio de Hematologia, Orense, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Hematologia, Valencia, Spain|Universitetssjukhuset i Linköping, Hematologkliniken, Linkoeping, Sweden|Skane University Hospital Malmo/Lund, Dept.of Hematology and Coagulation Disorders, Malmö, Sweden|Uddevalla Sjukhus; Medicinkliniken, Uddevalla, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie & Transfusionsmedizin, Aarau, Switzerland|Universitätsspital Basel; Hämatologie, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|HUG; Hématologie, Geneve, Switzerland|Luzerner Kantonsspital, Hämatologie, Luzern, Switzerland|OnkoZentrum Zuerich, Zürich, Switzerland|King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Ramathibodi Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Chiang Mai Uni Hospital; Division of Hematology,Dept of Medicine,Faculty of Medicine, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Cukurova Uni ; Hematology, Adana, Turkey|Ankara Numune Egitim Ve Arastirma Hastanesi; Hematoloji Klinigi, Ankara, Turkey|Ankara University; Hematology, Ankara, Turkey|Pamukkale Uni. Med. Fac., Denizli, Turkey|Gaziantep University Medical School; Hematology, Gaziantep, Turkey|Istanbul Uni Capa Hospital; Hematology, Istanbul, Turkey|Dokuz Eylul Uni ; Hematology, Izmir, Turkey|Ege Uni Medical School; Hematology, Izmir, Turkey|Erciyes Uni ; Hematology, Kayseri, Turkey|Ondokuzmayis University Medical Faculty Heamatology Department, Samsun, Turkey|Karadeniz Technical Uni School of Medicine; Hematology, Trabzon, Turkey","https://ClinicalTrials.gov/show/NCT01905943"
655,"NCT01649856","A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma","Completed","Has Results","All","Phase 3","572","Industry","Interventional","August 24, 2012","October 21, 2014","September 16, 2016","July 25, 2012","February 12, 2016","October 11, 2017","EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward, Blida, Algeria|Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie, Tizi Ouzou, Algeria|Cemic; Haematology, Buenos Aires, Argentina|Hospital Privado de Comunidad; Oncology, Mar Del Plata, Argentina|Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|CHU Brugmann (Victor Horta), Bruxelles, Belgium|Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium|CHU Charleroi-ISPPC-Espace Santé, Charleroi, Belgium|CHU de Charleroi, Charleroi, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Gent, Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|AZ Turnhout Sint Elisabeth, Turnhout, Belgium|CHR de Verviers - East Belgium, Verviers, Belgium|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, Brazil|Hospital Giovanni Battista - Mae de Deus Center; Instituto do Cancer, Porto Alegre, RS, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Hospital das Clinicas - FMUSP; Hematologia, Sao Paulo, SP, Brazil|University Hospital Sv.Georgi Clnic of Hematology; Hematology, Plovdiv, Bulgaria|Military Medical Academy; Hematology And Oncology, Sofia, Bulgaria|UMHAT Alexandrovska EAD; Hematology, Sofia, Bulgaria|Lion'S Gate Hospital, North Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Regional health authority A vitalite health network, Moncton, New Brunswick, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|Southlake Regional Health Center; Community Care Clinic / Oncology, Newmarket, Ontario, Canada|Toronto East General Hospital; Haematology/Oncology, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|Clínica Imbanaco; Oncology, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Middle Finland Central Hospital, Jyväskylä, Finland|Oulu University Hospital; Oncology, Oulu, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Ch Victor Dupouy; Hematologie, Argenteuil, France|Hopital Augustin Morvan; Hematologie, Brest, France|Ch Du Mans; Medecine Hematologie Oncologie, Le Mans, France|Centre ONCOGARD - Institut de Cancerologie du Gard, Nimes, France|Ch De Saint Quentin; Medecine B10, Saint Quentin, France|Hopital Sud; Hematologie Clinique, Salouel, France|Hopital Yves Le Foll; Hematologie Oncologie, St Brieuc, France|Clinique Ste Anne, Strasbourg, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Hia Sainte Anne; Medecine Interne Oncologie, Toulon, France|University General Hospital of Alexandroupolis; Haemotology, Alexandroupolis, Greece|General Hospital of Athens Evangelismos; Hematology, Athens, Greece|Laiko General Hospital; Hematology Clinic, Athens, Greece|Metropolitan Hospital; Hematology Dept, Athens, Greece|Periph. University General Hospital of Heraklion; Hematology, Heraklion, Greece|University Hospital of Ioannina; Hematology, Ioannina, Greece|University Hospital Of Patras; Dept. Of Internal Medicine-Hematology Division, Patras, Greece|Theagenio Anticancer Hospital; Dept. of Haematology, Thessaloniki, Greece|Georgios Papanikolaou Hospital; Hematology Department, Thessaloniki, Greece|Cork Uni Hospital; Oncology Dept, Cork, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Haemek Medical Center; Hematology Department, Afula, Israel|Rambam Medical Center; Heamatology & Bone Marrow Transplantation, Haifa, Israel|Wolfson Mc; Haematology, Holon, Israel|Shaare Zedek Medical Center; Hematology Dept., Jerusalem, Israel|Meir Medical Center; Heamatology Dept, Kfar Saba, Israel|Beilinson Medical Center; Haematology, Petach Tikva, Israel|Chaim Sheba Medical Center; Hematology BMT & CBB, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Ichilov Sourasky Medical Center; Heamatology, Tel Aviv, Israel|Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia, Pescara, Abruzzo, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia, Rimini, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|AOU Ospedali Riuniti; Ematologia, Trieste, Friuli-Venezia Giulia, Italy|Uni Cattolica; Divisione Di Ematologia, Roma, Lazio, Italy|Az. Osp. Sant'Andrea; U.O. C. Ematologia, Roma, Lazio, Italy|ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy|ASST DI CREMONA; U.O.S. di Ematologia, Cremona, Lombardia, Italy|Ospedale Di Circolo E Fondazione Macchi; Ematologia, Varese, Lombardia, Italy|Ospedale Civile; S.C. Ematologia, Pesaro, Marche, Italy|A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia, Torrette Di Ancona, Marche, Italy|Ospedale Mauriziano Umberto I, Torino, Piemonte, Italy|Az. Osp. G. Moscati; U.O. Do Ematologia, Taranto, Puglia, Italy|Ospedale Oncologico A Businco-Cagliari; Ematologia Sez., Cagliari, Sardegna, Italy|Azienda Ospedaliero Uni Ria Policlinico G. Martino; U.O. Di Oncologia Medica, Messina, Sicilia, Italy|Casa Di Cura La Maddalena; Oncoematologia E Trapianto Del Midollo Osseo, Palermo, Sicilia, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia, Padova, Veneto, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Meander Medisch Centrum; Locatie Lichtenberg, Amersfoort, Netherlands|Deventer Ziekenhuis; Interne Geneeskunde, Deventer, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Maxima Medisch Centrum; Inwendige Geneeskunde, Eindhoven, Netherlands|Groene Hart Ziekenhuis Bleulandlocatie; Inwendige Geneeskunde, Gouda, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Atrium Medisch Centrum, Heerlen, Netherlands|Spaarne Ziekenhuis; Inwendige Geneeskunde, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden; Interne, Leeuwarden, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus Mc - Locatie Centrum; Dept of Hematology, Rotterdam, Netherlands|Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed, Rotterdam, Netherlands|Maasstad ziekenhuis, Rotterdam, Netherlands|Zuyderland ziekenhuis locatie Geleen, Sittard-Geleen, Netherlands|Isala Klinieken, Locatie Sophia; Inwendige Geneeskunde, Zwolle, Netherlands|Hospital Nacional Almanzor Aguinaga Asenjo; Unidad De Investigacion Del Servicio De Oncologia Medica, Chiclayo, Peru|Instituto;Oncologico Miraflores, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Katedra i Klinika Hematologii i Transplantacji Szpiku SUM, Katowice, Poland|Swietokrzyskie Centrum Onkologii; Onkologia Ogolna, Kielce, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Szpital Wojewodzki w Opolu, Oddzial Hematologii i Onkologii Hematologicznej, Opole, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddział Chorób Wewnetrznych/Hematologiczny, Slupsk, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|HUC; Servico de Hematologia, Coimbra, Portugal|Hospital Santo Antonio dos Capuchos; Servico de Hemato-Oncologia, Lisboa, Portugal|Hospital de Santa Maria; Servico de Hematologia e Transplantacao de Medula, Lisboa, Portugal|IPO do Porto; Servico de Onco-Hematologia, Porto, Portugal|Hospital de Sao Joao; Servico de Hematologia Clinica, Porto, Portugal|Regional Oncology Center, Chelyabinsk, Russian Federation|Central City Hospital #7; Hematology, Ekaterinburg, Russian Federation|Republican Clinical Oncologic Dispensary of Republic Of Tatarstan, Kazan, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|Rus Med Academy for Postgraduate Education; Oncology Department, Moscow, Russian Federation|Vladimirskiy Regional Scientific Research Inst. ; Hematology, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|Clinical MSCh No1, Perm, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|Riyadh Military Hospital, Riyadh, Saudi Arabia|Clinical Center Kragujevac;Center for Hematology, Kragujevac, Serbia|Clinic of Haematology Cc Nis, NIS, Serbia|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Tygerberg Hospital; Haematology Department, Cape Town, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Hospital de Cabueñes; Servicio de Hematología y Hemoterapia, Gijon, Asturias, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Hematologia, Sabadell, Barcelona, Spain|Hospital Punta Europa; Servicio de Hematologia, Algeciras, Cadiz, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Hematologia, Santander, Cantabria, Spain|Hospital de Donostia; Servicio de Hematologia, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Hematologia, Las Palmas de Gran Canarias, Las Palmas, Spain|Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia, Las Palmas de Gran Canaria, Las Palmas, Spain|Hospital de Cruces; Servicio de Hematologia, Barakaldo, Vizcaya, Spain|Hospital General Univ. de Alicante; Servicio de Oncologia, Alicante, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Hematologia, Girona, Spain|Hospital Lucus Augusti; Servicio de Hematologia, Lugo, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Hematología, Madrid, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Hospital Costa del Sol; Servicio de Hematologia, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario Dr. Peset; Servicio de Hematologia, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia, Zaragoza, Spain|Hospital Universitario Miguel Servet; Servicio Hematologia, Zaragoza, Spain|King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Ramathibodi Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Cukurova Uni ; Hematology, Adana, Turkey|Diskapi Research And Training Hospital; hematology, Ankara, Turkey|Hacettepe Uni Medical Faculty; Hematology, Ankara, Turkey|Ankara University; Hematology, Ankara, Turkey|Gaziantep Uni Medical School; Hematology, Gaziantep, Turkey|Istanbul University Cerrahpasa Medical Faculty; Hematology Department, Istanbul, Turkey|Dokuz Eylul Uni ; Hematology, Izmir, Turkey|Ege Uni Medical School; Hematology, Izmir, Turkey|Erciyes Uni ; Hematology, Kayseri, Turkey|Ondokuzmayis University Medical Faculty Heamatology Department, Samsun, Turkey|Cumhuriyet Uni. Med. Fac.; Hematology, Sivas, Turkey|Karadeniz Technical Uni School of Medicine; Hematology, Trabzon, Turkey|Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU; Chair of Oncology and Medical Radiology, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center; Chemotherapy Department, Kiev, Ukraine|State Oncology Regional Treatment-Diagnostic Center; Chemotherapy Department, Lviv, Ukraine|SOUTHMEAD HOSPITAL; Richard Bright Dialysis Centre, Bristol, United Kingdom|Ipswich Hospital; Oncology Pharmacy, Ipswich, United Kingdom|Macclesfield District General Hospital, Macclesfield, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom|Singleton Hospital: Pharmacy Department, Swansea, United Kingdom|Instituto de Oncologia y Hematologia UCV, Caracas, Venezuela|Banco Municipal de Sangre; Hematología, Caracas, Venezuela","https://ClinicalTrials.gov/show/NCT01649856"
656,"NCT01722487","Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL","Completed","Has Results","All","Phase 3","269","Industry","Interventional","March 2013","May 2015","May 2015","November 6, 2012","May 4, 2016","November 30, 2017","Site Reference ID/Investigator #047, Duarte, California, United States|Site Reference ID/Investigator #408, La Jolla, California, United States|Site Reference ID/Investigator #720, Santa Rosa, California, United States|Site Reference ID/Investigator #038, Stanford, California, United States|Site Reference ID/Investigator #125, Atlanta, Georgia, United States|Site Reference ID/Investigator #126, Chicago, Illinois, United States|Site Reference ID/Investigator #071, Louisville, Kentucky, United States|Site Reference ID/Investigator #307, Worcester, Massachusetts, United States|Site Reference ID/Investigator #387, Ann Arbor, Michigan, United States|Site Reference ID/Investigator #221, Saint Louis, Missouri, United States|Site Reference ID/Investigator #712, Las Vegas, Nevada, United States|Site Reference ID/Investigator #350, New Hyde Park, New York, United States|Site Reference ID/Investigator #127, Rochester, New York, United States|Site Reference ID/Investigator #656, Goldsboro, North Carolina, United States|Site Reference ID/Investigator #734, Columbus, Ohio, United States|Site Reference ID/Investigator #677, Portland, Oregon, United States|Site Reference ID/Investigator #050, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator #032, Houston, Texas, United States|Site Reference ID/Investigator #381, Laredo, Texas, United States|Site Reference ID/Investigator #653, San Antonio, Texas, United States|Site Reference ID/Investigator #404, Seattle, Washington, United States|Site Reference ID/Investigator #731, Walla Walla, Washington, United States|Site Reference ID/Investigator #654, Kogarah, New South Wales, Australia|Site Reference ID/Investigator #503, Woolloongabba, Queensland, Australia|Site Reference ID/Investigator #163, Bedford Park, South Australia, Australia|Site Reference ID/Investigator #555, Hobart, Tasmania, Australia|Site Reference ID/Investigator #193, Box Hill, Victoria, Australia|Site Reference ID/Investigator #556, Clayton, Victoria, Australia|Site Reference ID/Investigator #501, Fitzroy, Victoria, Australia|Site Reference ID/Investigator #715, Frankston, Victoria, Australia|Site Reference ID/Investigator #558, Geelong, Victoria, Australia|Site Reference ID/Investigator #170, Heidelberg, Victoria, Australia|Site Reference ID/Investigator #164, Bruxelles, Brussells, Belgium|Site Reference ID/Investigator #727, Yvoir, Namur, Belgium|Site Reference ID/Investigator #560, Gent, Oost-Vlaanderen, Belgium|Site Reference ID/Investigator #559, Leuven, Vlaams Brabant, Belgium|Site Reference ID/Investigator #628, Brugge, West-Vlaanderen, Belgium|Site Reference ID/Investigator #561, Antwerpen, Belgium|Site Reference ID/Investigator #184, Brussells, Belgium|Site Reference ID/Investigator #157, Calgary, Alberta, Canada|Site Reference ID/Investigator #018, Edmonton, Alberta, Canada|Site Reference ID/Investigator #159, Ottawa, Ontario, Canada|Site Reference ID/Investigator #674, Guangzhou, Guangdong, China|Site Reference ID/Investigator #671, Nanjing, Jiangsu, China|Site Reference ID/Investigator #675, Hangzhou, Zhejiang, China|Site Reference ID/Investigator #670, Beijing, China|Site Reference ID/Investigator #673, Beijing, China|Site Reference ID/Investigator #564, Hradec Kralove, Kralovehradecky Kraj, Czechia|Site Reference ID/Investigator #562, Brno, Czechia|Site Reference ID/Investigator #566, Plzen-Lochotin, Czechia|Site Reference ID/Investigator #572, Dublin, Ireland|Site Reference ID/Investigator #570, Dublin, Ireland|Site Reference ID/Investigator #571, Galway, Ireland|Site Reference ID/Investigator #573, Haifa, Israel|Site Reference ID/Investigator #576, Haifa, Israel|Site Reference ID/Investigator #577, Jerusalem, Israel|Site Reference ID/Investigator #578, Nahariya, Israel|Site Reference ID/Investigator #575, Petaẖ Tiqwa, Israel|Site Reference ID/Investigator #574, Ramat Gan, Israel|Site Reference ID/Investigator #583, Roma, Lazio, Italy|Site Reference ID/Investigator #522, Rozzano, Milano, Italy|Site Reference ID/Investigator #582, Novara, Piemonte, Italy|Site Reference ID/Investigator #527, Padova, Veneto, Italy|Site Reference ID/Investigator #580, Bologna, Italy|Site Reference ID/Investigator #584, Milano, Italy|Site Reference ID/Investigator #523, Milano, Italy|Site Reference ID/Investigator #581, Milano, Italy|Site Reference ID/Investigator #524, Modena, Italy|Site Reference ID/Investigator #589, Christchurch, Canterbury, New Zealand|Site Reference ID/Investigator #586, Hamilton, Waikato, New Zealand|Site Reference ID/Investigator #663, Auckland, New Zealand|Site Reference ID/Investigator #588, Auckland, New Zealand|Site Reference ID/Investigator #587, Wellington, New Zealand|Site Reference ID/Investigator #590, Lublin, Lubelskie, Poland|Site Reference ID/Investigator #592, Brzozowie, Podkarpackie, Poland|Site Reference ID/Investigator #591, Chorzow, Poland|Site Reference ID/Investigator #529, Gdansk, Poland|Site Reference ID/Investigator #531, Lodz, Poland|Site Reference ID/Investigator #707, Ryazan, Russian Federation|Site Reference ID/Investigator #304, Yaroslavl, Russian Federation|Site Reference ID/Investigator #536, Majadahonda, Madrid, Spain|Site Reference ID/Investigator #534, Barcelona, Spain|Site Reference ID/Investigator #533, Barcelona, Spain|Site Reference ID/Investigator #535, Barcelona, Spain|Site Reference ID/Investigator #604, Barcelona, Spain|Site Reference ID/Investigator #537, Madrid, Spain|Site Reference ID/Investigator #608, Ankara, Turkey|Site Reference ID/Investigator #606, Ankara, Turkey|Site Reference ID/Investigator #599, Istanbul, Turkey|Site Reference ID/Investigator #714, Izmir, Turkey|Site Reference ID/Investigator #601, Izmir, Turkey|Site Reference ID/Investigator #602, Kayseri, Turkey|Site Reference ID/Investigator #597, Cherkasy, Cherkas'ka Oblast, Ukraine|Site Reference ID/Investigator #594, Dnipropetrovsk, Dnipropetrovs'ka Oblast', Ukraine|Site Reference ID/Investigator #725, Kharkiv, Kharkivs'ka Oblast, Ukraine|Site Reference ID/Investigator #596, Lviv, L'vivs'ka Oblast, Ukraine|Site Reference ID/Investigator #598, Simferopol, Respublika Krym, Ukraine|Site Reference ID/Investigator #595, Vinnytsia, Vinnyts'ka Oblast, Ukraine|Site Reference ID/Investigator #724, Zhytomyr, Zhytomyrs'ka Oblast', Ukraine|Site Reference ID/Investigator #551, Bournemouth, Dorset, United Kingdom|Site Reference ID/Investigator #544, London, England, United Kingdom|Site Reference ID/Investigator #668, Oxford, England, United Kingdom|Site Reference ID/Investigator #549, Colchester, Essex, United Kingdom|Site Reference ID/Investigator #607, Cardiff, South Glamergon, United Kingdom|Site Reference ID/Investigator #550, Leeds, Yorkshire, United Kingdom|Site Reference ID/Investigator #721, Birmingham, United Kingdom|Site Reference ID/Investigator #548, Nottingham, United Kingdom|Site Reference ID/Investigator #367, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01722487"
657,"NCT01482962","Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma","Completed","Has Results","All","Phase 3","271","Industry","Interventional","June 11, 2012","June 30, 2015","December 18, 2017","December 1, 2011","July 31, 2018","July 31, 2018","Birmingham, Alabama, United States|La Jolla, California, United States|Orlando, Florida, United States|Tampa, Florida, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Rochester, Minnesota, United States|Jefferson City, Missouri, United States|Saint Louis, Missouri, United States|Lebanon, New Hampshire, United States|Hackensack, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Burlington, Vermont, United States|Seattle, Washington, United States|Morgantown, West Virginia, United States|Adelaide, Australia|Concord, Australia|Gosford, Australia|Hobart, Australia|St Leonards, Australia|Graz, Austria|Innsbruck, Austria|Salzburg, Austria|Wien, Austria|Minsk Didtrict, Belarus|Vitebsk, Belarus|Brugge, Belgium|Brussels, Belgium|Gent, Belgium|Kortrijk, Belgium|Turnhout, Belgium|Yvoir, Belgium|Belo Horizonte, Brazil|Campianas, Brazil|Caxias Do Sul, Brazil|Curitiba, Brazil|Goiania, Brazil|Porto Alegre/rs, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Salvador, Brazil|SAO Paulo - SP, Brazil|Sao Paulo, Brazil|Pleven, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Concepcion, Chile|Santiago, Chile|Praha 2, Czechia|Arhus C, Denmark|Kobenhavn O, Denmark|Alexandria, Egypt|Beni Swef, Egypt|Cairo, Egypt|Dakahlia, Egypt|Bordeaux, France|Marseille, France|Paris, France|Pessac, France|Pierre Benite, France|Tours, France|Berlin, Germany|Essen, Germany|Freiburg, Germany|Goettingen, Germany|Homburg/saar, Germany|Mainz, Germany|Muenchen, Germany|Munchen, Germany|ULM, Germany|Budapest, Hungary|Debrecen, Hungary|Kaposvar, Hungary|Pecs, Hungary|Beer-sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat-gan, Israel|Tel Aviv, Israel|Bari, Italy|Bologna, Italy|Cagliari, Italy|Firenze, Italy|Meldola, Italy|Modena, Italy|Ravenna, Italy|Rimini, Italy|Roma, Italy|Torino, Italy|Durango Durango, Mexico|Mexico, Mexico|Monterrey Nuevo LEON, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Maastricht, Netherlands|Nieuwegein, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Takapuna, New Zealand|Arequipa, Peru|Lima, Peru|Bydgoszcz, Poland|Chorzow, Poland|Krakow, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Braga, Portugal|Coimbra, Portugal|Porto, Portugal|San Juan, Puerto Rico|Bucuresti, Romania|Chelyabinsk, Russian Federation|Moscow, Russian Federation|Petrozavodsk, Russian Federation|St Petersburg, Russian Federation|Bratislava, Slovakia|Martin, Slovakia|Barcelona, Spain|Girona, Spain|Madrid, Spain|Pamplona, Spain|Salamanca, Spain|Sevilla, Spain|Valencia, Spain|Linkoping, Sweden|Lund, Sweden|Solna, Sweden|Ankara, Turkey|Denizli, Turkey|Istanbul, Turkey|Kayseri, Turkey|Samsun, Turkey|Birmingham, United Kingdom|Cardiff, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Southampton, United Kingdom|Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01482962"
658,"NCT01659021","Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia","Completed","Has Results","All","Phase 3","261","Industry","Interventional","December 4, 2012","January 15, 2015","August 15, 2018","August 7, 2012","March 31, 2017","November 19, 2018","City of Hope, Duarte, California, United States|California Cancer Associates for Research and Excellence (CCARE), Fresno, California, United States|Kaiser Permanente, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Stanford University Medical Center, Stanford, California, United States|Kaiser Permanente Vallejo Medical Center, Vallejo, California, United States|Kaiser Permanente of Colorado, Denver, Colorado, United States|Saint Mary's Regional Cancer Center, Grand Junction, Colorado, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Georgia Regents University, Augusta, Georgia, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Center for Cancer and Blood Disorders, PC, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Weill Cornell Medical Center, New York, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Upstate Oncology Associates, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tenessee Oncology, PLLC, Nashville, Tennessee, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Saint George and Sutherland Hospitals, Kogarah, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Haematology and Oncology Clinics of Australia at Mater, Milton, Queensland, Australia|Ashford Cancer Centre Research, Ashford, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Frankston Hospital, Melbourne, Victoria, Australia|Queen Elizabeth Hospital, Woodville, Australia|Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium|Cliniques Universitaires Saint Luc, Brussels, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|Universitaire Ziekenhuis Gasthuisberg, Leuven, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Hopital Regional De Sudbury Regional Hospital (HRSRH) - Regional Cancer Program (RCP), Sudbury, Ontario, Canada|Centre Hospitalier Universitaire de Montréal, Montréal, Quebec, Canada|Centre Hospitalier Regional de Rimouski, Rimouski, Quebec, Canada|Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada|Cancer Care Manitoba, Winnipeg, Canada|Aalborg Hospital, Aalborg, Denmark|Aarhus University Hospital, Århus, Denmark|Center Hospitalier Universitaire de Bordeaux, Pessac Cedex, Aquitaine, France|Hôpital Saint Louis, Paris Cedex 10, Ile-de-france, France|Centre Hospitalier de Perpignan, Perpignan, Languedoc-Roussillon, France|Centre Hospitalier Universitaire Nancy, Vandoeuvre, Limousin, Lorraine, France|Centre Hospitalier Universitaire Purpan, Toulouse Cedex, Midi-pyrenees, France|CHRU Clermont- Ferrand CHU Estaing, Auvergne, France|Centre Hospitalier Universitaire Hôpital Avicenne, Ile-de-france, France|University College Cork, Cork, Ireland|Saint James's Hospital, Dublin, Ireland|Collegium Medicum Uniwersytetu Jagiellonskiego w K, Kraków, Malopolskie, Poland|Wojewódzki Szpital Specjalistyczny im. Janusza Kor, Slupsk, Pomorskie, Poland|Szpital Specjalistyczny w Brzozowie, Brzozow, Poland|Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi, Lódz, Poland|Centralny Szpital Kliniczny MSW, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny N1 Klinika, Wroclaw, Poland|Hospital Clínic i Provincial, Barcelona, Spain|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Puerta de Hierro Majadahonda, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Sunderby Sjukhus, Luleå, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Birmingham Heartlands Hospital, Birmingham, England, United Kingdom|Darent Valley Hospital, Dartford, England, United Kingdom|Royal Surrey County Hospital NHS Trust, Guildford, England, United Kingdom|Haematology and Transplant Unit, Manchester, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom|Saint James's University Hospital, Leeds, United Kingdom|University College London, London, United Kingdom|University College London, London, United Kingdom|Department of Haematology, Cancer and Haematology Centre, Churchill Hospital (Oxford University Hospitals), Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01659021"
659,"NCT02044276","A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia","Completed","No Results Available","All","Phase 3","101","Industry","Interventional","March 31, 2014","August 29, 2017","April 24, 2018","January 23, 2014","null","May 25, 2018","Teva Investigational Site 32284, Aurich, Germany|Teva Investigational Site 32314, Bad Soden Am Taunus, Germany|Teva Investigational Site 32267, Berlin, Germany|Teva Investigational Site 32277, Berlin, Germany|Teva Investigational Site 32292, Bochum, Germany|Teva Investigational Site 32282, Dresden, Germany|Teva Investigational Site 32269, Dresden, Germany|Teva Investigational Site 32303, Dresden, Germany|Teva Investigational Site 32302, Frankfurt-Hochst, Germany|Teva Investigational Site 32276, Frechen, Germany|Teva Investigational Site 32293, Freiburg, Germany|Teva Investigational Site 32290, Freiburg, Germany|Teva Investigational Site 32322, Fulda, Germany|Teva Investigational Site 32320, Furth, Germany|Teva Investigational Site 32273, Goslar, Germany|Teva Investigational Site 32296, Gutersloh, Germany|Teva Investigational Site 32272, Hamburg, Germany|Teva Investigational Site 32295, Heilbronn, Germany|Teva Investigational Site 32270, Herne, Germany|Teva Investigational Site 32401, Herne, Germany|Teva Investigational Site 32279, Hof, Germany|Teva Investigational Site 32297, Kaiserslautern, Germany|Teva Investigational Site 32310, Kassel, Germany|Teva Investigational Site 32280, Kiel, Germany|Teva Investigational Site 32275, Koeln, Germany|Teva Investigational Site 32309, Krefeld, Germany|Teva Investigational Site 32287, Lahr, Germany|Teva Investigational Site 32289, Langen, Germany|Teva Investigational Site 32313, Lebach, Germany|Teva Investigational Site 32311, Leer, Germany|Teva Investigational Site 32278, Leipzig, Germany|Teva Investigational Site 32301, Munchen, Germany|Teva Investigational Site 32274, Oldenburg, Germany|Teva Investigational Site 32306, Poessneck, Germany|Teva Investigational Site 32291, Rotenburg, Germany|Teva Investigational Site 32300, Stade, Germany|Teva Investigational Site 32268, Stuttgart, Germany|Teva Investigational Site 32321, Stuttgart, Germany|Teva Investigational Site 32317, Villingen-Schwenningen, Germany|Teva Investigational Site 30061, Campobasso, Italy|Teva Investigational Site 31074, Barcelona, Spain|Teva Investigational Site 31071, Madrid, Spain|Teva Investigational Site 31070, Madrid, Spain|Teva Investigational Site 31073, Valencia, Spain|Teva Investigational Site 31072, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02044276"
660,"NCT01287741","A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)","Completed","Has Results","All","Phase 3","1418","Industry|Other","Interventional","July 31, 2011","April 29, 2016","January 31, 2018","February 1, 2011","August 17, 2017","August 1, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Ironwood Cancer TX & Rsch Ctrs, Chandler, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States|cCare, Encinitas, California, United States|UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, United States|Rocky Mountain Cancer Center - Aurora, Aurora, Colorado, United States|Florida Cancer Specialists; Department of Oncology, Fort Myers, Florida, United States|Florida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, United States|Central Georgia Cancer Care PC, Macon, Georgia, United States|Illinois Cancer Care, P.C. - Galesburg, Galesburg, Illinois, United States|Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois, United States|Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Mercy Oncology / Hematology Center; Oncology, Portland, Maine, United States|Park Nicollet Clin-Cancer Ctr, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology Woodbury, Woodbury, Minnesota, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Mecklenburg Medical Group Charlotte, Charlotte, North Carolina, United States|Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates, Winston-Salem, North Carolina, United States|Signal Point Clinical; Research Center, LLC, Middletown, Ohio, United States|Cleveland CL N Coast Cancer Cr, Sandusky, Ohio, United States|Willamette Valley Cancer Insitute and Research Center, Springfield, Oregon, United States|Medical University of SC (MUSC), Charleston, South Carolina, United States|South Carolina Oncology Associates - SCRI, Columbia, South Carolina, United States|Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States|Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States|Texas Oncology, Pa - Amarillo, Amarillo, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|MD Anderson Cancer Center Department of Lymphoma & Myeloma, Houston, Texas, United States|Cancer Care Centers of South Texas-HOAST - San Antonio, New Braunfels, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Virginia Cancer Specialists - Winchester, Winchester, Virginia, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Instituto Damic, Cordoba, Argentina|Sanatorio Britanico: Hematologia, Rosario, Argentina|Sanatorio Parque de Rosario, Rosario, Argentina|Cairns Base Hospital; Cancer Care Centre, Cairns, Queensland, Australia|Frankston Hospital; Oncology/Haematology, Frankston, Victoria, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, Innsbruck, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie, Wien, Austria|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, SP, Brazil|Hospital Santa Marcelina;Oncologia, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|Chum Hopital Notre Dame; Centre D'Oncologie, Montreal, Quebec, Canada|Mcgill University - Royal Victoria Hospital; Oncology, Montreal, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital de L'Enfant-Jesus; Hematology, Quebec City, Quebec, Canada|Centre de sante et de services sociaux Rimouski Neigette, Rimouski, Quebec, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Peking University First Hospital, Beijing, China|The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|Beijing Cancer Hospital, Beijing, China|Beijing Hospital of Ministry of Health; Hematology, Beijing, China|General Hospital of Chinese PLA; Department of Hematology, Beijing, China|the First Hospital of Jilin University, Changchun, China|Hu Nan Provincial Cancer Hospital, Changsha, China|Fujian Medical University Union Hospital, Fujian, China|Fujian Cancer Hospital, Fuzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|The Second Affiliated Hospital to Nanchang University, Nanchang, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|The First Affiliate Hospital of Guangxi Medical University, Nanning, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Changhai Hospital of Shanghai, Shanghai, China|First Hospital of China Medical University, Shenyang, China|The Second Affiliated Hospital of Soochow University, Suzhou, China|First Affiliated Hospital of Soochow University, Suzhou, China|Tianjin Cancer Hospital, Tianjin, China|Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan, China|Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center, Wuhan, China|The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital), Xi'an, China|Fundacion Cardioinfantil, Bogota, Colombia|Organizacion Sanitas Internacional, Bogota, Colombia|FOSCAL, Floridablanca, Colombia|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Fn Hr. Kralove; IV. Interni Hematologicka Klinika, Hradec Kralove, Czechia|Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Praha 2, Czechia|Righospitalet, Haematologisk Klinik, Kobenhavn, Denmark|Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium, Roskilde, Denmark|Aarhus Universitetshospital, Hæmatologisk Afdeling R, Århus, Denmark|Uniklinik RWTH Aachen; Med. Klinik IV; Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammz, Aachen, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik und Poliklinik I, Dresden, Germany|Friedrich-Alexander-Universität Erlangen-Nürnberg; Medizinische Klinik V, Erlangen, Germany|Klinik der Justus-Liebig-Universität; Innere Medizin, Gießen, Germany|Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V, Heidelberg, Germany|Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Hämatologie / Onkologie, Würzburg, Germany|Pamela Youde Nethersole Eastern Hospital; Department of Medicine, Hong Kong, Hong Kong|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Semmelweis University, First Dept of Medicine, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B, Debrecen, Hungary|Petz Aladar Megyei Korhaz; Hematologia, Gyor, Hungary|Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology, Kaposvar, Hungary|University of Pecs, I st Dept of Internal Medicine, Pecs, Hungary|University of Szeged, II Dept of Internal Medicine, Szeged, Hungary|Ospedale Riuniti; Divisione Di Ematologia, Reggio Calabria, Calabria, Italy|Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica, Napoli, Campania, Italy|Nuovo Policlinico, Ii Facolta; Divisione Di Ematologia, Napoli, Campania, Italy|Ospedale ""A.Tortora"" - Ematologia; Dipartimento Di Ematologia, Pagani (Sa), Campania, Italy|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia, Reggio Emilia, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica, Udine, Friuli-Venezia Giulia, Italy|Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol, Roma, Lazio, Italy|A.O. Universitaria S. Martino Di Genova; Ematologia 1, Genova, Liguria, Italy|A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia, Brescia, Lombardia, Italy|Hospital San Raffaele, Milano, Lombardia, Italy|Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia, Milano, Lombardia, Italy|Irccs Policlinico San Matteo; Divisione Di Ematologia, Pavia, Lombardia, Italy|Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia, Alessandria, Piemonte, Italy|Ospedali Riuniti del Canavese, Ivrea, Piemonte, Italy|Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad, Novara, Piemonte, Italy|Az. Osp. S. Luigi Gonzaga; S.C.D.U. Medicina Interna Ii, Orbassano, Piemonte, Italy|A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1, Torino, Piemonte, Italy|A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia, Torino, Piemonte, Italy|Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica, Bari, Puglia, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo, San Giovanni Rotondo, Puglia, Italy|Az. Osp. C. Panico; Rep. Ematologia E Trapianto, Tricase - LE, Puglia, Italy|Azienda Ospedaliero Univ, Catania, Sicilia, Italy|Az. Osp. Papardo; Struttura Complessa Di Ematologia, Messina, Sicilia, Italy|Azienda Ospedaliera Univ, Firenze, Toscana, Italy|Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy|Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy|Ospedale Ca Foncello; Ematologia, Treviso, Veneto, Italy|Uni Di Verona Policlinico G.B. Rossi; Divisione E Cattedra Di Ematologia, Verona, Veneto, Italy|Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy|Nagoya Daini Red Cross Hospital; Hematology & Oncology, Aichi, Japan|Chiba University Hospital; Hematology, Chiba, Japan|Kyushu University Hospital; Hematology, Oncology & Cardiovascular medicine, Fukuoka, Japan|Kurume University Hospital; Hematology and Oncology, Fukuoka, Japan|Gifu University Hospital; First Department of Internal Medicine, Gifu, Japan|Hokkaido University Hospital; Hematology, Hokkaido, Japan|Kobe City Medical Center General Hospital; Hematology, Hyogo, Japan|Iwate Medical University Hospital;Hematology and Oncology, Iwate, Japan|Yokohama City University Hospital; Hematology, Rheumatology, Infectious Disease, Kanagawa, Japan|Kyoto University Hospital; Department of Hematology/Oncology, Kyoto, Japan|Niigata Cancer Center Hospital; Internal Medicine, Niigata, Japan|Kurashiki Central Hospital; Hematology, Okayama, Japan|Osaka City University Hospital; Hematology, Osaka, Japan|Osaka University Hospital; Hematology and Oncology, Osaka, Japan|Kindai University Hospital; Hematology and Rheumatology, Osaka, Japan|Shimane University Hospital;Hematology, Shimane, Japan|Jichi Medical University Hospital; Hematology, Tochigi, Japan|National Cancer Center Hospital; Hematology, Tokyo, Japan|Toranomon Hospital; Hematology, Tokyo, Japan|Nippon Medical School Hospital; Hematology, Tokyo, Japan|The Cancer Institute Hospital of JFCR; Hematology Oncology, Tokyo, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|St. Mary'S Hospital, the Catholic University School of Medicine; Internal Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico|Hospital Universitario Dr. Jose E. Gonzalez; Haematology, Monterrey, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Centro de Estudios Clinicos de Queretaro, SC, Queretaro, Mexico|Centro Hemato Oncologico Panama, Panama, Panama|Instituto;Oncologico Miraflores, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica de Especialidades Medicas, Lima, Peru|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland|Medical University of Lodz; Hematology, Lodz, Poland|Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie, Lublin, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Medical Uni of Wroclaw; Hematology, Wroclaw, Poland|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Blokhin Cancer Research Center; Clinical Oncology, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|Republican Clinical Hospital n.a. Baranov; Haematology, Petrozavodsk, Russian Federation|Research Inst. of Hematology & Blood Transfusion ; Hematology, St Petersburg, Russian Federation|Institute of Hematology, Belgrade, Serbia|Clinical Center Vojvodine; Clinic for Hematology, Novi Sad, Serbia|National Oncology Inst. ; Dept. of Haematology, Bratislava, Slovakia|Constantiaberg Medical Clinic; Dept. of Haematology & Bone Marrow Translant, Cape Town, South Africa|Mary Potter Oncology Centre, Groenkloof, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, South Africa|Drs Thomson, Brittain an Partners Inc, Pretoria, South Africa|Hospital de Navarra, Servicio de Hematología, Pamplona, Navarra, Spain|Hospital Universitari Sant Joan de Reus; Servicio de Oncologia, Reus, Tarragona, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Duran i Reynals; Servicio de Hematologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Hematologia, Madrid, Spain|Complejo Hospitalario de Pontevedra; Servicio de Oncologia, Pontevedra, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, Spain|Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie & Transfusionsmedizin, Aarau, Switzerland|Ospedale San Giovanni; Oncologia, Bellinzona, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland|Veterans General Hospital; Division of Oncology, Taipei, Taiwan|National Taiwan Universtiy Hospital; Division of Hematology, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology, Taoyuan, Taiwan|King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|National Cancer Inst., Bangkok, Thailand|Rajavithi Hospital; Medicine, Bangkok, Thailand|Ramathibodi Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand|Aberdeen Royal Infirmary; Haematology - Ward 16, Aberdeen, United Kingdom|Birmingham Heartlands Hospital; Department of Haematology, Birmingham, United Kingdom|Addenbrookes Hospital; Haematology, Cambridge, United Kingdom|The HOPE Clinical Trials Unit, Leicester, United Kingdom|New Cross Hospital; Dept. Of Haematology, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01287741"
661,"NCT01292603","A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia","Completed","Has Results","All","Phase 1","240","Industry","Interventional","April 18, 2011","May 7, 2014","November 17, 2017","February 9, 2011","December 15, 2015","December 18, 2017","Fundaleu; Haematology, Buenos Aires, Argentina|Cemic; Haematology, Buenos Aires, Argentina|HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología, Córdoba, Argentina|St George Hospital; Department of Haematology, Kogarah, New South Wales, Australia|Royal Brisbane and Women'S Hospital; Haematology, Herston, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Queen Elizabeth Hospital; Haematology, Woodville South, South Australia, Australia|St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia|Frankston Hospital; Oncology/Haematology, Frankston, Victoria, Australia|Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia, Passo Fundo, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Hospital Sirio Libanes; Centro de Oncologia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, Brazil|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Centre de sante et de services sociaux Rimouski Neigette, Rimouski, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Instituto Nacional del Cancer, Santiago, Chile|Centro Internacional de Estudios Clínicos (CIEC), Santiago, Chile|Clinical Hospital Merkur; Dept of Haematology, Zagreb, Croatia|University Hospital Center Zagreb; Haematology Department, Zagreb, Croatia|Fakultni nemocnice Brno; Interni hematoonkologicka klinika, Brno, Czechia|University Hospital and Medical School; IV.Dept. of Internal Medicine and Hematology, Hradec Kralove, Czechia|Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Praha 2, Czechia|Centre Francois Baclesse, Caen, France|Institut J Paolii Calmettes; Onco Hematologie 1, Marseille, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Hopital Robert Debre; Hematologie Clinique, Reims, France|Hopitaux De Brabois; Hematologie Medecine Interne, Vandoeuvre Les Nancy, France|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Onkologischer Schwerpunkt am Oskar-Helene-Heim; Dres. Herrenberger, Keitel-Wittig u. Kirsch, Berlin, Germany|BAG Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany|Klinikum Frankfurt Medizinische Klinik I, Frankfurt an der Oder, Germany|Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik, Greifswald, Germany|Onkologische Schwerpunktpraxis Dres. Bernd Gaede, Hans-Ulrich Ehlers, Ulrike Rodewig u.w., Hannover, Germany|Gemeinschaftspraxis Dr. Siehl & Dr. Soeling, Kassel, Germany|Klinik der Uni zu Köln; Klinik für Innere Medizin, Köln, Germany|K&K Studien GbR, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Gemeinschaftspraxis Fr. Dr. med. Balser & Hr. Dr. med. Weidenbach, Marburg, Germany|Klinikum Grosshadern der LMU, Muenchen, Germany|Medizinisches Versorgungszentrum MOP, München, Germany|Praxis Dr.med. Peter Schmidt, Neunkirchen/Saar, Germany|Prosper-Hospital, Medizinische Klinik I, Recklinghausen, Germany|Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine, Athens, Greece|Papageorgiou General Hospital of Thessaloniki; Hematology Clinic, Thessaloniki, Greece|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia, Rimini, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica, Udine, Friuli-Venezia Giulia, Italy|Istituto S. Raffaele Monte Tabor; Divisione Ematologia E Utmo, Milano, Lombardia, Italy|ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Struttura Complessa di Ematologia, Milano, Lombardia, Italy|Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad, Novara, Piemonte, Italy|Policlinico G. B. Rossi; Divisione Di Ematologia, Verona, Veneto, Italy|Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico|Hospital General De Culiacan; Servicio De Hematologia, Culiacan, Mexico|Hospital Universitario Dr. Jose E. Gonzalez; Haematology, Monterrey, Mexico|Canterbury Health Laboratories; Haematology, Christchurch, New Zealand|Wellington Hospital; Wellington Blood and Cancer Centre, Newtown, New Zealand|Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland|Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie, Lublin, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Lymphoma Dept., Warszawa, Poland|Medical Uni of Wroclaw; Hematology, Wroclaw, Poland|Hospital de Santa Maria; Servico de Hematologia e Transplantacao de Medula, Lisboa, Portugal|IPO do Porto; Servico de Onco-Hematologia, Porto, Portugal|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Hospital After Botkin; Hematology, Moscow, Russian Federation|Haematology Research Center; Haematology, Moscow, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|Clinical MSCh No1, Perm, Russian Federation|St. Petersburg State Medical University n.a. I.P. Pavlov; Hematology, transfusiology and transplanta, Saint-Petersburg, Russian Federation|National Oncology Inst. ; Dept. of Haematology, Bratislava, Slovakia|University Hospital; Clinic of Hematology & Transfusiology, Bratislava, Slovakia|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario de la Princesa; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Hematología, Toledo, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hacettepe Uni Medical Faculty; Hematology, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty; Hematology Department, Istanbul, Turkey|Dokuz Eylul Uni ; Hematology, Izmir, Turkey|Ege University ARGEFAR, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT01292603"
662,"NCT01419665","GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma","Completed","No Results Available","All","Phase 3","629","Industry","Interventional","December 1, 2011","July 10, 2015","January 22, 2018","August 18, 2011","null","October 16, 2018","Investigative site, La Plata, Argentina|Investigative site, Rosario, Argentina|Investigative site, San Miguel de Tucuman, Argentina|Investigative site, Adelaide, Australia|Investigative site, Ballarat, Australia|Investigative site, Epping, Australia|Investigative site, Footscray, Australia|Investigative site, Wodonga, Australia|Investigative site, Graz, Austria|Investigative site, Wien, Austria|Investigative site, Barretos, Brazil|Investigative site, Botucatu, Brazil|Investigative site, Campinas, Brazil|Investigative site, Curitiba, Brazil|Investigative site, Florianopolis, Brazil|Investigative site, Fortaleza, Brazil|Investigative site, Goiania, Brazil|Investigative site, Jau, Brazil|Investigative site, Passo Fundo, Brazil|Investigative site, Porto Alegre, Brazil|Investigative Site, Rio de Janeiro, Brazil|Investigative site, Santo Andre, Brazil|Investigative site, Sao Paulo, Brazil|Investigative site, Sorocaba, Brazil|Investigative site, Pleven, Bulgaria|Investigative site, Plovdiv, Bulgaria|Investigative site, Ruse, Bulgaria|Investigative site, Sofia, Bulgaria|Investigative site, Varna, Bulgaria|Investigative site, Medellin, Colombia|Investigative site, Monteria, Colombia|Investigative site, Colmar, France|Investigative site, Nimes, France|Investigative site, Strasbourg, France|Investigative site, Bad Saarow, Germany|Investigative site, Koblenz, Germany|Investigative site, Athens, Greece|Investigative site, Ioannina, Greece|Investigative site, Larissa, Greece|Investigative site, Patras, Greece|Investigative site, Györ, Hungary|Investigative site, Kaposvar, Hungary|Investigative site, Ahmedabad, India|India, Amritsar, India|Investigative site, Aurangabad, India|Investigative site, Bangalore, India|Investigative site, Chennai, India|Investigative site, Hyderabad, India|Investigative site, Kolkata, India|Investigtive site, Kolkata, India|Investigative site, Madurai, India|Investigative site, Mumbai, India|Investigative site, Nashik, India|Investigative site, New Delhi, India|Investigative site, Pune, India|Investigative site, Surat, India|Investigative site, Trivandrum, India|Investigative site, Vellore, India|Investigative site, Dublin, Ireland|Investigative site, Limerick, Ireland|Investigative site, Waterford, Ireland|Investigative site, Ashkelon, Israel|Investigative site, Nahariya, Israel|Investigative site, Bari, Italy|Investigative site, Firenze, Italy|Investigative site, Meldola, Italy|Investigative site, Milano, Italy|Investigative site, Palermo, Italy|Investigative site, Pavia, Italy|Investigative site, Pescara, Italy|Investigative site, Piacenza, Italy|Investigative site, Ravenna, Italy|Investigative site, Reggio Calabria, Italy|Investigative site, Varese, Italy|Investigative site, Aomori, Japan|Investigative site, Fukuoka, Japan|Investigative site, Gifu, Japan|Investigative site, Kagoshima, Japan|Investigative site, Kitakyushu, Japan|Investigative site, Kobe, Japan|Investigative site, Komaki, Japan|Investigative site, Matsuyama, Japan|Investigative site, Ogaki, Japan|Investigative site, Okayama, Japan|Invstigative site, Omura, Japan|Investigative site, Saga, Japan|Investigative site, Tachikawa, Japan|Investigative site, Ōtake, Japan|Investigative site, Alor Setar, Malaysia|Investigative site, Ampang, Malaysia|Investigative site, George Town, Malaysia|Investigative site, Ipoh, Malaysia|Investigative site, Johor Bahru, Malaysia|Investigative site, Klang, Malaysia|Investigative site, Kuala Lumpur, Malaysia|Investigative site, Kuching, Malaysia|Investigative site, Melaka, Malaysia|Investigative site, Pulau Pinang, Malaysia|Investigative site, Subang Jaya, Malaysia|Investigative site, Amsterdam, Netherlands|Investigative site, Delft, Netherlands|Investigative site, Gouda, Netherlands|Investigative site, Heerlen, Netherlands|Investigative site, Rotterdam, Netherlands|Investigative site, Schiedam, Netherlands|Investigative site, Sittard, Netherlands|Investigative site, Zwolle, Netherlands|Investigative site, Lima, Peru|Investigative site, Brzozow, Poland|Investigative site, Bydgoszcz, Poland|Investigative site, Chorzow, Poland|Investigative site, Krakow, Poland|Investigative site, Lublin, Poland|Investigative site, Warszawa, Poland|Investigative site, Braga, Portugal|Investigative site, Coimbra, Portugal|Investigative site, Lisboa, Portugal|Investigative site, Porto, Portugal|Investigative site, Brasov, Romania|Investigative site, Bucharest, Romania|Investigative site, Cluj-Napoca, Romania|Investigative site, Iasi, Romania|Investigative site, Timisoara, Romania|Investigative site, Arkhangelsk, Russian Federation|Investigative site, Chelyabinsk, Russian Federation|Investigative site, Krasnodar, Russian Federation|Investigative site, Kursk, Russian Federation|Investigative site, Moscow, Russian Federation|Investigative site, Nizhniy Novgorod, Russian Federation|Investigative site, Rostov-on -Don, Russian Federation|Investigative site, St. Petersburg, Russian Federation|Investigative site, Cape Town, South Africa|Investigative site, George, South Africa|Investigative site, Johannesburg, South Africa|Investigative site, Port Elizabeth, South Africa|Investigative site, Pretoria, South Africa|Investigative site, Barcelona, Spain|Investigative site, Madrid, Spain|Investigative site, Oviedo, Spain|Investigative site, San Sebastian, Spain|Investigative site, Sevilla, Spain|Investigative site, Zaragoza, Spain|Investigative site, Cherkasy, Ukraine|Investigative site, Dnipropetrovsk, Ukraine|Investigative site, Donetsk, Ukraine|Investigative site, Ivano-Frankivsk, Ukraine|Investigative site, Kharkiv, Ukraine|Investigative site, Kyiv, Ukraine|Investigative site, Lviv, Ukraine|Investigative site, Eastbourne, United Kingdom|Investigative site, London, United Kingdom|Investigative site, Worthing, United Kingdom","https://ClinicalTrials.gov/show/NCT01419665"
663,"NCT01056510","A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)","Completed","Has Results","All","Phase 4","357","Industry","Interventional","March 2010","March 2014","March 2014","January 26, 2010","June 25, 2015","June 25, 2015","Pori, Finland|Vantaa, Finland|Argenteuil, France|Avignon, France|Blois, France|Bordeaux, France|Brest, France|La Roche Sur Yon, France|La Tronche, France|Le Mans, France|Lens, France|Limoges, France|Lyon, France|Marseille, France|Mulhouse, France|Nice, France|Nimes, France|Paris, France|Paris, France|Perpignan, France|Pierre Benite, France|Salouel, France|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Vitoria, Alava, Spain|Elche, Alicante, Spain|Jerez de La Frontera, Cadiz, Spain|Torrelavega, Cantabria, Spain|La Coruna, La Coruña, Spain|Alcorcon, Madrid, Spain|Cartagena, Murcia, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Huelva, Spain|Leon, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Tarragona, Spain|Valencia, Spain|Zaragoza, Spain|Falun, Sweden|Kristianstad, Sweden|Luleå, Sweden|Sundsvall, Sweden|Uddevalla, Sweden|Umea, Sweden|Uppsala, Sweden|Tunis, Tunisia|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Bursa, Turkey|Edirne, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Samsun, Turkey|Blackpool, United Kingdom|Bournemouth, United Kingdom|Edinburgh, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Manchester, United Kingdom|Manchester, United Kingdom|Oxford, United Kingdom|Romford, United Kingdom|Somerset, United Kingdom|Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01056510"
664,"NCT01010061","CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)","Completed","Has Results","All","Phase 3","787","Industry|Other","Interventional","December 21, 2009","July 1, 2012","August 23, 2017","November 9, 2009","April 1, 2014","September 14, 2018","San Diego, California, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Green Bay, Wisconsin, United States|Waukesha, Wisconsin, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Rosario, Argentina|Adelaide, New South Wales, Australia|Gosford, New South Wales, Australia|Kogarah, New South Wales, Australia|Liverpool, New South Wales, Australia|St. Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Greenslopes, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Kurralta Park, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Graz, Austria|Innsbruck, Austria|Wien, Austria|Wien, Austria|Goiania, GO, Brazil|Belo Horizonte, MG, Brazil|Porto Alegre, RS, Brazil|Santo Andre, SP, Brazil|Sao Paulo, SP, Brazil|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Barrie, Ontario, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Rimouski, Quebec, Canada|Zagreb, Croatia|Brno, Czechia|Hradec Kralove, Czechia|Praha 2, Czechia|Aalborg, Denmark|København, Denmark|Odense, Denmark|Vejle, Denmark|Århus, Denmark|Cairo, Egypt|Tallinn, Estonia|Tartu, Estonia|Angers, France|Bobigny, France|Caen, France|Clermont Ferrand, France|Creteil, France|Le Mans, France|Lille, France|Lyon, France|Marseille, France|Montpellier, France|Nantes, France|Paris, France|Paris, France|Pessac, France|Pierre Benite, France|Poitiers, France|Reims, France|Rennes, France|Rouen, France|Toulouse, France|Tours, France|Vandoeuvre Les Nancy, France|Ahaus, Germany|Amberg, Germany|Ansbach, Germany|Bamberg, Germany|Berlin, Germany|Bonn, Germany|Bremen, Germany|Bremen, Germany|Bremen, Germany|Delitzsch, Germany|Detmold, Germany|Dresden, Germany|Dresden, Germany|Duisburg, Germany|Erlangen, Germany|Erlangen, Germany|Eschweiler, Germany|Essen, Germany|Essen, Germany|Esslingen, Germany|Frankfurt am Main, Germany|Frankfurt an der Oder, Germany|Frankfurt, Germany|Frechen, Germany|Freiburg, Germany|Giessen, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hamm, Germany|Hannover, Germany|Heidelberg, Germany|Homburg/Saar, Germany|Kaiserslautern, Germany|Karlsruhe, Germany|Kempten, Germany|Kiel, Germany|Koblenz, Germany|Koeln, Germany|Kronach, Germany|Köln, Germany|Landshut, Germany|Lebach, Germany|Leer, Germany|Lemgo, Germany|Lörrach, Germany|Lüdenscheid, Germany|Magedburg, Germany|Mainz, Germany|Mannheim, Germany|Muenchen, Germany|Mutlangen, Germany|München, Germany|München, Germany|München, Germany|München, Germany|Neunkirchen/Saar, Germany|Nürnberg, Germany|Oldenburg, Germany|Porta Westfalica, Germany|Ravensburg, Germany|Recklinghausen, Germany|Regensburg, Germany|Regensburg, Germany|Rostock, Germany|Rüsselsheim, Germany|Saarbruecken, Germany|Sindelfingen, Germany|Stuttgart, Germany|Trier, Germany|Tübingen, Germany|Ulm, Germany|Villingen-Schwenningen, Germany|Weilheim, Germany|Wendlingen, Germany|Witten, Germany|Worms, Germany|Wuerzburg, Germany|Würzburg, Germany|Hong Kong, Hong Kong|Cagliari, Italy|Cosenza, Italy|Ferrara, Italy|Genova, Italy|Messina, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Orbassano, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Terni, Italy|Torino, Italy|Aguascalientes, Mexico|Culiacan, Mexico|Hermosillo, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Delftzijl, Netherlands|Enschede, Netherlands|Leeuwarden, Netherlands|Nieuwegein, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Bucharest, Romania|Bucuresti, Romania|Targu-mures, Romania|Kazan, Russian Federation|Nizhny Novgorod, Russian Federation|Penza, Russian Federation|Perm, Russian Federation|Rostov-na-donu, Russian Federation|UFA, Russian Federation|Bratislava, Slovakia|Oviedo, Asturias, Spain|Manresa, Barcelona, Spain|Sabadell, Barcelona, Spain|Jerez de La Frontera, Cadiz, Spain|Santander, Cantabria, Spain|San Sebastian, Guipuzcoa, Spain|La Coruna, LA Coruña, Spain|Santiago de Compostela, LA Coruña, Spain|Pamplona, Navarra, Spain|La Laguna, Tenerife, Spain|Gandia, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Jaen, Spain|Las Palmas, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Malaga, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Toledo, Spain|Toledo, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Aarau, Switzerland|Basel, Switzerland|Bern, Switzerland|Chur, Switzerland|Luzern, Switzerland|St. Gallen, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Khon Kaen, Thailand|Bournemouth, United Kingdom|Cambridge, United Kingdom|Canterbury, United Kingdom|Cardiff, United Kingdom|Cottingham, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|Leicester, United Kingdom|London, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01010061"
665,"NCT01028222","A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation","Completed","Has Results","All","Phase 2","55","Industry","Interventional","June 2010","December 2014","December 2014","December 9, 2009","November 26, 2015","December 30, 2015","City of Hope National Medical Center City of Hope national Med Ctr, Duarte, California, United States|University of California San Diego - Moores Cancer Center UCSD Moores Cancer Center, La Jolla, California, United States|University of California at Los Angeles UCLA, Los Angeles, California, United States|California Pacific Medical Center California Pacific Med, San Francisco, California, United States|University of Colorado Univ Colorado 2, Aurora, Colorado, United States|Rush University Medical Center SC, Chicago, Illinois, United States|Oncology Specialists, SC Dept.of Oncology Specialists, Park Ridge, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology, Baltimore, Maryland, United States|Dana Farber Cancer Institute DFCI - Brookline, Boston, Massachusetts, United States|Mayo Clinic - Rochester Mayo Clinic- Gonda, Rochester, Minnesota, United States|Washington University School of Medicine CAMN107B2301, St. Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Case Western Reserve Case Western, Cleveland, Ohio, United States|Baylor Health Care System/Sammons Cancer Center Baylor 2, Dallas, Texas, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Cataluña, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Malmö, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT01028222"
666,"NCT01646021","Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy","Completed","Has Results","All","Phase 3","280","Industry","Interventional","December 10, 2012","June 5, 2015","December 15, 2016","July 20, 2012","March 1, 2017","January 19, 2018","Antwerpen, Belgium|Brugge, Belgium|Brussels, Belgium|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|Wilrijk, Belgium|Goiânia, Brazil|Porto Alegre, Brazil|Ribeirão Preto, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Temuco, Chile|Bogota, Colombia|Medellin, Colombia|Brno, Czechia|Praha 10, Czechia|Praha 2, Czechia|Mulhouse, France|Paris Cedex 15, France|Paris, France|Pessac, France|Villejuif, France|Berlin, Germany|Essen, Germany|Heidelberg, Germany|Homburg, Germany|Kiel, Germany|Koln, Germany|Mainz, Germany|Munchen, Germany|Ulm, Germany|Budapest, Hungary|Debrecen, Hungary|Pécs N/A, Hungary|Szeged, Hungary|Dublin, Ireland|Goyang-Si, Korea, Republic of|Seoul, Korea, Republic of|Monterrey, Mexico|Oaxaca, Mexico|Queretaro, Mexico|Amsterdam, Netherlands|Rotterdam, Netherlands|Brzozow, Poland|Chorzow, Poland|Gdansk, Poland|Krakow, Poland|Opole, Poland|Slupsk, Poland|Wroclaw, Poland|Coimbra, Portugal|Lisboa, Portugal|Lisbon, Portugal|Porto, Portugal|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Krasnodar, Russian Federation|Moscow N/A, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Obninsk, Russian Federation|Rostov-Na-Donu, Russian Federation|Saint Petersburg, Russian Federation|Sochi, Russian Federation|St-Petersburg, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Barcelona, Spain|Madrid, Spain|Palma De Mallorca, Spain|Salamanca, Spain|Valencia, Spain|Göteborg, Sweden|Lund, Sweden|Stockholm, Sweden|Umeå, Sweden|Uppsala, Sweden|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Donetsk, Ukraine|Khmelnitskiy, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Birmingham, United Kingdom|Harrow, United Kingdom|Leeds, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Plymouth, United Kingdom|Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01646021"
667,"NCT01039376","Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy","Completed","Has Results","All","Phase 3","480","Industry","Interventional","May 6, 2010","June 19, 2014","June 26, 2018","December 25, 2009","April 21, 2015","July 31, 2018","Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, La Verne, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Pablo, California, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Lake Worth, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Pembroke Pines, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Post Falls, Idaho, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Iowa City, Iowa, United States|Novartis Investigative Site, Westwood, Kansas, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Cumberland, Maryland, United States|Novartis Investigative Site, Hagerstown, Maryland, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Orem, Utah, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Derqui, Pilar, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Salvador, Bahía, Brazil|Novartis Investigative Site, Goiania - GO, Goiás, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Hradec Kralove, Czechia|Novartis Investigative Site, Olomouc, Czechia|Novartis Investigative Site, Pelhrimov, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Kobenhavn, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Pori, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Blois cedex, France|Novartis Investigative Site, Caen cedex 5, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Marseille Cedex 9, France|Novartis Investigative Site, Mulhouse, France|Novartis Investigative Site, Pessac cedex, France|Novartis Investigative Site, Saint Pierre cedex, France|Novartis Investigative Site, Strasbourg cedex, France|Novartis Investigative Site, Toulouse cedex 9, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy, France|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Piraeus, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Ahmedabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Nahariya, Israel|Novartis Investigative Site, Petach-Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel-Aviv, Israel|Novartis Investigative Site, Zrifin, Israel|Novartis Investigative Site, Modena, Emilia-Romagna, Italy|Novartis Investigative Site, Piacenza, Emilia-Romagna, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Torino, Piemonte, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Den Bosch, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard-geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Penza, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Orebro, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Cherkasy, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Khmelnytskyi, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Makiivka, Ukraine|Novartis Investigative Site, Vinnitsa, Ukraine|Novartis Investigative Site, Zhytomyr, Ukraine","https://ClinicalTrials.gov/show/NCT01039376"
668,"NCT00865969","Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma","Completed","No Results Available","All","Phase 2","129","Industry","Interventional","December 2008","October 2014","October 2014","March 20, 2009","null","December 8, 2014","City of Hope National Medical Center, Duarte, California, United States|Wilshire Oncology Medical Group, Inc, La Verne, California, United States|Comprehensive Cancer Center, Palm Springs, California, United States|Yale Cancer Center-Section of Medical Oncology, New Haven, Connecticut, United States|Oncology Associates of Bridgeport, Trumbull, Connecticut, United States|Boca Raton Clinical Research Associates, Boca Raton, Florida, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Kellogg Cancer Care Center, Evanston, Illinois, United States|Illinois Cancer Specialists/Cancer Care & Hematology Specialists of Chicagoland, Niles, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Center for Cancers and Blood Disorders, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Saint Louis University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Northern New Jersey Cancer Associates, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Bronx River Medical Associates, PC, Bronx, New York, United States|Erie County Medical Center (Roswell Park), Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|New York University, New York City, New York, United States|New York University Cancer Institute, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Upstate Medical Univeristy Syracuse, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Hematology Associates, Bedford, Ohio, United States|St Luke's Cancer Center, Bethlehem, Pennsylvania, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Avera Cancer Center, Sioux Falls, South Dakota, United States|Associates In Oncology and Hematology, Chattanooga, Tennessee, United States|University of Tennessee Cancer Institute, Knoxville, Tennessee, United States|Accelerated Community Oncology Reseaerch Network, Inc. (ACORN), Memphis, Tennessee, United States|UT - M. D. Anderson Cancer Center, Houston, Texas, United States|The UT Health Science Centre at San Antonio, San Antonio, Texas, United States|Massey Cancer Center, Richmond, Virginia, United States|Cascade Cancer Center, Kirkland, Washington, United States|Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance, Seattle, Washington, United States|ZNA Middelheim, Antwerpen, Belgium|ZNA Stuivenberg, Antwerpen, Belgium|Clinique Universitaire Saint Luc, Service Hématologie, Bruxelles, Belgium|AZ St. Jan, Brügge, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|University of Liege, Divisions of Hematology and Medical Oncology, Liege, Belgium|Cliniques Universitaires UCL Mont Godinne, Service Hématologie, Yvoir, Belgium|University of British Columbia, Vancouver, British Columbia, Canada|CHA Hôpital de l'Enfant-Jésus, Quebec City, Quebec, Canada|McGill University, Montreal, Canada|CHC Split Clinic of Internal Diseases, Split, Croatia|CHC Zagreb Clinic of Internal Diseases, Zagreb, Croatia|UH Dubrava Clinic of Internal Diseases, Zagreb, Croatia|CHC Rijeka, Clinic of Internal Diseases, Zagreb, Croatia|H:S Rigshospitalet, The Finsen Centre, KAT, Haematology Department 4241, Copenhagen, Denmark|Hôpital de l'Archet, Centre Hospitalier Universitaire (CHU) de Nice, Hématologie Clinique, Nice, France|Groupe Hospitalier Sud Réunion, Site Saint-Pierre, Saint-Pierre Cedex, France|Klinik Essen Süd, Evangelisches Krankenhaus, Essen, Germany|Leitender Oberarzt/Klinik für Onkologie und Hämatologie, Frankfurt, Germany|Universität Göttingen, Abteilung Hämatologie und Onkologie, Göttingen, Germany|Universitätsklinikum (AöR) der Martin-Luther-Universität Halle-Wittenberg, Halle, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Germany|Universitätsmedizin der johannes Gutenberg -Universität Mainz, Mainz, Germany|University Hospital Marburg, Marburg, Germany|Münchner Studienzentrum Klinikum Rechts der Isar, München, Germany|Klinikum Nuernberg Nord, Nuernberg, Germany|Universitätsklinikum Rostock, Rostock, Germany|Universitätsklinikum Ulm, Ulm, Germany|Szt István és Szt. Laszlo, Budapest, Hungary|Belgyógyászati Klinika, Debrecen, Hungary|Belgyógyászati Klinika Györ, Györ, Hungary|Belgyógyászati Klinika es Kardiologial Központ, Szeged, Hungary|The Soroka University Medical Center, Beer Sheva, Israel|Rambam Medical Center Department of Hematology, Haifa, Israel|Hadassah University Hospital Sharet Building Department of Hematology, Jerusalem, Israel|Rabin Medical Center Belinson Campus, Petach Tikva, Israel|Ospedale Sant'Orsola, Instituto di Ematologia e Oncologia Medica, Bologna, Italy|Ospedale Policlinico Careggi, Firenze, Italy|VU Medical Center, Department of Haematology, Amsterdam, Netherlands|University Medical Center Groningen UMCG, Department of Haematologie, Groningen, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|Isala Clinics, Department of Haematololgy, Zwolle, Netherlands|Klinika Nowotworów Ukladu Chlonnego Centrum Onkologii Instytut Marii Sklodowskiej-Curie, Warszawa, Mazowieckie, Poland|Uniwersyteckie Centrum Kliniczne Klinika Hematologii i Transplantologii, Gdansk, Poland|Małopolskie Centrum Medyczne, Kraków, Poland|Szpital Wojewódzki w Opolu/Oddział Hematologii, Opole, Poland|MTZ Clinical Research Sp z o.o., Warszawa, Poland|Instytut Hematologii i Transfuzjologii Klinika Hematologii, Warszawa, Poland|Wojskowy Instytut Medyczny Klinika Chorób/Wewnętrznych i Hematologii Centralnego Szpitala, Warszawa, Poland|Wojewódzki Szpital Specjalistyczny im M. Kopernika w Łodzi Oddział Hematologii - Klinika Hematologii, Łódź, Poland|State Therapeutical and Prophylactic Institution Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Russian Federation|Russian Cancer Research Centre named after N.N. Blokhin of Russian Academy of Medical Sciences, Moscow, Russian Federation|Research Center of Haematology, Moscow, Russian Federation|Narodny Onkologicky Ustav (NOU), Bratislava, Slovakia|Klinika Hematologie a Onkohematologie FNLP a LF UPJS, Kosice, Slovakia|Tygerberg Hospital, Department of Radiation Oncology, Bellville, South Africa|Drs pirjol, Szpak and Moodley Inc., Durban, South Africa|Medical Oncology 2nd Floor Radiotherapy building Steve Biko Academic Hospital, Pretoria, South Africa|Pretoria Academic Hospital, Department of Radiation Oncology, Pretoria, South Africa|Complexo Hospitalario a Coruna, A Coruna, Spain|ICO Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Duran i Reinals, Barcelona, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain|Hospital General Universitario Gregorio Maranón, Madrid, Spain|Hospital Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Clinico Universitario de Santiago, Santiago De Compostella, La Coruna, Spain|St James's Institute of Oncology Bexley Wing, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Institute of Cancer/ Centre for Medical Oncology/Barts and The London School of Medicine and Dentistry, London, United Kingdom|The Christie NHS Foundation Trust, The Christie Hospital,, Manchester, United Kingdom|Northern Centre for Cancer Care, Freeman Hospital, Newcastle Upon Tyne, United Kingdom|The Royal Marsden Haemato-Oncology Wards, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT00865969"
669,"NCT01934361","Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme","Completed","No Results Available","All","Phase 1","35","Industry","Interventional","February 28, 2014","July 7, 2016","July 7, 2016","September 4, 2013","null","August 3, 2018","Barrow Neurological Insitute St. Joseph's Hospital, Phoenix, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Northwestern University, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Marseille Cedex 05, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain","https://ClinicalTrials.gov/show/NCT01934361"
670,"NCT00574873","Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML","Completed","Has Results","All","Phase 3","502","Industry","Interventional","February 2008","August 2010","May 2015","December 17, 2007","November 5, 2012","October 17, 2016","Pacific Cancer Medical Center Inc, Anaheim, California, United States|Tower Cancer Research Foundation (TCRF), Beverly Hills, California, United States|Robert A Moss, MD, FACP, Inc, Fountain Valley, California, United States|UCSD Medical Center-Thornton, La Jolla, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|UCSD Medical Center-Hillcrest, San Diego, California, United States|Stanford Hospital and Clinics Investigational Drug Services, Stanford,, California, United States|Stanford Hospitals and Clinics, Stanford, California, United States|Stanford University Medical Center, Stanford, California, United States|Cancer Care Centers of Florida, Hudson, Florida, United States|Cancer Care Centers of Florida, New Port Richey, Florida, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Pasco Pinellas Cancer Center, Tarpon Springs, Florida, United States|Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States|The University Of Chicago Medical Center (Ucmc), Chicago, Illinois, United States|The University of Chicago Biological Sciences, Chicago, Illinois, United States|Indiana Blood and Marrow Transplantation Research, Indianapolis, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Cancer Center of Kansas, Salinas, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Josephine Ford Cancer - Downriver, Brownstown, Michigan, United States|Henry Ford Medical Center- Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Henry Ford Hospital - West Bloomfield, Detroit, Michigan, United States|Drug Shipment: Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Study Supplies: Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Somerset Hematology Oncology Associates, Somerville, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Associates In Oncology and Hematology, Chattanooga, Tennessee, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Hospital Italiano de la Plata, La Plata, Buenos Aires, Argentina|Hospital Privado de Cordoba, Cordoba, Prov. de Cordoba, Argentina|Centro de Investigaciones Oncologicas, Bahia Blanca, Provincia Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina|Cliniques Universitaires Saint Luc, Brussels, Belgium|C.H.R.ST. - R. Fabiola (N-D), Charleroi, Belgium|University Hospital Gent - Department of Hematology, Gent, Belgium|Centre Hospitalier de Jolimont - Lobbes, La Louviere, Belgium|CHU de Charleroi - Hopital civil Marie Curie, Lodelinsart, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Centro De Hematologia E Hemoterapia Da Unicamp, Campinas/ SP, Brazil|Vancouver General Hospital, Vancouver, British Columbia, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada|Instituto Oncologico del Sur, Temuco, Chile|Instituto Oncologico, Vina del Mar, Chile|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, China|The Chinese PLA General Hospital, Beijing, China|Ruiging Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China|The Hematology Hospital of Chinese Academy of Medical Science, Tianjin, China|Fundacion Santa Fe de Bogota, Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|CIOSAD Centro de Investigaciones Oncologicas, Bogota, Colombia|Institut Bergonie, Bordeaux, France|CHU Caen - Cote de Nacre, Caen, France|Centre Hospitalier de Versailles Hopital Andre Mignot, Le Chesnay Cedex, France|Hopital EDOUARD HERRIOT, Lyon, France|Hopital HOTEL DIEU, Nantes, France|Hospital Archet 1, Nice Cedex 3, France|Centre d'Investigation Clinique- CIC INSERM802, Poitiers, France|CHU de Poitiers, Poitiers, France|Clinique Sainte Anne, Strasbourg, France|Hopitaux Universitaires de Strasbourg - Hopital Civil, Strasbourg, France|Charite University Medical Center - Campus Virchow Klinikum, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Univeristatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig Zentrum fur Innere Medizin, Leipzig, Germany|III. Medizinische Klinik, Universitaetsklinikum Mannheim gGmbH, Mannheim, Germany|III. Medizinischen Klinik und Poliklinik des Klinikums Rechts der Isar der TU-MUNCHEN, Muenchen, Germany|Prince Of Wales Hospital, Shatin N.T., Hong Kong|Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Kaposi Mor Oktato Korhaz, Belgyogyaszati Osztaly, Kaposvar, Hungary|Josa Andras Hospital, Nyiregyhaza, Hungary|Tata Memorial Center, Tata Memorial Hospital, Mumbai, Maharashtra, India|Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre,, Pune, Maharashtra, India|Birla Cancer Centre, Jaipur, Rajasthan, India|SEAROC Cancer Center, Soni Manipal Hospital, Jaipur, Rajasthan, India|Azienda Ospedaliera San Gerardo, Monza, Lombardia, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Ospedale Ferrarotto - Divisione di Ematologia, Catania, Italy|Dipartimento Di Ematologia Ospedale Santo Eugenio, Roma, Italy|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Akita University Hospital, Akita City, Akita, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Tohoku Univesity Hospital, Sendai, Miyagi, Japan|Kinki University School of Medicine, Osakasayama, Osaka, Japan|Jikei University Hospital Daisan, Komae-shi, Tokyo, Japan|Japanese Red Cross Nagoya First Hospital, Aichi, Japan|Aichi Cancer Center Hospital, Aichi, Japan|Chiba University Hospital, Chiba, Japan|Tokai University Hospital, Kanagawa, Japan|Nagasaki University Hospital, Nagasaki, Japan|Niigata University Medical and Dental Hospital, Niigata, Japan|Osaka University Hospital, Osaka, Japan|Hamamatsu Medical University Hospital Faculty of Medicine, Shizuoka, Japan|Tokyo Metropolitan Cancer & Infectious Disease Centre Komagome Hp, Tokyo, Japan|The Catholic University of Korea, Seoul St. Mary's Hospital/Division of Hematology, Seoul, Korea, Republic of|Riga Centre Of Haematology, Riga, Latvia|Hematology, Oncology & Transfusion Medicine Center, Vilnius, Lithuania|Centro Medico de las Americas, Merida, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny Im. A. Mieleckiego Slaskiego Uniwersytetu Medycznego, Katowice, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|GUZ Komi Republican Oncology Center, Syktyvkar, Komi Republic, Russian Federation|Regional State Budgetary Healthcare Institution ""Barnaul City Hospital #8"", Barnaul, Russian Federation|Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg, Russian Federation|Central City Hospital #7, Ekaterinburg, Russian Federation|Kirov Research Institute of Hematology and Blood Transfusion of, Kirov, Russian Federation|Federal State Budget Institution Hematology Scientific Center of Minzdravsotsrazvitiya of Russia, Moscow, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation|Perm Territory State Budgetary Healthcare Inst, Perm, Russian Federation|Republican Hospital na Baranov, Petrozavodsk, Russian Federation|Rostov Regional Clinical Hospital, Rostov-on-Don, Russian Federation|Rostov State Medical University of the Minzdravsotsrazvitiya of Russia, Rostov-On-Don, Russian Federation|Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|St-Petersburg Pavlov's State Medical University, Saint Petersburg, Russian Federation|St-Petersburg State Medical University, Saint Petersburg, Russian Federation|Samara Regional Clinical Hospital M.I. Kalinin, Samara, Russian Federation|St-Petersburg Pavlov's State Medical University, St. Petersburg, Russian Federation|Yaroslavl Region State Budgetary Healthcare Institution Regional Clinical Hospital, Yaroslavl, Russian Federation|Singapore General Hospital, Singapore, Singapore|University Witwatersrand and Oncology, Johannesburg, South Africa|Johannesburg Hospital, Department of Medical Oncology, Parktown, South Africa|Clinical Haematology Unit - Department of Medicine, Soweto, South Africa|Department of Cardiology, Chris Hani Baragwanath Hospital, Soweto, South Africa|Department of Radiology, Chris Hani Baragwanath Hospital, Soweto, South Africa|Hospital Universitari Clinic de Barcelona, Barcelona, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Madrid Norte-Sanchinarro Centro Integral Oncologico, Madrid, Spain|Complejo Hospitalario de Toledo- Servicio de Hematologia., Toledo, Spain|Hospital Clinico Universitario de Valencia (CHUV), Valencia, Spain|Changhua Christian Hospital, Changhua City, Taiwan|National Taiwan University Hospital, Taipei TOC, Taiwan|Division of Hematology, Department of Medicine, Bangkoknoi, Bangkok, Thailand|Hacettepe Universitesi Tip Fakultesi, Ankara, Sihhiye, Turkey|Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Turkey|Gaziantep Universitesi Tip Fakultesi, Gaziantep, Turkey|Cherkaskiy oblasniy onkologichniy dispanser, Cherkassy, Ukraine|Clinical Assocation of Emergency Care, Dnipropetrovsk, Ukraine|Clinical Diagnostic Laboratory of Komunalnyj Zaklad, Dnipropetrovsk, Ukraine|Komunalnyj Zaklad ""Dnipropetrovska Miska Bagatoprofilna Klinichna Likarnja #4"", Dnipropetrovsk, Ukraine|Instytut Nevidkladnoi ta Vidnovnoi Hirurgii im. P.K. Husaka NAMN Ukrainy, Viddilennja Hematologii, Donetsk, Ukraine|Oleksandrovska clinical hospital cardiological rehabilitation department, Kiev, Ukraine|Miska klinichna likarnja # 9, Kyev, Ukraine|Institut Klinichnoi Radiologii DU ""Natsionalnyj Naukovyj Centr Radiacijnoi Medicini NAMN Ukraini"", Kyiv, Ukraine|Institut Klinichnoi Radiologii Naukovogo Centru Radiacijnoi Medicini NAMN Ukraini, Kyiv, Ukraine|Institut Klinichnoi Radiologii Naukovogo, Kyiv, Ukraine|Ultrasaund Educational and Diagnostic Center, Lviv, Ukraine|Instutut Patologii Krovi to Transfuziynoi Medicinu AMN Ukraini, Lviv, Ukraine|Polyclinic of 5th Municipal Hospital, Lviv, Ukraine|3rd Floor Centre for Clinical Haematology, Nottingham, East Midlands, United Kingdom|Pharmacy (Drug Shipment ONLY) - Nottingham University Hospital, Nottingham, East Midlands, United Kingdom|The Park Hospital, Nottingham, East Midlands, United Kingdom|Hammersmith Hospital Clinical Trial Units, Hammersmith, London, United Kingdom|Good Hope Hospital, Birmingham, West Midlands, United Kingdom|Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom|Pharmacy (Drug Shipment ONLY), Birmingham, West Midlands, United Kingdom|Department of Haematology - Level 3, Bexley Wing, Leeds, West Yorkshire, United Kingdom|Pharmacy (Drug shipment ONLY), Leeds, West Yorkshire, United Kingdom|Department of Haematology, London, United Kingdom|Hammersmith Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00574873"
671,"NCT01473901","A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma","Completed","No Results Available","All","Phase 1","38","Industry","Interventional","December 30, 2011","May 17, 2017","May 17, 2017","November 17, 2011","null","September 13, 2017","Highlands Oncology Group Highlands Oncology, Fayetteville, Arkansas, United States|Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States|University of Texas/MD Anderson Cancer Center MD Anderson DeGrout, Houston, Texas, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01473901"
672,"NCT00722137","Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma","Completed","Has Results","All","Phase 3","487","Industry","Interventional","May 1, 2008","January 1, 2014","June 17, 2017","July 25, 2008","November 17, 2014","July 12, 2018","St. Francis Hosptial and Medical Center, Hartford, Connecticut, United States|Center for Cancer Care at Goshen Hospital, Goshen, Indiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Capitol Comp. Cancer Center, Jefferson City, Missouri, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Legacy Pharma Research, Bismarck, North Dakota, United States|Division of Hematology and Oncology Vanderbilt University, Nashville, Tennessee, United States|Cancer Outreach Associates, PC, Abingdon, Virginia, United States|St.Johanns Spital/Landeskrankenhaus Salzburg, Salzburg, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|AZ Stuivenberg Oncologie/ Hematologie, Antwerpen, Belgium|AZ St Jan AV, Brugge, Belgium|UZ Brussel Department Medical Oncology, Brussels, Belgium|UZA Hematologie, 1e verdiep, Edegem, Belgium|Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Gent, Belgium|UZ Leuven Gasthuisberg Hematologie, Leuven, Belgium|C.H.R. Citadelle, Liege, Belgium|Centre Hospitalier Universitaire, Liege, Belgium|Ucl de Mont-Godinne, Yvoir, Belgium|Centro de Hematologia E Hemoterapia - Unicamp, Campinas, Brazil|Fundacao Hospital Amaral Carvalho, Jau, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital Sao Lucas Puc-Rs, Porto Alegre, Brazil|Inca - Instituto Nacional Do Cancêr, Rio de Janeiro, Brazil|Centro de Estudos de Hematologia E Oncologia Da Fmabc, Sao Paulo, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Sao Paulo, Brazil|Hospital Ac Camargo, Sao Paulo, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paulo, Brazil|Santa Casa de Misericórida de São Paulo, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada|Hospital Clinico Universidad Catolica de Chile, Santiago, Chile|Hospital Del Salvador, Santiago, Chile|Instituto Nacional Del Cancer, Santiago, Chile|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Zhejiang University First Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Cancer Institute & Cancer Hospital, CAMS&PUMC, Beijing, China|Peking University Third Hospital, Beijing, China|Cancer hospital, Fudan University, Shanghai, China|Ruijin Hospital, Shanghai, China|Tianjin Medical University Cancer Hospital and Institute, Tianjin, China|Clinica Reina Sofia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Hospital Universitario San Vicente de Paul, Medellin, Colombia|Interni hematoonkoligicka klinika, Brno, Czechia|Interni klinika - Oddeleni klin. hematologie Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Oddeleni klinicke hematologie, Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Vivantes Klinikum Neukölln Klinik für Innere Medizin Hämatologie und Onkologie, Berlin, Germany|Vivantes Klinikum Spandau Klinik für Innere Medizin - Hämatologie, Onkologie und Gastroenterologie, Berlin, Germany|Städt. Kliniken Frankfurt-Hoechst Med. Klinik II - Hämatologie und Onkologie, Frankfurt, Germany|Tumorklinik SANAFONTIS Alpine GmbH, Freiburg, Germany|Wilhelm-Anton-Hospital Goch gGmbH Klinik für Hämatologie und internistische Onkologie, Goch, Germany|Klinikum Lippe-Lemgo Med. Klinik II - Hämatologie und Onkologie, Lemgo, Germany|Johannes-Gutenberg-Universität Mainz III. Med. Klinik, Mainz, Germany|Mutterhaus der Borromäerinnen Med. Klinik I, Trier, Germany|Schwarzwald-Baar-Kliniken Innere Med. II, Villingen, Germany|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, III. sz. Belgyogyaszati Klinika, Debrecen, Hungary|Petz Aladár Kórház, II. Belgyógyászat, Győr, Hungary|Kaposi Mor Megyei Korhaz, Belgyogyaszat, Kaposvar, Hungary|Apollo Hospital and Research Foundation, Apollo Hospitals, Hyderabad 500033, Andhra Pradesh, India|Sir Ganga Ram Hospital, New Delhi- 110060, Delhi, India|Kidwai Memorial Institute of Oncology, Bangalore 560 029, Karnataka, India|Regional Cancer Centre, Medical Oncology, Thiruvananthapuram, Kerala-695011, India|Jehangir Hospital, Pune-411002, Maharashtra, India|Apollo Speciality Hospital, Chennai, Chennai-600035, Tamil Nadu, India|Netaji Subash Chanda Bose Cancer Research Institute, Kolkata- 700016, West Bengal, India|Rambam Medical Center-Hematology department, Haifa, Israel|Hadassah Medical Center - Hematology department, Jerusalem, Israel|Rabin Medical Center, Beilinson Campus, Petach Tiqva, Israel|Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center - Hematology Institute, Rechovot, Israel|Azienda Ospedaliera Universitaria di Bologna Policlinico S.Orsola-Malpighi Dipartimento di Ematologia e Scienze Oncologiche ""L. e A. Seragnoli"", Bologna, Italy|Spedali Civili di Brescia, Brescia, Italy|Dipartimento di Oncologia ed Ematologia Università di Modena e Reggio Emilia, Modena, Italy|AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO TOR VERGATA DIPARTIMENTO DI MEDICINA U.O.C. Ematologia, Roma, Italy|Azienda Ospedaliera San Giovanni Battista ""Molinette"" Struttura Complessa Ematologia 2, Torino, Italy|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Gleneagles Medical Centre, Pulau Pinang, Malaysia|Hopital Du 20 Aout 1953, Casablanca, Morocco|Centre D'oncologie Al Azhar, Rabat, Morocco|Institut National D'oncologie, Rabat, Morocco|National Kidney and Transplant Institute, Quezon City, Philippines|St Lukes Medical Center, Quezon City, Philippines|Szpital Morski im. PCK w Gdyni Gdynskie Centrum Onkologii Oddzial Chemioterapii, Gdynia, Poland|Klinika Hematologii Uniwersytetu Medycznego w Lodzi, Lodz, Poland|""Katedra i Klinika Hematologii i Chorob Rozrostowych Ukladu Krwiotworczego, Poznan, Poland|Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku Akademii Medycznej we Wroclawiu, Wroclaw, Poland|Hospital Sao Marcos, Braga, Portugal|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Instituto Portugues de Oncologia, Porto, Portugal|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"", Hematologie, Baia Mare, Romania|Institutul Clinic Fundeni, Hematologie, Bucuresti, Romania|Spitalul Clinic Coltea, Clinica Hematologie, Bucuresti, Romania|Spitalul Clinic Universitar de Urgenta Bucuresti, Hematologie, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta ""Sf. Spiridon"" Iasi, Oncologie Medicala, Iasi, Romania|Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|Belgorod Regional Oncology Center, Belgorod, Russian Federation|Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation|Sverdlovsk Regional Oncology Dispensary, Ekaterinburg, Russian Federation|1st Republican Clinical Hospital of Udmurtia, Izhevsk, Russian Federation|Cancer Research Center RAMS - N.N. Blokhin - Academy of Medical Science, Moscow, Russian Federation|Hematology Scientific Center, Moscow, Russian Federation|Moscow Regional Clinical Research Institute, Moscow, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation|Medical Scientific Radiology - Center, Obninsk, Russian Federation|Omsk Regional Oncology Dispensary, Omsk, Russian Federation|Medical Sanitary Unit # 1, Perm, Russian Federation|Republikan Hospital named after V.A/ Baranov, Petrozavodsk, Russian Federation|Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation|City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Central Res. Inst. of Roentgen-Radiology, St-Petersburg, Russian Federation|Pavlov State Medical Univercity, St-Petersburg, Russian Federation|Leningrad Region Clinical Hospital, St. Petersburg, Russian Federation|St.-Petersburg Clinical Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation|National Cancer Centre, Singapore, Singapore|Singapore General Hospital - Hematology, Singapore, Singapore|Chris Hani Baragwanath Hospital, Johannesburg, Gauteng, South Africa|Medical Oncology Center of Rosebank, Johannesburg, Gauteng, South Africa|University of the Witwatersrand Oncology, Johannesburg, Gauteng, South Africa|Pretoria Academic Hospital-Dr. Savage Road, 3rd Floor Radiotherapy Building, Prinshof, Pretoria, Gauteng, South Africa|Dr AI Pirjol & Dr WM Szpak Inc., Durban, Kwazulu Natal, South Africa|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario Salamanca, Salamanca, Spain|Chang Gung Memorial Hospital, Linkou, Tao-Yuan, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Siriraj Hospital-Hematology Unit, Bangkok, Thailand|Maharaj Nakorn Chiang Mai hospital - Faculty of Medicine, Chiang Mai, Thailand|Hôpital Farhat Hached, Sousse, Tunisia|Centre National de Greffe de Moelle osseuse, Tunis, Tunisia|Hôpital Aziza Othmana, Tunis, Tunisia|Institut Salah Azaiz, Tunis, Tunisia|Hacettepe University Medical Faculty, Ankara, Turkey|Dokuz Eylul University Med. Fac., Izmir, Turkey|Cherkassy Regional Oncology Center, Dept. of Hematology, Cherkassy, Ukraine|Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Ukraine|Institute of Urgent and Recovery Surgery named after V.K.Gusaka of AMS of Ukraine, Haematology Dept., Donetsk, Ukraine|Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitsky, Ukraine|National Cancer Institute, Department of chemotherapy of hemoblastosis, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv Clinical Hospital #5, Hematology Dept., Lviv, Ukraine|Crimean Republic Clinical Oncology Dispensary, Haematology Department, Simferopol, Ukraine","https://ClinicalTrials.gov/show/NCT00722137"
673,"NCT01472887","SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients","Completed","No Results Available","All","Phase 2","61","Industry","Interventional","January 2012","September 2016","September 2016","November 17, 2011","null","January 25, 2018","Investigational Site Number 840001, Denver, Colorado, United States|Investigational Site Number 840003, Augusta, Georgia, United States|Investigational Site Number 840005, Boise, Idaho, United States|Investigational Site Number 056002, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 203002, Brno, Czechia|Investigational Site Number 203003, Praha 10, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 376003, Jerusalem, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380004, Bologna, Italy|Investigational Site Number 380008, Mestre, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380007, Modena, Italy|Investigational Site Number 380003, Palermo, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 616003, Brzozow, Poland|Investigational Site Number 616002, Kielce, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724003, Valencia, Spain|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 826001, Leicester, United Kingdom|Investigational Site Number 826002, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01472887"
674,"NCT01949805","Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","Completed","No Results Available","All","Phase 3","257","Industry|Other","Interventional","September 2013","July 2016","July 2016","September 25, 2013","null","November 28, 2016","LKH Graz, Graz, Austria|University Hospital Innsbruck, Innsbruck, Austria|Elisabethinen Hospital Linz, Linz, Austria|Salzburg Regional Hospital, Salzburg, Austria|Hanusch Hospital, Vienna, Austria|Medical University Vienna, Vienna, Austria|Hospital Wels-Grieskirchen, Wels, Austria|Centre du Cancer et D'hematologie, Brussels, Belgium|UZA, Antwerp University Hospital, Edegem, Belgium|UZ Leuven, Leuven, Belgium|Haematolgy, University of Liège, Liège, Belgium|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine, Vratsa, Bulgaria|University Hospital Brno, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|Institute of Hematology and Blood Transfusion, Prague, Czech Republic|University Hospital Kralovske Vinohrady, Prague, Czech Republic|University Hospital Motol, Prague, Czech Republic|Institute Paoli-Calmettes, Marseilles, France|Hospital Saint-Louis, Paris, France|Clinical Research Center CIC, Poitiers, France|Aachen University Hospital, Medical Clinic IV, Aachen, Germany|University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III, Bonn, Germany|University Hospital Carl Gustav Carus, Medical Clinic and Polyclinic I, Dresden, Germany|St Istvan and St Laszlo Hospital of Budapest, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology, Gyula, Hungary|Kaposi Mor County Teaching Hospital, Kaposvar, Hungary|University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6, Szeged, Hungary|Careggi University Hospital, Florence, Italy|Foundation IRCCS Policlinico San Matteo, Pavia, Italy|Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Katowice, Poland|University Hospital in Cracow, Krakow, Poland|Independent Public Teaching Hospital No.1 in Lublin, Lublin, Poland|Fryderyk Chopin Provincial Specialized Hospital, Rzeszow, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland|Institute of Hematology and Transfusion Medicine, Warsaw, Poland|Emergency Clinical County Hospital Brasov, Brasov, Romania|Bucharest University Emergency Hospital, Bucharest, Romania|Coltea Clinical Hospital, Bucharest, Romania|""Prof. Dr. Ion Chiricuta"" Institute of Oncology, Cluj-Napoca, Romania|Baranov Republican Hospital, Petrozavodsk, Russian Federation|Samara Kalinin Regional Clinical Hospital, Samara, Russian Federation|First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation|Komi Republican Oncology Center, Syktyvkar, Russian Federation|Tula Regional Clinical Hospital, Tula, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|University Hospital with Outpatient Clinic F.D. Roosevelt, Banska Bystrica, Slovakia|Saint Cyril and Metod University Hospital Bratislava, Bratislava, Slovakia|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center, Cherkasy, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipropetrovsk, Ukraine|National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr, Ukraine","https://ClinicalTrials.gov/show/NCT01949805"
675,"NCT00930514","A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma","Completed","No Results Available","All","Phase 1","281","Industry","Interventional","September 2009","July 2013","July 2013","June 30, 2009","null","November 2, 2016","Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Córdoba, Argentina|Rosario, Argentina|Kogarah, New South Wales, Australia|Sydney, New South Wales, Australia|Kurralta Park, South Australia, Australia|Fitzroy, Victoria, Australia|Porto Alegre, RS, Brazil|Barretos, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Calgary, Alberta, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Montreal, Quebec, Canada|Quebec, Canada|Brno, Czech Republic|Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Herlev, Denmark|Guayaquil, Ecuador|Quito, Ecuador|Helsinki, Finland|Tampere, Finland|Turku, Finland|Marseille, France|Montpellier, France|Reims, France|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Pisa, Toscana, Italy|Seoul, Korea, Republic of|Aguascalientes, Mexico|Mexico City, Distrito Federal, Mexico|Monterrey, Mexico|Oslo, Norway|Lima, Peru|Lima, Peru|Warszawa, Poland|Wroclaw, Poland|Moscow, Russian Federation|Bratislava, Slovakia|Barcelona, Spain|Barcelona, Spain|Salamanca, Spain|Sevilla, Spain|Huddinge, Sweden|Sundsvall, Sweden|Umea, Sweden|Uppsala, Sweden|Basel, Switzerland|Cambridge, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT00930514"
676,"NCT00737529","A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The ""EMERGE"" Trial","Completed","Has Results","All","Phase 2","134","Industry","Interventional","December 22, 2008","October 15, 2012","November 8, 2017","August 19, 2008","September 9, 2013","December 5, 2017","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Tower Cancer Research Foundation, Los Angeles, California, United States|Boca Raton Community Hospital, Inc., Research Dept., Boca Raton, Florida, United States|Pasco Hernando Oncology Associates, PA, Brooksville, Florida, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|MD Anderson Cancer Center, Orlando Regional Healthcare, Orlando, Florida, United States|Lake County Oncology and Hematology, The Villages, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Medical Center - Smith, Maywood, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Alvin and Lois Lapidus Cancer Institute Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU School of Medicine, New York, New York, United States|University of Rochester Cancer Center, James P. Wilmot Cancer Center, Rochester, New York, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Hillman Cancer Institute at UPMC, Pittsburgh, Pennsylvania, United States|South Carolina Cancer Specialists, Hilton Head Island, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|University of Virginia Cancer Center Clinical Trials Office, Charlottesville, Virginia, United States|Universitaetsklinik Innsbruck, Innsbruck, Austria|Landeskrankenhaus Salzburg, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|AZ Sint-Jan AV Brugge, Brugge, Belgium|UZ Gent, Gent, Belgium|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium|Hospital Universitario San Ignacio, Bogota, Colombia|Oncologos del occidente S.A., Pereira, Colombia|Hopital Sud, CHU d'Amiens, Amiens, France|Institut Bergonie, Bordeaux, France|Hopital Henri Mondor, Créteil, France|Hopital Emile Muller, Mulhouse, France|Hopital Cochin, Paris, France|Institut Curie, Paris, France|Hopital Robert Debre, Reims Cedex, France|Institut de Cancerologie de la Loire, Saint Jean Priest En Jarez, France|Hopital Hautepierre, Strasbourg, France|University Hospital Wuerzburg, Wuerzburg, Germany|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|University of Debrecen, DEOEC, Institute of Internal Medicine, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat, Gyor, Hungary|Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petch Tikva, Israel|Sheba Medical Center, Tel Hashomer, Israel|Universita Federico II di Napoli Nuovo Policlinico, Napoli, Italy|Ospedale Civile dello Spirito Santo, Pescara, Italy|Universita Cattololica del Sacro Cuore, Roma, Italy|Centro De Cancer, Hospital Espanol Auxilio De Puerto Rico, San Juan, Puerto Rico|Singapore General Hospital, Singapore, Singapore|Hospital General De Elche, Alicante, Spain|Duran i Reynals Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario La Fe, Valencia, Spain|Gazi Universitesi, Besevler Ankara, Turkey|Istanbul Universitesi Istanbul, Istanbul, Turkey|Ankara Universitesi Tip Fakultesi, Sihhiye Ankara, Turkey|Royal Cornwall Hospitals Trust, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT00737529"
677,"NCT01779791","A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma","Completed","No Results Available","All","Phase 2","110","Industry","Interventional","April 17, 2013","May 18, 2016","May 18, 2016","January 30, 2013","null","July 18, 2017","Los Angeles, California, United States|Stanford, California, United States|Washington, D.C., District of Columbia, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Westwood, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Hackensack, New Jersey, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Greenville, North Carolina, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Burlington, Vermont, United States|Seattle, Washington, United States|Adelaide, Australia|Concord, Australia|Melbourne, Australia|Milton, Australia|Prahran, Australia|Courrière, Belgium|Gent, Belgium|Leuven, Belgium|Creteil, France|Nice Cedex 2, France|Nimes Cedex 9, France|Paris, France|Pessac, France|Pierre Benite, France|Rennes, France|Heidelberg, Germany|Köln, Germany|Mainz, Germany|Ulm, Germany|Krakow, Poland|Warszawa, Poland|Wroclaw, Poland|Ekaterinburg, Russian Federation|Moscow N/A, Russian Federation|Nizhny Novgorod, Russian Federation|St-Petersburg, Russian Federation|Volgograd, Russian Federation|Barcelona, Spain|Marbella, Spain|Salamanca, Spain|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01779791"
678,"NCT01578499","A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)","Completed","Has Results","All","Phase 3","131","Industry","Interventional","June 11, 2012","May 31, 2016","July 6, 2018","April 17, 2012","March 16, 2018","August 21, 2018","Los Angeles, California, United States|Palo Alto, California, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|New York, New York, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Concord, New South Wales, Australia|South Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Nedlands, Western Australia, Australia|East Melbourne, Australia|St. Poelten, Austria|Wien, Austria|Leuven, Belgium|Sao Paulo, Brazil|Nantes Cedex 01, France|Paris, France|Pessac Cedex, France|Pierre Benite, France|Reims, France|Kiel, Germany|Krefeld, Germany|Mainz, Germany|Mannheim, Germany|Minden, Germany|Wurzburg, Germany|Bologna, Italy|Firenze, Italy|Meldola, Italy|Warszawa, Poland|Pamplona, Navarra, Spain|Barcelona, Spain|Madrid, Spain|Zurich, Switzerland|Leeds, West Yorkshire, United Kingdom|Birmingham, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01578499"
679,"NCT01486277","A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma","Completed","No Results Available","All","Phase 2","26","Industry","Interventional","November 2011","November 2014","July 2016","December 6, 2011","null","November 3, 2016","Pittsburgh, Pennsylvania, United States|Nantes Cedex 1, France|Paris, France|Pessac, France|Kiel, Germany|Minden, Germany|Lisboa, Portugal|Porto, Portugal|Madrid N/A, Spain|Málaga, Spain|Valencia, Spain|London, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01486277"
680,"NCT01188681","Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia","Completed","Has Results","All","Phase 1|Phase 2","79","Industry","Interventional","September 2010","December 2014","December 2014","August 25, 2010","January 6, 2017","June 28, 2017","For additional information regarding sites for this trial call (919) 465-4648, Denver, Colorado, United States|For additional information regarding sites for this trial call (919) 465-4648, Augusta, Georgia, United States|For additional information regarding sites for this trial call (919) 465-4648, Chicago, Illinois, United States|For additional information regarding sites for this trial call (919) 465-4648, Hackensack, New Jersey, United States|For additional information regarding sites for this trial call (919) 465-4648, Syracuse, New York, United States|For additional information regarding sites for this trial call (919) 465-4648, Durham, North Carolina, United States|For additional information regarding sites for this trial call (919) 465-4648, Cleveland, Ohio, United States|For additional information regarding sites for this trial call (919) 465-4648, Columbus, Ohio, United States|For additional information regarding sites for this trial call (919) 465-4648, Seattle, Washington, United States|For additional information regarding sites for this trial call (919) 465-4648, Vienna, Austria|For additional information regarding sites for this trial call (919) 465-4648, Bremen, Germany|For additional information regarding sites for this trial call (919) 465-4648, Cologne, Germany|For additional information regarding sites for this trial call (919) 465-4648, Frankfurt, Germany|For additional information regarding sites for this trial call (919) 465-4648, Gottingen, Germany|For additional information regarding sites for this trial call (919) 465-4648, Kiel, Germany|For additional information regarding sites for this trial call (919) 465-4648, Mainz, Germany|For additional information regarding sites for this trial call (919) 465-4648, Mutlangen, Germany|For additional information regarding sites for this trial call (919) 465-4648, Regensburg, Germany|For additional information regarding sites for this trial call (919) 465-4648, Bialystok, Poland|For additional information regarding sites for this trial call (919) 465-4648, Gdansk, Poland|For additional information regarding sites for this trial call (919) 465-4648, Lodz, Poland|For additional information regarding sites for this trial call (919) 465-4648, Poznan, Poland|For additional information regarding sites for this trial call (919) 465-4648, Warsaw, Poland|For additional information regarding sites for this trial call (919) 465-4648, Madrid, Spain|For additional information regarding sites for this trial call (919) 465-4648, Navarra, Spain","https://ClinicalTrials.gov/show/NCT01188681"
681,"NCT02008318","A Study of LY2157299 in Participants With Myelodysplastic Syndromes","Completed","No Results Available","All","Phase 2|Phase 3","140","Industry","Interventional","March 2014","March 2016","September 2017","December 11, 2013","null","October 17, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Düsseldorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jena, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lübeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Westerstede, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Novara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salamanca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain","https://ClinicalTrials.gov/show/NCT02008318"
682,"NCT01693614","Safety and Efficacy of BKM120 in Relapsed and Refractory NHL","Completed","Has Results","All","Phase 2","72","Industry","Interventional","February 28, 2013","July 21, 2017","July 21, 2017","September 26, 2012","September 28, 2018","September 28, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center Univ Nebraska, Omaha, Nebraska, United States|Memorial Sloan Kettering Dept of Onc., New York, New York, United States|Medical University of South Carolina -Hollings Cancer Center Medical Univ of South Carolina, Charleston, South Carolina, United States|University of Texas MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, United States|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Pierre-Benite Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Samsun, Turkey","https://ClinicalTrials.gov/show/NCT01693614"
683,"NCT01456676","Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy","Completed","No Results Available","All","Phase 1","11","Industry","Interventional","January 2012","February 2014","February 2014","October 21, 2011","null","September 2, 2016","Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01456676"
684,"NCT01599949","A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy","Completed","No Results Available","All","Phase 2","120","Industry","Interventional","August 2012","May 2015","May 2015","May 16, 2012","null","June 1, 2016","La Jolla, California, United States|Los Angeles, California, United States|Stanford, California, United States|Norwalk, Connecticut, United States|Jacksonville, Florida, United States|Chicago, Illinois, United States|Peoria, Illinois, United States|Goshen, Indiana, United States|Iowa City, Iowa, United States|Sioux City, Iowa, United States|Westwood, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Metairie, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Jefferson City, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|New York, New York, United States|Syracuse, New York, United States|Watertown, South Dakota, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Burlington, Vermont, United States|Charlottesville, Virginia, United States|Morgantown, West Virginia, United States|Madison, Wisconsin, United States|Brugge, Belgium|Gent, Belgium|Grenoble, France|Mulhouse N/A, France|Nantes, France|Pessac, France|Vandoeuvre Les Nancy, France|Afula, Israel|Beer Yaakov, Israel|Hadera, Israel|Haifa, Israel|Nahariya, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Chorzow, Poland|Lodz, Poland|San Juan, Puerto Rico|Nizhny Novgorod, Russian Federation|Rostov-Na-Donu, Russian Federation|St-Petersburg, Russian Federation|St.-Petersburg, Russian Federation|Barcelona, Spain|Salamanca, Spain|London, United Kingdom|Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT01599949"
685,"NCT01275209","Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma","Completed","No Results Available","All","Phase 1","1","Industry","Interventional","February 2011","May 2012","May 2012","January 12, 2011","null","December 5, 2012","Dana Farber Cancer Institute SC-5, Boston, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute Dept.of KarmanosCancerInst (6), Detroit, Michigan, United States|Duke University Medical Center Duke Hem & Onc, Durham, North Carolina, United States|Sarah Cannon Research Institute SC - 2, Chattanooga, Tennessee, United States|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01275209"
686,"NCT00963105","Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","Completed","Has Results","All","Phase 2","104","Industry","Interventional","October 19, 2009","September 5, 2017","September 5, 2017","August 21, 2009","October 2, 2018","October 31, 2018","UCSD Moores Cancer Center, La Jolla, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Stanford University School of Medicine, Stanford, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Northwestern University Medical Center Division of Hematology Oncology, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Long Island Jewish Medical Center CLL Research and Treatment Program, New Hyde Park, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Drexel University, College of Medicine, Clinical Research Group, Philadelphia, Pennsylvania, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|CHU Sud, Amiens, France|Hopital Avicenne, Bobigny Cedex, France|CHU Grenoble, Grenoble Cedex 09, France|Clinique Victor Hugo, Le Mans, France|Institut Paoli Calmettes, Marseille Cedex 9, France|CHU Montpellier - Hôpital Saint Eloi, Montpellier Cedex 5, France|Hopital Emile Muller, Mulhouse, France|Hopital Pitie Salpetriere, Paris, France|CH Perpignan - Hopital Saint-Jean, Perpignan, France|CHRU - Hopital du Haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Hopital Robert Debre, REIMS cedex, France|CHU Rennes Hematology, Rennes cedex, France|CHRU Hopital Brabois, Vandoeuvre les Nancy, France|Charite -Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Essen, Essen, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Universitatsklinikum Schleswig Holstein, Kiel, Germany|Klinikum der Universitat zu Koln, Köln, Germany|University of Ulm Abteilung Innere Medizin III, Ulm, Germany|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ematologia ed Immunologia, Azienda Ospedaliera ""Vito Fazzi"" di Lecce, Lecce, Italy|I.R.C.C.S. Ospedale San Raffaele, Milano, Italy|Istituto Europeo di Oncologia - IEO, Milano, Italy|Universita degli Studi di Padova, Padova, Italy|Universita' Degli Studi Di Perugia, Perugia, Italy|Hospital Clinic Provincial de Barcelona, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Karolinska Universitetssjukhuset, Stockholm, Sweden|St James's Institute of Oncology, Leeds, United Kingdom|St.Bartholomew's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT00963105"
687,"NCT01868477","Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.","Completed","Has Results","All","Phase 2","28","Industry","Interventional","January 28, 2014","March 22, 2017","April 5, 2017","June 4, 2013","October 31, 2018","October 31, 2018","Novartis Investigative Site, Oran, Algeria|Novartis Investigative Site, Sidi Bel abbes, Algeria|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Lütten-Klein, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Cagliari, CA, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Girona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Gothenburg, Sweden|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Oldham, Lancashire, United Kingdom","https://ClinicalTrials.gov/show/NCT01868477"
688,"NCT02633020","Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease","Completed","No Results Available","All","Phase 2","28","Industry","Interventional","April 13, 2016","April 11, 2017","May 2, 2017","December 17, 2015","null","February 1, 2018","Clinical Site, San Diego, California, United States|Clinical Site, New York, New York, United States|Clinical Site, Tampere, Finland|Clinical Site, Paris, France|Clinical Site, Amsterdam, Netherlands|Clinical Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT02633020"
689,"NCT01003015","Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma","Completed","No Results Available","All","Phase 2","36","Industry","Interventional","September 2009","November 2010","March 2013","October 28, 2009","null","April 3, 2015","Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Rozzano, Milano, Italy|Bologna, Italy|Milano, Italy|Milano, Italy|Roma, Italy|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01003015"
690,"NCT00730925","Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients","Completed","Has Results","All","Phase 2","41","Industry","Interventional","June 2008","January 2012","null","August 8, 2008","October 23, 2013","March 26, 2014","1200.41.32003 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium|1200.41.32007 Boehringer Ingelheim Investigational Site, Charleroi, Belgium|1200.41.32001 Boehringer Ingelheim Investigational Site, Jette, Belgium|1200.41.32011 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1200.41.32008 Boehringer Ingelheim Investigational Site, Liège, Belgium|1200.41.32006 Boehringer Ingelheim Investigational Site, Namur, Belgium|1200.41.34001 Boehringer Ingelheim Investigational Site, Badalona (Barcelona), Spain","https://ClinicalTrials.gov/show/NCT00730925"
691,"NCT01559844","Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant","Completed","Has Results","All","Phase 2","61","Industry","Interventional","March 2012","May 2014","October 2014","March 21, 2012","May 28, 2015","July 27, 2016","UCLA Medical Center-The Pfleger Liver Institute, Los Angeles, California, United States|UC San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. Louis University Hospital, St. Louis, Missouri, United States|Columbia University, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Baylor Health Care System, Dallas, Texas, United States|Auckland Clinical Studies, Auckland, New Zealand|Liver Unit Clinica University de Navara, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT01559844"
692,"NCT01753154","The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis","Completed","No Results Available","All","Phase 4","25","Industry","Interventional","July 2011","March 2013","December 2013","December 20, 2012","null","May 2, 2016","Centrum Dializ Fresenius Nephrocare, Gdańsk,, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Poland|Uniwersytecki Szpital Kliniczny nr 1, Łódź, Poland|Complejo hospitalario universitario de Albacete, Albacete, Spain|Fundación Hospital Alcorcón, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01753154"
693,"NCT01137682","Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","Completed","Has Results","All","Phase 3","198","Industry","Interventional","July 19, 2010","January 22, 2013","February 28, 2017","June 4, 2010","January 21, 2015","April 5, 2018","University of Michigan, Ann Arbor, Michigan, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Texas Southwestern Medical Center Division of Hematology/Oncolog, Dallas, Texas, United States|Swedish Neuroscience Institute 550 17th Avenue, Suite 500, Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Sao Luis, MA, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Bron, Cedex, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Saint Herblain - Nantes, France|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT01137682"
694,"NCT01492088","Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma","Completed","Has Results","All","Phase 1|Phase 2","36","Industry","Interventional","April 16, 2012","October 12, 2016","April 12, 2018","December 14, 2011","May 15, 2017","November 20, 2018","Aurora, Colorado, United States|Kansas City, Missouri, United States|New York, New York, United States|Houston, Texas, United States|Bordeaux Cedex, France|Lyon, France|Paris Cedex 12, France|Berlin, Germany|Frankfurt, Germany|Giessen, Germany|Halle, Germany|Munster, Germany|Padova, Italy|Roma, Italy|Mexico Df, Mexico|Rotterdam, Netherlands|Barcelona, Spain|London, United Kingdom","https://ClinicalTrials.gov/show/NCT01492088"
695,"NCT01377922","A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)","Completed","Has Results","All","Phase 3","38","Industry","Interventional","June 2011","July 2016","July 2016","June 22, 2011","January 4, 2018","January 4, 2018","Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Los Angeles, California, United States|Palo Alto, California, United States|Kansas City, Kansas, United States|New York, New York, United States|Lyon, France|Munich, Bavaria, Germany|Berlin, Germany|Pecs, Hungary|Warsaw, Poland|Moscow, Russian Federation|Belgrade, Serbia|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01377922"
696,"NCT01024036","A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease","Completed","Has Results","All","Phase 2","79","Industry","Interventional","March 18, 2010","March 25, 2013","February 24, 2017","December 2, 2009","August 20, 2014","March 21, 2018","Little Rock, Arkansas, United States|Los Angeles, California, United States|Tampa, Florida, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|Rochester, Minnesota, United States|Chapel Hill, North Carolina, United States|Greenville, South Carolina, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|East Melbourne, Australia|Brussels, Belgium|Leuven, Belgium|Brasilia, Brazil|Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|Toronto, Canada|Beijing, China|Chengdu, China|Guangzhou, China|Hangzhou, China|Shanghai, China|Cairo, Egypt|Clermont Ferrand, France|Grenoble Cedex 1, France|Lille Cedex, France|Montpellier, France|Paris, France|Rennes, France|Tours Cedex 9, France|Vandoeuvre Les Nancy, France|Berlin, Germany|Mainz, Germany|München, Germany|Sha Tin, Hong Kong|Budapest, Hungary|Hyderabad N/A, India|Pune, India|Petach Tikva, Israel|Ramat Gan, Israel|Seoul, Korea, Republic of|Pandan, Malaysia|Rotterdam, Netherlands|Auckland, New Zealand|Oslo, Norway|Kazan, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|St.-Petersburg, Russian Federation|Singapore, Singapore|Barcelona, Spain|Madrid, Spain|Taipei, Taiwan|London, United Kingdom|Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01024036"
